1	Microdetermination	O
2	of	O
3	adrenocortical	O
4	steroids	O
5	by	O
6	double	O
7	isotope	O
8	method	O
9	.	O

1	Analysis	O
2	by	O
3	cell	O
4	surface	O
5	immunofluorescence	O
6	showed	O
7	that	O
8	the	O
9	UL28	O
10	gene	B
11	is	I
12	not	I
13	required	I
14	for	I
15	expression	I
16	of	I
17	viral	I
18	glycoproteins	I
19	on	I
20	the	O
21	surface	O
22	of	O
23	infected	B
24	cells	I
25	.	I

1	Sequence	O
2	conservation	O
3	is	O
4	greatest	O
5	for	O
6	residues	O
7	located	O
8	near	O
9	the	O
10	active	O
11	centers	O
12	of	O
13	the	O
14	exo	O
15	and	O
16	pol	O
17	domains	O
18	of	O
19	the	O
20	E	O
21	.	O
22	coli	O
23	DNA	O
24	polymerase	O
25	I	O
26	structure	O
27	.	O

1	Since	O
2	MEK	O
3	acts	O
4	as	O
5	a	O
6	cytoplasmic	O
7	anchor	O
8	for	O
9	the	O
10	ERKs	O
11	,	O
12	the	O
13	lack	O
14	of	O
15	a	O
16	MEK	O
17	interaction	O
18	resulted	O
19	in	O
20	the	O
21	aberrant	O
22	nuclear	O
23	localization	O
24	of	O
25	ERK2	O
26	-	O
27	Delta19	O
28	-	O
29	25	O
30	mutants	O
31	in	O
32	serum	O
33	-	O
34	starved	O
35	cells	O
36	.	O

1	The	O
2	B	O
3	-	O
4	oligomer	O
5	of	O
6	pertussis	O
7	toxin	B
8	deactivates	I
9	CC	I
10	chemokine	O
11	receptor	O
12	5	O
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	O
18	-	O
19	tropic	O
20	HIV	O
21	-	O
22	1	O
23	strains	O
24	.	O

1	The	O
2	5	O
3	'	O
4	external	O
5	transcribed	O
6	spacer	O
7	(	O
8	ETS	O
9	)	O
10	region	O
11	of	O
12	the	O
13	pre	B
14	-	I
15	rRNA	O
16	in	O
17	Saccharomyces	B
18	cerevisiae	O
19	contains	O
20	a	O
21	sequence	O
22	with	O
23	10	O
24	bp	O
25	of	O
26	perfect	O
27	complementarity	O
28	to	O
29	the	B
30	U3	B
31	snoRNA	O
32	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	named	O
6	this	O
7	gene	B
8	UBP43	I
9	.	I

1	When	O
2	statistically	O
3	analyzed	O
4	in	O
5	various	O
6	subgroupings	B
7	,	I
8	the	I
9	obtained	I
10	average	O
11	sedimentation	O
12	coefficients	O
13	and	O
14	polydispersity	O
15	profiles	O
16	supported	O
17	the	O
18	following	O
19	conclusions	O
20	:	O
21	(	O
22	a	O
23	)	O
24	loss	O
25	of	O
26	proteoglycan	O
27	aggregation	O
28	and	O
29	sedimentability	O
30	is	O
31	confirmed	O
32	to	O
33	be	O
34	a	O
35	primary	O
36	sign	O
37	of	O
38	cartilage	O
39	matrix	O
40	degradation	O
41	;	O
42	(	B
43	b	I
44	)	I
45	higher	O
46	S	O
47	values	O
48	for	O
49	proteoglycans	O
50	of	O
51	the	O
52	high	O
53	weight	O
54	(	O
55	HW	I
56	)-	I
57	bearing	O
58	areas	O
59	and	I
60	lower	O
61	values	I
62	for	O
63	those	O
64	of	O
65	the	O
66	low	O
67	weight	O
68	(	O
69	LW	O
70	)-	O
71	bearing	O
72	areas	O
73	were	O
74	a	O
75	typical	O
76	finding	I
77	in	O
78	normal	O
79	cartilage	O
80	samples	O
81	;	I
82	(	O
83	c	O
84	)	O
85	inversion	O
86	of	O
87	this	O
88	pattern	O
89	was	O
90	indicative	O
91	of	O
92	matrix	B
93	degradation	I
94	,	I
95	suggesting	B
96	that	I
97	the	I
98	HW	O
99	regions	O
100	are	O
101	more	O
102	affected	O
103	than	O
104	the	O
105	LW	O
106	-	O
107	bearing	O
108	areas	O
109	;	O
110	(	O
111	d	O
112	)	O
113	the	O
114	average	O
115	S	O
116	value	O
117	distribution	O
118	across	O
119	cartilage	O
120	thickness	O
121	tended	O
122	to	O
123	resemble	O
124	the	O
125	corresponding	O
126	proteoglycan	O
127	content	O
128	versus	O
129	distance	O
130	from	O
131	articular	O
132	surface	O
133	;	O
134	and	B
135	(	B
136	e	O
137	)	O
138	the	O
139	deepest	O
140	cartilage	O
141	layer	O
142	had	O
143	,	O
144	in	O
145	most	O
146	cases	O
147	,	O
148	the	O
149	smallest	O
150	amount	O
151	of	O
152	aggregates	O
153	while	O
154	the	O
155	highest	O
156	average	O
157	sedimentability	O
158	was	O
159	observed	O
160	at	O
161	the	O
162	middle	O
163	zone	O
164	of	O
165	the	O
166	normal	O
167	samples	O
168	.	O

1	A	O
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	O
13	RNA	O
14	polymerase	O
15	II	O
16	transcripts	O
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	Antithrombin	O
2	III	O
3	in	O
4	hip	O
5	surgery	O

1	A	O
2	high	O
3	-	O
4	frequency	O
5	restriction	O
6	fragment	B
7	length	I
8	polymorphism	I
9	was	O
10	evident	O
11	in	O
12	the	O
13	DNA	O
14	from	O
15	29	O
16	unrelated	O
17	individuals	O
18	using	O
19	the	O
20	enzyme	B
21	BglII	I
22	.	O

1	271	O
2	:	O
3	31290	O
4	-	O
5	31295	O
6	,	O
7	1996	O
8	).	O

1	RESULTS	O
2	:	O
3	Significant	O
4	changes	O
5	from	B
6	pretreatment	I
7	to	I
8	posttreatment	I
9	were	I
10	observed	O
11	(	O
12	p	O
13	<	O
14	0	O
15	.	O
16	001	O
17	).	O

1	Both	O
2	functional	O
3	analyses	O
4	in	O
5	undifferentiated	O
6	and	O
7	differentiated	O
8	F9	O
9	cells	O
10	and	O
11	characterization	O
12	of	O
13	DNA	O
14	-	O
15	protein	O
16	complexes	O
17	in	O
18	vitro	O
19	have	B
20	identified	I
21	the	I
22	sequence	I
23	motifs	O
24	GTGACT	O
25	(	O
26	C	O
27	),	O
28	ATTGT	O
29	,	O
30	and	O
31	GATA	O
32	as	O
33	the	O
34	key	O
35	transcription	O
36	factor	O
37	binding	O
38	sites	O
39	.	O

1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	O
7	-	B
8	kDa	I
9	nuclear	I
10	pore	I
11	glycoprotein	I
12	shows	I
13	little	I
14	similarity	I
15	to	I
16	other	I
17	characterized	O
18	proteins	O
19	and	O
20	elucidates	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	O
31	pore	O
32	glycoproteins	O
33	.	O

1	Both	O
2	the	O
3	intact	O
4	A1	O
5	protein	O
6	and	O
7	its	O
8	proteolytic	O
9	fragment	O
10	,	O
11	the	O
12	UP1	O
13	protein	O
14	,	O
15	can	O
16	be	O
17	cleaved	O
18	by	O
19	Staphylococcus	O
20	aureus	O
21	V	O
22	-	O
23	8	O
24	protease	O
25	to	O
26	produce	O
27	two	O
28	polypeptides	O
29	of	O
30	92	O
31	amino	O
32	acids	O
33	.	O

1	Alanine	O
2	substitution	O
3	mutations	O
4	in	O
5	the	O
6	Zta	O
7	activation	O
8	domain	O
9	which	O
10	eliminate	O
11	the	O
12	ability	B
13	of	I
14	Zta	I
15	to	I
16	stimulate	I
17	the	I
18	D	O
19	-	O
20	A	O
21	complex	O
22	were	O
23	examined	O
24	.	O

1	A	O
2	114	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	of	O
8	predominantly	O
9	repeating	O
10	purine	O
11	-	O
12	pyrimidine	O
13	nucleotides	O
14	separates	O
15	these	O
16	two	O
17	d	O
18	(	O
19	AC	O
20	)	O
21	repeats	O
22	.	O

1	Role	O
2	of	O
3	the	B
4	3	I
5	'	I
6	untranslated	I
7	region	I
8	of	I
9	baculovirus	O
10	p10	O
11	mRNA	O
12	in	O
13	high	B
14	-	I
15	level	I
16	expression	I
17	of	I
18	foreign	O
19	genes	O
20	.	O

1	The	O
2	SH2	O
3	and	O
4	SH3	O
5	domains	O
6	of	O
7	pp60src	O
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	O
16	and	O
17	p110	O
18	.	O

1	However	O
2	,	O
3	unlike	O
4	the	O
5	SIN3	O
6	gene	O
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	,	O
11	pst1	O
12	(+)	O
13	is	O
14	essential	O
15	for	O
16	cell	O
17	viability	O
18	.	O

1	Current	O
2	status	O
3	and	O
4	future	O
5	perspectives	O

1	Immunofluorescence	O
2	microscopy	O
3	revealed	B
4	extensive	I
5	deposition	I
6	of	I
7	such	I
8	extracellular	I
9	matrices	O
10	as	O
11	type	O
12	IV	O
13	collagen	O
14	and	O
15	laminin	O
16	in	O
17	the	B
18	vascular	I
19	wall	O
20	.	B

1	Fourth	O
2	,	O
3	sometime	O
4	between	O
5	4	O
6	and	O
7	24	O
8	hours	O
9	of	O
10	recovery	O
11	is	O
12	necessary	O
13	to	B
14	reverse	I
15	the	O
16	effect	O
17	of	O
18	chronic	O
19	hypoxia	O
20	on	O
21	cerebral	O
22	blood	O
23	flow	O
24	.	B

1	A	O
2	heterologous	O
3	promoter	O
4	construct	O
5	containing	O
6	three	O
7	repeats	O
8	of	O
9	a	B
10	consensus	I
11	Sp1	I
12	site	I
13	,	I
14	cloned	I
15	upstream	I
16	of	I
17	a	I
18	single	O
19	copy	O
20	of	O
21	the	O
22	ZII	O
23	(	O
24	CREB	O
25	/	O
26	AP1	O
27	)	O
28	element	O
29	from	O
30	the	O
31	BZLF1	O
32	promoter	O
33	linked	O
34	to	O
35	the	O
36	beta	O
37	-	O
38	globin	O
39	TATA	O
40	box	O
41	,	O
42	exhibited	O
43	phorbol	O
44	ester	O
45	inducibility	B
46	.	I

1	The	O
2	authors	O
3	report	O
4	the	O
5	clinicopathologic	O
6	findings	O
7	in	O
8	four	O
9	cases	O
10	of	O
11	adult	O
12	women	O
13	with	O
14	rhabdomyosarcomas	O
15	that	O
16	originated	O
17	in	O
18	the	O
19	endometrium	O
20	or	O
21	cervix	O
22	,	O
23	or	O
24	both	O
25	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	measured	O
7	absorption	O
8	of	O
9	low	O
10	doses	O
11	of	O
12	vitamin	O
13	A	O
14	,	O
15	which	O
16	may	O
17	provide	O
18	a	O
19	more	O
20	physiological	O
21	approach	O
22	to	O
23	assessment	O
24	of	O
25	fat	O
26	malabsorption	O
27	.	O

1	These	O
2	six	O
3	districts	O
4	have	O
5	an	O
6	area	O
7	of	O
8	34	O
9	,	O
10	000	O
11	km2	O
12	and	O
13	hold	O
14	a	O
15	population	O
16	of	O
17	30	O
18	million	O
19	.	O

1	As	O
2	high	O
3	-	O
4	speed	O
5	,	O
6	volumetric	O
7	imaging	O
8	,	O
9	computed	O
10	tomographic	O
11	scan	O
12	machines	O
13	such	O
14	as	O
15	the	O
16	Dynamic	O
17	Spatial	O
18	Reconstructor	O
19	become	O
20	available	O
21	with	O
22	higher	O
23	density	O
24	resolution	O
25	,	O
26	perhaps	O
27	a	O
28	single	O
29	injection	O
30	of	O
31	contrast	O
32	agent	O
33	into	O
34	the	O
35	right	O
36	atrium	O
37	or	O
38	even	O
39	a	O
40	peripheral	O
41	vein	O
42	may	O
43	be	O
44	adequate	O
45	to	O
46	obtain	O
47	all	O
48	these	O
49	measurements	O
50	.	O

1	It	O
2	has	O
3	repeatedly	O
4	been	O
5	shown	O
6	that	O
7	HCMV	O
8	IE1	O
9	/	O
10	IE2	O
11	can	O
12	independently	O
13	transactivate	O
14	HIV	O
15	-	O
16	1	O
17	LTR	O
18	.	O

1	AgMNPV	O
2	and	B
3	Orgyia	I
4	pseudotsugata	I
5	MNPV	I
6	(	I
7	OpMNPV	I
8	)	O
9	are	O
10	similar	O
11	in	O
12	terms	O
13	of	O
14	promoter	O
15	structure	O
16	and	O
17	polyhedrin	O
18	primary	O
19	sequence	O
20	,	O
21	and	O
22	the	O
23	polyhedrin	O
24	gene	O
25	of	O
26	both	O
27	viruses	O
28	is	O
29	transcribed	O
30	in	O
31	the	O
32	anti	O
33	-	O
34	clockwise	O
35	direction	O
36	in	O
37	relation	O
38	to	B
39	their	B
40	physical	I
41	maps	O
42	.	B

1	The	O
2	PDH	O
3	complex	O
4	-	O
5	encoding	O
6	genes	O
7	were	O
8	identified	O
9	by	O
10	hybridization	O
11	experiments	O
12	and	O
13	sequence	B
14	analysis	O
15	in	O
16	two	O
17	separate	O
18	gene	O
19	regions	O
20	in	B
21	the	O
22	genome	O
23	of	O
24	Z	O
25	.	O
26	mobilis	O
27	.	O

1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	B
12	to	I
13	an	I
14	exon	I
15	of	I
16	the	I
17	human	I
18	tyrosine	I
19	phosphatase	I
20	1	O
21	gene	O
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O

1	Plasma	O
2	renin	O
3	activity	O
4	did	O
5	not	O
6	change	O
7	in	O
8	response	O
9	to	O
10	head	O
11	-	O
12	up	O
13	tilt	O
14	or	O
15	isoprenaline	O
16	infusion	O
17	in	O
18	the	O
19	patients	O
20	.	O

1	Its	O
2	cognate	O
3	binding	O
4	protein	O
5	,	O
6	REST	O
7	/	O
8	NRSF	O
9	,	O
10	is	O
11	an	O
12	essential	O
13	transcription	O
14	factor	O
15	;	B
16	its	I
17	null	I
18	mutations	I
19	result	O
20	in	B
21	embryonic	I
22	lethality	O
23	,	B
24	and	I
25	its	I
26	dominant	I
27	negative	I
28	mutants	I
29	produce	O
30	aberrant	O
31	expression	B
32	of	O
33	neuron	I
34	-	I
35	specific	I
36	genes	O
37	.	O

1	Definite	O
2	JPsA	O
3	(	O
4	24	O
5	patients	O
6	)	O
7	was	O
8	defined	O
9	as	O
10	arthritis	O
11	associated	O
12	,	O
13	but	O
14	not	O
15	necessarily	B
16	coincident	I
17	,	I
18	with	I
19	a	O
20	typical	O
21	psoriatic	B
22	rash	I
23	,	I
24	or	O
25	arthritis	O
26	plus	O
27	at	O
28	least	O
29	3	O
30	of	O
31	4	O
32	minor	O
33	criteria	O
34	:	O
35	dactylitis	O
36	,	O
37	nail	O
38	pitting	O
39	,	O
40	psoriasis	O
41	-	O
42	like	O
43	rash	O
44	,	O
45	or	O
46	family	O
47	history	O
48	of	O
49	psoriasis	O
50	.	O

1	One	O
2	of	O
3	these	O
4	,	O
5	an	O
6	AACA	O
7	motif	O
8	,	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	be	O
14	a	O
15	negative	O
16	regulator	O
17	in	O
18	non	O
19	-	O
20	seed	O
21	tissues	O
22	and	O
23	has	O
24	a	O
25	similarity	O
26	to	O
27	the	O
28	barley	O
29	gibberellin	O
30	responsive	O
31	element	O
32	recognized	O
33	by	O
34	MYB	O
35	-	O
36	like	O
37	DNA	O
38	binding	O
39	proteins	O
40	.	O

1	Effect	O
2	of	O
3	castration	O
4	on	O
5	pituitary	O
6	and	O
7	serum	O
8	LH	O
9	and	O
10	FSH	O
11	in	O
12	testosterone	O
13	-	O
14	sterilized	O
15	rats	O
16	.	O

1	The	O
2	TA	O
3	muscle	O
4	was	O
5	fatigued	O
6	by	O
7	four	B
8	forms	O
9	of	O
10	repeated	O
11	isometric	O
12	contractions	O
13	:	O
14	(	O
15	1	O
16	)	O
17	maximal	O
18	voluntary	O
19	contractions	O
20	(	B
21	MVC	I
22	),	I
23	(	I
24	2	I
25	)	O
26	MVC	O
27	with	O
28	circulation	O
29	occluded	O
30	,	O
31	(	O
32	3	O
33	)	O
34	electrically	O
35	evoked	O
36	contractions	O
37	with	O
38	20	B
39	Hz	B
40	supramaximal	O
41	voltage	O
42	stimulation	O
43	and	O
44	(	O
45	4	O
46	)	O
47	electrically	O
48	evoked	O
49	contractions	O
50	with	O
51	circulation	O
52	occluded	O
53	.	O

1	Plectin	O
2	and	O
3	desmoplakin	O
4	have	O
5	GSR	O
6	-	O
7	containing	O
8	domains	B
9	at	I
10	their	I
11	C	I
12	-	I
13	termini	I
14	and	O
15	we	O
16	further	B
17	demonstrate	I
18	that	I
19	the	I
20	GSR	O
21	-	O
22	containing	I
23	domain	O
24	of	O
25	plectin	O
26	,	B
27	but	I
28	not	O
29	desmoplakin	O
30	,	O
31	can	O
32	bind	O
33	to	O
34	MTs	O
35	in	O
36	vivo	O
37	.	O

1	In	O
2	contrast	B
3	to	I
4	previously	O
5	characterized	O
6	proteophosphoglycans	O
7	,	O
8	the	O
9	ppg1	O
10	gene	O
11	product	O
12	is	O
13	predominantly	O
14	membrane	B
15	-	I
16	associated	O
17	and	B
18	it	I
19	is	I
20	expressed	O
21	on	O
22	the	B
23	promastigote	B
24	cell	O
25	surface	O
26	.	B

1	Supershift	O
2	EMSAs	O
3	identified	O
4	that	O
5	upstream	O
6	stimulatory	O
7	factor	O
8	-	O
9	1	O
10	and	O
11	-	O
12	2	O
13	(	O
14	USF	O
15	-	O
16	1	O
17	and	O
18	-	O
19	2	O
20	)	O
21	were	O
22	part	O
23	of	O
24	these	O
25	complexes	O
26	.	O

1	The	O
2	method	O
3	is	O
4	applied	O
5	to	B
6	determine	I
7	aberration	I
8	constants	I
9	of	O
10	a	O
11	CM300	O
12	FEG	O
13	/	O
14	UT	O
15	microscope	O
16	with	O
17	correction	O
18	of	B
19	the	I
20	three	I
21	-	I
22	fold	I
23	astigmatism	I
24	.	I

1	Mean	O
2	(+/-	O
3	SE	O
4	)	O
5	measurements	O
6	of	O
7	clearance	O
8	(	O
9	24	O
10	.	O
11	5	O
12	+/-	O
13	2	O
14	.	O
15	06	O
16	v	O
17	26	O
18	.	O
19	5	O
20	+/-	O
21	2	O
22	.	O
23	05	O
24	mL	O
25	/	O
26	min	O
27	/	O
28	m2	O
29	),	O
30	half	O
31	-	O
32	life	O
33	(	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	0	O
39	.	O
40	5	O
41	v	O
42	6	O
43	.	O
44	4	O
45	+/-	O
46	0	O
47	.	O
48	5	O
49	hours	O
50	),	O
51	and	O
52	volume	O
53	of	O
54	distribution	O
55	(	O
56	12	O
57	.	O
58	4	O
59	+/-	O
60	1	O
61	.	O
62	1	O
63	v	O
64	13	O
65	.	O
66	7	O
67	+/-	O
68	1	O
69	.	O
70	6	O
71	L	O
72	/	O
73	m2	O
74	)	O
75	were	O
76	not	O
77	significantly	O
78	different	O
79	in	O
80	patients	O
81	with	O
82	jaundice	O
83	when	O
84	compared	O
85	with	O
86	controls	O
87	.	O

1	In	O
2	studies	O
3	of	O
4	many	O
5	different	O
6	phenotypically	O
7	distinct	O
8	cells	O
9	,	O
10	the	B
11	CRE	I
12	of	I
13	the	I
14	somatostatin	I
15	gene	I
16	promoter	I
17	is	I
18	a	I
19	prototype	O
20	of	O
21	a	O
22	highly	B
23	cAMP	I
24	-	I
25	responsive	I
26	element	I
27	regulated	I
28	by	I
29	CREB	O
30	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	an	O
6	internal	O
7	short	O
8	element	O
9	located	O
10	at	O
11	the	O
12	very	O
13	5	O
14	'	B
15	terminal	I
16	of	I
17	L1	O
18	sequence	O
19	and	O
20	the	O
21	nuclear	O
22	factor	O
23	binding	O
24	to	O
25	the	O
26	element	O
27	play	O
28	a	O
29	crucial	O
30	role	O
31	in	O
32	the	O
33	transcription	O
34	of	O
35	human	O
36	L1	O
37	.	O

1	In	O
2	about	O
3	one	O
4	third	O
5	of	O
6	the	O
7	cases	O
8	this	O
9	operation	O
10	results	O
11	in	O
12	tonal	O
13	and	O
14	vocal	O
15	improvement	O
16	for	O
17	patients	O
18	suffering	O
19	from	O
20	progressive	O
21	perceptive	O
22	deafness	O
23	.	O

1	We	O
2	found	O
3	the	O
4	following	O
5	:	O
6	Specific	O
7	mutations	O
8	affected	O
9	the	O
10	precise	O
11	carbohydrate	B
12	structure	I
13	and	I
14	folding	I
15	of	O
16	the	O
17	HA	O
18	trimer	O
19	.	O

1	False	O
2	positive	O
3	amniotic	O
4	fluid	O
5	alpha	O
6	fetoprotein	O
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	We	O
2	have	O
3	performed	O
4	toeprinting	O
5	analyses	O
6	on	B
7	repA	I
8	mRNA	I
9	of	I
10	plasmid	I
11	R1	O
12	,	O
13	both	O
14	free	O
15	and	O
16	in	O
17	duplex	O
18	with	O
19	the	O
20	antisense	O
21	RNA	O
22	,	O
23	CopA	B
24	.	I

1	The	O
2	results	O
3	showed	O
4	that	O
5	MIP	O
6	,	O
7	MMIF	O
8	,	O
9	FIC	O
10	,	O
11	Wimax	O
12	,	B
13	P0	I
14	.	I
15	1	O
16	and	B
17	minute	I
18	ventilation	I
19	(	I
20	Vr	I
21	)	I
22	were	I
23	significantly	I
24	increased	O
25	after	B
26	administration	I
27	of	I
28	methylphenidatum	I
29	and	I
30	aminophylline	I
31	.	O

1	A	O
2	new	O
3	non	O
4	-	O
5	LTR	O
6	retrotransposon	O
7	provides	O
8	evidence	O
9	for	O
10	multiple	O
11	distinct	O
12	site	O
13	-	O
14	specific	O
15	elements	B
16	in	I
17	Crithidia	I
18	fasciculata	O
19	miniexon	B
20	arrays	I
21	.	O

1	The	O
2	site	B
3	-	I
4	specific	I
5	DNA	I
6	inversion	I
7	system	O
8	Cin	O
9	encoded	I
10	by	I
11	the	O
12	bacteriophage	O
13	P1	O
14	consists	O
15	of	O
16	a	O
17	recombinase	O
18	,	O
19	two	O
20	inverted	O
21	crossing	O
22	-	O
23	over	O
24	sites	O
25	and	O
26	a	O
27	recombinational	O
28	enhancer	O
29	.	O

1	Hemodynamic	O
2	assessment	O
3	was	O
4	obtained	O
5	before	O
6	and	O
7	following	O
8	administration	O
9	of	O
10	digoxin	O
11	10	O
12	micrograms	O
13	/	O
14	kg	O
15	IV	O
16	or	O
17	dopamine	O
18	,	O
19	5	O
20	to	O
21	12	O
22	micrograms	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	IV	O
28	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	29	O
6	patients	O
7	who	O
8	received	O
9	concurrent	O
10	chemotherapy	O
11	and	O
12	G	O
13	-	O
14	CSF	O
15	,	O
16	ten	O
17	(	O
18	34	O
19	%;	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	[	O
25	CI	O
26	],	O
27	17	O
28	.	O
29	9	O
30	to	O
31	54	O
32	.	O
33	3	O
34	%)	O
35	were	O
36	believed	O
37	to	O
38	have	O
39	clinically	O
40	significant	O
41	bleomycin	O
42	toxicity	O
43	.	O

1	Generally	O
2	the	O
3	differences	O
4	between	O
5	short	O
6	gut	O
7	and	O
8	sham	O
9	operation	O
10	animals	O
11	disappeared	O
12	when	O
13	the	O
14	data	O
15	were	O
16	normalised	O
17	for	O
18	mucosal	O
19	weight	O
20	.	O

1	To	O
2	characterize	O
3	the	O
4	O7	O
5	-	O
6	LPS	B
7	region	I
8	,	I
9	the	I
10	recombinant	I
11	cosmids	I
12	pJHCV31	I
13	and	O
14	pJHCV32	O
15	were	O
16	mutagenized	O
17	by	O
18	transposon	O
19	mutagenesis	O
20	with	O
21	Tn3HoHo1	O
22	,	O
23	which	O
24	carries	O
25	a	O
26	promoterless	O
27	lac	O
28	operon	B
29	and	I
30	can	I
31	therefore	O
32	generate	O
33	lacZ	O
34	transcriptional	O
35	fusions	O
36	with	O
37	target	O
38	DNA	O
39	sequences	O
40	.	O

1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	HMGR1	O
8	mRNA	O
9	(	O
10	HMGR1S	O
11	mRNA	O
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	HMGR1L	O
27	mRNA	O
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	mostly	O
40	to	O
41	seedlings	O
42	,	O
43	roots	O
44	and	O
45	inflorescences	O
46	.	O

1	Similar	O
2	waves	O
3	were	O
4	seen	O
5	on	O
6	cross	O
7	-	O
8	correlating	B
9	a	I
10	motor	I
11	unit	I
12	with	I
13	an	I
14	electronic	O
15	oscillator	O
16	,	O
17	confirming	O
18	that	O
19	their	O
20	occurrence	O
21	does	O
22	not	O
23	necessarily	O
24	demonstrate	O
25	the	O
26	existence	O
27	of	O
28	active	O
29	neural	O
30	interactions	O
31	.	O

1	Working	O
2	session	B
3	report	I
4	:	I
5	in	O
6	vivo	O
7	-	O
8	in	O
9	vitro	O
10	screening	O
11	.	O

1	The	O
2	metabolic	O
3	clearance	O
4	rate	O
5	of	O
6	progesterone	O
7	was	O
8	295	O
9	+/-	O
10	49	O
11	(	O
12	S	O
13	.	O
14	E	O
15	.)	O
16	1	O
17	/	O
18	day	O
19	.	O

1	The	O
2	maximum	O
3	amplitude	O
4	of	O
5	evoked	O
6	responses	O
7	in	O
8	the	O
9	cervical	O
10	sympathetic	O
11	trunk	O
12	was	O
13	obtained	O
14	when	O
15	the	O
16	T2	O
17	white	O
18	ramus	O
19	was	O
20	stimulated	O
21	and	O
22	decreased	O
23	gradually	O
24	when	O
25	followed	O
26	by	O
27	the	O
28	stimulation	O
29	of	O
30	T1	O
31	,	O
32	T3	O
33	,	O
34	T4	O
35	and	O
36	T5	O
37	white	O
38	rami	O
39	.	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	B
6	protein	I
7	kinase	I
8	,	I
9	termed	I
10	hematopoietic	I
11	progenitor	I
12	kinase	I
13	1	I
14	(	I
15	HPK1	I
16	),	O
17	that	O
18	is	O
19	expressed	O
20	predominantly	O
21	in	O
22	hematopoietic	O
23	cells	O
24	,	O
25	including	O
26	early	O
27	progenitor	O
28	cells	O
29	.	O

1	Inhibition	O
2	of	O
3	phosphatidylinositol	O
4	-	O
5	3	O
6	kinase	O
7	did	B
8	not	I
9	have	I
10	a	I
11	significant	I
12	effect	I
13	on	I
14	p53	O
15	conformation	O
16	but	O
17	did	B
18	have	I
19	a	O
20	weak	O
21	but	O
22	significant	O
23	effect	O
24	on	O
25	Tpo	O
26	-	O
27	enhanced	O
28	viability	O
29	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	B
7	vessels	I
8	at	I
9	a	I
10	light	I
11	dose	I
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	dopamine	O
6	receptor	O
7	stimulation	O
8	by	O
9	different	O
10	dopamine	O
11	agonists	O
12	produces	O
13	a	O
14	different	O
15	pattern	O
16	of	O
17	effects	O
18	on	O
19	the	O
20	characteristics	O
21	of	O
22	the	O
23	reaction	O
24	time	O
25	response	O
26	.	O

1	The	O
2	membrane	O
3	-	O
4	distal	B
5	cytoplasmic	I
6	region	I
7	of	I
8	human	I
9	granulocyte	O
10	colony	O
11	-	O
12	stimulating	O
13	factor	O
14	receptor	O
15	is	O
16	required	O
17	for	O
18	STAT3	O
19	but	O
20	not	B
21	STAT1	I
22	homodimer	I
23	formation	O
24	.	I

1	Transcription	O
2	readthrough	O
3	into	O
4	the	O
5	inverted	O
6	repeats	O
7	has	O
8	little	O
9	effect	O
10	on	O
11	this	O
12	event	O
13	.	O

1	This	O
2	sequence	O
3	similarity	O
4	raises	O
5	the	O
6	possibility	O
7	that	B
8	GCN1	I
9	interacts	I
10	with	I
11	ribosomes	O
12	or	O
13	tRNA	O
14	molecules	O
15	and	O
16	functions	O
17	in	O
18	conjunction	O
19	with	O
20	GCN2	O
21	in	O
22	monitoring	O
23	uncharged	O
24	tRNA	O
25	levels	O
26	during	O
27	the	O
28	process	O
29	of	O
30	translation	O
31	elongation	O
32	.	O

1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O

1	Demonstration	O
2	of	O
3	tissue	O
4	lesions	O
5	after	O
6	intramuscular	O
7	injection	O
8	by	O
9	determination	O
10	of	O
11	creatine	O
12	kinase	O
13	in	O
14	blood	O

1	Moreover	O
2	,	O
3	by	O
4	complementation	O
5	of	O
6	the	O
7	WA	O
8	fyuA	O
9	mutant	O
10	by	O
11	the	O
12	cloned	O
13	fyuA	O
14	gene	O
15	,	O
16	yersiniabactin	O
17	uptake	O
18	and	O
19	mouse	O
20	virulence	O
21	were	O
22	restored	O
23	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	Xenopus	O
5	U7	O
6	gene	B
7	contains	I
8	two	I
9	adjacent	I
10	octamer	I
11	-	I
12	binding	O
13	motifs	B
14	located	I
15	only	I
16	12	I
17	and	I
18	24	I
19	bp	O
20	upstream	O
21	from	O
22	the	O
23	PSE	O
24	,	O
25	instead	O
26	of	O
27	the	O
28	usual	O
29	location	O
30	around	O
31	150	O
32	-	O
33	200	O
34	bp	O
35	upstream	O
36	.	B

1	Chloramphenicol	O
2	acetyltransferase	O
3	assays	O
4	examining	O
5	the	O
6	ability	O
7	of	O
8	IE86	O
9	to	O
10	repress	O
11	activity	O
12	from	O
13	the	O
14	HCMV	O
15	major	O
16	IE	O
17	promoter	O
18	or	O
19	activate	O
20	the	O
21	HCMV	O
22	early	O
23	promoter	O
24	for	O
25	the	O
26	2	O
27	.	O
28	2	O
29	-	O
30	kb	O
31	class	O
32	of	O
33	RNAs	O
34	demonstrated	O
35	the	O
36	functional	O
37	integrity	O
38	of	O
39	the	O
40	IE86	O
41	protein	O
42	.	O

1	The	O
2	factor	O
3	designated	O
4	B	O
5	formed	O
6	a	O
7	complex	O
8	centered	O
9	on	B
10	the	I
11	sequence	I
12	TGTGGT	I
13	,	I
14	a	I
15	core	I
16	motif	I
17	recognized	I
18	by	I
19	members	I
20	of	I
21	the	I
22	AML	I
23	/	I
24	CBFalpha	I
25	transcription	I
26	factor	I
27	family	O
28	.	O

1	In	O
2	addition	O
3	,	O
4	mutation	O
5	of	O
6	the	O
7	Sp1	B
8	site	I
9	also	I
10	significantly	I
11	reduced	O
12	promoter	O
13	activity	O
14	.	O

1	In	O
2	conclusion	O
3	,	O
4	changes	O
5	in	O
6	carotid	O
7	sinus	O
8	stimulation	O
9	alters	O
10	blood	O
11	flow	O
12	to	O
13	the	O
14	hindlimb	O
15	through	O
16	changes	O
17	in	O
18	both	O
19	Pcrit	O
20	and	O
21	Ra	O
22	.	O

1	Using	O
2	5	O
3	'	O
4	RACE	O
5	and	O
6	reverse	O
7	transcription	O
8	-	O
9	PCR	O
10	(	O
11	RT	O
12	-	O
13	PCR	O
14	)	O
15	methodologies	O
16	,	O
17	we	O
18	cloned	O
19	these	O
20	sequences	O
21	from	O
22	brain	B
23	and	I
24	placenta	I
25	and	I
26	found	I
27	this	I
28	material	I
29	to	I
30	be	I
31	composed	I
32	of	I
33	alternatively	I
34	spliced	O
35	exons	B
36	using	B
37	a	I
38	previously	I
39	reported	O
40	noncoding	O
41	exon	O
42	(	O
43	1A	O
44	)	O
45	and	O
46	a	O
47	novel	O
48	97	O
49	-	I
50	bp	O
51	noncoding	O
52	exon	O
53	(	O
54	1B	O
55	).	O

1	Several	O
2	7SL	O
3	RNA	O
4	-	O
5	encoding	O
6	sequences	O
7	and	O
8	various	O
9	intergenic	O
10	spacers	O
11	were	B
12	amplified	I
13	from	O
14	the	O
15	individual	O
16	HindIII	O
17	fragments	O
18	of	O
19	about	O
20	1	O
21	.	O
22	3	O
23	and	O
24	2	O
25	.	O
26	8	O
27	kb	O
28	.	O

1	Although	O
2	heart	O
3	rate	O
4	and	O
5	diastolic	O
6	pressure	O
7	rose	O
8	in	O
9	some	O
10	degree	O
11	1	O
12	min	O
13	after	O
14	intubation	O
15	,	O
16	free	O
17	and	O
18	total	O
19	CA	O
20	concentrations	O
21	did	O
22	not	O
23	increase	O
24	during	O
25	study	O
26	period	O
27	.	O

1	The	O
2	RNA	O
3	polymerase	O
4	III	O
5	-	O
6	recruiting	O
7	factor	O
8	TFIIIB	O
9	induces	O
10	a	O
11	DNA	O
12	bend	O
13	between	O
14	the	O
15	TATA	O
16	box	O
17	and	O
18	the	O
19	transcriptional	O
20	start	O
21	site	O
22	.	O

1	Furthermore	O
2	,	O
3	interactions	B
4	were	I
5	identified	O
6	between	O
7	endogenous	O
8	E	O
9	-	O
10	cadherin	O
11	and	O
12	the	O
13	chimera	O
14	containing	O
15	the	O
16	E	B
17	-	I
18	cadherin	I
19	extracellular	O
20	domain	O
21	and	O
22	the	O
23	desmoglein	O
24	1	B
25	intracellular	I
26	domain	O
27	providing	O
28	in	O
29	vivo	O
30	evidence	O
31	for	O
32	previously	O
33	predicted	O
34	lateral	O
35	interactions	O
36	of	O
37	E	B
38	-	I
39	cadherin	I
40	extracellular	O
41	domains	B
42	.	I

1	The	O
2	plateau	O
3	MO2	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	allometric	O
10	relation	O
11	.	O

1	These	O
2	kinases	O
3	belong	O
4	to	O
5	a	O
6	new	O
7	subfamily	O
8	related	O
9	to	O
10	the	O
11	Trk	O
12	subfamily	O
13	.	O

1	In	O
2	contrast	O
3	,	O
4	tobacco	O
5	GS	O
6	-	B
7	2	I
8	is	I
9	composed	I
10	of	I
11	subunits	I
12	of	I
13	identical	I
14	size	I
15	in	I
16	all	I
17	organs	I
18	examined	I
19	.	I

1	Aviators	O
2	from	O
3	the	O
4	Light	O
5	Attack	O
6	Wing	O
7	,	O
8	Pacific	O
9	were	O
10	surveyed	O
11	and	O
12	the	O
13	results	O
14	were	O
15	categorized	O
16	by	O
17	aircraft	O
18	type	O
19	.	O

1	Among	O
2	the	O
3	patients	O
4	grades	O
5	1	O
6	-	O
7	2	B
8	-	I
9	3	I
10	,	O
11	81	O
12	%	O
13	had	O
14	a	O
15	good	O
16	out	O
17	come	O
18	without	O
19	any	O
20	neurological	O
21	abnormality	O
22	,	B
23	among	I
24	the	I
25	patients	I
26	graded	I
27	4	O
28	-	O
29	5	O
30	,	O
31	only	O
32	27	O
33	%	O
34	had	O
35	a	O
36	fair	O
37	out	O
38	come	O
39	.	I

1	Regarding	O
2	"	O
3	the	O
4	relation	O
5	between	O
6	sexual	O
7	orientation	O
8	and	O
9	penile	O
10	size	O
11	,"	O
12	by	O
13	A	O
14	.	O

1	During	O
2	conventional	O
3	hemofiltration	O
4	using	O
5	substitution	O
6	fluid	O
7	with	O
8	a	O
9	Na	O
10	+	O
11	concentration	O
12	of	O
13	140	O
14	mEq	O
15	/	O
16	L	O
17	,	O
18	a	O
19	decrease	O
20	in	B
21	extracellular	I
22	fluid	I
23	volume	I
24	was	I
25	noted	I
26	whereas	I
27	the	O
28	intracellular	O
29	fluid	O
30	volume	O
31	was	O
32	unaltered	O
33	.	O

1	In	O
2	this	O
3	article	O
4	we	O
5	propose	O
6	to	O
7	find	O
8	out	O
9	the	O
10	percentage	O
11	of	O
12	normal	O
13	occlusion	O
14	and	O
15	the	O
16	distribution	O
17	of	O
18	maloclusions	O
19	,	O
20	according	O
21	to	O
22	the	O
23	anteroposterior	O
24	relationship	O
25	between	O
26	the	O
27	dental	O
28	archs	O
29	(	O
30	following	O
31	the	O
32	ANGLE3	O
33	classification	O
34	).	O

1	Methysergide	O
2	is	O
3	a	O
4	serotonin	O
5	antagonist	O
6	and	O
7	has	O
8	been	O
9	demonstrated	O
10	to	O
11	reduce	O
12	wound	O
13	blood	O
14	flow	O
15	and	O
16	edema	O
17	formation	B
18	.	O

1	These	O
2	cells	O
3	fail	O
4	to	O
5	generate	O
6	the	O
7	signals	O
8	to	O
9	phosphorylate	O
10	CREB	O
11	and	O
12	produce	O
13	significantly	O
14	less	O
15	of	O
16	the	O
17	cytokine	O
18	Interleukin	O
19	-	O
20	2	O
21	(	O
22	IL	O
23	-	O
24	2	O
25	)	O
26	in	O
27	response	O
28	to	O
29	agents	O
30	that	O
31	either	O
32	increase	O
33	intracellular	O
34	Ca2	O
35	+	O
36	and	O
37	/	O
38	or	O
39	activate	O
40	protein	O
41	kinase	O
42	C	O
43	.	O

1	The	O
2	transcription	O
3	factor	O
4	Jun	O
5	(	B
6	c	I
7	-	O
8	Jun	O
9	)	O
10	functions	O
11	as	O
12	a	O
13	recipient	O
14	of	O
15	extracellular	O
16	growth	O
17	signals	O
18	and	O
19	converts	O
20	them	O
21	into	O
22	patterns	O
23	of	O
24	gene	O
25	expression	I
26	.	I

1	In	O
2	contrast	O
3	,	O
4	c	O
5	-	O
6	Src	O
7	activated	O
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	O
16	and	O
17	subsequent	O
18	Erk	O
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	O
27	or	O
28	Stat3	O
29	.	O

1	The	O
2	Cdk2	O
3	-	O
4	cyclin	O
5	-	O
6	D1	O
7	complex	O
8	did	O
9	not	O
10	phosphorylate	O
11	any	O
12	tested	O
13	substrates	O
14	,	O
15	such	O
16	as	O
17	H1	O
18	histone	O
19	,	O
20	pRB	O
21	,	O
22	SV40	O
23	large	O
24	T	O
25	antigen	O
26	,	O
27	p53	O
28	,	O
29	E2F	O
30	-	O
31	1	O
32	or	O
33	a	O
34	preparation	O
35	of	O
36	nuclear	O
37	proteins	O
38	from	O
39	HeLa	O
40	cells	O
41	;	O
42	in	O
43	contrast	O
44	,	O
45	Cdk2	O
46	-	O
47	cyclin	O
48	-	O
49	E	O
50	and	O
51	Cdk2	O
52	-	O
53	cyclin	O
54	-	O
55	A	O
56	phosphorylated	O
57	these	O
58	proteins	O
59	.	O

1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	B
11	at	I
12	home	I
13	.	O

1	There	O
2	was	O
3	a	O
4	significant	O
5	correlation	O
6	between	O
7	tubular	O
8	diameter	O
9	and	O
10	spg	O
11	(	O
12	r	O
13	=	O
14	0	O
15	.	O
16	68	O
17	,	O
18	P	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	)	O
25	suggesting	O
26	that	O
27	tubular	O
28	diameter	O
29	measurements	O
30	in	O
31	histological	O
32	sections	O
33	could	O
34	be	O
35	used	O
36	to	O
37	predict	O
38	sperm	O
39	production	O
40	.	O

1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	B
14	left	I
15	lower	I
16	lobe	I
17	bronchus	I
18	followed	O
19	very	B
20	gradually	I
21	and	I
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	O
27	--	B
28	Type	I
29	Kappa	I
30	)	O
31	was	B
32	demonstrated	B
33	.	I

1	Mature	O
2	and	O
3	old	O
4	B6AF1	O
5	and	O
6	B6D2F1	B
7	mice	I
8	were	I
9	given	O
10	acidified	O
11	tap	O
12	water	O
13	or	O
14	promethazine	O
15	HCl	O
16	(	O
17	a	O
18	phenothiazine	O
19	with	O
20	H1	O
21	receptor	O
22	blocking	O
23	activity	O
24	),	O
25	chlorpheniramine	O
26	(	O
27	an	O
28	H1	O
29	blocker	O
30	)	O
31	or	O
32	trifluoperazine	O
33	(	O
34	a	O
35	phenothiazine	O
36	with	O
37	no	O
38	H1	O
39	blocking	O
40	activity	O
41	)	O
42	in	O
43	their	B
44	drinking	I
45	water	I
46	,	O
47	and	O
48	the	O
49	effects	O
50	of	O
51	these	O
52	agents	O
53	on	O
54	bone	O
55	mineral	O
56	content	O
57	were	O
58	assessed	O
59	by	O
60	intermittently	O
61	measuring	O
62	the	O
63	24	O
64	-	O
65	h	O
66	whole	O
67	body	O
68	retention	O
69	of	O
70	Tc	O
71	99m	O
72	methylene	O
73	diphosphonate	O
74	(	O
75	Tc	O
76	99m	O
77	MDP	O
78	,	O
79	an	O
80	indicator	O
81	of	O
82	bone	O
83	metabolism	O
84	)	O
85	and	O
86	at	O
87	the	O
88	end	O
89	of	O
90	the	O
91	studies	O
92	by	O
93	determining	O
94	ash	O
95	weights	O
96	of	O
97	femur	I
98	,	O
99	ilium	O
100	and	O
101	sacrum	O
102	.	O

1	Eight	O
2	induced	O
3	cDNA	O
4	sequences	O
5	were	O
6	identified	O
7	and	O
8	designated	O
9	message	O
10	up	O
11	-	O
12	regulated	O
13	during	O
14	death	O
15	(	O
16	mud	O
17	)-	O
18	1	O
19	-	O
20	8	O
21	.	O

1	Six	O
2	tandem	O
3	repeats	O
4	of	O
5	the	O
6	P	O
7	element	O
8	linked	O
9	to	O
10	the	O
11	SV40	O
12	promoter	O
13	responded	O
14	to	O
15	phorbol	O
16	12	O
17	-	O
18	myristate	O
19	13	O
20	-	O
21	acetate	O
22	,	O
23	while	O
24	that	O
25	of	O
26	other	O
27	elements	O
28	did	O
29	not	O
30	.	O

1	However	O
2	,	O
3	2	O
4	minimum	O
5	alveolar	O
6	concentration	O
7	anesthesia	B
8	did	I
9	significantly	I
10	decrease	O
11	the	B
12	calculated	I
13	VE	I
14	at	O
15	a	B
16	PCO2	B
17	of	O
18	60	O
19	mmHg	O
20	(	O
21	from	O
22	7	O
23	.	O
24	4	O
25	+/-	O
26	1	O
27	.	O
28	2	O
29	to	O
30	4	O
31	.	O
32	0	O
33	+/-	O
34	0	O
35	.	O
36	6	O
37	l	O
38	.	O
39	min	O
40	-	O
41	1	O
42	),	O
43	indicating	B
44	a	I
45	rightward	I
46	shift	O
47	in	B
48	the	I
49	response	O
50	relationship	O
51	.	O

1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	B
6	CTD	I
7	-	I
8	binding	I
9	motif	O
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	B
18	the	I
19	essential	I
20	function	I
21	of	O
22	Nrd1	O
23	.	O

1	Acylation	O
2	with	O
3	the	O
4	palmitate	O
5	analog	O
6	was	O
7	prevented	O
8	when	O
9	Gly	O
10	-	O
11	2	O
12	was	O
13	mutated	O
14	to	O
15	alanine	O
16	,	O
17	implying	O
18	that	O
19	N	O
20	-	O
21	myristylation	O
22	is	O
23	required	O
24	for	O
25	palmitylation	O
26	,	O
27	and	O
28	when	O
29	either	O
30	Cys	O
31	-	O
32	3	O
33	or	O
34	Cys	O
35	-	O
36	6	O
37	was	O
38	mutated	O
39	to	O
40	serine	O
41	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	lengths	O
11	of	O
12	the	O
13	5	O
14	'	O
15	mdr1b	O
16	sequences	O
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	247	O
25	to	O
26	-	O
27	126	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O

1	After	O
2	phosphorylation	O
3	,	O
4	STAT	O
5	proteins	O
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O

1	Both	O
2	betaAPP	O
3	mRNA	O
4	and	O
5	Abeta	O
6	levels	O
7	are	O
8	increased	O
9	in	O
10	trisomy	O
11	21	O
12	.	O

1	The	O
2	novel	O
3	Notch	O
4	homologue	O
5	mouse	O
6	Notch	O
7	3	O
8	lacks	O
9	specific	O
10	epidermal	O
11	growth	O
12	factor	O
13	-	O
14	repeats	O
15	and	O
16	is	O
17	expressed	O
18	in	O
19	proliferating	O
20	neuroepithelium	O
21	.	O

1	Furthermore	O
2	,	O
3	overexpression	O
4	of	O
5	AML3	O
6	/	O
7	CBFalpha1	O
8	could	O
9	rescue	O
10	the	O
11	AML1	O
12	-	O
13	ETO	O
14	repression	O
15	.	O

1	Ume6p	O
2	,	O
3	which	O
4	also	O
5	controls	O
6	the	O
7	expression	O
8	of	O
9	early	O
10	meiotic	O
11	genes	O
12	,	O
13	represses	O
14	CAR1	O
15	expression	O
16	through	O
17	a	O
18	sequence	O
19	called	O
20	URS	O
21	,	O
22	as	O
23	a	O
24	function	O
25	of	O
26	nitrogen	O
27	availability	O
28	.	O

1	313	O
2	,	O
3	98	O
4	-	O
5	102	O
6	).	O

1	One	O
2	of	O
3	its	O
4	lysine	O
5	residues	O
6	is	O
7	modified	O
8	by	O
9	spermidine	O
10	to	O
11	form	O
12	hypusine	O
13	,	O
14	a	O
15	posttranslational	O
16	modification	O
17	unique	O
18	to	O
19	eIF	O
20	-	O
21	5A	O
22	.	O

1	Toxicity	O
2	was	O
3	significant	O
4	in	O
5	selected	O
6	cases	O
7	;	O
8	three	O
9	patients	O
10	developed	O
11	WBC	O
12	counts	O
13	less	O
14	than	O
15	1	O
16	,	O
17	000	O
18	/	B
19	mm3	I
20	and	I
21	one	I
22	of	I
23	these	I
24	patients	I
25	died	O
26	with	O
27	sepsis	O
28	.	O

1	Although	O
2	no	O
3	differences	O
4	were	O
5	noted	B
6	in	I
7	the	I
8	decrease	I
9	in	I
10	platelet	O
11	counts	O
12	between	O
13	the	O
14	two	O
15	groups	O
16	,	O
17	fibrinogen	B
18	levels	I
19	and	I
20	alpha	I
21	2	I
22	-	I
23	antiplasmin	I
24	levels	O
25	declined	O
26	less	O
27	drastically	O
28	in	O
29	the	O
30	antithrombin	O
31	-	O
32	treated	O
33	group	O
34	.	O

1	This	O
2	combined	O
3	intravenous	O
4	anaesthetic	O
5	regimen	O
6	gave	O
7	good	B
8	anaesthesia	I
9	and	I
10	analgesia	I
11	to	I
12	pigs	I
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	B
23	.	I

1	The	O
2	murine	O
3	facilitative	O
4	glucose	O
5	transporter	O
6	isoform	O
7	3	O
8	(	O
9	Glut	O
10	3	O
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O

1	Specific	O
2	IgE	O
3	levels	O
4	decreased	O
5	slightly	O
6	,	O
7	but	B
8	always	I
9	remained	I
10	within	I
11	the	I
12	pathological	I
13	range	I
14	.	I

1	One	O
2	was	O
3	allowed	O
4	fresh	O
5	drinking	O
6	water	O
7	ad	O
8	libitum	O
9	whilst	O
10	the	O
11	other	O
12	received	O
13	Aludrox	O
14	in	O
15	their	O
16	drinking	O
17	water	O
18	.	O

1	Vitamin	O
2	D3	O
3	plus	O
4	nicotine	O
5	treatment	O
6	produced	O
7	parallel	O
8	increases	B
9	in	I
10	cardiac	I
11	mass	O
12	and	O
13	elastic	O
14	modulus	O
15	,	O
16	with	O
17	a	O
18	significant	O
19	correlation	O
20	between	O
21	the	O
22	two	O
23	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	ISIS	O
6	-	O
7	2	O
8	trial	O
9	and	O
10	the	O
11	data	O
12	from	O
13	the	O
14	Antiplatelet	O
15	Trialists	O
16	'	O
17	Collaboration	O
18	indicated	O
19	that	B
20	aspirin	B
21	is	I
22	mandatory	I
23	in	O
24	patients	O
25	with	O
26	acute	O
27	myocardial	O
28	infarction	O
29	and	O
30	for	O
31	secondary	O
32	prevention	O
33	.	O

1	Handgrip	O
2	dynamometry	B
3	was	I
4	also	I
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	B
11	patients	I
12	.	I

1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O

1	Sci	O
2	.	B

1	The	O
2	regional	O
3	blockade	O
4	of	O
5	H1R	O
6	was	O
7	observed	O
8	mainly	O
9	in	O
10	the	O
11	frontal	O
12	,	O
13	temporal	O
14	and	O
15	anterior	O
16	cingulate	O
17	cortices	O
18	,	O
19	and	O
20	the	O
21	intravenous	O
22	administration	O
23	of	O
24	d	O
25	-	O
26	chlorpheniramine	O
27	as	O
28	a	O
29	therapeutic	O
30	dose	O
31	(	O
32	2	O
33	mg	O
34	)	O
35	blocked	O
36	over	O
37	60	O
38	%	O
39	of	O
40	H1R	O
41	in	O
42	the	O
43	frontal	O
44	cortices	O
45	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	directional	O
6	chromosome	O
7	walking	O
8	studies	O
9	starting	O
10	from	O
11	D8S260	O
12	as	O
13	well	O
14	as	O
15	D8S285	O
16	.	O

1	Umweltchem	O
2	.	O

1	E2F	O
2	-	O
3	6	O
4	shares	O
5	significant	O
6	homology	O
7	with	O
8	E2Fs	O
9	1	O
10	-	O
11	5	O
12	,	O
13	especially	O
14	within	O
15	the	O
16	DNA	O
17	binding	O
18	,	O
19	heterodimerization	O
20	and	O
21	marked	O
22	box	O
23	domains	O
24	.	O

1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	O
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O

1	Thyrotropin	O
2	-	O
3	releasing	O
4	hormone	O
5	-	O
6	induced	O
7	contraction	O
8	of	O
9	urethral	O
10	and	O
11	vaginal	O
12	muscle	O
13	.	O

1	These	O
2	data	O
3	will	O
4	help	O
5	us	O
6	to	O
7	better	O
8	detail	O
9	the	O
10	CXCR4	O
11	structural	O
12	requirements	O
13	exhibited	O
14	by	O
15	different	O
16	HIV	O
17	-	O
18	1	O
19	strains	O
20	and	O
21	will	O
22	direct	O
23	further	O
24	mutagenesis	O
25	efforts	O
26	aimed	O
27	at	O
28	better	O
29	defining	O
30	the	O
31	domains	O
32	in	O
33	CXCR4	O
34	involved	O
35	in	O
36	the	O
37	HIV	O
38	-	O
39	1	O
40	Env	O
41	-	O
42	mediated	O
43	fusion	O
44	process	O
45	.	O

1	TPA	O
2	and	O
3	TGF	O
4	-	O
5	beta	O
6	1	O
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	The	O
2	topology	B
3	and	I
4	chain	I
5	folding	O
6	of	O
7	the	O
8	beta	O
9	subunits	O
10	in	O
11	the	O
12	artifactual	O
13	beta	O
14	60	O
15	capsid	O
16	are	O
17	similar	O
18	to	O
19	the	O
20	native	I
21	alpha	O
22	3	O
23	beta	O
24	60	O
25	enzyme	O
26	.	O

1	A	O
2	simple	O
3	analytical	O
4	method	O
5	for	O
6	l	O
7	-	O
8	menthol	O
9	by	O
10	high	O
11	-	O
12	performance	O
13	liquid	O
14	chromatography	O
15	with	O
16	a	I
17	polarized	I
18	photometric	I
19	detector	O
20	was	O
21	established	O
22	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	O
9	and	O
10	pelB	O
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	O
17	-	O
18	glucuronidase	O
19	gene	O
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	O
34	-	O
35	glucuronidase	O
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O

1	Using	O
2	site	O
3	-	O
4	directed	O
5	mutagenesis	O
6	,	O
7	we	O
8	show	O
9	that	O
10	the	O
11	RAREoct	O
12	contributes	O
13	to	O
14	the	O
15	transcriptional	O
16	activation	O
17	of	O
18	Oct	O
19	-	O
20	3	O
21	/	O
22	4	O
23	promoter	O
24	in	O
25	P19	O
26	cells	O
27	and	O
28	,	O
29	most	O
30	interestingly	O
31	,	O
32	mediates	O
33	the	O
34	RA	O
35	-	O
36	induced	O
37	repression	O
38	in	O
39	RA	O
40	-	O
41	differentiated	O
42	EC	O
43	cells	O
44	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	chloroplast	O
7	(	O
8	cp	O
9	)	O
10	DNA	O
11	from	O
12	maize	O
13	(	O
14	Zea	O
15	mays	O
16	)	O
17	has	O
18	been	O
19	completed	O
20	.	O

1	An	O
2	increase	B
3	in	I
4	hypothalamic	I
5	expression	I
6	of	I
7	at	I
8	least	O
9	two	O
10	of	O
11	the	O
12	erbB	O
13	receptors	O
14	is	O
15	initiated	O
16	before	O
17	the	O
18	pubertal	O
19	augmentation	O
20	of	O
21	gonadal	O
22	steroid	O
23	secretion	O
24	and	O
25	is	O
26	completed	O
27	on	O
28	the	O
29	day	O
30	of	O
31	the	O
32	first	O
33	preovulatory	O
34	surge	O
35	of	O
36	gonadotropins	B
37	.	B

1	The	O
2	RAS	O
3	-	O
4	cyclic	O
5	AMP	O
6	-	O
7	dependent	O
8	protein	O
9	kinase	O
10	cAPK	O
11	pathway	O
12	prevents	B
13	the	I
14	UAS	O
15	activity	B
16	of	I
17	IREu	I
18	in	I
19	the	O
20	presence	O
21	of	O
22	glucose	O
23	as	O
24	the	O
25	sole	O
26	carbon	O
27	source	O
28	,	O
29	while	O
30	the	O
31	transcriptional	O
32	activators	O
33	Msn2p	O
34	and	O
35	Msn4p	O
36	promote	O
37	the	O
38	UAS	O
39	activity	O
40	of	O
41	this	O
42	repeat	O
43	in	O
44	the	O
45	presence	O
46	of	O
47	acetate	O
48	.	B

1	The	O
2	third	O
3	ORF	O
4	generates	O
5	a	O
6	transcript	O
7	of	O
8	1	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	382	O
18	residues	O
19	including	O
20	a	O
21	perfect	B
22	match	I
23	to	I
24	the	I
25	consensus	O
26	sequence	O
27	of	O
28	a	O
29	C2H2	O
30	zinc	O
31	finger	O
32	domain	O
33	;	O
34	it	O
35	shares	O
36	a	O
37	strong	O
38	homology	O
39	with	O
40	yeast	O
41	Mig1p	O
42	and	O
43	Cre	O
44	-	O
45	A	O
46	from	O
47	Aspergillus	O
48	,	O
49	Emericella	O
50	and	O
51	E	O
52	.	O
53	coli	O
54	.	O

1	Althoug	O
2	RBF	O
3	tended	O
4	to	O
5	increase	O
6	after	O
7	the	O
8	therapy	O
9	,	O
10	there	O
11	was	O
12	no	O
13	statistically	O
14	significant	O
15	change	O
16	in	O
17	RBF	O
18	,	O
19	GFR	O
20	and	O
21	cardiac	O
22	output	O
23	.	O

1	I	O
2	.	O

1	Acoust	O
2	.	O

1	No	O
2	homologs	O
3	of	O
4	other	O
5	members	O
6	of	O
7	the	O
8	Surfeit	O
9	gene	O
10	cluster	O
11	were	O
12	detected	O
13	in	O
14	close	O
15	proximity	O
16	to	B
17	the	O
18	D	O
19	.	B
20	melanogaster	I
21	Surf	I
22	-	O
23	3	O
24	/	B
25	rpL7a	I
26	gene	I
27	.	I

1	A	O
2	comparison	O
3	of	O
4	the	O
5	Flavobacterium	O
6	glycosylasparaginase	O
7	with	O
8	a	O
9	mammalian	O
10	glycosylasparaginase	O
11	revealed	O
12	30	O
13	%	O
14	structural	O
15	identity	O
16	and	O
17	60	O
18	%	O
19	overall	O
20	similarity	O
21	between	O
22	the	O
23	prokaryotic	O
24	and	O
25	eukaryotic	O
26	forms	O
27	of	O
28	the	O
29	enzyme	O
30	.	O

1	Leukemia	O
2	-	O
3	inhibitory	O
4	factor	O
5	(	O
6	LIF	B
7	)	I
8	is	I
9	a	I
10	neuropoietin	I
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O

1	They	O
2	were	O
3	found	O
4	to	O
5	stimulate	O
6	at	O
7	nanomolar	O
8	concentrations	O
9	the	O
10	turnover	O
11	of	O
12	biosynthetically	O
13	labeled	O
14	ceramide	O
15	,	O
16	glucosylceramide	O
17	,	O
18	and	O
19	lactosylceramide	O
20	.	O

1	Effect	O
2	of	O
3	bromazepam	O
4	on	O
5	growth	O
6	hormone	O
7	and	O
8	prolactin	O
9	secretion	O
10	in	O
11	normal	O
12	subjects	O
13	.	O

1	40	O
2	.	O
3	3	O
4	+/-	O
5	10	O
6	.	O
7	1	O
8	mg	O
9	/	O
10	l	O
11	(	O
12	SD	O
13	)	O
14	vs	O
15	31	O
16	.	O
17	2	O
18	+/-	O
19	8	O
20	.	O
21	0	O
22	,	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	).	O
30	beta	O
31	2m	O
32	was	O
33	not	O
34	significantly	O
35	higher	O
36	in	O
37	patients	O
38	with	O
39	bone	O
40	cysts	O
41	(	O
42	37	O
43	.	O
44	7	O
45	+/-	O
46	11	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	l	O
52	vs	O
53	37	O
54	.	O
55	0	O
56	+/-	O
57	10	O
58	.	O
59	0	O
60	),	O
61	but	O
62	median	O
63	duration	O
64	of	O
65	dialysis	O
66	was	O
67	significantly	O
68	(	O
69	P	O
70	less	O
71	than	O
72	0	O
73	.	O
74	01	O
75	)	O
76	longer	O
77	in	O
78	patients	O
79	with	O
80	bone	O
81	cysts	O
82	(	O
83	90	O
84	vs	O
85	57	O
86	months	O
87	).	O
88	beta	O
89	2m	O
90	was	O
91	lower	O
92	in	O
93	patients	O
94	maintained	O
95	on	O
96	dialysis	O
97	for	O
98	less	O
99	than	O
100	1	O
101	year	O
102	and	O
103	whose	O
104	residual	O
105	urine	O
106	volume	O
107	was	O
108	greater	O
109	than	O
110	0	O
111	.	O
112	1	O
113	litre	O
114	per	O
115	day	O
116	.	O

1	Dopamine	O
2	receptor	O
3	blockade	O
4	and	O
5	the	O
6	neuroleptics	B
7	,	I
8	a	I
9	crystallographic	I
10	study	I
11	.	O

1	The	O
2	small	O
3	GTPase	O
4	Rho	O
5	is	O
6	implicated	O
7	in	O
8	physiological	O
9	functions	O
10	associated	O
11	with	O
12	actin	O
13	-	O
14	myosin	O
15	filaments	O
16	such	O
17	as	O
18	cytokinesis	O
19	,	O
20	cell	O
21	motility	O
22	,	O
23	and	O
24	smooth	O
25	muscle	O
26	contraction	O
27	.	O

1	During	O
2	the	O
3	2h	O
4	resuscitation	O
5	period	O
6	,	O
7	extracellular	O
8	aspartate	O
9	and	O
10	glutamate	O
11	concentrations	O
12	in	O
13	the	O
14	cerebral	O
15	striatum	O
16	were	B
17	higher	I
18	during	I
19	hypoxaemic	I
20	resuscitation	I
21	(	O
22	p	B
23	=	I
24	0	I
25	.	I
26	044	O
27	and	O
28	p	B
29	=	I
30	0	I
31	.	I
32	055	I
33	,	I
34	respectively	I
35	)	I
36	than	I
37	during	I
38	resuscitation	I
39	with	I
40	21	O
41	%	O
42	O2	O
43	or	O
44	100	O
45	%	O
46	O2	O
47	,	O
48	suggesting	O
49	an	O
50	unfavourable	O
51	accumulation	O
52	of	O
53	potent	O
54	excitotoxins	I
55	during	O
56	hypoxaemic	O
57	resuscitation	O
58	.	O

1	The	O
2	natural	O
3	history	O
4	of	O
5	these	O
6	lesions	O
7	,	O
8	locoregional	O
9	efficiency	O
10	of	O
11	the	O
12	different	O
13	treatments	O
14	used	O
15	,	O
16	the	O
17	part	O
18	played	O
19	by	O
20	chemotherapy	O
21	,	O
22	survival	O
23	,	O
24	causes	O
25	of	O
26	death	O
27	and	O
28	therapeutic	O
29	modalities	O
30	used	O
31	as	O
32	a	O
33	last	O
34	measure	O
35	,	O
36	have	O
37	been	O
38	analysed	O
39	.	O

1	Pneumothorax	O
2	following	O
3	lung	O
4	abscess	O
5	in	O
6	the	O
7	renal	O
8	transplant	O
9	patient	O
10	.	O

1	In	O
2	doses	O
3	of	O
4	0	B
5	.	I
6	03	O
7	-	O
8	0	O
9	.	O
10	3	O
11	mg	O
12	/	O
13	kg	O
14	i	O
15	.	O
16	v	O
17	.,	O
18	SG	O
19	-	O
20	75	O
21	did	O
22	not	O
23	significantly	O
24	affect	O
25	pulse	O
26	pressure	O
27	,	O
28	heart	O
29	rate	O
30	,	O
31	aortic	O
32	blood	O
33	flow	O
34	,	O
35	left	O
36	ventricular	O
37	pressure	O
38	(	O
39	LVP	O
40	)	B
41	and	O
42	LVdP	O
43	/	O
44	dt	O
45	max	O
46	.	O

1	Alternating	O
2	proline	B
3	/	I
4	alanine	I
5	sequence	O
6	of	O
7	beta	O
8	B1	O
9	subunit	O
10	originates	O
11	from	O
12	a	O
13	repetitive	O
14	DNA	O
15	sequence	O
16	.	O

1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	sought	O
8	to	O
9	investigate	O
10	whether	O
11	constitutive	O
12	NF	O
13	-	O
14	kappaB	O
15	activity	O
16	in	O
17	chronically	O
18	HIV	O
19	-	O
20	1	O
21	-	O
22	infected	O
23	promonocytic	O
24	U937	O
25	(	O
26	U9	O
27	-	O
28	IIIB	O
29	)	O
30	and	O
31	myeloblastic	O
32	PLB	O
33	-	O
34	985	O
35	(	O
36	PLB	O
37	-	O
38	IIIB	O
39	)	O
40	cells	O
41	affects	O
42	apoptotic	O
43	signaling	O
44	.	O

1	Transcervical	O
2	amnioinfusion	O
3	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	malignant	O
5	melanoma	O
6	of	O
7	soft	O
8	parts	O
9	or	O
10	soft	O
11	tissue	O
12	clear	O
13	cell	O
14	sarcoma	O
15	which	O
16	shares	O
17	t	O
18	(	O
19	12	O
20	;	O
21	22	O
22	)	O
23	chromosome	O
24	translocation	O
25	revealed	O
26	fusion	O
27	of	O
28	EWS	O
29	with	O
30	a	O
31	transcriptional	O
32	factor	O
33	gene	O
34	ATF	O
35	-	O
36	1	O
37	.	O

1	Separation	O
2	of	O
3	malaria	O
4	-	O
5	infected	O
6	erythrocytes	B
7	from	I
8	whole	I
9	blood	I
10	:	I
11	use	I
12	of	I
13	a	O
14	selective	O
15	high	O
16	-	B
17	gradient	I
18	magnetic	I
19	separation	I
20	technique	I
21	.	I

1	[	O
2	Pulmonary	O
3	vascular	O
4	resistance	O
5	(	O
6	PVR	O
7	)	O
8	during	O
9	10	B
10	%	I
11	O2	I
12	-	O
13	PVR	O
14	during	O
15	21	O
16	%	O
17	O2	O
18	/	O
19	PVR	O
20	during	O
21	21	O
22	%	O
23	O2	O
24	]	O
25	x	O
26	100	O
27	was	O
28	termed	O
29	as	O
30	hypoxic	O
31	pulmonary	O
32	vasoconstriction	O
33	(	O
34	HPV	O
35	).	O

1	According	O
2	to	O
3	pilot	O
4	experiments	B
5	which	I
6	considered	I
7	various	I
8	durations	I
9	of	O
10	global	O
11	no	O
12	-	O
13	flow	O
14	ischemia	O
15	ranging	O
16	from	O
17	10	O
18	to	O
19	20	O
20	minutes	O
21	,	O
22	two	O
23	durations	O
24	were	O
25	chosen	O
26	for	B
27	the	I
28	present	I
29	study	I
30	:	I
31	20	O
32	minutes	O
33	(	O
34	group	O
35	20	O
36	)	B
37	in	I
38	which	I
39	ventricular	I
40	fibrillation	O
41	(	B
42	VF	I
43	)	I
44	was	I
45	the	I
46	predominant	I
47	form	O
48	of	O
49	arrhythmias	O
50	,	O
51	and	O
52	18	O
53	minutes	B
54	(	I
55	group	B
56	18	O
57	)	B
58	in	I
59	which	I
60	the	O
61	prevalence	I
62	of	I
63	VF	O
64	was	O
65	markedly	I
66	lower	O
67	despite	O
68	the	O
69	small	O
70	difference	O
71	in	O
72	the	B
73	duration	I
74	of	I
75	ischemia	I
76	.	I

1	Shift	O
2	-	O
3	down	O
4	experiments	O
5	indicated	O
6	that	B
7	the	I
8	10	I
9	(	O
10	4	O
11	)-	O
12	to	O
13	10	O
14	(	O
15	5	O
16	)-	O
17	fold	O
18	reduction	O
19	in	O
20	virus	O
21	yield	O
22	at	O
23	the	O
24	nonpermissive	O
25	temperature	O
26	was	O
27	due	O
28	to	O
29	the	O
30	disfunction	O
31	of	O
32	alpha	O
33	TIF	O
34	late	O
35	in	O
36	infection	O
37	,	O
38	presumably	B
39	in	O
40	virion	B
41	maturation	O
42	.	B

1	Studies	O
2	on	O
3	immunoglobulin	O
4	E	O
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	B
10	sojourn	I
11	with	I
12	Professor	I
13	Dan	O
14	H	O
15	.	O

1	Cat	O
2	-	O
3	1	O
4	is	O
5	identical	O
6	to	O
7	the	O
8	recently	O
9	identified	O
10	binding	O
11	partner	O
12	for	O
13	the	O
14	beta	O
15	-	O
16	adrenergic	O
17	receptor	O
18	kinase	O
19	(	O
20	betaARK	O
21	or	O
22	GRK	O
23	-	O
24	2	O
25	),	O
26	which	O
27	was	O
28	shown	O
29	to	O
30	have	O
31	Arf	O
32	-	O
33	GAP	O
34	activity	O
35	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	differentiation	O
6	of	O
7	neoplastically	O
8	transformed	O
9	cells	O
10	does	O
11	not	O
12	repress	O
13	mitogenic	O
14	responsiveness	O
15	or	O
16	junB	O
17	or	O
18	c	O
19	-	O
20	fos	O
21	inducibility	O
22	.	O

1	Scientific	O
2	cooperation	O
3	of	O
4	CMEA	O
5	member	O
6	countries	O
7	has	O
8	been	O
9	carried	O
10	out	O
11	since	O
12	1974	O
13	under	O
14	the	O
15	sponsorship	O
16	of	O
17	the	O
18	Cancer	O
19	Research	O
20	Institute	O
21	,	O
22	Slovak	O
23	Academy	O
24	of	O
25	Sciences	O
26	(	O
27	Czechoslovakia	O
28	)	O
29	within	O
30	the	O
31	framework	O
32	of	O
33	CMEA	O
34	.	O

1	The	O
2	peroxisome	O
3	biogenesis	O
4	disorders	O
5	(	O
6	PBDs	O
7	)	O
8	are	O
9	a	O
10	set	O
11	of	O
12	lethal	O
13	genetic	O
14	diseases	O
15	characterized	O
16	by	O
17	peroxisomal	O
18	metabolic	O
19	deficiencies	O
20	,	O
21	multisystem	O
22	abnormalities	O
23	,	B
24	mental	I
25	retardation	I
26	,	O
27	and	B
28	premature	I
29	death	I
30	.	O

1	PRH75	O
2	,	O
3	a	O
4	new	O
5	nucleus	O
6	-	O
7	localized	O
8	member	O
9	of	O
10	the	O
11	DEAD	O
12	-	O
13	box	O
14	protein	O
15	family	B
16	from	I
17	higher	I
18	plants	I
19	.	O

1	Identification	O
2	and	O
3	structure	O
4	of	O
5	the	O
6	Marek	O
7	'	O
8	s	O
9	disease	O
10	virus	O
11	serotype	O
12	2	O
13	glycoprotein	O
14	M	O
15	gene	O
16	:	O
17	comparison	O
18	with	O
19	glycoprotein	O
20	M	O
21	genes	O
22	of	O
23	Herpesviridae	O
24	family	O
25	.	O

1	Deregulation	O
2	of	O
3	their	O
4	expression	O
5	may	O
6	contribute	O
7	to	O
8	malignant	O
9	transformation	O
10	associated	O
11	with	O
12	HTLV	O
13	-	O
14	1	O
15	infection	O
16	.	O

1	The	O
2	84	B
3	.	I
4	1C	I
5	mAb	I
6	recognizes	I
7	a	I
8	site	I
9	on	O
10	IgE	B
11	which	I
12	is	O
13	identical	O
14	or	O
15	very	O
16	close	O
17	to	O
18	the	O
19	Fc	O
20	epsilon	O
21	R	O
22	binding	O
23	site	O
24	,	O
25	and	O
26	95	O
27	.	O
28	3	O
29	recognizes	O
30	a	O
31	site	O
32	on	O
33	IgE	O
34	which	O
35	is	O
36	related	O
37	,	O
38	but	O
39	not	O
40	identical	O
41	to	O
42	the	O
43	Fc	O
44	epsilon	O
45	R	O
46	binding	B
47	site	O
48	.	O

1	We	O
2	have	O
3	recently	O
4	shown	O
5	that	B
6	the	I
7	tissue	I
8	-	O
9	specific	O
10	expression	O
11	of	O
12	the	O
13	RAR	O
14	beta	O
15	2	O
16	gene	O
17	in	O
18	mouse	O
19	embryos	O
20	is	O
21	regulated	O
22	at	O
23	the	O
24	translational	O
25	level	O
26	by	O
27	short	O
28	upstream	O
29	open	O
30	reading	O
31	frames	O
32	(	O
33	uORFs	O
34	)	O
35	In	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	Zimmer	O
43	,	O
44	A	O
45	.,	O
46	A	O
47	.	O
48	M	O
49	.	O

1	Esophageal	O
2	brush	O
3	cytological	O
4	screening	O
5	was	O
6	undertaken	O
7	and	O
8	blood	O
9	concentrations	O
10	of	O
11	micronutrients	O
12	(	O
13	vitamin	O
14	A	O
15	,	O
16	E	O
17	,	O
18	B12	O
19	,	O
20	folic	O
21	acid	O
22	and	O
23	methionine	O
24	)	O
25	determined	B
26	from	I
27	adults	O
28	at	B
29	risk	I
30	for	I
31	esophageal	O
32	carcinoma	O
33	(	O
34	EC	O
35	)	O
36	in	O
37	Transkei	O
38	and	O
39	Ciskei	O
40	,	O
41	Southern	O
42	Africa	O
43	.	B

1	Our	O
2	findings	O
3	confirm	O
4	the	O
5	high	O
6	frequency	O
7	of	O
8	proximal	O
9	nerve	O
10	lesions	O
11	in	O
12	early	O
13	GBS	O
14	and	O
15	CIDP	O
16	,	O
17	not	O
18	all	O
19	of	O
20	which	O
21	are	O
22	associated	O
23	with	O
24	distal	O
25	motor	O
26	conduction	O
27	abnormalities	O
28	,	O
29	and	O
30	suggest	O
31	that	O
32	assessment	O
33	of	O
34	multiple	O
35	F	O
36	wave	O
37	parameters	O
38	,	O
39	in	O
40	particular	O
41	chronodispersion	O
42	,	O
43	mean	O
44	latency	O
45	and	O
46	mean	O
47	amplitude	O
48	(	O
49	in	O
50	addition	O
51	to	O
52	absence	O
53	and	O
54	minimum	O
55	latency	O
56	),	O
57	increases	O
58	the	O
59	yield	O
60	of	O
61	F	O
62	wave	O
63	studies	O
64	.	O

1	Here	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	TAFII250	O
8	,	O
9	the	O
10	largest	O
11	subunit	O
12	of	O
13	TFIID	O
14	,	O
15	contains	O
16	two	O
17	tandem	O
18	bromodomain	O
19	modules	O
20	that	O
21	bind	O
22	selectively	O
23	to	O
24	multiply	O
25	acetylated	B
26	histone	I
27	H4	I
28	peptides	O
29	.	O

1	Follow	O
2	-	O
3	up	O
4	controls	O
5	of	O
6	luteinizing	O
7	hormone	O
8	(	O
9	LH	O
10	),	O
11	follicle	O
12	stimulating	O
13	hormone	O
14	(	O
15	FSH	O
16	),	O
17	prolactin	O
18	(	O
19	HPRL	O
20	),	O
21	oestradiol	O
22	(	O
23	E2	O
24	),	O
25	progesterone	O
26	(	O
27	P	O
28	)	O
29	and	O
30	testosterone	O
31	(	O
32	T	O
33	)	O
34	in	O
35	the	O
36	catabolic	O
37	and	O
38	healing	O
39	phase	O
40	of	O
41	burn	O
42	disease	O
43	.	O

1	Triumph	O
2	of	O
3	Leninist	O
4	national	O
5	policy	O

1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	B
7	montoux	B
8	negative	I
9	healthy	I
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	O
24	anti	O
25	bodies	O
26	to	O
27	A60	O
28	antigen	O
29	.	O

1	Alginate	O
2	biosynthesis	O
3	is	O
4	controlled	O
5	by	O
6	a	O
7	complex	O
8	regulatory	O
9	mechanism	O
10	.	O

1	(	O
2	3	O
3	).	O

1	Among	O
2	these	O
3	are	O
4	:	O
5	(	O
6	1	O
7	)	O
8	Is	O
9	there	O
10	sufficient	O
11	understanding	O
12	of	O
13	family	O
14	pathophysiology	O
15	,	O
16	of	O
17	the	O
18	sensitivity	O
19	and	O
20	specificity	O
21	of	O
22	diagnostic	O
23	techniques	O
24	and	O
25	of	O
26	the	O
27	safety	O
28	and	O
29	efficacy	O
30	of	O
31	therapeutic	O
32	modalities	O
33	to	O
34	make	O
35	true	O
36	family	O
37	health	O
38	care	O
39	possible	O
40	?	O
41	(	O
42	2	O
43	)	O
44	If	O
45	this	O
46	type	O
47	of	O
48	care	O
49	is	O
50	possible	O
51	,	O
52	how	O
53	are	O
54	the	O
55	needs	O
56	of	O
57	the	O
58	family	O
59	and	O
60	its	O
61	individual	O
62	members	O
63	met	O
64	,	O
65	or	O
66	value	O
67	judgements	O
68	made	O
69	about	O
70	their	O
71	relative	O
72	importance	O
73	?	O
74	and	O
75	(	O
76	3	O
77	)	O
78	What	O
79	are	O
80	the	O
81	consequences	O
82	for	O
83	the	O
84	health	O
85	care	O
86	delivery	O
87	system	O
88	of	O
89	this	O
90	type	O
91	of	O
92	care	O
93	?	O
94	An	O
95	extensive	O
96	literature	O
97	review	O
98	is	O
99	used	O
100	in	O
101	an	O
102	attempt	O
103	to	O
104	answer	O
105	these	O
106	queries	O
107	,	O
108	from	O
109	which	O
110	questions	O
111	for	O
112	further	O
113	study	O
114	are	O
115	posed	O
116	.	O

1	Anoxia	O
2	was	O
3	introduced	O
4	by	O
5	perfusing	O
6	the	O
7	gill	O
8	with	O
9	water	O
10	deprived	O
11	of	O
12	oxygen	O
13	or	O
14	by	O
15	halting	O
16	the	O
17	water	O
18	flow	O
19	to	O
20	the	O
21	gill	O
22	.	O

1	Lengthy	O
2	and	O
3	repeated	O
4	hemodialyses	O
5	were	O
6	required	O
7	to	O
8	lower	O
9	lithemia	O
10	to	O
11	nontoxic	O
12	ranges	B
13	.	I

1	A	O
2	mutational	O
3	analysis	O
4	has	O
5	resolved	O
6	a	O
7	region	O
8	of	O
9	seven	O
10	amino	O
11	acids	O
12	(	B
13	amino	I
14	acids	O
15	26	O
16	-	O
17	32	O
18	)	O
19	in	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	of	O
25	Bob1	O
26	that	O
27	are	O
28	important	O
29	for	O
30	contacting	O
31	the	O
32	DNA	O
33	binding	O
34	POU	O
35	domain	O
36	of	O
37	Oct	O
38	-	O
39	1	O
40	or	O
41	Oct	O
42	-	O
43	2	O
44	.	O

1	The	O
2	rear	O
3	silver	O
4	liquid	O
5	chamber	O
6	was	O
7	threefold	O
8	thick	O
9	to	O
10	17	O
11	MeV	B
12	protons	B
13	in	I
14	water	O
15	and	B
16	it	B
17	efficiently	I
18	produced	O
19	either	O
20	13N	O
21	by	O
22	the	O
23	16O	O
24	(	O
25	p	O
26	,	O
27	alpha	O
28	)	O
29	13N	O
30	reaction	O
31	or	O
32	[	O
33	18F	O
34	]	O
35	fluoride	O
36	ion	O
37	by	O
38	the	O
39	18O	O
40	(	O
41	p	O
42	,	O
43	n	O
44	)	O
45	18F	O
46	reaction	O
47	.	B

1	As	O
2	in	O
3	S	O
4	.	O
5	cerevisiae	O
6	,	O
7	the	O
8	sequence	O
9	of	O
10	rhp51	O
11	+	O
12	showed	O
13	two	O
14	MluI	O
15	cell	O
16	-	O
17	cycle	O
18	boxes	O
19	and	O
20	a	O
21	putative	O
22	DNA	O
23	damage	O
24	-	O
25	responsive	O
26	element	O
27	in	O
28	its	O
29	upstream	O
30	region	O
31	.	O

1	Recombinant	O
2	Ffh	O
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	B
11	degreesC	I
12	.	I

1	Thus	O
2	,	O
3	the	O
4	system	O
5	can	O
6	be	B
7	used	I
8	to	I
9	detect	I
10	and	O
11	study	O
12	dynamic	O
13	perfusion	O
14	changes	O
15	from	O
16	the	O
17	brain	O
18	surface	O
19	with	O
20	minimal	B
21	tissue	I
22	damage	I
23	.	I

1	Liver	O
2	regional	O
3	blood	O
4	volume	O
5	(	O
6	LRBV	O
7	)	O
8	is	O
9	altered	O
10	by	O
11	several	O
12	disease	B
13	states	I
14	and	I
15	various	I
16	drugs	I
17	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	B
5	signature	I
6	-	I
7	tagged	O
8	mutagenesis	O
9	is	O
10	a	O
11	viable	O
12	approach	O
13	to	O
14	identify	O
15	bacterial	O
16	genes	O
17	associated	O
18	with	O
19	the	O
20	ability	O
21	to	O
22	infect	O
23	the	O
24	urinary	O
25	tract	O
26	.	O

1	Protein	O
2	cHMGI	B
3	binds	I
4	preferentially	O
5	to	O
6	AT	O
7	-	O
8	rich	O
9	DNA	O
10	with	O
11	a	O
12	half	O
13	-	O
14	saturation	O
15	value	O
16	of	B
17	1	I
18	.	I
19	1	I
20	nM	I
21	.	I

1	The	O
2	study	O
3	goals	O
4	were	O
5	to	O
6	isolate	O
7	a	O
8	full	B
9	-	I
10	length	I
11	clone	I
12	encoding	I
13	CO	O
14	-	B
15	Ag	I
16	from	I
17	a	I
18	bovine	I
19	corneal	I
20	cDNA	O
21	library	O
22	and	O
23	to	O
24	express	O
25	this	O
26	clone	O
27	in	O
28	Escherichia	O
29	coli	O
30	(	O
31	E	O
32	.	O
33	coli	O
34	).	O

1	The	O
2	patients	O
3	are	O
4	two	O
5	healthy	O
6	adult	O
7	males	O
8	.	O

1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	36K	O
8	protein	O
9	and	O
10	known	B
11	structures	B
12	of	I
13	proteins	O
14	.	B

1	Thus	O
2	,	O
3	as	O
4	expected	O
5	,	O
6	trans	O
7	-	O
8	splicing	O
9	depends	O
10	on	O
11	the	O
12	integrity	O
13	of	O
14	U2	O
15	,	O
16	U4	O
17	,	O
18	and	O
19	U6	O
20	snRNAs	O
21	.	O

1	Drosophila	O
2	orthodenticle	O
3	(	O
4	otd	O
5	)	O
6	and	O
7	murine	O
8	Otx	O
9	genes	O
10	exemplify	O
11	this	O
12	,	O
13	both	O
14	in	O
15	terms	O
16	of	O
17	expression	O
18	patterns	O
19	and	O
20	mutant	O
21	phenotypes	O
22	.	O

1	A	O
2	decamer	O
3	sequence	O
4	,	O
5	5	O
6	'-	O
7	CGA	O
8	-	O
9	CCCCUCC	O
10	-	O
11	3	O
12	',	O
13	complementary	O
14	to	O
15	a	O
16	conserved	O
17	sequence	O
18	adjacent	O
19	to	O
20	the	O
21	enzymatic	O
22	cleavage	O
23	site	O
24	on	O
25	the	O
26	mitochondrial	O
27	RNA	O
28	substrate	O
29	,	O
30	is	O
31	present	O
32	in	O
33	the	O
34	RNAase	O
35	MRP	O
36	RNA	O
37	.	O

1	Results	O
2	from	O
3	the	O
4	mechanism	O
5	study	O
6	have	O
7	revealed	O
8	that	O
9	YY1	B
10	is	I
11	able	I
12	to	I
13	inhibit	O
14	transactivation	O
15	mediated	O
16	by	O
17	either	O
18	AP1	O
19	or	O
20	the	O
21	Sp1	O
22	-	O
23	related	O
24	protein	O
25	,	O
26	and	O
27	YY1	O
28	suppressive	O
29	activity	O
30	is	O
31	DNA	O
32	binding	O
33	dependent	O
34	.	O

1	The	O
2	actuarial	O
3	local	O
4	control	O
5	rates	O
6	at	O
7	10	O
8	years	O
9	for	O
10	the	O
11	three	O
12	treatment	O
13	groups	O
14	were	O
15	as	O
16	follows	O
17	:	O
18	subtotal	O
19	excision	O
20	alone	O
21	,	O
22	18	O
23	%;	O
24	subtotal	O
25	excision	O
26	plus	O
27	postoperative	O
28	radiation	O
29	therapy	O
30	,	O
31	82	O
32	%;	O
33	and	O
34	total	O
35	excision	O
36	alone	O
37	,	O
38	77	O
39	%.	O

1	The	O
2	resulting	O
3	clone	O
4	pKB11	O
5	,	O
6	which	O
7	has	B
8	a	I
9	1369	I
10	-	I
11	base	I
12	pair	I
13	(	I
14	bp	I
15	)	I
16	cDNA	O
17	insert	B
18	,	B
19	overlapping	I
20	pCAD142	I
21	by	I
22	781	I
23	bp	I
24	,	O
25	was	O
26	identified	B
27	by	O
28	hybridization	O
29	methods	O
30	and	O
31	sequence	O
32	analysis	O
33	and	O
34	found	O
35	to	O
36	contain	O
37	the	O
38	entire	O
39	cDNA	O
40	sequence	O
41	for	I
42	the	O
43	amino	O
44	end	I
45	of	I
46	the	O
47	CAD	I
48	polypeptide	I
49	.	I

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'	O
7	flanking	B
8	region	I
9	revealed	I
10	several	I
11	GC	I
12	boxes	O
13	but	B
14	no	B
15	identifiable	I
16	TATA	O
17	box	B
18	.	I

1	Ras2p	O
2	activates	O
3	invasive	O
4	growth	O
5	using	O
6	either	O
7	of	O
8	two	O
9	downstream	O
10	signaling	O
11	pathways	O
12	,	O
13	the	O
14	filamentation	O
15	MAPK	O
16	(	O
17	Cdc42p	O
18	/	O
19	Ste20p	O
20	/	O
21	MAPK	O
22	)	O
23	cascade	O
24	or	O
25	the	O
26	cAMP	O
27	-	O
28	dependent	O
29	protein	O
30	kinase	O
31	(	O
32	Cyr1p	O
33	/	O
34	cAMP	O
35	/	O
36	PKA	O
37	)	O
38	pathway	O
39	.	O

1	Substrate	O
2	specificity	O
3	of	O
4	the	O
5	RNase	O
6	activity	O
7	of	O
8	yeast	O
9	RNA	O
10	polymerase	O
11	III	O
12	.	O

1	We	O
2	investigated	O
3	the	O
4	diagnostic	O
5	value	O
6	of	O
7	a	O
8	new	O
9	in	O
10	vitro	O
11	test	O
12	,	O
13	Pharmacia	O
14	CAP	O
15	System	O
16	(	O
17	Pharmacia	O
18	Diagnostics	O
19	AB	O
20	,	O
21	Uppsala	O
22	,	O
23	Sweden	O
24	),	O
25	for	O
26	the	O
27	quantitative	O
28	measurement	O
29	of	O
30	allergen	O
31	-	O
32	specific	O
33	IgE	O
34	antibodies	O
35	by	O
36	comparison	O
37	with	O
38	RAST	O
39	in	O
40	2	O
41	groups	O
42	of	O
43	patients	O
44	,	O
45	71	O
46	atopic	O
47	and	O
48	48	O
49	non	O
50	-	O
51	atopic	O
52	.	O

1	Using	O
2	the	O
3	yeast	O
4	one	O
5	-	O
6	hybrid	O
7	screen	O
8	with	O
9	integrated	O
10	NRE	O
11	and	O
12	flanking	O
13	DNA	O
14	as	O
15	bait	O
16	,	O
17	the	O
18	predominant	O
19	clone	O
20	obtained	O
21	was	O
22	bovine	O
23	Nrl	O
24	.	O

1	All	O
2	clinical	O
3	isolates	O
4	were	O
5	concomitantly	O
6	tested	O
7	by	O
8	disk	O
9	diffusion	O
10	and	O
11	agar	O
12	dilution	O
13	procedures	O
14	as	O
15	outlined	O
16	by	O
17	the	O
18	National	O
19	Committee	O
20	for	O
21	Clinical	O
22	Laboratory	O
23	Standards	O
24	.	I

1	Here	O
2	,	O
3	we	O
4	describe	O
5	the	O
6	isolation	O
7	of	O
8	bovine	O
9	and	O
10	rat	O
11	GHF	O
12	-	O
13	1	O
14	cDNA	O
15	clones	O
16	.	O

1	The	O
2	DNase	O
3	I	O
4	footprint	O
5	extended	O
6	5	O
7	'	O
8	in	O
9	the	O
10	silencer	O
11	region	O
12	to	O
13	include	O
14	an	O
15	inverted	O
16	repeat	O
17	of	O
18	a	O
19	six	O
20	-	O
21	nucleotide	O
22	motif	O
23	(	O
24	epsilon	O
25	-	O
26	267	O
27	to	O
28	-	O
29	278	O
30	bp	O
31	)	O
32	which	O
33	shares	O
34	5	O
35	of	O
36	6	O
37	bases	O
38	with	O
39	the	O
40	GATA	O
41	-	O
42	1	O
43	consensus	O
44	sequence	O
45	.	O

1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	O
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O

1	Time	O
2	-	O
3	activity	O
4	curves	O
5	from	B
6	the	I
7	gastric	O
8	region	B
9	of	I
10	interest	I
11	were	I
12	used	I
13	,	O
14	after	O
15	subjection	O
16	to	O
17	appropriate	O
18	corrective	O
19	procedures	O
20	,	O
21	to	O
22	calculate	O
23	the	O
24	mean	O
25	gastric	O
26	transit	O
27	time	O
28	(	O
29	MTT	O
30	90	O
31	)	O
32	and	O
33	the	O
34	fraction	O
35	of	O
36	the	O
37	test	O
38	meal	O
39	retained	O
40	in	O
41	the	B
42	stomach	B
43	after	O
44	90	B
45	min	I
46	(	I
47	F90	I
48	).	O

1	Three	O
2	group	O
3	1	O
4	patients	O
5	developed	O
6	CMV	O
7	disease	O
8	;	O
9	1	O
10	group	B
11	2	I
12	patient	I
13	developed	I
14	CMV	I
15	hepatitis	I
16	.	I

1	Examination	O
2	of	O
3	immediate	O
4	-	O
5	early	O
6	transcription	O
7	factor	O
8	expression	O
9	during	O
10	the	O
11	MDI	O
12	regimen	O
13	revealed	O
14	that	O
15	RA	O
16	mediated	O
17	an	O
18	elevated	O
19	,	O
20	prolonged	O
21	expression	O
22	of	O
23	c	O
24	-	O
25	Jun	O
26	mRNA	O
27	accompanied	O
28	by	O
29	diminished	O
30	expression	O
31	of	O
32	c	O
33	-	O
34	Fos	O
35	and	O
36	Jun	O
37	-	O
38	B	O
39	mRNAs	O
40	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	PecS	O
9	attenuates	O
10	pelD	O
11	and	O
12	pelE	O
13	expression	O
14	rather	O
15	than	O
16	acting	O
17	as	O
18	a	O
19	true	O
20	repressor	O
21	like	O
22	KdgR	O
23	.	O

1	The	O
2	two	O
3	IL6	O
4	mRNA	O
5	species	O
6	are	O
7	generated	O
8	by	O
9	alternative	O
10	polyadenylation	O
11	at	O
12	sites	O
13	separated	O
14	by	O
15	a	O
16	distance	O
17	of	O
18	1	O
19	.	O
20	2	O
21	kilobases	O
22	.	O

1	SAECG	O
2	,	O
3	echocardiography	O
4	and	O
5	thallium	O
6	-	O
7	201	O
8	imaging	O
9	were	O
10	performed	O
11	before	O
12	and	O
13	1	O
14	month	O
15	after	O
16	attempted	O
17	angioplasty	O
18	.	O

1	When	O
2	CSF	O
3	[	O
4	HCO3	O
5	-]	O
6	is	O
7	shown	O
8	as	O
9	a	O
10	function	O
11	of	O
12	CSF	O
13	PCO2	O
14	the	O
15	data	O
16	of	O
17	K	O
18	-	O
19	depleted	O
20	rats	O
21	are	O
22	no	O
23	longer	O
24	displaced	O
25	when	O
26	compared	O
27	to	O
28	controls	O
29	but	O
30	still	O
31	have	O
32	a	O
33	significantly	O
34	greater	O
35	slope	O
36	(	O
37	1	O
38	.	O
39	21	O
40	+/-	O
41	0	O
42	.	O
43	23	O
44	vs	O
45	.	O

1	We	O
2	have	O
3	identified	O
4	in	O
5	the	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	of	O
11	the	O
12	Drosophila	O
13	copia	O
14	retrotransposon	O
15	,	O
16	3	O
17	'	O
18	to	O
19	the	O
20	left	O
21	LTR	O
22	,	O
23	a	O
24	sequence	O
25	for	O
26	transcriptional	O
27	regulation	O
28	by	O
29	homeoproteins	O
30	.	O

1	This	O
2	lack	O
3	of	O
4	correlation	B
5	may	I
6	be	I
7	due	I
8	to	O
9	variations	O
10	in	O
11	the	O
12	metabolic	O
13	activity	O
14	of	O
15	the	O
16	endometriotic	O
17	implants	O
18	present	O
19	at	O
20	different	O
21	stages	O
22	of	O
23	the	O
24	disease	O
25	.	O

1	Apart	O
2	from	O
3	two	O
4	proline	O
5	-	O
6	rich	O
7	regions	B
8	(	I
9	amino	I
10	acids	I
11	1	I
12	-	I
13	117	I
14	and	I
15	239	I
16	-	I
17	270	I
18	),	I
19	p230	I
20	contains	I
21	a	O
22	very	O
23	high	O
24	frequency	O
25	of	O
26	heptad	O
27	repeats	O
28	,	O
29	characteristic	O
30	of	O
31	alpha	O
32	-	O
33	helices	O
34	that	O
35	form	O
36	dimeric	O
37	coiled	O
38	-	O
39	coil	O
40	structures	O
41	.	O
42	p230	O
43	also	O
44	includes	I
45	the	O
46	sequence	O
47	ESLALEELEL	O
48	(	I
49	amino	O
50	acids	O
51	538	O
52	-	O
53	546	O
54	),	O
55	a	O
56	motif	I
57	found	O
58	in	O
59	the	O
60	granin	O
61	family	I
62	of	I
63	acidic	I
64	proteins	I
65	present	I
66	in	I
67	secretory	I
68	granules	I
69	of	O
70	neuroendocrine	O
71	cells	O
72	.	O

1	The	O
2	strategies	O
3	by	O
4	which	O
5	hepatitis	B
6	B	I
7	and	I
8	hepatitis	O
9	D	O
10	can	O
11	be	O
12	diminished	O
13	and	O
14	eventually	O
15	eliminated	O
16	are	O
17	:	O
18	immunization	O
19	,	O
20	measures	O
21	to	O
22	prevent	O
23	exposure	O
24	to	O
25	infective	O
26	blood	O
27	or	O
28	blood	O
29	derivatives	O
30	and	O
31	education	O
32	(	O
33	in	O
34	particular	O
35	awareness	O
36	that	O
37	hepatitis	O
38	B	B
39	is	O
40	a	B
41	sexually	B
42	transmitted	I
43	disease	O
44	).	O

1	A	O
2	total	O
3	number	O
4	of	O
5	1628	O
6	cases	O
7	were	O
8	collected	O
9	from	O
10	135	O
11	medical	O
12	institutions	O
13	.	O

1	The	O
2	intron	O
3	8	O
4	enhancer	O
5	region	O
6	was	O
7	not	O
8	activated	O
9	by	O
10	GATA	O
11	-	O
12	1	O
13	together	O
14	with	O
15	Sp1	O
16	in	O
17	transactivation	O
18	experiments	O
19	in	O
20	COS	O
21	-	O
22	1	O
23	cells	O
24	indicating	O
25	the	O
26	involvement	O
27	of	O
28	a	O
29	related	O
30	Sp1	O
31	protein	O
32	or	O
33	of	O
34	another	O
35	unidentified	O
36	erythroid	O
37	factor	O
38	.	O

1	Southwestern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	this	O
7	phosphoprotein	O
8	can	O
9	bind	O
10	the	O
11	kappa	O
12	B	O
13	element	O
14	directly	O
15	and	O
16	specifically	O
17	.	O

1	This	O
2	machine	O
3	drift	O
4	,	O
5	which	O
6	was	O
7	not	O
8	associated	O
9	with	O
10	a	O
11	rise	O
12	in	B
13	water	I
14	phantom	I
15	temperature	I
16	and	I
17	did	I
18	not	I
19	consistently	I
20	correlate	O
21	with	O
22	estimated	O
23	x	O
24	-	O
25	ray	O
26	tube	O
27	heat	O
28	,	O
29	could	O
30	result	O
31	in	O
32	a	O
33	significant	O
34	overestimation	O
35	of	O
36	regional	O
37	cerebral	O
38	blood	O
39	flow	O
40	(	O
41	rCBF	O
42	)	O
43	for	O
44	a	O
45	xenon	O
46	/	O
47	CT	O
48	rCBF	O
49	protocol	O
50	involving	O
51	5	O
52	-	B
53	7	O
54	sequential	O
55	scans	O
56	obtained	O
57	at	O
58	1	O
59	-	O
60	min	O
61	interscan	O
62	intervals	O
63	.	O

1	Effects	O
2	of	O
3	a	O
4	low	O
5	-	O
6	energy	O
7	laser	O
8	beam	O
9	on	O
10	the	O
11	cells	O
12	of	O
13	the	O
14	newt	O
15	embryo	O

1	However	O
2	,	O
3	kidneys	O
4	perfused	O
5	for	O
6	72	O
7	hr	O
8	demonstrated	O
9	more	O
10	similar	O
11	renal	O
12	functions	O
13	when	O
14	tested	O
15	by	O
16	either	O
17	IMPK	O
18	or	O
19	IBPK	O
20	.	O

1	Effects	O
2	of	O
3	a	O
4	selective	O
5	monoamine	O
6	oxidase	O
7	(	O
8	MAO	O
9	)--	O
10	A	O
11	inhibitor	O
12	,	O
13	clorgyline	O
14	,	O
15	a	O
16	selective	O
17	MAO	O
18	-	O
19	B	O
20	inhibitor	O
21	,	B
22	deprenyl	I
23	,	I
24	and	I
25	a	O
26	non	O
27	-	O
28	selective	O
29	MAO	O
30	inhibitor	O
31	,	O
32	nialamide	O
33	,	O
34	were	O
35	investigated	O
36	on	O
37	footshock	O
38	-	O
39	induced	O
40	aggression	O
41	(	O
42	FIA	O
43	)	O
44	in	O
45	paired	O
46	rats	O
47	.	O

1	A	O
2	limiting	O
3	factor	O
4	were	O
5	disturbances	O
6	in	O
7	the	O
8	system	O
9	of	O
10	energy	O
11	transport	B
12	(	I
13	creatine	I
14	phosphate	O
15	,	B
16	creatine	I
17	phosphokinase	I
18	)	I
19	and	I
20	of	I
21	the	I
22	calcium	I
23	pump	O
24	(	B
25	Ca	I
26	++-	I
27	ATPase	O
28	of	O
29	the	O
30	sarcoplasmic	O
31	reticulum	O
32	,	O
33	SPR	O
34	),	B
35	which	I
36	evidently	I
37	led	O
38	to	O
39	a	B
40	decrease	I
41	of	I
42	the	O
43	inotropic	O
44	properties	O
45	of	O
46	the	O
47	myocardium	O
48	at	O
49	70	O
50	%	O
51	restriction	O
52	of	B
53	coronary	B
54	blood	I
55	flow	O
56	.	O

1	Martin	O
2	Luther	O
3	and	B
4	his	I
5	physicians	I
6	.	I

1	1	O
2	.	O

1	A	O
2	developmentally	O
3	modulated	O
4	chromatin	O
5	structure	O
6	at	O
7	the	O
8	mouse	O
9	immunoglobulin	O
10	kappa	O
11	3	O
12	'	O
13	enhancer	O
14	.	O

1	The	O
2	COOH	O
3	-	O
4	terminus	O
5	of	O
6	this	O
7	new	O
8	isoform	O
9	,	O
10	which	O
11	we	O
12	designate	O
13	beta	O
14	4	O
15	,	O
16	lacks	O
17	a	O
18	22	O
19	amino	O
20	acid	O
21	lysine	O
22	-	O
23	rich	O
24	sequence	O
25	common	O
26	to	O
27	both	O
28	the	O
29	human	O
30	red	O
31	cell	O
32	alpha	O
33	-	O
34	and	O
35	beta	O
36	-	O
37	adducin	O
38	subunits	O
39	and	O
40	homologous	O
41	to	O
42	a	O
43	highly	O
44	conserved	O
45	region	O
46	in	O
47	MARCKS	O
48	,	O
49	a	O
50	filamentous	O
51	actin	O
52	-	O
53	cross	O
54	linking	O
55	protein	O
56	regulated	O
57	by	O
58	protein	O
59	kinase	O
60	C	O
61	and	O
62	calcium	O
63	/	O
64	calmodulin	O
65	.	O
66	beta	O
67	4	O
68	-	O
69	adducin	O
70	preserves	O
71	a	O
72	previously	O
73	identified	O
74	calmodulin	O
75	binding	O
76	domain	O
77	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	microinjection	O
6	of	O
7	an	O
8	anti	O
9	-	O
10	CBP	O
11	antiserum	O
12	into	O
13	fibroblasts	O
14	can	O
15	inhibit	O
16	transcription	O
17	from	O
18	a	O
19	cAMP	O
20	responsive	O
21	promoter	O
22	.	O

1	Joys	O
2	and	O
3	F	O
4	.	O

1	RESULT	O
2	(	O
3	S	O
4	):	O
5	In	O
6	patients	O
7	with	O
8	elevated	O
9	FSH	O
10	levels	O
11	on	O
12	cycle	O
13	day	B
14	3	I
15	,	I
16	a	O
17	low	O
18	oocyte	O
19	yield	O
20	was	O
21	achieved	O
22	(	O
23	7	B
24	versus	I
25	11	I
26	)	I
27	and	I
28	a	I
29	high	I
30	number	I
31	of	I
32	ampules	I
33	of	O
34	hMG	O
35	was	O
36	necessary	O
37	(	O
38	56	O
39	versus	O
40	33	O
41	).	O

1	The	O
2	"	O
3	28	O
4	percent	O
5	"	O
6	Venturi	O
7	mask	O
8	in	O
9	obstructive	O
10	airway	O
11	disease	O
12	.	O

1	S	O
2	.,	O
3	Kim	O
4	,	O
5	S	O
6	.	O

1	Practical	O
2	use	O
3	and	O
4	interpretation	O
5	of	O
6	viral	O
7	hepatitis	O
8	B	O
9	markers	O
10	and	O
11	hepatic	O
12	biopsy	O
13	in	O
14	HBs	O
15	Ag	O
16	carriers	O
17	and	O
18	at	O
19	the	B
20	chronic	I
21	hepatitis	I
22	stage	I

1	The	O
2	number	O
3	of	O
4	muricidal	O
5	rats	O
6	increased	O
7	with	O
8	increase	O
9	in	O
10	the	O
11	duration	O
12	of	O
13	Cd	O
14	administration	O
15	in	O
16	association	O
17	with	O
18	greater	O
19	accumulation	O
20	of	O
21	Cd	O
22	in	O
23	the	O
24	olfactory	O
25	bulb	O
26	than	O
27	in	O
28	any	O
29	other	O
30	region	O
31	of	O
32	the	O
33	brain	O
34	.	O

1	Patients	O
2	with	O
3	types	O
4	I	O
5	and	O
6	III	O
7	MPGN	O
8	did	O
9	not	O
10	differ	O
11	in	O
12	age	O
13	at	O
14	apparent	O
15	onset	O
16	,	O
17	age	O
18	at	O
19	diagnosis	O
20	,	O
21	or	O
22	interval	O
23	from	O
24	apparent	O
25	onset	O
26	of	O
27	symptoms	O
28	to	O
29	diagnosis	O
30	(	O
31	biopsy	O
32	).	O

1	Conversely	O
2	,	O
3	treatment	O
4	of	O
5	human	O
6	protein	O
7	-	O
8	tyrosine	O
9	phosphatase	O
10	alpha	O
11	-	O
12	overexpressing	O
13	cells	O
14	with	O
15	phenylarsine	O
16	oxide	O
17	led	O
18	to	O
19	a	O
20	loss	O
21	of	O
22	the	B
23	constitutive	I
24	NF	I
25	-	I
26	kappa	I
27	B	I
28	activity	I
29	.	I

1	However	O
2	,	O
3	when	O
4	a	O
5	second	O
6	,	O
7	upstream	O
8	IRE	O
9	-	O
10	like	O
11	sequence	O
12	was	O
13	evaluated	O
14	by	O
15	EMSA	O
16	,	O
17	a	O
18	DNA	O
19	binding	O
20	pattern	O
21	distinct	O
22	from	O
23	that	O
24	seen	O
25	following	O
26	exposure	O
27	to	O
28	IFN	O
29	-	O
30	gamma	O
31	alone	O
32	was	O
33	observed	O
34	after	O
35	prolonged	O
36	stimulation	O
37	with	O
38	both	O
39	IFN	O
40	-	O
41	alpha	O
42	and	O
43	IFN	O
44	-	O
45	gamma	O
46	.	O

1	The	O
2	Italian	O
3	Lung	O
4	Cancer	O
5	Task	O
6	Force	B
7	(	I
8	FONICAP	I
9	).	I

1	We	O
2	conclude	B
3	from	I
4	this	I
5	study	O
6	that	O
7	Arix	O
8	and	O
9	NBPhox	O
10	exhibit	O
11	indistinguishable	O
12	and	O
13	independent	O
14	transcriptional	O
15	regulatory	B
16	properties	I
17	on	I
18	the	I
19	DBH	I
20	promoter	O
21	.	O

1	We	O
2	show	O
3	,	O
4	by	O
5	injection	O
6	of	O
7	synthetic	O
8	mRNAs	O
9	,	O
10	that	O
11	the	O
12	cis	O
13	-	O
14	acting	O
15	sequences	O
16	responsible	O
17	for	O
18	repression	O
19	of	O
20	cyclin	O
21	B1	O
22	mRNA	O
23	reside	O
24	within	O
25	its	O
26	3	O
27	'	O
28	UTR	O
29	.	O

1	As	O
2	no	O
3	complete	O
4	PPARgamma	O
5	antagonists	O
6	have	O
7	been	O
8	described	O
9	hitherto	O
10	,	O
11	we	O
12	have	O
13	constructed	O
14	a	O
15	dominant	O
16	-	O
17	negative	O
18	mutant	O
19	receptor	B
20	to	B
21	inhibit	I
22	wild	O
23	-	O
24	type	O
25	PPARgamma	O
26	action	O
27	.	O

1	Wnt	O
2	-	O
3	1	O
4	overexpression	O
5	in	O
6	mammary	O
7	epithelial	O
8	cells	B
9	induced	I
10	cyclin	I
11	D1	I
12	mRNA	I
13	and	O
14	targeted	O
15	overexpression	B
16	of	I
17	Wnt	I
18	-	O
19	1	O
20	in	O
21	the	O
22	mammary	O
23	gland	O
24	of	O
25	transgenic	O
26	mice	O
27	increased	O
28	both	O
29	ILK	O
30	activity	O
31	and	O
32	cyclin	O
33	D1	O
34	levels	O
35	.	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	O
11	and	O
12	cdc14	O
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	Because	O
2	of	O
3	the	O
4	operon	O
5	structure	O
6	of	O
7	this	O
8	organism	O
9	,	O
10	traditional	O
11	methods	O
12	such	O
13	as	O
14	insertional	O
15	mutagenesis	O
16	run	O
17	the	O
18	risk	O
19	of	O
20	introducing	O
21	polar	O
22	effects	O
23	on	O
24	downstream	O
25	genes	O
26	or	O
27	creating	O
28	secondary	O
29	mutations	O
30	elsewhere	O
31	in	O
32	the	O
33	genome	O
34	.	O

1	Two	O
2	patients	O
3	withdrew	O
4	from	O
5	therapy	O
6	,	O
7	one	O
8	for	B
9	personal	I
10	reasons	I
11	and	O
12	one	O
13	because	O
14	a	O
15	paraspinal	B
16	mass	I
17	developed	O
18	.	O

1	Digestion	O
2	of	O
3	NF	O
4	-	O
5	IL6	O
6	with	O
7	endoprotease	O
8	Asp	O
9	-	O
10	N	O
11	produced	O
12	a	O
13	domain	O
14	smaller	O
15	than	O
16	the	O
17	TCD	O
18	(	O
19	NF	O
20	-	O
21	IL6	O
22	bZIP	O
23	domains	O
24	(	O
25	NFBD	B
26	)	I
27	(	I
28	272	O
29	-	O
30	345	O
31	)),	O
32	a	B
33	domain	I
34	identified	I
35	either	O
36	in	O
37	the	O
38	absence	O
39	or	O
40	the	O
41	presence	O
42	of	O
43	DNA	O
44	.	O

1	The	O
2	RNA	O
3	transcripts	O
4	structurally	O
5	equivalent	O
6	to	O
7	I	O
8	(	B
9	2	I
10	)	I
11	sgRNAs	I
12	of	I
13	TMV	I
14	U1	I
15	and	O
16	crTMV	O
17	,	O
18	but	O
19	containing	O
20	a	O
21	hairpin	O
22	structure	O
23	(	O
24	H	O
25	)	O
26	immediately	O
27	upstream	O
28	of	O
29	IRES	O
30	(	O
31	MP	O
32	,	O
33	75	O
34	)	O
35	(	O
36	HIRES	O
37	(	O
38	MP	O
39	),	O
40	(	O
41	75	O
42	)(	O
43	CR	O
44	)-	B
45	MP	O
46	-	I
47	CP	O
48	-	I
49	3	O
50	'	O
51	UTR	O
52	;	O
53	HIRES	O
54	(	O
55	MP	O
56	,	O
57	75	O
58	)(	I
59	U1	B
60	)-	O
61	MP	O
62	-	I
63	CP	I
64	-	I
65	3	I
66	'	I
67	UTR	O
68	),	O
69	were	O
70	able	O
71	to	O
72	express	O
73	the	O
74	MP	O
75	gene	O
76	in	B
77	vitro	O
78	.	O

1	This	O
2	is	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	proposing	O
8	that	O
9	SSV	O
10	was	O
11	generated	O
12	by	O
13	recombination	O
14	between	O
15	proviral	O
16	DNA	O
17	of	O
18	a	O
19	simian	O
20	sarcoma	O
21	associated	O
22	virus	O
23	and	O
24	proto	O
25	-	O
26	sis	O
27	and	O
28	that	O
29	introns	O
30	were	O
31	spliced	O
32	out	O
33	subsequently	O
34	from	O
35	a	O
36	fused	O
37	viral	O
38	-	O
39	sis	O
40	messenger	O
41	RNA	B
42	.	I

1	Human	O
2	Duo	O
3	contains	O
4	a	O
5	guanine	O
6	nucleotide	O
7	exchange	O
8	factor	O
9	(	O
10	GEF	O
11	)	O
12	domain	O
13	that	O
14	is	O
15	likely	O
16	to	O
17	be	O
18	rac1	O
19	-	O
20	specific	O
21	,	O
22	a	O
23	pleckstrin	O
24	homology	O
25	(	O
26	PH	O
27	)	O
28	domain	O
29	and	O
30	spectrin	O
31	-	O
32	like	O
33	repeat	O
34	units	O
35	.	O

1	MCh	O
2	infusion	O
3	caused	O
4	a	O
5	concentration	O
6	-	O
7	dependent	O
8	increase	O
9	in	O
10	airway	O
11	resistance	O
12	at	O
13	constant	O
14	QBA	O
15	.	O

1	Linkage	O
2	studies	O
3	have	O
4	shown	O
5	locus	O
6	heterogeneity	O
7	with	O
8	one	O
9	TSC	O
10	gene	O
11	mapped	O
12	to	O
13	chromosome	O
14	9q34	O
15	and	O
16	a	O
17	second	O
18	to	O
19	16p13	O
20	.	O
21	3	O
22	.	O

1	In	O
2	the	O
3	case	O
4	of	O
5	the	O
6	unspliceable	O
7	intron	O
8	,	B
9	repression	I
10	of	I
11	luciferase	O
12	expression	B
13	likely	I
14	involved	I
15	two	O
16	AUF1	O
17	-	O
18	binding	O
19	sequences	O
20	,	O
21	since	O
22	luciferase	O
23	expression	O
24	was	O
25	increased	O
26	by	O
27	deletion	O
28	of	O
29	these	O
30	sites	O
31	.	O

1	Analysis	O
2	of	O
3	hematopoietic	O
4	growth	O
5	factor	O
6	prescriptions	B
7	in	I
8	19	I
9	french	O
10	cancer	O
11	centers	O

1	Ectopic	O
2	expression	O
3	of	B
4	d	I
5	-	I
6	axin	I
7	inhibited	I
8	Wingless	I
9	signaling	I
10	.	O

1	IFN	O
2	-	O
3	stimulated	O
4	gene	O
5	factor	O
6	-	O
7	3	O
8	and	O
9	STAT1	O
10	homodimers	B
11	formed	I
12	and	I
13	bound	O
14	an	O
15	IFN	O
16	-	O
17	stimulated	B
18	response	I
19	element	O
20	(	O
21	ISRE	O
22	)	O
23	and	O
24	gamma	O
25	-	O
26	activated	O
27	sequence	O
28	(	O
29	GAS	O
30	)	O
31	element	O
32	,	O
33	respectively	O
34	.	O

1	Preflight	O
2	,	O
3	inflight	O
4	,	O
5	and	O
6	postflight	O
7	exercise	O
8	response	O
9	tests	O
10	were	O
11	conducted	O
12	on	O
13	the	O
14	astronauts	O
15	of	O
16	the	O
17	second	O
18	Skylab	O
19	mission	O
20	(	O
21	Skylab	O
22	3	O
23	)	O
24	as	O
25	part	O
26	of	O
27	an	O
28	evaluation	O
29	of	O
30	physiological	O
31	adaptation	O
32	to	B
33	long	I
34	-	I
35	term	O
36	weightlessness	O
37	.	O

1	The	O
2	peptide	O
3	sequences	O
4	reveal	O
5	that	O
6	the	O
7	factor	O
8	consists	O
9	of	O
10	GABP	O
11	alpha	O
12	and	O
13	GABP	O
14	beta	O
15	1	O
16	with	O
17	Ets	O
18	and	O
19	Notch	O
20	motifs	O
21	,	O
22	respectively	O
23	.	O

1	In	O
2	memory	O
3	of	O
4	Magdelaine	O
5	Comtesse	O

1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	disease	O
7	-	O
8	free	O
9	survival	O
10	(	O
11	DFS	O
12	)	O
13	and	O
14	overall	O
15	survival	O
16	(	O
17	OS	O
18	),	O
19	prognostic	O
20	factors	O
21	,	O
22	and	O
23	treatment	O
24	-	O
25	related	O
26	mortality	O
27	of	O
28	women	O
29	with	O
30	stage	O
31	IIIB	O
32	inflammatory	O
33	breast	O
34	cancer	O
35	(	O
36	IBC	O
37	)	O
38	treated	O
39	with	O
40	combined	O
41	modality	O
42	therapy	O
43	(	O
44	CMT	O
45	)	O
46	and	O
47	high	O
48	-	O
49	dose	O
50	chemotherapy	O
51	(	O
52	HDCT	O
53	)	O
54	with	O
55	autologous	O
56	stem	O
57	-	O
58	cell	O
59	transplantation	O
60	.	O

1	Selection	O
2	was	O
3	based	O
4	on	O
5	expression	O
6	of	O
7	an	O
8	integrated	O
9	DNA	O
10	fragment	O
11	containing	O
12	the	O
13	con	O
14	-	O
15	10	O
16	promoter	O
17	-	O
18	regulatory	O
19	region	O
20	followed	O
21	by	O
22	the	O
23	initial	O
24	segment	O
25	of	O
26	the	O
27	con	O
28	-	O
29	10	O
30	open	O
31	reading	O
32	frame	O
33	fused	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	bacterial	O
39	hygromycin	O
40	B	O
41	phosphotransferase	O
42	structural	O
43	gene	O
44	(	O
45	con10	O
46	'-'	O
47	hph	O
48	).	O

1	The	O
2	double	O
3	-	O
4	stranded	O
5	RNA	O
6	binding	O
7	domain	O
8	(	O
9	dsRBD	O
10	)	O
11	is	O
12	an	O
13	approximately	O
14	65	O
15	amino	O
16	acid	O
17	motif	O
18	that	O
19	is	O
20	found	O
21	in	O
22	a	O
23	variety	O
24	of	O
25	proteins	O
26	that	O
27	interact	B
28	with	I
29	double	I
30	-	I
31	stranded	I
32	(	O
33	ds	O
34	)	O
35	RNA	O
36	,	O
37	such	O
38	as	O
39	Escherichia	O
40	coli	O
41	RNase	O
42	III	O
43	and	O
44	the	O
45	dsRNA	O
46	-	O
47	dependent	O
48	kinase	O
49	,	O
50	PKR	O
51	.	O

1	In	O
2	summary	O
3	,	O
4	p56	O
5	(	O
6	lck	O
7	)	O
8	activity	O
9	stimulates	O
10	G1	O
11	/	O
12	S	O
13	transition	O
14	in	O
15	immature	B
16	thymoblasts	I
17	and	I
18	maintains	O
19	cell	O
20	viability	O
21	via	O
22	transduction	O
23	of	O
24	constitutive	O
25	activation	O
26	signals	B
27	downstream	I
28	to	I
29	components	O
30	of	B
31	the	I
32	Ras	I
33	/	O
34	Raf	B
35	/	O
36	MAPK	B
37	pathway	B
38	.	I

1	Control	O
2	of	O
3	transcription	O
4	of	O
5	the	O
6	erbB	O
7	-	O
8	2	O
9	gene	O
10	is	O
11	an	O
12	important	O
13	determinant	O
14	of	O
15	receptor	O
16	expression	O
17	.	O

1	Serum	O
2	levels	O
3	of	O
4	IgG	O
5	and	O
6	IgM	O
7	were	O
8	also	O
9	raised	B
10	,	I
11	but	I
12	contrary	I
13	to	I
14	the	I
15	findings	I
16	of	I
17	other	O
18	observers	O
19	IgA	O
20	levels	O
21	were	O
22	normal	O
23	.	O

1	Fundamental	O
2	and	O
3	clinical	O
4	evaluation	O
5	of	O
6	equilibrium	O
7	dialysis	O
8	--	O
9	radioimmunoassay	O
10	system	O
11	for	O
12	measurement	O
13	of	O
14	serum	O
15	free	O
16	thyroxine	O

1	In	O
2	addition	O
3	,	O
4	using	O
5	biochemical	O
6	activity	O
7	assays	O
8	for	B
9	Rho	I
10	-	I
11	like	I
12	GTPases	O
13	,	O
14	we	O
15	show	O
16	that	O
17	the	B
18	expression	I
19	of	I
20	beta1A	O
21	,	O
22	beta1D	O
23	,	O
24	or	O
25	IL2R	O
26	-	O
27	beta1A	B
28	in	I
29	GE11	I
30	or	I
31	GD25	I
32	cells	I
33	triggers	I
34	activation	O
35	of	B
36	both	I
37	RhoA	I
38	and	I
39	Rac1	O
40	,	O
41	but	O
42	not	O
43	of	O
44	Cdc42	O
45	.	O

1	Mutations	O
2	at	O
3	the	O
4	suf12	O
5	locus	O
6	were	O
7	isolated	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	as	O
12	extragenic	O
13	suppressors	O
14	of	O
15	+	O
16	1	O
17	frameshift	O
18	mutations	O
19	in	O
20	glycine	O
21	(	O
22	GGX	O
23	)	O
24	and	O
25	proline	O
26	(	O
27	CCX	O
28	)	O
29	codons	O
30	,	O
31	as	O
32	well	O
33	as	O
34	UGA	O
35	and	O
36	UAG	O
37	nonsense	O
38	mutations	O
39	.	O

1	The	O
2	IL	O
3	-	B
4	8	I
5	receptor	I
6	is	O
7	a	B
8	seven	I
9	-	I
10	transmembrane	O
11	spanning	O
12	receptor	O
13	coupled	O
14	to	O
15	specific	O
16	heterotrimeric	O
17	G	O
18	proteins	O
19	including	O
20	Gi	O
21	and	O
22	G16	O
23	.	O

1	To	O
2	the	O
3	problem	O
4	of	O
5	the	O
6	stimulation	O
7	of	O
8	the	O
9	growth	O
10	of	O
11	transplantable	O
12	tumors	O
13	of	O
14	animals	O
15	previously	O
16	treated	O
17	with	O
18	antineoplastic	O
19	antibiotics	O

1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	O
15	myoglobin	O
16	gene	O
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	B
38	site	I
39	)	I
40	linked	I
41	to	I
42	a	O
43	firefly	O
44	luciferase	O
45	gene	O
46	.	O

1	Reaction	O
2	of	B
3	human	I
4	organism	I
5	to	I
6	exercise	I
7	.	I

1	Biol	O
2	.	O

1	Type	O
2	I	O
3	position	O
4	-	O
5	vestibular	O
6	-	O
7	pause	O
8	(	O
9	PVP	O
10	I	O
11	)	O
12	and	O
13	vestibular	O
14	-	O
15	only	O
16	(	O
17	V	O
18	I	O
19	)	O
20	neurons	O
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	smaller	O
27	number	O
28	of	O
29	other	O
30	type	O
31	I	O
32	and	O
33	type	O
34	II	O
35	eye	O
36	-	O
37	plus	O
38	-	O
39	vestibular	O
40	neurons	O
41	were	O
42	studied	O
43	.	O

1	R	O
2	.	O

1	Diagnosis	O
2	of	O
3	primary	O
4	sclerosing	O
5	cholangitis	O
6	in	O
7	a	O
8	blood	O
9	donor	O
10	with	O
11	elevated	O
12	serum	O
13	alanine	O
14	aminotransferase	O
15	.	O

1	Losartan	O
2	Intervention	O
3	For	O
4	Endpoint	O
5	.	O

1	The	O
2	prevalence	O
3	of	O
4	hepatitis	O
5	B	B
6	surface	I
7	antigen	I
8	(	I
9	HBsAg	O
10	)	O
11	and	B
12	anti	I
13	-	I
14	HBs	I
15	was	I
16	determined	I
17	by	I
18	a	I
19	sensitive	I
20	double	O
21	-	O
22	antibody	O
23	radio	O
24	-	O
25	immunoassay	O
26	technique	O
27	in	O
28	a	O
29	series	O
30	of	O
31	patients	O
32	with	O
33	chronic	O
34	liver	O
35	diseases	O
36	.	O

1	Nuclear	O
2	factor	O
3	III	O
4	(	O
5	NFIII	O
6	)	O
7	is	O
8	a	O
9	protein	O
10	from	O
11	HeLa	O
12	cells	O
13	that	O
14	stimulates	O
15	the	O
16	initiation	O
17	of	O
18	adenovirus	B
19	type	I
20	2	I
21	(	O
22	Ad2	O
23	)	O
24	DNA	O
25	replication	O
26	by	O
27	binding	O
28	to	O
29	a	O
30	specific	O
31	nucleotide	O
32	sequence	O
33	in	O
34	the	O
35	origin	O
36	,	O
37	adjacent	B
38	to	I
39	the	I
40	nuclear	O
41	factor	O
42	I	O
43	recognition	O
44	site	O
45	.	O

1	Xenopus	O
2	homolog	O
3	of	B
4	the	I
5	mos	I
6	protooncogene	I
7	transforms	I
8	mammalian	I
9	fibroblasts	O
10	and	B
11	induces	B
12	maturation	I
13	of	O
14	Xenopus	O
15	oocytes	O
16	.	O

1	Six	O
2	patients	O
3	with	O
4	human	O
5	T	O
6	-	O
7	cell	O
8	lymphotropic	O
9	virus	O
10	type	O
11	I	O
12	(	O
13	HTLV	O
14	-	O
15	I	O
16	)-	O
17	associated	O
18	myelopathy	O
19	(	O
20	HAM	O
21	)	O
22	were	O
23	studied	O
24	by	O
25	electrophysiologic	O
26	methods	O
27	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	class	O
7	of	O
8	proline	O
9	-	O
10	rich	O
11	activator	O
12	proteins	O
13	and	O
14	RNA	O
15	polymerase	O
16	II	O
17	possess	O
18	a	O
19	common	O
20	structural	O
21	and	O
22	functional	O
23	component	O
24	which	O
25	can	O
26	interact	O
27	with	O
28	the	O
29	same	O
30	target	O
31	in	O
32	the	O
33	general	O
34	transcription	O
35	machinery	O
36	.	O

1	Particularly	O
2	striking	O
3	was	O
4	the	O
5	conservation	O
6	of	O
7	an	O
8	AP	O
9	-	O
10	4	O
11	binding	O
12	site	O
13	within	O
14	100	O
15	nucleotides	O
16	upstream	O
17	of	O
18	the	O
19	transcription	O
20	initiation	O
21	site	O
22	in	O
23	both	O
24	Aal	O
25	-	O
26	rpL34	O
27	and	O
28	Aal	O
29	-	O
30	rpL8	O
31	genes	O
32	.	O

1	Both	O
2	HERV	O
3	-	O
4	K	O
5	type	O
6	1	O
7	and	O
8	2	O
9	clones	B
10	were	I
11	isolated	I
12	.	I

1	Assessment	O
2	of	O
3	nutrient	O
4	media	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	diptheria	O

1	This	O
2	L	O
3	-	O
4	myc	O
5	sequence	O
6	is	O
7	amplified	O
8	10	O
9	-	O
10	20	O
11	-	O
12	fold	O
13	in	O
14	four	O
15	SCLC	O
16	cell	O
17	line	O
18	DNAs	O
19	and	O
20	in	O
21	one	O
22	SCLC	O
23	tumour	O
24	specimen	O
25	taken	O
26	directly	O
27	from	O
28	a	O
29	patient	O
30	.	O

1	Two	O
2	patients	O
3	were	B
4	treated	I
5	successfully	I
6	with	I
7	a	I
8	combination	I
9	of	I
10	metronidazole	I
11	(	I
12	a	O
13	tissue	B
14	amoebicide	O
15	)	O
16	and	O
17	diloxanide	O
18	(	O
19	a	O
20	lumenal	I
21	amoebicide	I
22	).	I

1	Harmful	O
2	effects	O
3	in	O
4	animals	O
5	and	O
6	man	O
7	may	O
8	result	O
9	from	O
10	both	O
11	deficient	O
12	or	O
13	excessive	O
14	amounts	B
15	of	I
16	intake	I
17	.	I

1	In	O
2	the	O
3	multivariate	O
4	analysis	O
5	,	O
6	six	O
7	variables	O
8	were	O
9	independently	O
10	correlated	O
11	with	O
12	survival	O
13	:	O
14	blood	B
15	urea	I
16	nitrogen	I
17	level	I
18	,	I
19	serum	I
20	aspartate	I
21	aminotransferase	O
22	level	O
23	,	O
24	community	O
25	-	O
26	acquired	O
27	vs	O
28	.	O
29	hospital	O
30	-	O
31	acquired	O
32	peritonitis	O
33	,	O
34	age	O
35	,	O
36	Child	O
37	-	O
38	Pugh	O
39	score	O
40	and	B
41	ileus	I
42	.	I

1	The	O
2	pattern	B
3	of	I
4	RNase	I
5	E	I
6	digestion	I
7	of	O
8	finP305	O
9	RNA	O
10	differed	O
11	from	O
12	FinP	O
13	,	O
14	and	O
15	GST	O
16	-	O
17	FinO	O
18	did	O
19	not	O
20	protect	O
21	finP305	B
22	RNA	I
23	from	I
24	cleavage	I
25	in	I
26	vitro	O
27	.	O

1	The	O
2	first	O
3	contains	O
4	ATF	O
5	/	O
6	CRE	O
7	and	O
8	TBP	O
9	/	O
10	TATA	O
11	sequence	O
12	motifs	O
13	within	O
14	an	O
15	87	O
16	-	O
17	bp	O
18	region	O
19	.	O

1	P	O
2	.,	O
3	Peyron	O
4	,	O
5	J	O
6	.	O

1	When	O
2	RNA	O
3	encoding	O
4	the	O
5	tail	O
6	domain	O
7	of	O
8	desmoglein	O
9	was	O
10	coinjected	O
11	with	O
12	plakoglobin	O
13	RNA	O
14	,	O
15	both	O
16	the	O
17	dorsalizing	O
18	effect	O
19	and	O
20	nuclear	O
21	accumulation	O
22	of	O
23	plakoglobin	O
24	were	O
25	suppressed	O
26	.	O

1	Pressure	O
2	ulcers	O
3	.	O

1	Single	O
2	-	O
3	photon	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	hexamethylpropyleneamine	O
14	oxime	O
15	(	O
16	HMPAO	B
17	)	I
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	B
27	in	I
28	seven	I
29	patients	I
30	with	I
31	cortical	I
32	visual	I
33	impairment	I
34	.	I

1	Their	O
2	effect	O
3	on	O
4	the	O
5	guinea	O
6	pig	O
7	vas	O
8	deferens	O
9	.	O

1	Gas6	O
2	contains	B
3	an	I
4	NH2	O
5	-	O
6	terminal	O
7	Gla	O
8	domain	O
9	followed	O
10	by	O
11	four	O
12	epidermal	O
13	growth	O
14	factor	O
15	-	B
16	like	I
17	repeats	O
18	and	O
19	tandem	O
20	globular	O
21	(	O
22	G	O
23	)	O
24	domains	O
25	.	O

1	The	O
2	results	B
3	confirm	I
4	and	I
5	extend	I
6	previous	I
7	work	O
8	by	O
9	other	O
10	researchers	O
11	.	O

1	Two	O
2	members	B
3	of	I
4	the	I
5	Cbl	I
6	family	I
7	have	O
8	since	O
9	been	O
10	defined	O
11	in	O
12	mammals	O
13	(	B
14	c	I
15	-	I
16	Cbl	I
17	and	I
18	Cbl	I
19	-	I
20	b	I
21	),	I
22	one	I
23	in	I
24	C	I
25	.	O
26	elegans	O
27	(	O
28	Sli	O
29	-	O
30	1	O
31	)	O
32	and	O
33	one	O
34	in	O
35	Drosophila	O
36	(	O
37	D	O
38	-	O
39	Cbl	O
40	).	O

1	Facts	O
2	on	O
3	the	O
4	Economic	O
5	Recovery	O
6	Tax	O
7	Act	O
8	of	O
9	1981	O
10	for	O
11	speech	O
12	-	O
13	language	O
14	pathologists	O
15	and	O
16	audiologists	O
17	.	O

1	The	O
2	effect	O
3	of	O
4	acute	O
5	,	O
6	mid	O
7	-	O
8	cervical	O
9	spinal	O
10	cord	O
11	lesions	O
12	on	O
13	neuronal	O
14	and	O
15	reflex	O
16	activity	O
17	evoked	O
18	by	O
19	the	O
20	noxious	O
21	visceral	O
22	stimulus	O
23	,	O
24	colorectal	O
25	distension	O
26	(	O
27	CRD	O
28	;	O
29	80	O
30	mmHg	O
31	,	O
32	20	O
33	s	O
34	),	O
35	was	O
36	determined	O
37	in	O
38	halothane	O
39	-	O
40	anesthetized	O
41	rats	O
42	.	O

1	Location	O
2	and	B
3	orientation	I
4	of	I
5	an	O
6	activating	O
7	region	O
8	in	O
9	the	O
10	Escherichia	O
11	coli	O
12	transcription	O
13	factor	O
14	,	O
15	FNR	O
16	.	O

1	TCZ	O
2	provides	O
3	quick	O
4	,	O
5	inexpensive	O
6	,	O
7	noninvasive	O
8	indication	O
9	of	O
10	tissue	O
11	necrosis	O
12	,	O
13	moderate	O
14	-	O
15	to	O
16	-	O
17	severe	O
18	intracranial	O
19	hemorrhage	O
20	,	O
21	and	O
22	delayed	O
23	brain	O
24	maturation	O
25	.	O

1	Characterization	O
2	of	O
3	the	O
4	promoter	O
5	for	O
6	the	O
7	human	O
8	85	O
9	kDa	O
10	cytosolic	O
11	phospholipase	O
12	A2	O
13	gene	O
14	.	O

1	No	O
2	case	O
3	of	O
4	SMF	O
5	demonstrated	O
6	expansive	O
7	tumorous	O
8	growth	O
9	.	O

1	We	O
2	have	O
3	developed	O
4	a	O
5	new	O
6	method	O
7	for	O
8	estimation	O
9	of	O
10	regional	O
11	CBF	O
12	(	O
13	rCBF	O
14	)	O
15	and	O
16	cerebrovascular	O
17	reserve	O
18	capacity	O
19	on	O
20	a	O
21	pixel	O
22	-	O
23	by	O
24	-	O
25	pixel	O
26	basis	O
27	by	O
28	means	O
29	of	O
30	dynamic	O
31	magnetic	O
32	resonance	O
33	imaging	O
34	(	O
35	MRI	O
36	).	O

1	Intraoperative	O
2	measurement	B
3	of	I
4	activated	I
5	partial	I
6	thromboplastin	I
7	time	I
8	and	O
9	prothrombin	B
10	time	I
11	with	O
12	a	O
13	new	O
14	compact	O
15	monitor	O
16	.	O

1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O

1	This	O
2	laser	O
3	provided	O
4	sufficient	O
5	power	O
6	in	O
7	an	O
8	amniotic	O
9	fluid	B
10	medium	I
11	to	I
12	occlude	O
13	placental	O
14	vessels	O
15	as	O
16	large	O
17	as	O
18	7	O
19	mm	O
20	in	O
21	diameter	O
22	within	O
23	6	O
24	seconds	O
25	at	O
26	a	O
27	power	O
28	density	O
29	of	O
30	2000	O
31	W	O
32	/	O
33	cm2	O
34	.	O

1	Drosophila	O
2	230	O
3	-	O
4	kD	O
5	TFIID	O
6	subunit	O
7	,	O
8	a	O
9	functional	O
10	homolog	O
11	of	O
12	the	O
13	human	O
14	cell	O
15	cycle	O
16	gene	O
17	product	O
18	,	O
19	negatively	O
20	regulates	O
21	DNA	O
22	binding	O
23	of	O
24	the	O
25	TATA	O
26	box	O
27	-	O
28	binding	O
29	subunit	O
30	of	B
31	TFIID	I
32	.	I

1	16	O
2	women	O
3	were	O
4	treated	O
5	with	B
6	methadone	I
7	to	O
8	prevent	O
9	withdrawal	O
10	symptoms	O
11	.	O

1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	O
10	oxidase	O
11	(	O
12	cox1	O
13	to	B
14	3	I
15	),	I
16	apocytochrome	I
17	b	I
18	(	I
19	cob	I
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	O
26	dehydrogenase	O
27	complex	O
28	(	O
29	nad1	B
30	to	O
31	6	B
32	,	O
33	nad4L	O
34	),	O
35	two	O
36	ATPase	O
37	subunits	O
38	(	O
39	atp6	O
40	and	O
41	atp9	O
42	),	O
43	three	O
44	ribosomal	O
45	RNAs	O
46	(	O
47	rrn5	O
48	,	O
49	srn	B
50	and	I
51	lrn	O
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	O
58	proteins	O
59	(	O
60	rps3	O
61	,	B
62	rps11	O
63	,	O
64	rps12	B
65	and	B
66	rpl16	O
67	).	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	O
6	ERK2	B
7	as	I
8	a	I
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	B
15	and	I
16	are	I
17	consistent	I
18	with	I
19	a	I
20	model	I
21	in	O
22	which	O
23	HePTP	O
24	negatively	O
25	regulates	O
26	ERK2	O
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O

1	Htra2	O
2	-	O
3	beta3	O
4	is	O
5	developmentally	O
6	regulated	B
7	and	I
8	expressed	I
9	predominantly	I
10	in	I
11	brain	O
12	,	O
13	liver	O
14	testis	O
15	,	O
16	and	O
17	weakly	O
18	in	B
19	kidney	I
20	.	I

1	However	O
2	,	O
3	the	O
4	elderly	O
5	group	O
6	showed	O
7	significantly	O
8	longer	O
9	mean	O
10	residence	O
11	times	O
12	(	O
13	MRTs	O
14	)	O
15	and	O
16	lower	B
17	plasma	B
18	clearance	I
19	of	I
20	lidocaine	O
21	during	O
22	the	O
23	period	O
24	compared	B
25	with	I
26	the	I
27	adult	I
28	group	I
29	(	I
30	P	O
31	<	O
32	.	B
33	05	B
34	).	I

1	To	O
2	identify	O
3	structural	O
4	features	O
5	of	O
6	residues	O
7	flanking	O
8	the	O
9	c	O
10	-	O
11	region	O
12	that	O
13	influence	O
14	the	O
15	fidelity	O
16	and	O
17	efficiency	O
18	of	O
19	signal	O
20	peptidase	O
21	cleavage	O
22	as	O
23	well	O
24	as	O
25	co	O
26	-	O
27	translational	O
28	translocation	O
29	,	O
30	we	O
31	introduced	O
32	six	O
33	amino	O
34	acid	O
35	substitutions	O
36	into	O
37	the	O
38	COOH	O
39	terminus	O
40	of	O
41	the	O
42	hydrophobic	O
43	core	O
44	and	O
45	seven	O
46	substitutions	O
47	at	O
48	the	O
49	NH2	O
50	terminus	O
51	of	O
52	the	O
53	mature	O
54	region	O
55	(	O
56	the	O
57	+	O
58	1	O
59	position	O
60	)	O
61	of	O
62	a	O
63	model	O
64	eukaryotic	O
65	preprotein	O
66	-	O
67	human	O
68	pre	O
69	(	O
70	delta	O
71	pro	O
72	)	O
73	apoA	O
74	-	O
75	II	O
76	.	O

1	These	O
2	protective	O
3	influences	O
4	were	O
5	observed	O
6	throughout	O
7	the	O
8	range	O
9	of	O
10	filling	O
11	pressures	O
12	measured	O
13	,	O
14	from	O
15	0	O
16	to	O
17	30	O
18	mmHg	O
19	.	O

1	Estimated	O
2	daily	O
3	intakes	O
4	(	O
5	EDIs	O
6	)	O
7	per	O
8	person	O
9	were	O
10	0	O
11	.	O
12	56	O
13	microgram	O
14	for	O
15	total	O
16	HCH	O
17	,	O
18	0	O
19	.	O
20	20	O
21	microgram	O
22	for	O
23	gamma	O
24	-	O
25	HCH	O
26	,	O
27	0	O
28	.	O
29	09	O
30	microgram	O
31	for	O
32	dieldrin	O
33	,	O
34	1	O
35	.	O
36	42	O
37	micrograms	O
38	for	O
39	total	O
40	DDT	O
41	,	O
42	and	O
43	0	O
44	.	O
45	15	O
46	microgram	O
47	for	O
48	HCB	O
49	.	O

1	Effect	O
2	of	O
3	the	O
4	methods	O
5	of	O
6	cutaneous	O
7	administration	O
8	of	O
9	methyl	O
10	isobutyl	O
11	ketone	O
12	on	O
13	its	O
14	toxicity	O

1	The	O
2	4	O
3	days	O
4	dexamethasone	O
5	suppression	O
6	test	O
7	showed	O
8	more	O
9	than	O
10	80	O
11	%	O
12	suppression	O
13	of	O
14	dehydroepiandrosterone	O
15	-	O
16	sulphate	O
17	and	O
18	a	O
19	variable	O
20	(	O
21	40	O
22	-	O
23	60	O
24	%)	O
25	reduction	O
26	of	O
27	testosterone	O
28	and	O
29	androstenedione	O
30	levels	O
31	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	B
9	human	I
10	stomach	I
11	in	I
12	vivo	I
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	After	O
2	90	O
3	d	O
4	a	O
5	subsurface	O
6	,	O
7	radiolucent	O
8	caries	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O

1	A	O
2	previous	O
3	report	O
4	described	O
5	that	O
6	a	O
7	548	O
8	-	O
9	bp	O
10	BglII	O
11	-	O
12	SmaI	O
13	fragment	O
14	has	O
15	an	O
16	SSO	O
17	activity	O
18	(	O
19	ori2	O
20	;	O
21	Kataoka	O
22	et	O
23	al	O
24	.,	O
25	Mol	O
26	.	O

1	Two	O
2	such	O
3	genes	B
4	,	B
5	designated	I
6	hsiggll150	I
7	and	I
8	hsiggll295	I
9	,	I
10	were	I
11	cloned	I
12	and	I
13	sequenced	I
14	from	I
15	genomic	I
16	DNA	O
17	.	O

1	G	O
2	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	interaction	O
6	between	O
7	Jak2	O
8	and	O
9	PRLR	O
10	requires	O
11	a	O
12	proline	O
13	-	O
14	rich	O
15	sequence	O
16	in	O
17	the	O
18	membrane	O
19	proximal	O
20	region	O
21	of	O
22	the	O
23	receptor	O
24	,	O
25	which	O
26	is	O
27	conserved	O
28	among	O
29	the	O
30	different	O
31	members	O
32	of	O
33	the	O
34	cytokine	O
35	receptor	O
36	superfamily	O
37	.	O

1	Effects	O
2	of	O
3	methiothepin	O
4	and	O
5	lysergic	O
6	acid	O
7	diethylamide	O
8	on	O
9	serotonin	O
10	release	O
11	in	O
12	vitro	O
13	and	O
14	serotonin	O
15	synthesis	O
16	in	O
17	vivo	O
18	:	O
19	possible	O
20	relation	O
21	to	O
22	serotonin	O
23	autoreceptor	O
24	function	O
25	.	O

1	Prospects	O
2	for	O
3	controlled	O
4	-	O
5	delivery	O
6	systems	O
7	.	O

1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O

1	Comparison	O
2	of	O
3	sequences	O
4	from	O
5	-	O
6	215	O
7	to	O
8	+	O
9	1	B
10	bp	I
11	identified	I
12	consensus	O
13	binding	O
14	sites	O
15	for	O
16	the	O
17	homeodomain	O
18	transcription	O
19	factor	O
20	thyroid	O
21	transcription	O
22	factor	O
23	-	O
24	1	O
25	(	O
26	TTF	B
27	-	O
28	1	O
29	).	O

1	Cytogenetic	O
2	and	O
3	molecular	O
4	characterization	O
5	of	O
6	random	O
7	chromosomal	O
8	rearrangements	O
9	activating	O
10	the	O
11	drug	O
12	resistance	O
13	gene	I
14	,	I
15	MDR1	I
16	/	B
17	P	I
18	-	I
19	glycoprotein	I
20	,	I
21	in	I
22	drug	O
23	-	O
24	selected	O
25	cell	O
26	lines	O
27	and	O
28	patients	O
29	with	O
30	drug	O
31	refractory	O
32	ALL	O
33	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	was	O
6	observed	B
7	only	I
8	for	I
9	a	I
10	12	I
11	-	I
12	month	I
13	period	I
14	in	O
15	4	O
16	children	O
17	with	O
18	a	O
19	bone	O
20	age	O
21	of	O
22	7	O
23	to	O
24	8	O
25	years	O
26	.	O

1	This	O
2	constitutes	O
3	evidence	O
4	for	O
5	an	O
6	in	O
7	vivo	O
8	role	O
9	of	O
10	SRC	O
11	-	O
12	1	O
13	in	O
14	dimerization	O
15	-	O
16	induced	O
17	activation	O
18	by	O
19	OR1	O
20	/	O
21	RXRalpha	O
22	.	O

1	However	O
2	,	O
3	a	O
4	>	O
5	10	O
6	-	O
7	fold	O
8	increase	O
9	in	O
10	ERK3	O
11	activity	O
12	in	O
13	each	O
14	PKC	O
15	beta	O
16	transfectant	O
17	was	O
18	shown	O
19	by	O
20	immunoprecipitation	O
21	with	O
22	anti	O
23	-	O
24	ERK3	O
25	monoclonal	O
26	antibody	O
27	followed	O
28	by	O
29	either	O
30	immune	O
31	complex	O
32	kinase	O
33	assay	O
34	or	O
35	by	O
36	in	O
37	gel	O
38	kinase	O
39	assay	B
40	.	I

1	In	O
2	vitro	O
3	precipitation	O
4	with	O
5	a	O
6	glutathione	O
7	-	O
8	S	O
9	-	O
10	transferase	O
11	-	O
12	fusion	O
13	protein	O
14	containing	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	transactivation	O
20	domain	O
21	of	O
22	STAT5a	O
23	showed	O
24	GH	O
25	-	O
26	regulated	O
27	association	O
28	of	O
29	ERK1	O
30	/	O
31	2	O
32	with	O
33	the	O
34	fusion	O
35	protein	O
36	,	O
37	while	O
38	this	O
39	was	O
40	not	O
41	seen	O
42	when	O
43	serine	O
44	780	O
45	in	O
46	STAT5a	O
47	was	O
48	changed	O
49	to	O
50	alanine	O
51	.	O

1	These	O
2	HPV16	O
3	E6	O
4	/	O
5	E7	O
6	cDNAs	O
7	were	O
8	cloned	O
9	under	O
10	the	B
11	SV40	I
12	enhancer	I
13	/	I
14	promoter	I
15	and	I
16	the	O
17	MMTV	O
18	LTR	O
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	O
25	-	B
26	collaborative	I
27	transformation	I
28	and	I
29	induction	I
30	of	I
31	cellular	I
32	DNA	I
33	synthesis	I
34	,	I
35	both	I
36	of	I
37	which	O
38	depend	O
39	on	O
40	the	O
41	E7	O
42	gene	O
43	product	O
44	.	O

1	Interleukin	O
2	-	O
3	6	O
4	may	O
5	possibly	O
6	potentiate	O
7	metastasis	O
8	of	O
9	cardiac	O
10	myxoma	B
11	.	I

1	Metastasis	O
2	of	O
3	colon	O
4	carcinoma	O
5	to	O
6	the	O
7	lip	O
8	.	O

1	Histological	O
2	slides	O
3	of	O
4	one	O
5	biopsy	O
6	of	O
7	each	O
8	patient	O
9	(	O
10	formalin	O
11	-	O
12	fixed	O
13	and	O
14	paraffin	O
15	-	O
16	embedded	O
17	)	O
18	were	O
19	stained	O
20	with	O
21	a	O
22	Modified	O
23	Giemsa	O
24	(	O
25	MG	O
26	),	O
27	the	O
28	Warthin	O
29	-	O
30	Starry	O
31	(	O
32	WS	O
33	),	O
34	and	O
35	an	O
36	immunohistochemical	O
37	method	O
38	(	O
39	IMM	O
40	)	O
41	using	O
42	purified	O
43	polyclonal	O
44	H	O
45	.	O
46	pylori	O
47	antiserum	O
48	(	O
49	DAKO	O
50	B471	O
51	).	O

1	The	O
2	effects	B
3	of	I
4	contrast	O
5	media	O
6	on	O
7	coagulation	O
8	factor	O
9	XII	O
10	.	O

1	The	O
2	sub	O
3	-	O
4	acute	O
5	inhalation	O
6	toxicity	O
7	of	O
8	furfural	O
9	was	O
10	studied	O
11	in	O
12	Syrian	O
13	golden	O
14	hamsters	O
15	.	O

1	Adverse	O
2	reaction	O
3	of	O
4	the	O
5	apparently	O
6	healthy	O
7	partner	O
8	in	O
9	response	O
10	to	O
11	improvement	O
12	in	O
13	the	O
14	overtly	O
15	dysfunctional	O
16	partner	O
17	.	O

1	The	O
2	sample	O
3	is	O
4	deproteinized	O
5	and	O
6	after	O
7	centrifugation	O
8	valproic	O
9	acid	O
10	in	O
11	the	O
12	supernatant	O
13	is	O
14	measured	O
15	in	O
16	the	O
17	free	O
18	form	O
19	by	O
20	direct	O
21	injection	O
22	into	O
23	the	O
24	gas	O
25	chromatograph	O
26	.	O

1	Biol	O
2	.	O

1	Two	O
2	copies	O
3	of	O
4	the	O
5	72	O
6	-	O
7	bp	O
8	repeat	O
9	provided	O
10	efficient	O
11	activation	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	A	O
2	role	O
3	for	O
4	the	O
5	small	O
6	GTPase	B
7	Rac	I
8	in	I
9	polyomavirus	I
10	middle	I
11	-	I
12	T	I
13	antigen	O
14	-	O
15	mediated	B
16	activation	I
17	of	I
18	the	I
19	serum	I
20	response	I
21	element	I
22	and	I
23	in	I
24	cell	O
25	transformation	B
26	.	I

1	We	O
2	conclude	O
3	that	O
4	the	O
5	'	O
6	morning	O
7	dip	O
8	'	O
9	observed	O
10	in	O
11	asthmatic	O
12	patients	O
13	cannot	O
14	simply	O
15	be	O
16	explained	O
17	by	O
18	changes	O
19	in	O
20	cell	O
21	receptor	O
22	number	O
23	or	O
24	affinity	O
25	,	O
26	as	O
27	our	O
28	results	O
29	suggest	O
30	that	O
31	both	O
32	groups	O
33	have	O
34	intact	O
35	beta	O
36	-	O
37	adrenoceptor	O
38	function	O
39	.	O

1	Major	O
2	clinical	O
3	symptoms	O
4	of	O
5	the	O
6	disease	O
7	were	O
8	defined	B
9	in	I
10	this	I
11	group	I
12	of	I
13	patients	O
14	.	O

1	All	O
2	six	O
3	ARF	O
4	cDNAs	O
5	are	O
6	more	O
7	similar	O
8	to	O
9	each	O
10	other	O
11	than	O
12	to	B
13	other	I
14	approximately	I
15	20	I
16	-	O
17	kDa	B
18	guanine	I
19	nucleotide	I
20	-	I
21	binding	I
22	proteins	O
23	.	B

1	Clone	O
2	39	O
3	was	O
4	a	B
5	homolog	I
6	of	I
7	CONSTANS	I
8	,	I
9	which	I
10	is	I
11	a	O
12	gene	O
13	involved	O
14	in	O
15	controlling	O
16	the	O
17	flowering	O
18	time	O
19	in	O
20	Arabidopsis	O
21	.	O

1	In	O
2	subjects	O
3	(	O
4	n	O
5	=	O
6	5	O
7	)	O
8	with	O
9	quadriplegia	O
10	and	O
11	reduced	B
12	sympathetic	I
13	tone	I
14	secondary	I
15	to	O
16	cervical	O
17	cord	O
18	trauma	O
19	,	O
20	TcpO2	O
21	at	O
22	42	O
23	degrees	B
24	C	O
25	and	I
26	vasodilation	O
27	index	O
28	were	O
29	increased	O
30	(	O
31	45	O
32	.	O
33	0	O
34	mmHg	O
35	and	O
36	0	O
37	.	O
38	61	O
39	);	O
40	TcpO2	O
41	at	O
42	45	O
43	degrees	O
44	C	O
45	did	O
46	not	O
47	change	O
48	.	O

1	This	O
2	gave	O
3	rise	O
4	to	O
5	RNA	O
6	molecules	O
7	with	O
8	3	O
9	'-	O
10	untranslated	O
11	regions	O
12	of	O
13	roughly	O
14	375	O
15	,	O
16	655	O
17	,	O
18	and	O
19	945	O
20	base	O
21	pairs	O
22	.	O

1	A	O
2	new	O
3	semi	O
4	-	O
5	automatic	O
6	method	O
7	for	O
8	quantifying	O
9	regional	O
10	cerebral	O
11	uptake	O
12	of	O
13	99m	O
14	technetium	O
15	-	O
16	hexamethylpropylene	O
17	amine	O
18	oxime	O
19	(	O
20	99mTc	B
21	-	I
22	HMPAO	I
23	)	O
24	was	O
25	used	O
26	to	O
27	assess	O
28	single	O
29	photon	B
30	emission	O
31	tomograms	O
32	from	O
33	5	O
34	normal	O
35	subjects	O
36	,	O
37	14	O
38	patients	O
39	with	O
40	Alzheimer	O
41	'	O
42	s	O
43	disease	O
44	,	O
45	14	O
46	patients	O
47	with	O
48	dementia	O
49	of	O
50	frontal	O
51	lobe	O
52	type	O
53	and	O
54	4	O
55	patients	O
56	with	O
57	dementia	O
58	with	O
59	motor	O
60	neurone	B
61	disease	O
62	.	O

1	Our	O
2	data	O
3	therefore	O
4	indicate	O
5	that	O
6	it	O
7	is	O
8	possible	O
9	to	O
10	engineer	O
11	the	O
12	HA	O
13	envelope	O
14	glycoprotein	O
15	by	O
16	fusing	O
17	ligands	O
18	to	O
19	its	O
20	amino	O
21	-	O
22	terminal	O
23	end	O
24	without	O
25	affecting	O
26	its	O
27	fusion	O
28	activity	O
29	.	O

1	To	O
2	confirm	O
3	the	O
4	binding	O
5	of	O
6	protein	O
7	to	O
8	these	O
9	sites	B
10	in	I
11	cells	I
12	,	O
13	we	O
14	carried	O
15	out	O
16	an	O
17	in	O
18	vivo	O
19	genomic	O
20	footprinting	O
21	analysis	O
22	of	O
23	this	O
24	portion	O
25	of	O
26	the	O
27	TGF	O
28	alpha	O
29	promoter	O
30	in	O
31	normal	O
32	and	O
33	transformed	O
34	rat	O
35	liver	O
36	epithelial	O
37	cell	O
38	lines	O
39	that	O
40	express	O
41	the	O
42	endogenous	O
43	gene	O
44	at	O
45	varying	B
46	levels	B
47	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	binding	B
7	sites	I
8	for	I
9	the	I
10	repressor	I
11	proteins	I
12	BP1	I
13	and	O
14	BP2	O
15	in	O
16	the	O
17	upstream	O
18	portion	O
19	of	O
20	the	O
21	beta	O
22	globin	O
23	gene	O
24	flanking	O
25	region	B
26	led	I
27	to	I
28	a	I
29	4	I
30	-	I
31	6	I
32	fold	I
33	increase	I
34	in	I
35	promoter	O
36	activity	O
37	.	B

1	Selected	O
2	topics	O
3	in	O
4	pediatric	O
5	ultrasonography	O
6	--	O
7	1992	O
8	.	O

1	The	O
2	location	O
3	of	O
4	multiple	O
5	GRK2	O
6	and	O
7	GRK5	O
8	phosphoacceptor	O
9	sites	O
10	at	O
11	the	O
12	extreme	O
13	carboxyl	O
14	terminus	O
15	of	O
16	the	O
17	beta2AR	O
18	is	O
19	highly	O
20	reminiscent	O
21	of	O
22	GRK1	O
23	-	O
24	mediated	O
25	phosphorylation	O
26	of	O
27	rhodopsin	O
28	.	O

1	DIBA	O
2	was	O
3	more	O
4	sensitive	O
5	and	O
6	had	O
7	a	O
8	better	B
9	negative	I
10	predictive	I
11	value	I
12	and	O
13	a	O
14	lower	O
15	false	O
16	negative	O
17	percentage	B
18	than	I
19	DFAT	O
20	.	O

1	Detection	O
2	of	O
3	poisoning	O
4	by	O
5	Impila	O
6	(	O
7	Callilepis	B
8	laureola	I
9	)	I
10	in	I
11	a	O
12	mother	O
13	and	B
14	child	I
15	.	O

1	Such	O
2	mutations	O
3	are	O
4	thought	B
5	to	I
6	exert	I
7	their	I
8	dominant	O
9	phenotype	O
10	by	O
11	sequestration	O
12	of	O
13	the	O
14	guanine	O
15	nucleotide	O
16	exchange	O
17	factor	O
18	(	O
19	GNEF	O
20	).	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	the	O
6	sensitivity	O
7	of	O
8	the	O
9	3	O
10	given	O
11	guinea	O
12	pig	O
13	strains	O
14	was	O
15	comparable	O
16	.	O

1	These	O
2	residues	O
3	,	O
4	Ile244	O
5	at	O
6	the	O
7	extracellular	O
8	end	O
9	of	O
10	transmembrane	O
11	helix	O
12	3	O
13	,	O
14	and	O
15	Tyr318	O
16	at	O
17	the	B
18	COOH	I
19	-	I
20	terminal	I
21	portion	I
22	of	O
23	extracellular	O
24	loop	O
25	2	O
26	,	O
27	are	O
28	replaced	O
29	by	O
30	Leu	O
31	and	O
32	Ile	O
33	in	O
34	the	B
35	PTH	I
36	-	I
37	1	O
38	receptor	B
39	,	I
40	respectively	I
41	.	O

1	Immunohistochemical	O
2	analysis	O
3	of	O
4	several	O
5	rat	O
6	organs	O
7	also	O
8	showed	O
9	staining	O
10	in	O
11	epithelial	O
12	cells	O
13	.	O

1	Both	O
2	variants	O
3	display	O
4	the	O
5	seven	O
6	-	O
7	transmembrane	O
8	topology	O
9	that	O
10	is	B
11	typical	I
12	for	I
13	G	I
14	protein	I
15	-	I
16	coupled	I
17	receptors	I
18	.	I

1	The	O
2	plasma	O
3	growth	O
4	hormone	O
5	concentration	O
6	of	O
7	the	O
8	foetal	O
9	lamb	O
10	.	O

1	Nonteratogenicity	O
2	in	O
3	rats	O
4	of	O
5	blighted	B
6	potatoes	I
7	and	I
8	compounds	O
9	contained	B
10	in	I
11	them	I
12	.	I

1	Thus	O
2	,	O
3	elongin	O
4	C	O
5	is	O
6	found	O
7	to	O
8	oligomerize	O
9	in	O
10	solution	O
11	and	O
12	to	O
13	undergo	O
14	significant	O
15	structural	O
16	rearrangements	O
17	upon	O
18	binding	O
19	of	O
20	two	O
21	different	O
22	partner	O
23	proteins	O
24	.	O

1	A	O
2	polymorphic	O
3	dinucleotide	O
4	(	O
5	GT	O
6	/	O
7	CA	O
8	)	O
9	n	O
10	repeat	O
11	contained	O
12	in	O
13	the	O
14	NHE5	O
15	cosmid	O
16	was	O
17	identified	O
18	and	O
19	developed	O
20	into	O
21	a	O
22	microsatellite	O
23	PCR	O
24	marker	O
25	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Dupuytren	O
5	'	O
6	s	O
7	contracture	O

1	RESULTS	O
2	:	O
3	Soluble	O
4	CD23	O
5	levels	O
6	were	O
7	significantly	O
8	higher	O
9	in	O
10	women	O
11	with	O
12	endometriosis	O
13	before	O
14	treatment	O
15	than	O
16	in	O
17	ten	O
18	normal	O
19	controls	O
20	.	O

1	The	O
2	single	B
3	site	I
4	of	I
5	glycosylation	I
6	is	I
7	located	O
8	near	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	in	O
14	the	O
15	N	O
16	-	O
17	glycosylation	O
18	sequon	O
19	-	O
20	Asn	O
21	-	O
22	Cys	B
23	-	I
24	Ser	I
25	-	I
26	in	I
27	which	I
28	Cys	I
29	forms	I
30	part	I
31	of	I
32	a	I
33	disulphide	I
34	bridge	I
35	.	I

1	These	O
2	results	O
3	were	B
4	superior	I
5	to	I
6	those	I
7	in	I
8	24	I
9	patients	I
10	with	O
11	conventional	O
12	end	O
13	-	O
14	to	O
15	-	O
16	end	O
17	sutures	O
18	on	O
19	clinical	O
20	testing	O
21	.	O

1	When	O
2	the	O
3	promoter	O
4	region	O
5	was	O
6	linked	O
7	with	O
8	a	O
9	heterologous	O
10	reporter	O
11	gene	O
12	,	O
13	we	O
14	found	O
15	that	O
16	the	O
17	promoter	O
18	region	O
19	is	O
20	inducible	O
21	by	O
22	both	O
23	interferons	O
24	(	O
25	interferon	O
26	-	O
27	alpha	O
28	and	O
29	-	O
30	gamma	O
31	)	O
32	and	O
33	interferon	O
34	regulatory	O
35	factor	O
36	1	O
37	.	O

1	Nerve	O
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	potent	O
6	splicing	O
7	enhancer	O
8	sequence	O
9	isolated	O
10	in	O
11	the	O
12	selection	O
13	specifically	O
14	binds	O
15	a	O
16	20	O
17	-	O
18	kDa	O
19	SR	O
20	protein	O
21	.	O

1	Carbonic	O
2	anhydrase	O
3	V	O
4	(	O
5	CA	O
6	V	O
7	)	O
8	is	O
9	expressed	O
10	in	O
11	mitochondrial	O
12	matrix	O
13	in	O
14	liver	O
15	and	O
16	several	O
17	other	O
18	tissues	O
19	.	O

1	It	O
2	bound	O
3	to	O
4	vitamin	O
5	D	O
6	receptor	O
7	(	O
8	VDR	O
9	)	O
10	but	O
11	not	O
12	retinoic	O
13	acid	O
14	Xalpha	O
15	receptor	O
16	(	O
17	RXRalpha	O
18	)	O
19	in	O
20	the	O
21	human	O
22	T	O
23	cell	O
24	line	O
25	MT2	O
26	cells	O
27	.	O

1	Plasmid	O
2	pAL618	O
3	contains	O
4	the	O
5	genetic	O
6	determinants	O
7	for	O
8	H2	O
9	uptake	O
10	(	O
11	hup	O
12	)	O
13	from	O
14	Rhizobium	O
15	leguminosarum	O
16	bv	O
17	.	O
18	viciae	O
19	,	O
20	including	O
21	a	O
22	cluster	O
23	of	O
24	17	O
25	genes	O
26	named	O
27	hupSLCDEFGHIJK	O
28	-	O
29	hypABFCDE	O
30	.	O

1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	O
6	single	O
7	-	O
8	chain	O
9	Fv	O
10	and	O
11	Fv	O
12	fragments	O
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O

1	Using	O
2	immunogold	O
3	electron	O
4	microscopy	O
5	,	O
6	we	O
7	found	O
8	that	O
9	p58	O
10	/	O
11	p45	O
12	and	O
13	p54	I
14	are	O
15	localized	O
16	on	O
17	both	O
18	sides	B
19	of	I
20	the	O
21	nuclear	B
22	pore	I
23	complex	O
24	,	O
25	like	B
26	p62	I
27	.	I

1	The	O
2	protein	O
3	-	O
4	tyrosine	O
5	kinase	O
6	fer	O
7	associates	O
8	with	O
9	signaling	O
10	complexes	O
11	containing	O
12	insulin	O
13	receptor	O
14	substrate	O
15	-	O
16	1	O
17	and	O
18	phosphatidylinositol	O
19	3	O
20	-	O
21	kinase	O
22	.	O

1	Most	O
2	recently	B
3	,	I
4	the	I
5	use	I
6	of	I
7	the	O
8	product	O
9	of	O
10	brain	O
11	weight	O
12	and	O
13	clearance	O
14	has	O
15	been	O
16	proposed	O
17	.	O

1	A	O
2	controlled	O
3	trial	O
4	of	O
5	recombinant	O
6	human	O
7	granulocyte	O
8	-	O
9	macrophage	O
10	colony	O
11	-	O
12	stimulating	O
13	factor	O
14	after	B
15	total	I
16	body	I
17	irradiation	I
18	,	I
19	high	I
20	-	O
21	dose	O
22	chemotherapy	O
23	,	B
24	and	O
25	autologous	I
26	bone	I
27	marrow	O
28	transplantation	B
29	for	I
30	acute	I
31	lymphoblastic	I
32	leukemia	O
33	or	O
34	malignant	B
35	lymphoma	B
36	.	I

1	Mobilization	O
2	with	O
3	cyclophosphamide	O
4	and	O
5	granulocyte	O
6	-	O
7	colony	O
8	stimulating	O
9	factor	O
10	was	O
11	effective	O
12	in	O
13	terms	O
14	of	O
15	CD34	O
16	+	O
17	cell	O
18	shift	O
19	to	O
20	peripheral	O
21	blood	O
22	and	O
23	the	O
24	good	O
25	quality	O
26	autograft	O
27	reliably	O
28	led	O
29	to	O
30	haematopoetic	O
31	recovery	O
32	after	O
33	megachemotherapy	O
34	.	O

1	(	O
2	1992	O
3	)	O
4	J	O
5	.	O

1	Tendon	O
2	also	O
3	shows	O
4	a	O
5	degree	O
6	of	O
7	extensibility	O
8	.	O

1	Specific	O
2	clotting	O
3	factor	O
4	assays	O
5	showed	O
6	an	O
7	isolated	O
8	deficiency	O
9	of	O
10	factor	O
11	X	O
12	ranging	O
13	from	O
14	7	O
15	to	O
16	12	O
17	per	O
18	cent	O
19	on	O
20	three	O
21	determinations	O
22	.	O

1	The	O
2	TCF	O
3	-	O
4	1	O
5	alpha	O
6	binding	O
7	site	O
8	was	O
9	also	O
10	required	O
11	for	O
12	TCR	O
13	alpha	O
14	enhancer	O
15	activity	O
16	in	O
17	transcriptionally	O
18	active	O
19	extracts	O
20	from	O
21	Jurkat	O
22	but	O
23	not	O
24	HeLa	O
25	cells	O
26	,	O
27	confirming	O
28	that	O
29	TCF	O
30	-	O
31	1	O
32	alpha	O
33	is	O
34	a	O
35	T	O
36	-	O
37	cell	O
38	-	O
39	specific	O
40	transcription	O
41	factor	O
42	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	the	O
5	importance	O
6	of	O
7	phosphate	O
8	and	O
9	calcium	O
10	in	O
11	influencing	O
12	the	O
13	secretion	O
14	of	O
15	PTH	O
16	and	O
17	CT	O
18	in	O
19	uremia	O
20	.	O

1	Therefore	O
2	,	O
3	ICSBP	O
4	may	O
5	be	O
6	involved	O
7	in	O
8	maintaining	O
9	submaximal	O
10	transcriptional	O
11	activity	O
12	of	O
13	IFN	O
14	-	O
15	inducible	O
16	genes	O
17	in	O
18	hematopoietic	O
19	cells	O
20	.	O

1	The	O
2	U17	O
3	/	O
4	U16	O
5	and	O
6	the	O
7	U16	O
8	+	O
9	gene	O
10	products	O
11	transactivated	O
12	the	O
13	HIV	O
14	LTR	O
15	.	O

1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	B
9	dimethylation	I
10	reactions	I
11	by	I
12	the	O
13	recombinant	O
14	pfTrm1p	O
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	O
27	(	O
28	Asp	O
29	)	O
30	and	O
31	tRNA	O
32	(	O
33	Phe	O
34	)	O
35	from	O
36	yeast	O
37	.	O

1	The	O
2	TEA1	O
3	(	O
4	Ty	O
5	enhancer	O
6	activator	O
7	)	O
8	gene	O
9	sequence	O
10	predicts	O
11	a	O
12	protein	O
13	of	O
14	86	O
15	.	O
16	9	O
17	kDa	O
18	whose	O
19	N	O
20	terminus	O
21	contains	O
22	a	O
23	zinc	O
24	cluster	O
25	and	O
26	dimerization	O
27	motif	O
28	typical	O
29	of	O
30	the	O
31	Gal4	O
32	-	O
33	type	O
34	family	O
35	of	O
36	DNA	O
37	-	O
38	binding	O
39	proteins	O
40	.	O

1	E2	O
2	treatments	O
3	elevated	O
4	hen	O
5	plasma	O
6	TG	O
7	7	O
8	.	B
9	2X	I
10	,	I
11	PL	O
12	5	O
13	.	O
14	1X	O
15	,	O
16	and	O
17	C	O
18	7	O
19	.	O
20	2X	O
21	;	O
22	and	O
23	pullet	O
24	plasma	O
25	TG	O
26	6	O
27	.	O
28	8X	O
29	,	O
30	PL	O
31	3	O
32	.	O
33	7X	O
34	,	O
35	and	O
36	C	O
37	2	O
38	.	O
39	5X	O
40	.	O

1	As	O
2	hGM	O
3	-	O
4	CSF	O
5	receptor	O
6	(	O
7	hGMR	O
8	)	O
9	does	O
10	not	O
11	contain	O
12	a	O
13	consensus	O
14	sequence	O
15	for	O
16	binding	O
17	of	O
18	PI	O
19	3	O
20	-	O
21	kinase	O
22	,	O
23	hGMR	O
24	must	O
25	use	O
26	a	O
27	distinct	O
28	mechanism	O
29	for	O
30	its	O
31	association	O
32	with	O
33	and	O
34	activation	O
35	of	O
36	PI	O
37	3	O
38	-	O
39	kinase	O
40	.	O

1	New	O
2	alkaloids	O
3	from	O
4	bark	O
5	of	O
6	Erythrophleum	O
7	ivorense	O
8	.	O

1	Palindromic	O
2	rheumatism	O

1	The	O
2	number	O
3	of	O
4	lactotropes	O
5	,	O
6	somatotropes	O
7	,	O
8	thyrotropes	O
9	,	O
10	and	O
11	gonadotropes	O
12	was	O
13	not	O
14	altered	O
15	compared	O
16	with	O
17	controls	O
18	,	O
19	indicating	O
20	that	O
21	in	O
22	the	O
23	adult	O
24	pituitary	O
25	,	O
26	POMC	O
27	products	O
28	are	O
29	not	O
30	required	O
31	to	O
32	maintain	O
33	the	O
34	distribution	O
35	of	O
36	cell	O
37	types	O
38	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	GRE	O
8	sufficient	O
9	to	O
10	account	O
11	for	O
12	full	O
13	glucocorticoid	O
14	inducibility	O
15	and	O
16	an	O
17	HNF	O
18	-	O
19	1	O
20	site	O
21	close	O
22	to	O
23	the	O
24	promoter	O
25	that	O
26	are	O
27	major	O
28	determinants	O
29	of	O
30	transcriptional	O
31	control	O
32	of	O
33	the	O
34	Xenopus	O
35	fibrinogen	O
36	B	O
37	beta	O
38	subunit	O
39	gene	O
40	in	O
41	cells	O
42	from	O
43	normal	O
44	liver	O
45	tissue	O
46	.	O

1	Human	O
2	alpha	O
3	-	O
4	galactosidase	O
5	A	O
6	:	O
7	nucleotide	O
8	sequence	O
9	of	O
10	a	O
11	cDNA	O
12	clone	O
13	encoding	O
14	the	O
15	mature	O
16	enzyme	O
17	.	O

1	Construction	O
2	of	O
3	a	O
4	RIP1	O
5	deletion	O
6	strain	O
7	and	O
8	isolation	O
9	of	O
10	temperature	B
11	-	O
12	sensitive	O
13	mutants	O
14	.	O

1	A	O
2	chicken	O
3	paxillin	O
4	cDNA	O
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	O
21	paxil	O
22	-	O
23	lin	O
24	.	O

1	Transient	O
2	,	O
3	high	O
4	-	O
5	level	O
6	Ras	O
7	-	O
8	expression	O
9	induces	O
10	transcriptional	O
11	activation	O
12	of	O
13	p21	O
14	mediated	O
15	by	O
16	a	O
17	GC	O
18	-	O
19	rich	B
20	region	I
21	in	I
22	p21	I
23	promoter	I
24	-	I
25	83	I
26	-	O
27	54	O
28	bp	O
29	relative	O
30	to	O
31	the	O
32	transcription	O
33	initiation	O
34	site	O
35	containing	O
36	binding	O
37	sites	O
38	for	O
39	Sp1	O
40	-	O
41	family	O
42	transcription	O
43	factors	O
44	.	O

1	The	O
2	corticosterone	O
3	synthesis	O
4	inhibitor	O
5	metyrapone	O
6	(	O
7	75	O
8	mg	O
9	/	O
10	kg	O
11	i	O
12	.	O
13	p	O
14	.)	O
15	was	O
16	given	O
17	to	O
18	attenuate	O
19	the	O
20	rise	O
21	of	O
22	corticosterone	O
23	to	O
24	a	O
25	level	O
26	typical	O
27	of	O
28	stressed	O
29	males	O
30	.	O

1	Fewer	O
2	recombination	O
3	events	O
4	are	O
5	detected	O
6	in	O
7	four	O
8	different	O
9	B	O
10	and	O
11	T	O
12	cell	O
13	lines	O
14	that	O
15	do	O
16	not	O
17	undergo	O
18	switch	O
19	recombination	O
20	of	O
21	their	O
22	endogenous	O
23	genes	O
24	.	O

1	Another	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	exonic	B
8	splicing	I
9	suppressor	I
10	1	I
11	(	O
12	ESS1	O
13	),	O
14	represses	O
15	use	O
16	of	O
17	the	O
18	nt	O
19	3225	O
20	3	O
21	'	O
22	splice	O
23	site	O
24	.	O

1	Finally	O
2	,	O
3	using	O
4	in	O
5	vitro	O
6	binding	O
7	studies	O
8	,	O
9	we	O
10	showed	O
11	that	O
12	SREBP2	O
13	was	O
14	able	O
15	to	O
16	displace	O
17	ADD1	O
18	/	O
19	SREBP1	O
20	binding	O
21	from	O
22	the	O
23	sterol	O
24	regulatory	O
25	element	O
26	(	O
27	SRE	O
28	)	O
29	site	O
30	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	release	O
6	of	O
7	interleukin	O
8	-	O
9	1	O
10	beta	O
11	(	O
12	IL	O
13	-	B
14	1	I
15	)	I
16	and	I
17	tumour	O
18	necrosis	B
19	factor	I
20	-	I
21	alpha	O
22	(	O
23	TNF	O
24	)	B
25	by	I
26	unstimulated	O
27	monocytes	O
28	and	O
29	monocytes	O
30	stimulated	O
31	with	O
32	lipopolysaccharide	O
33	(	O
34	LPS	O
35	)	O
36	isolated	O
37	from	O
38	the	O
39	peripheral	O
40	blood	O
41	of	O
42	two	O
43	patients	O
44	with	O
45	acute	O
46	poststreptococcal	O
47	glomerulonephritis	O
48	(	O
49	AGN	O
50	)	O
51	and	O
52	16	O
53	healthy	O
54	controls	O
55	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	elements	O
6	that	O
7	control	O
8	promoter	O
9	activity	O
10	include	O
11	binding	O
12	sites	O
13	for	O
14	transcription	O
15	factors	O
16	Sp1	O
17	and	O
18	alphaCbf	O
19	,	O
20	a	O
21	60	O
22	-	O
23	kDa	O
24	CCAAT	O
25	box	O
26	-	O
27	binding	O
28	protein	O
29	.	O

1	This	O
2	study	O
3	compared	O
4	the	O
5	gross	O
6	and	O
7	fine	O
8	motor	O
9	performance	O
10	of	O
11	14	O
12	traumatically	O
13	brain	O
14	-	O
15	injured	O
16	children	O
17	(	O
18	five	O
19	to	O
20	15	O
21	years	O
22	old	O
23	,	O
24	with	O
25	loss	O
26	of	O
27	consciousness	O
28	for	O
29	at	O
30	least	O
31	24	O
32	hours	O
33	)	O
34	to	O
35	14	O
36	normal	O
37	children	O
38	group	O
39	matched	O
40	for	O
41	age	O
42	and	O
43	sex	O
44	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	the	O
7	structures	B
8	of	I
9	the	I
10	b	I
11	-	O
12	Zip	O
13	domain	O
14	are	O
15	well	O
16	conserved	O
17	among	O
18	these	O
19	Maf	O
20	-	O
21	related	O
22	proteins	O
23	.	O

1	The	O
2	COL7A1	O
3	gene	O
4	,	O
5	which	O
6	encodes	O
7	type	O
8	VII	O
9	collagen	O
10	,	O
11	has	O
12	been	O
13	implicated	O
14	as	O
15	a	O
16	candidate	O
17	gene	O
18	for	O
19	dominantly	O
20	and	O
21	recessively	O
22	inherited	O
23	forms	O
24	of	O
25	dystrophic	O
26	epidermolysis	O
27	bullosa	O
28	.	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	Using	O
2	homology	B
3	cloning	I
4	techniques	O
5	,	O
6	we	B
7	identified	I
8	a	I
9	mouse	I
10	homologue	I
11	of	I
12	E	O
13	(	O
14	Pc	O
15	),	O
16	termed	B
17	Epc1	I
18	,	I
19	a	O
20	yeast	O
21	protein	O
22	that	B
23	we	I
24	name	I
25	EPL1	O
26	,	O
27	and	O
28	as	O
29	well	O
30	as	O
31	additional	O
32	ESTs	O
33	from	O
34	Caenorhabditis	B
35	elegans	I
36	,	I
37	mice	I
38	and	I
39	humans	O
40	.	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	O
10	receptor	O
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	purification	O
6	of	O
7	this	O
8	larger	O
9	form	O
10	as	O
11	an	O
12	approximately	O
13	320	O
14	-	O
15	kDa	O
16	particle	O
17	that	O
18	contains	O
19	mRNP3	O
20	+	O
21	4	O
22	and	O
23	nine	O
24	additional	O
25	polypeptides	O
26	,	O
27	including	O
28	mRNA	O
29	-	O
30	binding	O
31	polypeptides	O
32	of	O
33	34	O
34	and	O
35	36	O
36	kDa	O
37	and	O
38	a	O
39	doublet	O
40	of	O
41	110	O
42	/	O
43	105	O
44	kDa	O
45	that	O
46	proved	O
47	to	O
48	be	O
49	nucleolin	O
50	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	PPSF	O
6	+	O
7	DBP	O
8	side	O
9	showed	B
10	large	I
11	amounts	I
12	of	O
13	bone	B
14	formation	B
15	,	I
16	and	O
17	bone	O
18	almost	O
19	covered	O
20	the	O
21	implant	O
22	.	O

1	Air	O
2	ion	O
3	action	O
4	on	O
5	bacteria	O
6	.	O

1	The	O
2	iron	O
3	dependence	O
4	of	O
5	transcription	B
6	and	I
7	expression	I
8	of	I
9	cvaA	I
10	,	I
11	which	I
12	encodes	O
13	a	O
14	transporter	O
15	accessory	O
16	protein	O
17	,	O
18	and	O
19	cvi	O
20	,	O
21	encoding	O
22	the	O
23	colicin	O
24	V	O
25	immunity	O
26	protein	O
27	,	O
28	was	O
29	assessed	O
30	under	O
31	conditions	O
32	of	O
33	iron	O
34	excess	O
35	or	O
36	depletion	O
37	.	O

1	U24	O
2	has	O
3	two	O
4	separate	O
5	12	O
6	nt	O
7	long	O
8	complementarities	O
9	to	O
10	a	O
11	highly	O
12	conserved	O
13	tract	O
14	of	O
15	28S	O
16	rRNA	O
17	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	properties	O
6	of	O
7	the	O
8	protein	O
9	encoded	O
10	by	O
11	neu	O
12	,	O
13	we	O
14	created	O
15	a	O
16	fusion	O
17	gene	O
18	that	B
19	joins	I
20	the	I
21	cytoplasmic	O
22	domain	O
23	of	O
24	neu	O
25	to	O
26	the	O
27	extracellular	O
28	portion	O
29	of	O
30	an	O
31	immunoglobulin	O
32	heavy	O
33	chain	O
34	.	O

1	Insulin	O
2	stimulation	O
3	promoted	O
4	the	O
5	association	O
6	of	O
7	mIRS3	O
8	with	O
9	p85	O
10	,	O
11	SHP2	O
12	,	O
13	Nck	O
14	,	O
15	and	O
16	Shc	B
17	.	I

1	Chenodeoxycholic	O
2	acid	O
3	(	O
4	cheno	O
5	)	O
6	and	O
7	ursodeoxycholic	O
8	acid	O
9	(	O
10	urso	O
11	)	O
12	dissolve	O
13	cholesterol	O
14	gallstones	O
15	in	O
16	man	O
17	.	O

1	The	O
2	ability	O
3	of	O
4	A20	O
5	to	O
6	block	O
7	NF	O
8	-	O
9	kappaB	O
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	O
15	C	O
16	-	O
17	terminal	O
18	zinc	O
19	finger	O
20	domain	O
21	.	O

1	Examination	O
2	of	O
3	the	O
4	MMP	O
5	-	O
6	2	O
7	RE1	O
8	sequence	O
9	revealed	O
10	an	O
11	incomplete	O
12	Y	O
13	-	O
14	box	O
15	sequence	O
16	(	O
17	CTGCTGGGCAAG	O
18	),	O
19	which	O
20	specifically	O
21	interacted	O
22	with	O
23	recombinant	O
24	YB	O
25	-	O
26	1	O
27	on	O
28	DMS	O
29	protection	O
30	footprinting	O
31	analysis	O
32	.	O

1	D	O
2	.	O
3	melanogaster	O
4	HeT	O
5	-	O
6	A	O
7	coding	O
8	sequences	O
9	have	O
10	a	O
11	polymorphic	B
12	region	I
13	with	I
14	insertions	I
15	/	I
16	deletions	I
17	of	I
18	1	I
19	-	I
20	31	I
21	codons	I
22	and	O
23	many	O
24	nucleotide	O
25	changes	O
26	.	O

1	This	O
2	conclusion	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	B
7	blotting	I
8	analysis	I
9	of	I
10	the	I
11	5	I
12	'-	O
13	flanking	O
14	region	O
15	of	O
16	CAD	O
17	gene	O
18	.	O

1	A	O
2	highly	O
3	hydrophobic	O
4	sequence	O
5	located	O
6	near	O
7	the	O
8	carboxyl	O
9	-	O
10	terminal	O
11	extremity	O
12	of	O
13	the	O
14	molecule	O
15	most	O
16	likely	O
17	constitutes	O
18	the	O
19	anchor	O
20	to	O
21	the	O
22	plasma	O
23	membrane	O
24	.	O

1	Oncological	O
2	,	O
3	clinical	O
4	and	O
5	psychological	O
6	aspects	O
7	are	O
8	evaluated	O
9	according	O
10	to	O
11	experience	O
12	accumulated	O
13	in	B
14	recent	I
15	years	I
16	,	O
17	with	O
18	immediate	O
19	and	O
20	delayed	O
21	reconstruction	O
22	,	O
23	carried	B
24	out	I
25	in	I
26	the	O
27	most	O
28	diverse	O
29	specialized	O
30	centers	O
31	.	O

1	Cheung	O
2	and	O
3	S	O
4	.	O

1	Our	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	hexamer	O
7	and	O
8	the	O
9	octamer	O
10	motifs	O
11	may	O
12	play	O
13	important	O
14	role	O
15	(	O
16	s	O
17	)	O
18	in	O
19	regulation	O
20	of	O
21	replication	O
22	-	O
23	dependent	O
24	but	O
25	not	O
26	of	O
27	replication	O
28	-	O
29	independent	O
30	expression	O
31	of	O
32	the	O
33	wheat	O
34	histone	O
35	H3	O
36	gene	O
37	.	O

1	Mapping	O
2	the	O
3	cAMP	O
4	receptor	O
5	protein	O
6	contact	O
7	site	O
8	on	O
9	the	O
10	alpha	O
11	subunit	O
12	of	O
13	Escherichia	O
14	coli	O
15	RNA	O
16	polymerase	O
17	.	O

1	In	O
2	protocol	O
3	2	O
4	,	O
5	eight	O
6	different	O
7	subjects	O
8	performed	O
9	Con	B
10	and	I
11	Ecc	I
12	arm	I
13	curls	I
14	to	O
15	fatigue	B
16	,	I
17	followed	I
18	by	I
19	postexercise	I
20	muscle	I
21	ischemia	O
22	,	O
23	by	O
24	using	O
25	the	O
26	same	O
27	resistance	O
28	as	O
29	in	O
30	protocol	O
31	1	O
32	.	O

1	After	O
2	treatment	O
3	with	O
4	tunicamycin	O
5	,	O
6	the	O
7	transfectants	O
8	secreted	O
9	unglycosylated	O
10	18	O
11	-	O
12	kDa	O
13	polypeptides	O
14	which	O
15	could	O
16	also	O
17	bind	O
18	IgE	O
19	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	pattern	O
7	of	O
8	blood	O
9	supply	O
10	is	B
11	relevant	I
12	to	I
13	the	I
14	structural	I
15	organisation	O
16	of	O
17	mature	O
18	lamellar	O
19	bone	O
20	around	O
21	the	O
22	implant	O
23	.	O

1	Infants	O
2	of	O
3	this	O
4	sample	O
5	had	O
6	monocular	B
7	PL	I
8	visual	I
9	acuities	I
10	similar	I
11	to	I
12	those	I
13	established	I
14	by	I
15	McDonald	I
16	et	I
17	al	I
18	.	O
19	in	O
20	a	O
21	laboratory	O
22	setting	O
23	.	O

1	We	O
2	have	O
3	therefore	O
4	evaluated	O
5	the	O
6	efficacy	O
7	and	O
8	safety	B
9	of	I
10	doxazosin	I
11	,	O
12	a	B
13	new	I
14	orally	O
15	active	O
16	selective	O
17	alpha	O
18	1	O
19	blocker	O
20	,	O
21	in	O
22	patients	O
23	with	O
24	systemic	O
25	hypertension	O
26	with	O
27	concomitant	O
28	airflow	O
29	limitation	O
30	.	O

1	Previous	O
2	analysis	O
3	of	O
4	the	O
5	98	O
6	-	O
7	bp	O
8	sequence	B
9	has	I
10	delineated	I
11	several	I
12	protein	I
13	-	I
14	binding	O
15	domains	O
16	that	O
17	are	O
18	recognized	O
19	by	O
20	nuclear	O
21	factors	O
22	present	O
23	in	O
24	human	O
25	brain	O
26	cells	O
27	.	O

1	Nuclear	O
2	extracts	O
3	prepared	O
4	from	O
5	both	O
6	neural	O
7	and	O
8	non	B
9	-	I
10	neural	I
11	cell	I
12	lines	O
13	,	B
14	mouse	I
15	brain	I
16	,	I
17	and	O
18	mouse	O
19	liver	O
20	contain	O
21	proteins	O
22	that	O
23	recognize	O
24	and	O
25	bind	O
26	to	O
27	the	O
28	PROX	O
29	and	O
30	PAL	O
31	sequences	O
32	indicating	O
33	that	O
34	proteins	O
35	which	O
36	bind	O
37	to	O
38	these	O
39	target	O
40	sequences	O
41	are	O
42	widespread	O
43	.	O

1	Thus	O
2	in	O
3	this	O
4	region	O
5	of	O
6	the	O
7	vessel	O
8	pyridinoline	O
9	represents	O
10	the	O
11	major	B
12	stabilising	I
13	crosslink	O
14	of	O
15	collagen	O
16	.	O

1	However	O
2	,	O
3	mechanisms	O
4	underlying	O
5	HIV	O
6	-	O
7	1	O
8	gene	O
9	expression	B
10	in	I
11	the	I
12	CNS	I
13	are	I
14	poorly	O
15	understood	O
16	.	O

1	CONCLUSIONS	O
2	:	B
3	We	I
4	obtained	O
5	normal	B
6	EPO	I
7	levels	I
8	for	O
9	mothers	O
10	and	O
11	newborns	O
12	for	O
13	our	O
14	area	O
15	,	O
16	similarly	O
17	to	O
18	the	O
19	previously	O
20	described	O
21	ones	O
22	.	O

1	Initial	O
2	results	O
3	indicate	O
4	that	O
5	this	O
6	23S	O
7	pre	O
8	-	O
9	rRNA	O
10	is	O
11	the	O
12	same	O
13	as	O
14	the	O
15	species	O
16	detected	O
17	on	O
18	depletion	O
19	of	O
20	the	O
21	small	O
22	nucleolar	O
23	RNA	O
24	-	O
25	associated	O
26	proteins	O
27	NOP1	O
28	and	O
29	GAR1	O
30	and	O
31	in	O
32	an	O
33	snr10	O
34	mutant	O
35	strain	O
36	.	O

1	Spontaneous	O
2	degradation	O
3	of	O
4	atracurium	O
5	in	O
6	plasma	O
7	is	O
8	the	O
9	major	O
10	route	O
11	of	O
12	elimination	O
13	in	O
14	man	O
15	and	O
16	contributes	O
17	to	O
18	a	O
19	short	O
20	elimination	O
21	half	O
22	-	O
23	life	O
24	(	O
25	approximatively	O
26	20	O
27	min	O
28	).	O

1	Northern	O
2	blot	O
3	hybridization	O
4	demonstrated	O
5	that	O
6	HEP	O
7	-	O
8	COP	O
9	was	O
10	expressed	O
11	in	O
12	a	O
13	wide	O
14	range	O
15	of	O
16	human	O
17	adult	O
18	and	O
19	fetal	O
20	tissues	O
21	.	O

1	We	O
2	discuss	O
3	these	O
4	results	O
5	in	O
6	terms	O
7	of	O
8	the	B
9	influence	I
10	that	I
11	time	I
12	and	O
13	nutritional	O
14	constraints	O
15	have	O
16	on	O
17	odonate	O
18	development	O
19	patterns	O
20	and	O
21	fitness	O
22	.	O

1	Records	O
2	of	O
3	31	B
4	children	I
5	with	I
6	AIDS	I
7	or	I
8	AIDS	I
9	-	I
10	related	I
11	complex	I
12	admitted	I
13	to	I
14	the	I
15	pediatric	I
16	intensive	I
17	care	O
18	unit	O
19	for	O
20	acute	O
21	respiratory	O
22	failure	O
23	throughout	O
24	a	O
25	46	O
26	-	B
27	month	I
28	period	I
29	were	I
30	reviewed	I
31	.	I

1	Point	O
2	mutations	O
3	of	O
4	the	O
5	site	O
6	that	O
7	suppressed	O
8	Pit	O
9	-	O
10	1	O
11	binding	O
12	in	O
13	vitro	O
14	restored	O
15	full	O
16	tiGH	O
17	promoter	O
18	activity	O
19	.	O

1	None	O
2	were	O
3	restricted	O
4	from	O
5	clinical	O
6	duties	O
7	,	B
8	were	I
9	given	I
10	varicella	I
11	-	I
12	zoster	O
13	immune	O
14	globulin	O
15	,	O
16	or	O
17	developed	O
18	disease	O
19	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	B

1	Disruption	O
2	of	B
3	the	I
4	IRA2	I
5	gene	O
6	resulted	O
7	in	O
8	(	O
9	i	O
10	)	O
11	increased	B
12	sensitivity	I
13	to	I
14	heat	I
15	shock	I
16	and	I
17	nitrogen	O
18	starvation	O
19	,	O
20	(	O
21	ii	O
22	)	O
23	sporulation	O
24	defects	O
25	,	O
26	and	O
27	(	O
28	iii	O
29	)	O
30	suppression	O
31	of	O
32	the	O
33	lethality	O
34	of	O
35	the	O
36	cdc25	O
37	mutant	O
38	.	O

1	The	O
2	FBF	O
3	questionnaire	O
4	did	O
5	not	O
6	highlight	O
7	a	O
8	characteristic	O
9	basic	O
10	symptoms	O
11	profile	O
12	of	O
13	schizoaffective	O
14	disorder	O
15	,	O
16	when	O
17	compared	O
18	with	O
19	bipolar	O
20	affective	O
21	disorder	O
22	and	O
23	schizophrenia	O
24	.	O

1	Sources	O
2	of	O
3	noise	O
4	in	O
5	these	O
6	signals	O
7	were	O
8	evaluated	B
9	in	I
10	preparations	I
11	stained	O
12	with	O
13	the	O
14	potentiometric	O
15	probe	O
16	RH	O
17	-	B
18	414	I
19	.	I

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	CBF	O
9	/	O
10	NF	O
11	-	O
12	Y	O
13	to	O
14	the	O
15	inverted	O
16	CCAAT	O
17	box	O
18	is	O
19	responsible	O
20	for	O
21	transcriptional	O
22	activation	O
23	of	O
24	the	O
25	nTPH	O
26	gene	O
27	.	O

1	When	O
2	the	O
3	PHT	O
4	and	O
5	CSA	O
6	groups	O
7	were	O
8	compared	O
9	,	O
10	Hyp	O
11	levels	O
12	were	O
13	significantly	O
14	higher	O
15	in	O
16	the	O
17	PHT	O
18	-	O
19	GO	O
20	+	O
21	group	O
22	than	O
23	in	O
24	the	O
25	CSA	O
26	-	O
27	GO	O
28	+	O
29	group	O
30	.	O

1	In	O
2	both	O
3	cases	O
4	,	O
5	at	O
6	the	O
7	end	O
8	of	O
9	exposure	O
10	the	O
11	same	O
12	level	O
13	of	O
14	blood	O
15	carboxyhemoglobin	O
16	(	O
17	COHb	O
18	)	O
19	(	O
20	about	O
21	50	O
22	%)	O
23	was	O
24	reached	O
25	.	O

1	On	O
2	the	O
3	basis	O
4	of	B
5	size	I
6	,	I
7	the	I
8	CRS	O
9	sequence	O
10	to	O
11	which	O
12	it	O
13	binds	O
14	,	O
15	and	O
16	its	O
17	tentative	O
18	identification	O
19	as	O
20	a	O
21	zinc	O
22	finger	B
23	protein	I
24	,	I
25	Adx	O
26	factor	O
27	has	O
28	been	O
29	identified	O
30	as	O
31	a	O
32	Kruppel	O
33	-	O
34	like	O
35	zinc	O
36	finger	B
37	protein	B
38	(	I
39	a	I
40	mouse	B
41	ZBP	O
42	-	I
43	89	O
44	homologue	O
45	).	O

1	Micro	O
2	high	O
3	-	O
4	performance	O
5	liquid	O
6	chromatographic	O
7	system	O
8	with	O
9	micro	O
10	precolumn	O
11	and	O
12	dual	O
13	electrochemical	O
14	detector	O
15	for	O
16	direct	O
17	injection	O
18	analysis	O
19	of	O
20	catecholamines	O
21	in	O
22	body	O
23	fluids	O
24	.	O

1	A	O
2	quantitative	O
3	analysis	O
4	of	O
5	the	O
6	diffraction	O
7	intensity	O
8	as	O
9	function	O
10	of	O
11	the	O
12	accumulated	O
13	electron	O
14	dose	O
15	suggests	O
16	the	O
17	possibility	O
18	of	O
19	recording	O
20	up	O
21	to	O
22	250	O
23	diffraction	O
24	patterns	O
25	with	O
26	3	O
27	.	O
28	5	O
29	A	O
30	resolution	O
31	from	O
32	a	B
33	single	I
34	crotoxin	I
35	complex	I
36	crystal	I
37	128	I
38	A	O
39	thick	O
40	.	O

1	These	O
2	"	O
3	nucleocapsid	O
4	-	O
5	like	O
6	"	O
7	structures	O
8	were	O
9	readily	O
10	purified	O
11	by	O
12	density	O
13	gradient	O
14	centrifugation	O
15	.	O

1	Review	O
2	:	O
3	deterioration	O
4	of	O
5	glucose	O
6	tolerance	O
7	with	O
8	age	O
9	:	O
10	the	O
11	role	O
12	of	O
13	insulin	B
14	resistance	I
15	.	I

1	The	O
2	experimental	O
3	design	O
4	represents	O
5	a	O
6	2	O
7	x	O
8	3	O
9	factorial	O
10	arrangement	O
11	of	O
12	treatments	O
13	with	O
14	three	O
15	dietary	O
16	levels	O
17	of	O
18	incorporation	O
19	of	O
20	RSB	O
21	(	O
22	0	O
23	,	O
24	50	O
25	,	O
26	and	O
27	100	O
28	%),	O
29	and	O
30	chickens	O
31	either	O
32	infected	O
33	or	O
34	uninfected	O
35	.	O

1	A	O
2	major	O
3	task	O
4	for	O
5	sports	O
6	scientists	O
7	may	O
8	be	O
9	to	O
10	verify	O
11	empirically	O
12	the	O
13	nature	O
14	of	O
15	an	O
16	integrated	O
17	model	O
18	of	B
19	the	I
20	sport	I
21	performer	I
22	.	O

1	The	O
2	effects	O
3	of	O
4	dominant	O
5	interfering	O
6	forms	O
7	of	O
8	the	O
9	JNK	O
10	/	O
11	p38	O
12	signaling	O
13	pathway	O
14	demonstrate	O
15	that	O
16	activation	O
17	of	O
18	these	O
19	kinases	O
20	is	O
21	critical	O
22	for	O
23	cytokine	O
24	-	O
25	induced	O
26	E	O
27	-	O
28	selectin	O
29	gene	O
30	expression	O
31	.	O

1	The	O
2	side	O
3	-	O
4	to	O
5	-	O
6	side	O
7	difference	O
8	was	O
9	statistically	O
10	significant	O
11	at	O
12	EXT	O
13	30	O
14	degrees	O
15	/	O
16	s	O
17	and	O
18	60	O
19	degrees	O
20	/	O
21	s	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	A	O
2	substantial	O
3	fraction	O
4	of	O
5	Cbl	O
6	was	O
7	constitutively	O
8	associated	O
9	with	O
10	Grb2	O
11	and	O
12	this	O
13	interaction	O
14	was	O
15	mediated	O
16	by	O
17	Grb2	O
18	SH3	O
19	domains	O
20	.	O

1	Interdomain	O
2	signaling	O
3	in	O
4	a	O
5	two	O
6	-	O
7	domain	O
8	fragment	O
9	of	O
10	the	O
11	human	O
12	glucocorticoid	O
13	receptor	O
14	.	O

1	Overproduction	O
2	of	O
3	HrcA	O
4	protein	O
5	from	O
6	a	O
7	second	O
8	copy	O
9	of	O
10	hrcA	O
11	derived	O
12	from	O
13	a	O
14	plasmid	O
15	(	O
16	phrcA	O
17	+)	O
18	in	O
19	B	O
20	.	O
21	subtilis	O
22	wild	O
23	-	O
24	type	O
25	and	O
26	delta	O
27	hrcA	O
28	strains	O
29	prevented	O
30	heat	O
31	shock	O
32	induction	O
33	of	O
34	the	O
35	dnaK	O
36	and	O
37	groE	O
38	operons	O
39	at	O
40	the	O
41	level	O
42	of	O
43	transcription	O
44	almost	O
45	completely	O
46	and	O
47	strongly	O
48	reduced	O
49	the	O
50	amounts	O
51	of	O
52	mRNA	O
53	at	O
54	a	O
55	low	O
56	temperature	O
57	as	O
58	well	O
59	.	O

1	The	O
2	clinical	O
3	tolerance	O
4	and	O
5	pharmacokinetics	O
6	of	O
7	FCE	O
8	22101	O
9	(	O
10	sodium	O
11	(	O
12	5R	O
13	,	O
14	6S	O
15	)-	O
16	6	O
17	-[(	O
18	1R	O
19	)-	O
20	hydroxyethyl	O
21	]-	O
22	2	O
23	-	O
24	carbamoyloxymethyl	O
25	-	O
26	2	O
27	-	O
28	penem	O
29	-	O
30	3	O
31	-	O
32	carboxylate	O
33	),	O
34	a	O
35	new	O
36	penem	O
37	antibiotic	O
38	,	O
39	have	O
40	been	O
41	studied	O
42	after	O
43	giving	O
44	a	O
45	single	O
46	i	O
47	.	O
48	v	O
49	.	O
50	dose	O
51	of	O
52	4	O
53	mg	O
54	.	O
55	kg	O
56	-	O
57	1	O
58	to	O
59	ten	O
60	healthy	O
61	male	O
62	volunteers	O
63	.	O

1	A	O
2	.	O

1	Furthermore	O
2	,	O
3	beta	O
4	2	O
5	-	O
6	adrenoceptor	O
7	sensitivity	B
8	appears	I
9	to	I
10	be	I
11	unaltered	I
12	in	I
13	BHT	I
14	.	I

1	Efficient	O
2	phosphorylation	O
3	of	O
4	BRDG1	O
5	by	O
6	Tec	O
7	required	O
8	the	O
9	PH	O
10	and	O
11	SH2	O
12	domains	O
13	as	O
14	well	O
15	as	O
16	the	O
17	kinase	O
18	domain	O
19	of	O
20	the	O
21	latter	O
22	.	O

1	Second	O
2	,	B
3	the	I
4	transcription	I
5	factor	I
6	Gal	I
7	-	I
8	ER	I
9	was	I
10	rendered	O
11	more	B
12	potent	I
13	and	I
14	less	O
15	susceptible	O
16	to	O
17	cell	O
18	type	O
19	-	O
20	specific	O
21	variation	O
22	by	O
23	fusing	O
24	the	O
25	strong	O
26	activating	O
27	domain	O
28	of	O
29	the	O
30	herpesvirus	O
31	protein	O
32	VP16	O
33	onto	O
34	its	O
35	C	O
36	terminus	O
37	.	O

1	Patients	O
2	were	O
3	subclassified	O
4	into	O
5	age	O
6	-	O
7	matched	O
8	groups	O
9	of	O
10	primary	O
11	untreated	O
12	cancer	O
13	(	O
14	21	O
15	),	O
16	recurrent	O
17	cancer	O
18	(	O
19	18	O
20	),	O
21	and	O
22	"	O
23	cured	O
24	"	O
25	patients	O
26	who	O
27	had	O
28	been	O
29	free	O
30	of	O
31	disease	O
32	for	O
33	at	O
34	least	O
35	9	O
36	months	O
37	(	O
38	16	O
39	).	O

1	Morphine	O
2	produced	O
3	a	O
4	dose	B
5	-	I
6	dependent	I
7	bradycardia	I
8	followed	O
9	by	O
10	tachycardia	O
11	.	O

1	This	O
2	correlated	O
3	with	O
4	reduced	O
5	levels	O
6	of	O
7	secreted	O
8	hepatitis	O
9	B	O
10	e	O
11	antigen	O
12	and	O
13	increased	O
14	intracellular	O
15	levels	O
16	of	O
17	core	O
18	and	O
19	Pol	O
20	proteins	O
21	and	O
22	replicative	O
23	HBV	O
24	DNA	O
25	intermediates	O
26	.	O

1	Range	O
2	,	O
3	variations	O
4	and	O
5	neoplastic	O
6	potential	O
7	.	O

1	Kodak	O
2	XV	O
3	-	O
4	2	O
5	film	O
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	Abstracts	O
2	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	a	O
6	raised	O
7	hydroxykynurenine	O
8	/	O
9	hydroxyanthranilic	O
10	acid	O
11	ratio	O
12	does	O
13	not	O
14	necessarily	O
15	indicate	O
16	vitamin	O
17	B6	O
18	deficiency	O
19	but	O
20	may	O
21	represent	O
22	a	O
23	nonspecific	O
24	response	O
25	of	O
26	tryptophan	O
27	metabolism	O
28	to	O
29	stress	O
30	.	O

1	Preface	O
2	.	O

1	A	O
2	sheep	O
3	testicular	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	pcDNA1	O
9	vector	O
10	was	O
11	screened	B
12	with	I
13	a	I
14	probe	I
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	B
31	fragment	I
32	of	I
33	the	I
34	rat	O
35	luteinizing	O
36	hormone	O
37	receptor	O
38	cDNA	O
39	.	O

1	The	O
2	responses	O
3	of	O
4	the	O
5	"	O
6	stress	O
7	hormones	O
8	"	O
9	cortisol	O
10	,	O
11	11	O
12	-	O
13	deoxycortisol	O
14	,	O
15	ACTH	O
16	,	O
17	vasopressin	O
18	(	O
19	AVP	O
20	),	O
21	and	O
22	corticotropin	O
23	releasing	O
24	factor	O
25	(	O
26	CRF	O
27	)	O
28	were	O
29	studied	O
30	in	O
31	6	O
32	normal	O
33	males	O
34	in	O
35	response	B
36	to	I
37	acute	I
38	cortisol	O
39	deficiency	O
40	induced	O
41	by	O
42	the	O
43	11	O
44	-	O
45	beta	O
46	-	O
47	hydroxylase	O
48	inhibitor	O
49	,	O
50	metyrapone	O
51	.	O

1	These	O
2	studies	O
3	point	O
4	to	O
5	the	O
6	involvement	O
7	of	O
8	the	O
9	MAP	O
10	kinase	O
11	pathway	O
12	in	O
13	the	O
14	activation	O
15	of	O
16	monocytic	O
17	cells	O
18	during	O
19	transmigration	O
20	to	O
21	inflammatory	O
22	sites	O
23	.	O

1	The	O
2	high	O
3	conservation	O
4	of	O
5	the	O
6	3	O
7	'	O
8	terminus	O
9	suggests	O
10	that	O
11	this	O
12	region	O
13	directs	O
14	the	O
15	assembly	B
16	of	I
17	proteins	I
18	required	I
19	for	I
20	the	O
21	initiation	B
22	of	I
23	RNA	I
24	replication	I
25	.	I

1	The	O
2	cDNA	O
3	contained	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1392	O
10	bp	O
11	that	O
12	predicted	O
13	a	O
14	protein	O
15	of	O
16	464	O
17	amino	O
18	acids	O
19	and	O
20	a	O
21	molecular	O
22	mass	O
23	of	O
24	52	O
25	kDa	O
26	;	B
27	this	I
28	protein	O
29	has	O
30	97	O
31	%	O
32	identity	O
33	to	O
34	rat	B
35	liver	I
36	glucokinase	O
37	.	O

1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O

1	We	O
2	emphasize	O
3	that	O
4	ANCA	O
5	-	O
6	associated	O
7	vasculitis	O
8	is	O
9	another	O
10	important	O
11	complication	O
12	of	O
13	RA	O
14	.	O

1	Within	O
2	this	O
3	sequence	B
4	the	I
5	MSAS	I
6	gene	O
7	was	O
8	identified	O
9	as	O
10	a	O
11	5322	B
12	-	O
13	bp	O
14	-	O
15	long	O
16	open	B
17	reading	I
18	frame	I
19	coding	O
20	for	O
21	a	O
22	protein	O
23	of	O
24	1774	O
25	amino	O
26	acids	O
27	and	O
28	190	O
29	,	O
30	731	O
31	Da	O
32	molecular	O
33	mass	O
34	.	O

1	SF	O
2	-	O
3	1	O
4	does	O
5	not	O
6	have	O
7	an	O
8	N	O
9	-	O
10	terminal	O
11	AF1	O
12	domain	O
13	.	O

1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	B
9	latent	I
10	genes	I
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	B
29	normal	I
30	and	I
31	T	I
32	.	I
33	brucei	O
34	-	B
35	infected	I
36	rabbits	I
37	by	I
38	Southern	I
39	blotting	I
40	.	O

1	The	O
2	mouse	O
3	extracellular	O
4	signal	O
5	-	O
6	regulated	O
7	kinase	O
8	2	O
9	gene	O
10	.	O

1	The	O
2	virus	O
3	-	O
4	associated	O
5	VAI	O
6	RNA	O
7	of	O
8	adenovirus	O
9	is	O
10	a	O
11	small	O
12	highly	O
13	structured	O
14	RNA	O
15	that	O
16	is	O
17	required	O
18	for	O
19	the	O
20	efficient	O
21	translation	O
22	of	O
23	cellular	O
24	and	O
25	viral	O
26	mRNAs	O
27	at	O
28	late	O
29	times	O
30	after	O
31	infection	O
32	.	O

1	The	O
2	3	O
3	'	O
4	terminus	O
5	of	B
6	the	I
7	genome	I
8	can	I
9	be	I
10	folded	O
11	into	O
12	a	O
13	tRNA	O
14	-	O
15	like	O
16	secondary	O
17	structure	O
18	that	O
19	has	O
20	a	O
21	valine	O
22	anticodon	O
23	;	O
24	the	O
25	tRNA	O
26	-	O
27	like	O
28	structure	O
29	lacks	O
30	a	O
31	pseudoknot	O
32	in	O
33	the	O
34	aminoacyl	O
35	stem	O
36	,	O
37	a	O
38	feature	O
39	common	O
40	to	O
41	both	O
42	genera	O
43	of	O
44	tetraviruses	O
45	.	O

1	Concomitantly	O
2	,	O
3	p34CDC2	O
4	histone	O
5	H1	O
6	kinase	O
7	activity	O
8	increases	O
9	in	O
10	the	O
11	former	O
12	,	O
13	but	O
14	not	O
15	in	O
16	the	O
17	latter	O
18	cell	O
19	lines	O
20	,	O
21	hence	O
22	suggesting	O
23	a	O
24	role	O
25	for	O
26	this	O
27	protein	O
28	in	O
29	radiation	O
30	-	O
31	induced	O
32	cell	O
33	death	O
34	.	O

1	We	O
2	present	B
3	the	B
4	preliminary	I
5	results	O
6	obtained	O
7	on	O
8	36	O
9	patients	O
10	which	O
11	were	O
12	followed	O
13	for	O
14	a	B
15	mean	I
16	period	I
17	of	I
18	12	O
19	months	B
20	.	I

1	These	O
2	characteristic	O
3	structural	O
4	features	O
5	were	O
6	used	O
7	to	O
8	create	O
9	the	O
10	abbreviation	O
11	AZF1	O
12	(	O
13	Asparagine	O
14	-	O
15	rich	O
16	Zinc	O
17	Finger	O
18	protein	O
19	).	O

1	The	O
2	gene	O
3	structure	O
4	of	B
5	Elk1	I
6	spans	I
7	15	I
8	.	I
9	2	I
10	kb	I
11	and	I
12	consists	I
13	of	O
14	seven	B
15	exons	I
16	and	I
17	six	I
18	introns	I
19	.	I

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	SOS1	O
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	O
19	-	O
20	gamma1	O
21	SH3	O
22	domain	O
23	.	O

1	These	O
2	studies	O
3	support	O
4	the	O
5	view	O
6	that	O
7	HMG	O
8	I	O
9	(	O
10	Y	O
11	)	O
12	is	O
13	an	O
14	important	O
15	cofactor	O
16	for	O
17	HLA	O
18	-	O
19	DRA	O
20	gene	O
21	activation	O
22	by	O
23	Oct	O
24	-	O
25	2A	O
26	and	O
27	provide	O
28	insights	O
29	into	O
30	its	O
31	mechanism	O
32	of	O
33	action	O
34	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	RPE65	O
7	,	O
8	a	O
9	novel	O
10	retinal	O
11	pigment	O
12	epithelium	O
13	-	O
14	specific	O
15	microsomal	O
16	protein	O
17	that	O
18	is	O
19	post	O
20	-	O
21	transcriptionally	O
22	regulated	O
23	in	O
24	vitro	O
25	.	O

1	In	O
2	addition	O
3	,	O
4	two	O
5	internal	O
6	promoters	O
7	,	O
8	PmiaA	O
9	and	O
10	P1hfq	O
11	were	O
12	identified	O
13	and	O
14	mapped	O
15	to	O
16	201	O
17	and	O
18	837	O
19	nucleotides	O
20	upstream	O
21	from	O
22	the	O
23	respective	O
24	translation	O
25	start	O
26	sites	O
27	.	O

1	Mapping	O
2	of	O
3	the	O
4	mouse	O
5	ornithine	O
6	decarboxylase	O
7	-	B
8	related	I
9	sequence	I
10	family	I
11	.	O

1	Heterozygous	O
2	mutation	O
3	in	O
4	the	O
5	G	O
6	+	O
7	5	O
8	position	O
9	of	O
10	intron	O
11	33	O
12	of	O
13	the	O
14	pro	O
15	-	O
16	alpha	O
17	2	O
18	(	O
19	I	O
20	)	O
21	gene	O
22	(	O
23	COL1A2	O
24	)	O
25	that	O
26	causes	O
27	aberrant	O
28	RNA	O
29	splicing	O
30	and	O
31	lethal	O
32	osteogenesis	O
33	imperfecta	O
34	.	O

1	None	O
2	of	O
3	the	O
4	five	O
5	proprotein	O
6	processing	O
7	proteases	O
8	tested	O
9	were	O
10	capable	O
11	of	O
12	cleaving	O
13	human	O
14	pro	O
15	-	O
16	LPH	O
17	,	O
18	strongly	O
19	suggesting	O
20	that	O
21	they	O
22	are	O
23	not	O
24	involved	O
25	in	O
26	the	O
27	maturation	O
28	of	O
29	this	O
30	enzyme	O
31	.	O

1	An	O
2	aromatic	O
3	stacking	O
4	interaction	O
5	between	O
6	subunits	O
7	helps	O
8	mediate	O
9	DNA	O
10	sequence	O
11	specificity	O
12	:	O
13	operator	O
14	site	O
15	discrimination	O
16	by	O
17	phage	O
18	lambda	O
19	cI	O
20	repressor	O
21	.	O

1	The	O
2	results	O
3	indicate	O
4	that	B
5	the	I
6	bradycardic	I
7	agents	I
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	I
22	infarction	I
23	in	O
24	conscious	O
25	dogs	O
26	.	O

1	The	O
2	liver	O
3	in	O
4	the	O
5	severely	O
6	ill	O

1	In	O
2	support	O
3	of	O
4	a	O
5	role	O
6	at	O
7	the	O
8	spindle	O
9	,	O
10	two	O
11	-	O
12	hybrid	O
13	library	O
14	screening	O
15	with	O
16	HEF1	O
17	identifies	O
18	the	O
19	human	O
20	homolog	O
21	of	O
22	the	O
23	G2	O
24	/	O
25	M	O
26	spindle	O
27	-	O
28	regulatory	O
29	protein	O
30	Dim1p	O
31	as	O
32	a	O
33	specific	O
34	interactor	O
35	with	O
36	a	O
37	region	O
38	of	O
39	HEF1	O
40	encompassed	O
41	in	O
42	p55	O
43	(	O
44	HEF1	O
45	).	O

1	The	O
2	enzymatic	O
3	response	O
4	of	O
5	neutrophils	O
6	and	O
7	monocytes	O
8	was	O
9	similar	O
10	although	O
11	the	O
12	magnitude	O
13	of	O
14	the	O
15	NADPH	O
16	oxidase	O
17	activity	O
18	was	O
19	significantly	O
20	higher	O
21	in	O
22	neutrophils	O
23	than	O
24	in	O
25	monocytes	O
26	.	O

1	With	O
2	both	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	the	O
8	mutant	O
9	enzymes	O
10	,	O
11	ATP	O
12	activates	O
13	both	O
14	[	O
15	14C	O
16	]	O
17	Asp	O
18	in	O
19	equilibrium	O
20	N	O
21	-	O
22	carbamyl	O
23	-	O
24	L	O
25	-	O
26	aspartate	O
27	(	O
28	C	O
29	-	O
30	Asp	O
31	)	O
32	and	O
33	the	O
34	[	O
35	32P	O
36	]	O
37	carbamyl	O
38	phosphate	O
39	(	O
40	C	O
41	-	O
42	P	O
43	)	O
44	in	O
45	equilibrium	O
46	Pi	O
47	exchanges	O
48	.	O

1	A	O
2	potential	O
3	outcome	O
4	of	O
5	these	O
6	biochemical	O
7	effects	O
8	may	O
9	include	O
10	the	O
11	limited	O
12	responsiveness	O
13	of	B
14	infected	B
15	T	I
16	cells	O
17	to	O
18	antigenic	O
19	stimulation	O
20	observed	O
21	during	O
22	HIV	O
23	-	O
24	1	O
25	infection	O
26	.	O

1	The	O
2	pen	O
3	can	O
4	heal	O
5	.	O

1	An	O
2	anchored	O
3	AFLP	O
4	-	O
5	and	O
6	retrotransposon	O
7	-	O
8	based	O
9	map	O
10	of	O
11	diploid	O
12	Avena	O
13	.	O

1	Oligonucleotides	O
2	,	O
3	designed	O
4	on	O
5	the	O
6	basis	O
7	of	O
8	conserved	O
9	flanking	O
10	amino	O
11	acid	B
12	sequence	I
13	segments	I
14	within	I
15	the	I
16	catalytic	I
17	domain	I
18	of	I
19	eukaryotic	I
20	protein	I
21	kinase	I
22	C	I
23	(	O
24	PKC	O
25	)	O
26	proteins	O
27	,	O
28	were	O
29	used	O
30	as	O
31	primers	O
32	for	O
33	polymerase	O
34	chain	O
35	reactions	O
36	to	O
37	amplify	O
38	a	O
39	427	O
40	-	O
41	bp	O
42	chromosomal	O
43	DNA	O
44	fragment	O
45	from	O
46	the	O
47	filamentous	B
48	fungus	I
49	Trichoderma	O
50	reesei	I
51	.	B

1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	O
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	O
19	-	O
20	fos	O
21	gene	O
22	family	O
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O

1	For	O
2	monocytes	O
3	,	O
4	as	O
5	measured	O
6	on	O
7	the	O
8	Hematrak	O
9	,	O
10	it	O
11	was	O
12	13	O
13	.	O
14	4	O
15	%.	O

1	Furthermore	O
2	,	O
3	as	O
4	in	O
5	the	O
6	human	O
7	gene	O
8	,	O
9	the	O
10	3	O
11	'	O
12	end	O
13	of	O
14	the	O
15	Cacna1f	O
16	gene	O
17	maps	O
18	within	O
19	5	O
20	kb	O
21	of	O
22	the	O
23	5	O
24	'	O
25	end	O
26	of	O
27	the	O
28	mouse	O
29	synaptophysin	O
30	gene	O
31	in	O
32	a	O
33	region	O
34	orthologous	O
35	to	O
36	Xp11	O
37	.	O
38	23	O
39	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	total	B
7	protein	O
8	profiles	O
9	of	O
10	wild	O
11	-	O
12	type	O
13	S	O
14	.	O
15	entomophila	O
16	UC9	O
17	and	O
18	mutant	O
19	UC21	O
20	revealed	O
21	that	O
22	the	O
23	mutant	O
24	lacked	O
25	an	O
26	approximately	O
27	44	O
28	-	B
29	kDa	I
30	protein	O
31	and	O
32	overexpressed	O
33	an	O
34	approximately	O
35	20	B
36	-	I
37	kDa	O
38	protein	O
39	.	O

1	The	O
2	C2C	O
3	-	O
4	Prx	O
5	is	O
6	encoded	O
7	as	O
8	a	O
9	preprotein	O
10	of	O
11	273	O
12	amino	O
13	acids	O
14	containing	O
15	a	O
16	putative	O
17	chloroplast	O
18	-	O
19	targeting	O
20	signal	B
21	of	I
22	65	I
23	amino	I
24	acids	I
25	at	I
26	its	I
27	N	I
28	-	I
29	terminus	O
30	.	O

1	A	O
2	tyrosine	O
3	-	O
4	based	O
5	sorting	O
6	signal	O
7	in	O
8	the	O
9	beta2	O
10	integrin	O
11	cytoplasmic	O
12	domain	B
13	mediates	I
14	its	O
15	recycling	O
16	to	O
17	the	O
18	plasma	O
19	membrane	O
20	and	O
21	is	O
22	required	O
23	for	O
24	ligand	O
25	-	O
26	supported	O
27	migration	O
28	.	O

1	Horvath	O
2	,	O
3	I	O
4	.	O

1	In	O
2	vivo	O
3	,	O
4	CARbeta	O
5	/	O
6	RXRalpha	O
7	activated	O
8	transcription	O
9	from	O
10	an	O
11	HD	O
12	-	O
13	PPRE	O
14	luciferase	O
15	reporter	O
16	construct	O
17	.	O

1	To	O
2	begin	O
3	to	O
4	examine	O
5	the	O
6	mechanism	O
7	controlling	O
8	expression	O
9	of	B
10	this	B
11	gene	O
12	during	O
13	the	O
14	cell	O
15	-	O
16	cycle	O
17	,	O
18	a	O
19	mouse	O
20	B	O
21	-	O
22	myb	O
23	5	B
24	'	I
25	flanking	I
26	sequence	I
27	was	I
28	isolated	I
29	from	O
30	a	B
31	cosmid	I
32	library	I
33	and	I
34	shown	O
35	to	O
36	promote	O
37	efficiently	O
38	the	O
39	transcription	O
40	of	O
41	a	O
42	luciferase	O
43	reporter	O
44	gene	O
45	when	B
46	transfected	I
47	into	O
48	NIH3T3	O
49	fibroblasts	O
50	.	O

1	Eleven	O
2	strains	O
3	of	O
4	Fusarium	O
5	poae	O
6	and	O
7	F	O
8	.	O
9	sporotrichioides	O
10	from	O
11	the	B
12	U	I
13	.	I
14	S	I
15	.	I
16	S	O
17	.	O
18	R	O
19	.	O
20	and	O
21	7	O
22	strains	O
23	of	O
24	these	O
25	species	O
26	and	O
27	one	O
28	of	O
29	F	O
30	.	O
31	sporotrichioides	O
32	var	O
33	.	O
34	tricinctum	O
35	from	O
36	U	O
37	.	O
38	S	O
39	.	O
40	A	O
41	.	O
42	and	O
43	France	O
44	have	O
45	been	O
46	compared	O
47	as	O
48	to	O
49	their	O
50	capacity	O
51	to	O
52	yield	O
53	T	O
54	-	O
55	2	O
56	toxin	O
57	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	how	B
6	these	I
7	expression	I
8	patterns	O
9	are	B
10	established	I
11	,	I
12	we	I
13	fused	I
14	promoter	I
15	regions	O
16	of	O
17	an	O
18	acidic	O
19	and	O
20	a	O
21	basic	O
22	glucanase	O
23	gene	O
24	to	O
25	the	O
26	beta	O
27	-	O
28	glucuronidase	O
29	(	O
30	GUS	O
31	)	O
32	reporter	O
33	gene	O
34	and	O
35	examined	O
36	expression	B
37	of	I
38	these	I
39	constructs	O
40	in	B
41	transgenic	I
42	tobacco	O
43	plants	O
44	.	B

1	A	O
2	conserved	O
3	role	O
4	for	O
5	L1	O
6	as	O
7	a	O
8	transmembrane	O
9	link	O
10	between	O
11	neuronal	O
12	adhesion	O
13	and	O
14	membrane	O
15	cytoskeleton	O
16	assembly	O
17	.	O

1	Ca2	O
2	+/	O
3	calmodulin	O
4	-	O
5	dependent	O
6	protein	O
7	kinase	O
8	II	O
9	(	B
10	CaMK	I
11	II	I
12	)	O
13	is	O
14	a	O
15	multifunctional	O
16	serine	O
17	/	O
18	threonine	B
19	protein	I
20	kinase	I
21	that	O
22	regulates	I
23	ion	O
24	channels	O
25	,	O
26	metabolic	O
27	enzymes	O
28	,	O
29	cytoskeletal	O
30	proteins	O
31	,	O
32	and	O
33	possibly	B
34	transcription	I
35	factors	O
36	.	O

1	Evolution	O
2	of	O
3	lesions	O
4	did	O
5	not	O
6	necessarily	O
7	follow	B
8	a	I
9	regular	I
10	progression	O
11	through	O
12	the	B
13	later	I
14	stages	O
15	of	O
16	the	O
17	vitelliform	O
18	classification	O
19	.	O

1	Oestrogen	O
2	implant	O
3	overdose	B
4	.	I

1	GnRH	O
2	treatment	O
3	was	B
4	found	I
5	to	I
6	increase	I
7	the	I
8	phosphorylation	I
9	of	I
10	tyrosine	I
11	residues	I
12	of	I
13	MAPK	O
14	and	B
15	to	I
16	increase	I
17	MAPK	O
18	activity	O
19	,	O
20	as	O
21	determined	O
22	by	B
23	an	I
24	immune	I
25	complex	I
26	kinase	I
27	assay	O
28	.	B

1	Lipiodol	O
2	was	O
3	covalently	O
4	conjugated	O
5	with	O
6	EDTB	O
7	.	O

1	In	O
2	76	O
3	%	O
4	of	O
5	59	O
6	lead	O
7	-	O
8	toxic	O
9	children	O
10	,	O
11	bone	O
12	lead	O
13	values	O
14	measured	O
15	by	O
16	LXRF	O
17	were	O
18	equal	O
19	to	O
20	or	O
21	greater	O
22	than	O
23	those	O
24	measured	O
25	in	O
26	normal	O
27	and	O
28	industrially	O
29	exposed	O
30	adults	O
31	.	O

1	Ras	O
2	-	O
3	and	O
4	ultra	O
5	-	O
6	violet	O
7	-	O
8	responsive	B
9	protein	I
10	kinases	I
11	that	I
12	phosphorylate	I
13	c	I
14	-	I
15	Jun	I
16	on	O
17	serine	B
18	residues	I
19	at	I
20	positions	I
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O

1	Transformation	O
2	of	B
3	the	I
4	sconC3	I
5	mutant	I
6	with	O
7	sconB	O
8	+	O
9	restores	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	phenotype	O
15	.	O

1	All	O
2	problems	O
3	were	O
4	associated	O
5	with	O
6	fractured	O
7	or	O
8	lost	O
9	screws	O
10	.	O

1	The	O
2	initial	O
3	inpatient	O
4	experience	O
5	for	O
6	individuals	O
7	with	O
8	HIV	O
9	-	O
10	related	O
11	TB	O
12	may	O
13	be	O
14	pivotal	O
15	to	O
16	the	O
17	acceptance	O
18	of	O
19	and	O
20	participation	O
21	in	O
22	ongoing	O
23	TB	O
24	care	O
25	.	O

1	Thrombophlebitis	O
2	and	B
3	pulmonary	I
4	embolism	I
5	in	I
6	congenital	I
7	factor	I
8	XII	O
9	deficiency	O

1	Prostacyclin	O
2	formation	O
3	,	O
4	reflected	O
5	by	O
6	the	O
7	excretion	O
8	rate	O
9	of	O
10	its	O
11	stable	O
12	metabolite	O
13	6	O
14	-	O
15	keto	O
16	-	O
17	prostaglandin	O
18	F1	O
19	alpha	O
20	,	O
21	was	O
22	measured	O
23	by	O
24	means	O
25	of	O
26	radioimmunoassay	O
27	in	O
28	4	O
29	-	O
30	hour	O
31	urine	O
32	specimens	O
33	obtained	O
34	during	O
35	a	O
36	smoking	O
37	-	O
38	free	O
39	period	O
40	and	O
41	after	O
42	participants	O
43	had	O
44	inhaled	O
45	smoke	O
46	from	O
47	four	O
48	high	O
49	-	O
50	nicotine	O
51	cigarettes	O
52	.	O

1	The	O
2	RS447	O
3	human	O
4	megasatellite	O
5	tandem	O
6	repetitive	O
7	sequence	O
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	An	O
2	alternatively	O
3	spliced	O
4	MAdCAM	O
5	-	O
6	1	O
7	variant	O
8	was	O
9	identified	O
10	that	O
11	lacks	O
12	exon	O
13	4	O
14	encoding	O
15	the	O
16	mucin	O
17	domain	O
18	,	O
19	and	O
20	may	O
21	mediate	O
22	leukocyte	O
23	adhesion	O
24	to	O
25	LPAM	O
26	-	O
27	1	O
28	without	O
29	adhesion	O
30	to	O
31	the	O
32	alternate	O
33	receptor	O
34	,	O
35	L	O
36	-	O
37	selectin	O
38	.	O

1	The	O
2	Harleco	O
3	apparatus	O
4	is	O
5	a	O
6	simple	O
7	,	O
8	useful	O
9	,	O
10	cost	O
11	-	O
12	effective	O
13	adjunct	O
14	to	O
15	the	O
16	diagnosis	O
17	and	O
18	treatment	O
19	of	O
20	this	O
21	life	O
22	-	O
23	threatening	O
24	condition	O
25	.	O

1	Comprehensive	O
2	care	O
3	of	O
4	the	O
5	patient	B
6	exposed	I
7	to	O
8	a	O
9	human	O
10	teratogen	O
11	may	O
12	also	O
13	include	O
14	discussion	O
15	of	O
16	prenatal	O
17	diagnostic	O
18	procedures	O
19	and	O
20	other	O
21	pregnancy	O
22	management	O
23	options	O
24	.	O

1	Total	O
2	cholesterol	O
3	was	B
4	measured	I
5	in	I
6	amniotic	O
7	fluids	B
8	collected	I
9	at	I
10	different	I
11	stages	O
12	of	B
13	gestation	B
14	.	I

1	Incidence	O
2	correlated	O
3	with	O
4	the	O
5	grade	O
6	of	O
7	oral	O
8	hygiene	O
9	und	O
10	periodontal	O
11	disease	O
12	.	O

1	Developmental	O
2	follow	O
3	-	O
4	up	B
5	at	I
6	age	I
7	2	I
8	years	O
9	was	O
10	performed	O
11	.	O

1	Alterations	O
2	in	O
3	DNase	O
4	I	B
5	reactivity	I
6	of	I
7	the	I
8	GC	I
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	O
16	receptor	O
17	-	O
18	GC	O
19	complexes	O
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O

1	Biol	O
2	.	O

1	There	O
2	are	O
3	four	O
4	polyglutamine	O
5	motifs	O
6	interspersed	O
7	with	O
8	histidine	O
9	-	O
10	rich	O
11	regions	O
12	.	O

1	Previous	O
2	work	O
3	showed	O
4	that	O
5	repA	O
6	(	O
7	initiator	O
8	protein	O
9	)	O
10	expression	O
11	requires	O
12	tap	O
13	(	O
14	leader	O
15	peptide	O
16	)	O
17	translation	B
18	.	O

1	Together	O
2	,	O
3	our	O
4	results	O
5	show	O
6	that	O
7	tinman	O
8	is	O
9	controlled	O
10	by	O
11	an	O
12	array	O
13	of	O
14	discrete	O
15	enhancer	O
16	elements	O
17	that	O
18	are	O
19	activated	O
20	successively	O
21	by	O
22	differential	O
23	genetic	O
24	inputs	O
25	,	O
26	as	O
27	well	O
28	as	O
29	by	O
30	closely	O
31	linked	O
32	activator	O
33	and	O
34	repressor	O
35	binding	O
36	sites	O
37	within	O
38	an	O
39	early	O
40	-	O
41	acting	O
42	enhancer	O
43	,	O
44	which	O
45	restrict	O
46	twist	O
47	activity	O
48	to	O
49	specific	O
50	areas	O
51	within	O
52	the	O
53	twist	O
54	expression	O
55	domain	O
56	.	O

1	Hydrocortisone	O
2	caused	O
3	lymphopenia	O
4	and	O
5	inhibited	O
6	the	O
7	blastogenic	O
8	response	O
9	of	O
10	peripheral	O
11	blood	O
12	lymphocytes	O
13	to	O
14	phytohemagglutinin	O
15	and	O
16	concanavalin	O
17	A	O
18	mitogens	O
19	.	O

1	The	O
2	C	O
3	-	B
4	terminal	I
5	end	I
6	of	I
7	this	O
8	polypeptide	O
9	harbors	O
10	three	O
11	types	O
12	of	O
13	repeated	O
14	sequences	O
15	.	O

1	It	O
2	is	O
3	reported	O
4	that	O
5	,	O
6	at	O
7	present	O
8	,	O
9	most	O
10	of	O
11	the	O
12	MRSAs	O
13	spreading	O
14	in	O
15	Japan	O
16	are	O
17	acceleratedly	O
18	acquiring	O
19	resistance	O
20	to	O
21	many	O
22	drugs	O
23	,	O
24	and	O
25	especially	O
26	,	O
27	they	O
28	are	O
29	developing	O
30	high	O
31	resistance	O
32	against	O
33	beta	O
34	-	O
35	lactams	O
36	.	O

1	Commun	O
2	.	O

1	In	O
2	contrast	O
3	to	O
4	other	O
5	known	O
6	retroviruses	O
7	,	O
8	the	O
9	FV	O
10	pol	O
11	genes	O
12	are	O
13	expressed	O
14	via	O
15	spliced	O
16	transcripts	O
17	.	O

1	Paleoceanographic	O
2	data	O
3	from	O
4	the	I
5	Laurentian	I
6	Fan	I
7	,	I
8	used	I
9	as	I
10	a	I
11	proxy	I
12	for	I
13	sea	I
14	surface	I
15	temperature	O
16	,	O
17	reveal	O
18	that	O
19	surface	O
20	slope	O
21	waters	O
22	north	O
23	of	O
24	the	B
25	Gulf	I
26	Stream	I
27	experienced	I
28	warming	O
29	during	O
30	the	O
31	Little	O
32	Ice	O
33	Age	O
34	of	O
35	the	O
36	16th	O
37	to	O
38	19th	O
39	centuries	O
40	and	B
41	support	I
42	the	I
43	notion	I
44	of	O
45	an	O
46	NAO	O
47	-	O
48	driven	O
49	coupled	O
50	system	O
51	.	O

1	Is	O
2	criticism	O
3	of	O
4	patient	O
5	care	O
6	justified	B
7	and	I
8	does	I
9	it	I
10	have	I
11	educational	O
12	value	B
13	?	I
14	Patients	O
15	'	O
16	criticism	O
17	contributes	O
18	to	B
19	improved	I
20	patient	I
21	care	I

1	DPA	O
2	attenuated	O
3	the	O
4	increase	O
5	of	O
6	the	O
7	intensity	O
8	of	O
9	the	O
10	ischemic	O
11	and	O
12	pressure	O
13	pain	O
14	components	O
15	with	O
16	increasing	O
17	ischemia	O
18	duration	O
19	,	O
20	but	O
21	only	O
22	the	O
23	effect	O
24	on	O
25	the	O
26	pressure	O
27	pain	O
28	component	O
29	was	O
30	significant	O
31	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	Sp1	O
8	and	O
9	Sp3	O
10	as	O
11	major	O
12	factors	O
13	binding	O
14	to	O
15	the	O
16	Sp1	O
17	sites	O
18	of	O
19	the	O
20	p21	O
21	/	O
22	WAF1	O
23	/	O
24	Cip1	O
25	promoter	O
26	in	O
27	MG63	O
28	cells	O
29	through	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assays	O
34	and	O
35	showed	O
36	that	O
37	TSA	O
38	treatment	O
39	did	O
40	not	O
41	change	O
42	their	O
43	binding	O
44	activities	O
45	.	O

1	Mutations	O
2	at	O
3	the	O
4	extreme	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	EIAV	O
10	Tat	O
11	impaired	O
12	both	O
13	RNA	O
14	binding	O
15	and	O
16	activation	O
17	domain	O
18	functions	O
19	,	O
20	suggesting	O
21	effects	O
22	on	O
23	secondary	O
24	or	O
25	tertiary	O
26	structure	O
27	.	O

1	Purified	O
2	P7	O
3	could	B
4	be	I
5	assembled	I
6	onto	I
7	particles	I
8	lacking	I
9	P7	I
10	and	O
11	particles	O
12	lacking	O
13	both	O
14	P2	O
15	(	O
16	RNA	O
17	polymerase	B
18	)	I
19	and	O
20	P7	B
21	.	I

1	The	O
2	effect	O
3	of	O
4	hydrostatic	O
5	pressure	O
6	on	O
7	the	O
8	swimming	O
9	activity	O
10	of	O
11	three	O
12	hyponeustonic	O
13	crustacea	O
14	,	O
15	Anomalocera	O
16	patersoni	O
17	,	O
18	Pontella	O
19	mediterranea	B
20	,	I
21	Labidocera	O
22	wollastoni	I

1	Six	O
2	(	O
3	four	O
4	FAP	O
5	;	O
6	two	O
7	primary	O
8	amyloidosis	O
9	)	O
10	also	O
11	had	O
12	diffusely	O
13	positive	O
14	myocardial	O
15	uptakes	O
16	,	O
17	but	O
18	the	O
19	intensity	O
20	was	O
21	less	O
22	than	O
23	that	O
24	of	O
25	the	O
26	sternum	O
27	.	O

1	Reconstitution	O
2	of	O
3	Raf	O
4	-	O
5	1	O
6	activity	O
7	was	O
8	observed	O
9	only	O
10	with	B
11	kinase	I
12	active	I
13	Jak1	O
14	in	O
15	both	O
16	cell	O
17	lines	O
18	.	O

1	As	O
2	a	O
3	result	O
4	,	O
5	we	O
6	have	O
7	defined	O
8	two	O
9	arginine	O
10	-	O
11	rich	O
12	motifs	O
13	(	O
14	ARM1	O
15	and	O
16	ARM2	O
17	)	O
18	that	O
19	mediate	O
20	the	O
21	RNA	O
22	binding	O
23	activity	O
24	of	O
25	SU	O
26	(	O
27	S	O
28	).	O

1	TNF	O
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	O
8	MAP	O
9	kinase	O
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	O
19	MAP	O
20	kinase	O
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	O
27	protein	O
28	MAPKAP	O
29	kinase	O
30	-	O
31	2	O
32	,	O
33	and	O
34	culminating	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	O
41	shock	O
42	protein	O
43	27	O
44	(	O
45	hsp27	O
46	).	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	O
8	protease	O
9	,	O
10	RNK	O
11	-	O
12	Met	O
13	-	O
14	1	O
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O

1	To	O
2	better	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	Ets	O
8	proteins	O
9	in	O
10	Ras	O
11	transformation	O
12	,	O
13	we	O
14	have	O
15	now	O
16	analyzed	O
17	the	O
18	effects	O
19	of	O
20	stably	O
21	expressing	O
22	a	O
23	variety	O
24	of	O
25	Ets2	O
26	constructs	O
27	in	O
28	Ras	O
29	-	O
30	transformed	O
31	NIH3T3	O
32	(	O
33	DT	O
34	)	O
35	cells	O
36	.	O

1	Recent	O
2	work	O
3	in	O
4	this	O
5	laboratory	B
6	has	I
7	shown	I
8	that	O
9	the	B
10	gene	I
11	coding	O
12	for	O
13	acetate	O
14	kinase	B
15	(	I
16	ackA	I
17	)	I
18	in	I
19	Sinorhizobium	I
20	meliloti	I
21	is	I
22	up	O
23	-	B
24	regulated	I
25	in	I
26	response	I
27	to	I
28	phosphate	O
29	limitation	O
30	.	O

1	Monitoring	O
2	of	O
3	rheumatoid	O
4	arthritis	O
5	.	O

1	Salivary	O
2	estradiol	O
3	17	O
4	beta	B
5	(	I
6	E2	I
7	-	I
8	17	I
9	beta	I
10	)	I
11	and	I
12	progesterone	I
13	(	I
14	P	I
15	)	I
16	were	I
17	determined	I
18	by	O
19	using	O
20	radioimmunoassay	O
21	techniques	O
22	in	O
23	30	O
24	pregnant	O
25	females	O
26	in	O
27	the	O
28	first	B
29	,	I
30	second	I
31	and	I
32	third	O
33	trimesters	O
34	as	O
35	well	O
36	as	O
37	in	O
38	10	O
39	non	B
40	-	I
41	pregnant	O
42	controls	O
43	during	O
44	the	O
45	luteal	O
46	phase	O
47	of	O
48	the	O
49	menstrual	O
50	cycle	O
51	.	O

1	Results	O
2	of	B
3	a	I
4	controlled	O
5	study	O

1	Chronic	O
2	hepatitis	O
3	B	O
4	in	O
5	adopted	O
6	Romanian	O
7	children	O
8	.	O

1	Since	O
2	sildenafil	O
3	came	O
4	on	O
5	the	O
6	market	O
7	,	O
8	it	O
9	seems	O
10	that	O
11	the	B
12	place	B
13	of	I
14	MUSE	I
15	is	I
16	reduced	I
17	because	O
18	comparative	O
19	studies	O
20	give	O
21	better	O
22	results	O
23	for	O
24	sildenafil	O
25	than	O
26	MUSE	O
27	(	O
28	70	O
29	%	O
30	vs	O
31	40	O
32	%)	O
33	and	O
34	of	O
35	course	O
36	with	O
37	a	O
38	better	O
39	acceptance	O
40	.	O

1	Some	O
2	research	O
3	studies	O
4	have	O
5	related	O
6	this	O
7	kind	O
8	of	O
9	tumors	O
10	with	O
11	prolonged	O
12	ingestion	O
13	of	O
14	H2	O
15	inhibitors	O
16	and	O
17	others	O
18	antacid	O
19	.	O

1	Allergy	O
2	and	O
3	Tourette	O
4	'	O
5	s	O
6	syndrome	O
7	.	O

1	Alveolar	O
2	lymphocytes	O
3	were	O
4	surprisingly	O
5	increased	B
6	in	I
7	most	I
8	patients	I
9	with	I
10	AIDS	I
11	(	I
12	mean	I
13	26	I
14	.	I
15	1	O
16	+/-	O
17	21	O
18	.	O
19	9	O
20	%;	O
21	range	O
22	1	O
23	-	O
24	76	O
25	%)	O
26	and	O
27	CGL	O
28	(	O
29	mean	O
30	26	O
31	.	O
32	6	O
33	+/-	B
34	22	I
35	.	I
36	6	O
37	%;	O
38	range	O
39	3	O
40	-	O
41	76	O
42	%)	O
43	with	O
44	criteria	O
45	of	O
46	activation	O
47	contrasting	O
48	with	O
49	the	O
50	blood	O
51	lymphopenia	O
52	.	B

1	However	O
2	,	O
3	mandibular	O
4	position	O
5	(	O
6	S	O
7	-	O
8	N	O
9	-	O
10	B	O
11	and	O
12	S	O
13	-	O
14	N	O
15	-	B
16	Pog	B
17	)	I
18	was	O
19	found	O
20	to	O
21	be	O
22	significantly	O
23	more	O
24	retrusive	O
25	in	O
26	Class	O
27	II	O
28	when	O
29	compared	O
30	with	O
31	Class	O
32	I	O
33	subjects	O
34	.	O

1	Primer	O
2	extension	O
3	and	O
4	cDNA	O
5	cloning	O
6	were	O
7	used	O
8	to	O
9	isolate	O
10	the	O
11	complete	O
12	5	O
13	'	O
14	end	O
15	of	O
16	the	O
17	Nramp1	O
18	mRNA	O
19	.	O

1	Is	O
2	desensitization	O
3	'	O
4	for	O
5	ragweed	O
6	hay	O
7	fever	O
8	immunologically	O
9	specific	O
10	?	O

1	Training	O
2	for	O
3	audit	O
4	.	O

1	A	O
2	control	O
3	group	O
4	of	O
5	nine	O
6	women	O
7	(	B
8	age	I
9	23	O
10	-	O
11	40	O
12	years	O
13	)	O
14	on	O
15	oral	O
16	contraceptives	O
17	(	O
18	Nordette	O
19	-	O
20	28	O
21	)	O
22	was	O
23	also	O
24	studied	O
25	four	O
26	times	O
27	during	O
28	a	O
29	pill	O
30	cycle	O
31	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	RV	O
6	5	O
7	'(+)	O
8	SL	O
9	sequence	O
10	had	O
11	the	O
12	primary	O
13	enhancing	O
14	effect	O
15	on	O
16	translation	O
17	.	O

1	Atrial	O
2	fibrillation	O
3	and	O
4	the	O
5	autonomic	O
6	nervous	O
7	system	O

1	CONCLUSIONS	O
2	:	O
3	Free	O
4	protein	O
5	S	O
6	deficiency	O
7	is	O
8	common	O
9	among	O
10	hospitalized	O
11	patients	O
12	,	O
13	even	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	a	O
19	recognized	O
20	predisposing	O
21	condition	O
22	.	O

1	The	O
2	effects	O
3	of	O
4	oral	O
5	vanadyl	O
6	sulfate	O
7	(	O
8	VOSO4	O
9	)	O
10	(	O
11	0	O
12	.	O
13	5	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	on	O
21	anthropometry	O
22	,	O
23	body	O
24	composition	O
25	,	O
26	and	O
27	performance	O
28	were	O
29	investigated	O
30	in	O
31	a	O
32	12	O
33	-	O
34	week	O
35	,	O
36	double	O
37	-	O
38	blind	O
39	,	O
40	placebo	O
41	-	O
42	controlled	O
43	trial	O
44	involving	O
45	weight	O
46	-	O
47	training	O
48	volunteers	O
49	.	O

1	In	O
2	general	O
3	,	O
4	the	O
5	filtration	O
6	rate	O
7	in	O
8	relevant	O
9	areas	O
10	appears	O
11	to	B
12	be	I
13	an	I
14	integrative	I
15	and	I
16	easily	I
17	determined	O
18	parameter	O
19	,	O
20	reflecting	O
21	hormonal	O
22	and	O
23	neurogenic	O
24	vascular	B
25	as	B
26	well	I
27	as	O
28	local	B
29	interstitial	I
30	control	I
31	of	O
32	the	B
33	Starling	O
34	forces	O
35	.	O

1	Five	O
2	of	O
3	the	O
4	patients	O
5	with	O
6	increased	O
7	L	O
8	-	O
9	L	B
10	size	I
11	had	I
12	a	I
13	normal	I
14	A	I
15	-	I
16	P	I
17	diameter	I
18	.	I

1	Transcription	O
2	factors	O
3	containing	O
4	a	O
5	basic	O
6	helix	O
7	-	O
8	loop	O
9	-	O
10	helix	O
11	(	O
12	bHLH	O
13	)	O
14	motif	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	tissue	O
20	-	O
21	specific	O
22	genes	O
23	in	O
24	a	O
25	number	O
26	of	O
27	mammalian	O
28	and	O
29	insect	O
30	systems	O
31	.	O

1	Effect	O
2	of	O
3	separate	O
4	and	O
5	combined	B
6	effects	O
7	of	O
8	plutonium	O
9	-	O
10	239	O
11	,	O
12	hexachlorobutadiene	O
13	and	O
14	tributyl	O
15	phosphate	O
16	on	O
17	the	O
18	thymus	O
19	gland	O
20	of	O
21	rats	O

1	In	O
2	addition	O
3	,	O
4	negatively	O
5	regulatory	O
6	region	O
7	may	O
8	exist	O
9	from	O
10	-	O
11	1782	O
12	to	O
13	-	O
14	1295	O
15	bp	O
16	.	O

1	81	O
2	milk	O
3	samples	O
4	collected	O
5	from	O
6	35	O
7	donors	O
8	3	O
9	days	O
10	to	O
11	7	O
12	months	O
13	after	O
14	delivery	O
15	were	O
16	examined	O
17	for	O
18	the	O
19	occurrence	O
20	of	O
21	cytomegalovirus	O
22	(	O
23	CMV	O
24	).	O

1	Abnormal	O
2	calcium	O
3	metabolism	O
4	in	O
5	normocalcaemic	O
6	sarcoidosis	O
7	.	O

1	The	O
2	major	O
3	neurological	O
4	manifestations	O
5	of	O
6	brain	O
7	injury	O
8	in	O
9	these	O
10	babies	O
11	are	O
12	spastic	O
13	motor	O
14	deficits	O
15	.	O

1	Recovery	O
2	was	O
3	characterized	O
4	by	O
5	rapid	O
6	improvement	O
7	such	O
8	that	O
9	all	O
10	measured	O
11	parameters	O
12	normalized	O
13	by	O
14	1	O
15	week	O
16	,	O
17	except	O
18	for	O
19	cross	O
20	-	O
21	sectional	O
22	cardiac	O
23	area	O
24	which	O
25	remained	O
26	dilated	O
27	up	O
28	to	O
29	4	O
30	weeks	O
31	(	O
32	14	O
33	+/-	O
34	3	O
35	cm2	O
36	,	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	05	O
43	versus	O
44	control	O
45	).(	O
46	ABSTRACT	O
47	TRUNCATED	O
48	AT	O
49	250	O
50	WORDS	O
51	)	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	each	O
6	of	O
7	the	O
8	three	O
9	proteins	O
10	has	O
11	about	O
12	70	O
13	%	O
14	homology	O
15	with	O
16	that	O
17	of	O
18	mouse	O
19	contrapsin	O
20	,	O
21	in	O
22	contrast	O
23	to	O
24	43	O
25	-	O
26	46	O
27	%	O
28	homology	O
29	with	O
30	that	O
31	of	O
32	rat	O
33	alpha	O
34	1	O
35	-	O
36	protease	B
37	inhibitor	I
38	.	I

1	For	O
2	Al	O
3	,	O
4	the	O
5	exposure	O
6	to	O
7	1	O
8	.	O
9	36	O
10	mg	O
11	/	O
12	m3	O
13	during	O
14	the	O
15	shift	O
16	corresponded	O
17	to	O
18	a	O
19	urinary	O
20	concentration	O
21	at	O
22	the	O
23	end	O
24	of	O
25	the	O
26	shift	O
27	of	O
28	200	O
29	microgram	O
30	/	O
31	g	O
32	creatinine	B
33	.	I

1	An	O
2	epidemic	O
3	of	O
4	hepatitis	O
5	B	O
6	virus	O
7	infection	B
8	among	I
9	intravenous	I
10	drug	I
11	users	I
12	in	O
13	Iceland	O
14	.	O

1	Substituting	O
2	a	O
3	Ser	O
4	for	O
5	Gly69	O
6	or	B
7	a	I
8	Glu	I
9	for	O
10	Lys	O
11	71	O
12	in	O
13	the	O
14	conserved	O
15	TGEK	O
16	tetrapeptide	O
17	in	O
18	finger	O
19	II	O
20	of	O
21	TFIIIA	O
22	resulted	O
23	in	O
24	the	O
25	loss	O
26	of	O
27	DNA	O
28	binding	O
29	.	B

1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O

1	XXI	O
2	.	O

1	The	O
2	method	O
3	involves	B
4	preliminary	I
5	isolation	I
6	of	I
7	oxiracetam	I
8	and	I
9	internal	O
10	standard	O
11	from	O
12	plasma	O
13	by	O
14	solid	O
15	-	O
16	phase	B
17	extraction	I
18	prior	O
19	to	B
20	the	I
21	formation	I
22	of	O
23	their	O
24	n	O
25	-	O
26	propyl	O
27	carbamate	O
28	derivatives	O
29	.	O

1	Thus	O
2	,	O
3	blocks	O
4	in	O
5	the	O
6	RARalpha	O
7	-	O
8	specific	O
9	pathway	O
10	of	O
11	retinoid	O
12	-	B
13	induced	I
14	differentiation	I
15	may	I
16	be	I
17	bypassed	I
18	during	I
19	retinoid	I
20	induction	I
21	of	O
22	FR	O
23	-	O
24	beta	O
25	expression	O
26	.	O

1	The	O
2	characterization	B
3	of	I
4	the	I
5	promoter	I
6	region	I
7	indicated	I
8	that	O
9	three	O
10	distinct	O
11	regulatory	O
12	elements	O
13	corresponding	O
14	to	O
15	an	O
16	AP	O
17	-	O
18	1	O
19	binding	O
20	site	O
21	(	O
22	or	O
23	TRE	O
24	),	O
25	a	O
26	PRDII	O
27	/	O
28	kappaB	O
29	domain	O
30	,	O
31	and	O
32	a	O
33	CAAT	O
34	box	O
35	are	O
36	involved	O
37	in	O
38	the	O
39	activation	B
40	by	I
41	pp60	I
42	(	I
43	v	O
44	-)	O
45	src	O
46	.	O

1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	O
7	mRNA	O
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	B
18	and	B
19	3	I
20	.	I
21	1	I
22	-	I
23	fold	I
24	in	I
25	the	I
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O

1	Southern	O
2	blot	O
3	analyses	O
4	demonstrated	O
5	a	O
6	low	O
7	,	O
8	if	B
9	not	I
10	single	I
11	,	I
12	copy	I
13	number	I
14	for	I
15	this	I
16	gene	I
17	and	I
18	conservation	I
19	of	I
20	this	O
21	domain	O
22	in	O
23	other	B
24	vertebrates	I
25	.	I

1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	B
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	O
30	alpha	O
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O

1	Those	O
2	dosages	O
3	that	O
4	inhibited	O
5	mean	O
6	NTE	O
7	activity	O
8	in	O
9	spinal	O
10	cord	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	72	O
17	%	O
18	and	O
19	brain	O
20	greater	O
21	than	O
22	or	O
23	equal	O
24	to	O
25	66	O
26	%	O
27	of	O
28	control	O
29	values	O
30	within	O
31	44	O
32	hr	O
33	postexposure	O
34	produced	O
35	marked	O
36	spinal	O
37	cord	O
38	pathology	O
39	14	O
40	days	O
41	postexposure	O
42	in	O
43	greater	O
44	than	O
45	or	O
46	equal	O
47	to	O
48	90	O
49	%	O
50	of	O
51	similarly	O
52	dosed	O
53	animals	O
54	.	O

1	Mg2	O
2	+	O
3	and	O
4	Mn2	O
5	+	O
6	compete	O
7	for	O
8	binding	O
9	sites	O
10	,	O
11	with	O
12	the	O
13	former	O
14	having	O
15	lower	O
16	affinity	O
17	.	O

1	The	O
2	two	O
3	bases	O
4	immediately	O
5	flanking	O
6	the	O
7	5	O
8	'	O
9	end	O
10	of	O
11	the	O
12	element	O
13	proved	O
14	to	O
15	be	O
16	very	O
17	important	O
18	to	O
19	its	O
20	function	O
21	as	O
22	a	O
23	UAS	O
24	element	O
25	as	O
26	did	O
27	the	O
28	two	O
29	bases	O
30	immediately	O
31	3	O
32	'	O
33	of	O
34	the	O
35	bHLH	O
36	core	O
37	motif	O
38	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	alignment	O
5	between	O
6	mouse	O
7	and	O
8	human	O
9	CA	O
10	IV	O
11	shows	O
12	69	O
13	%	O
14	identity	O
15	in	B
16	the	I
17	coding	O
18	region	O
19	and	O
20	all	O
21	of	B
22	the	I
23	exon	O
24	-	O
25	intron	B
26	boundaries	I
27	are	I
28	conserved	I
29	,	I
30	as	I
31	are	I
32	the	O
33	sizes	O
34	of	O
35	the	O
36	introns	O
37	.	O

1	This	O
2	sequence	O
3	,	O
4	Thr	O
5	-	O
6	Gly	O
7	-	B
8	X	I
9	-	O
10	X	B
11	-	I
12	Gly	I
13	-	I
14	Asp	O
15	-	O
16	Gly	O
17	-	O
18	Lys	O
19	-	O
20	Ile	B
21	-	I
22	Phe	I
23	,	O
24	forms	O
25	part	O
26	of	O
27	the	O
28	B	O
29	-	O
30	loop	O
31	and	O
32	is	O
33	conserved	O
34	in	O
35	a	O
36	wide	B
37	variety	I
38	of	I
39	organisms	O
40	that	O
41	include	O
42	bacteria	O
43	,	O
44	algae	O
45	and	O
46	archeabacteria	O
47	.	O

1	The	O
2	first	O
3	involved	O
4	complementation	O
5	of	O
6	a	O
7	nonphotosynthetic	O
8	mutant	O
9	of	O
10	Chlamydomonas	O
11	,	O
12	CC	O
13	-	O
14	2341	O
15	(	O
16	ac	O
17	-	O
18	u	O
19	-	O
20	g	O
21	-	O
22	2	O
23	.	O
24	3	O
25	),	O
26	which	O
27	has	O
28	a	O
29	frameshift	O
30	mutation	O
31	in	O
32	the	O
33	psaB	O
34	gene	O
35	,	O
36	and	O
37	selection	O
38	of	O
39	photosynthetic	O
40	transformants	O
41	on	O
42	minimal	O
43	medium	O
44	.	O

1	Cyclin	O
2	D1	O
3	could	O
4	not	O
5	be	O
6	displaced	O
7	from	O
8	cdk4	O
9	in	O
10	the	O
11	resistant	O
12	184A1L5R	O
13	cell	O
14	lysates	O
15	.	O

1	The	O
2	adenovirus	B
3	E1A	I
4	gene	I
5	encodes	I
6	a	I
7	protein	I
8	that	I
9	transcriptionally	I
10	activates	O
11	viral	O
12	early	O
13	genes	O
14	.	O

1	Using	O
2	either	O
3	a	O
4	p50	O
5	-	O
6	or	O
7	p65	O
8	-	O
9	selected	O
10	kappa	O
11	B	O
12	motif	O
13	,	O
14	which	O
15	displayed	O
16	differential	O
17	binding	B
18	with	B
19	respect	I
20	to	I
21	the	O
22	other	O
23	protein	O
24	,	O
25	little	O
26	to	O
27	no	O
28	binding	O
29	was	B
30	observed	O
31	with	O
32	the	O
33	heterodimeric	O
34	NF	O
35	-	O
36	kappa	O
37	B	O
38	complex	O
39	.	O

1	Nonlocal	O
2	approach	O
3	to	O
4	scattering	O
5	in	O
6	a	O
7	one	O
8	-	O
9	dimensional	O
10	problem	O
11	.	O

1	The	O
2	MCA	O
3	and	O
4	UA	B
5	PI	I
6	values	I
7	showed	I
8	the	I
9	greatest	O
10	deviation	O
11	for	B
12	any	I
13	single	I
14	-	I
15	vessel	I
16	parameter	O
17	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	B
6	regions	I
7	may	I
8	provide	I
9	a	I
10	basis	I
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	O
16	-	O
17	kappa	B
18	function	I
19	.	I

1	TRAF2	O
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	O
9	-	O
10	kDa	B
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	I
16	germinal	O
17	center	O
18	kinase	O
19	related	O
20	(	O
21	GCKR	O
22	,	O
23	also	O
24	referred	B
25	to	O
26	as	O
27	KHS1	O
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	O
35	pathway	O
36	.	O

1	The	O
2	consensus	O
3	gene	O
4	order	O
5	deduced	O
6	by	O
7	combining	O
8	data	O
9	from	O
10	both	O
11	crosses	O
12	is	O
13	D2Mit1	O
14	-(	O
15	Dbh	O
16	,	O
17	Notch1	O
18	)-(	O
19	Col5a1	O
20	,	O
21	Rxra	O
22	)-	O
23	Spna2	O
24	-	O
25	Ab	O
26	l	O
27	-(	O
28	Ak1	O
29	,	O
30	Fpgs	O
31	)-	O
32	(	O
33	Grp78	O
34	,	O
35	Pbx3	O
36	)-(	O
37	Epb7	O
38	.	O
39	2	O
40	,	O
41	Hc	O
42	,	O
43	Gsn	O
44	)-	O
45	Acra	O
46	.	O

1	A	O
2	new	O
3	bioencapsulation	O
4	technology	O
5	for	O
6	microbial	O
7	inoculants	O
8	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	negative	O
6	Smad2	O
7	significantly	O
8	reduces	O
9	the	O
10	level	O
11	of	O
12	luciferase	O
13	reporter	O
14	activity	O
15	induced	O
16	by	O
17	nodal	O
18	treatment	O
19	.	O

1	It	O
2	has	O
3	been	O
4	calculated	O
5	that	B
6	600	I
7	,	I
8	000	I
9	new	O
10	cases	O
11	of	O
12	lung	O
13	cancer	O
14	occur	O
15	worldwide	O
16	every	O
17	year	O
18	,	O
19	most	O
20	of	O
21	them	O
22	due	O
23	to	O
24	smoking	O
25	.	O

1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	mDAP	O
7	-	O
8	3	O
9	/	O
10	EGFP	B
11	fusion	I
12	protein	I
13	,	I
14	cell	I
15	fractionation	I
16	and	I
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	mDAP	O
22	-	O
23	3	O
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	B
5	22	I
6	,	I
7	846	I
8	bp	O
9	of	O
10	the	O
11	left	O
12	arm	O
13	of	O
14	chromosome	O
15	IV	O
16	is	O
17	described	O
18	.	O

1	51	O
2	.	O
3	9	O
4	%	O
5	(	O
6	P	O
7	=	O
8	0	O
9	.	O
10	0006	O
11	)	O
12	in	O
13	the	O
14	MMF	O
15	versus	O
16	the	O
17	AZA	O
18	groups	O
19	,	B
20	respectively	I
21	.	I

1	Mnt	O
2	:	O
3	Max	O
4	complexes	O
5	also	O
6	efficiently	O
7	suppress	O
8	Myc	O
9	-	O
10	dependent	O
11	activation	O
12	from	O
13	the	O
14	same	O
15	promoter	O
16	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	a	O
6	sequence	O
7	match	O
8	between	O
9	enhancers	O
10	and	O
11	certain	O
12	promoter	O
13	elements	O
14	is	O
15	critical	O
16	.	O

1	The	O
2	quantitative	O
3	determination	O
4	of	O
5	HBSAG	O
6	--	B
7	a	I
8	valuable	I
9	aid	I
10	in	O
11	evaluating	B
12	the	I
13	infectiousness	I
14	of	I
15	hepatitis	I
16	B	I
17	virus	I
18	carriers	I

1	Certain	O
2	characteristics	O
3	of	O
4	eye	O
5	changes	O
6	in	O
7	patients	O
8	with	O
9	pheochromocytoma	O
10	including	O
11	Sipple	O
12	'	B
13	s	I
14	syndrome	I

1	Hybrid	O
2	-	O
3	selection	O
4	experiments	O
5	against	O
6	total	O
7	PB	O
8	-	O
9	inducible	O
10	RNA	O
11	were	O
12	performed	O
13	with	O
14	plasmid	O
15	DNA	O
16	derived	O
17	from	O
18	clones	O
19	enriched	O
20	in	O
21	PB	O
22	-	O
23	inducible	O
24	information	O
25	.	O

1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O

1	The	O
2	CEM	O
3	receives	O
4	registration	O
5	updates	O
6	via	O
7	an	O
8	HL7	O
9	message	O
10	and	O
11	evaluates	O
12	data	O
13	dependencies	O
14	in	O
15	rules	I
16	via	I
17	an	I
18	interface	I
19	to	O
20	the	O
21	relational	O
22	database	O
23	.	O

1	Northern	O
2	blot	O
3	analyses	O
4	show	B
5	that	I
6	the	I
7	hBub1	I
8	mRNA	O
9	level	O
10	is	O
11	abundantly	O
12	expressed	O
13	in	O
14	tissues	O
15	or	O
16	cells	O
17	with	B
18	a	I
19	high	I
20	mitotic	I
21	index	I
22	.	I

1	The	O
2	data	O
3	show	O
4	conclusively	O
5	that	O
6	phosphorylation	O
7	of	O
8	His	O
9	-	O
10	304	O
11	is	O
12	not	O
13	essential	O
14	for	O
15	any	O
16	of	O
17	the	O
18	known	O
19	functions	O
20	of	O
21	A	O
22	.	O
23	vinelandii	O
24	NifL	O
25	.	O

1	Measurement	O
2	of	O
3	magnesium	O
4	absorption	O
5	in	O
6	man	O
7	using	O
8	stable	O
9	26Mg	O
10	as	O
11	a	O
12	tracer	O
13	.	O

1	In	O
2	all	O
3	cells	O
4	,	O
5	the	O
6	accumulation	O
7	of	O
8	high	O
9	Dsg	O
10	protein	O
11	levels	O
12	required	O
13	calcium	O
14	and	O
15	was	O
16	not	O
17	observed	O
18	in	O
19	low	O
20	calcium	O
21	(	O
22	0	O
23	.	O
24	05	O
25	-	O
26	0	O
27	.	O
28	07	O
29	mM	O
30	)	O
31	media	O
32	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	these	O
6	unique	O
7	properties	O
8	,	O
9	the	O
10	newly	O
11	characterized	O
12	hemagglutinin	O
13	has	O
14	been	O
15	termed	O
16	Limulus	O
17	18K	O
18	agglutination	O
19	-	O
20	aggregation	O
21	factor	O
22	(	O
23	18K	O
24	-	O
25	LAF	O
26	).	O

1	Intracavitary	O
2	irradiation	O
3	was	O
4	carried	O
5	out	O
6	with	O
7	a	O
8	microSelectron	O
9	HDR	O
10	afterloading	O
11	device	O
12	and	O
13	usually	O
14	22	O
15	.	O
16	5	O
17	Gy	O
18	was	O
19	given	O
20	in	O
21	three	O
22	fractions	O
23	repeated	O
24	weekly	O
25	.	O

1	The	O
2	Stat5b	O
3	mRNA	O
4	has	O
5	a	O
6	size	O
7	of	O
8	5	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	786	B
18	amino	I
19	acids	I
20	.	I

1	One	O
2	month	O
3	after	O
4	the	O
5	DTaP	O
6	booster	O
7	vaccination	O
8	,	O
9	both	O
10	groups	O
11	had	O
12	6	O
13	-	O
14	to	O
15	40	O
16	-	O
17	fold	O
18	increases	O
19	in	O
20	serum	O
21	antibody	O
22	concentrations	O
23	to	O
24	all	O
25	antigens	O
26	tested	O
27	;	O
28	the	O
29	concentrations	O
30	against	O
31	the	O
32	three	O
33	pertussis	O
34	antigens	O
35	were	O
36	higher	O
37	in	O
38	the	O
39	DTaP	O
40	-	O
41	primed	O
42	children	O
43	(	O
44	p	O
45	<	O
46	0	O
47	.	O
48	05	O
49	).	O

1	The	O
2	average	O
3	birth	O
4	mass	O
5	of	O
6	these	O
7	newborns	O
8	was	O
9	3491	O
10	.	O
11	9	O
12	+/-	O
13	2	O
14	SD	O
15	780	O
16	.	O
17	5	O
18	g	O
19	and	O
20	that	O
21	in	O
22	the	O
23	control	O
24	group	O
25	3	O
26	,	O
27	767	O
28	.	O
29	5	O
30	+/-	O
31	2	O
32	SD	O
33	824	O
34	.	O
35	2	O
36	g	O
37	(	O
38	P	O
39	less	O
40	than	O
41	0	O
42	.	O
43	05	O
44	).	O

1	Additionally	O
2	,	O
3	the	O
4	mouse	O
5	promoter	O
6	contains	O
7	22	O
8	copies	O
9	of	O
10	a	O
11	CT	O
12	dinucleotide	O
13	repeat	O
14	sequence	O
15	located	O
16	approximately	O
17	155	O
18	bp	O
19	5	O
20	'	O
21	to	O
22	exon	O
23	1	O
24	.	O

1	It	O
2	applies	O
3	Udry	O
4	'	O
5	s	O
6	biosocial	O
7	perspective	O
8	,	O
9	which	O
10	attempts	O
11	to	B
12	reconcile	I
13	the	I
14	biological	O
15	and	O
16	sociological	O
17	models	B
18	of	B
19	premarital	I
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O

1	Similar	O
2	observations	O
3	were	O
4	made	O
5	with	O
6	unilateral	O
7	pneumothorax	O
8	of	O
9	15	O
10	cmH2O	O
11	for	O
12	30	O
13	min	O
14	.	O

1	The	O
2	MVV	O
3	-	O
4	value	B
5	is	B
6	under	I
7	the	I
8	predicted	O
9	level	O
10	in	O
11	the	O
12	case	O
13	of	O
14	67	O
15	-	B
16	76	I
17	percent	O
18	.	O

1	The	O
2	simultaneous	B
3	recording	I
4	of	I
5	electrical	O
6	activity	O
7	from	O
8	the	O
9	surface	O
10	electrocardiogram	O
11	,	O
12	right	O
13	ventricular	O
14	apex	O
15	,	O
16	His	O
17	bundle	O
18	,	O
19	high	O
20	right	O
21	atrium	O
22	,	O
23	coronary	O
24	sinus	O
25	,	O
26	with	O
27	or	O
28	without	O
29	a	O
30	roving	O
31	mapping	O
32	catheter	O
33	,	O
34	enables	O
35	us	O
36	to	O
37	precisely	O
38	map	O
39	the	O
40	electrical	O
41	activation	O
42	sequence	O
43	in	O
44	the	O
45	heart	O
46	.	O

1	Each	O
2	mRNA	O
3	contained	O
4	five	O
5	or	O
6	six	O
7	internal	O
8	uridine	O
9	residues	O
10	,	O
11	which	O
12	were	O
13	transcribed	O
14	using	O
15	a	O
16	mixture	O
17	of	O
18	UTP	O
19	and	O
20	thio	O
21	-	O
22	UTP	O
23	.	O

1	We	O
2	analyzed	O
3	the	O
4	P	O
5	-	O
6	SAECG	O
7	in	O
8	the	O
9	time	B
10	and	I
11	frequency	I
12	domain	O
13	in	O
14	23	O
15	patients	O
16	with	O
17	Paf	B
18	and	I
19	19	I
20	controls	I
21	.	I

1	The	O
2	murine	O
3	mutation	O
4	dominant	O
5	white	O
6	spotting	O
7	(	O
8	W	O
9	)	O
10	is	O
11	in	O
12	the	O
13	proto	O
14	-	O
15	oncogene	O
16	,	O
17	c	O
18	-	O
19	kit	O
20	.	O

1	ECP	O
2	and	O
3	tryptase	O
4	levels	O
5	in	O
6	serum	O
7	were	O
8	measured	O
9	before	O
10	and	O
11	after	O
12	the	O
13	last	O
14	oral	O
15	challenge	O
16	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	O
9	-	O
10	1	O
11	)	O
12	preferentially	O
13	infects	O
14	CD4	O
15	+	O
16	T	O
17	lymphocytes	O
18	and	O
19	may	B
20	exist	I
21	as	I
22	a	I
23	latent	I
24	provirus	I
25	within	O
26	these	O
27	cells	O
28	for	O
29	extended	O
30	periods	O
31	.	O

1	Temporal	O
2	relationships	O
3	and	O
4	the	O
5	development	O
6	phase	O
7	affected	O
8	.	O

1	To	O
2	elucidate	O
3	whether	O
4	potential	O
5	endocrine	O
6	changes	O
7	resulted	O
8	from	O
9	acute	O
10	hypoxaemia	O
11	alone	O
12	,	O
13	the	O
14	underlying	O
15	disease	O
16	,	O
17	or	O
18	unspecific	O
19	influences	O
20	connected	O
21	with	O
22	the	O
23	ICU	O
24	setting	O
25	,	O
26	all	O
27	measurements	O
28	were	O
29	compared	O
30	to	O
31	those	O
32	of	O
33	a	O
34	completely	O
35	healthy	O
36	reference	O
37	group	O
38	(	O
39	REF	O
40	)	O
41	with	O
42	comparable	B
43	acute	I
44	experimental	I
45	hypoxaemia	I
46	.	I

1	Solution	O
2	structure	O
3	and	O
4	mechanism	O
5	of	O
6	the	O
7	MutT	O
8	pyrophosphohydrolase	O
9	.	O

1	Expression	O
2	of	O
3	PTPRO	O
4	was	O
5	also	O
6	observed	O
7	in	O
8	human	O
9	CD34	O
10	+	O
11	bone	O
12	marrow	O
13	cells	O
14	and	O
15	5	O
16	-	O
17	FU	O
18	-	O
19	treated	O
20	murine	O
21	primitive	O
22	stem	O
23	cells	O
24	.	O

1	These	O
2	synergistic	O
3	effects	O
4	were	O
5	strongly	O
6	Jem	O
7	-	O
8	1	O
9	dose	O
10	-	O
11	dependent	O
12	.	O

1	Sulfhydryl	O
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	B
19	biotin	I
20	,	O
21	revealed	B
22	a	I
23	striking	I
24	difference	O
25	in	B
26	the	B
27	apparent	I
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O

1	Among	O
2	booked	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	unbooked	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	1000	O
21	deliveries	O
22	.	O

1	The	O
2	fracture	O
3	groups	O
4	were	O
5	significantly	O
6	older	O
7	and	O
8	had	O
9	more	O
10	years	O
11	since	O
12	menopause	O
13	than	O
14	the	O
15	control	O
16	groups	O
17	.	O

1	A	O
2	"	O
3	Level	O
4	A	O
5	"	O
6	in	O
7	vitro	O
8	/	O
9	in	O
10	vivo	O
11	correlation	O
12	was	O
13	established	O
14	for	O
15	a	O
16	sustained	O
17	release	O
18	theophylline	O
19	(	O
20	CAS	O
21	58	O
22	-	O
23	55	O
24	-	O
25	9	O
26	)	O
27	preparation	O
28	(	O
29	Bronchoretard	O
30	)	O
31	under	O
32	investigation	O
33	.	O

1	The	O
2	flow	B
3	rate	I
4	of	I
5	phosphate	I
6	buffered	O
7	saline	O
8	through	O
9	dermis	O
10	was	O
11	measured	O
12	as	O
13	a	O
14	function	O
15	of	O
16	applied	I
17	pressure	I
18	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	the	B
6	complete	I
7	structure	I
8	of	I
9	the	O
10	human	B
11	topoisomerase	B
12	IIalpha	I
13	gene	O
14	,	O
15	which	O
16	consists	O
17	of	O
18	35	O
19	exons	O
20	spanning	O
21	27	O
22	.	O
23	5	O
24	kb	O
25	.	O

1	At	O
2	least	O
3	one	O
4	clone	O
5	,	O
6	lambda	O
7	HHG	O
8	41	B
9	,	I
10	contains	I
11	,	I
12	in	I
13	addition	I
14	to	O
15	the	O
16	histone	O
17	genes	O
18	,	O
19	a	O
20	region	O
21	that	O
22	hybridizes	O
23	with	B
24	a	I
25	cytoplasmic	I
26	RNA	I
27	approximately	I
28	330	I
29	nucleotides	O
30	in	O
31	length	O
32	.	B

1	INTERVENTIONS	O
2	:	O
3	Subcutaneous	O
4	tissue	O
5	PO2	O
6	and	O
7	PCO2	O
8	tensions	O
9	were	O
10	measured	O
11	directly	O
12	in	O
13	patients	O
14	with	O
15	necrotising	O
16	fasciitis	O
17	and	O
18	in	O
19	healthy	O
20	volunteers	O
21	during	O
22	normobaric	O
23	and	O
24	hyperbaric	O
25	conditions	O
26	.	O

1	Some	O
2	of	O
3	these	O
4	targets	O
5	were	O
6	reported	O
7	to	O
8	code	O
9	for	O
10	molecules	O
11	involved	O
12	in	O
13	cell	O
14	-	O
15	cell	O
16	interactions	O
17	,	O
18	whereas	O
19	no	O
20	relationship	O
21	has	O
22	yet	O
23	been	O
24	demonstrated	O
25	between	O
26	Hox	O
27	genes	O
28	and	O
29	other	O
30	transcription	O
31	factors	O
32	involved	O
33	in	O
34	determining	O
35	and	O
36	/	O
37	or	O
38	maintaining	O
39	tissue	O
40	specificity	O
41	.	O

1	Tilmicosin	O
2	is	O
3	a	O
4	novel	O
5	macrolide	O
6	antibiotic	O
7	developed	O
8	for	O
9	exclusive	O
10	use	O
11	in	O
12	veterinary	O
13	medicine	O
14	.	O

1	Mutational	O
2	analysis	B
3	of	I
4	the	I
5	-	I
6	84	I
7	/-	O
8	55	O
9	DNA	O
10	showed	O
11	that	O
12	JEG	O
13	-	O
14	3	O
15	nuclear	O
16	proteins	O
17	bound	O
18	to	O
19	a	O
20	site	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	identical	O
26	to	O
27	,	O
28	the	O
29	SF	O
30	-	O
31	1	O
32	sequence	O
33	.	O

1	Furthermore	O
2	,	O
3	DNA	O
4	-	O
5	bound	O
6	LAZ3	O
7	/	O
8	BCL6	O
9	recruits	O
10	SMRT	O
11	in	O
12	vivo	O
13	,	O
14	and	O
15	both	O
16	overexpressed	O
17	proteins	O
18	completely	O
19	colocalize	O
20	in	O
21	nuclear	O
22	dots	O
23	.	O

1	Clinico	O
2	-	O
3	physiological	O
4	experiment	O

1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	O
7	ubiquitination	O
8	,	O
9	mE6	O
10	-	O
11	AP	B
12	was	I
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	O
23	-	O
24	4	O
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O

1	In	O
2	flies	O
3	,	O
4	the	O
5	dShc	O
6	protein	O
7	physically	O
8	associates	O
9	with	O
10	the	O
11	activated	O
12	Drosophila	O
13	epidermal	B
14	growth	I
15	factor	I
16	receptor	I
17	homolog	I
18	(	I
19	DER	O
20	)	O
21	and	O
22	is	O
23	inducibly	O
24	phosphorylated	O
25	on	O
26	tyrosine	O
27	by	O
28	DER	O
29	.	O

1	The	O
2	remaining	O
3	RAD	O
4	+	O
5	cells	O
6	progressed	O
7	to	O
8	form	O
9	microcolonies	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	aberrantly	O
16	shaped	O
17	inviable	O
18	cells	O
19	.	O

1	Involvement	O
2	of	O
3	early	O
4	growth	O
5	response	O
6	factor	O
7	Egr	O
8	-	O
9	1	O
10	in	O
11	apolipoprotein	O
12	AI	O
13	gene	O
14	transcription	O
15	.	O

1	VP	O
2	-	O
3	16	O
4	,	O
5	ifosfamide	O
6	and	O
7	cisplatin	O
8	(	O
9	VIP	O
10	)	O
11	for	O
12	extensive	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	.	O

1	Cytogenetic	O
2	analysis	B
3	of	B
4	LOH	I
5	mutants	I
6	by	I
7	chromosome	O
8	painting	O
9	indicated	O
10	a	O
11	mosaic	O
12	of	O
13	chromosomal	O
14	aberrations	O
15	involving	O
16	chromosome	O
17	17	I
18	,	I
19	in	O
20	which	O
21	partial	O
22	chromosome	B
23	deletions	I
24	,	I
25	amplifications	I
26	,	I
27	and	O
28	multiple	O
29	translocations	O
30	appeared	O
31	heterogeneously	O
32	in	B
33	a	O
34	single	O
35	mutant	B
36	.	I

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	trans	O
6	-	O
7	activation	O
8	from	O
9	the	O
10	prothymosin	O
11	intron	O
12	enhancer	O
13	is	O
14	a	O
15	faithful	O
16	reflection	O
17	of	O
18	the	O
19	transforming	O
20	properties	O
21	of	O
22	the	O
23	Myc	O
24	protein	O
25	.	O

1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	O
16	-	O
17	tubulin	O
18	2	O
19	(	O
20	BTU2	O
21	)	O
22	gene	O
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	O
33	-	O
34	I	O
35	gene	O
36	.	O

1	In	O
2	ferrets	O
3	naturally	B
4	infected	I
5	with	I
6	H	I
7	.	I
8	mustelae	O
9	,	O
10	a	O
11	single	O
12	dose	O
13	(	O
14	50	O
15	mg	O
16	/	O
17	kg	O
18	,	O
19	per	O
20	os	O
21	)	O
22	of	O
23	fluorofamide	O
24	completely	O
25	inhibited	O
26	bacterial	O
27	urease	O
28	.	O

1	The	O
2	sequenced	O
3	cDNA	O
4	predicts	O
5	a	O
6	704	O
7	-	B
8	amino	I
9	acid	I
10	protein	I
11	80	I
12	%	I
13	identical	I
14	to	O
15	human	O
16	progelatinase	O
17	B	O
18	.	O

1	But	O
2	no	O
3	influence	O
4	was	O
5	observed	O
6	at	O
7	lower	O
8	concentrations	O
9	than	O
10	1	O
11	/	O
12	4	O
13	MIC	O
14	of	O
15	AMK	O
16	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	18	O
6	beta	O
7	-	O
8	glycyrrhetate	O
9	(	O
10	SGA	O
11	)	O
12	on	O
13	experimental	O
14	arrhythmia	O
15	was	O
16	investigated	O
17	.	O

1	The	O
2	apparatus	O
3	consists	O
4	of	O
5	an	O
6	Am	O
7	-	O
8	241	O
9	exciting	O
10	source	O
11	(	O
12	300	O
13	mCi	O
14	)	O
15	and	O
16	pure	O
17	Ge	O
18	detector	O
19	(	O
20	50	O
21	mm2	O
22	X	O
23	5	O
24	mm	O
25	)	O
26	for	O
27	measuring	O
28	K	O
29	alpha	O
30	fluorescent	O
31	x	O
32	-	O
33	rays	O
34	(	O
35	28	O
36	.	O
37	3	O
38	and	O
39	28	O
40	.	O
41	6	O
42	KeV	O
43	)	O
44	emitted	O
45	from	O
46	exited	O
47	iodine	O
48	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	wild	O
6	-	O
7	type	O
8	strain	O
9	containing	O
10	a	O
11	temperature	O
12	-	O
13	sensitive	O
14	threonyl	B
15	-	I
16	tRNA	O
17	synthetase	O
18	mutation	O
19	showed	O
20	increased	O
21	thr	O
22	operon	O
23	expression	O
24	at	O
25	the	O
26	non	O
27	-	O
28	permissive	B
29	temperature	I
30	,	O
31	whereas	O
32	none	O
33	of	B
34	the	I
35	mutants	O
36	showed	O
37	any	O
38	change	O
39	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	lumenal	O
6	domains	O
7	of	O
8	Sec12p	O
9	,	B
10	Stl1p	I
11	and	I
12	Stl2p	I
13	are	O
14	very	B
15	different	I
16	in	I
17	size	O
18	and	O
19	do	O
20	not	O
21	show	B
22	any	O
23	appreciable	O
24	homology	O
25	.	O

1	Importance	O
2	of	O
3	determining	O
4	the	O
5	blood	O
6	sulfhydryl	O
7	groups	O
8	in	O
9	fractures	O
10	of	O
11	the	O
12	long	O
13	tubular	O
14	bones	O
15	complicated	O
16	by	O
17	infection	O

1	HeLa	O
2	and	O
3	Jurkat	O
4	cell	O
5	lines	O
6	carrying	O
7	the	O
8	nef	O
9	gene	O
10	linked	O
11	to	O
12	the	O
13	CMV	O
14	promoter	O
15	or	O
16	the	O
17	HIV	O
18	-	O
19	1	O
20	LTR	O
21	were	O
22	isolated	O
23	by	O
24	coselection	O
25	for	O
26	neomycin	O
27	resistance	O
28	.	O

1	Incorporation	O
2	of	O
3	0	O
4	.	O
5	1	O
6	or	O
7	0	O
8	.	O
9	2	O
10	M	O
11	sodium	O
12	dihydrogen	O
13	phosphate	O
14	in	O
15	the	O
16	sugar	O
17	solutions	O
18	resulted	O
19	in	O
20	a	O
21	decrease	O
22	in	O
23	the	O
24	shelf	O
25	-	O
26	life	O
27	of	O
28	diltiazem	O
29	.	O

1	To	O
2	dissect	O
3	these	O
4	mechanisms	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	and	O
10	mutant	O
11	Raf	O
12	-	O
13	1	O
14	proteins	O
15	were	O
16	studied	O
17	in	O
18	an	O
19	in	O
20	vitro	O
21	system	O
22	with	O
23	purified	O
24	plasma	O
25	membranes	O
26	from	O
27	v	O
28	-	O
29	Ras	O
30	-	O
31	and	O
32	v	O
33	-	O
34	Src	O
35	-	O
36	transformed	O
37	cells	O
38	(	O
39	transformed	O
40	membranes	O
41	).	O

1	This	O
2	GAP	O
3	activity	O
4	was	O
5	observed	O
6	in	O
7	3T3	O
8	-	O
9	L1	B
10	adipocyte	I
11	lysates	I
12	,	I
13	and	O
14	was	B
15	able	I
16	to	I
17	accelerate	I
18	the	O
19	hydrolysis	B
20	of	I
21	the	I
22	[	O
23	alpha	O
24	-	O
25	32P	O
26	]	B
27	GTP	I
28	bound	I
29	to	O
30	GST	O
31	-	O
32	Rab4	O
33	into	O
34	[	O
35	alpha	B
36	-	I
37	32P	I
38	]	O
39	GDP	B
40	.	I

1	Circulating	O
2	oxytocin	O
3	in	O
4	male	B
5	guinea	I
6	pigs	I
7	affected	I
8	by	I
9	the	I
10	female	I
11	cohabitation	I
12	and	I
13	reproductive	O
14	condition	O
15	.	O

1	A	O
2	case	O
3	of	O
4	AIDS	O
5	-	O
6	related	O
7	complex	O
8	(	O
9	ARC	O
10	/	O
11	LAS	O
12	)	O
13	in	B
14	a	I
15	health	I
16	worker	I

1	This	O
2	Tbx6	O
3	-	O
4	subfamily	O
5	gene	O
6	is	O
7	likely	O
8	to	O
9	participate	O
10	in	O
11	paraxial	O
12	mesoderm	O
13	formation	O
14	and	O
15	somitogenesis	B
16	in	I
17	human	I
18	embryo	I
19	.	I

1	Together	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	carboxyl	O
9	terminus	O
10	of	O
11	CFTR	O
12	contains	O
13	a	O
14	tyrosine	O
15	-	O
16	based	B
17	internalization	I
18	signal	I
19	that	I
20	interacts	O
21	with	B
22	the	I
23	endocytic	I
24	adaptor	I
25	complex	O
26	AP	O
27	-	O
28	2	O
29	to	O
30	facilitate	O
31	efficient	O
32	entry	O
33	of	O
34	CFTR	O
35	into	O
36	clathrin	O
37	-	O
38	coated	O
39	vesicles	O
40	.	O

1	Molecular	O
2	cloning	B
3	and	I
4	functional	I
5	characterization	O
6	of	O
7	murine	O
8	sphingosine	O
9	kinase	O
10	.	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	When	O
2	normalized	O
3	for	O
4	imaging	O
5	time	O
6	,	O
7	all	O
8	parameters	B
9	are	I
10	significantly	I
11	higher	O
12	with	B
13	RASE	I
14	,	I
15	with	O
16	a	O
17	C	O
18	/	O
19	A	O
20	per	O
21	unit	B
22	time	I
23	that	I
24	was	I
25	338	O
26	%	O
27	higher	B
28	.	I

1	In	O
2	this	B
3	paper	I
4	,	O
5	an	O
6	analysis	O
7	of	O
8	the	O
9	dynamics	B
10	in	I
11	the	I
12	closing	I
13	phase	I
14	of	I
15	the	I
16	occluder	I
17	of	I
18	a	O
19	mechanical	O
20	monoleaflet	O
21	heart	O
22	valve	O
23	prosthesis	O
24	is	O
25	presented	O
26	.	O

1	Localized	O
2	fluorescence	O
3	was	O
4	detectable	O
5	only	O
6	in	O
7	cells	O
8	containing	O
9	a	O
10	visible	O
11	midcell	O
12	constriction	O
13	,	O
14	suggesting	O
15	that	O
16	FtsK	O
17	targeting	O
18	normally	O
19	occurs	O
20	only	O
21	at	O
22	a	O
23	late	O
24	stage	O
25	of	O
26	septation	O
27	.	O

1	"	O
2	Complex	O
3	partial	O
4	"	O
5	seizures	O
6	.	O

1	Single	O
2	photon	O
3	emission	O
4	computerized	O
5	tomography	O
6	(	O
7	SPECT	O
8	),	O
9	by	O
10	providing	O
11	three	O
12	-	O
13	dimensional	O
14	representation	O
15	of	O
16	myocardial	O
17	Tl	O
18	-	O
19	201	O
20	,	O
21	offers	O
22	promise	O
23	for	O
24	improved	O
25	localization	O
26	of	O
27	CAD	O
28	.	O

1	Pigmentary	O
2	rhythms	O
3	as	O
4	indicators	O
5	of	O
6	neurosecretion	O
7	.	B

1	The	O
2	activated	O
3	glucocorticoid	O
4	receptor	O
5	forms	O
6	a	O
7	complex	O
8	with	O
9	Stat5	O
10	and	O
11	enhances	O
12	Stat5	O
13	-	O
14	mediated	O
15	transcriptional	O
16	induction	O
17	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	v	O
6	-	O
7	Rel	O
8	,	O
9	the	O
10	oncoprotein	O
11	of	O
12	the	O
13	avian	O
14	retrovirus	O
15	Rev	O
16	-	O
17	T	O
18	,	O
19	can	O
20	increase	O
21	expression	O
22	from	O
23	promoters	O
24	containing	O
25	binding	O
26	sites	O
27	for	O
28	the	O
29	cellular	O
30	transcription	O
31	factor	O
32	Sp1	O
33	in	O
34	chicken	O
35	embryo	O
36	fibroblasts	O
37	(	O
38	S	O
39	.	O

1	Elevated	O
2	IOP	O
3	developed	O
4	in	O
5	35	O
6	patients	O
7	(	O
8	44	B
9	eyes	I
10	)	I
11	during	I
12	the	O
13	study	O
14	.	O

1	Perturbation	O
2	of	O
3	dNTP	O
4	pools	O
5	also	O
6	affected	O
7	the	O
8	frameshift	O
9	fidelity	O
10	of	O
11	the	O
12	replicative	O
13	yeast	B
14	DNA	I
15	polymerase	I
16	alpha	I
17	.	O

1	The	O
2	mRNAs	O
3	of	O
4	these	O
5	genes	O
6	contain	O
7	respectively	O
8	one	O
9	(	O
10	YAP1	O
11	uORF	O
12	)	O
13	and	O
14	two	O
15	(	O
16	YAP2	O
17	uORF1	O
18	and	O
19	uORF2	O
20	)	O
21	upstream	O
22	open	O
23	reading	O
24	frames	O
25	.	O
26	uORF	O
27	-	O
28	mediated	O
29	modulation	O
30	of	O
31	post	O
32	-	O
33	termination	O
34	events	O
35	on	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	5	O
43	'-	O
44	UTR	O
45	)	O
46	directs	O
47	differential	O
48	control	O
49	not	O
50	only	O
51	of	O
52	translation	O
53	but	O
54	also	O
55	of	O
56	mRNA	O
57	decay	O
58	.	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	kinase	O
6	,	O
7	Nlk	O
8	,	O
9	that	O
10	is	O
11	a	O
12	murine	O
13	homolog	O
14	of	O
15	the	O
16	Drosophila	O
17	nemo	O
18	(	O
19	nmo	O
20	)	B
21	gene	I
22	.	I

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	specific	O
6	DNA	O
7	-	O
8	binding	O
9	complexes	O
10	containing	O
11	members	O
12	of	O
13	the	O
14	Myc	O
15	/	O
16	Max	O
17	/	O
18	Mad	O
19	network	O
20	of	O
21	transcriptional	O
22	regulators	B
23	.	I

1	Changes	O
2	in	O
3	xanthine	O
4	oxidase	O
5	activity	O
6	in	O
7	patients	O
8	with	O
9	circulatory	O
10	failure	O

1	PRL	O
2	receptor	O
3	also	O
4	activates	O
5	SHP	O
6	-	O
7	2	O
8	,	O
9	a	O
10	cytosolic	O
11	tyrosine	O
12	phosphatase	B
13	.	I

1	We	O
2	conclude	O
3	that	O
4	class	O
5	I	O
6	cytologic	O
7	smears	O
8	with	O
9	moderate	O
10	to	O
11	severe	O
12	inflammation	O
13	may	O
14	be	O
15	associated	O
16	with	O
17	findings	O
18	of	O
19	condylomata	O
20	and	O
21	cervical	O
22	dysplasia	O
23	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	the	O
5	0	O
6	.	O
7	38	O
8	kb	O
9	promoter	O
10	sequence	O
11	with	O
12	the	O
13	promoters	O
14	of	O
15	the	O
16	Sm	O
17	-	O
18	E	O
19	gene	O
20	and	B
21	U1	I
22	snRNA	I
23	genes	I
24	revealed	O
25	several	O
26	homologous	O
27	motifs	O
28	,	O
29	suggesting	O
30	that	O
31	genes	B
32	encoding	I
33	the	I
34	snRNP	I
35	components	O
36	may	B
37	be	I
38	coordinately	I
39	regulated	I
40	.	I

1	Likewise	O
2	,	O
3	rad6	O
4	-	O
5	delta	O
6	reduces	O
7	silencing	O
8	of	O
9	the	O
10	telomere	O
11	-	O
12	located	O
13	RNAP	O
14	II	O
15	-	O
16	transcribed	O
17	genes	O
18	URA3	O
19	and	O
20	ADE2	O
21	.	O

1	Gng3lg	O
2	transcripts	O
3	are	O
4	expressed	O
5	in	O
6	a	O
7	variety	O
8	of	O
9	tissues	O
10	including	O
11	both	O
12	brain	O
13	and	O
14	testes	O
15	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	B
10	status	I
11	,	I
12	spirometry	O
13	measurements	B
14	,	I
15	salivary	I
16	and	I
17	serum	I
18	lysozyme	O
19	levels	O
20	or	O
21	rates	B
22	of	I
23	respiratory	I
24	tract	O
25	colonization	B
26	with	I
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	To	O
2	evaluate	O
3	the	O
4	effect	O
5	of	O
6	altitude	B
7	on	I
8	adolescent	O
9	growth	B
10	and	I
11	development	O
12	,	O
13	three	O
14	groups	O
15	of	O
16	healthy	O
17	,	O
18	well	O
19	-	O
20	nourished	O
21	youth	O
22	of	O
23	similar	I
24	socioeconomic	I
25	status	I
26	and	O
27	ethnic	O
28	grouping	O
29	who	I
30	resided	I
31	at	I
32	sea	O
33	level	O
34	(	O
35	n	O
36	=	O
37	1262	O
38	subjects	O
39	),	O
40	mid	O
41	-	O
42	altitude	O
43	(	O
44	n	O
45	=	B
46	1743	I
47	subjects	I
48	),	I
49	and	I
50	high	I
51	altitude	I
52	(	I
53	n	O
54	=	O
55	1137	O
56	subjects	O
57	)	O
58	were	O
59	studied	B
60	.	I

1	After	O
2	recovery	O
3	,	O
4	a	O
5	hypertonic	O
6	saline	O
7	challenge	O
8	was	O
9	performed	O
10	.	O

1	Responsiveness	O
2	to	O
3	beta	O
4	-	O
5	2	O
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	B
12	agents	I
13	(	I
14	p	I
15	less	I
16	than	I
17	0	I
18	.	I
19	05	O
20	).	O

1	In	O
2	summary	O
3	,	O
4	WT1	O
5	is	O
6	enriched	O
7	by	O
8	oligo	O
9	(	O
10	dT	O
11	)	O
12	chromatography	O
13	,	O
14	as	O
15	are	O
16	U2AF65	O
17	,	O
18	the	O
19	U5	B
20	small	I
21	nuclear	I
22	RNP	O
23	-	O
24	associated	O
25	protein	O
26	p116	O
27	and	O
28	hnRNP	O
29	A1	O
30	.	B

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	isolated	O
9	and	O
10	sequenced	O
11	several	B
12	p15E	I
13	cDNA	I
14	gene	O
15	fragments	B
16	amplified	I
17	by	O
18	means	O
19	of	O
20	polymerase	O
21	chain	O
22	reaction	O
23	(	O
24	PCR	O
25	)	O
26	from	O
27	parental	O
28	(	O
29	P815	O
30	)	O
31	and	O
32	xenogenized	O
33	(	O
34	P815	O
35	/	O
36	DTIC	O
37	)	O
38	tumour	O
39	cells	O
40	.	O

1	WR	O
2	-	O
3	2721	O
4	(	O
5	S	O
6	-	O
7	2	O
8	-(	O
9	3	O
10	aminopropylamino	O
11	)	O
12	ethylphosphorothioic	O
13	acid	O
14	)	O
15	has	O
16	been	O
17	investigated	O
18	for	O
19	its	O
20	ability	O
21	to	O
22	protect	O
23	gut	B
24	,	I
25	lung	O
26	,	O
27	and	O
28	testis	O
29	,	B
30	as	I
31	well	I
32	as	O
33	fibrosarcoma	O
34	(	O
35	FSa	O
36	)	O
37	tumor	O
38	nodules	O
39	,	B
40	in	I
41	the	O
42	lungs	O
43	of	O
44	mice	O
45	from	O
46	gamma	O
47	-	O
48	radiation	O
49	injury	O
50	.	O

1	Results	O
2	of	O
3	the	O
4	ECAT	O
5	Angina	O
6	Pectoris	O
7	Study	O
8	Group	O
9	.	O

1	The	O
2	two	O
3	larger	O
4	peptides	O
5	,	O
6	one	O
7	containing	O
8	amino	O
9	acids	O
10	1	O
11	-	O
12	228	O
13	and	O
14	the	O
15	other	O
16	containing	O
17	amino	O
18	acids	O
19	85	O
20	-	O
21	228	O
22	,	O
23	formed	O
24	dimers	O
25	in	O
26	solution	O
27	and	O
28	bound	O
29	DNA	O
30	specifically	O
31	as	O
32	a	O
33	dimer	O
34	.	O

1	Responsibility	O
2	matters	O
3	--	O
4	this	O
5	is	O
6	a	O
7	scientific	O
8	council	O

1	PaO2	O
2	threshold	O
3	was	O
4	determined	O
5	through	O
6	an	O
7	indwelling	O
8	O2	O
9	sensor	O
10	catheter	B
11	.	I

1	Thus	O
2	,	O
3	diamide	O
4	treatment	O
5	of	O
6	nuclear	O
7	extracts	O
8	strongly	O
9	reduces	O
10	the	B
11	binding	I
12	of	I
13	NFI	O
14	proteins	O
15	,	O
16	and	O
17	the	B
18	addition	I
19	of	I
20	higher	I
21	concentrations	O
22	of	B
23	dithiothreitol	B
24	to	I
25	nuclear	I
26	extracts	O
27	from	O
28	TG	B
29	-	I
30	treated	I
31	cells	O
32	restores	O
33	NFI	O
34	-	O
35	DNA	O
36	binding	O
37	to	O
38	levels	O
39	in	O
40	extracts	O
41	from	O
42	untreated	O
43	cells	B
44	.	O

1	All	O
2	three	O
3	NR	O
4	isoforms	O
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	Cys	O
2	-	B
3	757	I
4	within	I
5	the	O
6	(	O
7	Fe4S4	O
8	)-	O
9	siroheme	B
10	-	I
11	binding	I
12	domain	O
13	was	B
14	essential	I
15	for	I
16	native	I
17	enzyme	I
18	activity	I
19	.	O

1	The	O
2	hydrophobicity	O
3	plot	O
4	of	O
5	NHE	O
6	-	O
7	3	O
8	is	O
9	very	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	NHE	O
15	-	O
16	1	O
17	and	O
18	NHE	O
19	-	O
20	2	B
21	.	I

1	In	O
2	all	O
3	eight	O
4	cases	O
5	,	O
6	neither	O
7	FL	O
8	nor	O
9	DLL	O
10	cells	O
11	showed	B
12	alterations	I
13	of	I
14	bcl	O
15	-	O
16	2	O
17	gene	O
18	sequences	O
19	in	O
20	the	O
21	breakpoint	O
22	region	O
23	,	O
24	suggesting	O
25	high	B
26	conservation	I
27	of	O
28	the	B
29	bcl	I
30	-	I
31	2	I
32	gene	I
33	during	I
34	both	I
35	t	O
36	(	O
37	14	O
38	;	O
39	18	O
40	)	O
41	translocation	O
42	and	O
43	morphologic	O
44	transformation	O
45	of	O
46	the	O
47	FL	O
48	cells	O
49	.	O

1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	O
7	lymphocyte	O
8	antigen	O
9	receptor	O
10	-	O
11	induced	O
12	calcium	O
13	flux	O
14	.	O

1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O

1	Isolation	O
2	and	O
3	characterization	B
4	of	I
5	a	I
6	cDNA	I
7	encoding	I
8	a	I
9	putative	I
10	cytokine	O
11	which	O
12	is	O
13	induced	O
14	by	O
15	stimulation	O
16	via	O
17	the	O
18	CD2	O
19	structure	O
20	on	O
21	human	O
22	T	O
23	lymphocytes	O
24	.	O

1	Fregnac	O
2	,	O
3	M	O
4	.	O

1	Studied	O
2	groups	O
3	were	O
4	(	O
5	1	O
6	)	O
7	untreated	O
8	control	O
9	,	B
10	n	I
11	=	I
12	12	O
13	;	O
14	(	B
15	2	I
16	)	I
17	FK	I
18	-	I
19	1	O
20	,	O
21	n	O
22	=	O
23	8	O
24	;	O
25	(	O
26	3	B
27	)	B
28	FK	I
29	-	O
30	3	O
31	,	O
32	n	I
33	=	B
34	8	O
35	.	O

1	The	O
2	UV	O
3	induction	B
4	of	I
5	c	I
6	-	I
7	jun	I
8	is	I
9	mediated	O
10	by	O
11	two	O
12	UV	O
13	response	O
14	elements	O
15	consisting	O
16	of	O
17	AP	O
18	-	O
19	1	O
20	-	O
21	like	O
22	sequences	O
23	within	O
24	its	O
25	5	O
26	'	O
27	control	O
28	region	O
29	.	O

1	From	O
2	day	O
3	10	O
4	,	O
5	a	O
6	significant	O
7	increase	O
8	in	O
9	platelet	O
10	count	O
11	was	O
12	observed	O
13	in	O
14	eight	O
15	of	O
16	the	O
17	ten	O
18	patients	O
19	treated	O
20	with	O
21	heparin	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	),	O
29	with	O
30	return	O
31	to	O
32	the	O
33	initial	O
34	value	O
35	after	O
36	heparin	O
37	cessation	O
38	in	O
39	six	O
40	of	O
41	the	O
42	responders	O
43	.	O

1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O

1	Production	O
2	of	O
3	C	O
4	mu	O
5	RNAs	O
6	,	O
7	unlike	O
8	mu	O
9	mRNAs	O
10	,	O
11	does	B
12	not	I
13	require	I
14	recombination	I
15	with	I
16	the	O
17	joining	O
18	region	O
19	(	O
20	JH	O
21	)	O
22	locus	O
23	.	O

1	Cotransfection	O
2	with	O
3	the	O
4	ie1	O
5	gene	O
6	resulted	O
7	in	O
8	a	O
9	dramatic	O
10	increase	O
11	in	O
12	the	O
13	amount	O
14	of	O
15	the	O
16	two	O
17	enzymes	O
18	expressed	O
19	in	O
20	the	O
21	transfected	O
22	cells	O
23	.	O

1	8	O
2	%	O
3	(	O
4	95	O
5	%	O
6	CI	O
7	,	O
8	21	O
9	.	B
10	3	I
11	-	I
12	44	I
13	.	I
14	3	O
15	%).	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	BOX	O
9	DNA	O
10	enhances	O
11	transcription	O
12	from	O
13	the	O
14	thymidine	O
15	kinase	O
16	(	O
17	TK	O
18	)	O
19	promoter	O
20	in	O
21	various	O
22	EC	O
23	cells	O
24	.	O

1	The	O
2	murine	O
3	chromosomal	O
4	locations	O
5	of	O
6	the	O
7	five	O
8	NMDA	O
9	receptor	O
10	channel	O
11	subunits	O
12	,	O
13	the	O
14	epsilon	O
15	1	O
16	(	O
17	Grin2a	B
18	),	I
19	epsilon	I
20	2	I
21	(	I
22	Grin2b	I
23	),	O
24	epsilon	O
25	3	O
26	(	O
27	Grin2c	O
28	),	O
29	epsilon	O
30	4	O
31	(	O
32	Grin2d	O
33	)	O
34	and	O
35	zeta	O
36	1	O
37	(	O
38	Grinl	O
39	)	O
40	subunits	O
41	,	O
42	were	O
43	determined	O
44	using	O
45	an	O
46	interspecific	O
47	backcross	O
48	mapping	O
49	panel	O
50	derived	O
51	from	O
52	crosses	O
53	of	B
54	[(	I
55	C57BL	O
56	/	O
57	6JxM	O
58	.	O
59	spretus	O
60	)	O
61	F1xC57BL	O
62	/	O
63	6J	O
64	]	O
65	mice	O
66	.	O

1	A	O
2	strong	O
3	trithorax	O
4	binding	O
5	site	O
6	was	O
7	found	O
8	at	O
9	the	O
10	cytological	O
11	location	O
12	of	O
13	the	O
14	fork	O
15	head	O
16	gene	O
17	,	O
18	a	O
19	region	O
20	-	O
21	specific	O
22	homeotic	O
23	gene	O
24	not	O
25	located	O
26	within	O
27	a	O
28	homeotic	O
29	complex	O
30	.	O

1	Intriguingly	O
2	,	O
3	three	B
4	hypomorphic	I
5	Scm	O
6	mutations	B
7	,	I
8	which	I
9	map	O
10	within	B
11	an	I
12	mbt	I
13	repeat	I
14	,	O
15	interact	O
16	with	O
17	PcG	O
18	mutations	O
19	more	O
20	strongly	O
21	than	O
22	do	O
23	Scm	O
24	null	O
25	alleles	O
26	.	O

1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	B
13	of	I
14	both	I
15	acid	I
16	and	O
17	solvent	B
18	formation	I
19	,	O
20	whereas	B
21	the	I
22	physiological	I
23	function	I
24	of	O
25	ThlB	O
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	HIV	O
6	-	O
7	1	O
8	Gag	O
9	sequences	O
10	can	O
11	influence	O
12	the	O
13	viral	O
14	PR	O
15	-	O
16	mediated	O
17	processing	O
18	of	B
19	the	B
20	MuLV	I
21	TM	O
22	Env	B
23	protein	B
24	p15	I
25	(	I
26	E	O
27	).	O

1	It	O
2	is	O
3	the	O
4	human	O
5	homolog	O
6	of	O
7	the	O
8	mouse	O
9	Mx	O
10	protein	O
11	involved	O
12	in	O
13	resistance	O
14	to	O
15	influenza	O
16	virus	O
17	.	O

1	RESULTS	O
2	:	O
3	Surprisingly	O
4	,	O
5	PAF	O
6	blockade	O
7	increased	O
8	mortality	O
9	after	O
10	trauma	O
11	(	O
12	5	O
13	of	O
14	11	O
15	WEB	O
16	-	O
17	2086	O
18	animals	O
19	versus	O
20	1	O
21	of	O
22	9	O
23	vehicle	O
24	animals	O
25	;	O
26	p	O
27	=	O
28	0	O
29	.	O
30	15	O
31	)	O
32	and	O
33	depressed	O
34	cardiac	O
35	index	O
36	and	O
37	O2	O
38	delivery	O
39	at	O
40	72	O
41	hours	O
42	(	O
43	p	O
44	<	O
45	0	O
46	.	O
47	05	O
48	).	O

1	This	O
2	protein	O
3	with	O
4	a	O
5	hydrophobic	O
6	amino	O
7	terminus	O
8	appears	O
9	to	O
10	be	O
11	a	O
12	secreted	O
13	protein	O
14	.	O

1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O

1	The	O
2	protooncogene	O
3	c	O
4	-	O
5	myb	O
6	encodes	O
7	a	O
8	nuclear	O
9	transcription	O
10	factor	O
11	that	O
12	binds	O
13	to	O
14	DNA	O
15	in	O
16	a	O
17	sequence	O
18	-	O
19	specific	O
20	manner	O
21	and	O
22	transactivates	O
23	transcription	O
24	of	O
25	several	O
26	viral	O
27	and	O
28	cellular	O
29	genes	O
30	.	O

1	The	O
2	Drosophila	O
3	melanogaster	O
4	Gart	O
5	gene	O
6	encodes	O
7	three	O
8	enzymatic	O
9	activities	O
10	in	O
11	the	O
12	pathway	O
13	for	O
14	purine	O
15	de	O
16	novo	O
17	synthesis	O
18	.	O

1	Diagnosis	O
2	and	O
3	treatment	B
4	planning	I
5	in	I
6	Class	I
7	II	I
8	,	O
9	division	O
10	2	O

1	Initial	O
2	experience	O
3	with	O
4	the	O
5	new	O
6	technology	O
7	indicates	O
8	that	O
9	SieScape	O
10	is	O
11	an	B
12	alternative	I
13	to	I
14	other	I
15	methods	O
16	such	O
17	as	O
18	CT	O
19	and	O
20	MRI	O
21	.	O

1	Relaxation	O
2	of	O
3	catch	O
4	in	O
5	a	O
6	molluscan	O
7	smooth	O
8	muscle	O
9	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	results	O
5	demonstrate	O
6	that	O
7	at	O
8	the	O
9	site	O
10	of	B
11	lumbar	I
12	disc	I
13	herniation	O
14	,	O
15	inflammatory	O
16	cytokines	O
17	such	O
18	as	O
19	interleukin	O
20	-	O
21	1	O
22	alpha	O
23	are	B
24	produced	I
25	,	I
26	which	O
27	increases	O
28	prostaglandin	O
29	E2	O
30	production	O
31	.	O

1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	O
13	TATA	O
14	motif	O
15	.	O

1	These	O
2	results	B
3	indicate	I
4	that	I
5	the	O
6	cis	O
7	-	O
8	regulatory	O
9	elements	O
10	required	O
11	for	O
12	developmental	O
13	control	O
14	of	O
15	the	B
16	HaG3	I
17	-	I
18	A	I
19	helianthinin	I
20	gene	I
21	are	O
22	located	O
23	in	O
24	a	O
25	2	O
26	.	O
27	4	O
28	kb	O
29	upstream	O
30	region	O
31	of	O
32	this	I
33	gene	O
34	.	O

1	Finger	O
2	associated	O
3	box	O
4	-	O
5	zinc	O
6	finger	O
7	proteins	O
8	(	O
9	FAX	O
10	-	O
11	ZFPs	O
12	)	O
13	constitute	O
14	a	O
15	subfamily	O
16	of	O
17	the	O
18	many	O
19	C2H2	O
20	type	O
21	ZFPs	O
22	in	O
23	Xenopus	O
24	laevis	O
25	.	O

1	Role	O
2	of	O
3	NH	O
4	(	O
5	2	O
6	)-	O
7	and	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	of	O
13	the	O
14	P	O
15	protein	O
16	of	O
17	human	O
18	parainfluenza	O
19	virus	O
20	type	O
21	3	O
22	in	O
23	transcription	O
24	and	O
25	replication	O
26	.	O

1	Our	O
2	data	O
3	showed	O
4	that	O
5	activation	O
6	of	O
7	the	O
8	raf	O
9	-	O
10	ERK	O
11	pathway	O
12	led	O
13	to	O
14	activation	O
15	of	O
16	TF	O
17	expression	O
18	in	B
19	breast	I
20	carcinoma	I
21	cells	I
22	and	O
23	suggested	B
24	that	I
25	constitutive	I
26	activation	I
27	of	I
28	this	O
29	pathway	O
30	leads	O
31	to	O
32	high	O
33	TF	O
34	expression	O
35	in	O
36	MDA	O
37	-	O
38	MB	O
39	-	O
40	231	O
41	cells	O
42	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	contains	O
4	four	O
5	known	O
6	acyl	O
7	-	O
8	CoA	O
9	synthetases	O
10	(	O
11	fatty	O
12	acid	O
13	activation	O
14	proteins	O
15	,	O
16	Faaps	O
17	).	O

1	Once	O
2	P	O
3	-	O
4	450scc	O
5	mRNA	O
6	is	O
7	induced	O
8	as	O
9	a	O
10	consequence	O
11	of	O
12	the	O
13	LH	O
14	/	O
15	hCG	O
16	surge	O
17	it	O
18	is	O
19	constitutively	O
20	maintained	O
21	by	O
22	luteinized	O
23	cells	O
24	in	O
25	vivo	O
26	(	O
27	0	O
28	-	O
29	4	O
30	days	O
31	)	O
32	and	O
33	in	O
34	vitro	O
35	(	O
36	0	O
37	-	O
38	9	O
39	days	O
40	)	O
41	in	O
42	the	O
43	absence	O
44	of	O
45	gonadotropins	O
46	,	O
47	is	O
48	susceptible	O
49	to	O
50	modulation	O
51	by	O
52	prolactin	O
53	and	O
54	is	O
55	no	O
56	longer	O
57	regulated	O
58	by	O
59	cAMP	O
60	.	O

1	Demyelinating	O
2	diseases	O
3	involving	O
4	the	O
5	grey	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	B
13	must	B
14	consider	I
15	the	I
16	presence	O
17	of	B
18	symmetrical	B
19	thalamic	I
20	involvement	I
21	in	O
22	patients	O
23	with	O
24	ADEM	O
25	.	O

1	This	O
2	hypothesis	O
3	was	O
4	tested	O
5	by	O
6	introducing	O
7	mutations	O
8	at	O
9	each	O
10	of	O
11	the	O
12	three	O
13	histidine	O
14	pairs	O
15	,	O
16	the	O
17	H382	O
18	-	O
19	X2	O
20	-	O
21	H385	O
22	pair	O
23	,	O
24	the	O
25	H411	O
26	-	O
27	X2	O
28	-	B
29	H414	I
30	pair	I
31	and	I
32	the	I
33	H430	O
34	-	O
35	X5	O
36	-	O
37	H436	O
38	pair	O
39	,	O
40	which	O
41	constitute	O
42	the	O
43	histidine	O
44	-	O
45	rich	O
46	region	O
47	near	O
48	the	O
49	C	O
50	terminus	O
51	of	O
52	gp17	O
53	.	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	neuron	O
10	-	O
11	specific	O
12	protein	O
13	kinase	O
14	C	O
15	substrate	O
16	neurogranin	O
17	(	O
18	RC3	O
19	protein	O
20	).	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	presented	O
6	with	O
7	Transient	O
8	Ischemic	O
9	Attacks	O
10	(	O
11	64	O
12	%)	O
13	or	O
14	Reversible	O
15	Ischemic	O
16	Neurologic	O
17	Deficits	O
18	(	O
19	19	O
20	%).	O

1	This	O
2	protein	O
3	,	O
4	designated	O
5	p532	O
6	based	O
7	on	O
8	its	O
9	predicted	O
10	molecular	O
11	weight	O
12	(	O
13	EMBO	O
14	J	O
15	15	O
16	:	O
17	5738	O
18	,	O
19	1996	O
20	),	O
21	contains	O
22	multiple	O
23	structural	O
24	domains	O
25	including	O
26	two	O
27	regions	O
28	of	O
29	seven	O
30	internal	O
31	repeats	O
32	highly	O
33	related	O
34	to	O
35	the	O
36	cell	O
37	cycle	O
38	regulator	O
39	RCC1	O
40	,	O
41	a	O
42	guanine	O
43	nucleotide	O
44	exchange	O
45	factor	O
46	for	O
47	the	O
48	small	O
49	GTP	O
50	-	O
51	binding	O
52	protein	O
53	Ran	O
54	,	O
55	seven	O
56	beta	O
57	-	O
58	repeat	O
59	domains	O
60	characteristic	O
61	of	O
62	the	O
63	beta	O
64	subunit	O
65	of	O
66	heterotrimeric	O
67	G	O
68	proteins	O
69	,	O
70	three	O
71	putative	O
72	SH3	O
73	binding	O
74	sites	O
75	,	O
76	a	O
77	putative	O
78	leucine	O
79	-	O
80	zipper	O
81	and	O
82	a	O
83	carboxy	O
84	-	O
85	terminal	O
86	HECT	O
87	domain	O
88	characteristic	O
89	of	O
90	E3	O
91	ubiquitin	O
92	-	O
93	protein	O
94	ligases	O
95	.	O

1	Anti	O
2	-	O
3	B	O
4	.	O
5	burgdorferi	O
6	,	O
7	anti	O
8	-	O
9	B	O
10	.	O
11	turicatae	O
12	and	O
13	anti	I
14	-	I
15	B	O
16	.	O
17	parkeri	O
18	antibodies	O
19	,	O
20	tested	O
21	by	O
22	the	O
23	indirect	O
24	immunofluorescent	O
25	assay	O
26	(	O
27	IFA	O
28	),	O
29	were	O
30	detected	O
31	in	O
32	10	O
33	.	O
34	8	O
35	,	O
36	16	O
37	.	O
38	1	O
39	and	O
40	8	O
41	.	O
42	2	O
43	%	O
44	of	O
45	the	O
46	serum	O
47	samples	O
48	tested	O
49	,	O
50	and	O
51	confirmed	O
52	by	O
53	IFA	O
54	-	O
55	ABS	O
56	in	O
57	1	O
58	.	O
59	3	O
60	,	O
61	1	O
62	.	O
63	3	O
64	and	O
65	1	O
66	.	O
67	0	O
68	%,	O
69	respectively	O
70	.	O

1	Further	O
2	,	O
3	we	O
4	show	O
5	that	O
6	this	O
7	EIA	O
8	-	O
9	inducible	O
10	CBF	O
11	/	O
12	cdc2	O
13	is	O
14	related	O
15	to	O
16	the	O
17	CBF	O
18	which	O
19	was	O
20	shown	O
21	to	O
22	activate	O
23	the	O
24	heat	O
25	shock	O
26	protein	O
27	70	O
28	promoter	O
29	.	O

1	Genes	O
2	belonging	O
3	to	O
4	the	O
5	ras	O
6	superfamily	O
7	encode	O
8	low	O
9	-	O
10	molecular	O
11	-	O
12	weight	O
13	GTP	O
14	/	O
15	GDP	O
16	-	O
17	binding	O
18	proteins	O
19	that	O
20	are	O
21	highly	O
22	conserved	O
23	in	O
24	wide	O
25	variety	O
26	of	O
27	organisms	O
28	.	O

1	The	O
2	peak	O
3	velocities	O
4	of	O
5	the	O
6	atrial	O
7	systolic	O
8	waves	O
9	of	O
10	the	O
11	transmitral	O
12	and	O
13	pulmonary	O
14	venous	O
15	flow	O
16	velocities	O
17	(	O
18	A	O
19	and	O
20	PVA	O
21	,	O
22	respectively	O
23	)	O
24	and	O
25	first	O
26	systolic	O
27	wave	O
28	(	O
29	PVS1	O
30	)	O
31	of	O
32	pulmonary	O
33	venous	O
34	flow	O
35	,	O
36	durations	O
37	of	O
38	both	O
39	atrial	O
40	systolic	O
41	waves	O
42	,	O
43	and	O
44	amplitude	O
45	of	O
46	interatrial	O
47	septal	O
48	motion	O
49	during	O
50	atrial	O
51	systole	O
52	increased	O
53	significantly	O
54	ten	O
55	days	O
56	after	O
57	cardioversion	O
58	compared	O
59	with	O
60	those	O
61	measured	O
62	within	O
63	a	O
64	day	O
65	of	O
66	cardioversion	O
67	in	O
68	all	O
69	patients	O
70	except	O
71	the	O
72	5	O
73	patients	O
74	with	O
75	dilated	O
76	cardiomyopathy	O
77	.	O

1	The	O
2	RAD18	O
3	gene	O
4	open	O
5	reading	O
6	frame	O
7	encodes	O
8	a	O
9	protein	B
10	of	I
11	487	O
12	amino	B
13	acids	B
14	,	O
15	with	O
16	a	O
17	calculated	O
18	molecular	O
19	weight	O
20	of	O
21	55	O
22	,	O
23	512	O
24	.	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	O
6	cDNA	O
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	Jerseys	O
2	had	O
3	higher	O
4	hepatic	O
5	Cu	O
6	concentrations	O
7	than	O
8	did	O
9	Holsteins	O
10	on	O
11	d	O
12	60	O
13	(	O
14	346	O
15	vs	O
16	.	O

1	A	O
2	suspected	O
3	hypothalamic	O
4	dysfunction	O
5	and	O
6	a	O
7	slightly	O
8	impaired	O
9	pituitary	O
10	function	O
11	manifested	O
12	as	O
13	GH	O
14	deficiency	O
15	were	O
16	their	O
17	common	O
18	endocrinological	O
19	features	O
20	.	O

1	The	O
2	complete	O
3	gene	O
4	organization	O
5	was	O
6	obtained	O
7	by	O
8	combining	O
9	the	O
10	results	O
11	of	O
12	the	O
13	sequence	O
14	of	O
15	these	O
16	clones	O
17	and	O
18	those	O
19	of	O
20	the	O
21	characterization	O
22	of	O
23	polymerase	O
24	chain	O
25	reaction	O
26	-	O
27	amplified	O
28	genomic	O
29	segments	O
30	.	O

1	In	O
2	44	O
3	evaluable	O
4	patients	O
5	the	O
6	response	O
7	rate	O
8	was	O
9	50	O
10	%,	O
11	with	O
12	one	O
13	complete	O
14	response	O
15	.	O

1	To	O
2	understand	O
3	the	O
4	function	O
5	of	O
6	receptor	O
7	-	O
8	linked	O
9	tyrosine	O
10	phosphatases	O
11	in	O
12	neural	O
13	development	O
14	,	O
15	we	O
16	sought	O
17	to	O
18	identify	O
19	LAR	O
20	isoforms	O
21	preferentially	O
22	expressed	O
23	in	O
24	the	O
25	nervous	O
26	system	O
27	and	O
28	cellular	O
29	processes	O
30	regulating	O
31	LAR	O
32	alternative	O
33	splicing	O
34	.	O

1	Nevertheless	O
2	,	O
3	inactivation	B
4	of	I
5	the	I
6	cyclin	I
7	E	O
8	-	B
9	Cdk2	I
10	complex	O
11	in	O
12	response	O
13	to	O
14	mitogen	O
15	starvation	O
16	occurs	O
17	normally	O
18	in	O
19	MEFs	O
20	that	O
21	have	O
22	a	O
23	homozygous	O
24	deletion	O
25	of	O
26	the	O
27	p27	O
28	gene	O
29	.	O

1	Although	O
2	isl	O
3	-	O
4	1	O
5	binds	O
6	to	O
7	both	O
8	the	O
9	insulin	O
10	and	O
11	amylin	O
12	gene	O
13	promoter	O
14	elements	O
15	in	B
16	vitro	I
17	,	I
18	these	I
19	sequences	I
20	display	O
21	marked	O
22	differences	O
23	in	O
24	their	O
25	relative	O
26	transcriptional	O
27	properties	O
28	when	O
29	ligated	O
30	adjacent	O
31	to	O
32	a	O
33	heterologous	O
34	promoter	O
35	and	O
36	transfected	O
37	into	B
38	InR1	I
39	-	I
40	G9	I
41	islet	I
42	cells	O
43	.	B

1	This	O
2	sensitivity	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	practical	B
8	limits	I
9	of	I
10	the	O
11	accuracy	O
12	of	O
13	the	O
14	used	O
15	screening	B
16	test	B
17	jeopardize	O
18	the	O
19	estimation	O
20	of	O
21	the	O
22	true	O
23	herd	O
24	prevalence	O
25	within	O
26	reasonable	O
27	confidence	O
28	limits	O
29	,	O
30	because	O
31	the	B
32	within	I
33	-	I
34	herd	O
35	PTB	O
36	true	O
37	prevalence	O
38	was	O
39	low	O
40	.	O
41	For	O
42	this	O
43	reason	O
44	we	O
45	augmented	O
46	the	O
47	herd	O
48	specificity	O
49	for	O
50	herds	O
51	with	B
52	larger	O
53	adult	I
54	herd	O
55	size	O
56	(>	I
57	5	O
58	).	O

1	The	O
2	Cox	O
3	proportional	B
4	hazards	I
5	model	I
6	was	I
7	applied	I
8	to	I
9	the	I
10	data	O
11	in	O
12	order	O
13	to	O
14	determine	O
15	the	O
16	prognostic	O
17	factors	O
18	for	O
19	long	O
20	-	O
21	term	O
22	survival	B
23	.	I

1	The	O
2	multiple	O
3	factors	O
4	affecting	O
5	plasma	O
6	renin	O
7	activity	O
8	in	O
9	essential	O
10	hypertension	O
11	.	O

1	The	O
2	ultrastructural	O
3	findings	O
4	,	O
5	as	O
6	well	O
7	as	O
8	the	O
9	urinary	O
10	C	O
11	-	O
12	peptide	O
13	excretion	O
14	,	O
15	confirmed	O
16	that	O
17	the	O
18	glycemic	O
19	effects	O
20	should	B
21	not	I
22	be	I
23	thought	O
24	to	O
25	be	O
26	due	O
27	to	O
28	a	O
29	direct	O
30	action	O
31	of	O
32	the	B
33	drugs	I
34	used	I
35	on	I
36	the	I
37	endocrine	I
38	pancreas	I
39	.	O

1	Reverse	O
2	transcriptase	O
3	-	O
4	polymerase	O
5	chain	O
6	reaction	O
7	(	O
8	RT	O
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O

1	This	O
2	R	B
3	-	B
4	domain	I
5	may	O
6	modulate	B
7	the	I
8	interaction	I
9	with	I
10	SRF	I
11	,	O
12	providing	B
13	a	I
14	mechanism	O
15	that	O
16	would	O
17	be	O
18	unique	O
19	to	O
20	FLI1	O
21	and	O
22	EWS	O
23	-	O
24	FLI1	O
25	,	O
26	thus	O
27	implicating	O
28	a	O
29	novel	O
30	function	O
31	for	O
32	these	O
33	ETS	O
34	transcription	O
35	factors	B
36	in	I
37	the	I
38	regulation	O
39	of	O
40	the	O
41	Egr1	B
42	gene	I
43	.	I

1	Reduced	O
2	NK	O
3	activity	O
4	correlates	O
5	with	O
6	active	O
7	disease	O
8	in	O
9	HIV	O
10	-	O
11	patients	O
12	with	O
13	multidrug	O
14	-	O
15	resistant	O
16	pulmonary	O
17	tuberculosis	O
18	.	O

1	The	O
2	exon	O
3	-	O
4	intron	O
5	distribution	O
6	of	O
7	Cdebp	O
8	appears	O
9	strikingly	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	the	O
15	App	O
16	gene	O
17	in	O
18	the	O
19	regions	O
20	encoding	O
21	the	O
22	conserved	O
23	domains	O
24	,	O
25	with	O
26	a	O
27	divergent	O
28	structure	O
29	in	O
30	the	O
31	other	O
32	parts	O
33	.	O

1	(	O
2	3	O
3	)	O
4	This	O
5	effect	O
6	occurs	O
7	without	O
8	removing	O
9	TRs	O
10	from	O
11	the	O
12	TRE	O
13	.	O

1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	O
7	nuclease	O
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O

1	Early	O
2	heparin	O
3	therapy	O
4	in	O
5	60	O
6	children	O
7	with	O
8	acute	O
9	meningococcemia	O
10	.	O

1	In	O
2	metabolic	O
3	acidosis	O
4	there	O
5	was	O
6	a	O
7	marked	O
8	stimulation	O
9	when	O
10	clamped	O
11	at	O
12	-	O
13	10	O
14	to	O
15	-	O
16	100	O
17	mV	O
18	.	O

1	An	O
2	NF1	O
3	-	O
4	related	O
5	vitellogenin	O
6	activator	O
7	element	O
8	mediates	O
9	transcription	O
10	from	O
11	the	O
12	estrogen	O
13	-	O
14	regulated	O
15	Xenopus	O
16	laevis	O
17	vitellogenin	O
18	promoter	O
19	.	O

1	Neither	O
2	mutant	O
3	exhibited	O
4	derepression	O
5	of	O
6	the	O
7	silent	O
8	mating	O
9	type	O
10	loci	O
11	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	gluconeogenic	B
6	genes	I
7	are	I
8	derepressed	I
9	upon	I
10	binding	I
11	of	I
12	Cat8p	I
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	Cat4p	O
22	(	O
23	Mig1p	O
24	)	O
25	from	O
26	the	B
27	CAT8	I
28	promoter	I
29	.	I

1	The	O
2	Siglecs	B
3	are	O
4	a	O
5	subfamily	O
6	of	O
7	I	O
8	-	O
9	type	B
10	lectins	B
11	(	O
12	immunoglobulin	O
13	superfamily	O
14	proteins	O
15	that	O
16	bind	O
17	sugars	O
18	)	O
19	that	O
20	specifically	O
21	recognize	O
22	sialic	O
23	acids	O
24	.	O

1	Transcriptional	O
2	repression	O
3	mediated	O
4	by	O
5	LysR	O
6	-	O
7	type	O
8	regulator	O
9	CatR	O
10	bound	O
11	at	O
12	multiple	O
13	binding	O
14	sites	O
15	.	O

1	This	O
2	article	O
3	describes	O
4	the	O
5	collaborative	O
6	care	O
7	of	O
8	the	O
9	woman	O
10	participating	O
11	in	O
12	maternal	O
13	blood	O
14	donation	O
15	for	O
16	intrauterine	O
17	transfusion	O
18	.	O

1	The	O
2	consequences	O
3	of	O
4	intensive	O
5	swine	O
6	production	O
7	on	O
8	the	O
9	environment	O
10	and	O
11	possible	O
12	solutions	O
13	by	O
14	means	O
15	of	O
16	nutrition	O
17	are	O
18	outlined	O
19	.	O

1	Phenotypic	O
2	changes	O
3	induced	O
4	by	O
5	wild	O
6	type	O
7	and	O
8	variant	O
9	c	O
10	-	O
11	src	O
12	genes	O
13	carrying	O
14	C	O
15	-	O
16	terminal	O
17	sequence	O
18	alterations	O
19	.	O

1	Thus	O
2	analysis	O
3	indicated	O
4	no	O
5	reliable	O
6	evidence	O
7	that	O
8	conscious	O
9	presleep	O
10	suggestions	O
11	become	O
12	incorporated	O
13	into	O
14	dream	O
15	content	O
16	.	O

1	We	O
2	also	O
3	isolated	O
4	two	O
5	alternatively	O
6	spliced	O
7	forms	O
8	of	O
9	human	O
10	CD6	O
11	cDNA	O
12	lacking	O
13	sequences	O
14	encoding	O
15	membrane	O
16	-	O
17	proximal	O
18	regions	O
19	of	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	which	O
24	maintain	O
25	the	O
26	same	O
27	reading	O
28	frame	O
29	as	O
30	CD6	O
31	-	O
32	PB1	O
33	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	bacteriophage	B
10	-	I
11	type	I
12	RNA	I
13	polymerase	I
14	from	I
15	the	O
16	higher	O
17	plant	O
18	Chenopodium	O
19	album	O
20	.	O

1	Ha	O
2	-	O
3	RasV12	O
4	and	O
5	activated	O
6	proteins	O
7	in	O
8	both	O
9	the	O
10	extra	O
11	-	O
12	cellular	O
13	regulated	O
14	kinase	O
15	(	O
16	ERK	O
17	)	O
18	and	O
19	the	O
20	stress	O
21	-	O
22	activated	B
23	protein	I
24	kinase	I
25	(	O
26	SAPK	O
27	)	O
28	or	O
29	Jun	O
30	N	O
31	-	O
32	terminal	O
33	kinase	O
34	(	O
35	JNK	O
36	)	O
37	cascades	O
38	independently	O
39	stimulated	O
40	PEA3	O
41	-	O
42	mediated	O
43	gene	O
44	expression	O
45	.	O

1	Mutation	O
2	of	O
3	the	O
4	central	O
5	Tyr497	O
6	to	B
7	Phe	I
8	blocks	I
9	the	I
10	tyrosine	I
11	phosphorylation	O
12	of	O
13	the	O
14	insulin	O
15	receptor	O
16	substrate	O
17	1	O
18	(	O
19	IRS1	O
20	)	O
21	and	O
22	diminishes	O
23	proliferation	O
24	in	B
25	response	I
26	to	I
27	IL	I
28	-	I
29	4	O
30	.	O

1	Treatment	O
2	of	O
3	hypertension	O
4	with	O
5	a	O
6	combination	O
7	of	O
8	the	O
9	adrenergic	O
10	beta	O
11	receptor	O
12	blockader	O
13	,	O
14	obsidan	O
15	,	O
16	and	O
17	the	O
18	vasodilator	O
19	,	O
20	apressin	O

1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	B
6	differential	I
7	display	I
8	method	I
9	to	I
10	compare	I
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O

1	These	O
2	data	O
3	indicate	O
4	a	O
5	functional	O
6	role	O
7	for	O
8	U1	O
9	in	O
10	NRS	O
11	-	O
12	mediated	O
13	splicing	O
14	inhibition	O
15	.	O

1	The	O
2	investigation	O
3	was	O
4	thereafter	O
5	continued	O
6	in	O
7	an	O
8	open	O
9	fashion	O
10	by	O
11	administering	O
12	a	O
13	single	O
14	10	O
15	mg	O
16	dose	B
17	of	I
18	the	I
19	MAO	I
20	-	I
21	B	I
22	inhibitor	O
23	deprenyl	O
24	to	O
25	the	O
26	same	O
27	subjects	O
28	.	O

1	The	O
2	abundance	O
3	of	B
4	transcripts	I
5	from	I
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	O
13	-	O
14	1	O
15	mutant	O
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	O
33	gene	O
34	,	O
35	persists	O
36	in	B
37	an	O
38	aberrant	O
39	fashion	B
40	.	I

1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	LBP	O
7	-	O
8	1	O
9	represses	O
10	HIV	O
11	-	O
12	1	O
13	transcription	O
14	by	O
15	inhibiting	O
16	the	O
17	binding	O
18	of	O
19	TFIID	O
20	to	O
21	the	O
22	TATA	O
23	box	O
24	.	O

1	No	O
2	causal	O
3	relations	O
4	may	O
5	be	O
6	inferred	O
7	from	O
8	the	O
9	correlation	O
10	between	O
11	the	O
12	level	O
13	of	O
14	trapezius	O
15	activity	O
16	and	O
17	complaints	O
18	,	O
19	though	O
20	it	O
21	indicates	O
22	that	O
23	individual	O
24	,	O
25	inexpedient	O
26	muscle	O
27	activity	O
28	patterns	O
29	may	O
30	constitute	O
31	an	O
32	important	O
33	risk	O
34	factor	O
35	for	O
36	development	O
37	of	O
38	musculo	O
39	-	O
40	skeletal	O
41	complaints	O
42	.	O

1	PKC	O
2	-	O
3	gamma	O
4	,	O
5	which	O
6	is	O
7	not	O
8	present	O
9	in	O
10	keratinocytes	O
11	,	O
12	also	O
13	induces	O
14	involucrin	O
15	gene	O
16	expression	O
17	in	O
18	a	O
19	TPA	O
20	-	O
21	independent	O
22	manner	O
23	,	O
24	when	O
25	introduced	O
26	into	O
27	SVHK	O
28	cells	O
29	.	O

1	Furthermore	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	IL	O
8	-	O
9	6	O
10	/	O
11	interferon	O
12	gamma	O
13	(	O
14	IFN	O
15	gamma	B
16	)	I
17	response	I
18	element	O
19	in	O
20	the	O
21	IRF	O
22	-	O
23	1	O
24	promoter	O
25	(	O
26	IR	O
27	/	O
28	IRF	O
29	-	O
30	1	O
31	),	O
32	which	O
33	contains	O
34	a	O
35	Stat	O
36	-	O
37	binding	O
38	site	O
39	and	O
40	an	O
41	adjacent	O
42	CRE	O
43	-	O
44	like	O
45	site	O
46	,	O
47	also	O
48	makes	O
49	IL	O
50	-	O
51	6	O
52	-	O
53	induced	O
54	binding	O
55	complexes	O
56	similar	O
57	to	O
58	JRE	O
59	-	O
60	IL6	O
61	-	O
62	BCs	O
63	.	O

1	Carbohydrate	O
2	metabolism	O
3	and	O
4	the	O
5	semen	O
6	profile	O
7	:	O
8	glucose	O
9	,	O
10	insulin	O
11	,	O
12	and	O
13	sperm	O
14	studies	O
15	.	O

1	IgM	O
2	and	O
3	IgG	O
4	anti	O
5	A	O
6	and	O
7	anti	O
8	B	O
9	antibody	O
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	B
21	O	I
22	group	I
23	husbands	I
24	)	I
25	were	I
26	studied	I
27	.	I

1	Serum	O
2	and	O
3	peritoneal	O
4	dialysis	O
5	fluid	O
6	(	O
7	PDF	O
8	)	O
9	were	O
10	collected	O
11	for	O
12	assay	O
13	throughout	O
14	the	B
15	course	I
16	of	I
17	the	I
18	study	I
19	and	I
20	for	I
21	5	I
22	days	O
23	thereafter	O
24	.	O

1	Histamine	O
2	-	O
3	2	O
4	blockade	O
5	in	O
6	psoriasis	O

1	We	O
2	report	O
3	here	O
4	on	O
5	the	O
6	molecular	O
7	nature	B
8	of	B
9	an	B
10	EMS	I
11	-	I
12	induced	I
13	mutant	I
14	,	I
15	mn1	I
16	-	I
17	89	O
18	,	B
19	a	O
20	leaky	O
21	semidominant	O
22	allele	O
23	of	B
24	the	B
25	Miniature1	I
26	(	I
27	Mn1	I
28	)	I
29	seed	I
30	locus	I
31	that	O
32	encodes	O
33	a	O
34	seed	O
35	-	O
36	specific	O
37	cell	O
38	wall	O
39	invertase	O
40	,	O
41	INCW2	O
42	.	O

1	Likewise	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	the	O
7	hypotensive	O
8	action	B
9	of	I
10	converting	I
11	enzyme	O
12	inhibitors	O
13	is	O
14	age	O
15	-	O
16	related	O
17	is	O
18	as	O
19	yet	O
20	unknown	O
21	.	O

1	The	O
2	dopamine	O
3	D4	O
4	receptor	O
5	as	O
6	well	O
7	as	O
8	many	O
9	other	O
10	catecholaminergic	O
11	receptors	O
12	contain	O
13	several	O
14	putative	O
15	SH3	O
16	binding	O
17	domains	O
18	.	O

1	Deletions	O
2	in	O
3	each	O
4	of	O
5	these	O
6	regions	B
7	abolish	I
8	membrane	I
9	localization	I
10	of	O
11	Tiam1	O
12	and	O
13	membrane	O
14	ruffling	O
15	,	O
16	suggesting	O
17	that	B
18	they	I
19	function	I
20	cooperatively	I
21	.	I

1	METHODS	O
2	:	O
3	Out	O
4	of	O
5	171	B
6	patients	I
7	receiving	I
8	anticoagulation	O
9	between	B
10	July	I
11	1992	I
12	and	I
13	December	O
14	1993	O
15	,	O
16	83	O
17	patients	O
18	with	O
19	hemispheric	O
20	embolisms	O
21	received	O
22	heparin	O
23	within	O
24	72	O
25	hours	O
26	from	O
27	onset	O
28	(	O
29	activated	O
30	partial	O
31	thromboplastin	O
32	time	O
33	[	O
34	aPTT	O
35	]	O
36	1	O
37	.	O
38	5	O
39	times	O
40	control	O
41	value	O
42	).	O

1	The	O
2	latent	O
3	periods	O
4	from	O
5	the	O
6	antral	O
7	exclusion	O
8	to	O
9	the	O
10	occurrence	B
11	of	I
12	anastomotic	I
13	ulcers	O
14	after	O
15	a	O
16	subtotal	O
17	gastrectomy	O
18	with	B
19	Billroth	I
20	'	I
21	s	I
22	type	I
23	II	O
24	reconstruction	O
25	varied	B
26	from	I
27	a	O
28	few	O
29	days	O
30	to	B
31	19	B
32	years	I
33	,	I
34	with	I
35	an	I
36	average	O
37	of	O
38	2	O
39	.	O
40	8	O
41	years	O
42	.	O

1	The	O
2	11	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	specifically	O
8	linked	O
9	to	O
10	Ewing	O
11	sarcoma	B
12	and	I
13	primitive	I
14	neuroectodermal	I
15	tumor	I
16	results	I
17	in	I
18	a	I
19	chimeric	I
20	molecule	I
21	fusing	I
22	the	I
23	amino	O
24	-	O
25	terminal	O
26	-	O
27	encoding	O
28	portion	O
29	of	O
30	the	O
31	EWS	O
32	gene	O
33	to	O
34	the	O
35	carboxyl	O
36	-	O
37	terminal	O
38	DNA	O
39	-	O
40	binding	O
41	domain	O
42	encoded	O
43	by	O
44	the	O
45	FLI1	O
46	gene	O
47	.	B

1	The	O
2	need	O
3	for	O
4	including	O
5	forensic	B
6	medical	I
7	expertise	O
8	in	O
9	the	O
10	list	O
11	of	O
12	urgent	O
13	criminal	O
14	investigative	B
15	actions	I

1	The	O
2	RPO1	O
3	of	O
4	LCDV	O
5	shows	O
6	the	O
7	highest	O
8	similarity	O
9	to	O
10	the	O
11	RPO1	O
12	of	O
13	IIV6	O
14	and	O
15	significant	O
16	lower	O
17	similarity	O
18	to	O
19	the	O
20	eukaryotic	O
21	polymerases	O
22	II	O
23	and	O
24	III	O
25	as	O
26	well	O
27	as	O
28	to	O
29	the	O
30	archaebacteral	O
31	subunit	O
32	.	O

1	Further	O
2	analysis	O
3	of	O
4	AP	O
5	-	O
6	1	O
7	DNA	O
8	binding	O
9	activities	O
10	in	O
11	7	O
12	-	O
13	to	O
14	14	O
15	-	O
16	day	O
17	culture	O
18	activated	O
19	HSCs	O
20	led	O
21	to	O
22	the	O
23	discovery	O
24	of	O
25	high	O
26	mobility	O
27	AP	O
28	-	O
29	1	O
30	complexes	O
31	(	O
32	HMAP	O
33	-	O
34	1	O
35	).	O

1	Functional	O
2	disorders	O
3	of	O
4	the	O
5	ureter	O
6	following	O
7	gynecologic	O
8	surgery	O

1	Using	O
2	a	O
3	natural	O
4	dominant	O
5	negative	O
6	for	O
7	AP	O
8	-	O
9	1	O
10	transcriptional	O
11	activity	O
12	in	O
13	ROS	O
14	17	O
15	/	O
16	2	O
17	.	O
18	8	O
19	cells	O
20	,	O
21	we	O
22	then	O
23	showed	O
24	that	O
25	AP	O
26	-	O
27	1	O
28	transcription	O
29	factors	O
30	mediated	O
31	TGF	O
32	-	O
33	beta1	O
34	-	O
35	and	O
36	BMP	O
37	-	O
38	2	O
39	-	O
40	regulated	O
41	expression	O
42	of	O
43	the	O
44	(	O
45	alpha1	O
46	)	O
47	collagen	O
48	I	O
49	gene	O
50	as	O
51	well	O
52	as	O
53	TGF	O
54	-	O
55	beta1	O
56	-	O
57	regulated	O
58	expression	O
59	of	O
60	the	O
61	parathyroid	O
62	hormone	O
63	(	O
64	PTH	O
65	)/	O
66	PTH	O
67	-	O
68	related	O
69	peptide	O
70	(	O
71	PTHrP	O
72	)	O
73	receptor	O
74	.	O

1	Objective	O
2	responses	O
3	also	O
4	occurred	O
5	in	O
6	studies	O
7	that	O
8	explored	O
9	sequential	O
10	use	O
11	of	O
12	exemestane	O
13	after	O
14	failure	O
15	of	O
16	aminoglutethimide	O
17	(	O
18	26	O
19	%	O
20	with	O
21	exemestane	O
22	200	O
23	mg	O
24	/	O
25	day	O
26	)	O
27	or	O
28	other	O
29	nonsteroidal	O
30	aromatase	O
31	inhibitors	O
32	(	O
33	6	O
34	.	O
35	6	O
36	%	O
37	with	O
38	exemestane	O
39	25	O
40	mg	O
41	/	O
42	day	O
43	).	O

1	To	O
2	gain	O
3	further	O
4	insight	O
5	into	O
6	the	O
7	pathogenesis	O
8	of	O
9	the	O
10	adult	O
11	respiratory	O
12	distress	O
13	syndrome	O
14	(	O
15	ARDS	O
16	),	O
17	the	O
18	authors	O
19	studied	O
20	possible	O
21	relationships	B
22	among	I
23	the	I
24	activation	I
25	status	I
26	of	I
27	circulating	I
28	polymorphonuclear	I
29	neutrophils	I
30	(	O
31	PMN	O
32	),	B
33	cytokine	O
34	levels	O
35	,	O
36	and	O
37	the	O
38	severity	O
39	of	O
40	lung	O
41	injury	O
42	in	O
43	31	O
44	patients	O
45	:	O
46	15	O
47	with	O
48	ARDS	O
49	,	O
50	9	O
51	with	O
52	severe	O
53	pneumonia	O
54	uncomplicated	O
55	by	O
56	ARDS	O
57	,	O
58	and	O
59	7	I
60	mechanically	O
61	ventilated	O
62	patients	O
63	with	O
64	neither	O
65	ARDS	O
66	nor	O
67	pneumonia	O
68	.	O

1	Characterization	O
2	and	O
3	hormonal	O
4	regulation	O
5	of	O
6	the	O
7	promoter	O
8	of	O
9	the	O
10	rat	O
11	prostaglandin	O
12	endoperoxide	O
13	synthase	O
14	2	O
15	gene	O
16	in	O
17	granulosa	O
18	cells	O
19	.	O

1	The	O
2	MCAD	O
3	nuclear	O
4	receptor	O
5	response	O
6	element	O
7	1	O
8	(	O
9	NRRE	B
10	-	I
11	1	I
12	)	I
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	ERR	O
18	alpha	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O

1	The	O
2	gene	O
3	encoding	O
4	IFN	O
5	-	O
6	gamma	O
7	was	O
8	previously	O
9	found	O
10	to	O
11	contain	O
12	an	O
13	intronic	O
14	enhancer	O
15	element	O
16	that	O
17	was	O
18	not	O
19	tissue	O
20	-	O
21	specific	O
22	in	O
23	its	O
24	activity	O
25	,	O
26	despite	O
27	the	O
28	restricted	O
29	expression	O
30	of	O
31	the	O
32	intact	O
33	IFN	O
34	-	O
35	gamma	O
36	-	O
37	encoding	O
38	gene	O
39	.	O

1	Quantitation	O
2	of	O
3	exocrine	O
4	IgA	O
5	in	O
6	human	O
7	serum	O
8	in	O
9	health	O
10	and	O
11	disease	O
12	.	O

1	Mutations	O
2	in	O
3	either	O
4	gene	O
5	block	O
6	some	O
7	crucial	O
8	late	O
9	step	O
10	in	O
11	assembly	O
12	of	O
13	F1	O
14	,	O
15	causing	O
16	the	O
17	alpha	O
18	and	O
19	beta	O
20	subunits	O
21	to	O
22	accumulate	O
23	in	O
24	mitochondria	O
25	as	O
26	inactive	O
27	aggregates	O
28	(	O
29	Ackerman	O
30	,	O
31	S	O
32	.	O

1	A	O
2	small	O
3	amount	O
4	of	O
5	HSP81	O
6	-	O
7	1	O
8	mRNA	O
9	was	O
10	detected	O
11	only	O
12	in	O
13	roots	O
14	.	O

1	This	O
2	fragment	O
3	can	O
4	bind	O
5	several	O
6	trans	O
7	-	O
8	acting	O
9	factors	O
10	in	O
11	vitro	O
12	,	O
13	including	O
14	GATA	O
15	-	O
16	1	O
17	and	O
18	members	O
19	of	O
20	the	O
21	Ets	O
22	family	O
23	.	O

1	Both	O
2	inhaled	O
3	and	O
4	superfused	O
5	isoflurane	O
6	dilated	O
7	the	O
8	baseline	O
9	vein	O
10	diameter	O
11	before	O
12	stimulation	O
13	.	O

1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	B
8	the	I
9	DSPP	I
10	is	I
11	cleaved	I
12	into	I
13	DSP	O
14	and	O
15	DPP	O
16	is	O
17	not	B
18	clear	I
19	.	I

1	Together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	TR2	O
9	orphan	O
10	receptor	O
11	may	O
12	be	O
13	a	O
14	master	O
15	regulator	O
16	in	O
17	modulating	O
18	the	O
19	activation	O
20	of	O
21	two	O
22	key	O
23	HREs	O
24	,	O
25	RARE	O
26	beta	O
27	and	O
28	CRBPIIp	O
29	,	O
30	involved	O
31	in	O
32	the	O
33	retinoic	O
34	acid	O
35	signal	O
36	transduction	O
37	pathway	O
38	.	O

1	Site	O
2	S	O
3	-	O
4	II	O
5	also	O
6	spans	O
7	a	O
8	23	B
9	bp	I
10	sequence	I
11	containing	I
12	two	I
13	tandem	I
14	consensus	O
15	binding	B
16	sites	I
17	with	O
18	three	O
19	base	B
20	pair	I
21	mismatches	I
22	in	I
23	each	I
24	and	I
25	a	I
26	one	O
27	base	B
28	pair	I
29	deletion	I
30	.	I

1	Year	O
2	one	O
3	of	O
4	the	O
5	first	O
6	general	O
7	practitioner	O
8	medical	O
9	unit	O
10	in	O
11	the	O
12	greater	O
13	Glasgow	O
14	area	O
15	.	O

1	A	O
2	water	O
3	-	O
4	vapour	O
5	giga	O
6	-	O
7	maser	O
8	in	O
9	the	O
10	active	O
11	galaxy	O
12	TXFS2226	O
13	-	O
14	184	O
15	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	provide	O
6	evidence	O
7	that	O
8	B	O
9	-	O
10	Myb	O
11	is	O
12	a	O
13	direct	O
14	physiological	O
15	target	O
16	for	O
17	cyclin	O
18	A	O
19	/	O
20	Cdk2	O
21	.	O

1	Curing	O
2	shrinkage	O
3	and	O
4	volumetric	O
5	changes	O
6	of	B
7	resin	I
8	-	I
9	modified	I
10	glass	I
11	ionomer	I
12	restorative	I
13	materials	O
14	.	O

1	GlcNAc	O
2	-	O
3	and	O
4	GlcNAc2	O
5	-	O
6	PP	O
7	-	O
8	Dolichol	O
9	biosynthesis	O
10	could	O
11	be	O
12	shown	O
13	with	O
14	isolated	O
15	S	O
16	.	O
17	cerevisiae	O
18	membranes	O
19	from	O
20	cells	O
21	harboring	O
22	the	O
23	recombinant	O
24	plasmid	O
25	and	O
26	grown	O
27	on	O
28	glucose	O
29	thus	O
30	suppressing	O
31	transcription	O
32	of	O
33	the	O
34	endogenous	O
35	gene	O
36	.	O

1	OBJECTIVE	O
2	:	O
3	1998	O
4	Surveillance	O
5	,	O
6	Epidemiology	O
7	,	O
8	and	O
9	End	O
10	Results	O
11	(	O
12	SEER	O
13	)	O
14	data	O
15	estimate	O
16	an	O
17	83	O
18	.	O
19	1	O
20	%	O
21	5	O
22	-	O
23	year	O
24	survival	O
25	rate	O
26	for	O
27	corpus	O
28	uteri	O
29	adenocarcinoma	O
30	FIGO	O
31	stage	O
32	II	O
33	.	O

1	Dominant	O
2	negative	O
3	Sos	O
4	did	O
5	not	O
6	affect	O
7	carbachol	O
8	stimulation	O
9	of	O
10	HA	O
11	-	O
12	ERK2	O
13	but	O
14	inhibited	O
15	the	O
16	stimulatory	O
17	effect	O
18	of	O
19	EGF	O
20	by	O
21	60	O
22	%.	O

1	15	O
2	,	O
3	2500	O
4	-	O
5	2508	O
6	;	O
7	O	O
8	'	O
9	Neill	O
10	,	O
11	T	O
12	.	O

1	Further	O
2	observations	O
3	on	O
4	resorption	O
5	in	O
6	guinea	O
7	pigs	O
8	following	O
9	injections	O
10	of	O
11	trypan	O
12	blue	O
13	.	O

1	The	O
2	SCMV	O
3	SNE	O
4	sites	O
5	contain	O
6	potential	B
7	overlapping	I
8	core	O
9	recognition	O
10	binding	O
11	motifs	O
12	for	O
13	SRF	O
14	,	O
15	Rel	O
16	/	O
17	NFkappaB	O
18	,	O
19	ETS	O
20	,	O
21	and	O
22	YY1	O
23	class	O
24	transcription	O
25	factors	O
26	but	O
27	fail	O
28	to	O
29	respond	O
30	to	O
31	either	O
32	serum	O
33	or	O
34	tumor	O
35	necrosis	O
36	factor	O
37	alpha	O
38	.	O

1	We	O
2	cloned	O
3	a	O
4	complete	O
5	cDNA	O
6	(	O
7	2	O
8	.	O
9	9	O
10	kb	O
11	)	O
12	for	O
13	HET	O
14	from	O
15	an	O
16	MCF	O
17	-	O
18	7	O
19	cDNA	O
20	library	O
21	.	O

1	Transcript	O
2	analysis	O
3	reveals	O
4	that	O
5	lethal	O
6	B	O
7	block	O
8	substitutions	O
9	reduce	O
10	U6	O
11	RNA	O
12	synthesis	O
13	at	O
14	least	O
15	10	O
16	-	O
17	fold	O
18	in	O
19	vivo	O
20	and	O
21	20	O
22	-	O
23	fold	O
24	in	O
25	vitro	O
26	.	O

1	A	O
2	hybridoma	O
3	clone	O
4	(	O
5	7H1	O
6	)	O
7	resulting	O
8	from	O
9	the	O
10	fusion	B
11	between	I
12	CEMLAI	O
13	/	O
14	NP	O
15	and	O
16	human	O
17	embryonic	O
18	fibroblasts	O
19	MRC5	O
20	cells	O
21	produced	O
22	very	O
23	large	O
24	amounts	O
25	of	O
26	P47	O
27	that	B
28	was	O
29	purified	O
30	using	O
31	Jacalin	O
32	lectin	O
33	(	O
34	specific	O
35	for	O
36	O	O
37	-	O
38	glycans	O
39	)	O
40	and	O
41	microsequenced	O
42	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	whether	O
6	administration	O
7	of	O
8	misoprostol	O
9	prevents	O
10	gastric	O
11	hemorrhage	O
12	in	O
13	healthy	O
14	dogs	O
15	treated	O
16	with	O
17	high	O
18	doses	O
19	of	O
20	methylprednisolone	O
21	sodium	O
22	succinate	O
23	(	O
24	MPSS	O
25	).	O

1	A	O
2	method	O
3	for	O
4	establishing	O
5	stimulus	O
6	control	O
7	of	O
8	ethanol	O
9	responding	O
10	was	O
11	developed	O
12	.	O

1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	Langer	O
8	-	O
9	Giedion	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	endpoints	O
36	.	O

1	In	O
2	4	O
3	spinalized	O
4	cats	O
5	,	O
6	the	O
7	effects	O
8	of	O
9	afferent	O
10	inputs	O
11	from	O
12	hindlimb	O
13	cutaneous	O
14	nerves	O
15	(	O
16	sural	O
17	cutaneous	O
18	nerve	O
19	:	O
20	Sur	O
21	)	O
22	on	O
23	mono	O
24	-	O
25	and	O
26	poly	O
27	-	O
28	synaptic	O
29	reflex	O
30	recorded	O
31	from	O
32	tail	O
33	muscle	O
34	motoneurons	O
35	were	O
36	studied	O
37	before	O
38	and	O
39	after	O
40	spinal	O
41	lesioning	O
42	at	O
43	S2	O
44	-	O
45	3	O
46	level	O
47	.	O

1	The	O
2	study	O
3	disclosed	O
4	generalized	O
5	atrophy	O
6	and	O
7	diffuse	O
8	symmetric	O
9	white	O
10	matter	O
11	hypodensities	O
12	.	O

1	Effects	O
2	of	O
3	cortisone	B
4	,	I
5	starvation	O
6	,	B
7	and	I
8	rickets	I
9	on	I
10	oxidative	I
11	enzyme	I
12	activities	I
13	of	I
14	epiphyseal	I
15	cartilage	I
16	from	I
17	rats	O
18	.	O

1	The	O
2	median	O
3	durations	B
4	for	B
5	response	I
6	and	I
7	survival	I
8	time	I
9	in	I
10	the	I
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	:	O
6	(	O
7	a	O
8	)	O
9	proSRIF	O
10	cleavage	O
11	is	O
12	initiated	O
13	in	O
14	the	O
15	TGN	O
16	,	O
17	and	O
18	(	O
19	b	O
20	)	O
21	this	O
22	reaction	O
23	requires	O
24	an	O
25	acidic	O
26	pH	O
27	which	O
28	is	O
29	facilitated	O
30	by	O
31	a	O
32	Golgi	O
33	-	O
34	associated	O
35	vacuolar	O
36	-	O
37	type	O
38	ATPase	O
39	.	O

1	A	O
2	comparative	O
3	analysis	O
4	of	O
5	the	O
6	reported	O
7	MOCT	O
8	-	O
9	associated	O
10	malignant	O
11	melanomas	O
12	emphasizes	O
13	the	O
14	singularity	O
15	of	O
16	our	O
17	case	O
18	in	O
19	the	O
20	amelanotic	O
21	character	O
22	of	O
23	the	O
24	melanoma	O
25	,	O
26	its	O
27	lymphotropism	O
28	and	O
29	the	O
30	coexistence	O
31	of	O
32	invasive	O
33	squamous	O
34	cell	O
35	carcinoma	O
36	.	O

1	Difficulties	O
2	bound	O
3	to	O
4	measuring	O
5	of	O
6	sputum	O
7	viscosity	O

1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O

1	Using	O
2	5	O
3	ng	O
4	/	O
5	mL	O
6	as	O
7	the	O
8	cutoff	O
9	,	O
10	the	O
11	sensitivity	O
12	of	O
13	CEA	B
14	was	I
15	68	I
16	%.	I

1	Insertion	O
2	of	B
3	4	I
4	bp	I
5	reduced	I
6	SV40	O
7	early	O
8	promoter	I
9	-	O
10	dependent	O
11	chloramphenicol	O
12	acetyltransferase	O
13	(	O
14	CAT	O
15	)	O
16	expression	O
17	by	O
18	six	O
19	-	O
20	to	O
21	eightfold	O
22	.	O

1	Taken	O
2	together	O
3	,	O
4	the	O
5	results	O
6	suggest	O
7	that	O
8	chlorphentermine	O
9	may	O
10	be	O
11	capable	O
12	of	O
13	producing	O
14	dual	O
15	stimulus	O
16	effects	O
17	in	O
18	animals	O
19	.	O

1	Skn	O
2	-	O
3	1a	O
4	lacking	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	completely	O
11	lost	O
12	transactivation	O
13	ability	O
14	,	O
15	irrespective	O
16	of	O
17	the	O
18	promoter	O
19	tested	O
20	,	O
21	and	O
22	was	O
23	able	O
24	to	O
25	block	O
26	transactivation	O
27	by	O
28	normal	O
29	Skn	O
30	-	O
31	1a	O
32	in	O
33	competition	O
34	assays	O
35	.	O

1	METHODS	O
2	:	O
3	rHb1	O
4	.	O
5	1	O
6	or	O
7	human	O
8	serum	O
9	albumin	O
10	was	O
11	administered	O
12	intravenously	O
13	to	O
14	fasting	O
15	male	O
16	volunteers	O
17	.	O

1	We	O
2	have	O
3	been	O
4	able	O
5	to	O
6	map	O
7	specific	O
8	DNA	O
9	fragments	O
10	at	O
11	the	O
12	bases	O
13	of	O
14	chromatin	O
15	loops	O
16	with	O
17	the	O
18	help	O
19	of	O
20	a	O
21	novel	O
22	extraction	O
23	procedure	O
24	by	O
25	using	O
26	lithium	O
27	-	O
28	3	O
29	',	O
30	5	O
31	'-	O
32	diiodosalicylate	O
33	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	exercise	O
5	responses	O
6	are	O
7	attenuated	O
8	in	O
9	heart	O
10	failure	O
11	.	O

1	We	O
2	had	O
3	previously	O
4	analyzed	O
5	repair	O
6	rates	O
7	of	O
8	cyclobutane	O
9	pyrimidine	O
10	dimers	O
11	at	B
12	nucleotide	I
13	resolution	I
14	along	I
15	the	I
16	human	O
17	JUN	O
18	gene	O
19	in	O
20	normal	O
21	fibroblasts	O
22	and	O
23	found	O
24	very	I
25	efficient	O
26	repair	O
27	of	B
28	sequences	I
29	near	I
30	the	O
31	transcription	I
32	initiation	O
33	site	O
34	but	O
35	slow	O
36	repair	O
37	along	O
38	the	O
39	promoter	O
40	.	O

1	A	O
2	.,	O
3	Bowers	O
4	,	O
5	K	O
6	.	O
7	E	O
8	,	O
9	and	O
10	Matthews	O
11	,	O
12	C	O
13	.	O

1	Histopathologic	O
2	observations	O
3	showed	O
4	that	O
5	both	O
6	somatostatin	O
7	and	O
8	triamcinolone	O
9	acetonide	O
10	reduced	O
11	the	O
12	inflammatory	O
13	signs	O
14	in	O
15	the	O
16	joint	O
17	structures	O
18	,	O
19	although	O
20	triamcinolone	O
21	acetonide	O
22	appeared	O
23	to	O
24	be	O
25	more	O
26	effective	O
27	.	O

1	Instead	O
2	,	O
3	the	O
4	results	O
5	support	O
6	the	O
7	idea	O
8	that	O
9	Pc	O
10	group	O
11	products	O
12	provide	O
13	stable	O
14	memory	O
15	or	O
16	imprinting	O
17	of	O
18	boundaries	O
19	which	O
20	are	O
21	initially	O
22	specified	O
23	by	O
24	gap	O
25	and	O
26	pair	O
27	-	O
28	rule	O
29	regulators	O
30	.	O

1	On	O
2	the	B
3	other	I
4	hand	I
5	,	I
6	cells	I
7	containing	I
8	a	I
9	PTP1C	I
10	in	O
11	which	B
12	the	I
13	catalytic	O
14	site	O
15	had	O
16	been	O
17	inactivated	O
18	through	O
19	mutagenesis	O
20	,	O
21	stably	O
22	phosphorylated	O
23	the	O
24	phosphatase	B
25	.	I

1	A	O
2	soap	O
3	and	O
4	water	O
5	(	O
6	1	O
7	:	O
8	1	O
9	,	O
10	v	O
11	/	O
12	v	O
13	)	O
14	solution	O
15	effectively	O
16	decontaminated	O
17	powdered	O
18	stratum	O
19	corneum	O
20	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	showed	O
8	no	O
9	TATA	O
10	box	O
11	but	O
12	identified	O
13	consensus	O
14	binding	O
15	motifs	O
16	for	O
17	Sp1	O
18	,	O
19	CREB	O
20	,	O
21	and	O
22	half	O
23	sites	O
24	of	O
25	the	O
26	estrogen	O
27	receptor	O
28	binding	O
29	site	O
30	.	O

1	However	O
2	,	O
3	a	O
4	strongly	O
5	increased	O
6	frequency	O
7	of	O
8	CpG	O
9	dinucleotides	O
10	was	O
11	found	O
12	.	O

1	Diffuse	O
2	white	O
3	matter	O
4	injury	O
5	can	O
6	be	O
7	attributed	O
8	to	O
9	radiation	B
10	and	I
11	associated	I
12	with	O
13	neurological	O
14	deficits	O
15	,	O
16	but	O
17	leukoencephalopathy	O
18	is	O
19	rarely	O
20	observed	O
21	in	O
22	the	O
23	absence	O
24	of	O
25	chemotherapy	B
26	.	B

1	Several	O
2	free	O
3	2nd	O
4	-	O
5	generation	O
6	schizonts	O
7	,	O
8	which	O
9	varied	O
10	in	O
11	diameter	O
12	from	B
13	11	I
14	to	O
15	21	O
16	.	O
17	6	O
18	micrometer	O
19	,	O
20	were	O
21	found	O
22	on	O
23	the	O
24	epithelial	O
25	surface	O
26	of	O
27	the	O
28	cecum	O
29	.	O

1	ICP4	O
2	has	O
3	been	O
4	shown	O
5	to	O
6	form	O
7	tripartite	O
8	complexes	O
9	cooperatively	O
10	with	O
11	the	O
12	TATA	B
13	box	I
14	-	I
15	binding	I
16	protein	O
17	and	O
18	TFIIB	O
19	on	O
20	DNA	O
21	containing	O
22	an	O
23	ICP4	O
24	binding	O
25	site	O
26	and	O
27	a	O
28	TATA	B
29	box	I
30	(	I
31	C	O
32	.	B

1	Behavior	O
2	of	O
3	aspartate	B
4	aminotransferase	I
5	(	I
6	EC	I
7	2	I
8	.	O
9	6	O
10	.	O
11	1	O
12	.	O
13	1	O
14	)	O
15	and	O
16	alanine	O
17	aminotransferase	O
18	(	O
19	EC	O
20	2	O
21	.	O
22	6	O
23	.	O
24	1	O
25	.	O
26	2	O
27	)	O
28	in	O
29	rat	O
30	serum	O
31	during	O
32	the	O
33	course	O
34	of	O
35	acute	B
36	radiation	I
37	syndrome	I
38	following	I
39	whole	B
40	body	I
41	X	I
42	-	I
43	irradiation	O

1	We	O
2	have	B
3	cloned	I
4	and	I
5	characterized	O
6	a	O
7	55	O
8	-	O
9	kb	O
10	region	O
11	of	O
12	DNA	O
13	surrounding	O
14	HRAS1	O
15	.	O

1	Effects	O
2	of	O
3	aging	O
4	and	O
5	beta	O
6	-	O
7	adrenergic	O
8	-	O
9	blockade	O
10	on	O
11	standing	O
12	-	O
13	induced	O
14	QT	O
15	/	O
16	QS2	O
17	changes	O
18	.	O

1	The	O
2	overall	O
3	results	O
4	of	O
5	this	O
6	paper	B
7	are	I
8	consistent	I
9	with	I
10	the	I
11	conclusion	I
12	that	I
13	the	I
14	carboxyl	I
15	-	O
16	terminal	O
17	LBD	O
18	is	O
19	not	O
20	sufficient	O
21	for	O
22	mediating	B
23	PR	I
24	dimerization	I
25	and	I
26	that	I
27	multiple	I
28	regions	I
29	,	O
30	including	O
31	the	O
32	hinge	O
33	and	O
34	amino	B
35	-	I
36	terminal	I
37	sequences	I
38	,	I
39	contribute	I
40	either	I
41	directly	I
42	or	I
43	indirectly	I
44	to	I
45	homodimerization	I
46	of	I
47	PR	I
48	.	I

1	Movement	O
2	time	O
3	and	O
4	kinematic	O
5	characteristics	O
6	were	O
7	analyzed	O
8	together	O
9	with	O
10	the	B
11	magnitude	B
12	of	I
13	cerebral	O
14	blood	O
15	flow	O
16	to	O
17	identify	O
18	areas	O
19	of	O
20	brain	O
21	activity	O
22	proportionate	O
23	to	O
24	task	O
25	and	O
26	movement	O
27	variables	O
28	.	O

1	The	O
2	native	O
3	enzyme	O
4	purified	O
5	from	O
6	protease	O
7	-	O
8	B	O
9	-	O
10	deficient	O
11	URA2	O
12	-	O
13	transformed	O
14	cells	O
15	,	B
16	was	O
17	phosphorylated	O
18	in	I
19	vitro	I
20	using	O
21	catalytic	O
22	subunits	B
23	of	I
24	pure	I
25	cAMP	O
26	-	B
27	dependent	I
28	protein	I
29	kinase	O
30	.	O

1	Tissues	O
2	and	O
3	exudates	O
4	contain	O
5	sufficient	O
6	thymidine	O
7	for	O
8	growth	O
9	of	O
10	anaerobic	O
11	bacteria	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	inhibitory	O
17	levels	O
18	of	O
19	trimethoprim	O
20	-	O
21	sulfamethoxazole	O
22	.	O

1	PhoP	O
2	-	O
3	PhoQ	O
4	homologues	O
5	in	O
6	Pseudomonas	O
7	aeruginosa	O
8	regulate	B
9	expression	I
10	of	O
11	the	O
12	outer	B
13	-	I
14	membrane	I
15	protein	I
16	OprH	O
17	and	O
18	polymyxin	O
19	B	O
20	resistance	O
21	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	SAGA	O
10	inhibits	O
11	TBP	O
12	binding	O
13	to	O
14	the	O
15	HIS3	O
16	promoter	O
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	O
22	lacking	O
23	Spt3	O
24	or	O
25	Spt8	O
26	is	O
27	not	O
28	inhibitory	O
29	.	O

1	TBPf	O
2	is	O
3	defined	O
4	as	O
5	a	O
6	quotient	O
7	of	O
8	the	O
9	difference	O
10	of	O
11	the	O
12	first	O
13	and	O
14	the	O
15	second	O
16	measurement	O
17	:	O
18	TBPf	O
19	=	O
20	(	O
21	P1	O
22	-	O
23	P2	O
24	)/(	O
25	A1	O
26	-	O
27	A2	O
28	).	O

1	To	O
2	accomplish	O
3	this	O
4	,	O
5	actin	O
6	cables	O
7	and	O
8	patches	O
9	are	O
10	redistributed	O
11	during	O
12	the	O
13	cell	O
14	cycle	O
15	to	O
16	direct	O
17	secretory	O
18	components	O
19	to	O
20	appropriate	O
21	sites	O
22	for	O
23	cell	O
24	growth	O
25	.	O

1	These	O
2	observations	O
3	,	O
4	together	O
5	with	B
6	the	I
7	occurrence	I
8	of	I
9	putative	I
10	4	I
11	'-	I
12	phosphopantetheine	I
13	-	O
14	attachment	O
15	sites	O
16	and	O
17	a	O
18	putative	O
19	thioesterase	O
20	site	O
21	,	O
22	are	O
23	discussed	O
24	with	O
25	reference	O
26	to	O
27	the	O
28	reaction	O
29	sequence	O
30	leading	O
31	to	O
32	production	O
33	of	O
34	the	O
35	ACV	O
36	tripeptide	O
37	.	O

1	A	O
2	pre	B
3	-	I
4	boutonniere	I
5	deformity	I
6	was	O
7	simulated	O
8	by	O
9	dividing	O
10	the	O
11	central	O
12	slip	O
13	.	O

1	Acta	O
2	572	O
3	,	O
4	113	O
5	-	O
6	120	O
7	].	O

1	Human	O
2	and	O
3	Chinese	O
4	hamster	O
5	S14	B
6	protein	I
7	sequences	O
8	deduced	O
9	from	B
10	the	I
11	cDNAs	I
12	are	I
13	identical	I
14	.	I

1	Inhibition	O
2	of	O
3	RNA2	O
4	translation	O
5	was	O
6	selective	O
7	,	O
8	with	O
9	no	O
10	effect	O
11	on	O
12	general	O
13	cellular	O
14	translation	O
15	or	O
16	translation	O
17	of	O
18	BMV	O
19	RNA1	O
20	-	O
21	encoded	O
22	replication	O
23	factor	O
24	1a	O
25	,	O
26	and	O
27	was	O
28	independent	O
29	of	O
30	p20	O
31	,	O
32	a	O
33	cellular	O
34	antagonist	O
35	of	O
36	DED1	O
37	function	O
38	in	O
39	translation	O
40	.	O

1	We	O
2	identify	O
3	the	O
4	"	O
5	M	O
6	region	O
7	"	O
8	of	O
9	the	O
10	muscle	O
11	-	O
12	specific	O
13	Xenopus	O
14	cardiac	O
15	actin	O
16	gene	O
17	promoter	O
18	from	O
19	-	O
20	282	O
21	to	O
22	-	O
23	348	O
24	as	O
25	necessary	O
26	for	O
27	the	O
28	embryonic	O
29	expression	O
30	of	O
31	a	O
32	cardiac	O
33	actin	O
34	-	O
35	beta	O
36	-	O
37	globin	O
38	reporter	O
39	gene	O
40	injected	O
41	into	O
42	fertilized	O
43	eggs	O
44	.	O

1	Plasma	O
2	lipid	O
3	and	O
4	lipoprotein	O
5	profiles	B
6	were	I
7	compared	I
8	in	I
9	elderly	O
10	female	B
11	runners	I
12	(	I
13	RU	I
14	:	I
15	n	O
16	=	O
17	15	O
18	,	O
19	aged	O
20	66	O
21	+/-	O
22	5	O
23	years	O
24	,	O
25	body	O
26	fat	O
27	20	O
28	+/-	O
29	4	O
30	%,	O
31	training	O
32	distance	O
33	35	O
34	+/-	O
35	15	O
36	km	O
37	week	O
38	-	O
39	1	O
40	,	O
41	VO2max	O
42	36	O
43	+/-	O
44	4	O
45	ml	O
46	kg	B
47	-	B
48	1	O
49	min	I
50	-	O
51	1	O
52	,	O
53	mean	B
54	+/-	I
55	SD	O
56	)	O
57	and	O
58	age	O
59	-	O
60	matched	O
61	untrained	O
62	women	O
63	(	B
64	UT	I
65	:	I
66	n	O
67	=	O
68	28	O
69	,	O
70	66	O
71	+/-	O
72	4	O
73	years	B
74	,	O
75	body	O
76	fat	O
77	26	O
78	+/-	O
79	6	O
80	%,	O
81	VO2max	I
82	26	I
83	+/-	I
84	3	O
85	ml	O
86	kg	O
87	-	O
88	1	O
89	min	B
90	-	B
91	1	B
92	).	O

1	These	O
2	articles	O
3	both	O
4	report	O
5	the	B
6	results	I
7	of	I
8	multi	O
9	-	O
10	institutional	O
11	,	O
12	randomized	O
13	,	O
14	phase	O
15	3	O
16	trials	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	patients	O
22	with	O
23	localized	O
24	(	O
25	T1	O
26	-	B
27	3	I
28	N0	I
29	-	O
30	1	O
31	M0	B
32	)	I
33	esophageal	I
34	squamous	I
35	cell	I
36	carcinoma	I
37	(	I
38	SCC	I
39	)	I
40	or	I
41	esophageal	I
42	adenocarcinoma	I
43	.	O

1	Anatomy	O
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	murine	O
9	p44	O
10	MAP	O
11	kinase	O
12	(	O
13	extracellular	O
14	signal	O
15	-	O
16	regulated	O
17	kinase	O
18	1	O
19	)	O
20	gene	O
21	,	O
22	the	O
23	determination	O
24	of	O
25	its	O
26	intron	O
27	/	O
28	exon	O
29	boundaries	O
30	,	O
31	and	O
32	the	O
33	characterization	O
34	of	O
35	its	O
36	promoter	O
37	.	O

1	The	O
2	approach	B
3	derives	I
4	from	I
5	a	I
6	recently	O
7	described	O
8	strategy	O
9	for	O
10	making	O
11	recombinants	O
12	from	O
13	five	O
14	overlapping	O
15	EBV	O
16	cosmid	O
17	-	O
18	cloned	O
19	DNAs	O
20	(	O
21	B	O
22	.	O

1	The	O
2	most	O
3	striking	O
4	difference	O
5	in	O
6	the	O
7	birch	O
8	NAD	B
9	(	B
10	P	I
11	)	O
12	H	B
13	-	B
14	NR	I
15	sequence	O
16	in	B
17	comparison	I
18	to	I
19	NADH	O
20	-	B
21	NR	I
22	sequences	I
23	was	O
24	found	B
25	at	I
26	the	I
27	putative	O
28	pyridine	O
29	nucleotide	B
30	binding	I
31	site	I
32	.	O

1	Canalith	O
2	repositioning	O
3	is	O
4	the	O
5	mainstay	O
6	of	O
7	treatment	O
8	.	O

1	Suggestive	O
2	evidence	O
3	was	O
4	obtained	O
5	that	O
6	cstA	O
7	is	O
8	involved	O
9	in	O
10	peptide	O
11	utilization	O
12	.	O

1	In	O
2	addition	O
3	,	O
4	IgM	O
5	can	O
6	be	O
7	absent	O
8	in	O
9	children	O
10	with	O
11	congenital	O
12	toxoplasmosis	O
13	or	O
14	subjects	O
15	with	O
16	secondary	O
17	reactivation	O
18	.	O

1	Three	O
2	radiologists	O
3	without	O
4	knowledge	O
5	of	O
6	patients	O
7	'	O
8	data	O
9	and	O
10	treatment	O
11	analyzed	O
12	30	O
13	angiograms	O
14	with	O
15	and	O
16	30	O
17	examinations	O
18	without	O
19	PGF	B
20	.	I

1	The	O
2	presence	O
3	of	O
4	an	O
5	additional	O
6	sequence	O
7	of	O
8	nucleotides	O
9	145	O
10	-	O
11	165	O
12	from	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	RNA3	O
19	enhanced	O
20	template	O
21	recognition	O
22	by	O
23	RdRp	O
24	in	O
25	vitro	O
26	and	O
27	accumulation	O
28	of	O
29	RNA3	O
30	in	O
31	vivo	O
32	to	O
33	wild	O
34	-	O
35	type	O
36	levels	O
37	.	O

1	These	O
2	are	O
3	the	O
4	long	O
5	terminal	O
6	repeat	O
7	(	O
8	LTR	O
9	)	O
10	promoter	O
11	,	O
12	which	O
13	regulates	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	structural	O
19	proteins	O
20	,	O
21	and	O
22	a	O
23	second	O
24	internal	O
25	promoter	O
26	,	O
27	located	O
28	towards	O
29	the	O
30	3	O
31	'	O
32	end	O
33	of	O
34	the	O
35	env	O
36	gene	O
37	,	O
38	that	O
39	directs	O
40	expression	O
41	of	O
42	the	O
43	viral	O
44	auxiliary	O
45	proteins	O
46	.	O

1	The	O
2	prevalence	O
3	of	O
4	CPAF	O
5	was	O
6	similar	O
7	in	O
8	type	O
9	1	O
10	and	O
11	type	O
12	2	O
13	diabetes	O
14	,	O
15	was	O
16	greater	O
17	in	O
18	women	B
19	than	I
20	in	I
21	men	O
22	,	O
23	and	O
24	was	O
25	significantly	O
26	greater	O
27	after	O
28	repeated	O
29	administrations	O
30	than	O
31	after	O
32	one	O
33	single	O
34	administration	O
35	of	O
36	chlorpropamide	O
37	.	O

1	The	O
2	c	O
3	-	O
4	myc	O
5	and	B
6	skeletal	I
7	alpha	I
8	-	O
9	actin	O
10	gene	O
11	promoters	O
12	contain	O
13	YY1	O
14	binding	O
15	sites	O
16	thought	O
17	to	O
18	act	O
19	either	O
20	as	B
21	positive	I
22	or	O
23	negative	O
24	cis	O
25	-	O
26	acting	O
27	elements	O
28	.	O

1	In	O
2	some	O
3	instances	O
4	,	O
5	this	O
6	is	O
7	partly	O
8	mediated	O
9	by	O
10	the	O
11	expression	O
12	of	B
13	virally	I
14	encoded	O
15	proteases	I
16	which	I
17	lead	O
18	to	O
19	the	O
20	cleavage	O
21	of	O
22	initiation	O
23	factor	O
24	eIF4G	O
25	.	O

1	To	O
2	determine	O
3	the	O
4	signal	O
5	recognition	O
6	particle	O
7	(	O
8	SRP	O
9	)-	O
10	SRP	O
11	receptor	O
12	(	O
13	Srb	O
14	)	O
15	system	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	(	O
20	Bs	O
21	),	O
22	we	O
23	cloned	O
24	the	O
25	Bs	O
26	srb	O
27	gene	O
28	,	O
29	which	O
30	encodes	O
31	a	O
32	homologue	O
33	of	O
34	the	O
35	mammalian	O
36	SRP	O
37	receptor	O
38	alpha	O
39	-	O
40	subunit	O
41	[	O
42	Oguro	O
43	et	O
44	al	O
45	.,	O
46	DNA	O
47	Res	O
48	.	O

1	Evidence	O
2	for	O
3	a	O
4	novel	O
5	MAPKKK	O
6	-	O
7	independent	O
8	pathway	O
9	controlling	O
10	the	O
11	stress	O
12	activated	O
13	Sty1	O
14	/	O
15	Spc1	B
16	MAP	O
17	kinase	O
18	in	O
19	fission	O
20	yeast	O
21	.	O

1	In	O
2	vitro	O
3	assessment	O
4	of	O
5	the	O
6	biocompatibility	O
7	of	O
8	dental	O
9	materials	O
10	--	O
11	the	B
12	millipore	I
13	filter	O
14	method	O
15	.	O

1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	O
15	/	B
16	Rta	I
17	gene	I
18	,	I
19	may	I
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O

1	Treatment	O
2	with	O
3	MK	O
4	-	O
5	801	O
6	induced	O
7	a	O
8	burst	O
9	suppression	O
10	in	O
11	the	O
12	EEG	O
13	and	O
14	a	O
15	transient	O
16	drop	O
17	(	O
18	11	O
19	.	O
20	4	O
21	+/-	O
22	6	O
23	.	O
24	5	O
25	mm	O
26	Hg	O
27	)	O
28	in	O
29	the	O
30	mean	O
31	arterial	O
32	pressure	O
33	.	O

1	Relations	O
2	between	O
3	cellular	O
4	electrical	O
5	activity	O
6	and	B
7	cardiac	I
8	mechanical	I
9	activity	O
10	in	O
11	man	O
12	,	O
13	the	O
14	dog	O
15	and	O
16	the	O
17	rabbit	O

1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	B
7	sequences	I
8	required	I
9	for	I
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	O
15	androgen	O
16	-	O
17	binding	B
18	protein	I
19	gene	I
20	.	I

1	P	O
2	-	O
3	CIP1	O
4	,	O
5	a	O
6	novel	O
7	protein	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	cytosolic	O
13	domain	O
14	of	O
15	peptidylglycine	O
16	alpha	O
17	-	O
18	amidating	O
19	monooxygenase	O
20	,	O
21	is	O
22	associated	O
23	with	O
24	endosomes	O
25	.	O

1	157	O
2	+/-	O
3	16	O
4	mg	O
5	/	O
6	dl	O
7	;	O
8	NS	O
9	),	O
10	glucose	O
11	levels	O
12	,	O
13	and	O
14	basal	O
15	(	O
16	17	O
17	+/-	O
18	4	O
19	vs	O
20	.	O

1	Second	O
2	report	O
3	of	O
4	the	O
5	Norwegian	O
6	Cancer	O
7	Society	O
8	.	O

1	RBP56	O
2	protein	O
3	turned	O
4	out	O
5	to	O
6	be	O
7	hTAFII68	O
8	which	O
9	was	O
10	isolated	O
11	as	O
12	a	O
13	TATA	O
14	-	O
15	binding	O
16	protein	O
17	associated	O
18	factor	O
19	(	O
20	TAF	O
21	)	O
22	from	O
23	a	O
24	sub	O
25	-	O
26	population	O
27	of	O
28	TFIID	O
29	complexes	O
30	(	O
31	Bertolotti	O
32	A	O
33	.,	O
34	Lutz	O
35	,	O
36	Y	O
37	.,	O
38	Heard	O
39	,	O
40	D	O
41	.	O
42	J	O
43	.,	O
44	Chambon	O
45	,	O
46	P	O
47	.,	O
48	Tora	O
49	,	O
50	L	O
51	.,	O
52	1996	O
53	.	O
54	hTAFII68	O
55	,	O
56	a	O
57	novel	O
58	RNA	O
59	/	O
60	ssDNA	O
61	-	O
62	binding	O
63	protein	O
64	with	O
65	homology	O
66	to	O
67	the	O
68	proto	O
69	-	O
70	oncoproteins	O
71	TLS	O
72	/	O
73	FUS	O
74	and	O
75	EWS	O
76	is	O
77	associated	O
78	with	O
79	both	O
80	TFIID	O
81	and	O
82	RNA	O
83	polymerase	O
84	II	O
85	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	STAT	O
8	activation	O
9	in	O
10	a	O
11	panel	O
12	of	O
13	rodent	O
14	fibroblast	O
15	cell	O
16	lines	O
17	stably	O
18	transformed	O
19	by	O
20	diverse	O
21	viral	O
22	oncoproteins	O
23	.	O

1	These	O
2	changes	O
3	were	O
4	the	O
5	result	O
6	of	O
7	a	O
8	decrease	O
9	in	O
10	afterload	O
11	:	O
12	mean	O
13	aortic	O
14	pressure	O
15	fell	O
16	from	O
17	85	O
18	+/-	O
19	11	O
20	.	O
21	8	O
22	to	O
23	68	O
24	+/-	O
25	19	O
26	.	O
27	6	O
28	mmHg	O
29	(	O
30	p	O
31	less	O
32	than	O
33	0	O
34	.	O
35	01	O
36	)	O
37	and	O
38	systemic	O
39	arterial	O
40	resistance	O
41	fell	O
42	from	O
43	2	O
44	886	O
45	+/-	O
46	745	O
47	to	O
48	2	O
49	010	O
50	+/-	O
51	610	O
52	dynes	O
53	/	O
54	cm	O
55	-	O
56	5	O
57	/	O
58	sec	O
59	/	O
60	m	O
61	-	O
62	2	O
63	(	O
64	p	O
65	less	O
66	than	O
67	0	O
68	.	O
69	01	O
70	).	O

1	As	O
2	stands	O
3	shifted	O
4	in	O
5	dominance	O
6	from	O
7	pine	O
8	to	O
9	fir	O
10	with	O
11	age	O
12	,	O
13	subalpine	O
14	fir	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	forest	O
25	productivity	O
26	until	O
27	stands	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	growth	O
10	-	O
11	regulated	O
12	Syrian	O
13	hamster	O
14	CAD	O
15	gene	O
16	.	O

1	Measurement	O
2	of	B
3	open	I
4	-	I
5	loop	I
6	responses	O
7	to	O
8	electrical	O
9	stimulation	O
10	in	O
11	olfactory	O
12	bulb	O
13	of	O
14	cat	B
15	.	I

1	IgE	O
2	levels	O
3	showed	O
4	higher	O
5	values	O
6	compared	O
7	to	O
8	normal	O
9	individuals	O
10	and	O
11	IgE	O
12	levels	O
13	were	O
14	higher	O
15	in	O
16	children	O
17	groups	O
18	than	O
19	in	O
20	adults	O
21	regardless	O
22	of	O
23	the	O
24	intensity	O
25	of	O
26	infection	O
27	.	O

1	Two	O
2	-	O
3	dimensional	O
4	phosphotryptic	O
5	analyses	O
6	indicate	O
7	that	O
8	phosphorylation	O
9	on	O
10	Ser	O
11	-	O
12	12	O
13	and	O
14	Ser	O
15	-	O
16	48	O
17	in	O
18	unstimulated	O
19	cells	O
20	is	O
21	associated	O
22	with	O
23	the	O
24	ability	O
25	of	O
26	overexpressed	O
27	pp60c	O
28	-	O
29	src	O
30	to	O
31	potentiate	O
32	beta	O
33	-	O
34	adrenergic	O
35	signalling	O
36	.	O

1	The	O
2	decay	O
3	curves	O
4	of	O
5	chlorophyll	O
6	fluorescence	O
7	showed	O
8	a	O
9	superposition	O
10	of	B
11	three	I
12	exponentially	I
13	decaying	O
14	components	O
15	with	O
16	time	O
17	constants	O
18	of	O
19	T1	O
20	=	O
21	100	O
22	-	O
23	200	O
24	ps	O
25	,	O
26	T2	O
27	=	O
28	300	O
29	-	O
30	500	O
31	ps	O
32	and	O
33	T3	O
34	=	O
35	2	O
36	.	O
37	0	O
38	-	O
39	3	O
40	.	O
41	5	O
42	ns	O
43	.	O

1	In	O
2	a	O
3	second	O
4	experiment	O
5	involving	O
6	an	O
7	18	O
8	-	O
9	h	O
10	lung	O
11	clearance	O
12	assay	O
13	,	O
14	we	O
15	used	O
16	the	O
17	mAb	O
18	3	O
19	.	O
20	2	O
21	.	O
22	3	O
23	to	O
24	deplete	O
25	rats	O
26	of	O
27	LGL	O
28	/	O
29	NK	O
30	cells	O
31	with	O
32	the	O
33	following	O
34	rationale	O
35	:	O
36	if	O
37	LGL	O
38	/	O
39	NK	O
40	cells	O
41	are	O
42	necessary	O
43	to	O
44	mediate	O
45	an	O
46	event	O
47	,	O
48	then	O
49	in	O
50	their	O
51	absence	O
52	,	O
53	that	O
54	event	O
55	should	O
56	not	O
57	occur	O
58	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	phosphorylation	O
6	of	O
7	M	O
8	protein	O
9	at	O
10	the	O
11	major	O
12	in	O
13	vivo	O
14	sites	O
15	is	O
16	not	O
17	essential	O
18	for	O
19	virus	O
20	assembly	O
21	.	O

1	Cardiac	O
2	myosin	O
3	-	O
4	binding	O
5	protein	B
6	C	I
7	(	I
8	MyBP	O
9	-	O
10	C	O
11	):	O
12	identification	O
13	of	O
14	protein	O
15	kinase	O
16	A	O
17	and	O
18	protein	O
19	kinase	B
20	C	I
21	phosphorylation	I
22	sites	I
23	.	O

1	The	O
2	duration	B
3	and	I
4	the	O
5	amplitude	B
6	of	I
7	the	I
8	negative	I
9	potential	O
10	were	O
11	greatest	O
12	for	O
13	completely	O
14	regenerating	O
15	ears	O
16	with	O
17	overgrowth	B
18	,	I
19	smaller	I
20	for	I
21	partially	I
22	regenerating	I
23	ears	I
24	,	I
25	and	I
26	smallest	O
27	for	O
28	the	O
29	nonregenerating	O
30	ears	O
31	.	O

1	In	O
2	contrast	O
3	,	O
4	dig1	O
5	dig2	O
6	cells	O
7	constitutively	O
8	invade	O
9	agar	O
10	medium	O
11	,	O
12	whereas	O
13	a	O
14	dig1	O
15	dig2	O
16	ste12	O
17	triple	O
18	mutant	O
19	does	O
20	not	O
21	,	O
22	indicating	O
23	that	O
24	Dig1	O
25	and	O
26	Dig2	O
27	share	O
28	a	O
29	role	O
30	in	O
31	negatively	O
32	regulating	O
33	the	O
34	invasive	O
35	growth	O
36	pathway	O
37	.	O

1	Homozygous	O
2	individuals	O
3	usually	O
4	develop	O
5	purpura	O
6	fulminans	B
7	as	O
8	newborns	B
9	;	I
10	heterozygous	I
11	protein	O
12	C	O
13	-	O
14	deficient	O
15	individuals	O
16	are	O
17	at	O
18	increased	O
19	risk	B
20	for	I
21	venous	I
22	thrombosis	I
23	and	I
24	pulmonary	I
25	embolism	I
26	.	I

1	Current	O
2	status	O
3	of	O
4	chemotherapy	O
5	for	O
6	Hodgkin	I
7	'	I
8	s	O
9	disease	O

1	The	O
2	mRNA	O
3	from	O
4	this	O
5	gene	O
6	,	O
7	termed	O
8	HES1	O
9	,	O
10	is	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	but	O
15	strongly	O
16	so	O
17	in	O
18	heart	O
19	and	O
20	skeletal	O
21	muscle	O
22	.	O

1	However	O
2	,	B
3	although	I
4	deletion	I
5	of	I
6	Fp1	O
7	in	O
8	the	O
9	hCRBP1	O
10	gene	O
11	yielded	O
12	increased	O
13	CAT	O
14	activity	O
15	,	O
16	pointing	B
17	toward	I
18	a	I
19	negative	I
20	regulatory	I
21	function	I
22	exerted	I
23	by	I
24	this	I
25	element	I
26	,	O
27	its	B
28	insertion	I
29	upstream	I
30	of	I
31	the	O
32	p12	O
33	basal	O
34	promoter	O
35	results	O
36	in	O
37	an	O
38	impressive	O
39	positive	O
40	stimulation	O
41	of	O
42	CAT	O
43	gene	O
44	expression	O
45	.	O

1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	O
17	loci	O
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O

1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	nonsustained	O
9	.	O

1	In	O
2	a	O
3	randomized	O
4	double	O
5	-	O
6	blind	O
7	cross	O
8	-	O
9	over	O
10	study	O
11	,	B
12	the	B
13	subjects	I
14	received	I
15	theophylline	I
16	5	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	per	O
23	day	O
24	with	O
25	omeprazole	O
26	20	O
27	mg	O
28	per	O
29	day	O
30	or	O
31	identical	O
32	placebo	O
33	during	O
34	two	O
35	periods	O
36	,	O
37	each	O
38	of	O
39	7	O
40	days	O
41	,	O
42	separated	O
43	by	O
44	a	O
45	washout	O
46	period	O
47	of	B
48	7	I
49	days	O
50	.	O

1	3	O
2	'	O
3	RNA	B
4	boundary	I
5	experiments	I
6	indicate	I
7	that	I
8	the	O
9	5	B
10	'	I
11	structure	I
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	B
18	/	I
19	U	I
20	)	I
21	AG	I
22	repeats	O
23	required	B
24	for	I
25	stable	I
26	TRAP	O
27	-	O
28	trp	O
29	leader	O
30	RNA	O
31	association	O
32	.	O

1	Cardiac	O
2	output	O
3	(	O
4	CO	O
5	)	O
6	was	O
7	significantly	O
8	higher	O
9	(	O
10	p	O
11	less	O
12	than	O
13	0	O
14	.	O
15	0005	O
16	)	O
17	in	O
18	the	O
19	MBBF	O
20	group	O
21	.	O

1	A	O
2	strong	O
3	correlation	O
4	exists	O
5	between	B
6	the	I
7	numbers	I
8	of	I
9	CFU	I
10	-	I
11	GM	I
12	transfused	O
13	and	O
14	the	O
15	rate	O
16	of	O
17	granulocytes	O
18	and	O
19	platelets	O
20	recovery	O
21	.	O

1	Effect	O
2	of	O
3	indoramin	O
4	in	O
5	small	O
6	doses	O
7	on	O
8	the	O
9	central	O
10	vasomotor	O
11	loci	O
12	has	O
13	been	O
14	studied	O
15	in	O
16	chloralose	O
17	anesthetized	O
18	cats	O
19	by	O
20	localizing	O
21	it	O
22	to	O
23	the	O
24	central	O
25	sites	O
26	.	O

1	The	O
2	primary	O
3	pancreatic	O
4	insult	O
5	seemed	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	O
19	lipase	O
20	nor	O
21	the	O
22	development	O
23	of	O
24	ascites	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O

1	Polyhomeotic	O
2	and	O
3	Posterior	O
4	Sex	O
5	Combs	O
6	may	O
7	participate	O
8	in	O
9	a	O
10	more	O
11	general	O
12	transcriptional	O
13	mechanism	O
14	that	O
15	causes	O
16	modulated	O
17	gene	O
18	repression	O
19	,	O
20	whereas	O
21	the	O
22	inclusion	O
23	of	O
24	Polycomb	O
25	protein	O
26	in	O
27	the	O
28	complex	O
29	at	O
30	PREs	O
31	leads	O
32	to	O
33	stable	O
34	silencing	O
35	.	O

1	Steroid	O
2	glucuronides	O
3	in	O
4	amniotic	O
5	fluid	O
6	at	O
7	term	O
8	.	O

1	REM	O
2	dream	O
3	content	O
4	was	O
5	scored	B
6	for	I
7	categories	O
8	suggesting	O
9	the	O
10	predominant	O
11	influence	O
12	of	O
13	the	O
14	left	O
15	hemisphere	O
16	,	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	good	O
22	ego	O
23	functioning	O
24	,	O
25	verbalization	O
26	,	O
27	or	O
28	the	O
29	right	O
30	hemisphere	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.,	O
36	music	B
37	,	B
38	spatial	B
39	salience	O
40	,	O
41	bizarreness	O
42	.	O

1	Among	O
2	38	B
3	patients	I
4	with	I
5	inducible	I
6	reentrant	I
7	VTs	I
8	who	I
9	underwent	O
10	electrophysiologic	O
11	study	O
12	(	O
13	EPS	O
14	),	O
15	10	O
16	VTs	O
17	of	O
18	six	O
19	patients	O
20	were	O
21	selected	O
22	.	O

1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	O
38	kinase	O
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O

1	Induction	O
2	of	O
3	proto	O
4	-	O
5	oncogene	O
6	fos	O
7	transcription	O
8	through	O
9	the	O
10	adenylate	O
11	cyclase	O
12	pathway	O
13	:	O
14	characterization	O
15	of	O
16	a	O
17	cAMP	O
18	-	O
19	responsive	O
20	element	O
21	.	O

1	Glutamic	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	B
15	in	B
16	the	I
17	form	I
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	B
36	day	I
37	injections	I
38	of	I
39	dexazone	I
40	.	I

1	Expression	O
2	of	O
3	the	O
4	wt1	O
5	gene	O
6	via	O
7	transient	O
8	transfection	O
9	in	O
10	COS	O
11	-	O
12	1	O
13	cells	O
14	revealed	O
15	a	O
16	52	O
17	kDa	O
18	protein	O
19	which	O
20	was	O
21	immunoprecipitated	O
22	by	O
23	both	O
24	the	O
25	N	O
26	-	O
27	terminal	O
28	-	O
29	and	O
30	C	O
31	-	O
32	terminal	O
33	-	O
34	specific	O
35	antisera	O
36	.	O

1	Previous	O
2	experimental	O
3	evidence	O
4	had	O
5	indicated	O
6	that	O
7	Reg1	O
8	might	O
9	target	O
10	Glc7	O
11	to	O
12	nuclear	O
13	substrates	O
14	such	O
15	as	O
16	the	O
17	Snf1	O
18	kinase	O
19	complex	O
20	.	O

1	The	O
2	carboxyl	B
3	-	I
4	terminal	I
5	CCCC	I
6	module	I
7	is	I
8	structurally	O
9	related	O
10	to	O
11	the	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	the	O
18	erythroid	O
19	transcription	O
20	factor	O
21	GATA	O
22	-	O
23	1	B
24	.	I

1	Cloning	O
2	by	O
3	complementation	B
4	and	I
5	subsequent	I
6	physical	O
7	and	O
8	genetic	O
9	analysis	O
10	revealed	O
11	that	O
12	it	O
13	maps	O
14	to	O
15	RAF1	O
16	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	lab	O
6	and	O
7	field	O
8	tests	O
9	yielded	O
10	high	O
11	levels	O
12	of	O
13	infestation	O
14	in	O
15	larvae	O
16	with	O
17	values	O
18	ranging	O
19	from	O
20	90	O
21	to	O
22	100	O
23	%	O
24	and	O
25	from	O
26	85	O
27	to	O
28	95	O
29	%,	O
30	respectively	O
31	.	O

1	Recombinant	O
2	Leishmania	B
3	surface	I
4	glycoprotein	I
5	GP63	O
6	is	O
7	secreted	O
8	in	O
9	the	O
10	baculovirus	O
11	expression	O
12	system	O
13	as	O
14	a	O
15	latent	O
16	metalloproteinase	O
17	.	O

1	The	O
2	Southern	O
3	technique	O
4	allowed	O
5	a	O
6	further	O
7	localization	O
8	of	O
9	the	O
10	region	O
11	of	O
12	most	O
13	extensive	O
14	transcription	O
15	to	O
16	a	B
17	1	I
18	.	I
19	8	O
20	kb	O
21	HindIII	O
22	-	O
23	EcoRI	O
24	fragment	O
25	.	O

1	In	O
2	the	O
3	tissues	B
4	tested	I
5	,	O
6	except	B
7	brain	I
8	,	I
9	the	I
10	message	O
11	for	O
12	CLIP	O
13	-	O
14	170	O
15	was	O
16	more	O
17	abundant	O
18	than	O
19	that	O
20	for	O
21	Restin	O
22	.	O

1	The	O
2	absolute	O
3	configuration	O
4	at	O
5	C	O
6	-	O
7	2	O
8	in	O
9	monocrotalic	O
10	acid	O
11	.	B

1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	O
9	response	O
10	factor	O
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O

1	Examination	O
2	of	O
3	neurohumoral	O
4	factors	O
5	revealed	O
6	a	O
7	hyperactive	O
8	sympathetic	O
9	nervous	O
10	system	O
11	and	O
12	an	O
13	increase	O
14	in	O
15	plasma	O
16	renin	O
17	activity	O
18	.	O

1	Deletion	O
2	analyses	O
3	of	O
4	the	O
5	pCD41	O
6	ORF	O
7	-	O
8	A	O
9	and	O
10	the	O
11	use	O
12	of	O
13	promoter	O
14	constructs	O
15	further	O
16	mapped	O
17	an	O
18	internal	O
19	functional	O
20	promoter	O
21	within	O
22	the	O
23	pCD41	O
24	sequence	O
25	that	O
26	can	O
27	direct	O
28	the	O
29	synthesis	O
30	of	O
31	the	O
32	trans	O
33	-	O
34	activating	O
35	protein	O
36	.	O

1	Engagement	O
2	of	O
3	human	B
4	CD2	I
5	by	I
6	mitogenic	I
7	pairs	I
8	of	I
9	anti	I
10	-	O
11	CD2	O
12	mAb	O
13	induces	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	a	O
18	number	O
19	of	O
20	intracellular	O
21	proteins	O
22	including	O
23	a	O
24	120	O
25	kDa	O
26	phosphoprotein	O
27	that	O
28	we	O
29	identify	O
30	as	O
31	the	O
32	proto	O
33	-	O
34	oncogene	O
35	c	O
36	-	B
37	Cbl	I
38	.	I

1	Gentamicin	O
2	given	O
3	by	O
4	DPI	O
5	and	O
6	SVN	O
7	significantly	O
8	decreased	O
9	the	O
10	sputum	B
11	Psa	I
12	density	I
13	(	I
14	p	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	by	B
21	almost	I
22	one	I
23	order	I
24	of	I
25	magnitude	O
26	.	O

1	Repair	O
2	of	O
3	a	O
4	cosmetic	O
5	defect	O
6	of	O
7	the	O
8	lower	O
9	leg	O
10	with	O
11	a	O
12	myocutaneous	O
13	free	O
14	flap	O
15	.	O

1	CKII	O
2	as	O
3	a	O
4	CD44	O
5	-	O
6	associated	O
7	serine	O
8	kinase	O
9	therefore	O
10	may	O
11	serve	O
12	as	O
13	an	O
14	important	O
15	molecule	O
16	in	O
17	a	B
18	signaling	I
19	cascade	I
20	that	I
21	produces	O
22	a	O
23	variety	O
24	of	O
25	cellular	O
26	responses	O
27	in	O
28	MDA231	O
29	breast	O
30	cancer	O
31	cells	O
32	.	O

1	During	O
2	exercise	O
3	,	O
4	the	O
5	Pes	O
6	-	O
7	Ves	O
8	relation	O
9	was	O
10	shifted	O
11	toward	O
12	the	O
13	left	O
14	and	O
15	the	O
16	slope	O
17	[	O
18	end	O
19	-	O
20	systolic	O
21	elastance	O
22	(	O
23	Ees	O
24	)]	O
25	increased	O
26	from	O
27	7	O
28	.	O
29	7	O
30	+/-	O
31	2	O
32	.	O
33	8	O
34	to	O
35	12	O
36	.	O
37	7	O
38	+/-	O
39	4	O
40	.	O
41	2	O
42	(	O
43	SD	O
44	)	O
45	mmHg	O
46	/	O
47	ml	O
48	(	O
49	P	O
50	<	O
51	0	O
52	.	O
53	05	O
54	).	O

1	A	O
2	DNA	B
3	motif	I
4	related	O
5	to	O
6	the	O
7	cAMP	O
8	-	O
9	responsive	O
10	element	O
11	and	O
12	an	O
13	exon	O
14	-	O
15	located	O
16	activator	O
17	protein	O
18	-	O
19	2	O
20	binding	O
21	site	O
22	in	O
23	the	O
24	human	O
25	tissue	O
26	-	O
27	type	O
28	plasminogen	O
29	activator	O
30	gene	O
31	promoter	O
32	cooperate	O
33	in	O
34	basal	O
35	expression	B
36	and	O
37	convey	O
38	activation	B
39	by	O
40	phorbol	O
41	ester	O
42	and	O
43	cAMP	O
44	.	O

1	1	O
2	.	O

1	In	O
2	vitro	O
3	transcription	O
4	results	O
5	indicate	O
6	that	O
7	this	O
8	5	O
9	'	O
10	structure	O
11	functions	O
12	in	O
13	the	O
14	attenuation	O
15	mechanism	O
16	,	O
17	since	O
18	deletion	O
19	of	O
20	the	O
21	stem	O
22	-	O
23	loop	O
24	caused	O
25	an	O
26	increase	O
27	in	O
28	transcription	O
29	readthrough	O
30	.	O

1	Leptinaemia	O
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	B

1	Patients	O
2	with	O
3	low	B
4	probability	I
5	of	I
6	having	O
7	aluminum	O
8	overload	O
9	(	O
10	serum	B
11	iron	I
12	levels	I
13	<	I
14	40	I
15	micrograms	I
16	/	O
17	L	B
18	and	I
19	DAI	I
20	<	I
21	150	I
22	micrograms	I
23	/	I
24	L	I
25	)	I
26	had	I
27	significantly	O
28	higher	O
29	values	O
30	of	O
31	serum	O
32	iron	O
33	,	O
34	iron	O
35	transferrin	O
36	saturation	O
37	,	O
38	and	O
39	serum	O
40	ferritin	O
41	levels	O
42	compared	O
43	with	O
44	those	O
45	patients	O
46	with	O
47	a	O
48	high	O
49	probability	O
50	of	O
51	having	O
52	aluminum	B
53	overload	O
54	(	O
55	serum	B
56	aluminum	B
57	levels	I
58	>	I
59	40	O
60	micrograms	B
61	/	I
62	L	O
63	and	B
64	DAI	I
65	>	I
66	150	O
67	micrograms	I
68	/	O
69	L	I
70	).	O

1	An	O
2	endogenous	O
3	mammalian	O
4	regulator	O
5	of	O
6	this	O
7	process	O
8	,	O
9	named	O
10	Usurpin	O
11	,	O
12	has	O
13	been	O
14	identified	O
15	(	O
16	aliases	O
17	for	O
18	Usurpin	O
19	include	O
20	CASH	O
21	,	O
22	Casper	O
23	,	O
24	CLARP	O
25	,	O
26	FLAME	O
27	-	O
28	1	O
29	,	O
30	FLIP	O
31	,	O
32	I	O
33	-	O
34	FLICE	O
35	and	O
36	MRIT	O
37	).	O

1	An	O
2	intravenous	O
3	drip	O
4	infusion	O
5	of	O
6	AMK	O
7	in	O
8	adequate	O
9	dosage	O
10	would	O
11	be	O
12	beneficial	O
13	to	O
14	use	O
15	against	O
16	some	O
17	infectious	O
18	diseases	O
19	of	O
20	otorhinolaryngologic	O
21	field	O
22	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	crucial	O
7	role	O
8	of	O
9	the	O
10	mutations	O
11	activating	O
12	v	O
13	-	O
14	erbA	O
15	as	O
16	an	O
17	oncogene	O
18	is	O
19	to	O
20	'	O
21	freeze	O
22	'	O
23	c	O
24	-	O
25	ErbA	O
26	/	O
27	TRalpha	O
28	in	O
29	its	O
30	non	O
31	-	O
32	liganded	O
33	,	O
34	repressive	O
35	conformation	O
36	and	O
37	to	O
38	facilitate	O
39	its	O
40	overexpression	O
41	.	O

1	Determination	O
2	of	O
3	transaminases	O
4	with	O
5	an	O
6	autoanalyzer	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	the	O
7	isolation	O
8	of	O
9	a	O
10	Fab	O
11	fragment	O
12	(	O
13	Fab	O
14	A8	O
15	)	B
16	showing	B
17	a	I
18	high	I
19	relative	I
20	affinity	I
21	for	O
22	the	O
23	receptor	O
24	(	O
25	0	O
26	.	O
27	5	O
28	nM	O
29	).	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	Childhood	O
2	misbehavior	O
3	and	O
4	the	O
5	risk	O
6	of	O
7	injecting	O
8	drug	O
9	use	O
10	.	O

1	This	O
2	distinction	O
3	was	O
4	based	O
5	upon	O
6	whether	O
7	the	O
8	diagnosis	O
9	provided	O
10	a	O
11	straightforward	O
12	range	O
13	of	O
14	prognoses	O
15	or	O
16	an	O
17	ambiguous	O
18	clinical	O
19	implication	O
20	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	B
9	level	I
10	boosts	I
11	the	I
12	current	I
13	values	I
14	by	I
15	2	O
16	-	B
17	3	I
18	orders	I
19	of	O
20	magnitude	O
21	;	B
22	contrariwise	I
23	,	I
24	the	I
25	voltage	I
26	values	I
27	rise	I
28	by	I
29	about	O
30	three	B
31	times	B
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O

1	E2F	O
2	activity	O
3	is	O
4	regulated	O
5	in	O
6	part	O
7	by	O
8	the	B
9	retinoblastoma	I
10	family	I
11	of	O
12	tumor	B
13	suppressor	I
14	proteins	O
15	.	O

1	The	O
2	Ng	O
3	/	O
4	RC3	O
5	and	O
6	PKC	O
7	-	O
8	gamma	O
9	genes	O
10	have	O
11	a	B
12	similar	I
13	expression	I
14	pattern	I
15	in	I
16	the	I
17	brain	I
18	during	I
19	development	O
20	.	B

1	Analysis	O
2	of	O
3	1	O
4	Mb	O
5	of	O
6	published	O
7	sequence	O
8	from	O
9	the	O
10	region	O
11	of	O
12	conserved	O
13	synteny	O
14	on	O
15	human	O
16	chromosome	O
17	5q31	O
18	-	O
19	q33	O
20	identified	O
21	45	O
22	gene	O
23	candidates	O
24	,	O
25	including	O
26	35	O
27	expressed	O
28	genes	O
29	in	O
30	the	O
31	human	O
32	IL	O
33	-	O
34	4	O
35	cytokine	O
36	gene	O
37	cluster	O
38	.	O

1	I	O
2	.	B

1	Based	O
2	on	O
3	the	O
4	estimated	O
5	values	O
6	of	O
7	divergence	O
8	of	O
9	apobec1	O
10	sequences	O
11	in	O
12	terms	O
13	of	O
14	the	O
15	numbers	O
16	of	O
17	synonymous	O
18	and	O
19	non	O
20	-	O
21	synonymous	O
22	suhstitutions	O
23	per	O
24	site	O
25	,	O
26	we	O
27	found	O
28	that	O
29	apobec1	O
30	is	O
31	a	O
32	fairly	O
33	rapidly	O
34	evolving	O
35	protein	O
36	.	O

1	These	O
2	striations	O
3	were	O
4	caused	O
5	by	O
6	contact	O
7	between	O
8	the	O
9	sharp	O
10	edge	O
11	of	O
12	the	O
13	upper	O
14	canine	O
15	and	O
16	the	O
17	P3	O
18	during	O
19	honing	O
20	(	O
21	canine	O
22	/	O
23	premolar	O
24	complex	O
25	).	O

1	Deletion	O
2	from	B
3	either	I
4	the	I
5	N	I
6	-	I
7	or	I
8	C	O
9	-	O
10	terminal	O
11	ends	O
12	of	O
13	repA	O
14	(	O
15	28	O
16	and	O
17	69	O
18	codons	O
19	,	O
20	respectively	O
21	,	O
22	out	O
23	of	O
24	the	O
25	286	O
26	-	O
27	codon	O
28	open	O
29	reading	O
30	frame	O
31	)	O
32	affected	B
33	the	B
34	initiator	O
35	but	B
36	not	I
37	the	B
38	inhibitory	B
39	activity	I
40	.	I

1	CsA	O
2	alone	O
3	resulted	O
4	in	O
5	elevated	O
6	bone	O
7	turnover	O
8	.	O

1	Incubation	O
2	of	O
3	the	O
4	purified	O
5	fusion	O
6	proteins	O
7	with	O
8	[	O
9	gamma	O
10	-	O
11	32P	B
12	]	I
13	ATP	I
14	in	I
15	an	I
16	in	I
17	vitro	O
18	assay	O
19	showed	B
20	that	I
21	both	O
22	proteins	O
23	were	O
24	capable	O
25	of	O
26	autophosphorylation	O
27	.	O

1	During	O
2	BH	O
3	the	O
4	ventilator	O
5	was	O
6	disconnected	O
7	and	O
8	a	O
9	bias	O
10	flow	O
11	of	O
12	50	O
13	%	O
14	O2	O
15	at	O
16	4	O
17	-	O
18	5	O
19	l	O
20	/	O
21	min	O
22	was	O
23	delivered	O
24	through	O
25	the	O
26	side	O
27	ports	O
28	of	O
29	a	O
30	small	O
31	catheter	O
32	whose	O
33	tip	O
34	was	O
35	positioned	O
36	1	O
37	cm	O
38	cephalad	O
39	of	O
40	the	O
41	carina	O
42	.	O

1	Prevention	O
2	,	O
3	differential	O
4	diagnosis	O
5	and	O
6	therapy	O
7	of	O
8	travel	O
9	diarrhea	O

1	Contingency	O
2	contracting	O
3	between	O
4	clients	O
5	and	O
6	their	O
7	parents	O
8	/	O
9	caregivers	O
10	was	O
11	used	O
12	to	O
13	specify	O
14	consequences	O
15	for	O
16	daily	O
17	self	O
18	-	O
19	monitoring	O
20	,	O
21	reduced	O
22	caloric	O
23	intake	O
24	,	B
25	weight	I
26	loss	I
27	,	I
28	and	I
29	exercise	O
30	.	O

1	Sequence	O
2	comparisons	O
3	have	O
4	shown	O
5	that	O
6	Aps1p	O
7	is	O
8	more	O
9	similar	O
10	to	O
11	the	O
12	sigma	O
13	subunit	O
14	of	O
15	the	O
16	Golgi	O
17	-	O
18	localized	O
19	mammalian	O
20	AP	O
21	-	O
22	1	O
23	complex	O
24	than	O
25	Aps2p	O
26	,	O
27	which	B
28	is	I
29	more	I
30	related	O
31	to	O
32	the	O
33	plasma	O
34	membrane	O
35	AP	O
36	-	O
37	2	O
38	sigma	O
39	subunit	O
40	.	O

1	We	O
2	mapped	O
3	two	O
4	overlapping	O
5	expressed	O
6	sequence	O
7	tag	B
8	clones	I
9	within	I
10	a	O
11	genomic	O
12	contig	O
13	on	O
14	human	O
15	chromosome	O
16	5	O
17	,	O
18	band	O
19	q31	O
20	.	B

1	The	O
2	incidence	O
3	of	O
4	early	O
5	neonatal	O
6	convulsions	O
7	for	O
8	inborn	O
9	babies	O
10	was	O
11	3	O
12	.	O
13	0	O
14	/	O
15	1000	O
16	live	O
17	births	O
18	.	O

1	Physical	O
2	analysis	B
3	maps	I
4	SAL6	O
5	to	O
6	chromosome	O
7	XVI	O
8	between	O
9	TPK2	O
10	and	O
11	spt14	O
12	.	O

1	In	O
2	none	O
3	of	O
4	the	O
5	44	O
6	type	B
7	I	I
8	attacks	I
9	and	O
10	29	O
11	type	O
12	II	O
13	attacks	O
14	which	O
15	were	O
16	recorded	O
17	did	O
18	circulatory	O
19	changes	O
20	;	O
21	the	O
22	latter	O
23	were	O
24	different	O
25	in	O
26	the	O
27	two	O
28	groups	O
29	.	O

1	Bacterial	O
2	meningitis	O
3	secondary	O
4	to	O
5	abscess	O
6	of	O
7	the	O
8	nasal	O
9	septum	O
10	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	O
17	and	O
18	EXT2	O
19	genes	O
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	:	O
6	1	O
7	)	O
8	the	O
9	initial	O
10	response	O
11	to	O
12	tethering	O
13	varies	O
14	according	O
15	to	O
16	previous	O
17	penning	O
18	and	O
19	handling	O
20	experience	O
21	,	O
22	2	O
23	)	O
24	although	O
25	the	O
26	circadian	O
27	rhythm	O
28	of	O
29	cortisol	O
30	was	O
31	either	O
32	altered	O
33	or	O
34	disrupted	O
35	during	O
36	estrus	O
37	,	O
38	such	O
39	disruptions	O
40	were	O
41	not	O
42	influenced	O
43	by	O
44	type	O
45	of	O
46	penning	O
47	and	O
48	3	O
49	)	O
50	tether	O
51	stalls	O
52	may	O
53	chronically	O
54	increase	O
55	cortisol	O
56	concentrations	O
57	in	O
58	gilts	O
59	.	O

1	Additional	O
2	studies	O
3	revealed	O
4	that	O
5	bovine	O
6	brain	O
7	Galpha	O
8	(	O
9	q	O
10	/	O
11	11	O
12	)	O
13	could	O
14	also	B
15	bind	I
16	to	I
17	an	I
18	N	O
19	-	O
20	terminal	O
21	construct	O
22	of	O
23	GRK2	O
24	,	O
25	while	O
26	no	O
27	binding	O
28	of	B
29	Galpha	I
30	(	I
31	q	I
32	/	O
33	11	O
34	),	O
35	Galpha	O
36	(	O
37	s	O
38	),	O
39	Galpha	O
40	(	O
41	i	O
42	),	O
43	or	O
44	Galpha	O
45	(	O
46	12	O
47	/	B
48	13	I
49	)	I
50	to	O
51	comparable	O
52	constructs	O
53	of	O
54	GRK5	O
55	or	O
56	GRK6	O
57	was	O
58	observed	O
59	.	O

1	The	O
2	mechanism	O
3	of	B
4	peroxisome	I
5	proliferation	I
6	is	I
7	poorly	O
8	understood	O
9	.	O

1	A	O
2	brief	O
3	account	O
4	of	O
5	the	O
6	1988	O
7	seminar	O
8	in	O
9	Shanghai	O
10	on	O
11	viral	O
12	hepatitis	O
13	A	O

1	In	O
2	Denmark	O
3	only	O
4	1	O
5	-	O
6	3	O
7	cases	O
8	of	O
9	transfusion	O
10	-	O
11	associated	B
12	hepatitis	I
13	NANB	I
14	(	I
15	TAH	O
16	-	O
17	NANB	B
18	)	I
19	are	I
20	registered	I
21	annually	I
22	or	O
23	about	O
24	1	O
25	case	O
26	per	O
27	100	O
28	,	O
29	000	O
30	units	O
31	transfused	O
32	.	O

1	The	O
2	absence	O
3	of	O
4	H4PteGlun	O
5	bound	O
6	to	O
7	the	O
8	T	O
9	protein	O
10	in	O
11	our	O
12	experimental	O
13	conditions	O
14	demonstrates	O
15	that	O
16	H4PteGlun	O
17	is	O
18	not	O
19	covalently	O
20	linked	O
21	to	O
22	the	O
23	T	O
24	protein	O
25	.	O

1	The	O
2	mean	O
3	serum	O
4	creatinine	O
5	levels	O
6	were	O
7	similar	B
8	at	I
9	one	I
10	year	O
11	(	O
12	SPK	O
13	1	O
14	.	O
15	8	O
16	,	O
17	KTA	B
18	1	B
19	.	I
20	9	O
21	mg	O
22	/	O
23	d	O
24	).(	O
25	ABSTRACT	O
26	TRUNCATED	O
27	AT	O
28	250	B
29	WORDS	I
30	)	I

1	Attenuation	O
2	from	O
3	the	O
4	vit	I
5	A2	I
6	consensus	I
7	ERE	O
8	is	I
9	not	O
10	necessarily	O
11	dependent	O
12	on	I
13	DNA	I
14	binding	O
15	as	O
16	the	O
17	TR	O
18	alpha	O
19	DNA	O
20	binding	O
21	mutant	O
22	was	O
23	still	O
24	able	O
25	to	O
26	inhibit	O
27	E	O
28	-	O
29	dependent	O
30	transactivation	O
31	.	O

1	Interferon	O
2	type	O
3	I	O
4	in	O
5	protective	O
6	body	O
7	reactions	O
8	in	O
9	an	O
10	experimental	O
11	Klebsiella	O
12	infection	O

1	In	O
2	retrospect	O
3	,	O
4	the	O
5	diagnoses	O
6	were	O
7	reconsidered	O
8	applying	O
9	strict	O
10	criteria	O
11	.	O

1	It	O
2	is	O
3	now	O
4	estimated	O
5	that	O
6	inactivation	O
7	mutants	O
8	of	O
9	PTEN	O
10	exist	O
11	in	O
12	60	O
13	%	O
14	of	B
15	all	I
16	forms	I
17	of	I
18	solid	O
19	tumors	O
20	.	B

1	The	O
2	genome	O
3	of	O
4	Thogoto	O
5	virus	O
6	comprises	O
7	six	O
8	segments	O
9	of	O
10	single	O
11	-	O
12	stranded	O
13	,	O
14	negative	O
15	sense	O
16	RNA	O
17	.	O

1	This	O
2	paper	O
3	brings	O
4	together	O
5	data	O
6	,	O
7	obtained	O
8	from	O
9	a	O
10	variety	O
11	of	O
12	sources	O
13	,	O
14	on	O
15	the	O
16	extent	O
17	of	O
18	prescription	O
19	and	O
20	use	O
21	of	O
22	psychotropic	O
23	drugs	O
24	in	O
25	the	O
26	late	O
27	1960s	O
28	and	O
29	early	O
30	1970s	O
31	.	O

1	Reverse	O
2	transcriptase	O
3	and	O
4	protease	O
5	activities	O
6	of	O
7	avian	O
8	leukosis	O
9	virus	O
10	Gag	O
11	-	O
12	Pol	O
13	fusion	O
14	proteins	O
15	expressed	O
16	in	O
17	insect	B
18	cells	I
19	.	O

1	PNT	O
2	,	O
3	ADD	O
4	and	O
5	BSS	O
6	in	O
7	the	O
8	initial	O
9	stage	O
10	of	O
11	kindling	O
12	,	O
13	kindling	O
14	rate	O
15	for	O
16	the	O
17	stage	O
18	-	O
19	3	O
20	and	O
21	-	O
22	5	O
23	seizures	O
24	,	O
25	seizure	O
26	parameters	O
27	at	O
28	the	O
29	first	O
30	stage	O
31	-	O
32	3	O
33	and	O
34	-	O
35	5	O
36	were	O
37	recorded	O
38	and	O
39	compared	O
40	to	O
41	the	O
42	values	O
43	of	O
44	saline	O
45	-	O
46	treated	O
47	,	O
48	control	O
49	group	O
50	.	O

1	The	O
2	importance	B
3	of	I
4	hepatitis	O
5	C	O
6	virus	B
7	(	I
8	HCV	I
9	)	I
10	infection	I
11	as	I
12	a	I
13	cause	I
14	of	I
15	chronic	O
16	liver	B
17	disease	I
18	has	O
19	become	O
20	clear	O
21	with	O
22	the	O
23	introduction	O
24	of	O
25	serologic	B
26	detection	I
27	methods	I
28	.	O

1	Although	O
2	elevated	O
3	serum	O
4	levels	O
5	of	O
6	antibodies	O
7	to	O
8	the	O
9	nicotinic	O
10	acetylcholine	O
11	receptor	O
12	(	O
13	nAChR	O
14	)	O
15	have	O
16	been	O
17	reported	O
18	in	O
19	neuroleptic	O
20	treated	O
21	patients	O
22	with	O
23	tardive	O
24	dyskinesia	O
25	,	O
26	such	O
27	antibodies	O
28	have	O
29	not	O
30	been	O
31	determined	O
32	in	O
33	comparable	O
34	nondyskinetic	O
35	patients	O
36	.	O

1	METHODS	O
2	:	O
3	T2	O
4	*-	O
5	weighted	O
6	,	O
7	three	O
8	-	O
9	dimensional	O
10	gradient	O
11	-	O
12	echo	O
13	images	O
14	were	O
15	acquired	O
16	by	O
17	exploiting	O
18	the	O
19	magnetic	O
20	susceptibility	O
21	difference	O
22	between	O
23	oxygenated	O
24	and	O
25	deoxygenated	O
26	hemoglobin	O
27	in	O
28	the	O
29	vasculature	O
30	and	O
31	microvasculature	O
32	.	O

1	Its	O
2	interaction	O
3	with	O
4	RFX5	O
5	and	O
6	RFXAP	O
7	is	O
8	essential	O
9	for	O
10	binding	O
11	of	O
12	the	O
13	RFX	O
14	complex	O
15	to	O
16	MHC	O
17	-	O
18	II	O
19	promoters	O
20	.	O

1	In	O
2	a	O
3	heterologous	O
4	transcriptional	O
5	system	O
6	in	O
7	which	O
8	the	O
9	upstream	O
10	regions	O
11	of	O
12	oIFNtau	O
13	were	O
14	inserted	O
15	in	O
16	front	O
17	of	O
18	simian	O
19	virus	O
20	40	O
21	(	O
22	SV40	O
23	)	O
24	promoter	O
25	,	O
26	the	O
27	regions	O
28	between	O
29	bases	O
30	-	O
31	654	O
32	and	O
33	-	O
34	555	O
35	were	O
36	determined	O
37	as	O
38	being	O
39	the	O
40	enhancer	O
41	region	O
42	required	O
43	for	O
44	oIFNtau	O
45	-	O
46	SV40	O
47	-	O
48	CAT	O
49	transactivation	O
50	.	O

1	This	O
2	soluble	O
3	form	O
4	of	O
5	the	O
6	HGFr	O
7	(	O
8	sHGFr	O
9	)	O
10	bound	O
11	HGF	O
12	with	O
13	an	O
14	affinity	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	authentic	O
21	,	O
22	membrane	O
23	-	O
24	associated	O
25	receptor	O
26	.	O

1	Snail	O
2	mortality	O
3	did	O
4	not	O
5	differ	O
6	among	O
7	the	O
8	various	O
9	treatment	O
10	conditions	O
11	.	O

1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	B
7	loss	I
8	in	I
9	the	I
10	DHED	I
11	-	I
12	treated	I
13	group	I
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	O
39	)	O
40	of	O
41	EC	O
42	-	O
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O

1	Filter	O
2	and	O
3	cytocentrifuge	O
4	preparations	O
5	of	O
6	the	O
7	urine	O
8	were	O
9	studied	O
10	and	O
11	all	O
12	cases	O
13	displayed	O
14	numerous	O
15	scattered	O
16	aggregates	O
17	or	O
18	single	O
19	tumor	O
20	cells	O
21	in	O
22	an	O
23	inflammatory	O
24	background	O
25	.	O

1	N	O
2	.,	O
3	and	O
4	Fanning	O
5	,	O
6	E	O
7	.	O

1	Identification	O
2	of	O
3	the	O
4	region	O
5	in	O
6	actin	O
7	-	O
8	binding	O
9	protein	O
10	that	O
11	binds	O
12	to	O
13	the	O
14	cytoplasmic	O
15	domain	O
16	of	O
17	glycoprotein	O
18	IBalpha	O
19	.	O

1	In	O
2	contrast	O
3	,	O
4	Y239	O
5	/	O
6	240F	O
7	Shc	O
8	,	O
9	but	O
10	not	O
11	Y317F	O
12	Shc	O
13	,	O
14	reduced	O
15	the	B
16	EGF	I
17	-	O
18	induced	O
19	c	O
20	-	O
21	myc	O
22	message	O
23	.	O

1	The	O
2	protein	O
3	predicted	O
4	by	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	human	O
10	pim	O
11	-	O
12	1	O
13	proto	O
14	-	O
15	oncogene	O
16	shares	O
17	extensive	O
18	homology	O
19	with	O
20	known	O
21	serine	O
22	/	O
23	threonine	O
24	protein	O
25	kinases	O
26	,	O
27	and	O
28	yet	O
29	the	O
30	human	O
31	Pim	O
32	-	O
33	1	O
34	enzyme	O
35	has	O
36	previously	O
37	been	O
38	reported	O
39	to	O
40	exhibit	O
41	protein	O
42	tyrosine	O
43	kinase	O
44	activity	O
45	both	O
46	in	O
47	vitro	O
48	and	O
49	in	O
50	vivo	O
51	.	O

1	Furthermore	O
2	,	O
3	the	O
4	UvrA	O
5	protein	O
6	interacts	O
7	with	O
8	the	O
9	UvrB	O
10	protein	O
11	to	O
12	modulate	O
13	its	O
14	activities	O
15	,	O
16	both	O
17	in	O
18	solution	O
19	and	B
20	in	I
21	association	I
22	with	I
23	DNA	I
24	,	I
25	where	I
26	the	I
27	UvrAB	I
28	complex	I
29	possesses	O
30	a	O
31	helicase	O
32	activity	O
33	.	O

1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	O
7	-	O
8	1	O
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	O
27	-	O
28	1	O
29	.	O

1	Jkappa	O
2	DNA	O
3	-	O
4	binding	O
5	sites	O
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	O
16	EBNA	O
17	-	O
18	3C	O
19	protein	O
20	unable	O
21	to	O
22	bind	O
23	Jkappa	O
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	O
29	wild	O
30	-	O
31	type	O
32	EBNA	O
33	-	O
34	3C	O
35	,	O
36	indicating	O
37	that	O
38	EBNA	O
39	-	O
40	3C	O
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	O
52	.	O

1	Calcitriol	O
2	therapy	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	decrease	O
8	in	O
9	serum	O
10	iPTH	O
11	levels	O
12	(	O
13	701	O
14	+/-	O
15	103	O
16	.	O
17	9	O
18	vs	O
19	.	O

1	CES4	O
2	on	O
3	a	O
4	multicopy	O
5	plasmid	O
6	was	B
7	unable	I
8	to	I
9	suppress	I
10	tif1	O
11	-	O
12	A79V	O
13	.	O

1	The	O
2	mRNA	O
3	identified	O
4	in	O
5	both	B
6	human	I
7	and	O
8	rat	O
9	cells	O
10	with	O
11	the	O
12	human	O
13	clathrin	O
14	clone	O
15	revealed	O
16	transcripts	O
17	of	O
18	approximately	O
19	6	B
20	.	I
21	5	O
22	kb	B
23	,	I
24	which	I
25	is	O
26	consistent	O
27	with	O
28	the	O
29	predicted	O
30	180	O
31	kDa	O
32	molecular	O
33	weight	O
34	of	O
35	the	O
36	clathrin	O
37	heavy	O
38	chain	B
39	.	O

1	Each	O
2	sample	O
3	was	O
4	analysed	O
5	as	O
6	soon	O
7	as	O
8	possible	O
9	,	O
10	and	O
11	repeated	O
12	15	O
13	,	O
14	30	O
15	,	O
16	60	O
17	and	O
18	120	O
19	min	O
20	after	O
21	sampling	O
22	.	O

1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	O
8	oxidase	O
9	,	O
10	peroxidase	B
11	and	I
12	in	I
13	the	I
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	B
28	.	I

1	cDNA	O
2	and	O
3	structural	O
4	organization	O
5	of	O
6	the	O
7	gene	O
8	Pole1	O
9	for	O
10	the	O
11	mouse	O
12	DNA	O
13	polymerase	O
14	epsilon	O
15	catalytic	O
16	subunit	O
17	.	O

1	Minor	O
2	differences	O
3	were	O
4	noted	O
5	with	O
6	latamoxef	O
7	producing	O
8	mild	O
9	persistant	O
10	elevation	O
11	of	O
12	prothrombin	O
13	time	O
14	(	O
15	0	O
16	.	O
17	7	O
18	second	O
19	)	O
20	associated	O
21	with	O
22	depression	B
23	of	I
24	factor	O
25	II	O
26	and	O
27	factor	O
28	VII	O
29	.	O

1	Curiously	O
2	,	O
3	testololactone	O
4	was	O
5	earlier	O
6	and	O
7	more	O
8	widely	O
9	used	O
10	than	O
11	aminoglutethimide	O
12	in	O
13	treating	O
14	advanced	O
15	breast	O
16	carcinoma	O
17	.	O

1	The	O
2	marker	O
3	orders	O
4	from	O
5	the	O
6	genetic	O
7	and	O
8	RH	O
9	maps	O
10	were	O
11	consistent	B
12	.	I

1	Fast	O
2	goal	O
3	-	O
4	directed	O
5	voluntary	O
6	movements	O
7	of	O
8	the	O
9	human	O
10	upper	O
11	extremity	O
12	are	O
13	known	O
14	to	O
15	be	O
16	associated	O
17	with	O
18	three	O
19	distinct	O
20	bursts	O
21	of	O
22	EMG	O
23	activity	O
24	in	O
25	antagonistic	O
26	muscles	O
27	.	O

1	Consistent	O
2	with	O
3	previous	O
4	reports	O
5	,	O
6	addition	O
7	of	O
8	a	O
9	myristoylation	O
10	signal	B
11	to	I
12	mSos1	I
13	(	I
14	MyrSos1	I
15	)	O
16	rendered	O
17	it	O
18	transforming	O
19	for	O
20	NIH	O
21	3T3	O
22	cells	O
23	and	O
24	deletion	O
25	of	O
26	the	O
27	mSos	O
28	C	O
29	terminus	O
30	(	O
31	MyrSos1	O
32	-	O
33	deltaC	O
34	)	O
35	did	O
36	not	O
37	interfere	O
38	with	O
39	this	O
40	activity	O
41	.	O

1	LDL	O
2	cholesterol	O
3	decreased	B
4	from	I
5	4	I
6	.	I
7	74	I
8	+/-	I
9	0	I
10	.	I
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	B
23	after	I
24	8	I
25	weeks	I
26	on	I
27	simvastatin	I
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	O
37	B	O
38	fell	O
39	from	O
40	142	O
41	+/-	B
42	31	I
43	to	I
44	112	I
45	+/-	I
46	22	O
47	mg	B
48	/	I
49	dl	I
50	(	I
51	P	I
52	<	O
53	0	O
54	.	B
55	001	I
56	).	I

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O

1	Point	O
2	mutations	O
3	of	O
4	the	O
5	five	O
6	tyrosine	O
7	residues	O
8	in	O
9	the	O
10	cytoplasmic	O
11	domain	O
12	of	O
13	the	O
14	receptor	O
15	were	O
16	subsequently	O
17	used	O
18	to	O
19	confirm	O
20	our	O
21	conclusions	O
22	.	O

1	Multivariate	O
2	logistic	O
3	regression	O
4	analysis	O
5	indicated	O
6	that	O
7	seropositivity	O
8	was	O
9	strongly	O
10	associated	O
11	with	O
12	the	O
13	prevalence	O
14	of	O
15	hepatitis	O
16	B	O
17	in	O
18	an	O
19	employee	O
20	'	O
21	s	O
22	country	O
23	of	O
24	birth	O
25	and	O
26	with	O
27	age	O
28	.	O

1	In	O
2	this	B
3	respect	I
4	C	I
5	reactive	I
6	protein	I
7	concentrations	I
8	are	O
9	superior	B
10	to	O
11	white	O
12	cell	O
13	count	O
14	,	O
15	erythrocyte	O
16	sedimentation	O
17	rate	O
18	,	O
19	and	O
20	temperature	O
21	and	O
22	the	O
23	concentrations	O
24	of	O
25	antiproteases	O
26	.	O

1	Overexpression	O
2	of	O
3	c	O
4	-	O
5	Myc	O
6	in	O
7	serum	O
8	-	O
9	starved	O
10	human	O
11	or	O
12	mouse	O
13	embryonic	O
14	cells	O
15	leads	O
16	to	O
17	apoptosis	O
18	which	O
19	is	O
20	significantly	O
21	reduced	O
22	in	O
23	the	O
24	presence	O
25	of	O
26	growth	O
27	factor	O
28	-	O
29	containing	O
30	serum	O
31	.	O
32	c	O
33	-	O
34	Myc	O
35	-	O
36	induced	O
37	apoptosis	O
38	appears	O
39	to	O
40	be	O
41	deficient	O
42	in	O
43	bax	O
44	-	O
45	null	O
46	as	O
47	compared	O
48	with	O
49	bax	O
50	-	O
51	wild	O
52	-	O
53	type	O
54	mouse	O
55	embryonic	O
56	fibroblasts	O
57	.	O

1	Dry	O
2	matter	O
3	intake	O
4	,	O
5	apparent	O
6	nutrient	O
7	digestibilities	O
8	,	O
9	serum	O
10	chemistry	O
11	profiles	O
12	,	O
13	sphingolipid	O
14	concentrations	O
15	,	O
16	and	O
17	persistency	O
18	of	O
19	FB1	O
20	in	O
21	tissues	O
22	were	O
23	evaluated	O
24	.	O

1	The	O
2	differential	O
3	investigation	O
4	of	O
5	lipoproteins	O
6	,	O
7	however	O
8	,	O
9	showed	O
10	that	O
11	the	O
12	high	O
13	-	O
14	density	O
15	lipoprotein	O
16	(	O
17	HDL	O
18	)	O
19	fractions	O
20	are	O
21	absolutely	B
22	or	I
23	relatively	I
24	decreased	O
25	with	B
26	respect	I
27	to	I
28	low	O
29	-	O
30	density	O
31	lipoproteins	O
32	(	O
33	LDL	O
34	)	B
35	in	I
36	cerebral	I
37	infarcts	I
38	and	I
39	in	O
40	transient	O
41	ischaemic	O
42	attacks	O
43	.	O

1	Psychiatry	O
2	and	O
3	the	O
4	skin	O
5	.	O

1	To	O
2	begin	O
3	to	O
4	characterize	O
5	the	O
6	role	O
7	of	O
8	the	O
9	RNA	O
10	subunits	O
11	in	O
12	enzyme	B
13	function	I
14	and	I
15	substrate	I
16	specificity	I
17	,	O
18	we	O
19	swapped	O
20	two	O
21	hairpin	O
22	structures	O
23	(	O
24	MRP3	O
25	and	O
26	P3	O
27	)	O
28	between	B
29	RNase	O
30	MRP	O
31	RNA	O
32	and	O
33	RNase	O
34	P	O
35	RNA	O
36	of	O
37	S	O
38	.	O
39	cerevisiae	O
40	.	O

1	PULSE	O
2	is	O
3	used	O
4	to	O
5	set	O
6	such	O
7	NMR	O
8	spectroscopic	O
9	parameters	O
10	as	O
11	the	O
12	delay	O
13	and	O
14	duration	O
15	of	O
16	rf	O
17	transmit	O
18	and	O
19	receive	O
20	gates	O
21	,	O
22	rf	O
23	phase	O
24	,	O
25	sampling	O
26	times	O
27	,	O
28	and	O
29	such	O
30	imaging	O
31	parameters	O
32	as	O
33	rf	O
34	pulse	O
35	shape	O
36	and	O
37	gradient	O
38	waveforms	O
39	.	O

1	Blood	O
2	pressure	O
3	also	O
4	was	O
5	increased	O
6	by	O
7	lidocaine	O
8	(	O
9	6	O
10	mg	O
11	kg	O
12	-	O
13	1	O
14	).	O

1	Of	O
2	202	O
3	initially	O
4	seronegative	O
5	caretakers	O
6	(	O
7	observed	O
8	for	O
9	an	O
10	average	O
11	of	O
12	305	O
13	days	O
14	per	O
15	woman	O
16	),	O
17	19	O
18	seroconverted	O
19	,	O
20	for	O
21	an	O
22	annual	O
23	seroconversion	O
24	rate	O
25	of	O
26	11	O
27	percent	O
28	.	O

1	(	O
2	2	O
3	)	O
4	The	O
5	inappropriateness	O
6	of	O
7	adaptive	O
8	segmentation	O
9	for	O
10	the	O
11	isolation	O
12	of	O
13	spikes	O
14	and	O
15	sharp	O
16	waves	O
17	,	O
18	which	O
19	had	O
20	been	O
21	anticipated	O
22	in	O
23	view	O
24	of	O
25	the	O
26	short	O
27	duration	O
28	of	O
29	such	O
30	transients	O
31	in	O
32	relation	O
33	to	O
34	the	O
35	length	O
36	of	O
37	the	O
38	window	O
39	(	O
40	1	O
41	.	O
42	2	O
43	sec	O
44	)	O
45	used	O
46	for	O
47	the	O
48	autocorrelation	O
49	functions	O
50	employed	O
51	in	O
52	the	O
53	segmentation	O
54	algorithm	O
55	,	O
56	was	O
57	confirmed	O
58	.	O

1	(	O
2	iv	O
3	)	O
4	Although	O
5	UCRBP	O
6	has	O
7	been	O
8	previously	O
9	shown	O
10	to	O
11	act	O
12	as	O
13	a	O
14	transcriptional	O
15	repressor	O
16	,	O
17	we	O
18	show	O
19	here	B
20	that	I
21	UCRBP	I
22	can	O
23	also	O
24	act	O
25	as	O
26	a	O
27	positive	O
28	transactivator	B
29	of	I
30	a	O
31	reporter	B
32	driven	I
33	by	I
34	UCR	I
35	elements	O
36	when	O
37	used	O
38	in	O
39	co	O
40	-	O
41	transfection	O
42	assays	O
43	.	O

1	Minor	O
2	initiation	O
3	sites	O
4	were	O
5	found	O
6	at	B
7	positions	I
8	-	I
9	128	I
10	,	I
11	-	I
12	111	O
13	,	O
14	-	O
15	91	O
16	,	O
17	and	O
18	-	O
19	74	O
20	.	O

1	Lower	O
2	extremity	B
3	weight	I
4	bearing	I
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O

1	Effects	O
2	of	O
3	early	O
4	monocular	O
5	deprivation	O
6	on	O
7	development	O
8	of	O
9	cortico	O
10	-	O
11	geniculate	O
12	projections	O
13	in	O
14	the	O
15	cat	O
16	.	O

1	Splicing	O
2	of	O
3	the	O
4	K	O
5	-	O
6	SAM	O
7	alternative	O
8	exon	O
9	of	O
10	the	O
11	fibroblast	O
12	growth	O
13	factor	O
14	receptor	O
15	2	O
16	gene	O
17	is	O
18	heavily	O
19	dependent	O
20	on	O
21	the	O
22	U	O
23	-	O
24	rich	O
25	sequence	O
26	IAS1	O
27	lying	O
28	immediately	O
29	downstream	O
30	from	O
31	its	O
32	5	O
33	'	O
34	splice	O
35	site	O
36	.	O

1	Tonometry	O
2	of	O
3	blood	O
4	samples	O
5	from	O
6	patients	O
7	may	O
8	also	O
9	be	O
10	used	O
11	in	O
12	the	O
13	determination	O
14	of	O
15	acid	O
16	-	O
17	base	O
18	quantities	O
19	and	O
20	hemoglobin	O
21	-	O
22	oxygen	O
23	affinity	O
24	e	O
25	.	O
26	g	O
27	.	O
28	p50	O
29	.	O

1	Substitution	O
2	of	O
3	the	O
4	Ser	O
5	-	O
6	Thr	O
7	sites	O
8	with	O
9	the	O
10	phosphomimetic	O
11	Asp	O
12	generated	O
13	a	O
14	constitutively	O
15	active	O
16	form	O
17	of	O
18	IRF	O
19	-	O
20	3	O
21	that	O
22	functioned	O
23	as	O
24	a	O
25	very	O
26	strong	O
27	activator	O
28	of	O
29	promoters	O
30	containing	O
31	PRDI	O
32	-	O
33	PRDIII	O
34	or	O
35	ISRE	O
36	regulatory	O
37	elements	O
38	.	O

1	The	O
2	Aie1	O
3	locus	O
4	was	O
5	mapped	O
6	to	O
7	mouse	O
8	chromosome	O
9	7A2	O
10	-	O
11	A3	O
12	by	O
13	fluorescent	O
14	in	O
15	situ	O
16	hybridization	O
17	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	mammalian	O
6	erythroid	B
7	alpha	I
8	-	I
9	spectrin	I
10	evolved	I
11	by	I
12	duplication	O
13	and	O
14	rapid	O
15	divergence	O
16	from	O
17	an	O
18	ancestral	O
19	alpha	O
20	-	B
21	fodrin	I
22	-	I
23	like	I
24	gene	I
25	.	I

1	There	O
2	are	O
3	regions	O
4	with	O
5	long	O
6	runs	O
7	of	O
8	up	O
9	to	O
10	45	O
11	%	O
12	C	O
13	or	O
14	35	O
15	%	O
16	G	O
17	residues	O
18	.	O

1	A	O
2	soluble	O
3	62	O
4	-	O
5	kDa	O
6	protein	O
7	was	O
8	produced	O
9	without	O
10	the	O
11	proteolytic	O
12	processing	O
13	by	O
14	inserting	O
15	the	O
16	coding	O
17	sequence	O
18	of	O
19	amino	O
20	acids	O
21	112	O
22	to	O
23	660	O
24	of	O
25	ORF	O
26	-	O
27	2	O
28	in	O
29	a	O
30	baculovirus	O
31	expression	O
32	vector	O
33	and	O
34	using	O
35	the	O
36	corresponding	O
37	virus	O
38	to	O
39	infect	O
40	Sf9	O
41	cells	O
42	.	O

1	Overexpression	O
2	of	O
3	ICBP90	O
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	B
17	topoisomerase	I
18	IIalpha	I
19	.	I

1	5	O
2	microU	O
3	/	O
4	l	O
5	thyrotropin	B
6	:	I
7	75	I
8	%	O
9	(	O
10	1974	O
11	),	O
12	45	B
13	%	I
14	(	I
15	1977	I
16	)	I
17	and	I
18	20	I
19	%	I
20	(	O
21	1980	O
22	).	O

1	Studies	O
2	in	O
3	mammalian	O
4	cells	O
5	have	B
6	correlated	I
7	induction	I
8	of	I
9	inhibitory	I
10	tyrosine	I
11	15	I
12	(	I
13	Y15	O
14	)	O
15	phosphorylation	O
16	on	B
17	p34cdc2	O
18	with	O
19	the	O
20	response	I
21	to	O
22	DNA	I
23	damage	I
24	.	I

1	Modification	O
2	of	O
3	the	O
4	growth	O
5	of	O
6	Tetrahymena	O
7	by	O
8	compounds	O
9	which	O
10	affect	O
11	the	O
12	adrenergic	O
13	mechanism	O
14	.	O

1	The	O
2	controversy	O
3	of	O
4	significance	O
5	testing	O
6	:	O
7	misconceptions	O
8	and	O
9	alternatives	O
10	.	O

1	Significant	O
2	clinical	O
3	differences	O
4	between	O
5	the	O
6	patients	O
7	treated	O
8	with	O
9	and	O
10	without	O
11	AMB	B
12	were	I
13	longer	I
14	survival	I
15	time	O
16	following	B
17	diagnosis	B
18	of	O
19	illness	O
20	(	B
21	P	I
22	less	O
23	than	B
24	0	I
25	.	I
26	05	O
27	)	O
28	and	O
29	more	O
30	frequent	O
31	cranial	O
32	nerve	O
33	signs	O
34	in	O
35	the	O
36	treated	O
37	patients	O
38	(	O
39	P	O
40	=	O
41	0	O
42	.	O
43	089	O
44	).	O

1	The	O
2	negative	O
3	predictive	O
4	value	O
5	is	O
6	92	O
7	%,	B
8	vs	I
9	80	I
10	%	I
11	for	O
12	the	O
13	NCEP	O
14	I	O
15	.	O

1	We	O
2	reviewed	O
3	the	O
4	records	O
5	of	O
6	151	O
7	patients	O
8	with	O
9	optic	O
10	neuritis	O
11	examined	O
12	over	O
13	an	O
14	eight	O
15	-	O
16	year	O
17	period	O
18	.	O

1	The	O
2	mutations	O
3	did	O
4	not	O
5	affect	O
6	the	O
7	repression	O
8	of	O
9	CPA1	O
10	by	O
11	arginine	O
12	.	O

1	The	O
2	use	O
3	of	O
4	this	O
5	model	O
6	for	O
7	investigating	O
8	pathophysiologically	O
9	significant	O
10	issues	O
11	in	O
12	denervating	O
13	diseases	O
14	is	O
15	illustrated	O
16	with	O
17	five	O
18	different	O
19	sets	O
20	of	O
21	parameters	O
22	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	depletion	O
7	of	O
8	protein	O
9	kinase	O
10	C	O
11	by	O
12	long	O
13	-	O
14	term	O
15	treatment	O
16	of	O
17	B16	O
18	mouse	O
19	melanoma	O
20	cells	O
21	with	O
22	phorbol	O
23	dibutyrate	O
24	(	O
25	PDBu	O
26	)	O
27	prevented	O
28	cell	O
29	density	O
30	-	O
31	dependent	O
32	melanogenesis	O
33	.	O

1	Estrogen	O
2	treatment	O
3	in	O
4	high	O
5	doses	O
6	is	O
7	effective	O
8	in	O
9	reducing	O
10	adult	O
11	stature	O
12	in	O
13	constitutionally	O
14	tall	O
15	girls	O
16	.	O

1	Calmodulin	O
2	-	B
3	binding	I
4	peptide	I
5	(	I
6	CBP	I
7	),	I
8	a	O
9	peptide	O
10	of	O
11	26	O
12	amino	O
13	acids	O
14	derived	O
15	from	O
16	muscle	O
17	myosin	O
18	light	O
19	chain	O
20	kinase	O
21	(	B
22	MLCK	I
23	),	I
24	binds	I
25	to	I
26	calmodulin	I
27	with	I
28	nanomolar	O
29	affinity	O
30	.	O

1	Expansins	O
2	are	O
3	a	O
4	family	O
5	of	O
6	proteins	O
7	that	O
8	catalyse	O
9	long	O
10	-	B
11	term	I
12	extension	I
13	of	I
14	isolated	O
15	plant	O
16	cell	O
17	walls	O
18	due	O
19	to	O
20	an	O
21	as	O
22	yet	O
23	unknown	O
24	biochemical	O
25	mechanism	O
26	.	O

1	Dilutions	O
2	of	O
3	H	O
4	-	O
5	2b	B
6	or	I
7	H	O
8	-	O
9	2d	O
10	NP	O
11	peptides	O
12	indicated	O
13	that	O
14	3	O
15	-	O
16	4	O
17	logs	O
18	less	O
19	H	O
20	-	O
21	2b	O
22	NP	O
23	peptide	O
24	was	B
25	required	B
26	to	I
27	sensitize	I
28	syngeneic	O
29	target	O
30	cells	O
31	for	O
32	CTL	O
33	-	O
34	specific	O
35	lysis	O
36	,	O
37	suggesting	O
38	that	O
39	the	O
40	differing	O
41	affinities	O
42	of	O
43	H	O
44	-	O
45	2b	O
46	and	O
47	H	O
48	-	O
49	2d	O
50	major	O
51	histocompatibility	O
52	complex	O
53	molecules	O
54	for	O
55	their	O
56	peptides	O
57	likely	B
58	account	I
59	for	O
60	the	O
61	total	O
62	removal	O
63	of	O
64	NP	O
65	CTL	O
66	in	O
67	the	O
68	H	O
69	-	O
70	2b	O
71	mice	O
72	but	O
73	only	O
74	partial	O
75	removal	O
76	in	O
77	H	O
78	-	O
79	2d	O
80	mice	O
81	made	O
82	to	O
83	express	O
84	thymic	O
85	NP	O
86	.	O

1	Teratogenic	O
2	effects	O
3	of	O
4	actinomycin	O
5	D	O
6	in	O
7	rats	O

1	In	O
2	this	O
3	report	B
4	,	I
5	we	I
6	describe	I
7	the	I
8	characterization	I
9	of	I
10	two	I
11	early	I
12	class	I
13	II	I
14	flagellar	I
15	genes	I
16	contained	I
17	in	O
18	the	B
19	orfX	I
20	-	I
21	fliP	O
22	locus	O
23	.	O

1	This	O
2	study	O
3	utilizes	O
4	the	O
5	mammalian	O
6	two	O
7	-	O
8	hybrid	O
9	system	O
10	to	O
11	examine	O
12	the	O
13	role	O
14	of	O
15	ligand	O
16	in	O
17	the	O
18	dimerization	O
19	of	O
20	human	O
21	progesterone	O
22	receptor	O
23	(	O
24	hPR	O
25	).	O

1	Behavioral	O
2	and	O
3	electrographic	O
4	expression	O
5	of	O
6	natural	O
7	sleep	O
8	and	O
9	wakefulness	O
10	in	O
11	reptiles	O

1	The	O
2	relationships	O
3	among	O
4	blood	O
5	concentrations	O
6	of	O
7	thyroid	O
8	hormones	O
9	and	O
10	selenium	O
11	,	O
12	zinc	O
13	,	O
14	retinol	O
15	,	O
16	and	O
17	alpha	O
18	-	O
19	tocopherol	O
20	were	O
21	studied	O
22	in	O
23	44	O
24	healthy	O
25	Northern	O
26	Italian	O
27	oldest	O
28	-	O
29	old	O
30	subjects	O
31	(	O
32	age	O
33	range	O
34	,	O
35	90	O
36	-	O
37	107	O
38	yr	O
39	),	O
40	selected	O
41	by	O
42	the	O
43	criteria	O
44	of	O
45	the	O
46	SENIEUR	O
47	protocol	O
48	.	O

1	In	O
2	vitro	O
3	translation	O
4	of	O
5	the	O
6	mTRF1	O
7	cDNA	O
8	resulted	O
9	in	O
10	a	O
11	56	O
12	kDa	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	TTAGGG	O
18	repeat	O
19	arrays	O
20	.	O
21	mTRF1	O
22	displayed	O
23	the	O
24	same	O
25	sequence	O
26	specificity	O
27	as	O
28	hTRF1	O
29	,	O
30	preferring	O
31	arrays	O
32	of	O
33	TTAGGG	O
34	repeats	O
35	as	O
36	a	O
37	binding	O
38	substrate	O
39	over	O
40	TTAGGC	O
41	and	O
42	TTGGGG	O
43	repeats	O
44	.	O

1	In	O
2	gel	O
3	retardation	O
4	assays	O
5	,	O
6	an	O
7	RCS	O
8	cell	O
9	-	O
10	specific	O
11	protein	O
12	and	O
13	another	O
14	closely	B
15	related	I
16	protein	I
17	expressed	I
18	only	O
19	in	O
20	RCS	O
21	cells	O
22	and	O
23	primary	O
24	chondrocytes	O
25	bound	O
26	to	O
27	a	O
28	10	O
29	-	O
30	bp	O
31	sequence	O
32	within	O
33	the	O
34	18	O
35	-	O
36	mer	O
37	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	the	O
6	GAL7	O
7	5	O
8	'	O
9	flanking	O
10	region	O
11	has	O
12	many	O
13	features	O
14	common	O
15	to	O
16	those	O
17	of	O
18	multicellular	O
19	eukaryotic	O
20	genes	O
21	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	RA	O
6	and	O
7	E1A	O
8	induce	O
9	phosphorylation	O
10	of	O
11	the	O
12	E1A	O
13	-	B
14	associated	O
15	300	O
16	kDa	O
17	protein	O
18	(	O
19	p300	O
20	)	O
21	during	O
22	the	O
23	differentiation	O
24	of	O
25	F9	O
26	cells	O
27	.	O

1	Furthermore	O
2	,	O
3	microinjection	O
4	of	O
5	dominant	O
6	negative	O
7	forms	O
8	of	O
9	Rac	B
10	and	I
11	Cdc42	I
12	or	O
13	of	O
14	the	O
15	Rho	O
16	inhibitor	O
17	C3	O
18	transferase	O
19	blocked	O
20	serum	O
21	-	O
22	induced	O
23	DNA	O
24	synthesis	O
25	.	O

1	The	O
2	results	O
3	also	O
4	imply	O
5	that	O
6	the	O
7	absence	O
8	of	O
9	perforin	O
10	expression	O
11	in	O
12	non	O
13	-	O
14	cytotoxic	O
15	cells	O
16	may	O
17	be	O
18	due	O
19	to	O
20	the	O
21	suppression	O
22	of	O
23	the	O
24	induction	O
25	of	O
26	the	O
27	killer	O
28	-	O
29	cell	O
30	-	O
31	specific	O
32	trans	O
33	-	O
34	acting	O
35	factor	O
36	NF	O
37	-	O
38	P2	O
39	.	O

1	The	O
2	3	O
3	.	O
4	3	O
5	-	O
6	fold	O
7	higher	O
8	expression	O
9	in	O
10	the	O
11	fetal	O
12	heart	O
13	than	O
14	in	O
15	the	O
16	adult	O
17	heart	O
18	suggests	O
19	that	O
20	HFHZ	O
21	mRNA	O
22	is	O
23	downregulated	O
24	in	O
25	the	O
26	process	O
27	of	O
28	development	O
29	.	O

1	No	O
2	difference	O
3	in	O
4	percentage	O
5	of	O
6	males	O
7	in	O
8	semen	O
9	production	O
10	was	O
11	noted	O
12	between	O
13	strains	O
14	,	O
15	CP	O
16	levels	O
17	,	O
18	or	O
19	feeding	O
20	regimens	O
21	.	O

1	GR63178A	O
2	is	B
3	a	I
4	water	I
5	-	I
6	soluble	O
7	analogue	O
8	of	O
9	mitoquidone	O
10	,	O
11	a	O
12	pentacyclic	O
13	pyrroloquinone	O
14	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	,	O
6	by	O
7	screening	O
8	a	O
9	lambda	O
10	gt11	O
11	expression	O
12	library	O
13	,	O
14	murine	O
15	protein	O
16	mXBP	O
17	,	O
18	which	O
19	binds	O
20	to	O
21	a	O
22	sequence	O
23	which	O
24	overlaps	O
25	the	O
26	3	O
27	'	O
28	end	O
29	of	O
30	the	O
31	murine	O
32	class	O
33	II	O
34	major	O
35	histocompatibility	O
36	complex	O
37	A	O
38	alpha	O
39	gene	O
40	X	O
41	box	O
42	,	O
43	a	O
44	conserved	O
45	transcription	O
46	element	O
47	found	O
48	upstream	O
49	of	O
50	all	O
51	class	O
52	II	O
53	genes	O
54	.	O

1	Valuing	O
2	families	O
3	:	O
4	social	O
5	work	O
6	practice	O
7	with	O
8	families	O
9	from	O
10	a	O
11	strengths	O
12	perspective	O
13	.	O

1	Two	O
2	other	O
3	patients	O
4	underwent	O
5	PRFR	O
6	.	O

1	RNA	O
2	blot	O
3	hybridizations	O
4	identified	O
5	an	O
6	1	O
7	.	O
8	8	O
9	-	O
10	kb	O
11	mRNA	O
12	common	O
13	to	O
14	cytochrome	O
15	b6	O
16	and	O
17	subunit	O
18	IV	O
19	,	O
20	and	O
21	an	O
22	intensely	O
23	hybridizing	O
24	0	O
25	.	O
26	8	O
27	-	O
28	kb	O
29	mRNA	O
30	specific	O
31	to	O
32	the	O
33	subunit	O
34	IV	O
35	gene	O
36	probe	O
37	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	the	O
7	structure	O
8	of	O
9	the	B
10	Spec1	I
11	gene	I
12	in	I
13	the	O
14	sea	O
15	urchin	O
16	Strongylocentrotus	B
17	purpuratus	I
18	.	I

1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O

1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	O
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O

1	The	O
2	hypothesis	B
3	of	B
4	Geisler	I
5	(	O
6	Brain	B
7	Res	I
8	.	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	O
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	Problems	O
2	remain	O
3	to	O
4	be	O
5	resolved	O
6	in	O
7	the	O
8	area	O
9	of	O
10	quantitative	O
11	risk	O
12	assessment	O
13	.	O

1	Therapeutic	O
2	use	B
3	of	I
4	continuous	O
5	subcutaneous	O
6	infusion	O
7	of	O
8	recombinant	O
9	human	O
10	erythropoietin	O
11	in	O
12	malnourished	O
13	predialysis	O
14	anemic	O
15	patients	O
16	with	O
17	diabetic	O
18	nephropathy	O
19	.	O

1	A	O
2	portion	O
3	of	O
4	p193	O
5	is	O
6	nuclear	O
7	and	O
8	localizes	O
9	to	O
10	the	O
11	mitotic	O
12	spindle	O
13	.	O

1	The	O
2	17	O
3	-	O
4	kDa	O
5	protein	O
6	is	O
7	required	O
8	for	O
9	the	O
10	systemic	O
11	infection	O
12	of	O
13	plants	O
14	.	O

1	A	O
2	dose	O
3	-	O
4	dependent	O
5	fall	O
6	in	O
7	GABA	O
8	content	O
9	was	O
10	observed	O
11	;	O
12	GABA	O
13	decrease	O
14	was	O
15	evident	O
16	15	O
17	min	O
18	after	O
19	the	O
20	administration	O
21	,	B
22	reached	I
23	its	I
24	nadir	I
25	at	I
26	60	O
27	min	B
28	and	I
29	disappeared	I
30	at	O
31	120	O
32	minutes	O
33	.	O

1	To	O
2	characterize	O
3	the	O
4	expression	O
5	of	O
6	this	O
7	DNA	O
8	repair	O
9	enzyme	O
10	,	O
11	we	O
12	have	O
13	isolated	O
14	the	O
15	corresponding	O
16	genomic	O
17	clone	O
18	.	O

1	Most	O
2	other	O
3	end	O
4	points	O
5	were	O
6	highly	O
7	significant	O
8	,	O
9	and	O
10	death	O
11	,	O
12	which	O
13	was	O
14	monitored	O
15	across	O
16	the	O
17	U	O
18	.	O
19	S	O
20	.	O
21	program	O
22	,	O
23	was	O
24	different	O
25	with	O
26	p	O
27	<	O
28	0	O
29	.	O
30	0001	O
31	.	O

1	Findings	O
2	of	O
3	positive	O
4	potentials	O
5	showed	O
6	that	O
7	N1	O
8	originated	O
9	in	O
10	the	O
11	area	O
12	of	O
13	ventral	O
14	gray	O
15	matter	O
16	through	O
17	the	O
18	ventro	O
19	-	O
20	lateral	O
21	column	O
22	and	O
23	N2	O
24	through	O
25	the	O
26	dorsal	O
27	column	O
28	.	O

1	Biochemical	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	BJ1	O
7	protein	O
8	is	O
9	associated	O
10	with	O
11	nucleosomes	O
12	and	O
13	is	O
14	released	O
15	from	O
16	chromatin	O
17	by	O
18	agents	O
19	which	O
20	intercalate	O
21	into	O
22	DNA	O
23	,	O
24	as	O
25	previously	O
26	shown	B
27	for	I
28	the	I
29	high	I
30	mobility	I
31	group	I
32	proteins	O
33	(	B
34	HMGs	I
35	).	O

1	In	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	the	B
7	upstream	O
8	portion	I
9	of	O
10	the	B
11	delta	O
12	promoter	I
13	led	O
14	to	B
15	a	O
16	10	I
17	fold	O
18	decrease	O
19	in	O
20	expression	O
21	.	O

1	The	O
2	spleen	O
3	rate	O
4	of	O
5	about	O
6	600	B
7	villagers	I
8	of	I
9	RK	I
10	I	O
11	examined	O
12	was	O
13	54	O
14	.	B
15	3	I
16	%	I
17	and	I
18	the	I
19	parasite	I
20	rate	O
21	13	O
22	.	B
23	2	I
24	%	I
25	before	O
26	the	B
27	drug	I
28	intervention	O
29	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	human	O
7	I	O
8	-	O
9	mfa	O
10	domain	O
11	-	O
12	containing	O
13	protein	O
14	that	O
15	differently	O
16	regulates	O
17	human	O
18	T	O
19	-	O
20	cell	O
21	leukemia	O
22	virus	O
23	type	O
24	I	O
25	and	O
26	HIV	O
27	-	O
28	1	O
29	expression	O
30	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	GATA	O
6	-	O
7	5	O
8	may	O
9	have	O
10	specific	O
11	downstream	O
12	targets	O
13	and	O
14	that	O
15	GATA	O
16	-	O
17	4	O
18	,	O
19	-	O
20	5	O
21	,	O
22	and	O
23	-	O
24	6	O
25	can	O
26	only	O
27	partially	O
28	substitute	O
29	for	O
30	each	O
31	other	O
32	in	O
33	cardiogenesis	O
34	.	O

1	None	O
2	of	O
3	the	O
4	patients	O
5	was	O
6	obese	O
7	.	O

1	66	O
2	:	O
3	469	O
4	-	O
5	479	O
6	,	O
7	1992	O
8	).	O

1	According	O
2	to	B
3	the	I
4	published	I
5	sequence	I
6	of	I
7	the	O
8	CHS1	O
9	gene	O
10	,	O
11	this	O
12	fragment	O
13	contains	O
14	four	O
15	repeats	O
16	of	O
17	a	O
18	TGAAACA	O
19	consensus	B
20	sequence	I
21	previously	I
22	identified	I
23	in	I
24	the	I
25	alpha	I
26	-	O
27	factor	O
28	-	O
29	inducible	O
30	BAR1	O
31	promoter	O
32	[	O
33	Kronstad	O
34	,	O
35	J	B
36	.	I

1	Oculus	O
2	-	O
3	500	O
4	is	O
5	a	O
6	group	O
7	of	O
8	high	O
9	resolution	O
10	imaging	O
11	boards	O
12	for	O
13	use	B
14	with	I
15	IBM	I
16	-	I
17	AT	O
18	and	O
19	compatible	O
20	computers	O
21	.	O

1	We	O
2	propose	O
3	that	O
4	plasmids	O
5	of	O
6	the	O
7	pLS1	O
8	family	O
9	(	O
10	pE194	O
11	,	B
12	pADB201	I
13	,	I
14	and	I
15	pLB4	I
16	)	I
17	share	O
18	functional	O
19	and	O
20	structural	O
21	characteristics	O
22	for	O
23	the	O
24	regulation	O
25	of	O
26	their	O
27	copy	O
28	numbers	O
29	.	O

1	Elevated	O
2	maternal	O
3	alpha	O
4	fetoproteins	O
5	and	O
6	oligoamnios	O
7	:	O
8	fetal	B
9	prognosis	I

1	The	O
2	clinical	O
3	efficacy	O
4	rates	O
5	evaluated	O
6	in	O
7	151	O
8	cases	O
9	(	O
10	KS	O
11	-	O
12	R1	O
13	group	O
14	in	O
15	77	O
16	cases	O
17	,	O
18	oral	O
19	group	O
20	in	O
21	74	O
22	cases	O
23	)	O
24	on	O
25	standard	O
26	criteria	O
27	of	O
28	committee	O
29	members	O
30	were	O
31	88	O
32	.	O
33	3	O
34	%	O
35	for	O
36	the	O
37	KS	O
38	-	O
39	R1	O
40	group	O
41	and	O
42	86	O
43	.	O
44	5	O
45	%	O
46	for	O
47	the	O
48	oral	O
49	group	O
50	,	O
51	respectively	O
52	.	O

1	Internal	O
2	amino	O
3	acid	O
4	sequence	O
5	has	B
6	now	I
7	been	O
8	obtained	O
9	from	O
10	this	O
11	protein	B
12	which	I
13	shares	I
14	50	O
15	-	O
16	100	O
17	%	O
18	sequence	O
19	identity	O
20	with	O
21	sequences	O
22	encoded	O
23	by	O
24	mammalian	O
25	G	O
26	alpha	O
27	11	O
28	and	O
29	G	O
30	alpha	O
31	q	O
32	cDNAs	O
33	.	O

1	Furthermore	O
2	,	O
3	freezing	O
4	in	O
5	the	O
6	presence	O
7	of	O
8	bovine	O
9	lactalbumin	O
10	resulted	O
11	in	O
12	a	O
13	good	O
14	maintenance	O
15	of	B
16	the	I
17	cellular	I
18	viability	I
19	and	I
20	of	O
21	the	O
22	CCCD	O
23	heterogeneity	O
24	in	O
25	respect	B
26	to	I
27	fresh	I
28	cells	I
29	.	I

1	The	O
2	possibility	O
3	of	O
4	a	O
5	hereditary	O
6	disorder	O
7	leading	O
8	to	O
9	a	O
10	minor	O
11	defect	O
12	in	O
13	elastic	O
14	fibre	O
15	structure	O
16	which	O
17	could	O
18	be	O
19	responsible	O
20	for	O
21	the	O
22	spontaneous	O
23	lesions	O
24	is	O
25	discussed	O
26	.	O

1	However	O
2	,	O
3	cotransfection	B
4	studies	I
5	indicate	I
6	that	I
7	RVR	I
8	does	I
9	not	I
10	activate	O
11	transcription	O
12	when	O
13	this	O
14	hormone	O
15	response	B
16	element	I
17	is	I
18	linked	I
19	to	I
20	a	I
21	reporter	I
22	gene	O
23	but	O
24	rather	O
25	acts	O
26	as	O
27	a	O
28	potent	O
29	competitive	O
30	repressor	O
31	of	O
32	ROR	O
33	alpha	O
34	function	O
35	.	O

1	Rac	O
2	causes	O
3	uncapping	O
4	of	O
5	actin	B
6	filaments	I
7	(	I
8	F	I
9	-	I
10	actin	I
11	)	I
12	at	I
13	the	I
14	plus	I
15	-	I
16	ends	I
17	,	O
18	through	O
19	phosphatidylinositol	O
20	4	O
21	,	O
22	5	O
23	bisphosphate	O
24	(	B
25	PIP2	I
26	),	O
27	and	O
28	eventually	O
29	induces	O
30	membrane	O
31	ruffling	O
32	.	O

1	Detailed	O
2	analysis	O
3	of	O
4	alpha1	O
5	,	O
6	3GT	O
7	transcripts	O
8	revealed	O
9	two	O
10	major	O
11	alternative	O
12	splicing	O
13	patterns	O
14	in	O
15	the	O
16	5	O
17	'-	O
18	untranslated	O
19	region	O
20	(	O
21	5	O
22	'-	B
23	UTR	I
24	)	I
25	and	O
26	evidence	O
27	for	O
28	minor	O
29	splicing	O
30	activity	O
31	that	O
32	occurs	O
33	in	O
34	a	O
35	tissue	O
36	-	O
37	specific	O
38	manner	O
39	.	O

1	Moreover	O
2	,	B
3	we	I
4	found	I
5	that	I
6	cyclin	I
7	E	I
8	,	I
9	in	I
10	contrast	I
11	to	I
12	cyclin	I
13	D1	I
14	,	O
15	was	O
16	required	O
17	for	O
18	the	O
19	G1	O
20	/	O
21	S	O
22	transition	O
23	even	I
24	in	I
25	cells	I
26	lacking	I
27	retinoblastoma	O
28	protein	O
29	function	O
30	.	O

1	Intracellular	O
2	pH	O
3	,	O
4	H	O
5	ion	O
6	flux	O
7	and	O
8	H	O
9	ion	O
10	permeability	O
11	coefficient	O
12	in	O
13	bullfrog	O
14	toe	O
15	muscle	O
16	.	O

1	65	O
2	-	O
3	kilodalton	O
4	protein	O
5	phosphorylated	O
6	by	O
7	interleukin	O
8	2	O
9	stimulation	O
10	bears	O
11	two	O
12	putative	O
13	actin	O
14	-	O
15	binding	O
16	sites	O
17	and	O
18	two	O
19	calcium	O
20	-	O
21	binding	O
22	sites	O
23	.	O

1	These	O
2	elements	O
3	comprise	O
4	a	O
5	binding	O
6	site	O
7	for	O
8	Krox	O
9	proteins	O
10	,	O
11	one	O
12	for	O
13	nuclear	O
14	factor	O
15	1	O
16	,	O
17	an	O
18	octamer	O
19	motif	O
20	that	O
21	binds	O
22	POU	O
23	-	O
24	homeodomain	O
25	proteins	O
26	,	O
27	and	O
28	a	O
29	novel	O
30	TN	O
31	control	O
32	element	O
33	.	O

1	The	O
2	mutant	O
3	allele	O
4	of	O
5	the	O
6	alpha	O
7	1	O
8	-	O
9	tubulin	O
10	gene	O
11	was	O
12	designated	O
13	tua1	O
14	-	O
15	1	O
16	.	B

1	San	O
2	Martin	O
3	'	B
4	s	I
5	psychological	I
6	traits	I
7	coupled	I
8	to	I
9	his	I
10	work	I
11	with	I
12	masonic	O
13	lodges	O
14	that	O
15	allowed	O
16	him	O
17	to	B
18	display	I
19	his	I
20	abilities	I
21	as	I
22	strategist	O
23	and	B
24	political	I
25	ruler	I
26	.	I

1	The	O
2	correct	O
3	termination	O
4	of	O
5	retroviral	O
6	transcripts	O
7	at	O
8	the	O
9	3	O
10	'	O
11	LTR	O
12	R	O
13	/	O
14	U5	O
15	junction	O
16	is	O
17	primarily	O
18	dependent	O
19	on	O
20	the	O
21	canonical	O
22	AAUAAA	O
23	polyadenylation	O
24	signal	O
25	,	O
26	so	O
27	we	O
28	have	O
29	analyzed	O
30	the	O
31	effect	O
32	of	O
33	mutating	O
34	the	O
35	polyadenylation	O
36	signal	O
37	sequences	O
38	on	O
39	the	O
40	properties	O
41	of	O
42	a	O
43	selectable	O
44	murine	O
45	retroviral	O
46	vector	O
47	.	O

1	Although	O
2	differences	O
3	were	B
4	not	I
5	significant	I
6	,	I
7	infants	O
8	in	O
9	the	O
10	experimental	O
11	group	O
12	had	O
13	more	O
14	changes	O
15	in	O
16	the	O
17	intermittent	O
18	mandatory	O
19	ventilation	O
20	(	O
21	IMV	O
22	)	O
23	settings	O
24	during	O
25	transport	O
26	,	O
27	and	O
28	more	O
29	such	O
30	infants	O
31	arrived	O
32	at	B
33	the	B
34	receiving	O
35	hospital	O
36	with	B
37	acceptable	I
38	pH	B
39	and	B
40	PCO2	I
41	values	O
42	.	O

1	To	O
2	determine	O
3	whether	O
4	mononuclear	O
5	cell	O
6	secretory	O
7	products	O
8	contribute	O
9	to	O
10	the	O
11	changes	O
12	in	O
13	bone	O
14	turnover	O
15	that	O
16	characterize	O
17	the	O
18	development	O
19	of	B
20	postmenopausal	I
21	osteoporosis	I
22	,	I
23	we	I
24	evaluated	I
25	the	I
26	effects	I
27	of	O
28	oophorectomy	O
29	and	O
30	subsequent	O
31	estrogen	O
32	replacement	B
33	on	I
34	the	I
35	spontaneous	I
36	secretion	I
37	of	I
38	interleukin	I
39	1	I
40	(	O
41	IL	B
42	-	I
43	1	O
44	)	O
45	and	O
46	tumor	O
47	necrosis	O
48	factor	O
49	alpha	O
50	(	O
51	TNF	O
52	-	B
53	alpha	I
54	)	I
55	and	I
56	on	O
57	the	B
58	phytohemagglutinin	I
59	A	O
60	-	O
61	induced	O
62	secretion	O
63	of	O
64	granulocyte	O
65	-	O
66	macrophage	O
67	colony	O
68	-	O
69	stimulating	O
70	factor	O
71	(	B
72	GM	B
73	-	B
74	CSF	I
75	)	O
76	from	O
77	peripheral	I
78	blood	O
79	mononuclear	O
80	cells	O
81	.	O

1	Comparison	O
2	was	O
3	made	O
4	with	O
5	other	O
6	neuroradiological	O
7	imaging	O
8	modalities	O
9	including	O
10	CT	O
11	,	O
12	myelography	O
13	,	O
14	CT	O
15	ventriculography	O
16	,	O
17	and	O
18	CT	O
19	myelocisternography	O
20	.	O

1	FAK	O
2	localizes	O
3	to	O
4	sites	O
5	of	O
6	transmembrane	O
7	integrin	O
8	receptor	B
9	clustering	I
10	and	I
11	facilitates	I
12	intracellular	I
13	signaling	I
14	events	I
15	.	I

1	Blood	O
2	serum	O
3	erythropoietin	O
4	level	O
5	and	B
6	basic	I
7	hematological	I
8	indices	I
9	during	I
10	the	O
11	adaptation	B
12	of	I
13	healthy	I
14	newborn	I
15	infants	O

1	In	O
2	the	O
3	mouse	O
4	,	O
5	CtBP1	O
6	is	O
7	expressed	O
8	from	O
9	embryo	O
10	to	O
11	adult	O
12	,	O
13	but	O
14	CtBP2	O
15	is	O
16	mainly	O
17	expressed	O
18	during	O
19	embryogenesis	O
20	.	O

1	In	O
2	a	O
3	second	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	the	O
9	efficacy	O
10	of	O
11	PDC	O
12	/	O
13	HDC	O
14	Ac	O
15	was	O
16	evaluated	O
17	in	O
18	both	O
19	single	O
20	and	O
21	multiple	O
22	dose	O
23	regiments	O
24	.	O

1	Transient	O
2	expression	O
3	of	O
4	human	O
5	and	O
6	chicken	O
7	progesterone	O
8	receptors	O
9	does	O
10	not	O
11	support	O
12	alternative	O
13	translational	O
14	initiation	O
15	from	O
16	a	O
17	single	O
18	mRNA	O
19	as	O
20	the	O
21	mechanism	O
22	generating	O
23	two	O
24	receptor	O
25	isoforms	O
26	.	O

1	Expression	O
2	and	O
3	regulation	O
4	by	O
5	interferon	O
6	of	O
7	a	O
8	double	O
9	-	O
10	stranded	O
11	-	O
12	RNA	O
13	-	O
14	specific	O
15	adenosine	O
16	deaminase	O
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	O
27	deaminase	O
28	.	O

1	The	O
2	other	O
3	transmembrane	O
4	regions	O
5	as	O
6	well	O
7	as	O
8	the	B
9	nucleoplasmic	I
10	domain	I
11	are	I
12	not	I
13	required	I
14	for	O
15	sorting	O
16	.	B

1	Calcification	O
2	of	B
3	a	I
4	cariogenic	I
5	Streptococcus	I
6	and	I
7	of	O
8	Corynebacterium	B
9	(	I
10	Bacterionema	I
11	)	I
12	matruchotii	O
13	.	O

1	That	O
2	of	B
3	the	I
4	T2	I
5	gene	I
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	O
14	transcription	O
15	factor	O
16	SP1	O
17	,	O
18	but	O
19	no	O
20	TATA	B
21	or	I
22	CCAAT	I
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	O
42	T1	O
43	gene	O
44	.	O

1	Today	O
2	there	O
3	is	O
4	no	O
5	doubt	O
6	that	O
7	elevated	O
8	plasma	O
9	cholesterol	O
10	levels	O
11	should	O
12	be	O
13	lowered	O
14	first	O
15	by	O
16	dietary	O
17	modification	O
18	even	O
19	in	O
20	early	O
21	childhood	O
22	,	O
23	beginning	O
24	at	O
25	the	O
26	age	O
27	of	O
28	two	O
29	years	O
30	.	O

1	The	O
2	transcription	B
3	factor	B
4	AP	I
5	-	I
6	2	I
7	is	I
8	encoded	I
9	by	O
10	a	B
11	gene	I
12	located	I
13	on	I
14	chromosome	O
15	6	O
16	near	O
17	the	O
18	HLA	B
19	locus	I
20	.	I

1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	O
15	-	O
16	PAR	O
17	gene	O
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O

1	The	O
2	transport	O
3	of	O
4	a	O
5	genetically	B
6	engineered	I
7	chimeric	I
8	transmembrane	O
9	protein	O
10	connected	O
11	to	O
12	this	O
13	ER	O
14	leader	O
15	sequence	O
16	was	O
17	as	O
18	efficient	O
19	as	O
20	that	O
21	of	O
22	the	O
23	original	O
24	protein	O
25	from	O
26	which	O
27	the	O
28	ER	O
29	sequence	O
30	has	B
31	been	I
32	derived	I
33	.	O

1	These	O
2	results	O
3	imply	O
4	that	O
5	the	O
6	GCN3	O
7	product	O
8	can	O
9	promote	O
10	either	O
11	repression	O
12	or	O
13	activation	O
14	of	O
15	GCN4	O
16	expression	O
17	depending	O
18	on	O
19	amino	O
20	acid	O
21	availability	O
22	.	O

1	The	O
2	mean	O
3	change	O
4	in	O
5	HbA1	O
6	,	O
7	adjusted	O
8	for	O
9	the	O
10	initial	O
11	value	O
12	,	O
13	was	O
14	-	O
15	0	O
16	.	O
17	4	O
18	%	O
19	in	O
20	the	O
21	experimental	O
22	and	O
23	+	O
24	0	O
25	.	O
26	5	O
27	%	O
28	in	O
29	the	O
30	control	O
31	group	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	It	O
2	was	O
3	suggested	O
4	that	O
5	the	O
6	absence	O
7	of	O
8	pronounced	O
9	differences	O
10	between	O
11	conditions	O
12	may	B
13	have	I
14	been	I
15	due	I
16	to	I
17	the	I
18	complexity	I
19	of	I
20	the	I
21	task	O
22	or	I
23	the	O
24	type	O
25	of	O
26	prompts	O
27	employed	B
28	.	I

1	A	O
2	cluster	O
3	of	B
4	basic	I
5	amino	O
6	acids	B
7	,	I
8	KKKR	O
9	,	O
10	generated	B
11	by	I
12	joining	I
13	of	I
14	the	O
15	sequences	O
16	encoded	O
17	by	O
18	the	B
19	constitutive	I
20	exon	I
21	13	O
22	and	O
23	the	O
24	alternative	O
25	exon	O
26	16	O
27	,	O
28	is	O
29	necessary	O
30	for	O
31	the	O
32	nuclear	B
33	targeting	O
34	of	O
35	4	O
36	.	B
37	1H	O
38	,	O
39	as	B
40	demonstrated	B
41	by	O
42	site	B
43	-	O
44	directed	O
45	mutagenesis	O
46	analysis	B
47	.	I

1	Mn2	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	B
15	.	I

1	Group	O
2	psychometric	O
3	functions	O
4	for	O
5	listeners	O
6	with	O
7	hearing	O
8	loss	O
9	do	O
10	not	O
11	show	O
12	a	O
13	decrease	O
14	in	O
15	performance	O
16	at	O
17	the	O
18	largest	O
19	values	O
20	of	O
21	delta	O
22	f	O
23	included	O
24	in	O
25	this	O
26	study	O
27	.	O

1	A	O
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	They	O
2	were	O
3	checked	O
4	for	O
5	anti	O
6	-	O
7	HCV	O
8	(	O
9	anti	O
10	-	O
11	C100	O
12	-	O
13	3	O
14	)	O
15	with	O
16	HCV	O
17	EIA	O
18	kit	O
19	(	O
20	Abbott	O
21	Lab	O
22	.,	O
23	North	O
24	Chicago	O
25	,	O
26	IL	O
27	).	O

1	This	O
2	interaction	O
3	inhibits	O
4	the	O
5	histone	O
6	acetyltransferase	O
7	activity	O
8	of	O
9	p300	O
10	,	O
11	resulting	O
12	in	O
13	drastic	O
14	reduction	O
15	of	O
16	nucleosomal	O
17	histone	O
18	acetylation	O
19	and	O
20	alteration	O
21	of	O
22	chromatin	O
23	structure	O
24	.	O

1	The	O
2	csbA	B
3	fusion	I
4	was	I
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O

1	The	O
2	transcripts	O
3	were	O
4	equally	O
5	active	O
6	with	O
7	or	O
8	without	O
9	a	O
10	5	O
11	'	O
12	methylated	O
13	capstructure	O
14	as	O
15	expected	O
16	,	O
17	since	O
18	EMCV	O
19	-	O
20	RNA	O
21	is	O
22	one	O
23	of	O
24	the	O
25	mRNAs	O
26	capable	O
27	of	O
28	internal	O
29	initiation	O
30	.	O

1	Phylogenetic	O
2	analyses	O
3	of	O
4	19	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	6	O
10	related	O
11	protein	O
12	types	O
13	indicate	O
14	that	O
15	actin	O
16	-	O
17	associated	O
18	proteins	O
19	related	O
20	to	O
21	gelsolin	O
22	are	O
23	monophyletic	O
24	to	O
25	a	O
26	common	O
27	ancestor	O
28	and	O
29	include	O
30	flightless	O
31	proteins	O
32	.	O

1	Internal	O
2	modes	O
3	of	O
4	a	O
5	soliton	O
6	.	O

1	A	O
2	number	O
3	of	O
4	serological	O
5	tests	O
6	measuring	O
7	the	O
8	presence	O
9	of	O
10	Helicobacter	O
11	pylori	O
12	-	O
13	specific	O
14	serum	O
15	immunoglobulin	O
16	G	O
17	(	O
18	IgG	O
19	)	O
20	are	B
21	now	I
22	commercially	I
23	available	I
24	.	I

1	Because	O
2	L	O
3	-	O
4	plastin	O
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	B
12	both	I
13	humans	I
14	and	I
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	O
25	-	O
26	plastin	O
27	gene	O
28	expression	O
29	in	B
30	human	I
31	and	I
32	rodent	I
33	cells	I
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	B
43	function	I
44	and	I
45	nucleotide	I
46	sequences	I
47	of	O
48	the	O
49	human	B
50	and	B
51	murine	I
52	L	O
53	-	O
54	plastin	O
55	gene	O
56	promoters	O
57	.	O

1	Plethysmographic	O
2	technique	O
3	and	O
4	indirect	O
5	blood	O
6	pressure	B
7	recordings	I
8	were	O
9	used	O
10	.	O

1	As	O
2	a	O
3	consequence	O
4	of	O
5	dark	O
6	rearing	O
7	,	O
8	the	O
9	numerical	O
10	density	O
11	of	O
12	cortical	O
13	neurons	O
14	in	O
15	area	O
16	17	O
17	amounted	O
18	to	O
19	about	O
20	double	O
21	of	O
22	the	O
23	value	O
24	observed	O
25	in	O
26	normally	O
27	reared	O
28	kittens	O
29	and	O
30	was	O
31	also	O
32	significantly	O
33	higher	O
34	in	O
35	area	O
36	18	O
37	.	O

1	Complete	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	bacteriophage	O
7	K1F	O
8	tail	O
9	gene	O
10	encoding	O
11	endo	O
12	-	O
13	N	O
14	-	O
15	acylneuraminidase	O
16	(	O
17	endo	O
18	-	B
19	N	I
20	)	I
21	and	I
22	comparison	I
23	to	O
24	an	O
25	endo	O
26	-	O
27	N	O
28	homolog	O
29	in	O
30	bacteriophage	O
31	PK1E	O
32	.	O

1	Pharmacologic	O
2	properties	O
3	of	B
4	serotonergic	I
5	agents	I
6	and	O
7	antidepressant	O
8	drugs	O
9	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	promoter	O
7	for	O
8	the	O
9	cytotactin	O
10	gene	O
11	.	O

1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	O
6	protein	O
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O

1	Deletion	O
2	analysis	B
3	of	I
4	the	I
5	ICL1	I
6	promoter	I
7	led	I
8	to	I
9	the	I
10	identification	I
11	of	I
12	an	I
13	upstream	I
14	activating	I
15	sequence	O
16	element	B
17	,	I
18	UASICL1	I
19	(	I
20	5	I
21	'	O
22	CATTCATCCG	O
23	3	O
24	'),	O
25	necessary	O
26	and	O
27	sufficient	B
28	for	I
29	conferring	I
30	carbon	I
31	source	I
32	-	I
33	dependent	I
34	regulation	I
35	on	I
36	a	O
37	heterologous	O
38	reporter	O
39	gene	O
40	.	O

1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	B
13	i	I
14	.	I
15	v	I
16	.	I

1	Supplementation	O
2	was	O
3	stopped	O
4	when	O
5	pl	O
6	-	O
7	ALB	O
8	reached	O
9	2	O
10	.	O
11	0	O
12	g	O
13	/	O
14	dL	O
15	.	O

1	Abdominal	O
2	tumors	O
3	in	O
4	childhood	O
5	.	O

1	For	O
2	this	O
3	reason	B
4	,	B
5	the	I
6	particle	I
7	forming	O
8	capacity	B
9	of	I
10	derivatives	I
11	of	I
12	the	O
13	HIV	B
14	-	I
15	1	O
16	group	O
17	specific	O
18	core	O
19	antigen	O
20	p55	O
21	gag	O
22	was	O
23	assayed	O
24	and	O
25	compared	O
26	dependent	O
27	on	O
28	various	O
29	expression	B
30	systems	I
31	:	I
32	recombinant	I
33	bacteria	O
34	,	B
35	vaccinia	I
36	-	O
37	and	B
38	baculoviruses	I
39	were	I
40	established	I
41	encoding	I
42	the	I
43	entire	O
44	core	B
45	protein	I
46	p55	O
47	either	B
48	in	I
49	its	I
50	authentic	I
51	sequence	I
52	or	O
53	lacking	O
54	the	O
55	myristylation	O
56	consensus	O
57	signal	O
58	.	O

1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	O
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O

1	Therefore	O
2	the	O
3	prevalences	O
4	of	O
5	total	O
6	diabetes	O
7	and	O
8	GDM	O
9	were	O
10	1	O
11	.	O
12	19	O
13	%	O
14	and	O
15	0	O
16	.	O
17	56	O
18	%,	O
19	respectively	O
20	.	O

1	Here	O
2	,	O
3	we	O
4	identified	O
5	three	O
6	cis	O
7	-	O
8	elements	O
9	required	O
10	for	O
11	replication	O
12	within	O
13	the	O
14	200	O
15	bp	O
16	promoter	O
17	,	O
18	using	O
19	autonomously	O
20	replicating	O
21	plasmids	O
22	carrying	O
23	various	O
24	mutations	O
25	and	I
26	deletions	O
27	.	B

1	Its	O
2	organization	B
3	and	I
4	regulation	I
5	indicate	I
6	that	O
7	the	O
8	S	O
9	.	O
10	pombe	O
11	URA1	O
12	gene	O
13	product	O
14	appears	O
15	very	O
16	similar	O
17	to	O
18	the	O
19	S	O
20	.	O
21	cerevisiae	O
22	URA2	O
23	gene	O
24	product	O
25	.	O

1	Contrary	O
2	to	O
3	1	O
4	,	O
5	8	O
6	-	O
7	dihydroxy	O
8	-	O
9	9	O
10	-	O
11	anthrone	O
12	,	I
13	1	I
14	,	I
15	8	O
16	,	O
17	9	O
18	-	O
19	triacetoxyanthracene	O
20	and	B
21	1	I
22	,	I
23	8	O
24	-	O
25	diacetoxy	O
26	-	B
27	9	I
28	-	I
29	anthrone	I
30	are	O
31	effective	O
32	against	O
33	psoriatic	O
34	lesions	B
35	without	I
36	accompanying	I
37	inflammations	I
38	of	I
39	the	I
40	skin	O
41	.	O

1	However	O
2	,	O
3	primary	O
4	transcripts	B
5	of	I
6	a	I
7	variant	I
8	tRNA	I
9	(	I
10	Val	I
11	)(	O
12	UAC	O
13	)	O
14	gene	O
15	are	O
16	processing	O
17	deficient	O
18	under	O
19	standard	O
20	growth	O
21	conditions	O
22	(	O
23	30	B
24	degrees	I
25	C	I
26	),	O
27	due	O
28	to	O
29	a	O
30	slightly	O
31	altered	O
32	5	O
33	'	O
34	flanking	O
35	region	O
36	.	B

1	To	O
2	modulate	O
3	transcription	O
4	,	O
5	regulatory	O
6	factors	O
7	communicate	O
8	with	O
9	basal	O
10	transcription	O
11	factors	O
12	and	O
13	/	O
14	or	O
15	RNA	B
16	polymerases	B
17	in	I
18	a	I
19	variety	O
20	of	O
21	ways	O
22	.	O

1	Alveolar	O
2	growth	O
3	,	O
4	contemporary	O
5	with	O
6	dental	O
7	eruption	O
8	,	O
9	is	O
10	sufficient	O
11	to	O
12	compensate	O
13	possible	O
14	hypotrophy	O
15	of	O
16	maxillary	O
17	bone	O
18	bases	O
19	.	O

1	Selective	O
2	macrophage	O
3	inhibition	O
4	abolishes	O
5	warfarin	O
6	-	O
7	induced	O
8	reduction	O
9	of	O
10	metastasis	O
11	.	O

1	The	O
2	rationale	O
3	for	O
4	continuous	O
5	dopaminergic	O
6	stimulation	O
7	in	O
8	patients	O
9	with	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	.	O

1	The	O
2	mapping	O
3	was	O
4	completed	O
5	with	O
6	Southern	O
7	blotting	O
8	and	O
9	restriction	O
10	analysis	O
11	.	O

1	DATA	O
2	SOURCES	O
3	:	O
4	Epidemiologic	O
5	studies	O
6	,	O
7	research	O
8	studies	O
9	,	O
10	review	O
11	articles	O
12	,	O
13	and	O
14	government	O
15	reports	O
16	pertaining	O
17	to	O
18	epidemiology	O
19	of	O
20	lung	O
21	cancer	O
22	.	O

1	Thus	O
2	,	O
3	NART	O
4	-	O
5	R	O
6	performance	O
7	may	O
8	not	O
9	be	O
10	a	O
11	valid	B
12	estimate	O
13	of	O
14	baseline	O
15	IQ	O
16	for	O
17	patients	O
18	with	O
19	neurologic	O
20	disorders	O
21	with	O
22	suspected	O
23	language	O
24	impairment	O
25	.	O

1	Domains	O
2	I	O
3	and	O
4	II	O
5	of	O
6	B	O
7	"	O
8	are	O
9	buried	O
10	upon	O
11	assembly	O
12	of	O
13	the	O
14	TFIIIB	O
15	-	O
16	DNA	O
17	complex	O
18	,	O
19	as	O
20	determined	O
21	by	O
22	protein	O
23	footprinting	B
24	.	B

1	Furthermore	O
2	,	O
3	Rac1	O
4	activation	O
5	of	O
6	JNK	O
7	or	O
8	SRF	O
9	,	O
10	or	O
11	induction	O
12	of	O
13	lamellipodia	O
14	,	O
15	was	O
16	neither	O
17	necessary	O
18	nor	O
19	sufficient	O
20	for	O
21	Rac1	O
22	transforming	O
23	activity	O
24	.	O

1	Fifty	O
2	-	O
3	one	O
4	patients	O
5	with	O
6	primary	O
7	refractory	O
8	or	O
9	relapsed	O
10	malignant	O
11	lymphoma	O
12	(	O
13	47	O
14	non	B
15	-	I
16	Hodgkin	I
17	'	I
18	s	O
19	lymphoma	O
20	and	O
21	four	O
22	Hodgkin	O
23	'	O
24	s	O
25	disease	O
26	)	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	new	O
32	chemotherapeutic	O
33	regimen	O
34	(	O
35	cisplatinum	O
36	,	O
37	methyl	O
38	GAG	O
39	,	O
40	bleomocyin	O
41	,	O
42	methyl	O
43	prednisolon	O
44	).	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	was	O
6	determined	O
7	to	O
8	be	O
9	residues	O
10	716	O
11	-	O
12	724	O
13	and	O
14	hence	O
15	lysine	O
16	residue	O
17	721	O
18	is	O
19	located	O
20	within	O
21	the	O
22	ATP	O
23	-	O
24	binding	O
25	site	O
26	.	O

1	Behind	O
2	the	O
3	ATPase	O
4	cluster	O
5	,	O
6	two	O
7	open	O
8	reading	O
9	frames	O
10	were	O
11	detected	O
12	that	O
13	are	O
14	not	O
15	homologous	B
16	to	I
17	any	I
18	known	I
19	chloroplast	O
20	gene	O
21	.	O

1	The	O
2	triple	O
3	combination	O
4	of	O
5	nizatidine	O
6	,	O
7	clarithromycin	O
8	,	O
9	and	O
10	bismuth	O
11	subcitrate	O
12	resulted	O
13	in	O
14	an	O
15	ulcer	O
16	healing	O
17	rate	O
18	of	O
19	98	O
20	%	O
21	and	O
22	an	O
23	H	O
24	.	O
25	pylori	O
26	eradication	O
27	rate	O
28	of	O
29	90	O
30	%.	O

1	The	O
2	catenins	B
3	bind	I
4	to	I
5	APC	O
6	and	O
7	E	B
8	-	I
9	cadherin	I
10	in	I
11	a	I
12	similar	I
13	fashion	O
14	,	O
15	but	O
16	APC	O
17	and	O
18	E	O
19	-	O
20	cadherin	O
21	do	O
22	not	O
23	associate	O
24	with	O
25	each	O
26	other	O
27	either	O
28	in	B
29	the	I
30	presence	I
31	or	I
32	absence	I
33	of	I
34	catenins	I
35	.	I

1	Feed	O
2	intake	O
3	and	O
4	BW	O
5	gains	O
6	were	O
7	decreased	O
8	(	O
9	P	O
10	<	O
11	0	O
12	.	O
13	05	O
14	)	O
15	by	O
16	dietary	O
17	treatments	O
18	containing	O
19	M	O
20	.	O

1	Fifty	O
2	six	O
3	young	O
4	patients	O
5	(	O
6	age	O
7	<	O
8	45	B
9	yr	I
10	)	I
11	with	I
12	doppler	O
13	-	O
14	proven	O
15	DVT	O
16	were	O
17	investigated	O
18	for	O
19	the	O
20	presence	O
21	of	O
22	resistance	O
23	to	O
24	activated	O
25	protein	O
26	C	O
27	(	O
28	APC	O
29	-	O
30	R	O
31	),	O
32	lupus	O
33	anticoagulant	O
34	(	O
35	LA	O
36	),	O
37	anticardiolipin	O
38	antibodies	O
39	and	O
40	deficiencies	O
41	of	O
42	protein	O
43	C	O
44	,	O
45	protein	O
46	S	O
47	,	O
48	ATIII	O
49	activities	O
50	.	O

1	A	O
2	needs	O
3	assessment	O
4	of	O
5	these	O
6	families	O
7	was	O
8	also	O
9	done	O
10	.	O

1	The	O
2	authors	O
3	evaluated	O
4	the	O
5	potential	O
6	for	O
7	thrombotic	O
8	complications	O
9	arising	O
10	from	O
11	implantation	O
12	of	O
13	a	O
14	ventricular	O
15	assist	O
16	device	O
17	(	O
18	Sarns	O
19	/	O
20	3M	O
21	-	O
22	VAD	O
23	)	O
24	in	O
25	four	O
26	calves	O
27	.	O

1	Pathogenetic	O
2	relationships	O
3	between	O
4	renal	O
5	tubular	O
6	acidosis	O
7	and	O
8	sodium	O
9	metabolism	O
10	alterations	O
11	in	O
12	liver	O
13	cirrhosis	O
14	.	O

1	Human	O
2	papillomavirus	O
3	type	O
4	31b	O
5	late	O
6	gene	O
7	expression	O
8	is	O
9	regulated	O
10	through	O
11	protein	O
12	kinase	O
13	C	O
14	-	O
15	mediated	O
16	changes	O
17	in	O
18	RNA	O
19	processing	O
20	.	O

1	However	O
2	,	B
3	the	I
4	relative	I
5	binding	I
6	affinity	I
7	for	I
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O

1	The	O
2	results	O
3	presented	O
4	in	O
5	this	O
6	report	O
7	suggest	O
8	that	O
9	the	O
10	SV40	O
11	G	O
12	-	O
13	C	O
14	-	O
15	rich	O
16	sequences	O
17	can	O
18	function	O
19	as	O
20	independent	O
21	RNA	O
22	polymerase	O
23	II	O
24	transcriptional	O
25	-	O
26	control	O
27	elements	O
28	.	O

1	Hypersplenism	O

1	Identical	O
2	components	O
3	of	O
4	yeast	O
5	transcription	O
6	factor	O
7	IIIB	O
8	are	O
9	required	O
10	and	O
11	sufficient	O
12	for	O
13	transcription	O
14	of	O
15	TATA	O
16	box	O
17	-	O
18	containing	O
19	and	O
20	TATA	O
21	-	O
22	less	O
23	genes	O
24	.	O

1	DNA	O
2	hybridization	O
3	analysis	O
4	revealed	O
5	that	O
6	both	O
7	pigmented	O
8	and	O
9	nonpigmented	B
10	cells	I
11	of	I
12	Y	I
13	.	I
14	pestis	I
15	possess	I
16	a	I
17	DNA	I
18	locus	I
19	homologous	I
20	to	O
21	the	O
22	Escherichia	O
23	coli	O
24	fur	O
25	gene	O
26	.	B

1	However	O
2	,	O
3	the	O
4	few	O
5	studies	O
6	that	O
7	address	O
8	antimicrobial	O
9	prophylaxis	O
10	in	O
11	bone	O
12	marrow	O
13	transplantation	O
14	have	O
15	not	O
16	always	O
17	shown	B
18	a	I
19	survival	I
20	benefit	O
21	.	O

1	Monitoring	O
2	patients	O
3	with	O
4	acute	O
5	leukemia	O
6	for	O
7	IL	O
8	-	O
9	1	O
10	and	O
11	TNF	O
12	levels	O
13	throughout	O
14	the	O
15	clinical	B
16	course	I
17	of	I
18	disease	I
19	may	I
20	help	I
21	clarify	O
22	the	O
23	causes	O
24	of	O
25	febrile	O
26	episodes	O
27	.	O

1	RESULTS	O
2	:	O
3	256	O
4	Periods	O
5	of	O
6	TTP	O
7	or	O
8	PUNP	O
9	were	O
10	reported	O
11	by	O
12	men	O
13	and	O
14	174	O
15	by	O
16	women	O
17	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	Neither	O
2	verapamil	B
3	nor	B
4	nifedipine	O
5	changed	B
6	collateral	O
7	myocardial	O
8	blood	O
9	flow	O
10	from	B
11	0	I
12	.	O
13	10	O
14	+/-	O
15	0	O
16	.	O
17	02	O
18	in	O
19	the	O
20	subendocardium	O
21	and	O
22	0	O
23	.	O
24	17	O
25	+/-	O
26	0	B
27	.	B
28	03	O
29	ml	O
30	/	O
31	min	O
32	/	O
33	g	O
34	in	O
35	the	O
36	subepicardium	O
37	.	O

1	Weaned	O
2	rats	O
3	were	O
4	fed	O
5	a	O
6	normal	O
7	diet	O
8	or	O
9	a	O
10	low	O
11	-	O
12	protein	O
13	,	O
14	low	O
15	-	O
16	energy	O
17	diet	O
18	,	O
19	and	B
20	injected	I
21	with	I
22	saline	I
23	or	O
24	thyroxine	B
25	(	I
26	5	O
27	micrograms	O
28	/	O
29	100	O
30	g	O
31	BW	O
32	)	O
33	for	O
34	22	O
35	days	O
36	.	O

1	In	O
2	addition	O
3	,	O
4	carp	O
5	JAK1	O
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	O
12	JAK1	B
13	in	I
14	both	I
15	the	I
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	O
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	O
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O

1	Drug	O
2	-	O
3	drug	O
4	interactions	O
5	are	O
6	most	O
7	likely	O
8	to	O
9	occur	O
10	in	O
11	patients	O
12	receiving	O
13	multiple	O
14	medications	O
15	and	O
16	with	O
17	drugs	O
18	that	O
19	have	O
20	a	O
21	narrow	O
22	therapeutic	O
23	window	O
24	.	O

1	TB	O
2	bone	O
3	area	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	001	O
10	),	O
11	height	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	01	O
18	),	O
19	years	O
20	in	O
21	present	O
22	colony	B
23	(	I
24	p	I
25	=	I
26	0	I
27	.	I
28	03	I
29	),	O
30	and	O
31	menses	O
32	(	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	)	O
39	predicted	O
40	TB	O
41	BMC	O
42	.	O

1	Sensory	O
2	evoked	O
3	field	O
4	potentials	O
5	were	O
6	recorded	O
7	from	O
8	the	O
9	mesencephalic	O
10	reticular	O
11	formation	O
12	(	O
13	MRF	O
14	),	O
15	central	O
16	gray	O
17	(	O
18	CG	O
19	)	O
20	and	O
21	somatosensory	O
22	cortex	O
23	(	O
24	SCX	O
25	),	O
26	following	O
27	incremental	O
28	doses	O
29	of	O
30	halothane	O
31	in	O
32	freely	O
33	-	O
34	moving	O
35	rats	O
36	.	O

1	In	O
2	the	O
3	Arithmetic	O
4	subtest	O
5	one	O
6	of	O
7	the	O
8	items	O
9	would	O
10	not	O
11	meet	O
12	the	O
13	difficulty	O
14	grading	O
15	shown	O
16	while	O
17	the	O
18	last	O
19	two	O
20	items	O
21	offer	O
22	very	O
23	little	O
24	possibility	O
25	of	O
26	success	O
27	for	O
28	all	B
29	subjects	I
30	.(	I
31	ABSTRACT	I
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	Subunit	O
2	composition	O
3	and	O
4	domain	O
5	structure	O
6	of	O
7	the	O
8	Spo0A	O
9	sporulation	O
10	transcription	O
11	factor	O
12	of	O
13	Bacillus	O
14	subtilis	O
15	.	O

1	Cyclosporine	O
2	treatment	O
3	for	O
4	intractable	O
5	polymyositis	O
6	.	O

1	This	O
2	is	O
3	in	O
4	contrast	O
5	with	O
6	the	O
7	classical	O
8	'	O
9	oxygen	O
10	debt	O
11	hypothesis	O
12	',	O
13	which	O
14	states	O
15	that	O
16	the	O
17	oxygen	O
18	debt	O
19	and	B
20	lactate	I
21	clearance	I
22	are	O
23	linked	O
24	.	O

1	GCD10	O
2	was	O
3	first	O
4	identified	O
5	genetically	O
6	as	O
7	a	O
8	translational	O
9	repressor	O
10	of	O
11	GCN4	O
12	.	O

1	In	O
2	the	B
3	study	I
4	on	I
5	PCI	I
6	mRNA	O
7	expression	O
8	in	O
9	the	O
10	reproductive	O
11	organs	O
12	,	O
13	we	O
14	first	O
15	cloned	O
16	rat	O
17	PCI	O
18	cDNA	O
19	and	O
20	then	O
21	evaluated	O
22	the	O
23	effect	O
24	of	O
25	androgen	O
26	on	O
27	the	O
28	PCI	O
29	mRNA	O
30	expression	O
31	.	O

1	Thus	O
2	,	O
3	the	O
4	class	O
5	C	O
6	-	O
7	Vps	O
8	complex	O
9	directs	O
10	multiple	O
11	reactions	O
12	during	B
13	the	I
14	docking	I
15	and	I
16	fusion	I
17	of	O
18	vesicles	B
19	with	I
20	the	I
21	vacuole	I
22	,	I
23	each	I
24	of	I
25	which	O
26	contributes	O
27	to	O
28	the	O
29	overall	O
30	specificity	O
31	and	O
32	efficiency	O
33	of	O
34	this	O
35	transport	O
36	process	O
37	.	O

1	The	O
2	MET4	O
3	gene	O
4	was	O
5	cloned	O
6	,	O
7	and	O
8	its	O
9	sequence	O
10	reveals	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	related	O
17	to	O
18	the	O
19	family	O
20	of	O
21	the	O
22	bZIP	O
23	transcriptional	O
24	activators	O
25	.	O

1	RESULTS	O
2	:	O
3	In	O
4	an	O
5	18	O
6	moth	O
7	period	B
8	and	I
9	out	I
10	of	I
11	a	O
12	total	B
13	of	I
14	284	I
15	positive	I
16	blood	I
17	cultures	I
18	(	I
19	154	I
20	significant	I
21	isolations	I
22	)	I
23	14	I
24	episodes	O
25	of	O
26	bacteremia	B
27	by	O
28	M	O
29	.	O
30	tuberculosis	O
31	were	O
32	studied	O
33	in	O
34	12	O
35	prison	O
36	patients	O
37	coinfected	O
38	by	O
39	the	O
40	human	O
41	immunodeficiency	O
42	virus	O
43	with	O
44	associated	I
45	severe	I
46	immunosuppression	I
47	(	O
48	mean	B
49	of	I
50	CD4	I
51	=	B
52	0	O
53	.	O
54	068	B
55	x	O
56	10	I
57	(	I
58	9	I
59	)/	I
60	l	I
61	).	O

1	State	O
2	of	B
3	the	I
4	body	O
5	in	O
6	disorders	O
7	of	O
8	diurnal	O
9	physiological	B
10	rhythms	I
11	and	O
12	long	B
13	-	I
14	term	I
15	hypokinesia	I

1	Here	O
2	we	O
3	report	O
4	that	O
5	expression	O
6	of	O
7	the	O
8	I	O
9	-	O
10	POU	O
11	/	O
12	tI	O
13	-	O
14	POU	O
15	message	O
16	is	O
17	maximal	O
18	late	O
19	in	O
20	the	O
21	embryonic	O
22	phase	O
23	of	O
24	Drosophila	O
25	development	O
26	,	O
27	and	O
28	I	O
29	-	O
30	POU	O
31	is	O
32	the	O
33	preferred	O
34	splice	O
35	variant	O
36	.	O

1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	B
12	)	I
13	substitutions	I
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	B
20	GP64	I
21	EFP	I
22	.	I

1	Serodiagnosis	O
2	of	O
3	trypanosomiasis	O
4	in	O
5	dromedary	B
6	camels	I
7	using	I
8	a	I
9	card	I
10	agglutination	I
11	test	O
12	set	O
13	(	O
14	Testryp	O
15	CATT	O
16	).	O

1	The	O
2	selenium	O
3	level	B
4	and	I
5	glutathione	I
6	peroxidase	I
7	activity	I
8	in	I
9	the	I
10	blood	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	stomach	O
16	mucosa	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	high	O
23	-	O
24	selenium	O
25	diet	O
26	group	O
27	than	O
28	in	O
29	the	O
30	low	O
31	-	O
32	selenium	O
33	diet	O
34	group	O
35	.	O

1	Schizosaccharomyces	O
2	pombe	O
3	cells	O
4	respond	O
5	to	O
6	nutrient	O
7	deprivation	O
8	by	B
9	altering	I
10	G2	I
11	/	I
12	M	O
13	cell	B
14	size	I
15	control	O
16	.	O

1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	B
13	.	I

1	Surprisingly	O
2	,	O
3	Northern	O
4	(	O
5	RNA	O
6	)	O
7	blot	O
8	analysis	O
9	and	O
10	reverse	O
11	transcriptase	O
12	-	O
13	PCRs	O
14	performed	O
15	after	O
16	transfection	O
17	of	O
18	COS	O
19	-	O
20	7	O
21	or	O
22	HeLa	O
23	cells	O
24	with	O
25	these	O
26	viral	O
27	RNAs	O
28	revealed	O
29	that	O
30	Y88S	O
31	and	O
32	Y88L	O
33	RNAs	O
34	replicated	O
35	at	O
36	only	O
37	very	O
38	low	O
39	levels	O
40	.	O

1	The	O
2	effective	O
3	and	O
4	low	O
5	toxic	O
6	dose	B
7	schedules	O
8	of	O
9	KW	O
10	-	O
11	2083	O
12	should	O
13	be	O
14	investigated	O
15	further	O
16	.	O

1	The	O
2	4	O
3	-	O
4	AP	O
5	(	O
6	4	O
7	-	B
8	20	I
9	mM	I
10	)	O
11	effect	I
12	resulted	O
13	in	O
14	a	O
15	decrease	O
16	of	O
17	the	O
18	sensory	O
19	activity	O
20	,	B
21	which	O
22	was	O
23	fully	B
24	restored	I
25	by	I
26	TEA	I
27	or	I
28	Ba2	O
29	+.	O

1	Current	O
2	evidence	O
3	for	O
4	this	O
5	type	O
6	of	O
7	DNA	O
8	supercoiling	O
9	-	O
10	dependent	O
11	transcriptional	O
12	coupling	O
13	,	O
14	based	O
15	largely	O
16	on	O
17	the	O
18	in	O
19	vivo	B
20	activities	I
21	of	I
22	promoters	I
23	contained	O
24	in	O
25	engineered	O
26	DNA	O
27	constructs	O
28	,	O
29	suggests	O
30	that	O
31	the	O
32	transcription	O
33	complex	O
34	must	O
35	be	O
36	physically	O
37	hindered	O
38	to	O
39	generate	O
40	DNA	O
41	supercoils	O
42	and	O
43	to	O
44	prevent	O
45	their	O
46	diffusion	O
47	throughout	O
48	the	O
49	DNA	O
50	duplex	O
51	.	O

1	When	O
2	both	O
3	lesions	O
4	were	O
5	complete	O
6	lateral	O
7	hemisections	O
8	in	O
9	weanling	O
10	operates	O
11	,	O
12	little	O
13	behavioral	B
14	recovery	I
15	was	O
16	observed	O
17	,	O
18	similar	O
19	to	O
20	complete	O
21	spinal	O
22	cord	O
23	transection	O
24	(	O
25	N	O
26	=	O
27	3	O
28	).	O

1	The	O
2	levels	B
3	of	I
4	NSE	O
5	and	O
6	MBP	O
7	in	B
8	the	I
9	IJVB	I
10	were	I
11	compared	I
12	to	I
13	those	I
14	in	O
15	the	O
16	PVB	O
17	.	O

1	The	O
2	other	O
3	two	O
4	clones	O
5	,	O
6	Ash	O
7	-	O
8	m	O
9	and	O
10	-	O
11	s	O
12	,	O
13	had	O
14	nucleotide	O
15	sequences	O
16	identical	O
17	with	O
18	Ash	O
19	-	O
20	l	O
21	cDNA	O
22	in	O
23	the	O
24	amino	O
25	-	O
26	terminal	O
27	region	O
28	.	O

1	The	O
2	promoter	O
3	was	O
4	stimulated	O
5	8	O
6	-	O
7	20	O
8	-	O
9	fold	O
10	by	O
11	phorbol	O
12	esters	O
13	accounting	O
14	for	O
15	the	O
16	previously	O
17	observed	O
18	transcriptional	O
19	activation	O
20	of	O
21	protein	O
22	kinase	O
23	C	O
24	beta	O
25	.	O

1	Identification	O
2	of	O
3	eotaxin	O
4	-	O
5	3	O
6	will	O
7	further	O
8	promote	O
9	our	O
10	understanding	O
11	of	O
12	the	O
13	control	O
14	of	O
15	eosinophil	O
16	trafficking	O
17	and	O
18	other	O
19	CCR3	O
20	-	O
21	mediated	O
22	biological	O
23	phenomena	O
24	.	O

1	Materials	O
2	science	O
3	studies	O
4	on	O
5	the	O
6	soldering	O
7	of	O
8	different	O
9	orthodontic	O
10	wires	O

1	RESULTS	O
2	:	O
3	At	O
4	the	O
5	beginning	B
6	of	I
7	the	I
8	QA	I
9	/	I
10	QI	I
11	process	I
12	,	I
13	monitoring	I
14	of	O
15	blood	O
16	administration	B
17	practices	I
18	revealed	I
19	that	O
20	a	O
21	variance	O
22	from	O
23	institutional	O
24	blood	O
25	administration	O
26	policy	O
27	occurred	O
28	during	O
29	50	O
30	percent	O
31	of	O
32	blood	O
33	and	O
34	component	O
35	transfusions	O
36	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	B
7	greatly	I
8	reduced	I
9	the	I
10	association	I
11	of	I
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	O
20	.	O

1	T2	O
2	cancers	O
3	should	O
4	not	O
5	be	O
6	excluded	O
7	from	O
8	the	O
9	benefit	O
10	of	O
11	preoperative	O
12	irradiation	O
13	.	O

1	We	O
2	have	O
3	isolated	B
4	a	I
5	new	I
6	,	I
7	larger	I
8	rat	I
9	B	I
10	-	I
11	myc	I
12	genomic	I
13	clone	I
14	.	I

1	Activation	O
2	of	O
3	alpha	B
4	4	I
5	beta	I
6	1	I
7	with	I
8	TS2	I
9	/	I
10	16	I
11	inhibited	I
12	the	I
13	cytoplasmic	I
14	protrusions	I
15	and	I
16	cell	I
17	migration	I
18	but	I
19	did	I
20	not	I
21	affect	I
22	the	O
23	pattern	O
24	of	O
25	phosphorylation	O
26	.	O

1	The	O
2	clinical	O
3	and	O
4	laboratory	O
5	features	O
6	of	O
7	72	O
8	children	B
9	with	I
10	Henoch	I
11	-	O
12	Schonlein	O
13	purpura	O
14	(	O
15	HSP	O
16	)	O
17	were	O
18	examined	O
19	to	O
20	determine	O
21	if	O
22	there	O
23	were	O
24	associations	O
25	between	O
26	the	O
27	laboratory	O
28	indices	B
29	--	B
30	including	I
31	white	O
32	blood	O
33	cell	O
34	(	O
35	WBC	O
36	)	O
37	counts	O
38	,	O
39	serum	O
40	C	O
41	-	O
42	reactive	O
43	protein	O
44	(	B
45	CRP	I
46	)	I
47	levels	O
48	,	O
49	platelet	O
50	(	O
51	PLT	O
52	)	O
53	counts	O
54	--	O
55	and	O
56	the	O
57	clinical	I
58	manifestations	O
59	of	O
60	acute	O
61	HSP	I
62	.	I

1	Otte	O
2	,	O
3	Mol	O
4	.	O

1	These	O
2	changes	O
3	correlate	O
4	directly	O
5	with	O
6	an	O
7	increase	O
8	in	O
9	the	O
10	acetylation	O
11	levels	O
12	of	O
13	all	O
14	four	B
15	core	I
16	histones	I
17	in	O
18	vivo	O
19	.	O

1	It	O
2	may	O
3	be	O
4	dependent	O
5	on	O
6	location	B
7	of	I
8	a	I
9	focus	I
10	(	I
11	according	I
12	to	I
13	EEG	I
14	)	I
15	as	O
16	well	O
17	as	O
18	on	O
19	the	O
20	character	O
21	and	O
22	manifestation	O
23	of	O
24	the	O
25	accompanying	O
26	neuropsychologic	O
27	symptomatology	O
28	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	morphological	O
6	criteria	O
7	,	O
8	the	O
9	few	O
10	data	O
11	available	O
12	from	O
13	recent	O
14	studies	O
15	at	O
16	the	O
17	genetic	O
18	level	O
19	have	O
20	suggested	O
21	that	O
22	EPVs	O
23	infecting	O
24	different	O
25	insect	O
26	orders	O
27	are	O
28	phylogenetically	O
29	distant	O
30	.	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	O
9	and	O
10	myogenin	O
11	fusion	O
12	proteins	O
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	Further	O
2	studies	O
3	of	O
4	mandibular	O
5	movement	O
6	at	O
7	initial	O
8	tooth	O
9	contact	O
10	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	HAC1	O
6	may	O
7	also	O
8	be	O
9	one	O
10	of	O
11	the	O
12	meiotic	O
13	genes	O
14	.	O

1	Platelet	O
2	activating	O
3	factor	O
4	was	O
5	given	O
6	in	O
7	six	B
8	doses	I
9	at	I
10	15	I
11	minute	O
12	intervals	O
13	and	O
14	airway	O
15	response	O
16	measured	B
17	as	B
18	change	I
19	in	O
20	partial	O
21	expiratory	O
22	flow	O
23	at	O
24	30	O
25	%	O
26	of	O
27	vital	B
28	capacity	I
29	(	I
30	Vp30	I
31	).	I

1	Randomised	O
2	comparison	O
3	of	O
4	addition	O
5	of	B
6	autologous	I
7	bone	I
8	-	I
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	B
14	for	I
15	acute	I
16	myeloid	I
17	leukaemia	I
18	in	O
19	first	O
20	remission	B
21	:	I
22	results	O
23	of	O
24	MRC	B
25	AML	I
26	10	O
27	trial	B
28	.	I

1	In	O
2	reviewing	O
3	a	O
4	number	O
5	of	O
6	the	O
7	most	O
8	intensely	O
9	studied	O
10	environmentally	O
11	inducible	O
12	promoters	O
13	it	O
14	becomes	O
15	clear	O
16	that	O
17	the	O
18	presence	O
19	of	O
20	two	O
21	cis	O
22	-	O
23	acting	O
24	elements	O
25	are	O
26	critical	O
27	for	O
28	promoter	O
29	activity	O
30	,	O
31	one	O
32	of	O
33	which	O
34	is	O
35	the	O
36	G	O
37	-	O
38	box	O
39	(	O
40	CCACGTGG	O
41	).	O

1	Repetitive	O
2	sequences	O
3	are	O
4	present	O
5	in	O
6	at	O
7	least	O
8	three	O
9	introns	O
10	of	O
11	the	O
12	cytochrome	O
13	P	O
14	-	B
15	450PBc2	I
16	gene	I
17	,	I
18	but	I
19	not	O
20	in	O
21	exons	O
22	or	O
23	the	O
24	5	O
25	'-	O
26	flanking	O
27	region	O
28	.	O

1	CONCLUSION	O
2	:	O
3	More	O
4	than	O
5	50	O
6	%	O
7	of	O
8	patients	O
9	with	O
10	perennial	O
11	rhinitis	O
12	and	O
13	CRS	B
14	do	B
15	not	O
16	improve	O
17	after	O
18	surgery	O
19	,	O
20	a	O
21	response	O
22	that	O
23	may	O
24	be	O
25	predicted	O
26	by	O
27	more	O
28	cells	O
29	expressing	O
30	IL	O
31	-	O
32	5	O
33	mRNA	O
34	in	O
35	the	O
36	ethmoid	O
37	sinuses	O
38	.	O

1	Examination	O
2	of	O
3	the	O
4	immediate	O
5	sequence	O
6	5	O
7	'	O
8	to	O
9	the	O
10	mRNA	O
11	start	O
12	site	O
13	reveals	O
14	no	O
15	TATA	O
16	box	O
17	and	O
18	multiple	O
19	known	B
20	enhancer	I
21	sequences	I
22	.	I

1	One	O
2	possible	O
3	solution	O
4	is	O
5	a	O
6	thin	O
7	radial	O
8	forearm	O
9	free	O
10	flap	O
11	.	O

1	Approximately	O
2	60	O
3	%	O
4	of	O
5	cell	O
6	bodies	O
7	of	O
8	primary	O
9	neurons	O
10	innervating	O
11	the	B
12	intra	I
13	and	I
14	perioral	I
15	structures	I
16	through	I
17	the	I
18	inferior	I
19	alveolar	I
20	,	O
21	lingual	O
22	,	O
23	mental	O
24	,	O
25	and	O
26	buccal	O
27	nerves	O
28	were	O
29	in	O
30	the	O
31	range	O
32	between	O
33	300	O
34	and	O
35	600	O
36	micron	O
37	2	O
38	in	O
39	cross	O
40	-	O
41	sectional	O
42	area	O
43	:	O
44	mean	O
45	+/-	O
46	SD	O
47	509	O
48	+/-	O
49	243	O
50	micron	O
51	2	O
52	,	O
53	420	B
54	+/-	I
55	181	I
56	micron	I
57	2	I
58	,	O
59	469	O
60	+/-	O
61	200	O
62	micron	O
63	2	O
64	,	O
65	and	O
66	444	O
67	+/-	O
68	186	O
69	micron	O
70	2	O
71	,	O
72	respectively	O
73	.	O

1	Of	O
2	254	O
3	children	O
4	with	O
5	neuroblastoma	O
6	treated	O
7	at	O
8	St	O
9	.	O

1	A	O
2	330	O
3	-	O
4	kb	O
5	YAC	O
6	,	O
7	A148A7	O
8	,	O
9	spanned	O
10	from	O
11	the	O
12	HLA	O
13	-	O
14	DQA1	O
15	locus	O
16	through	O
17	the	O
18	Y3	O
19	/	O
20	Ring	O
21	4	O
22	locus	O
23	and	O
24	extended	O
25	at	O
26	least	O
27	130	O
28	kb	O
29	centromeric	O
30	of	O
31	YAC	O
32	B1D12	O
33	.	O

1	G	O
2	-	O
3	CSF	O
4	activates	O
5	multiple	O
6	signaling	O
7	molecules	O
8	,	O
9	including	B
10	the	B
11	JAK1	O
12	and	B
13	JAK2	I
14	kinases	O
15	and	O
16	the	O
17	STAT	O
18	transcription	O
19	factors	O
20	.	O

1	The	O
2	histologic	O
3	grade	O
4	for	O
5	the	O
6	same	O
7	anatomic	O
8	site	O
9	varied	O
10	among	O
11	hearts	O
12	and	O
13	among	O
14	different	O
15	anatomic	O
16	sites	O
17	in	B
18	the	I
19	same	O
20	heart	O
21	.	O

1	Of	O
2	the	O
3	21	O
4	quadrants	O
5	positive	O
6	in	B
7	the	I
8	controls	I
9	,	I
10	17	I
11	were	O
12	correlated	O
13	with	O
14	previously	O
15	detected	O
16	jaw	B
17	pathoses	I
18	.	I

1	A	O
2	cDNA	O
3	clone	O
4	corresponding	O
5	to	O
6	the	O
7	putative	O
8	GA	O
9	20	O
10	-	O
11	oxidase	O
12	genomic	B
13	sequence	I
14	was	I
15	constructed	I
16	with	O
17	the	O
18	reverse	O
19	transcription	O
20	-	O
21	PCR	O
22	method	O
23	,	O
24	and	O
25	the	O
26	identity	O
27	of	O
28	the	O
29	cDNA	O
30	clone	O
31	was	O
32	confirmed	O
33	by	O
34	analyzing	O
35	the	O
36	capability	O
37	of	O
38	the	O
39	fusion	O
40	protein	O
41	expressed	O
42	in	O
43	Escherichia	O
44	coli	O
45	to	O
46	convert	O
47	GA53	O
48	to	B
49	GA44	I
50	and	I
51	GA19	O
52	to	O
53	GA20	O
54	.	O

1	Together	O
2	,	O
3	the	O
4	data	O
5	suggest	O
6	that	O
7	cAMP	O
8	-	O
9	dependent	O
10	control	O
11	of	O
12	the	O
13	amounts	O
14	of	O
15	the	O
16	activator	O
17	SF	O
18	-	O
19	1	O
20	vs	O
21	.	O
22	the	O
23	repressor	O
24	COUP	O
25	-	O
26	TF	O
27	could	O
28	influence	O
29	CRS2	O
30	-	O
31	dependent	O
32	transcription	O
33	.	O

1	Ivermectin	O
2	uptake	O
3	and	O
4	distribution	O
5	in	O
6	the	O
7	plasma	O
8	and	O
9	tissue	O
10	of	O
11	Sudanese	O
12	and	O
13	Mexican	O
14	patients	O
15	infected	O
16	with	O
17	Onchocerca	O
18	volvulus	O
19	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	O
6	desmin	O
7	in	O
8	SW13	O
9	(	O
10	vim	B
11	-)	I
12	cells	I
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	O
21	positive	O
22	material	O
23	dispersed	O
24	throughout	B
25	the	I
26	cytoplasm	O
27	.	O

1	Furthermore	O
2	,	O
3	an	O
4	upstream	O
5	element	O
6	,	O
7	collagen	O
8	element	O
9	I	O
10	(-	B
11	370	I
12	/-	I
13	344	I
14	),	I
15	which	I
16	shares	I
17	homology	I
18	with	I
19	the	O
20	LAP	O
21	binding	O
22	cis	O
23	-	O
24	element	O
25	of	O
26	the	O
27	albumin	B
28	promoter	O
29	(	I
30	9	O
31	of	O
32	13	I
33	bp	O
34	)	O
35	is	O
36	described	O
37	.	O

1	Although	O
2	no	O
3	statistical	O
4	significance	O
5	was	O
6	achieved	O
7	,	O
8	it	O
9	is	O
10	remarkable	B
11	that	B
12	there	I
13	was	O
14	a	B
15	clear	B
16	trend	I
17	for	O
18	the	O
19	superiority	O
20	of	O
21	Galphimia	O
22	D6	O
23	while	B
24	the	I
25	Galphimia	I
26	dilution	I
27	10	I
28	(-	I
29	6	I
30	)	I
31	was	I
32	about	O
33	equally	O
34	effective	O
35	compared	O
36	with	O
37	placebo	O
38	.	O

1	The	O
2	genes	O
3	at	B
4	each	I
5	locus	I
6	are	I
7	divergently	I
8	transcribed	I
9	and	I
10	the	I
11	coding	I
12	sequences	I
13	are	I
14	separated	I
15	by	I
16	646	I
17	base	I
18	-	I
19	pairs	I
20	at	O
21	one	O
22	locus	O
23	and	O
24	676	O
25	base	O
26	-	O
27	pairs	O
28	at	O
29	the	O
30	other	O
31	.	O

1	Albumin	O
2	and	O
3	cyclic	O
4	AMP	O
5	levels	O
6	in	O
7	peritoneal	O
8	fluids	O
9	in	O
10	the	O
11	child	O

1	Prostaglandins	O
2	and	O
3	gallstones	O

1	Attitudes	O
2	were	O
3	found	O
4	to	O
5	be	O
6	multidimensional	O
7	,	O
8	with	O
9	similar	O
10	dimensions	O
11	being	O
12	identified	O
13	in	O
14	both	O
15	samples	O
16	.	O

1	A	O
2	one	O
3	-	O
4	week	O
5	ulcer	O
6	therapy	O
7	with	O
8	atropine	O
9	and	O
10	Vikalin	O
11	(	O
12	Roter	O
13	)	O
14	led	O
15	to	O
16	a	O
17	significant	O
18	(	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	01	O
25	)	O
26	reduction	O
27	of	O
28	the	O
29	nocturnal	O
30	proteolytic	O
31	activity	O
32	.	O

1	Using	O
2	anchored	B
3	PCR	I
4	,	I
5	a	I
6	VL	O
7	element	O
8	rearranged	O
9	to	O
10	CL2	O
11	was	O
12	isolated	O
13	.	O

1	To	O
2	explore	B
3	the	I
4	functional	I
5	significance	I
6	of	I
7	these	I
8	subdomains	I
9	in	O
10	PRL	O
11	binding	O
12	and	O
13	signal	O
14	transduction	O
15	,	O
16	deletion	O
17	mutants	O
18	of	O
19	S1	O
20	or	O
21	/	O
22	and	O
23	S2	O
24	subdomains	O
25	were	O
26	constructed	O
27	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	is	O
6	characterized	O
7	by	O
8	a	O
9	putative	O
10	16	O
11	-	O
12	residue	O
13	amino	O
14	-	O
15	terminal	O
16	signal	O
17	peptide	O
18	that	O
19	is	O
20	cleaved	O
21	,	O
22	resulting	O
23	in	O
24	a	O
25	239	O
26	-	O
27	residue	O
28	polypeptide	O
29	.	O

1	Accordingly	O
2	,	O
3	we	O
4	designated	O
5	this	O
6	gene	O
7	CTL1	O
8	(	O
9	capping	O
10	enzyme	O
11	RNAtriphosphatase	O
12	-	O
13	like	O
14	1	O
15	).	O

1	Analysis	O
2	of	B
3	the	I
4	gag	I
5	and	O
6	rev	O
7	proteins	O
8	in	O
9	the	O
10	transfected	O
11	cells	O
12	demonstrated	O
13	that	O
14	these	O
15	proteins	O
16	were	O
17	not	O
18	detectable	B
19	in	I
20	cells	O
21	transfected	O
22	with	B
23	the	O
24	tat	O
25	mutants	O
26	but	O
27	could	O
28	be	O
29	readily	O
30	detected	O
31	when	O
32	the	O
33	mutations	O
34	were	O
35	complemented	B
36	in	B
37	trans	O
38	with	O
39	a	B
40	tat	O
41	expression	O
42	vector	O
43	.	O

1	RUSH	O
2	-	O
3	1	O
4	beta	O
5	is	O
6	a	B
7	95	I
8	-	I
9	kDa	O
10	truncated	O
11	version	O
12	of	O
13	RUSH	O
14	-	O
15	1	O
16	alpha	O
17	that	O
18	results	O
19	from	O
20	alternative	O
21	splicing	O
22	of	O
23	a	I
24	57	I
25	-	O
26	bp	O
27	exon	O
28	as	O
29	confirmed	O
30	by	O
31	genomic	O
32	cloning	O
33	.	O

1	Plasma	O
2	Al	O
3	was	O
4	obtained	O
5	during	O
6	each	O
7	baseline	O
8	and	O
9	drug	O
10	course	O
11	.	O

1	Study	O
2	groups	O
3	were	O
4	control	O
5	,	B
6	and	O
7	those	B
8	treated	I
9	with	I
10	the	O
11	alpha1	O
12	-	O
13	adrenoceptor	O
14	-	O
15	subtype	O
16	blockers	O
17	WB4101	O
18	(	O
19	0	O
20	.	O
21	5	O
22	mg	O
23	/	O
24	kg	O
25	i	O
26	.	O
27	v	O
28	.)	O
29	or	B
30	chloroethylclonidine	I
31	(	I
32	1	O
33	.	O
34	9	O
35	mg	O
36	/	O
37	kg	O
38	i	O
39	.	O
40	v	O
41	.).	O

1	The	O
2	structural	O
3	analysis	O
4	also	O
5	demonstrated	O
6	that	O
7	the	O
8	heterogeneity	O
9	of	O
10	the	O
11	HDC	O
12	mRNA	O
13	is	O
14	caused	O
15	by	O
16	an	O
17	insertion	O
18	of	O
19	the	O
20	seventh	O
21	intron	O
22	sequence	O
23	and	O
24	alternative	O
25	use	O
26	of	O
27	the	O
28	splicing	O
29	acceptor	O
30	site	O
31	at	O
32	the	O
33	12th	O
34	exon	O
35	.	O

1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	O
28	gene	O
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	O
35	,	O
36	Actcl	O
37	,	O
38	Ltk	O
39	,	O
40	and	O
41	B2M	O
42	loci	O
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	B

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	the	B
7	mouse	I
8	NMO1	I
9	cDNA	I
10	,	O
11	which	O
12	encodes	O
13	the	O
14	NAD	O
15	(	O
16	P	O
17	)	O
18	H	O
19	:	O
20	menadione	O
21	oxidoreductase	O
22	[	B
23	also	I
24	called	I
25	NAD	I
26	(	O
27	P	O
28	)	O
29	H	O
30	:(	O
31	quinone	O
32	acceptor	O
33	)	O
34	oxidoreductase	O
35	;	O
36	quinone	O
37	reductase	O
38	;	O
39	azo	O
40	dye	O
41	reductase	B
42	;	B
43	DT	B
44	diaphorase	I
45	;	O
46	EC	O
47	1	O
48	.	O
49	6	O
50	.	O
51	99	O
52	.	O
53	2	O
54	].	O

1	The	O
2	Trx	O
3	-	O
4	CT	O
5	fusion	O
6	protein	O
7	was	O
8	produced	O
9	less	O
10	efficiently	O
11	(	O
12	20	O
13	%	O
14	of	B
15	total	I
16	soluble	I
17	cellular	I
18	protein	I
19	).	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	O
9	/	O
10	Smarcal1	O
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	B
17	Caenorhabditis	I
18	elegans	I
19	ortholog	O
20	(	O
21	CEHARP	O
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O

1	Despite	O
2	this	O
3	there	O
4	was	O
5	no	O
6	difference	O
7	in	O
8	the	O
9	intubating	O
10	conditions	O
11	at	O
12	one	B
13	minute	I
14	with	I
15	25	I
16	excellent	O
17	/	O
18	5	O
19	good	O
20	in	O
21	the	O
22	suxamethonium	O
23	group	B
24	and	I
25	27	I
26	excellent	I
27	/	I
28	3	I
29	good	I
30	in	I
31	the	I
32	rocuronium	I
33	group	O
34	.	B

1	A	O
2	low	O
3	aspirin	O
4	esterase	O
5	activity	O
6	may	O
7	be	O
8	a	O
9	contributory	O
10	factor	B
11	in	I
12	precipitating	O
13	these	O
14	aspirin	O
15	sensitive	O
16	reactions	O
17	.	O

1	Furthermore	O
2	,	O
3	both	O
4	rhHR23	O
5	proteins	O
6	function	O
7	in	O
8	a	O
9	defined	O
10	NER	O
11	system	O
12	reconstituted	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	hHR23	O
22	proteins	O
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	B
30	with	I
31	XPC	O
32	.	O

1	For	O
2	EPV	O
3	3	O
4	,	O
5	10	B
6	,	I
7	or	O
8	40	O
9	,	O
10	the	O
11	bias	O
12	exceeded	B
13	25	I
14	%	I
15	for	I
16	7	I
17	,	I
18	3	I
19	,	I
20	and	I
21	1	O
22	in	O
23	the	O
24	8	O
25	-	O
26	predictor	O
27	model	O
28	respectively	O
29	,	I
30	when	O
31	a	O
32	conventional	O
33	selection	O
34	criterion	O
35	was	O
36	used	O
37	(	O
38	alpha	O
39	=	O
40	0	O
41	.	O
42	05	O
43	).	O

1	Another	O
2	common	O
3	mutation	O
4	involved	O
5	amino	O
6	acids	O
7	that	O
8	are	O
9	thought	O
10	to	O
11	make	O
12	specific	O
13	contacts	O
14	with	O
15	DNA	O
16	.	O

1	The	O
2	interaction	O
3	of	O
4	caffeine	O
5	,	O
6	theophylline	O
7	and	O
8	theobromine	O
9	with	O
10	monoamine	O
11	oxidase	O
12	inhibitors	O
13	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	beta	O
6	-	O
7	adrenergic	O
8	agonist	O
9	,	O
10	isoproterenol	O
11	,	O
12	has	O
13	little	O
14	influence	O
15	on	B
16	vascular	I
17	capacitance	O
18	or	O
19	liver	O
20	volume	O
21	of	O
22	dogs	O
23	,	B
24	unless	I
25	the	O
26	hepatic	O
27	outflow	O
28	resistance	O
29	is	O
30	elevated	O
31	by	O
32	agents	O
33	such	O
34	as	O
35	histamine	O
36	.	O

1	Carbohydrates	O
2	and	O
3	glycoconjugates	O
4	biophysical	O
5	methods	O
6	.	O

1	Transformations	O
2	in	O
3	the	O
4	morphine	O
5	series	O
6	.	O

1	In	O
2	whole	O
3	sardine	O
4	,	O
5	domoic	O
6	acid	O
7	was	O
8	detected	O
9	in	O
10	levels	O
11	exceeding	O
12	sometimes	O
13	the	O
14	regulatory	O
15	limit	O
16	.	O

1	Arachnoid	O
2	cyst	O
3	.	O

1	The	O
2	correlation	O
3	between	O
4	PaCO2	O
5	and	O
6	PtcO2	O
7	in	O
8	RDS	B
9	was	I
10	insufficient	I
11	to	I
12	make	O
13	clinical	O
14	judgement	O
15	.	O

1	One	O
2	complex	O
3	appears	O
4	to	O
5	be	O
6	ubiquitous	O
7	but	O
8	enriched	O
9	in	O
10	lymphoid	O
11	cells	O
12	and	O
13	represents	O
14	the	O
15	binding	O
16	of	O
17	a	O
18	potentially	O
19	novel	O
20	factor	O
21	with	O
22	an	O
23	apparent	O
24	molecular	O
25	mass	O
26	of	O
27	approximately	O
28	50	O
29	kDa	O
30	.	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	isolated	O
6	from	O
7	a	O
8	chicken	O
9	embryo	O
10	cDNA	O
11	library	O
12	employing	O
13	a	O
14	PCR	O
15	-	O
16	generated	O
17	radiolabeled	O
18	probe	O
19	specific	O
20	for	O
21	the	O
22	U3	O
23	region	O
24	of	O
25	the	O
26	Rous	O
27	sarcoma	O
28	virus	O
29	LTR	O
30	.	O

1	Three	O
2	groups	O
3	of	O
4	patients	O
5	who	B
6	had	I
7	undergone	O
8	subtotal	O
9	thyroidectomy	O
10	for	O
11	Graves	O
12	'	O
13	s	O
14	disease	O
15	,	O
16	toxic	O
17	multinodular	B
18	goitre	I
19	,	O
20	or	O
21	euthyroid	O
22	multinodular	O
23	goitre	O
24	12	O
25	to	O
26	15	O
27	years	O
28	before	O
29	and	I
30	in	I
31	whom	O
32	a	B
33	normal	I
34	serum	I
35	thyroxine	I
36	(	O
37	T	B
38	-	I
39	4	I
40	)	I
41	level	I
42	was	I
43	found	I
44	were	I
45	each	I
46	divided	I
47	into	I
48	two	O
49	subgroups	O
50	on	B
51	the	I
52	basis	I
53	of	I
54	a	I
55	normal	I
56	or	I
57	a	I
58	raised	O
59	serum	O
60	thyrotrophin	O
61	concentration	O
62	.	O

1	New	O
2	-	O
3	onset	O
4	angina	O
5	preceding	O
6	acute	O
7	myocardial	O
8	infarction	O
9	is	O
10	associated	O
11	with	O
12	improved	O
13	contractile	O
14	recovery	O
15	after	O
16	thrombolysis	O
17	.	O

1	Translation	O
2	of	O
3	specific	O
4	cellular	O
5	genes	B
6	from	I
7	the	O
8	chimeric	O
9	viral	O
10	-	O
11	cellular	O
12	transcripts	O
13	seems	O
14	to	O
15	be	O
16	unlikely	O
17	.	O

1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O

1	The	O
2	O2	O
3	deficit	O
4	was	O
5	not	O
6	related	O
7	to	O
8	blood	O
9	lactate	O
10	during	O
11	submaximal	O
12	exercise	O
13	,	O
14	muscle	O
15	enzyme	O
16	activity	O
17	(	O
18	citrate	O
19	synthase	O
20	,	O
21	3	B
22	-	I
23	hydroxyacyl	I
24	-	O
25	CoA	O
26	-	O
27	dehydrogenase	O
28	,	O
29	lactate	O
30	dehydrogenase	O
31	),	O
32	number	O
33	of	O
34	muscle	O
35	capillaries	O
36	,	O
37	%	O
38	ST	O
39	fibres	O
40	or	O
41	muscle	O
42	buffer	O
43	capacity	O
44	.	O

1	The	O
2	"	O
3	cracked	O
4	-	O
5	tooth	O
6	"	O
7	syndrome	O
8	.	O

1	As	O
2	with	O
3	the	O
4	heterologous	O
5	DNA	O
6	binding	O
7	domain	O
8	,	O
9	MZF	O
10	-	O
11	1	O
12	represses	O
13	reporter	O
14	gene	O
15	expression	O
16	in	O
17	nonhematopoietic	O
18	cell	O
19	lines	O
20	and	O
21	activates	O
22	expression	O
23	in	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	.	O

1	The	O
2	RNA	O
3	-	O
4	binding	O
5	and	B
6	RNA	I
7	-	O
8	DNA	O
9	helicase	O
10	activities	O
11	of	O
12	the	O
13	Escherichia	O
14	coli	O
15	transcription	O
16	termination	O
17	factor	O
18	rho	O
19	have	O
20	been	O
21	investigated	O
22	using	O
23	natural	O
24	RNA	O
25	molecules	O
26	that	O
27	are	O
28	255	O
29	and	O
30	391	O
31	nucleotide	O
32	residues	O
33	in	O
34	length	O
35	and	O
36	that	O
37	contain	O
38	the	O
39	trp	O
40	t	O
41	'	O
42	rho	O
43	-	O
44	dependent	O
45	termination	O
46	sequence	O
47	of	O
48	E	O
49	.	O
50	coli	O
51	.	O

1	In	O
2	this	O
3	regard	O
4	,	O
5	we	O
6	have	O
7	recently	O
8	observed	O
9	that	O
10	a	O
11	constitutively	O
12	active	O
13	G	O
14	protein	O
15	-	O
16	coupled	O
17	receptor	O
18	(	O
19	GPCR	O
20	)	O
21	encoded	O
22	by	O
23	the	O
24	Kaposi	O
25	'	O
26	s	O
27	sarcoma	O
28	-	O
29	associated	O
30	herpes	O
31	virus	O
32	(	O
33	KSHV	O
34	)/	O
35	human	O
36	herpes	O
37	virus	O
38	8	O
39	is	O
40	oncogenic	O
41	and	O
42	stimulates	O
43	angiogenesis	O
44	by	O
45	increasing	O
46	the	O
47	secretion	O
48	of	O
49	vascular	O
50	endothelial	O
51	growth	O
52	factor	O
53	(	O
54	VEGF	O
55	),	O
56	which	O
57	is	O
58	a	O
59	key	O
60	angiogenic	O
61	stimulator	O
62	and	O
63	a	O
64	critical	O
65	mitogen	O
66	for	O
67	the	O
68	development	O
69	of	O
70	Kaposi	O
71	'	O
72	s	O
73	sarcoma	O
74	.	O

1	In	O
2	a	O
3	recent	O
4	measles	O
5	epidemic	O
6	in	O
7	El	B
8	Paso	I
9	,	I
10	TX	I
11	,	I
12	120	I
13	,	O
14	000	O
15	records	O
16	were	B
17	screened	I
18	using	I
19	these	I
20	criteria	I
21	,	I
22	and	I
23	as	I
24	a	I
25	result	I
26	13	I
27	,	O
28	000	O
29	students	O
30	were	O
31	vaccinated	O
32	.	O

1	Paroxysmal	O
2	fluctuations	O
3	in	O
4	observed	O
5	parasitemia	O
6	in	O
7	Plasmodium	O
8	falciparum	O
9	malaria	O
10	.	O

1	Comparison	O
2	of	O
3	patients	O
4	receiving	O
5	phenytoin	O
6	and	B
7	those	I
8	who	I
9	were	I
10	not	I
11	showed	I
12	significantly	I
13	lower	O
14	serum	O
15	folate	O
16	in	O
17	the	O
18	sub	O
19	-	O
20	group	O
21	receiving	O
22	phenytoin	O
23	,	O
24	but	O
25	there	O
26	was	O
27	no	O
28	significant	O
29	difference	O
30	between	O
31	the	O
32	sub	O
33	-	O
34	groups	O
35	with	O
36	respect	O
37	to	O
38	vitamin	O
39	B12	O
40	or	O
41	behaviour	O
42	problem	B
43	rating	I
44	.	I

1	Seven	O
2	clones	O
3	encoding	O
4	interferon	B
5	response	I
6	element	I
7	binding	I
8	factors	I
9	have	I
10	been	O
11	isolated	O
12	from	O
13	a	O
14	mouse	O
15	fibroblast	O
16	lambda	O
17	gt11	O
18	cDNA	O
19	library	O
20	by	O
21	using	O
22	a	O
23	32P	O
24	end	O
25	-	O
26	labeled	O
27	tandem	O
28	trimer	O
29	of	O
30	the	O
31	mouse	O
32	(	O
33	2	O
34	'-	O
35	5	O
36	')	O
37	oligoadenylate	B
38	synthetase	I
39	gene	O
40	interferon	O
41	response	I
42	element	I
43	as	I
44	a	I
45	probe	O
46	.	O

1	The	O
2	M	O
3	-	O
4	3	O
5	subtype	O
6	was	O
7	an	O
8	adverse	O
9	prognostic	O
10	factor	O
11	.	O

1	Two	O
2	mutants	O
3	,	O
4	each	O
5	representative	O
6	of	O
7	a	O
8	separate	B
9	pet	I
10	complementation	I
11	group	I
12	,	I
13	have	I
14	been	I
15	analyzed	I
16	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	YY1	O
6	,	O
7	a	O
8	ubiquitously	O
9	expressed	O
10	DNA	O
11	-	O
12	binding	O
13	protein	O
14	,	O
15	regulates	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	c	O
21	-	O
22	fos	O
23	promoter	O
24	primarily	O
25	through	O
26	an	O
27	effect	O
28	on	O
29	DNA	O
30	structure	O
31	.	O

1	The	O
2	main	O
3	causes	O
4	of	O
5	liver	O
6	disease	O
7	in	O
8	the	O
9	patients	O
10	with	O
11	HCC	O
12	were	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	(	O
20	77	O
21	%),	O
22	alcohol	O
23	abuse	O
24	(	O
25	73	O
26	%),	O
27	and	O
28	the	O
29	combination	O
30	of	O
31	HCV	O
32	and	O
33	alcohol	O
34	abuse	O
35	(	O
36	50	O
37	%).	O

1	The	O
2	predicted	O
3	Pay4p	O
4	sequence	O
5	contains	O
6	two	O
7	putative	O
8	ATP	O
9	-	O
10	binding	O
11	domains	O
12	and	O
13	shows	O
14	structural	O
15	relationships	O
16	to	O
17	other	B
18	potential	I
19	ATP	I
20	-	I
21	binding	I
22	proteins	I
23	involved	I
24	in	I
25	biological	I
26	processes	O
27	as	O
28	diverse	O
29	as	O
30	peroxisome	O
31	biogenesis	O
32	,	O
33	vesicle	O
34	-	B
35	mediated	I
36	protein	I
37	transport	I
38	,	O
39	cell	B
40	cycle	I
41	control	I
42	,	O
43	and	B
44	transcriptional	I
45	regulation	I
46	.	O

1	However	O
2	,	O
3	if	O
4	the	O
5	spatial	O
6	resolution	O
7	is	O
8	not	O
9	critical	B
10	and	I
11	interest	O
12	is	O
13	to	O
14	compare	O
15	a	O
16	pathologic	O
17	area	B
18	with	I
19	a	I
20	contralateral	I
21	VOI	I
22	,	O
23	then	O
24	the	O
25	acquisition	O
26	of	O
27	two	O
28	single	O
29	-	O
30	voxel	O
31	spectra	O
32	may	O
33	be	O
34	preferred	O
35	.	B

1	Thus	O
2	,	O
3	the	O
4	consensus	O
5	sequences	O
6	for	O
7	phosphatase	O
8	regulation	O
9	are	O
10	5	O
11	'-	O
12	GCACGTGGG	O
13	-	O
14	3	O
15	'	O
16	and	O
17	5	O
18	'-	O
19	GCACGTTTT	O
20	-	O
21	3	O
22	'	B
23	which	I
24	differ	I
25	from	I
26	the	O
27	binding	O
28	sequences	O
29	for	O
30	the	O
31	Cpflp	O
32	protein	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	genes	O
39	in	O
40	methionine	O
41	biosynthesis	O
42	and	O
43	for	O
44	centromere	O
45	function	O
46	.	O

1	These	O
2	results	O
3	provide	O
4	direct	O
5	evidence	O
6	for	B
7	differential	I
8	susceptibility	I
9	to	I
10	endonuclease	I
11	-	I
12	mediated	O
13	mRNA	O
14	decay	O
15	resulting	O
16	from	O
17	the	O
18	differential	O
19	affinity	O
20	of	O
21	a	B
22	RNA	O
23	-	B
24	binding	I
25	protein	I
26	for	I
27	cis	I
28	-	I
29	acting	O
30	stability	O
31	determinants	O
32	.	O

1	Evaluation	O
2	of	O
3	automatic	O
4	blood	O
5	cell	O
6	counters	O
7	.	O

1	The	O
2	genomic	O
3	structure	O
4	of	O
5	four	O
6	members	O
7	of	O
8	the	O
9	SRC	O
10	-	O
11	family	O
12	revealed	O
13	nearly	O
14	identical	O
15	exon	O
16	/	O
17	intron	O
18	boundaries	O
19	within	O
20	the	O
21	catalytic	O
22	domain	O
23	of	O
24	this	O
25	family	O
26	.	O

1	Significance	O
2	of	O
3	the	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	reaction	O
8	to	O
9	physical	O
10	loading	O
11	in	O
12	evaluating	O
13	the	O
14	effectiveness	O
15	of	O
16	mitral	O
17	commissurotomy	O

1	A	O
2	transcription	O
3	factor	O
4	exclusion	O
5	assay	O
6	was	O
7	used	O
8	to	O
9	show	O
10	that	O
11	the	O
12	PCF1	O
13	mutation	O
14	affects	O
15	two	O
16	distinct	O
17	stages	O
18	in	O
19	transcription	O
20	:	O
21	one	O
22	prior	O
23	to	O
24	and	O
25	one	O
26	after	O
27	stable	O
28	complex	O
29	formation	O
30	;	O
31	and	O
32	that	O
33	these	O
34	effects	O
35	are	O
36	mediated	O
37	by	O
38	a	O
39	component	O
40	of	O
41	the	O
42	stable	O
43	complex	O
44	.	O

1	The	O
2	target	O
3	contained	O
4	between	O
5	positions	O
6	-	O
7	403	O
8	and	O
9	-	O
10	125	O
11	acts	O
12	independently	O
13	of	B
14	orientation	I
15	,	O
16	in	O
17	different	O
18	cell	O
19	types	O
20	and	O
21	species	O
22	,	O
23	and	O
24	in	O
25	the	O
26	context	O
27	of	O
28	a	O
29	heterologous	O
30	promoter	O
31	.	O

1	Rapid	O
2	detection	O
3	of	O
4	radioisotopically	O
5	contaminated	O
6	test	O
7	serum	O
8	before	O
9	radioassay	O
10	of	O
11	vitamin	O
12	B12	O
13	.	O

1	Normal	O
2	values	O
3	for	O
4	the	O
5	peripheral	O
6	blood	O
7	and	O
8	bone	O
9	marrow	O
10	of	O
11	the	O
12	grey	O
13	(	O
14	Armenian	O
15	)	O
16	hamster	O

1	B	O
2	cell	O
3	antigen	O
4	receptor	O
5	(	O
6	BCR	O
7	)-	O
8	mediated	O
9	formation	O
10	of	O
11	a	O
12	SHP	O
13	-	O
14	2	O
15	-	O
16	pp120	O
17	complex	O
18	and	O
19	its	O
20	inhibition	O
21	by	B
22	Fc	I
23	gamma	I
24	RIIB1	I
25	-	I
26	BCR	I
27	coligation	I
28	.	O

1	A	O
2	segmental	O
3	analysis	O
4	of	O
5	the	O
6	key	O
7	regions	O
8	of	O
9	HLA	O
10	-	O
11	DR1	O
12	that	B
13	control	I
14	T	I
15	cell	I
16	allorecognition	I
17	was	I
18	performed	I
19	by	I
20	using	O
21	a	O
22	series	O
23	of	O
24	transfected	O
25	cell	O
26	lines	O
27	expressing	O
28	the	B
29	products	I
30	of	O
31	recombinant	O
32	DRB	O
33	/	O
34	H	O
35	-	O
36	2Eb	O
37	genes	O
38	,	O
39	paired	O
40	with	O
41	either	O
42	DR	O
43	alpha	O
44	or	O
45	H	O
46	-	O
47	2E	O
48	alpha	B
49	.	I

1	Total	O
2	serum	O
3	calcium	O
4	was	O
5	7	O
6	.	O
7	8	O
8	+/-	O
9	0	O
10	.	O
11	8	O
12	mg	O
13	/	O
14	dl	O
15	,	O
16	whereas	O
17	ionized	O
18	calcium	O
19	was	O
20	5	O
21	.	O
22	7	O
23	+/-	O
24	0	O
25	.	O
26	7	O
27	mg	O
28	/	O
29	dl	O
30	,	O
31	phosphorus	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	1	O
37	.	O
38	2	O
39	mg	O
40	/	O
41	dl	O
42	,	O
43	and	O
44	alkaline	O
45	phosphatase	O
46	149	O
47	+/-	O
48	48	O
49	.	O
50	6	O
51	U	O
52	/	O
53	liter	O
54	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	show	O
8	that	O
9	SRm160	O
10	/	O
11	300	O
12	is	O
13	required	O
14	for	O
15	a	O
16	purine	O
17	-	B
18	rich	I
19	ESE	I
20	to	O
21	promote	O
22	the	O
23	splicing	O
24	of	O
25	a	O
26	pre	O
27	-	O
28	mRNA	O
29	derived	O
30	from	O
31	the	O
32	Drosophila	O
33	doublesex	O
34	gene	O
35	.	O

1	Isolation	O
2	of	O
3	tha	O
4	avian	O
5	reticuloendothelial	O
6	virus	O
7	(	O
8	strain	O
9	T	O
10	).	O

1	Moreover	O
2	,	O
3	the	O
4	observation	O
5	of	O
6	enhanced	O
7	luteal	O
8	HSP	O
9	-	O
10	27	O
11	phosphorylation	O
12	in	O
13	vivo	O
14	,	O
15	in	O
16	late	O
17	pregnancy	O
18	,	O
19	when	O
20	PKC	O
21	-	O
22	delta	O
23	is	O
24	abundant	O
25	and	O
26	active	O
27	,	O
28	suggests	O
29	that	O
30	select	O
31	PKC	O
32	family	O
33	members	O
34	contribute	O
35	to	O
36	sHSP	O
37	phosphorylation	O
38	events	O
39	in	O
40	vivo	O
41	.	O

1	Toward	O
2	absolute	O
3	methods	O
4	in	O
5	clinical	O
6	chemistry	O
7	:	I
8	application	I
9	of	O
10	mass	O
11	fragmentography	B
12	to	B
13	high	I
14	-	I
15	accuracy	I
16	analyses	I
17	.	I

1	The	O
2	results	O
3	revealed	O
4	increased	O
5	blood	O
6	lead	O
7	level	O
8	associated	B
9	with	I
10	decreased	I
11	blood	O
12	haemoglobin	O
13	and	O
14	increased	O
15	urinary	O
16	excretion	O
17	of	O
18	delta	O
19	amino	O
20	levulinic	O
21	acid	O
22	.	O

1	By	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	this	O
7	Ras	O
8	-	O
9	binding	O
10	site	O
11	did	O
12	not	O
13	diminish	O
14	activation	O
15	of	O
16	Raf	O
17	-	O
18	1	O
19	kinase	O
20	by	O
21	Src	O
22	,	O
23	implying	O
24	that	O
25	Src	O
26	and	O
27	Ras	O
28	can	O
29	activate	O
30	Raf	O
31	-	O
32	1	O
33	through	O
34	independent	O
35	mechanisms	O
36	.	O

1	In	O
2	treated	O
3	herds	O
4	,	O
5	cows	O
6	more	O
7	than	O
8	40	O
9	d	O
10	postpartum	O
11	with	O
12	a	O
13	corpus	O
14	luteum	O
15	received	O
16	prostaglandin	B
17	F2	I
18	alpha	I
19	.	O

1	In	O
2	the	O
3	former	O
4	cells	O
5	,	O
6	ets	O
7	-	O
8	2	O
9	was	O
10	a	O
11	CSF	O
12	-	O
13	1	O
14	immediate	O
15	-	O
16	early	O
17	response	O
18	gene	O
19	,	O
20	and	O
21	phosphorylated	O
22	ets	O
23	-	O
24	2	O
25	was	O
26	detected	O
27	after	O
28	2	O
29	to	O
30	4	O
31	h	O
32	,	O
33	coincident	O
34	with	O
35	expression	O
36	of	O
37	ets	O
38	-	O
39	2	O
40	protein	O
41	.	O

1	The	O
2	bronchial	O
3	epithelia	O
4	of	O
5	all	O
6	smoke	O
7	-	O
8	exposed	O
9	animals	O
10	were	O
11	hyperplastic	O
12	,	O
13	and	O
14	their	O
15	ultrastructure	O
16	showed	O
17	invaginations	O
18	,	O
19	tilt	O
20	of	O
21	nuclear	O
22	axes	O
23	,	O
24	an	O
25	increase	O
26	in	O
27	the	O
28	number	O
29	and	O
30	size	O
31	of	O
32	lysosomes	O
33	and	O
34	multivesiculated	O
35	bodies	O
36	,	O
37	and	O
38	increased	O
39	numbers	O
40	of	O
41	enlarged	O
42	intramitochondrial	O
43	granules	O
44	.	O

1	Hepatitis	O
2	B	O
3	virus	O
4	and	O
5	hepatoma	O
6	.	O

1	Aneurysmectomy	O
2	and	O
3	the	O
4	performance	O
5	of	O
6	CABG	O
7	were	O
8	not	O
9	significantly	O
10	associated	B
11	with	I
12	postoperative	I
13	ECG	I
14	changes	I
15	,	I
16	but	I
17	more	I
18	bypass	I
19	grafts	I
20	per	I
21	patient	I
22	grafted	I
23	appeared	I
24	in	O
25	the	B
26	group	I
27	with	I
28	postoperative	I
29	ECG	O
30	changes	O
31	,	B
32	suggesting	I
33	that	I
34	coronary	I
35	artery	I
36	disease	I
37	may	I
38	be	I
39	more	I
40	severe	I
41	in	I
42	that	I
43	group	I
44	.	I

1	In	O
2	contrast	O
3	to	O
4	some	O
5	results	O
6	previously	O
7	published	O
8	for	O
9	a	O
10	very	O
11	close	O
12	sequence	O
13	variant	O
14	(	O
15	see	O
16	ref	O
17	.	O

1	Since	O
2	the	O
3	RINX	O
4	gene	O
5	is	O
6	likely	O
7	an	O
8	ortholog	O
9	of	O
10	the	O
11	goldfish	O
12	Vsx1	O
13	gene	O
14	,	O
15	it	O
16	has	O
17	been	O
18	named	O
19	VSX1	O
20	by	O
21	the	O
22	Human	O
23	Gene	B
24	Nomenclature	B
25	Committee	I
26	.	O

1	Performance	O
2	on	O
3	two	O
4	verbal	O
5	measures	O
6	-	O
7	the	O
8	National	O
9	Adult	O
10	Reading	O
11	Test	O
12	-	O
13	Revised	O
14	(	O
15	NART	O
16	-	O
17	R	O
18	)	O
19	and	O
20	the	O
21	Vocabulary	O
22	subtest	O
23	from	O
24	the	O
25	Wechsler	O
26	Adult	O
27	Intelligence	O
28	Scale	O
29	-	O
30	Revised	O
31	(	O
32	WAIS	O
33	-	O
34	R	O
35	)-	O
36	showed	O
37	strong	O
38	correlations	O
39	with	O
40	level	O
41	of	O
42	education	O
43	.	O

1	Dissociation	O
2	and	O
3	complexation	O
4	of	O
5	the	O
6	fluoroquinolone	O
7	antimicrobials	O
8	--	O
9	an	O
10	update	O
11	.	O

1	Renal	O
2	response	O
3	to	B
4	captopril	I
5	in	I
6	severe	I
7	heart	O
8	failure	O
9	:	O
10	role	O
11	of	O
12	furosemide	O
13	in	O
14	natriuresis	O
15	and	O
16	reversal	O
17	of	O
18	hyponatremia	O
19	.	O

1	Rainbow	O
2	trout	O
3	were	O
4	obtained	O
5	from	O
6	a	O
7	commercial	O
8	trout	O
9	farm	O
10	,	O
11	kept	O
12	in	O
13	running	O
14	water	O
15	and	O
16	feeding	O
17	in	O
18	experimental	O
19	pellets	O
20	for	O
21	4	O
22	to	O
23	8	O
24	weeks	O
25	.	O

1	Co	O
2	-	O
3	existence	O
4	of	O
5	these	B
6	regulatory	I
7	elements	I
8	with	I
9	other	I
10	elements	I
11	,	I
12	such	I
13	as	O
14	the	O
15	AP	O
16	-	O
17	2	O
18	element	O
19	or	O
20	CCAAT	O
21	box	O
22	,	O
23	was	O
24	also	O
25	found	O
26	.	O

1	NPT	O
2	II	O
3	synthesis	O
4	,	O
5	measured	O
6	by	O
7	agar	O
8	plate	O
9	assays	O
10	of	O
11	kanamycin	O
12	resistance	O
13	and	O
14	by	O
15	immunoprecipitation	O
16	of	O
17	the	O
18	NPT	O
19	II	O
20	protein	O
21	,	O
22	was	O
23	repressed	O
24	in	O
25	the	O
26	presence	O
27	of	O
28	cysteine	O
29	and	O
30	derepressed	O
31	in	O
32	its	O
33	absence	B
34	.	I

1	Sequence	O
2	analysis	O
3	of	O
4	a	O
5	6	O
6	.	O
7	3	O
8	-	O
9	kbp	O
10	genomic	O
11	EcoRI	O
12	-	I
13	fragment	I
14	of	I
15	Alcaligenes	I
16	eutrophus	O
17	,	O
18	which	O
19	was	O
20	recently	B
21	identified	I
22	by	I
23	using	I
24	a	I
25	dihydrolipoamide	O
26	dehydrogenase	O
27	-	B
28	specific	I
29	DNA	I
30	probe	I
31	(	I
32	A	I
33	.	I

1	BSE	O
2	and	O
3	farmworkers	O
4	.	O

1	Along	O
2	with	O
3	previously	O
4	mapped	O
5	genes	O
6	including	O
7	Ly	O
8	-	O
9	1	O
10	and	O
11	CD20	O
12	,	O
13	OSBP	O
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O

1	Phosphorylation	O
2	and	O
3	spindle	O
4	pole	O
5	body	O
6	localization	O
7	of	O
8	the	O
9	Cdc15p	O
10	mitotic	O
11	regulatory	O
12	protein	O
13	kinase	O
14	in	O
15	budding	O
16	yeast	O
17	.	O

1	The	O
2	present	O
3	data	O
4	also	O
5	indicate	O
6	that	O
7	patients	O
8	with	O
9	TGBM	O
10	nephropathy	O
11	often	O
12	have	O
13	concomitant	B
14	IgA	I
15	nephropathy	O
16	and	O
17	mesangial	O
18	proliferative	O
19	glomerulonephritis	O
20	.	O

1	In	O
2	addition	O
3	,	O
4	computer	O
5	analysis	O
6	suggests	O
7	that	O
8	sequences	O
9	similar	O
10	to	O
11	the	O
12	A	O
13	stem	O
14	element	O
15	are	O
16	present	O
17	within	O
18	the	O
19	three	O
20	AAV	O
21	promoter	O
22	regions	O
23	.	O

1	Model	O
2	IV	O
3	:	O
4	primary	O
5	abutments	O
6	with	O
7	the	O
8	lateral	O
9	incisor	O
10	and	O
11	the	O
12	second	O
13	molar	B
14	as	I
15	secondary	I
16	abutments	I
17	.	I

1	Yeast	O
2	Gal11	O
3	protein	O
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	O
16	and	O
17	general	O
18	regulatory	O
19	factor	O
20	I	O
21	/	O
22	repressor	O
23	/	I
24	activator	I
25	site	O
26	binding	O
27	protein	O
28	1	O
29	/	O
30	translation	O
31	upstream	O
32	factor	O
33	.	O

1	The	O
2	results	O
3	supported	O
4	the	O
5	therapeutic	O
6	principle	O
7	of	O
8	TCM	O
9	:	O
10	Treating	O
11	patients	O
12	according	O
13	to	O
14	their	O
15	pathophysiological	O
16	patterns	O
17	.	B

1	Marinol	O
2	/	O
3	marijuana	O
4	usage	O
5	was	O
6	associated	O
7	with	O
8	depressed	O
9	CD4	O
10	+	O
11	counts	O
12	and	O
13	elevated	O
14	amylase	O
15	levels	O
16	within	O
17	the	O
18	DDI	O
19	subgroup	O
20	.	O

1	Whole	O
2	blood	O
3	serotonin	O
4	levels	O
5	were	O
6	investigated	O
7	in	O
8	a	O
9	control	O
10	group	B
11	(	I
12	n	I
13	=	O
14	35	B
15	)	I
16	and	I
17	in	O
18	a	O
19	group	O
20	of	O
21	chronic	O
22	renal	O
23	failure	O
24	patients	B
25	(	I
26	n	I
27	=	O
28	127	B
29	)	I
30	on	I
31	various	O
32	treatment	O
33	regimen	O
34	i	O
35	.	O
36	e	O
37	.	O
38	conservative	O
39	treatment	O
40	(	O
41	n	O
42	=	O
43	39	O
44	),	O
45	maintenance	O
46	haemodialysis	O
47	(	O
48	n	O
49	=	O
50	35	O
51	)	O
52	and	O
53	after	O
54	renal	B
55	transplantation	I
56	(	I
57	n	I
58	=	I
59	53	O
60	).	O

1	When	O
2	used	O
3	subcutaneously	O
4	or	O
5	intravenously	O
6	in	O
7	maximum	O
8	tolerated	O
9	doses	O
10	the	O
11	antibiotic	O
12	inhibited	O
13	the	O
14	development	O
15	of	O
16	lymphadenosis	O
17	NK	O
18	/	B
19	Li	I
20	by	I
21	90	I
22	and	I
23	70	I
24	per	I
25	cent	I
26	respectively	I
27	.	I

1	Replicating	O
2	simian	O
3	virus	O
4	40	O
5	(	O
6	SV40	O
7	)	O
8	chromosomes	O
9	were	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	to	O
15	other	O
16	eukaryotic	O
17	chromosomes	O
18	in	O
19	that	O
20	the	O
21	rate	O
22	and	O
23	extent	O
24	of	O
25	micrococcal	O
26	nuclease	O
27	(	O
28	MNase	O
29	)	O
30	digestion	O
31	were	O
32	greater	O
33	with	O
34	replicating	O
35	than	O
36	with	O
37	nonreplicating	O
38	mature	O
39	SV40	O
40	chromatin	O
41	.	O

1	Glucagon	O
2	also	O
3	induced	O
4	LUC	O
5	activity	O
6	very	O
7	strongly	O
8	when	O
9	the	O
10	CRE1	O
11	and	O
12	CRE2	O
13	sites	O
14	were	O
15	combined	O
16	;	O
17	induction	O
18	of	B
19	the	I
20	(	I
21	CRE1	I
22	)	I
23	3	I
24	(	I
25	CRE2	I
26	)	I
27	2SV40	I
28	-	O
29	LUC	O
30	constructs	O
31	was	O
32	positively	O
33	modulated	O
34	by	O
35	the	O
36	pO2	O
37	.	O

1	A	O
2	combined	O
3	series	O
4	of	O
5	patients	O
6	experienced	O
7	a	O
8	TOL	O
9	after	B
10	two	I
11	or	I
12	more	O
13	previous	O
14	cesarean	O
15	deliveries	O
16	;	O
17	the	O
18	rate	O
19	of	O
20	vaginal	O
21	delivery	O
22	was	O
23	66	O
24	%,	O
25	and	O
26	there	O
27	was	O
28	virtually	O
29	no	O
30	morbidity	O
31	.	O

1	Some	O
2	artificial	O
3	promoter	O
4	constructs	O
5	containing	O
6	multiple	O
7	Sp1	O
8	sites	B
9	were	I
10	highly	I
11	responsive	I
12	to	I
13	ethanol	O
14	,	O
15	but	O
16	others	O
17	were	O
18	not	O
19	,	O
20	suggesting	O
21	that	O
22	the	O
23	organization	O
24	of	O
25	the	B
26	proximal	I
27	promoter	I
28	region	I
29	was	I
30	an	I
31	additional	I
32	factor	O
33	that	O
34	affected	O
35	the	O
36	ethanol	O
37	response	O
38	.	O

1	Stoichiometric	O
2	phosphorylation	O
3	of	O
4	human	O
5	p53	O
6	at	O
7	Ser315	O
8	stimulates	O
9	p53	O
10	-	O
11	dependent	O
12	transcription	O
13	.	O
14	p53	O
15	protein	O
16	activity	O
17	as	O
18	a	O
19	transcription	O
20	factor	O
21	can	O
22	be	O
23	activated	O
24	in	O
25	vivo	O
26	by	O
27	antibodies	O
28	that	O
29	target	O
30	its	O
31	C	O
32	-	O
33	terminal	O
34	negative	O
35	regulatory	O
36	domain	O
37	suggesting	O
38	that	O
39	cellular	O
40	enzymes	O
41	that	O
42	target	O
43	this	O
44	domain	O
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	stimulating	O
51	p53	O
52	-	O
53	dependent	O
54	gene	O
55	expression	O
56	.	O

1	The	O
2	patient	O
3	underwent	O
4	two	O
5	intracytoplasmic	O
6	sperm	O
7	injection	O
8	cycles	O
9	with	O
10	thawed	O
11	epididymal	O
12	spermatozoa	O
13	,	O
14	in	O
15	which	O
16	,	O
17	due	O
18	to	O
19	a	O
20	pharmacist	O
21	'	O
22	s	O
23	mistake	O
24	,	O
25	ovarian	O
26	stimulation	O
27	was	O
28	carried	O
29	out	O
30	by	O
31	a	O
32	combination	O
33	of	O
34	long	O
35	-	O
36	acting	O
37	gonadotrophin	O
38	-	O
39	releasing	O
40	hormone	O
41	agonist	O
42	(	O
43	leuprolide	O
44	depot	O
45	)	O
46	and	O
47	gonadotrophins	O
48	.	O

1	Gastric	O
2	CO2	O
3	/	O
4	HCO3	O
5	was	O
6	determined	O
7	in	O
8	absence	O
9	of	O
10	simultaneous	O
11	inhibition	O
12	of	O
13	acid	O
14	secretion	O
15	by	O
16	intra	O
17	-	O
18	and	O
19	extragastric	O
20	pCO2	O
21	/	O
22	pH	O
23	measurements	O
24	in	O
25	23	O
26	persons	O
27	and	O
28	calculated	O
29	using	O
30	the	O
31	equation	O
32	of	O
33	Henderson	O
34	-	O
35	Hasselbalch	O
36	.	O
37	pCO2	O
38	was	O
39	measured	O
40	with	O
41	use	O
42	of	O
43	a	O
44	new	O
45	electrode	O
46	.	O

1	Analysis	O
2	of	B
3	various	I
4	deletion	I
5	mutants	I
6	indicates	O
7	that	O
8	the	O
9	sequence	O
10	requirements	O
11	for	I
12	binding	I
13	by	O
14	QBP	O
15	in	O
16	vitro	O
17	are	O
18	indistinguishable	O
19	from	O
20	those	O
21	necessary	I
22	for	O
23	Q	I
24	activity	I
25	in	O
26	vivo	O
27	,	O
28	strongly	O
29	suggesting	O
30	that	O
31	QBP	B
32	is	I
33	required	I
34	for	I
35	the	I
36	function	I
37	of	I
38	this	O
39	TATA	O
40	-	O
41	independent	O
42	promoter	O
43	.	O

1	However	O
2	,	O
3	the	O
4	signaling	O
5	cascade	O
6	utilized	O
7	by	O
8	the	O
9	urokinase	O
10	receptor	O
11	is	O
12	only	O
13	incompletely	O
14	understood	O
15	.	O

1	Bound	O
2	-	O
3	exciton	B
4	transfer	I
5	and	I
6	photoluminescence	I
7	undulation	O
8	spectra	B
9	for	I
10	acceptors	I
11	in	I
12	ZnTe	I
13	.	I

1	We	O
2	also	O
3	present	O
4	evidence	O
5	that	O
6	human	O
7	HYAL1	O
8	is	O
9	identical	O
10	to	O
11	an	O
12	uncharacterized	O
13	gene	O
14	positionally	O
15	cloned	O
16	by	O
17	others	O
18	from	O
19	chromosome	O
20	3p21	O
21	.	O
22	3	O
23	that	O
24	is	O
25	homozygously	O
26	deleted	O
27	in	O
28	several	O
29	small	O
30	-	O
31	cell	O
32	lung	O
33	carcinoma	O
34	cell	O
35	lines	O
36	.	O

1	Because	O
2	the	O
3	high	O
4	-	O
5	density	O
6	lipoprotein	O
7	receptor	O
8	(	O
9	HDL	O
10	-	O
11	R	O
12	)	O
13	is	O
14	a	O
15	key	O
16	element	O
17	in	O
18	cholesterol	O
19	homeostasis	O
20	and	B
21	a	I
22	potential	I
23	therapeutic	I
24	target	I
25	for	I
26	hypercholesterolemic	I
27	drugs	I
28	,	I
29	an	O
30	understanding	O
31	of	O
32	HDL	O
33	-	O
34	R	O
35	regulation	O
36	is	O
37	essential	O
38	.	O

1	For	O
2	signal	O
3	durations	O
4	less	O
5	than	O
6	10	O
7	ms	B
8	,	O
9	however	B
10	,	I
11	the	I
12	SoNo	I
13	and	O
14	S	O
15	pi	O
16	No	O
17	threshold	O
18	functions	O
19	converged	O
20	and	O
21	the	O
22	masking	O
23	-	O
24	level	O
25	difference	O
26	decreased	O
27	.	O

1	In	O
2	gel	O
3	mobility	B
4	shift	I
5	assays	I
6	,	I
7	low	I
8	binding	I
9	activity	O
10	of	O
11	CBF	O
12	to	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	AtpC	O
18	promoter	O
19	sequence	O
20	was	O
21	observed	O
22	with	O
23	nuclear	O
24	extracts	O
25	from	O
26	tissue	O
27	with	O
28	low	B
29	AtpC	I
30	expression	I
31	levels	O
32	,	O
33	i	O
34	.	O
35	e	O
36	.	B
37	extracts	B
38	from	O
39	etiolated	B
40	and	B
41	photobleached	I
42	seedlings	I
43	,	O
44	whereas	I
45	high	O
46	binding	O
47	activity	O
48	was	O
49	detectable	O
50	with	O
51	extracts	B
52	from	B
53	tissues	O
54	with	I
55	high	I
56	AtpC	I
57	expression	I
58	levels	O
59	,	O
60	i	O
61	.	I
62	e	O
63	.	O
64	extracts	O
65	from	I
66	light	O
67	-	O
68	grown	O
69	seedlings	O
70	and	O
71	etiolated	I
72	seedlings	I
73	treated	I
74	with	I
75	cytokinin	O
76	.	O

1	First	O
2	,	B
3	two	I
4	MCTs	I
5	using	I
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	B
15	were	I
16	performed	I
17	in	I
18	the	I
19	central	I
20	area	I
21	of	I
22	the	I
23	tumor	I
24	,	I
25	and	I
26	eight	I
27	MCTs	O
28	by	B
29	a	I
30	short	I
31	electrode	I
32	,	I
33	2	I
34	cm	I
35	in	O
36	size	B
37	,	I
38	were	I
39	done	I
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	B
46	of	I
47	the	I
48	tumor	O
49	.	O

1	Revascularization	O
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O

1	Furthermore	O
2	,	O
3	the	O
4	validity	O
5	of	O
6	this	O
7	new	O
8	subset	O
9	of	O
10	questions	O
11	was	O
12	shown	O
13	to	O
14	be	O
15	significant	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	037	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	)	O
29	for	O
30	the	O
31	correlation	O
32	between	O
33	a	O
34	measure	O
35	of	O
36	the	O
37	severity	O
38	of	O
39	binocular	O
40	visual	O
41	field	O
42	loss	O
43	and	O
44	the	O
45	mean	O
46	score	O
47	of	O
48	the	O
49	variables	O
50	used	O
51	in	O
52	the	O
53	glaucoma	O
54	specific	O
55	subgroup	O
56	of	O
57	questions	O
58	.	O

1	Immunostaining	O
2	of	O
3	cells	O
4	transfected	O
5	with	O
6	these	O
7	constructs	O
8	revealed	O
9	that	O
10	both	O
11	the	O
12	myristoylated	O
13	and	O
14	nonmyristoylated	B
15	mutants	B
16	were	I
17	localized	O
18	in	O
19	nuclei	O
20	,	O
21	whereas	O
22	wild	O
23	-	O
24	type	O
25	PKC	O
26	alpha	O
27	was	O
28	primarily	O
29	cytoplasmic	O
30	and	O
31	perinuclear	O
32	.	O

1	Mitogen	O
2	-	B
3	induced	I
4	lymphocyte	I
5	proliferation	I
6	was	I
7	diminished	I
8	.	I

1	The	O
2	complete	O
3	circular	O
4	TTV	O
5	genome	O
6	contained	O
7	a	O
8	novel	O
9	sequence	O
10	of	O
11	113	O
12	nt	O
13	(	O
14	nt	O
15	3740	O
16	to	O
17	3852	O
18	[=	O
19	0	O
20	])	O
21	in	O
22	between	O
23	the	O
24	known	O
25	3	O
26	'-	O
27	and	O
28	5	O
29	'-	O
30	end	O
31	arms	O
32	,	O
33	forming	O
34	a	O
35	117	O
36	-	O
37	nt	O
38	GC	O
39	-	O
40	rich	O
41	stretch	O
42	(	O
43	GC	O
44	content	O
45	,	O
46	90	O
47	.	O
48	6	O
49	%	O
50	at	O
51	nt	O
52	3736	O
53	to	O
54	3852	O
55	).	O

1	Judge	O
2	OKs	O
3	docs	O
4	'	O
5	bid	O
6	for	O
7	Chicago	O
8	hospital	O
9	.	O

1	While	O
2	this	O
3	Saccharomyces	O
4	cerevisiae	O
5	SIN4	B
6	gene	I
7	product	O
8	is	B
9	a	I
10	component	O
11	of	O
12	a	O
13	mediator	O
14	complex	O
15	associated	O
16	with	O
17	RNA	O
18	polymerase	O
19	II	O
20	,	O
21	various	O
22	studies	O
23	suggest	O
24	the	O
25	involvement	O
26	of	O
27	Sin4	O
28	in	O
29	the	O
30	alteration	O
31	of	O
32	higher	O
33	-	O
34	order	O
35	chromatin	O
36	structure	O
37	.	O

1	Absorption	O
2	was	O
3	rapid	O
4	,	O
5	with	O
6	a	O
7	mean	O
8	time	O
9	to	O
10	peak	O
11	of	O
12	39	O
13	min	O
14	.	O

1	The	O
2	model	O
3	is	O
4	able	O
5	to	O
6	anticipate	O
7	why	O
8	the	O
9	effect	O
10	of	O
11	water	O
12	fluoridation	O
13	on	O
14	caries	O
15	prevalence	B
16	is	I
17	most	I
18	pronounced	I
19	when	O
20	caries	O
21	is	O
22	diagnosed	O
23	at	O
24	cavity	O
25	level	O
26	.	O

1	Ovaries	O
2	of	O
3	10	O
4	animals	O
5	per	O
6	group	O
7	from	O
8	16	O
9	studies	O
10	in	O
11	CD	O
12	-	O
13	1	O
14	mice	O
15	and	O
16	1	O
17	study	O
18	each	O
19	in	O
20	C3H	O
21	and	O
22	C57BL	O
23	/	O
24	6	O
25	mice	O
26	were	O
27	sectioned	O
28	serially	O
29	at	O
30	6	O
31	microm	O
32	.	O

1	The	O
2	Drosophila	O
3	clathrin	O
4	heavy	O
5	chain	O
6	gene	O
7	:	O
8	clathrin	O
9	function	O
10	is	O
11	essential	O
12	in	O
13	a	O
14	multicellular	O
15	organism	O
16	.	O

1	Transfection	O
2	experiments	B
3	using	I
4	preformed	I
5	triplexes	I
6	with	O
7	a	O
8	reporter	B
9	plasmid	I
10	containing	O
11	the	B
12	collagen	I
13	promoter	O
14	sequence	O
15	showed	O
16	significant	O
17	inhibition	O
18	of	O
19	transcription	O
20	when	O
21	compared	O
22	with	O
23	a	O
24	control	O
25	phosphorothioate	O
26	ODN	O
27	.	O

1	Pigs	O
2	were	O
3	switched	O
4	from	O
5	the	O
6	growing	O
7	to	O
8	the	O
9	finishing	O
10	diet	O
11	at	O
12	57	O
13	and	O
14	61	O
15	kg	O
16	in	O
17	Exp	O
18	.	O

1	A	O
2	review	O
3	of	O
4	studies	O
5	published	O
6	between	O
7	1983	O
8	and	O
9	1995	O
10	shows	O
11	that	O
12	there	O
13	are	O
14	some	O
15	common	O
16	factors	O
17	as	O
18	regards	O
19	the	O
20	psychological	O
21	distress	O
22	and	O
23	social	O
24	and	O
25	functional	O
26	limitations	O
27	this	O
28	group	O
29	of	O
30	patients	O
31	has	O
32	to	O
33	deal	O
34	with	O
35	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	alpha	O
6	-	O
7	subunit	O
8	of	O
9	the	O
10	telomere	O
11	-	O
12	binding	O
13	protein	O
14	,	O
15	like	O
16	many	O
17	transcription	O
18	factors	O
19	,	O
20	has	O
21	separable	O
22	DNA	O
23	-	O
24	binding	O
25	and	O
26	protein	O
27	-	O
28	protein	O
29	interaction	O
30	domains	O
31	.	O

1	The	O
2	recovered	O
3	calves	O
4	were	O
5	tested	O
6	for	O
7	immunity	O
8	to	O
9	homologous	O
10	severe	O
11	challenge	O
12	,	O
13	50	O
14	or	O
15	73	O
16	days	O
17	after	O
18	the	O
19	first	O
20	infection	O
21	.	O

1	P	O
2	.	O

1	RESULTS	O
2	:	B
3	During	I
4	the	O
5	7	O
6	-	O
7	year	O
8	period	O
9	,	O
10	10	O
11	,	O
12	331	O
13	symptomatic	O
14	duodenal	O
15	ulcer	O
16	diseases	O
17	were	O
18	diagnosed	O
19	.	O

1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O

1	On	O
2	the	O
3	trail	O
4	of	O
5	Dr	O
6	.	O

1	(	O
2	ii	O
3	)	O
4	opening	O
5	of	O
6	KATP	O
7	attenuates	O
8	,	O
9	inhibition	O
10	of	O
11	the	O
12	channel	O
13	exacerbates	O
14	functional	O
15	consequences	O
16	of	O
17	coronary	O
18	occlusion	O
19	,	O
20	and	O
21	(	O
22	iii	O
23	)	O
24	KATP	O
25	opening	O
26	attenuates	O
27	reperfusion	O
28	-	O
29	induced	O
30	VF	O
31	,	O
32	but	O
33	it	O
34	triggers	O
35	ischemia	O
36	-	O
37	induced	O
38	VF	O
39	.	O

1	These	O
2	findings	O
3	indicate	O
4	the	O
5	involvement	O
6	of	O
7	Sp1	O
8	and	O
9	an	O
10	Inr	O
11	in	O
12	non	O
13	-	O
14	cell	O
15	-	O
16	specific	O
17	regulation	O
18	and	O
19	a	O
20	Kruppel	O
21	-	O
22	like	O
23	transcription	O
24	factor	O
25	and	O
26	Sp1	O
27	in	O
28	the	O
29	cell	O
30	-	O
31	specific	O
32	regulation	O
33	of	O
34	the	O
35	LTC	O
36	(	O
37	4	O
38	)	O
39	S	O
40	gene	O
41	.	O

1	Seventy	O
2	-	O
3	two	O
4	hours	O
5	after	O
6	administration	O
7	of	O
8	vitamin	O
9	K1	O
10	,	O
11	plasma	O
12	concentrations	O
13	of	O
14	the	O
15	vitamin	O
16	were	O
17	not	O
18	different	O
19	from	O
20	normal	O
21	.	O

1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	O
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	F2alpha	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	intrauterine	O
19	routes	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	menstrual	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	infertile	O
34	women	O
35	.	O

1	Lac	O
2	operators	O
3	were	O
4	introduced	O
5	into	O
6	several	O
7	positions	O
8	within	O
9	the	O
10	CAB	O
11	promoter	O
12	and	O
13	operator	O
14	-	O
15	free	O
16	plasmid	O
17	was	O
18	used	O
19	as	O
20	control	O
21	.	O

1	High	O
2	fibrinogen	O
3	levels	O
4	could	O
5	thus	O
6	be	O
7	a	B
8	risk	I
9	for	O
10	perioperative	O
11	thrombosis	O
12	.	O

1	To	O
2	investigate	O
3	the	O
4	functions	O
5	of	O
6	GE	B
7	,	I
8	IG	I
9	,	I
10	and	I
11	GS	I
12	sequences	I
13	in	I
14	transcription	O
15	,	B
16	we	I
17	constructed	I
18	plasmids	I
19	containing	I
20	cDNAs	I
21	of	I
22	the	I
23	full	O
24	-	O
25	length	B
26	SV5	I
27	genome	I
28	in	I
29	which	I
30	the	I
31	gene	I
32	junction	I
33	sequences	O
34	(	B
35	GE	I
36	,	I
37	IG	I
38	,	I
39	and	I
40	GS	I
41	sequences	I
42	)	O
43	located	O
44	between	O
45	the	O
46	hemagglutinin	O
47	-	O
48	neuraminidase	O
49	(	O
50	HN	O
51	)	O
52	and	O
53	the	O
54	polymerase	O
55	(	O
56	L	O
57	)	O
58	genes	O
59	were	O
60	replaced	O
61	with	O
62	the	O
63	counterpart	O
64	sequences	O
65	from	O
66	other	O
67	gene	O
68	junctions	O
69	.	O

1	We	O
2	have	O
3	identified	O
4	three	O
5	binding	O
6	sites	O
7	for	O
8	protein	O
9	complexes	O
10	:	O
11	a	O
12	palindrome	O
13	,	O
14	a	O
15	direct	O
16	repeat	O
17	,	O
18	and	O
19	a	O
20	C	O
21	+	O
22	T	O
23	sequence	O
24	that	O
25	corresponds	O
26	to	O
27	seven	O
28	GAGA	O
29	motifs	O
30	on	O
31	the	O
32	transcribed	O
33	strand	O
34	.	O

1	During	O
2	V	O
3	-	O
4	A	O
5	bypass	O
6	,	O
7	hemodynamics	O
8	were	O
9	stable	O
10	.	O

1	Blood	O
2	eosinophils	O
3	in	O
4	patients	I
5	with	I
6	Taenia	I
7	saginata	O
8	taeniasis	B
9	.	O

1	Immobilization	O
2	of	O
3	the	O
4	fracture	O
5	in	O
6	a	O
7	collar	O
8	and	O
9	cuff	O
10	sling	O
11	was	O
12	as	O
13	effective	O
14	as	O
15	more	O
16	elaborate	O
17	methods	O
18	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	similar	O
6	fragment	O
7	lacking	O
8	the	O
9	38	O
10	-	O
11	base	O
12	-	O
13	pair	O
14	region	B
15	had	I
16	no	I
17	such	O
18	stabilizing	O
19	effect	O
20	.	O

1	We	O
2	tried	O
3	amphotericin	O
4	B	O
5	(	O
6	AmB	O
7	),	O
8	and	O
9	remission	B
10	of	I
11	the	I
12	tumor	I
13	was	I
14	obtained	I
15	.	I

1	Interestingly	O
2	,	O
3	these	O
4	response	O
5	elements	O
6	display	O
7	dramatically	O
8	reduced	O
9	affinity	O
10	for	O
11	retinoic	O
12	acid	O
13	receptor	O
14	-	O
15	retinoid	O
16	-	O
17	X	O
18	receptor	O
19	heterodimers	O
20	.	O

1	Comparison	O
2	of	O
3	Tc	O
4	-	O
5	99m	O
6	sestamibi	O
7	perfusion	B
8	imaging	I
9	and	O
10	echocardiography	O
11	using	O
12	an	O
13	arbutamine	O
14	infusion	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	coronary	O
20	artery	O
21	disease	O
22	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	CD1	O
9	gene	O
10	contained	O
11	the	O
12	binding	O
13	motifs	O
14	for	O
15	two	O
16	cytokine	O
17	-	O
18	inducible	O
19	transcription	O
20	factors	O
21	,	O
22	NF	O
23	-	O
24	IL2	O
25	-	O
26	A	O
27	and	O
28	NF	O
29	-	O
30	IL6	O
31	.	O

1	In	O
2	a	O
3	model	O
4	of	O
5	the	O
6	ternary	O
7	complex	O
8	,	O
9	the	O
10	segment	O
11	of	O
12	NFAT	O
13	nearest	O
14	AP	O
15	-	O
16	1	O
17	is	O
18	the	O
19	Rel	O
20	insert	O
21	region	O
22	(	O
23	RIR	O
24	),	O
25	a	O
26	feature	O
27	that	O
28	is	O
29	notable	O
30	for	O
31	its	O
32	hypervariability	O
33	in	O
34	size	O
35	and	O
36	in	O
37	sequence	O
38	amongst	O
39	members	O
40	of	O
41	the	O
42	Rel	O
43	transcription	O
44	factor	O
45	family	O
46	.	O

1	A	O
2	mutant	O
3	in	O
4	the	O
5	AAV	O
6	terminal	O
7	resolution	O
8	site	O
9	(	O
10	trs	O
11	)	O
12	was	O
13	defective	O
14	for	O
15	DNA	O
16	replication	B
17	in	I
18	the	I
19	in	I
20	vitro	O
21	assay	O
22	.	O

1	Genetic	O
2	analysis	O
3	has	O
4	subsequently	O
5	identified	O
6	subpathways	O
7	of	O
8	the	O
9	DNA	O
10	structure	O
11	checkpoints	O
12	,	O
13	including	O
14	the	O
15	reversible	O
16	arrest	O
17	of	O
18	DNA	O
19	synthesis	O
20	.	O

1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	O
9	and	O
10	PPARgamma	O
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	In	O
6	25	O
7	open	O
8	-	O
9	chest	B
10	,	I
11	anesthetized	I
12	dogs	O
13	,	O
14	progressive	O
15	circumflex	O
16	artery	O
17	stenosis	O
18	led	O
19	to	B
20	a	B
21	concordant	I
22	decrease	O
23	of	B
24	circumflex	B
25	artery	I
26	resting	O
27	and	O
28	hyperemic	O
29	flow	O
30	,	O
31	coronary	O
32	flow	O
33	reserve	O
34	,	O
35	and	O
36	inverse	O
37	angiographic	O
38	mean	O
39	transit	O
40	time	O
41	Tmicro	O
42	-	O
43	1	O
44	(	O
45	P	B
46	<	B
47	.	I
48	01	O
49	).	O

1	Tyrosine	O
2	kinase	O
3	oncogenes	O
4	abrogate	O
5	interleukin	O
6	-	O
7	3	O
8	dependence	O
9	of	O
10	murine	O
11	myeloid	O
12	cells	O
13	through	O
14	signaling	O
15	pathways	O
16	involving	O
17	c	O
18	-	O
19	myc	O
20	:	O
21	conditional	O
22	regulation	O
23	of	O
24	c	O
25	-	O
26	myc	O
27	transcription	O
28	by	O
29	temperature	O
30	-	O
31	sensitive	O
32	v	O
33	-	O
34	abl	O
35	.	O

1	Ime1	O
2	plays	O
3	a	O
4	pivotal	O
5	role	O
6	in	O
7	the	O
8	initiation	O
9	of	O
10	meiosis	O
11	in	O
12	a	O
13	/	O
14	alpha	O
15	diploid	O
16	cells	O
17	of	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	Incorporation	O
2	of	O
3	the	O
4	polyene	O
5	antibiotic	O
6	amphotericin	O
7	B	O
8	(	O
9	AMB	O
10	)	O
11	in	O
12	liposomes	O
13	results	O
14	in	O
15	a	O
16	marked	O
17	reduction	O
18	in	O
19	drug	O
20	toxicity	O
21	with	O
22	no	O
23	loss	O
24	of	O
25	antifungal	O
26	potency	O
27	.	O

1	This	O
2	report	O
3	expands	O
4	on	O
5	previous	O
6	work	O
7	with	O
8	interferon	O
9	alfa	O
10	-	O
11	2b	O
12	(	O
13	Intron	O
14	A	O
15	;	O
16	Schering	O
17	-	O
18	Plough	O
19	)	O
20	in	O
21	the	O
22	treatment	O
23	of	O
24	hairy	O
25	cell	O
26	leukemia	O
27	(	O
28	HCL	O
29	).	O

1	Deletion	O
2	and	B
3	site	I
4	-	I
5	directed	I
6	mutagenesis	O
7	localized	B
8	a	I
9	novel	O
10	SF	O
11	-	O
12	1	O
13	regulatory	O
14	element	O
15	(	O
16	TCA	O
17	GGGCCA	O
18	;	O
19	-	O
20	137	O
21	to	O
22	-	O
23	129	O
24	)	I
25	adjacent	O
26	to	O
27	a	O
28	variant	O
29	cAMP	O
30	-	O
31	response	O
32	element	I
33	(	O
34	CRE	O
35	;	I
36	-	I
37	120	I
38	to	O
39	-	I
40	114	I
41	).	I

1	It	O
2	is	O
3	concluded	O
4	that	O
5	CT	O
6	should	O
7	be	O
8	routinely	O
9	employed	O
10	in	O
11	patients	O
12	with	O
13	N1	O
14	-	O
15	N3	O
16	neck	O
17	disease	O
18	to	O
19	determine	O
20	the	O
21	proper	O
22	electron	O
23	-	O
24	energy	O
25	prescription	O
26	.	O

1	Basal	O
2	plasma	O
3	renin	O
4	activity	O
5	(	O
6	PRA	O
7	)	O
8	was	O
9	slightly	O
10	raised	O
11	prior	O
12	to	O
13	training	O
14	(	O
15	P	O
16	<	O
17	0	B
18	.	I
19	07	I
20	)	I
21	compared	O
22	to	O
23	the	O
24	controls	O
25	and	O
26	post	O
27	-	O
28	training	O
29	.	O

1	Five	O
2	patients	O
3	developed	O
4	metastatic	O
5	spread	O
6	,	B
7	and	I
8	all	I
9	of	I
10	them	I
11	died	I
12	of	O
13	tumor	O
14	.	O

1	The	O
2	promoter	O
3	segment	O
4	was	O
5	inactive	O
6	when	O
7	introduced	O
8	into	O
9	the	O
10	rat	O
11	glioma	O
12	cell	O
13	line	B
14	C6B4	B
15	,	I
16	the	I
17	rat	I
18	submandibular	O
19	cell	B
20	line	I
21	RSMT	I
22	-	I
23	A5	I
24	,	I
25	and	O
26	the	O
27	rat	O
28	pancreatic	O
29	beta	O
30	cell	O
31	line	O
32	RIN	O
33	-	O
34	5AH	O
35	,	O
36	all	O
37	of	O
38	which	O
39	do	O
40	not	O
41	express	O
42	the	O
43	endogenous	O
44	alpha2c	O
45	-	O
46	AR	O
47	gene	O
48	.	O

1	Overlapping	O
2	cDNA	O
3	clones	O
4	were	O
5	isolated	O
6	and	O
7	sequenced	O
8	.	O

1	Comparison	O
2	of	O
3	1	O
4	.	O
5	5	O
6	Tesla	O
7	and	O
8	0	O
9	.	O
10	35	O
11	Tesla	O
12	field	O
13	strength	O
14	magnetic	O
15	resonance	O
16	imaging	O
17	scans	O
18	in	O
19	the	O
20	morphometric	O
21	evaluation	O
22	of	B
23	the	I
24	lumbar	I
25	intervertebral	I
26	foramina	I
27	.	O

1	The	O
2	properties	O
3	of	O
4	the	O
5	phi	O
6	29	O
7	SSB	O
8	-	O
9	ssDNA	O
10	complex	O
11	are	O
12	described	O
13	.	O

1	This	O
2	core	O
3	sequence	O
4	,	O
5	along	O
6	with	O
7	additional	O
8	nonspecific	O
9	downstream	O
10	nucleotides	O
11	,	O
12	is	O
13	sufficient	O
14	for	O
15	partial	O
16	suppression	O
17	of	O
18	spliceosome	O
19	assembly	O
20	and	O
21	splicing	O
22	of	O
23	BPV	O
24	-	O
25	1	O
26	pre	O
27	-	O
28	mRNAs	O
29	.	O

1	Although	O
2	no	O
3	Rh	O
4	-	O
5	antibodies	O
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O

1	HANYS	O
2	criticizes	O
3	laparoscopic	O
4	gall	O
5	bladder	O
6	guidelines	O
7	.	O

1	Tetrad	O
2	analysis	O
3	and	O
4	mitotic	O
5	recombination	O
6	experiments	O
7	localized	O
8	the	O
9	PEP4	O
10	gene	O
11	proximal	O
12	to	O
13	GAL4	O
14	on	O
15	chromosome	O
16	XVI	O
17	.	O

1	Serotonin	O
2	concentration	O
3	in	O
4	the	O
5	blood	O
6	of	O
7	patients	O
8	with	O
9	hemorrhagic	O
10	fever	O
11	with	O
12	renal	O
13	syndrome	O

1	Substantial	O
2	amounts	O
3	of	O
4	liposomal	O
5	ampicillin	O
6	were	O
7	recovered	O
8	from	O
9	isolated	O
10	Kupffer	B
11	cells	I
12	,	I
13	the	I
14	target	I
15	cells	O
16	of	O
17	L	O
18	.	O
19	monocytogenes	O
20	after	O
21	intravenous	O
22	inoculation	O
23	.	O

1	CONCLUSIONS	O
2	:	O
3	Translocation	O
4	of	O
5	bacteria	O
6	or	O
7	endotoxin	O
8	from	O
9	the	O
10	gastrointestinal	O
11	tract	O
12	into	O
13	the	O
14	bloodstream	O
15	has	O
16	been	O
17	noted	O
18	in	O
19	animal	O
20	experiments	O
21	;	O
22	however	O
23	,	O
24	translocation	O
25	was	O
26	not	O
27	detected	O
28	in	O
29	our	O
30	patients	O
31	with	O
32	hemorrhagic	O
33	shock	O
34	.	O

1	Tryptic	O
2	cleavage	O
3	and	O
4	peptide	O
5	sequence	O
6	analysis	O
7	demonstrated	O
8	that	O
9	the	O
10	98	O
11	-	O
12	kD	O
13	protein	O
14	is	O
15	identical	O
16	to	O
17	a	O
18	recently	O
19	cloned	O
20	protein	O
21	,	O
22	special	O
23	A	O
24	-	O
25	T	O
26	-	O
27	rich	O
28	binding	O
29	protein	O
30	1	O
31	(	O
32	SATB1	O
33	),	O
34	that	O
35	binds	O
36	selectively	O
37	to	O
38	nuclear	O
39	matrix	O
40	/	O
41	scaffold	O
42	-	O
43	associated	O
44	regions	O
45	of	O
46	DNA	O
47	(	O
48	MARs	O
49	/	O
50	SARs	O
51	).	O

1	Fentanyl	O
2	,	O
3	a	O
4	prototypic	O
5	mu	O
6	-	O
7	opiate	O
8	receptor	O
9	agonist	O
10	,	O
11	has	O
12	been	O
13	previously	O
14	shown	O
15	to	O
16	produce	O
17	a	O
18	syndrome	O
19	characterized	O
20	by	O
21	marked	O
22	analgesia	O
23	and	O
24	locomotor	O
25	stimulation	O
26	as	O
27	well	O
28	as	O
29	tachycardia	O
30	,	O
31	tachypnoea	O
32	and	O
33	behavioural	O
34	arousal	O
35	.	O

1	Perceptions	O
2	of	O
3	illness	O
4	intrusiveness	O
5	were	O
6	significantly	O
7	higher	O
8	when	O
9	both	O
10	muscle	O
11	cramp	O
12	and	O
13	headache	O
14	symptoms	O
15	occurred	O
16	during	O
17	one	B
18	or	I
19	more	I
20	assessment	I
21	intervals	I
22	as	I
23	compared	I
24	to	I
25	when	I
26	muscle	I
27	cramps	I
28	or	O
29	headaches	O
30	,	O
31	only	O
32	,	O
33	occurred	O
34	.	O

1	Two	O
2	independent	O
3	promoters	O
4	as	O
5	well	O
6	as	O
7	5	O
8	'	O
9	untranslated	O
10	regions	O
11	regulate	O
12	Dd	O
13	ras	O
14	expression	O
15	in	O
16	Dictyostelium	O
17	.	O

1	USA	O
2	80	O
3	,	O
4	802	O
5	-	O
6	806	O
7	]	O
8	was	O
9	used	O
10	to	O
11	isolate	O
12	a	O
13	genomic	O
14	clone	O
15	lambda	O
16	PGK	O
17	-	O
18	1	O
19	containing	O
20	a	O
21	portion	O
22	of	O
23	an	O
24	autosomal	O
25	locus	O
26	for	O
27	phosphoglycerate	O
28	kinase	O
29	(	O
30	PGK	O
31	).	O

1	This	O
2	effect	O
3	and	O
4	the	O
5	fact	O
6	that	O
7	all	O
8	three	O
9	doses	O
10	were	O
11	toxic	O
12	to	O
13	the	O
14	dams	O
15	dictated	O
16	that	O
17	a	O
18	second	O
19	experiment	O
20	be	O
21	carried	O
22	out	O
23	at	O
24	lower	O
25	doses	O
26	.	O

1	Contrary	O
2	to	O
3	the	O
4	observation	O
5	made	O
6	with	O
7	other	O
8	S	O
9	.	O
10	pombe	O
11	genes	O
12	transcribed	O
13	in	O
14	the	O
15	budding	O
16	yeast	O
17	,	O
18	the	O
19	heterologous	O
20	actin	O
21	gene	O
22	transcript	O
23	is	O
24	initiated	O
25	39	O
26	nucleotides	O
27	upstream	O
28	of	O
29	the	O
30	initiation	O
31	start	O
32	site	O
33	used	O
34	in	O
35	the	O
36	homologous	O
37	yeast	O
38	.	O

1	A	O
2	total	O
3	of	O
4	117	O
5	EVS	B
6	treatments	I
7	were	O
8	performed	B
9	on	I
10	34	I
11	patients	I
12	.	I

1	Mutational	O
2	analysis	O
3	of	O
4	potential	O
5	activating	O
6	phosphorylation	O
7	sites	O
8	found	O
9	in	O
10	NIMA	O
11	,	O
12	NIM	O
13	-	O
14	1	O
15	,	O
16	and	O
17	related	O
18	protein	O
19	kinases	O
20	was	O
21	performed	O
22	on	O
23	NIMA	O
24	.	O

1	Recombinant	O
2	erythropoietin	O
3	(	O
4	r	O
5	-	O
6	HuEPO	B
7	)	I
8	in	I
9	the	I
10	treatment	O
11	of	O
12	anemia	O
13	in	O
14	multiple	O
15	myeloma	O

1	The	O
2	encoded	O
3	polypeptide	O
4	is	O
5	similar	O
6	in	O
7	sequence	O
8	to	O
9	the	O
10	ABA	O
11	-	O
12	1	O
13	allergen	O
14	of	O
15	Ascaris	O
16	,	O
17	the	O
18	gp15	O
19	/	O
20	400	O
21	'	O
22	ladder	O
23	'	O
24	protein	O
25	of	O
26	Brugia	O
27	malayi	O
28	,	O
29	Brugia	O
30	pahangi	O
31	and	O
32	Wuchereria	O
33	bancrofti	O
34	,	O
35	and	O
36	a	O
37	15	O
38	-	O
39	kDa	O
40	antigen	O
41	of	O
42	Dirofilaria	O
43	immitis	O
44	.	O

1	Additionally	O
2	,	O
3	the	O
4	enzyme	O
5	shows	O
6	activity	O
7	towards	O
8	triglycerides	O
9	such	O
10	as	O
11	olive	O
12	oil	O
13	and	O
14	tributyrin	O
15	and	O
16	towards	O
17	egg	O
18	-	O
19	yolk	O
20	emulsions	O
21	.	O

1	Due	O
2	to	O
3	its	O
4	relatively	O
5	soluble	B
6	chemical	I
7	form	O
8	,	O
9	90Sr	O
10	was	O
11	rapidly	O
12	translocated	O
13	from	O
14	lung	O
15	to	O
16	bone	B
17	where	I
18	a	I
19	substantial	O
20	portion	O
21	was	O
22	retained	O
23	for	O
24	a	O
25	long	O
26	period	B
27	of	I
28	time	I
29	.	I

1	The	O
2	TIMP	O
3	(-	O
4	59	O
5	/	O
6	-	O
7	53	B
8	)	I
9	AP1	I
10	site	I
11	is	I
12	a	I
13	promiscuous	O
14	motif	O
15	that	O
16	binds	O
17	c	O
18	-	O
19	Fos	O
20	/	O
21	c	O
22	-	O
23	Jun	O
24	AP1	O
25	translated	O
26	in	O
27	vitro	O
28	and	O
29	is	O
30	an	O
31	effective	O
32	competitor	O
33	for	O
34	binding	O
35	of	O
36	nuclear	O
37	AP1	O
38	factors	O
39	to	O
40	the	O
41	consensus	I
42	TRE	O
43	,	O
44	but	I
45	in	I
46	addition	I
47	it	I
48	binds	I
49	factors	O
50	that	O
51	do	O
52	not	O
53	associate	O
54	with	O
55	the	O
56	consensus	O
57	TRE	B
58	.	I

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	a	O
7	perinephric	O
8	abscess	O
9	treated	O
10	with	O
11	amphotericin	O
12	B	O
13	and	O
14	nephrectomy	O
15	.	O

1	G	O
2	-	O
3	CSF	O
4	was	O
5	started	O
6	on	O
7	day	O
8	3	O
9	of	O
10	each	O
11	cycle	O
12	(	O
13	5	O
14	microg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	was	O
22	stopped	O
23	the	O
24	day	O
25	before	O
26	the	O
27	last	O
28	apheresis	O
29	or	O
30	when	O
31	absolute	O
32	neutrophil	O
33	count	O
34	was	O
35	above	O
36	0	O
37	.	O
38	5	O
39	x	O
40	10	O
41	(	O
42	9	O
43	)/	O
44	l	O
45	.	O

1	Low	O
2	-	O
3	grade	O
4	gastric	O
5	MALT	O
6	lymphoma	O
7	and	O
8	helicobacter	O
9	heilmannii	O
10	(	O
11	Gastrospirillum	O
12	hominis	O

1	ENV	O
2	also	O
3	was	O
4	secreted	O
5	from	O
6	P	O
7	.	O
8	pastoris	O
9	using	O
10	the	O
11	S	O
12	.	O
13	cerevisiae	O
14	alpha	O
15	-	O
16	factor	O
17	prepro	O
18	secretion	O
19	leader	O
20	and	O
21	the	O
22	S	O
23	.	O
24	cerevisiae	O
25	invertase	O
26	signal	O
27	sequence	O
28	.	O

1	Vibrio	O
2	cholerae	O
3	O139	O
4	in	O
5	Calcutta	O
6	.	O

1	Recombinant	O
2	human	O
3	TFIID	O
4	supported	O
5	weak	O
6	basal	O
7	transcription	O
8	in	O
9	heat	O
10	-	O
11	treated	O
12	nuclear	O
13	extracts	O
14	whereas	O
15	a	O
16	partially	O
17	purified	O
18	TFIID	O
19	fraction	O
20	from	O
21	HeLa	O
22	cells	O
23	reconstituted	O
24	a	O
25	maximal	O
26	level	O
27	of	O
28	transcription	O
29	.	O

1	Weight	O
2	loss	O
3	reduces	O
4	arterial	O
5	pressure	O
6	by	O
7	a	O
8	decrease	O
9	in	O
10	intravascular	O
11	volume	O
12	and	O
13	cardiac	O
14	output	O
15	associated	O
16	with	O
17	a	O
18	fall	O
19	in	O
20	sympathetic	O
21	activity	O
22	.	O

1	Intron	O
2	K1	O
3	cox1	O
4	.	O
5	2	O
6	is	O
7	not	O
8	found	O
9	in	O
10	S	O
11	.	O
12	cerevisiae	O
13	and	O
14	appears	O
15	at	O
16	an	O
17	unique	O
18	location	O
19	in	O
20	K	O
21	.	O
22	lactis	O
23	.	O

1	The	O
2	hydropathy	O
3	plot	O
4	revealed	O
5	a	O
6	rather	O
7	hydrophilic	O
8	N	O
9	-	O
10	terminal	O
11	region	O
12	and	O
13	the	O
14	absence	O
15	of	O
16	a	O
17	hydrophobic	O
18	signal	O
19	peptide	O
20	.	O

1	Post	O
2	-	O
3	operative	O
4	functional	O
5	outcome	O
6	is	O
7	related	O
8	to	O
9	pre	O
10	-	O
11	operative	O
12	functional	O
13	status	O
14	.	O

1	TSA	O
2	treatment	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	detectably	O
9	alter	O
10	enhancer	O
11	factor	O
12	binding	O
13	or	O
14	the	O
15	positioning	O
16	of	O
17	nuc	O
18	-	O
19	1	O
20	on	O
21	the	O
22	majority	O
23	of	O
24	the	O
25	chromatin	O
26	templates	O
27	indicating	O
28	that	O
29	protein	O
30	acetylation	O
31	and	O
32	chromatin	O
33	remodeling	O
34	may	O
35	be	O
36	limiting	O
37	steps	O
38	that	O
39	occur	O
40	only	O
41	on	O
42	transcriptionally	O
43	competent	O
44	templates	O
45	,	O
46	or	O
47	that	O
48	remodeling	O
49	of	O
50	nuc	O
51	-	O
52	1	O
53	requires	O
54	additional	O
55	factors	O
56	.	O

1	We	O
2	have	O
3	used	O
4	these	O
5	modified	O
6	assay	O
7	conditions	O
8	to	O
9	extend	O
10	studies	O
11	on	O
12	the	O
13	transposition	O
14	pathway	O
15	.	O

1	We	O
2	suggest	O
3	that	O
4	FlgN	O
5	and	O
6	FliT	O
7	are	O
8	substrate	O
9	-	O
10	specific	O
11	flagellar	O
12	chaperones	O
13	that	O
14	prevent	O
15	oligomerization	O
16	of	O
17	the	O
18	HAPs	O
19	by	O
20	binding	O
21	to	O
22	their	O
23	helical	O
24	domains	O
25	before	O
26	export	O
27	.	O

1	In	O
2	contrast	O
3	,	O
4	extracts	O
5	of	O
6	the	O
7	mutant	O
8	virions	B
9	catalyze	I
10	the	I
11	wild	I
12	-	I
13	type	O
14	level	O
15	of	O
16	transcription	O
17	from	O
18	an	O
19	exogenous	O
20	template	O
21	containing	O
22	an	O
23	early	O
24	promoter	O
25	.	O

1	Homologous	O
2	recombination	B
3	between	B
4	the	I
5	Autographa	O
6	californica	O
7	nuclear	O
8	polyhedrosis	O
9	virus	O
10	(	O
11	AcNPV	O
12	)	O
13	genome	O
14	and	B
15	a	I
16	0	I
17	.	O
18	6	O
19	-	O
20	kbp	O
21	-	O
22	long	O
23	DNA	O
24	fragment	O
25	derived	O
26	from	O
27	the	O
28	putative	O
29	DNA	O
30	helicase	O
31	gene	O
32	of	O
33	Bombyx	O
34	mori	O
35	nuclear	O
36	polyhedrosis	O
37	virus	O
38	generates	B
39	eh2	B
40	-	O
41	AcNPV	O
42	,	O
43	an	O
44	expanded	O
45	-	O
46	host	O
47	-	O
48	range	O
49	AcNPV	O
50	mutant	B
51	(	B
52	S	I
53	.	O

1	The	O
2	same	O
3	rhythmic	O
4	structure	O
5	enables	B
6	a	I
7	prediction	I
8	to	I
9	be	I
10	made	I
11	concerning	I
12	when	I
13	vowels	O
14	of	O
15	stressed	O
16	syllables	B
17	will	I
18	be	I
19	auditorily	I
20	perceived	I
21	.	I

1	Injection	O
2	of	O
3	double	O
4	-	O
5	stranded	O
6	RNA	O
7	into	O
8	C	O
9	.	O
10	elegans	O
11	results	O
12	in	O
13	embryonic	O
14	lethality	O
15	;	O
16	thus	O
17	,	O
18	the	O
19	SF1	O
20	gene	O
21	is	O
22	essential	O
23	not	O
24	only	O
25	in	O
26	yeast	O
27	but	O
28	also	O
29	in	O
30	at	O
31	least	O
32	one	O
33	metazoan	O
34	.	O

1	447	O
2	microns	O
3	for	O
4	A	O
5	.	O
6	microcephalum	O
7	and	O
8	350	O
9	microns	O
10	for	O
11	A	O
12	.	O
13	wedli	O
14	),	O
15	and	O
16	fewer	O
17	testes	O
18	per	O
19	proglottis	O
20	(	O
21	44	O
22	-	O
23	73	O
24	vs	O
25	.	O

1	The	O
2	cycle	O
3	length	O
4	of	O
5	induced	O
6	VT	O
7	(	O
8	n	O
9	=	O
10	10	B
11	VTs	I
12	)	I
13	was	I
14	380	I
15	+/-	I
16	41	I
17	msec	I
18	.	I

1	A	O
2	particularly	O
3	striking	O
4	HpaII	O
5	tiny	O
6	fragment	O
7	island	O
8	,	B
9	extending	I
10	over	I
11	nearly	O
12	2	O
13	,	O
14	000	O
15	base	O
16	pairs	O
17	,	O
18	surrounds	O
19	the	O
20	USF2	O
21	translation	O
22	initiation	O
23	site	O
24	.	O

1	Endotoxemia	O
2	induced	O
3	by	O
4	gram	O
5	-	O
6	negative	O
7	bacteria	O
8	leads	O
9	to	O
10	endotoxic	O
11	shock	O
12	pathogenetically	O
13	stemming	O
14	from	O
15	the	O
16	integral	O
17	component	O
18	of	O
19	the	O
20	bacterial	O
21	wall	O
22	--	O
23	lipid	O
24	A	O
25	.	O

1	We	O
2	report	O
3	the	O
4	isolation	O
5	of	O
6	genomic	B
7	and	I
8	cDNA	I
9	clones	I
10	of	I
11	the	I
12	light	O
13	-	O
14	independent	O
15	Sn	O
16	:	O
17	bol3	O
18	allele	O
19	.	O

1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	O
19	mRNA	O
20	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	total	O
7	number	O
8	of	O
9	subunit	O
10	c	O
11	in	O
12	F0	O
13	should	O
14	be	O
15	a	O
16	multiple	O
17	of	O
18	2	O
19	and	O
20	3	O
21	.	O

1	The	O
2	action	O
3	of	O
4	nef	O
5	was	O
6	specific	O
7	to	O
8	the	O
9	LTR	O
10	,	O
11	as	O
12	expression	O
13	of	O
14	nef	O
15	had	O
16	no	O
17	effect	O
18	on	O
19	the	O
20	activity	O
21	of	O
22	the	O
23	simian	O
24	virus	O
25	40	O
26	,	O
27	c	O
28	-	O
29	fms	O
30	,	O
31	urokinase	O
32	plasminogen	O
33	activator	O
34	,	O
35	or	O
36	type	O
37	5	O
38	acid	O
39	phosphatase	O
40	promoter	O
41	.	O
42	trans	O
43	-	O
44	activating	O
45	activity	O
46	was	O
47	also	O
48	manifested	O
49	by	O
50	a	O
51	frameshift	O
52	mutant	O
53	expressing	O
54	only	O
55	the	O
56	first	O
57	35	O
58	amino	O
59	acids	O
60	of	O
61	the	O
62	protein	O
63	.	O

1	Documentation	O
2	of	O
3	a	O
4	successful	O
5	intrauterine	O
6	fertilization	O
7	with	O
8	delivery	O
9	of	O
10	a	O
11	term	O
12	baby	O
13	supports	O
14	the	O
15	theoretical	O
16	feasibility	O
17	of	O
18	the	O
19	EP	O
20	;	O
21	however	O
22	,	O
23	anovulation	O
24	incurred	O
25	by	O
26	our	O
27	procedure	O
28	appears	O
29	to	O
30	be	O
31	the	O
32	major	O
33	drawback	O
34	.	O

1	Analysis	O
2	of	O
3	intragenic	O
4	revertants	O
5	shows	O
6	that	B
7	this	I
8	function	I
9	depends	I
10	on	I
11	the	I
12	amino	O
13	acid	O
14	preceding	B
15	the	B
16	first	I
17	cysteine	O
18	residue	B
19	of	I
20	the	I
21	DNA	O
22	-	O
23	binding	B
24	domain	I
25	of	I
26	Hap1p	I
27	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	during	O
6	pregnancy	O
7	there	O
8	are	O
9	increases	O
10	in	O
11	bone	O
12	formation	O
13	rates	O
14	contributing	O
15	to	O
16	the	O
17	increases	O
18	in	O
19	skeletal	O
20	mass	O
21	.	O

1	Cell	O
2	viability	O
3	and	O
4	lysosomal	O
5	enzymes	O

1	The	O
2	region	O
3	between	O
4	DXS52	O
5	and	O
6	Factor	O
7	VIII	O
8	gene	O
9	in	O
10	the	O
11	human	O
12	Xq28	O
13	chromosomal	O
14	band	O
15	contains	O
16	a	O
17	G	O
18	+	O
19	C	O
20	-	O
21	rich	O
22	isochore	O
23	to	O
24	which	O
25	many	O
26	genes	O
27	have	O
28	been	O
29	mapped	O
30	.	O

1	Overexpression	O
2	of	O
3	mcl	O
4	-	O
5	1	O
6	is	O
7	sufficient	O
8	to	O
9	protect	O
10	against	O
11	apoptosis	O
12	,	B
13	while	B
14	transfection	I
15	of	I
16	a	I
17	mcl	I
18	-	O
19	1	O
20	antisense	O
21	plasmid	O
22	causes	O
23	cell	O
24	death	O
25	.	O

1	Insulin	O
2	-	O
3	like	O
4	growth	O
5	factor	O
6	-	O
7	I	O
8	induces	O
9	bcl	O
10	-	O
11	2	O
12	promoter	O
13	through	O
14	the	O
15	transcription	O
16	factor	O
17	cAMP	O
18	-	O
19	response	O
20	element	O
21	-	O
22	binding	O
23	protein	O
24	.	O

1	The	O
2	interaction	O
3	between	O
4	piroxicam	O
5	and	O
6	poloxamer	O
7	was	O
8	studied	O
9	by	O
10	x	O
11	-	O
12	ray	O
13	diffractometry	O
14	(	O
15	XRD	O
16	),	O
17	infrared	O
18	(	O
19	IR	O
20	)	O
21	spectroscopy	O
22	and	O
23	differential	O
24	thermal	O
25	analysis	O
26	(	O
27	DTA	O
28	)	O
29	with	O
30	a	O
31	solid	O
32	dispersion	O
33	,	O
34	coprecipitate	O
35	,	O
36	or	O
37	physical	O
38	mixture	O
39	.	O

1	Deletion	O
2	mutagenesis	O
3	demonstrated	O
4	that	O
5	these	O
6	two	O
7	elements	O
8	are	O
9	involved	O
10	in	O
11	the	O
12	positive	O
13	regulation	O
14	of	O
15	MLC	O
16	-	O
17	2	O
18	gene	O
19	transcription	O
20	.	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	B
7	storage	I
8	time	I
9	,	I
10	although	I
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	The	O
2	deleted	O
3	nucleotide	O
4	sequence	O
5	corresponded	O
6	to	O
7	sequences	O
8	that	O
9	,	O
10	by	O
11	analogy	O
12	to	O
13	the	O
14	organization	O
15	of	O
16	the	O
17	type	O
18	I	O
19	collagen	O
20	genes	O
21	,	O
22	should	O
23	be	O
24	precisely	O
25	encoded	O
26	by	O
27	exon	O
28	41	O
29	of	O
30	the	O
31	COL3A1	O
32	gene	O
33	.	O

1	Praziquantel	O
2	and	O
3	Albendazole	O
4	were	O
5	found	O
6	effective	O
7	in	O
8	the	B
9	treatment	I
10	of	I
11	neurocysticercosis	O
12	,	B
13	but	I
14	because	I
15	of	O
16	serious	B
17	side	I
18	effects	I
19	encountered	I
20	in	O
21	some	O
22	cases	O
23	,	O
24	the	O
25	drugs	O
26	should	O
27	be	O
28	used	O
29	cautiously	O
30	in	O
31	selected	O
32	cases	O
33	only	O
34	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	specific	O
7	human	O
8	alpha	O
9	1	O
10	,	O
11	2	O
12	-	O
13	mannosidase	O
14	that	O
15	trims	O
16	Man9GlcNAc2	O
17	to	O
18	Man8GlcNAc2	O
19	isomer	O
20	B	O
21	during	O
22	N	O
23	-	O
24	glycan	O
25	biosynthesis	O
26	.	O

1	The	O
2	control	O
3	group	O
4	included	O
5	8	O
6	afterbirth	B
7	samples	I
8	from	I
9	physiological	I
10	full	I
11	-	I
12	term	I
13	pregnancies	I
14	.	I

1	Binding	O
2	affinities	O
3	of	O
4	these	O
5	recombinant	O
6	phages	O
7	as	O
8	determined	O
9	by	O
10	the	O
11	retention	O
12	of	O
13	these	O
14	phages	O
15	by	O
16	a	O
17	His	O
18	-	O
19	tag	O
20	immobilized	O
21	gp17	O
22	column	O
23	,	O
24	and	O
25	by	O
26	co	O
27	-	O
28	immunoprecipitation	O
29	with	O
30	purified	O
31	terminase	O
32	supported	O
33	the	O
34	specific	O
35	nature	O
36	of	O
37	the	O
38	portal	O
39	protein	O
40	and	O
41	terminase	O
42	interaction	O
43	sites	O
44	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	IRF	B
7	-	I
8	1	I
9	is	O
10	degraded	O
11	via	O
12	the	O
13	ubiquitin	O
14	-	O
15	proteasome	O
16	pathway	O
17	.	O

1	Regulatory	O
2	regions	O
3	in	O
4	the	O
5	promoter	O
6	and	O
7	third	O
8	intron	O
9	of	O
10	the	O
11	growth	O
12	hormone	O
13	gene	O
14	in	O
15	rainbow	O
16	trout	O
17	,	O
18	Oncorhynchus	O
19	mykiss	O
20	walbaum	O
21	.	O

1	Sp1	O
2	'	O
3	s	O
4	role	O
5	in	O
6	transactivation	O
7	of	O
8	the	O
9	pgp2	O
10	/	O
11	mdr1b	O
12	promoter	O
13	was	O
14	tested	O
15	in	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	.	O

1	HEED	O
2	was	O
3	found	O
4	to	O
5	bind	O
6	to	O
7	MA	O
8	protein	O
9	in	O
10	vitro	O
11	,	O
12	as	B
13	efficiently	B
14	as	I
15	in	I
16	vivo	I
17	in	I
18	yeast	O
19	cells	O
20	.	O

1	In	O
2	cellular	O
3	supernatant	O
4	fraction	O
5	,	O
6	SHRSP	O
7	showed	O
8	a	O
9	decrease	O
10	of	O
11	magnesium	O
12	in	O
13	many	O
14	tissues	O
15	and	O
16	an	O
17	elevation	O
18	of	O
19	the	O
20	calcium	O
21	to	O
22	magnesium	O
23	ratio	O
24	when	O
25	compared	O
26	to	O
27	age	O
28	-	O
29	matched	O
30	WKY	O
31	and	O
32	SHRSR	O
33	.	O

1	Extracellular	O
2	fibril	O
3	formation	O
4	by	O
5	neuroglial	O
6	cells	O
7	at	O
8	the	O
9	vitreoretinal	O
10	junction	O
11	of	O
12	the	O
13	human	O
14	eye	O
15	.	O

1	Activities	O
2	of	O
3	hepatic	O
4	cytochrome	O
5	P	O
6	-	O
7	450	O
8	-	O
9	dependent	O
10	metabolizing	O
11	enzymes	O
12	such	O
13	as	O
14	aminopyrine	O
15	-	O
16	and	O
17	TMO	O
18	N	O
19	-	O
20	demethylase	O
21	and	O
22	aniline	O
23	hydroxylase	O
24	activity	O
25	were	O
26	decreased	O
27	by	O
28	pretreatment	O
29	of	O
30	rats	O
31	with	O
32	cimetidine	O
33	,	O
34	whereas	O
35	in	O
36	the	O
37	rats	O
38	pretreated	O
39	with	O
40	ranitidine	O
41	,	O
42	these	O
43	enzyme	O
44	activities	O
45	were	O
46	not	O
47	changed	O
48	.	O

1	Tumour	O
2	necrosis	O
3	factor	O
4	and	O
5	adult	O
6	respiratory	O
7	distress	O
8	syndrome	O
9	.	O

1	The	O
2	front	O
3	(	O
4	F	O
5	)	O
6	interaction	O
7	occurs	O
8	ahead	O
9	of	O
10	the	O
11	growing	O
12	end	O
13	of	O
14	RNA	O
15	.	O

1	We	O
2	cloned	O
3	the	O
4	third	O
5	human	O
6	gene	O
7	for	O
8	the	O
9	LD78	O
10	,	O
11	termed	O
12	LD78	O
13	gamma	O
14	and	O
15	the	O
16	sequence	O
17	analysis	O
18	showed	O
19	that	O
20	it	O
21	is	O
22	a	O
23	5	O
24	'-	O
25	truncated	O
26	pseudogene	O
27	.	O

1	There	O
2	is	O
3	no	O
4	correlation	O
5	between	O
6	C2	O
7	-	O
8	C3	O
9	disk	O
10	morphology	O
11	and	O
12	the	O
13	diskographically	O
14	provoked	O
15	response	O
16	.	O

1	Here	O
2	we	O
3	review	O
4	progress	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O

1	Based	O
2	on	O
3	the	O
4	current	O
5	literature	O
6	,	O
7	the	O
8	mechanisms	O
9	involved	O
10	in	O
11	the	O
12	toxicity	O
13	of	O
14	OA	O
15	indicate	O
16	three	O
17	major	O
18	effects	O
19	:	O
20	(	O
21	1	O
22	)	O
23	inhibition	O
24	of	O
25	mitochondrial	O
26	respiration	O
27	correlated	O
28	with	O
29	a	O
30	depletion	O
31	of	O
32	ATP	O
33	;	O
34	(	O
35	2	O
36	)	O
37	inhibition	O
38	of	O
39	tRNA	O
40	-	O
41	synthetase	O
42	accompanied	O
43	by	O
44	a	O
45	reduced	O
46	protein	O
47	synthesis	O
48	;	O
49	and	O
50	(	O
51	3	O
52	)	O
53	enhanced	O
54	lipid	O
55	peroxidation	O
56	.	O

1	Disturbance	O
2	of	O
3	regeneration	O
4	in	O
5	the	O
6	above	O
7	pathological	O
8	condition	O
9	results	O
10	from	O
11	the	O
12	damage	O
13	to	O
14	tunica	O
15	propria	O
16	and	O
17	loss	O
18	of	O
19	its	O
20	function	O
21	for	O
22	the	O
23	support	O
24	of	O
25	structural	O
26	homeostasis	O
27	.	O

1	Wnt	O
2	-	O
3	1	O
4	(	O
5	int	O
6	-	O
7	1	O
8	)	O
9	is	O
10	a	O
11	cellular	O
12	oncogene	O
13	often	O
14	activated	O
15	by	O
16	insertion	O
17	of	O
18	proviral	O
19	DNA	O
20	of	O
21	the	O
22	mouse	O
23	mammary	O
24	tumor	O
25	virus	O
26	.	O

1	The	O
2	efficacy	O
3	of	O
4	a	O
5	Propionibacterium	O
6	acnes	O
7	product	O
8	for	O
9	treatment	O
10	of	O
11	coliform	O
12	mastitis	O
13	was	O
14	evaluated	O
15	following	O
16	intramammary	O
17	infusion	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	was	O
6	88	O
7	%	O
8	homologous	O
9	to	O
10	that	O
11	of	O
12	hNUC	O
13	I	O
14	,	O
15	isolated	O
16	from	O
17	human	O
18	osteosarcoma	O
19	cells	O
20	.	B

1	Among	O
2	blood	O
3	donors	O
4	in	O
5	the	O
6	Republic	O
7	of	O
8	Serbia	O
9	,	B
10	regardless	I
11	the	I
12	number	I
13	of	I
14	blood	O
15	donations	O
16	,	O
17	the	O
18	percentage	O
19	of	O
20	female	O
21	donors	O
22	is	O
23	significantly	O
24	lower	O
25	compared	B
26	to	I
27	the	I
28	percentage	I
29	of	I
30	male	I
31	blood	I
32	donors	I
33	.	I

1	Hepatitis	O
2	B	O
3	surface	O
4	antigen	O
5	was	O
6	detected	O
7	in	O
8	2	O
9	patients	O
10	,	O
11	with	O
12	negative	O
13	hepatitis	O
14	C	O
15	virus	O
16	antibody	O
17	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	tip	O
6	acts	O
7	at	O
8	an	O
9	early	O
10	stage	O
11	of	O
12	the	O
13	T	O
14	-	O
15	cell	O
16	signal	O
17	transduction	O
18	cascade	O
19	by	O
20	associating	O
21	with	O
22	Lck	O
23	and	O
24	downregulating	O
25	Lck	O
26	-	O
27	mediated	O
28	activation	O
29	.	O

1	cDNA	O
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	wheat	O
18	eIF	O
19	-(	O
20	iso	O
21	)	O
22	4F	O
23	and	O
24	mammalian	O
25	eIF	O
26	-	O
27	4G	O
28	.	O

1	Self	O
2	-	O
3	heating	O
4	after	O
5	deep	O
6	hypothermia	O
7	(	O
8	20	B
9	degrees	I
10	C	I
11	)	O
12	causes	B
13	a	I
14	considerable	I
15	increase	O
16	in	O
17	the	O
18	brain	O
19	tissues	O
20	glutaminase	O
21	activity	O
22	at	O
23	all	O
24	studied	O
25	incubation	O
26	temperatures	O
27	(	O
28	37	O
29	,	O
30	30	O
31	,	O
32	20	O
33	and	O
34	10	O
35	degrees	O
36	C	O
37	)	B
38	as	I
39	compared	O
40	to	O
41	control	O
42	rats	O
43	and	O
44	rats	B
45	under	B
46	hypothermia	O
47	.	O

1	In	O
2	vitro	O
3	translation	O
4	of	O
5	RNA	O
6	synthesized	O
7	from	O
8	the	O
9	cloned	O
10	cDNAs	O
11	predicts	O
12	that	O
13	P0	O
14	transcripts	O
15	are	O
16	translated	O
17	into	O
18	a	O
19	novel	O
20	12	O
21	.	O
22	5	B
23	-	I
24	kilodalton	I
25	protein	O
26	corresponding	O
27	to	O
28	the	O
29	first	O
30	open	O
31	reading	O
32	frame	B
33	.	I

1	In	O
2	the	O
3	COPD	O
4	patients	O
5	,	O
6	the	O
7	variability	O
8	of	O
9	Delta	O
10	-	O
11	inst	O
12	Rrs	O
13	(	O
14	30	O
15	%)	O
16	was	O
17	greater	O
18	than	O
19	that	O
20	of	O
21	FOT	O
22	Rrs	O
23	(	O
24	21	O
25	%).	O

1	The	O
2	p36	O
3	gene	O
4	is	O
5	at	O
6	least	O
7	22	O
8	kb	O
9	in	O
10	length	O
11	and	O
12	has	O
13	a	O
14	coding	O
15	sequence	O
16	of	O
17	approximately	O
18	1	O
19	kb	O
20	,	O
21	representing	O
22	only	O
23	4	O
24	.	O
25	5	O
26	%	O
27	of	O
28	the	O
29	gene	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	In	O
2	macrophages	O
3	,	O
4	LPS	O
5	-	O
6	inducible	O
7	HIV	O
8	-	O
9	1	O
10	gene	O
11	expression	O
12	is	O
13	mediated	O
14	in	O
15	part	O
16	by	O
17	binding	O
18	of	I
19	NF	I
20	-	O
21	kappa	O
22	B	O
23	to	B
24	identical	I
25	tandem	I
26	binding	I
27	sites	I
28	located	I
29	within	I
30	the	I
31	long	I
32	terminal	O
33	repeat	O
34	(	O
35	LTR	O
36	).	O

1	We	O
2	propose	O
3	that	O
4	noi	O
5	/	O
6	pax2	O
7	.	O
8	1	O
9	participates	B
10	in	I
11	sequential	I
12	signaling	I
13	processes	O
14	as	O
15	a	O
16	key	O
17	integrator	O
18	of	O
19	midbrain	O
20	-	O
21	hindbrain	O
22	boundary	O
23	development	O
24	.	O

1	By	O
2	contrast	O
3	,	O
4	mTRAP100	O
5	coprecipitates	O
6	in	O
7	vivo	O
8	with	O
9	another	O
10	component	O
11	of	O
12	the	O
13	TRAP	O
14	complex	O
15	(	O
16	TRAP220	O
17	),	O
18	which	O
19	directly	O
20	contacts	O
21	TR	O
22	and	O
23	the	O
24	vitamin	O
25	D	O
26	receptor	O
27	in	O
28	a	O
29	ligand	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	Intraperitoneal	O
2	administration	O
3	of	O
4	L	O
5	-	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	L	B
11	-	I
12	5	I
13	-	I
14	HTP	I
15	)	I
16	at	I
17	doses	I
18	of	O
19	25	O
20	to	O
21	100	O
22	mg	O
23	/	O
24	kg	O
25	dramatically	O
26	increase	O
27	defecation	O
28	in	O
29	mice	O
30	.	O

1	After	O
2	base	O
3	-	O
4	line	O
5	CBF	O
6	was	O
7	established	O
8	,	O
9	hexamethonium	O
10	bromide	O
11	(	O
12	2	O
13	mg	O
14	/	O
15	kg	O
16	iv	O
17	),	O
18	ipratropium	O
19	bromide	O
20	(	O
21	0	O
22	.	O
23	5	O
24	microgram	O
25	/	O
26	kg	O
27	iv	O
28	),	O
29	indomethacin	O
30	(	O
31	2	O
32	mg	O
33	/	O
34	kg	O
35	iv	O
36	),	O
37	or	O
38	intravenous	O
39	0	O
40	.	O
41	9	O
42	%	O
43	saline	O
44	was	O
45	administered	O
46	.	O

1	Recently	O
2	,	O
3	our	O
4	laboratory	O
5	developed	O
6	a	O
7	screen	O
8	that	O
9	identified	O
10	five	O
11	multicopy	O
12	suppressors	O
13	that	O
14	can	O
15	rescue	O
16	lethal	O
17	strains	O
18	of	O
19	clathrin	O
20	heavy	O
21	chain	O
22	-	O
23	deficient	O
24	yeast	O
25	(	O
26	Chc	O
27	-	O
28	scd1	O
29	-	O
30	i	O
31	)	O
32	to	O
33	viability	O
34	.	O

1	METHODS	O
2	:	O
3	We	O
4	studied	O
5	20	O
6	symptomatic	O
7	patients	O
8	with	O
9	HOCM	O
10	(	O
11	12	O
12	men	O
13	),	O
14	mean	O
15	age	O
16	52	O
17	+/-	O
18	17	O
19	years	O
20	,	O
21	before	B
22	and	I
23	after	I
24	septal	I
25	reduction	I
26	using	I
27	echocardiography	I
28	and	I
29	electrocardiogram	I
30	(	I
31	ECG	O
32	).	O

1	TaV	O
2	particles	O
3	have	O
4	a	O
5	buoyant	O
6	density	O
7	of	O
8	1	O
9	.	O
10	296	O
11	g	O
12	/	O
13	cm3	O
14	in	O
15	CsCl	O
16	and	O
17	consist	O
18	of	O
19	two	O
20	capsid	O
21	proteins	O
22	of	O
23	56	O
24	and	O
25	6	O
26	kDa	O
27	.	O

1	Maximum	O
2	number	O
3	of	O
4	strains	O
5	(	O
6	39	O
7	.	O
8	1	O
9	%)	O
10	were	O
11	resistant	O
12	in	O
13	S	O
14	.	O
15	bareilly	O
16	serotype	O
17	,	O
18	followed	B
19	by	I
20	S	O
21	.	O
22	typhimurium	O
23	(	O
24	21	O
25	.	O
26	7	O
27	%)	O
28	and	O
29	least	O
30	in	O
31	S	O
32	.	O
33	typhi	O
34	(	O
35	17	O
36	.	O
37	4	O
38	%).	O

1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	O
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O

1	Overproduction	O
2	,	O
3	purification	O
4	and	O
5	characterization	O
6	of	O
7	M	O
8	.	B
9	HinfI	I
10	methyltransferase	I
11	and	O
12	its	O
13	deletion	O
14	mutant	O
15	.	B

1	SETTING	O
2	:	O
3	University	O
4	hospital	O
5	-	O
6	based	O
7	,	O
8	tertiary	O
9	care	O
10	infertility	O
11	center	O
12	.	O

1	Research	O
2	was	O
3	carried	O
4	out	O
5	on	O
6	the	O
7	rheumatoid	O
8	factors	O
9	in	O
10	the	O
11	serum	O
12	of	O
13	917	O
14	patients	O
15	by	O
16	means	O
17	of	O
18	two	O
19	tests	O
20	(	O
21	one	O
22	using	O
23	polystyrene	O
24	and	O
25	one	B
26	with	I
27	erythrocytes	I
28	)	I
29	and	O
30	the	O
31	results	O
32	obtained	O
33	were	O
34	compared	O
35	using	O
36	a	O
37	method	O
38	of	O
39	reference	O
40	.	O

1	Of	O
2	those	O
3	injuries	O
4	,	O
5	143	O
6	cases	O
7	were	O
8	snowboard	O
9	related	O
10	and	O
11	158	O
12	cases	O
13	were	O
14	ski	O
15	related	O
16	.	O

1	Some	O
2	of	B
3	the	I
4	mutations	I
5	obtained	I
6	do	I
7	not	I
8	contain	I
9	a	O
10	copy	B
11	of	I
12	the	I
13	Ulysses	O
14	element	O
15	at	O
16	the	O
17	mutant	O
18	locus	O
19	,	O
20	suggesting	O
21	that	O
22	a	O
23	different	O
24	transposable	O
25	element	O
26	may	O
27	be	O
28	responsible	O
29	for	O
30	the	O
31	mutation	O
32	.	O

1	These	O
2	data	O
3	further	O
4	define	O
5	a	O
6	role	O
7	for	O
8	TRADD	O
9	and	O
10	TRAF2	O
11	in	O
12	JNK	O
13	activation	O
14	and	O
15	confirm	O
16	that	O
17	LMP1	O
18	utilizes	O
19	signalling	O
20	mechanisms	O
21	used	O
22	by	O
23	the	O
24	TNF	O
25	receptor	O
26	/	O
27	CD40	O
28	family	O
29	to	O
30	elicit	O
31	its	O
32	pleiotropic	O
33	activities	O
34	.	O

1	The	O
2	IC50	O
3	values	O
4	for	O
5	rat	O
6	and	O
7	dog	O
8	urinary	O
9	bladder	O
10	were	O
11	3	O
12	.	B
13	9	I
14	x	I
15	10	I
16	(-	I
17	6	I
18	)	I
19	M	I
20	and	O
21	3	I
22	.	I
23	8	O
24	x	O
25	10	O
26	(-	O
27	6	O
28	)	O
29	M	O
30	,	O
31	respectively	O
32	.	O

1	Early	O
2	disagnosis	O
3	of	O
4	cancer	O
5	--	O
6	50	O
7	per	O
8	cent	O
9	of	O
10	all	O
11	patients	O
12	could	O
13	be	O
14	cured	O

1	Certain	O
2	transcript	O
3	patterns	O
4	in	O
5	Epifagus	O
6	plastids	O
7	are	O
8	highly	O
9	complex	O
10	and	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	tobacco	O
16	operons	O
17	.	O

1	These	O
2	probable	O
3	border	O
4	sequences	O
5	are	O
6	closely	O
7	related	O
8	to	O
9	those	O
10	of	O
11	other	O
12	known	O
13	T	O
14	-	O
15	regions	O
16	and	O
17	define	O
18	a	O
19	second	O
20	T	O
21	-	O
22	region	O
23	of	O
24	pTiChry5	O
25	,	O
26	called	O
27	T	O
28	-	O
29	right	O
30	(	O
31	TR	O
32	),	O
33	that	O
34	confers	O
35	production	O
36	of	O
37	the	O
38	Amadoriopines	O
39	.	O

1	Analysis	O
2	of	O
3	several	O
4	Tat	O
5	mutants	O
6	indicated	O
7	that	O
8	both	O
9	the	O
10	cysteine	O
11	-	O
12	rich	O
13	and	O
14	the	O
15	core	O
16	domains	O
17	of	O
18	this	O
19	transactivator	O
20	are	O
21	necessary	O
22	and	O
23	sufficient	O
24	to	O
25	activate	O
26	transcription	O
27	when	O
28	TBP	O
29	is	O
30	overexpressed	O
31	.	O

1	Serum	O
2	IgG	O
3	was	O
4	initially	O
5	elevated	O
6	in	O
7	6	O
8	patients	O
9	.	O

1	Poly	O
2	(	O
3	dT	O
4	)	O
5	and	O
6	denatured	O
7	calf	O
8	thymus	O
9	DNA	O
10	were	O
11	more	O
12	effective	O
13	than	O
14	were	O
15	other	O
16	polynucleotides	O
17	tested	O
18	in	O
19	promoting	B
20	accumulation	I
21	of	I
22	19	I
23	HDP	O
24	*;	O
25	(	O
26	dT	O
27	)	O
28	8	B
29	was	I
30	as	I
31	effective	I
32	as	O
33	were	O
34	longer	O
35	molecules	O
36	of	O
37	(	O
38	dT	O
39	)	O
40	n	O
41	,	O
42	but	O
43	(	O
44	dT	O
45	)	O
46	4	O
47	and	O
48	(	O
49	dT	O
50	)	O
51	6	O
52	were	O
53	much	O
54	less	O
55	effective	O
56	,	O
57	indicating	O
58	that	O
59	the	O
60	binding	O
61	site	O
62	involved	O
63	in	O
64	19	O
65	HDP	O
66	*	O
67	accumulation	O
68	covered	O
69	between	O
70	6	O
71	and	O
72	8	O
73	residues	O
74	of	O
75	(	O
76	dT	O
77	)	O
78	n	O
79	.	O

1	Western	O
2	blotting	O
3	(	B
4	immunoblotting	I
5	)	I
6	with	I
7	an	O
8	antiserum	O
9	to	O
10	a	O
11	partial	O
12	SOD	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	revealed	O
18	two	O
19	proteins	O
20	with	O
21	estimated	O
22	molecular	O
23	masses	O
24	of	O
25	19	O
26	and	O
27	29	O
28	kDa	O
29	.	O

1	The	O
2	RNA	O
3	genome	O
4	of	O
5	rabbit	O
6	hemorrhagic	O
7	disease	O
8	virus	O
9	(	O
10	RHDV	O
11	)	O
12	was	O
13	molecularly	O
14	cloned	O
15	.	O

1	Significant	O
2	increases	O
3	in	O
4	mean	O
5	serum	O
6	E2	O
7	concentration	O
8	(	O
9	100	O
10	to	O
11	150	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	were	O
17	noted	O
18	at	O
19	6	O
20	and	O
21	8	O
22	hours	O
23	after	O
24	administration	O
25	on	O
26	day	O
27	1	O
28	and	O
29	at	O
30	8	O
31	hours	O
32	on	O
33	day	O
34	4	O
35	.	O

1	To	O
2	investigate	O
3	the	O
4	regulation	O
5	of	B
6	expression	I
7	of	I
8	the	O
9	human	O
10	mdr1	O
11	gene	O
12	,	O
13	the	O
14	response	O
15	of	O
16	the	O
17	mdr1	O
18	promoter	O
19	to	O
20	signals	O
21	involved	O
22	in	O
23	cell	O
24	proliferation	O
25	was	O
26	examined	O
27	.	O

1	Marked	O
2	hemolysis	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	phosphorus	B
11	,	I
12	total	I
13	protein	O
14	,	O
15	and	O
16	aspartate	O
17	aminotransferase	O
18	.	O

1	She	O
2	also	O
3	had	O
4	slight	O
5	weakness	O
6	of	O
7	the	O
8	upper	B
9	extremities	I
10	.	I

1	This	O
2	virus	O
3	is	O
4	not	O
5	merely	O
6	a	O
7	South	O
8	African	O
9	strain	O
10	of	O
11	passion	O
12	fruit	O
13	woodiness	O
14	virus	O
15	(	B
16	PWV	I
17	):	I
18	the	I
19	deduced	I
20	CP	I
21	sequence	I
22	is	I
23	only	I
24	distantly	I
25	related	I
26	to	I
27	CPs	O
28	of	O
29	other	B
30	sequenced	I
31	strains	I
32	of	I
33	PWV	O
34	,	O
35	although	O
36	it	O
37	is	O
38	part	O
39	of	O
40	a	O
41	distinct	O
42	subgroup	O
43	of	O
44	potyviruses	O
45	related	O
46	to	O
47	PWV	O
48	.	O

1	Immunolocalization	O
2	of	O
3	Sop1p	O
4	revealed	O
5	a	O
6	cytoplasmic	O
7	distribution	B
8	and	I
9	cell	I
10	fractionation	I
11	studies	I
12	showed	O
13	that	O
14	a	O
15	significant	O
16	fraction	O
17	of	O
18	Sop1p	O
19	was	B
20	recovered	I
21	in	I
22	a	I
23	sedimentable	O
24	fraction	O
25	of	O
26	the	O
27	cytosolic	O
28	material	O
29	.	O

1	Selective	O
2	visual	O
3	attention	O
4	involves	O
5	dynamic	O
6	interplay	O
7	between	O
8	attentional	O
9	control	O
10	systems	O
11	and	O
12	sensory	O
13	brain	O
14	structures	O
15	.	O

1	Adult	O
2	Amblyomma	O
3	lepidum	O
4	ticks	O
5	fed	O
6	as	O
7	nymphs	O
8	on	O
9	this	O
10	goat	O
11	transmitted	O
12	heartwater	O
13	to	O
14	a	O
15	Friesian	O
16	(	O
17	Bos	O
18	taurus	O
19	)	O
20	calf	O
21	.	O

1	Changes	O
2	induced	O
3	in	O
4	the	O
5	gills	O
6	of	O
7	milkfish	O
8	(	O
9	Chanos	O
10	chanos	O
11	Forsskal	O
12	)	O
13	fingerlings	O
14	after	O
15	acute	O
16	exposure	O
17	to	O
18	nifurpirinol	O
19	(	O
20	Furanace	O
21	;	O
22	P	O
23	-	O
24	7138	O
25	).	O

1	We	O
2	have	O
3	initiated	O
4	studies	O
5	to	O
6	identify	O
7	candidate	O
8	signal	O
9	transducers	B
10	that	I
11	associate	I
12	with	I
13	the	I
14	cytosolic	O
15	domain	O
16	(	O
17	cd	O
18	)	O
19	of	B
20	the	I
21	IL	O
22	-	B
23	1R	I
24	.	O

1	Results	O
2	of	O
3	this	O
4	study	O
5	indicate	O
6	that	O
7	GLC	O
8	of	O
9	short	O
10	chain	B
11	fatty	B
12	acids	O
13	produced	B
14	on	I
15	agar	I
16	medium	O
17	by	O
18	anaerobes	O
19	,	O
20	combined	O
21	with	O
22	simple	O
23	tests	O
24	such	O
25	as	O
26	Gram	O
27	'	O
28	s	O
29	stain	O
30	and	O
31	colonial	O
32	morphology	O
33	,	O
34	may	O
35	allow	O
36	fir	O
37	direct	O
38	presumptive	O
39	genus	O
40	identification	O
41	from	O
42	an	O
43	initial	O
44	pure	O
45	agar	O
46	culture	B
47	.	B

1	Influence	O
2	of	O
3	metoprolol	O
4	treatment	O
5	on	O
6	sympatho	O
7	-	O
8	adrenal	O
9	activation	O
10	of	O
11	fibrinolysis	O
12	.	O

1	Although	O
2	L	B
3	-	I
4	threo	I
5	-	I
6	dihydroxyphenylserine	O
7	(	O
8	DOPS	O
9	),	O
10	an	O
11	artificial	B
12	norepinephrine	I
13	(	I
14	NE	I
15	)	I
16	precursor	I
17	,	I
18	did	I
19	not	I
20	change	I
21	immobility	I
22	in	O
23	intact	O
24	mice	O
25	,	O
26	DOPS	O
27	significantly	O
28	reduced	O
29	immobility	O
30	in	O
31	mice	O
32	pretreated	O
33	with	O
34	the	O
35	selective	B
36	NE	I
37	neurotoxin	B
38	DSP4	O
39	.	I

1	When	O
2	the	O
3	high	O
4	affinity	O
5	hnRNP	O
6	A1	O
7	binding	O
8	site	O
9	was	O
10	inserted	O
11	into	O
12	the	O
13	beta	O
14	-	O
15	globin	O
16	reporter	O
17	,	O
18	Rev	O
19	was	O
20	able	O
21	to	O
22	increase	O
23	the	O
24	cytoplasmic	O
25	levels	O
26	of	O
27	unspliced	O
28	mRNAs	O
29	to	O
30	14	O
31	%.	O

1	Junctions	O
2	between	O
3	cells	O
4	of	O
5	the	O
6	human	O
7	enamel	O
8	organ	O
9	.	O

1	The	O
2	only	O
3	isolate	O
4	of	O
5	Aeromonas	O
6	hydrophila	O
7	produced	O
8	cytotoxic	O
9	enterotoxin	O
10	and	O
11	was	O
12	invasive	O
13	.	O

1	With	O
2	a	O
3	population	O
4	of	O
5	853	O
6	million	O
7	there	O
8	should	O
9	be	O
10	51	O
11	,	O
12	204	O
13	patients	O
14	with	O
15	hemophilia	O
16	A	O
17	in	O
18	India	O
19	assuming	O
20	a	O
21	prevalence	O
22	of	O
23	6	O
24	/	O
25	100	O
26	,	O
27	000	O
28	population	O
29	.	O

1	Fibrin	O
2	gels	O
3	and	O
4	their	O
5	possible	O
6	implication	O
7	for	O
8	surface	B
9	hemorheology	I
10	in	I
11	health	O
12	and	B
13	disease	I
14	.	I

1	Variations	O
2	of	O
3	the	O
4	timing	O
5	of	O
6	deflections	O
7	in	O
8	the	O
9	His	O
10	bundle	O
11	recordings	O
12	.	O

1	Therefore	O
2	,	O
3	the	O
4	strD	O
5	and	O
6	strE	I
7	genes	I
8	could	I
9	serve	O
10	as	B
11	universal	I
12	probes	O
13	indicative	O
14	of	O
15	the	O
16	presence	B
17	of	I
18	biosynthetic	O
19	capacity	B
20	for	I
21	6	I
22	-	O
23	deoxyhexose	B
24	moieties	I
25	.	I

1	One	O
2	site	O
3	,	B
4	PAL	I
5	,	I
6	occurs	I
7	within	I
8	the	I
9	10	I
10	bp	I
11	sequence	I
12	GGGGAGGAGG	I
13	.	I

1	The	O
2	range	O
3	of	O
4	serum	O
5	concentrations	O
6	,	O
7	mean	O
8	values	O
9	,	O
10	median	O
11	values	O
12	,	O
13	and	O
14	standard	O
15	deviations	O
16	for	O
17	each	O
18	analyte	O
19	are	O
20	reported	O
21	for	O
22	males	O
23	and	O
24	females	O
25	and	O
26	for	O
27	three	O
28	age	O
29	groups	B
30	(	I
31	25	I
32	-	I
33	44	O
34	,	O
35	45	O
36	-	O
37	59	O
38	,	O
39	60	O
40	-	O
41	70	O
42	).	O

1	Biochemical	O
2	examinations	O
3	of	O
4	calcium	O
5	-	B
6	phosphorus	I
7	metabolism	I
8	included	I
9	ions	I
10	and	O
11	PTH	B
12	concentrations	I
13	in	I
14	blood	O
15	serum	O
16	,	B
17	and	I
18	the	I
19	activity	I
20	of	I
21	bone	I
22	isoenzyme	I
23	of	I
24	AP	I
25	.	O

1	The	O
2	highest	O
3	doses	O
4	were	O
5	found	O
6	for	O
7	drivers	O
8	who	O
9	transported	O
10	large	O
11	numbers	O
12	of	O
13	99Mo	O
14	generators	O
15	.	O

1	As	O
2	for	O
3	31	O
4	stage	O
5	I	O
6	-	O
7	II	O
8	lung	O
9	cancer	O
10	patients	O
11	,	O
12	CR	O
13	has	O
14	been	O
15	observed	O
16	in	O
17	82	O
18	.	O
19	8	O
20	%	O
21	of	O
22	them	O
23	and	O
24	PR	O
25	in	O
26	13	O
27	.	O
28	8	O
29	%;	O
30	the	O
31	response	O
32	was	O
33	always	O
34	assessed	O
35	with	O
36	chest	O
37	radiography	O
38	,	O
39	CT	O
40	,	O
41	FBS	O
42	,	O
43	cytology	O
44	and	O
45	/	O
46	or	O
47	histology	O
48	.	O

1	Advanced	O
2	adenoma	O
3	was	O
4	defined	O
5	as	O
6	an	O
7	adenoma	O
8	larger	O
9	than	O
10	10	O
11	mm	O
12	or	O
13	an	O
14	adenoma	O
15	of	O
16	any	O
17	size	O
18	with	O
19	villous	O
20	component	O
21	,	O
22	high	O
23	-	O
24	grade	O
25	dysplasia	O
26	or	O
27	invasive	O
28	carcinoma	O
29	.	O

1	Antibodies	O
2	to	O
3	the	O
4	human	O
5	PTS1R	O
6	recognize	O
7	this	B
8	protein	I
9	in	I
10	human	I
11	,	O
12	monkey	B
13	,	I
14	rat	I
15	,	I
16	and	O
17	hamster	O
18	cells	O
19	.	B

1	The	O
2	enzyme	O
3	activities	O
4	studied	O
5	are	O
6	important	O
7	elements	O
8	in	O
9	the	O
10	pathophysiology	O
11	of	O
12	dental	O
13	caries	O
14	and	O
15	may	O
16	even	O
17	be	O
18	addressed	O
19	as	O
20	virulence	O
21	factors	O
22	.	O

1	This	O
2	locus	O
3	maps	O
4	approximately	O
5	160	O
6	kbp	O
7	from	O
8	the	O
9	genes	O
10	encoding	O
11	cytadherence	O
12	-	O
13	associated	O
14	proteins	O
15	HMW1	O
16	and	O
17	HMW3	O
18	,	O
19	and	O
20	yet	O
21	insertions	O
22	therein	B
23	result	I
24	in	O
25	loss	B
26	of	I
27	these	I
28	proteins	I
29	and	I
30	a	O
31	hemadsorption	O
32	-	O
33	negative	O
34	(	O
35	HA	O
36	-)	O
37	phenotype	O
38	,	O
39	prompting	O
40	the	O
41	designation	O
42	cytadherence	O
43	-	O
44	regulatory	O
45	locus	O
46	(	O
47	crl	O
48	).	O

1	The	O
2	real	O
3	challenge	O
4	for	O
5	the	O
6	future	O
7	will	O
8	be	O
9	the	O
10	management	O
11	of	O
12	patients	O
13	who	O
14	do	O
15	not	O
16	respond	O
17	to	O
18	first	O
19	-	O
20	line	O
21	treatment	O
22	.	O

1	Furthermore	O
2	,	O
3	upstream	O
4	insertion	O
5	of	O
6	the	O
7	GSTP1	O
8	silencer	O
9	element	O
10	failed	O
11	to	O
12	inhibit	O
13	activity	O
14	of	O
15	a	O
16	heterologous	O
17	promoter	O
18	in	O
19	MCF7	O
20	cells	O
21	.	O

1	It	O
2	was	O
3	shown	O
4	by	O
5	transient	O
6	expression	O
7	assay	O
8	that	O
9	HS	O
10	-	O
11	40	O
12	behaved	O
13	as	O
14	an	O
15	authentic	O
16	enhancer	O
17	for	O
18	high	O
19	-	O
20	level	O
21	zeta	O
22	2	B
23	globin	B
24	promoter	I
25	activity	O
26	in	B
27	K562	B
28	cells	I
29	,	O
30	an	O
31	erythroid	O
32	cell	O
33	line	O
34	of	O
35	embryonic	O
36	and	O
37	/	O
38	or	O
39	fetal	B
40	origin	I
41	.	I

1	Mutations	O
2	affecting	O
3	only	O
4	CD4	O
5	regulation	O
6	mapped	O
7	to	O
8	residues	O
9	previously	O
10	shown	O
11	to	O
12	mediate	O
13	the	O
14	binding	O
15	of	O
16	Nef	O
17	to	O
18	this	O
19	receptor	O
20	,	O
21	such	O
22	as	O
23	W57	O
24	and	O
25	L58	O
26	,	O
27	as	O
28	well	O
29	as	O
30	to	O
31	an	O
32	AP	O
33	-	O
34	recruiting	O
35	dileucine	O
36	motif	O
37	and	O
38	to	O
39	an	O
40	acidic	O
41	dipeptide	O
42	in	O
43	the	O
44	C	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	the	O
50	protein	O
51	.	O

1	Positron	O
2	emission	O
3	tomography	O
4	radioligands	O
5	for	O
6	dopamine	O
7	transporters	O
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	nonhuman	O
14	primates	O
15	.	O

1	To	O
2	see	O
3	if	O
4	a	O
5	pulse	O
6	oximeter	O
7	can	B
8	monitor	I
9	the	I
10	fetus	O
11	during	O
12	labour	O
13	we	O
14	recruited	O
15	100	O
16	Caucasian	B
17	women	I
18	in	I
19	normal	O
20	uncomplicated	O
21	labour	O
22	.	O

1	Its	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	shows	O
7	extensive	O
8	homology	O
9	to	O
10	those	O
11	of	O
12	Drosophila	O
13	hsp70	O
14	,	O
15	trout	O
16	hsp70	O
17	,	O
18	Xenopus	O
19	hsp70	O
20	,	O
21	yeast	O
22	hsp70	O
23	,	O
24	and	O
25	some	O
26	homology	O
27	to	O
28	the	O
29	heat	O
30	-	O
31	inducible	O
32	dnaK	O
33	gene	O
34	product	O
35	of	O
36	Escherichia	O
37	coli	O
38	.	O

1	Functional	O
2	magnetic	O
3	resonance	O
4	imaging	O
5	(	O
6	fMRI	O
7	)	O
8	has	O
9	been	O
10	increasingly	O
11	used	O
12	in	O
13	studying	O
14	human	O
15	brain	O
16	function	O
17	given	O
18	its	O
19	non	O
20	-	B
21	invasive	B
22	feature	O
23	and	B
24	good	I
25	spatial	O
26	resolution	O
27	.	O

1	The	O
2	transcription	O
3	factor	O
4	CHOP	O
5	(	O
6	C	O
7	/	O
8	EBP	O
9	homologous	O
10	protein	O
11	10	O
12	)	O
13	is	O
14	a	O
15	bZIP	O
16	protein	O
17	induced	O
18	by	O
19	a	O
20	variety	O
21	of	O
22	stimuli	O
23	that	O
24	evoke	O
25	cellular	O
26	stress	O
27	responses	O
28	and	O
29	has	O
30	been	O
31	shown	O
32	to	O
33	arrest	O
34	cell	O
35	growth	O
36	and	O
37	to	O
38	promote	O
39	programmed	O
40	cell	O
41	death	O
42	.	O

1	Clinical	O
2	research	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	post	O
12	-	O
13	transfusion	O
14	hepatitis	O

1	2	O
2	-	O
3	AP	O
4	induced	O
5	marked	O
6	,	O
7	steady	O
8	rises	O
9	in	O
10	mRNA	O
11	accumulation	O
12	from	O
13	both	O
14	transfected	O
15	and	O
16	chromosomally	O
17	integrated	O
18	HIV	O
19	-	O
20	1	B
21	constructs	I
22	but	I
23	no	O
24	increases	O
25	from	O
26	an	O
27	endogenous	O
28	gene	O
29	encoding	O
30	gamma	O
31	-	O
32	actin	O
33	or	O
34	glucose	O
35	6	O
36	-	O
37	phosphate	O
38	dehydrogenase	O
39	.	O

1	The	O
2	growth	O
3	-	O
4	promoting	O
5	properties	O
6	of	O
7	the	O
8	retroviral	O
9	v	O
10	-	O
11	erbA	O
12	oncogene	O
13	,	O
14	a	O
15	highly	O
16	mutated	O
17	version	O
18	of	O
19	the	O
20	chicken	O
21	thyroid	O
22	hormone	O
23	receptor	B
24	(	I
25	TR	I
26	)	I
27	alpha	O
28	,	O
29	have	O
30	so	O
31	far	O
32	exclusively	O
33	been	O
34	linked	O
35	to	O
36	dominant	O
37	repression	O
38	of	O
39	the	O
40	antimitogenic	O
41	roles	O
42	of	O
43	TR	O
44	and	O
45	retinoic	O
46	acid	O
47	receptors	O
48	.	O

1	Human	O
2	LTBP	O
3	-	O
4	1	O
5	is	O
6	known	O
7	to	O
8	exist	O
9	in	O
10	different	O
11	forms	O
12	.	O

1	We	O
2	have	O
3	identified	B
4	a	I
5	strong	I
6	Tas	I
7	-	I
8	responsive	O
9	element	B
10	,	I
11	designated	I
12	TRE	I
13	(	I
14	GP	I
15	),	I
16	near	I
17	the	I
18	3	O
19	'	O
20	end	O
21	of	B
22	the	I
23	gag	O
24	gene	O
25	and	O
26	preceding	O
27	the	O
28	pol	O
29	gene	O
30	of	O
31	SFV	O
32	-	O
33	1	O
34	.	O

1	To	O
2	map	O
3	this	O
4	regulatory	O
5	serine	O
6	phosphorylation	O
7	site	O
8	we	O
9	developed	O
10	a	O
11	baculovirus	O
12	-	O
13	mediated	O
14	expression	O
15	system	O
16	for	O
17	wild	O
18	-	O
19	type	O
20	annexin	O
21	II	O
22	and	O
23	for	O
24	a	O
25	series	O
26	of	O
27	annexin	O
28	II	O
29	mutants	O
30	which	O
31	contained	O
32	substitutions	O
33	in	O
34	one	O
35	or	O
36	more	O
37	serine	O
38	residues	O
39	present	O
40	in	O
41	the	O
42	N	O
43	-	O
44	terminal	O
45	domain	O
46	.	O

1	Similar	O
2	observations	O
3	have	O
4	been	O
5	made	O
6	previously	O
7	for	O
8	other	O
9	genes	O
10	.	O

1	Similar	O
2	mechanisms	O
3	leading	O
4	to	O
5	deregulation	O
6	of	O
7	Tcf	O
8	target	O
9	gene	B
10	activity	I
11	are	I
12	likely	I
13	to	I
14	be	I
15	involved	I
16	in	B
17	melanoma	I
18	and	I
19	other	I
20	forms	I
21	of	I
22	cancer	I
23	.	O

1	These	O
2	offspring	O
3	of	O
4	the	O
5	alpha	O
6	-	O
7	MSH	O
8	treated	O
9	mothers	O
10	were	O
11	less	O
12	sensitive	O
13	to	O
14	pain	O
15	and	O
16	as	O
17	adults	O
18	showed	O
19	a	O
20	reduced	O
21	analgesic	O
22	response	O
23	to	O
24	morphine	O
25	.	O

1	This	O
2	tendency	O
3	is	O
4	likely	O
5	due	O
6	to	O
7	the	O
8	biased	O
9	nucleotide	O
10	composition	O
11	of	O
12	the	O
13	asparagus	O
14	genome	I
15	,	O
16	rather	I
17	than	I
18	to	I
19	the	I
20	translational	I
21	selection	I
22	for	O
23	specific	O
24	codons	O
25	.	O

1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	possessing	B
8	IVS2C	I
9	beta	I
10	1	O
11	at	B
12	the	B
13	5	I
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	inefficient	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O

1	The	O
2	mode	O
3	of	O
4	resistance	O
5	to	O
6	quinupristin	O
7	/	O
8	dalfopristin	O
9	was	O
10	not	O
11	evident	O
12	(	O
13	sat	O
14	A	O
15	-	O
16	negative	O
17	by	O
18	PCR	O
19	);	O
20	and	O
21	these	O
22	cases	O
23	illustrate	O
24	the	O
25	existence	O
26	of	O
27	streptogramin	O
28	-	O
29	resistant	O
30	isolates	O
31	before	O
32	the	O
33	introduction	O
34	of	O
35	this	O
36	antimicrobial	O
37	class	O
38	into	O
39	human	O
40	clinical	O
41	practice	O
42	.	O

1	Antithrombin	O
2	III	O
3	deficiency	O
4	:	O
5	when	O
6	substitute	O
7	,	O
8	when	O
9	heparin	B
10	?	I
11	Thrombosis	O
12	ABC	B
13	,	I
14	3	O
15	:	O
16	The	O
17	role	O
18	of	O
19	antithrombin	B
20	III	I

1	In	O
2	HCMV	O
3	(	O
4	Towne	O
5	)-	O
6	infected	O
7	HF	O
8	cells	O
9	at	O
10	24	O
11	to	O
12	48	O
13	h	O
14	,	O
15	IE2	O
16	also	O
17	accumulated	O
18	in	O
19	newly	O
20	formed	O
21	viral	O
22	DNA	O
23	replication	O
24	compartments	O
25	containing	O
26	the	O
27	polymerase	O
28	processivity	O
29	factor	O
30	(	O
31	UL44	O
32	),	O
33	the	O
34	single	O
35	-	O
36	stranded	O
37	DNA	O
38	binding	O
39	protein	O
40	(	O
41	SSB	O
42	;	O
43	UL57	O
44	),	O
45	the	O
46	UL112	O
47	-	O
48	113	O
49	accessory	O
50	protein	O
51	,	O
52	and	O
53	newly	O
54	incorporated	O
55	bromodeoxyuridine	O
56	(	O
57	BrdU	O
58	).	O

1	In	O
2	PB	O
3	mice	O
4	,	O
5	there	O
6	was	O
7	only	O
8	a	O
9	small	O
10	deficit	O
11	in	O
12	the	O
13	number	O
14	of	O
15	the	O
16	hippocampal	O
17	pyramidal	O
18	neurons	O
19	compared	O
20	to	O
21	controls	O
22	(	O
23	15	O
24	%,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	01	O
31	),	O
32	and	O
33	no	O
34	deficit	O
35	in	O
36	the	O
37	granule	O
38	cells	O
39	.	O

1	Using	O
2	an	O
3	image	O
4	-	O
5	processing	O
6	computer	O
7	,	O
8	regional	O
9	LV	O
10	time	O
11	-	O
12	density	O
13	curves	O
14	were	O
15	constructed	O
16	for	O
17	one	O
18	cardiac	O
19	cycle	O
20	.	O

1	Transfer	O
2	RNA	O
3	genes	O
4	from	O
5	Dictyostelium	O
6	discoideum	O
7	are	O
8	frequently	O
9	associated	O
10	with	O
11	repetitive	O
12	elements	O
13	and	O
14	contain	O
15	consensus	O
16	boxes	O
17	in	B
18	their	B
19	5	I
20	'	O
21	and	O
22	3	O
23	'-	O
24	flanking	O
25	regions	O
26	.	O

1	Investigation	O
2	on	O
3	the	O
4	exchange	O
5	of	O
6	Ca45	O
7	in	O
8	intact	O
9	and	O
10	burned	O
11	rats	O
12	by	O
13	the	O
14	kinetic	O
15	analysis	O
16	method	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	B
22	to	I
23	the	I
24	cap	I
25	site	I
26	of	O
27	alpha	O
28	1	O
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	O
36	alpha	O
37	.	O

1	Detection	O
2	of	O
3	hemophilia	O
4	A	O
5	carriers	O
6	.	O

1	Familial	O
2	autoimmune	O
3	hepatitis	O
4	and	O
5	C4	O
6	deficiency	O

1	The	O
2	measurement	O
3	of	O
4	NO	O
5	in	O
6	biological	O
7	systems	O
8	using	O
9	chemiluminescence	O
10	.	O

1	Lactation	O
2	of	O
3	baboons	O
4	fed	O
5	a	O
6	low	O
7	protein	O
8	maintenance	O
9	diet	O
10	.	O

1	Short	O
2	-	O
3	course	O
4	amphotericin	O
5	B	O
6	therapy	O
7	for	O
8	candidemia	O
9	in	O
10	pediatric	O
11	patients	O
12	.	O

1	The	O
2	emerging	O
3	view	O
4	based	O
5	on	O
6	studies	O
7	in	O
8	yeast	O
9	is	O
10	that	O
11	each	O
12	class	O
13	of	O
14	snoRNPs	O
15	is	O
16	composed	O
17	of	O
18	a	O
19	unique	O
20	set	O
21	of	B
22	proteins	I
23	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	impact	O
7	of	I
8	the	I
9	introduction	I
10	of	O
11	clarithromycin	O
12	and	O
13	azithromycin	O
14	on	O
15	the	O
16	treatment	O
17	and	O
18	survival	O
19	of	O
20	patients	O
21	with	O
22	AIDS	O
23	and	O
24	disseminated	O
25	Mycobacterium	O
26	avium	O
27	complex	O
28	(	O
29	DMAC	O
30	).	O

1	Though	O
2	the	O
3	BACTEC	O
4	9000	O
5	MB	O
6	system	O
7	is	O
8	recommended	O
9	for	O
10	respiratory	O
11	specimens	O
12	,	O
13	we	O
14	demonstrated	O
15	that	O
16	it	O
17	can	O
18	be	O
19	successfully	O
20	used	O
21	also	O
22	for	O
23	recovery	O
24	of	O
25	mycobacteria	O
26	from	O
27	clinical	O
28	specimens	O
29	from	O
30	various	O
31	extrapulmonary	O
32	sites	O
33	.	O

1	Hemolytic	O
2	jaundice	O
3	due	O
4	to	O
5	G6PD	O
6	deficiency	O
7	causing	O
8	kernicterus	O
9	in	O
10	a	O
11	female	O
12	newborn	O
13	.	O

1	Recording	O
2	of	O
3	the	O
4	digital	O
5	sphygmic	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	extremities	O
11	with	O
12	the	O
13	photoplethysmographic	O
14	and	O
15	strain	O
16	-	O
17	gauge	O
18	methods	O
19	.	O

1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	O
10	gene	O
11	32	O
12	protein	O
13	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	V3	O
6	peptides	O
7	from	O
8	all	O
9	major	O
10	clades	O
11	of	B
12	HIV	I
13	-	I
14	1	I
15	carried	O
16	by	O
17	HIV	O
18	-	O
19	2	O
20	gag	O
21	can	O
22	be	O
23	used	O
24	as	O
25	a	O
26	potential	O
27	HIV	O
28	/	O
29	AIDS	O
30	vaccine	O
31	.	O

1	The	O
2	obvious	O
3	functional	B
4	necessity	I
5	for	I
6	editing	I
7	in	O
8	kinetoplastid	O
9	mitochondria	O
10	is	O
11	the	B
12	formation	O
13	of	B
14	translatable	I
15	mRNAs	I
16	.	I

1	Comparison	O
2	of	O
3	transmembrane	O
4	and	O
5	cytoplasmic	O
6	domains	O
7	to	B
8	a	I
9	third	I
10	cell	O
11	-	O
12	surface	O
13	proteoglycan	O
14	,	O
15	48K5	O
16	from	O
17	human	O
18	lung	O
19	fibroblasts	O
20	(	O
21	Marynen	O
22	,	O
23	P	O
24	.,	O
25	Zhang	O
26	,	O
27	J	O
28	.,	O
29	Cassiman	O
30	,	O
31	J	O
32	.,	O
33	Vanden	O
34	Berghe	O
35	,	O
36	H	O
37	.,	O
38	and	O
39	David	O
40	,	O
41	C	I
42	.	O

1	In	O
2	a	O
3	group	O
4	of	O
5	13	O
6	patients	O
7	with	O
8	obliterative	O
9	arteriopathies	O
10	of	O
11	the	O
12	lower	O
13	limbs	O
14	the	O
15	plasma	O
16	levels	O
17	of	O
18	thrombomodulin	O
19	(	O
20	TM	O
21	),	O
22	betathromboglobulin	O
23	(	B
24	beta	I
25	-	I
26	TG	O
27	),	O
28	D	O
29	-	O
30	dimer	O
31	(	O
32	DD	O
33	)	O
34	and	O
35	plasminogen	O
36	activator	O
37	-	O
38	inhibitor	O
39	(	O
40	pAI	O
41	-	O
42	1	O
43	)	O
44	were	O
45	measured	O
46	,	O
47	and	O
48	compared	O
49	to	O
50	the	O
51	values	O
52	obtained	O
53	from	O
54	10	O
55	healthy	O
56	volunteers	O
57	.	O

1	The	O
2	use	O
3	of	O
4	primary	O
5	GE	O
6	cells	O
7	thus	O
8	provides	O
9	a	O
10	convenient	O
11	in	O
12	vitro	O
13	system	O
14	for	O
15	further	O
16	study	O
17	of	O
18	the	O
19	endocrine	O
20	,	O
21	paracrine	O
22	,	O
23	and	O
24	autocrine	O
25	factors	O
26	regulating	O
27	endometrial	O
28	gene	O
29	expression	O
30	during	O
31	pregnancy	O
32	.	O

1	Dentalplaque	O
2	was	O
3	controlled	O
4	by	O
5	the	O
6	oral	O
7	higienic	O
8	index	O
9	of	O
10	the	O
11	whole	O
12	dentition	O
13	daily	O
14	,	O
15	after	O
16	staining	O
17	with	O
18	1	O
19	per	O
20	cent	O
21	alkaline	O
22	fuxin	O
23	.	O

1	The	O
2	number	O
3	of	O
4	polymerases	O
5	active	O
6	in	O
7	vitro	O
8	at	O
9	the	O
10	E	O
11	strand	O
12	promoter	O
13	was	O
14	similar	O
15	to	O
16	the	O
17	number	O
18	of	O
19	polymerases	O
20	at	O
21	the	O
22	L	O
23	strand	O
24	promoter	O
25	.	O

1	Determination	O
2	of	O
3	lead	O
4	in	O
5	blood	O
6	.	O

1	This	O
2	0	O
3	.	O
4	74	O
5	kb	O
6	cDNA	O
7	contains	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	(	B
13	ORF	I
14	)	I
15	of	I
16	477	I
17	bp	O
18	encoding	O
19	a	O
20	polypeptide	O
21	of	O
22	159	O
23	amino	O
24	acids	O
25	(	O
26	aa	O
27	)	O
28	which	O
29	differs	O
30	at	O
31	only	O
32	one	O
33	position	O
34	(	O
35	position	O
36	65	O
37	)	O
38	from	O
39	the	O
40	human	O
41	U1	O
42	-	O
43	C	O
44	protein	O
45	.	O

1	The	O
2	SH3	O
3	domains	O
4	of	O
5	Grb2	O
6	bound	O
7	in	O
8	vitro	O
9	to	O
10	specific	O
11	proline	O
12	-	O
13	rich	O
14	motifs	O
15	in	O
16	the	O
17	HPK1	O
18	tail	O
19	and	O
20	functioned	O
21	synergistically	O
22	to	O
23	direct	O
24	the	O
25	stable	O
26	binding	O
27	of	O
28	Grb2	O
29	to	O
30	HPK1	O
31	in	O
32	transfected	O
33	Cos1	O
34	cells	O
35	.	O

1	The	O
2	bioavailability	O
3	of	O
4	etodolac	O
5	from	O
6	capsules	O
7	exposed	O
8	to	O
9	stressed	O
10	conditions	O
11	was	O
12	compared	O
13	in	O
14	both	O
15	dogs	O
16	and	O
17	humans	O
18	to	O
19	capsules	O
20	stored	O
21	at	O
22	RT	O
23	conditions	O
24	.	O

1	There	O
2	was	O
3	no	O
4	competition	O
5	between	O
6	activin	O
7	A	O
8	and	O
9	OP	O
10	-	O
11	1	O
12	for	O
13	availability	O
14	of	O
15	Smad4	O
16	,	O
17	indicating	O
18	that	O
19	the	O
20	concentration	O
21	of	O
22	this	O
23	common	O
24	signal	O
25	transducer	O
26	is	O
27	not	O
28	limiting	O
29	for	O
30	generating	O
31	the	O
32	observed	O
33	biological	O
34	responses	O
35	.	O

1	The	O
2	8	O
3	patients	O
4	receiving	O
5	Ir192	O
6	implant	O
7	in	O
8	addition	O
9	to	O
10	external	B
11	radiation	I
12	showed	I
13	improved	I
14	(	O
15	p	O
16	=	O
17	0	O
18	.	O
19	06	O
20	)	O
21	survival	O
22	compared	O
23	to	O
24	the	O
25	9	O
26	receiving	O
27	external	O
28	only	O
29	:	O
30	median	O
31	15	O
32	months	O
33	(	O
34	range	O
35	1	O
36	.	O
37	5	O
38	-	O
39	34	O
40	+	O
41	months	O
42	)	O
43	versus	O
44	7	O
45	months	O
46	(	O
47	range	I
48	2	I
49	.	O
50	5	O
51	-	O
52	21	O
53	months	O
54	).	O

1	Sequencing	O
2	of	B
3	a	O
4	40	O
5	-	O
6	kb	O
7	DNA	O
8	segment	O
9	of	O
10	the	O
11	FK506	O
12	gene	O
13	cluster	O
14	from	O
15	Streptomyces	O
16	sp	O
17	.	O

1	A	O
2	single	O
3	amino	O
4	acid	O
5	difference	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	region	O
12	influences	O
13	dominant	O
14	negative	O
15	activity	O
16	and	O
17	receptor	O
18	dimer	O
19	formation	O
20	.	O

1	Sequence	O
2	and	O
3	genetic	B
4	organization	I
5	of	I
6	a	I
7	Zymomonas	I
8	mobilis	I
9	gene	I
10	cluster	O
11	that	O
12	encodes	O
13	several	O
14	enzymes	O
15	of	O
16	glucose	O
17	metabolism	O
18	.	O

1	Genomic	O
2	locus	O
3	of	O
4	chCTCF	O
5	contains	O
6	a	O
7	GC	O
8	-	O
9	rich	O
10	untranslated	O
11	exon	O
12	separated	O
13	from	O
14	seven	O
15	coding	O
16	exons	O
17	by	O
18	a	O
19	long	O
20	intron	O
21	.	O

1	We	O
2	infer	O
3	that	O
4	the	O
5	dominant	O
6	negative	O
7	inhibition	O
8	results	O
9	from	O
10	both	O
11	direct	O
12	proteolysis	O
13	of	O
14	the	O
15	beta	O
16	-	O
17	galactosidase	O
18	tetramer	O
19	by	O
20	the	O
21	fusion	O
22	subunit	O
23	and	O
24	detour	O
25	of	O
26	the	O
27	tetramer	O
28	to	O
29	the	O
30	lysosome	O
31	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	haemodialysis	O
6	patients	O
7	with	O
8	chronic	O
9	hepatitis	B
10	C	I
11	respond	O
12	well	O
13	to	O
14	interferon	O
15	treatment	O
16	and	O
17	that	O
18	a	O
19	long	O
20	-	O
21	term	O
22	response	O
23	is	O
24	achieved	O
25	in	B
26	a	O
27	high	O
28	proportion	O
29	of	O
30	patients	O
31	.	O

1	We	O
2	have	O
3	previously	O
4	isolated	O
5	a	O
6	cDNA	O
7	for	O
8	a	O
9	transcription	O
10	factor	O
11	referred	O
12	to	O
13	as	O
14	Zfhep	O
15	(	B
16	zinc	I
17	finger	I
18	homeodomain	I
19	enhancer	I
20	-	I
21	binding	O
22	protein	O
23	)	O
24	containing	O
25	two	O
26	separate	O
27	zinc	O
28	finger	O
29	domains	O
30	,	O
31	ZD1	O
32	and	O
33	ZD2	B
34	,	O
35	each	O
36	of	O
37	which	O
38	binds	O
39	DNA	O
40	,	O
41	and	O
42	a	O
43	homeodomain	O
44	.	O

1	CONCLUSION	O
2	:	O
3	Monitoring	B
4	SpO2	I
5	at	B
6	the	I
7	nasal	O
8	septum	B
9	site	I
10	is	I
11	more	I
12	reliable	I
13	than	I
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O

1	Ethylene	O
2	is	O
3	involved	O
4	in	O
5	endosperm	O
6	rupture	O
7	and	O
8	high	O
9	-	O
10	level	O
11	betaGLU	O
12	I	O
13	expression	O
14	;	O
15	but	O
16	,	O
17	it	O
18	does	O
19	not	O
20	affect	O
21	the	O
22	spatial	O
23	and	O
24	temporal	O
25	pattern	O
26	of	O
27	betaGLU	O
28	I	O
29	expression	O
30	.	O

1	We	O
2	detected	O
3	mos	O
4	transcripts	O
5	by	O
6	Northern	O
7	(	O
8	RNA	O
9	)	O
10	analyses	O
11	in	O
12	RNA	O
13	prepared	O
14	from	O
15	chicken	O
16	and	O
17	quail	O
18	ovaries	O
19	and	O
20	testes	O
21	.	O

1	The	O
2	diabetic	O
3	state	O
4	was	O
5	characterized	O
6	by	O
7	mild	O
8	insulin	O
9	deficiency	O
10	,	O
11	plasma	O
12	levels	O
13	being	O
14	73	O
15	%	O
16	of	O
17	controls	O
18	,	O
19	and	O
20	mild	O
21	hyperglycemia	O
22	,	O
23	with	O
24	nonfasting	O
25	plasma	O
26	glucose	O
27	levels	O
28	of	O
29	1	O
30	.	O
31	5	O
32	times	O
33	normal	O
34	.	O

1	Mutations	O
2	in	O
3	UPF1	O
4	lead	O
5	to	O
6	the	O
7	selective	O
8	stabilization	O
9	of	O
10	mRNAs	O
11	containing	O
12	early	O
13	nonsense	O
14	mutations	O
15	without	O
16	affecting	O
17	the	O
18	decay	O
19	rates	O
20	of	O
21	most	O
22	other	O
23	mRNAs	O
24	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	other	O
6	stabilizers	O
7	,	O
8	increased	B
9	sucrose	I
10	can	O
11	provide	O
12	increased	O
13	thermoresistance	O
14	to	O
15	the	O
16	virus	O
17	in	O
18	2	B
19	.	I
20	5	O
21	%	O
22	albumin	O
23	.	O

1	Sodium	O
2	-	O
3	taurocholate	O
4	-	O
5	induced	O
6	acute	O
7	necrotizing	O
8	pancreatitis	I
9	does	I
10	not	I
11	affect	I
12	jejunal	O
13	oxygenation	B
14	in	I
15	pigs	I
16	.	I

1	Standard	O
2	curve	O
3	correlation	O
4	coefficients	O
5	of	O
6	0	O
7	.	O
8	995	O
9	or	O
10	greater	O
11	were	O
12	obtained	O
13	during	O
14	validation	O
15	experiments	O
16	and	O
17	analysis	O
18	of	O
19	study	O
20	samples	O
21	.	O

1	The	O
2	monoexponential	O
3	rate	O
4	of	O
5	clearance	O
6	of	O
7	tracer	O
8	--	O
9	obtained	O
10	from	B
11	the	I
12	portion	I
13	of	I
14	the	I
15	residue	I
16	-	I
17	detection	O
18	curve	B
19	reflecting	B
20	metabolism	I
21	of	I
22	fatty	O
23	acid	B
24	incorporated	I
25	into	I
26	neutral	O
27	lipids	O
28	--	B
29	correlated	O
30	directly	O
31	with	O
32	induced	O
33	changes	O
34	in	O
35	tension	O
36	-	O
37	time	O
38	index	O
39	after	O
40	injections	O
41	into	O
42	the	O
43	left	O
44	atrium	O
45	(	O
46	r	B
47	=	I
48	0	I
49	.	I
50	96	I
51	,	O
52	n	O
53	=	O
54	12	B
55	),	B
56	right	I
57	atrium	I
58	(	O
59	r	O
60	=	I
61	0	O
62	.	O
63	86	B
64	,	I
65	n	I
66	=	I
67	14	I
68	),	I
69	and	I
70	ear	O
71	vein	I
72	(	B
73	r	O
74	=	O
75	0	O
76	.	O
77	93	I
78	,	O
79	n	O
80	=	O
81	14	O
82	).	O

1	I	O
2	.	O

1	Both	O
2	of	O
3	these	O
4	dogs	O
5	had	O
6	low	O
7	serum	O
8	IgG	O
9	(	O
10	3	O
11	.	O
12	5	O
13	to	O
14	7	O
15	.	O
16	2	O
17	mg	O
18	/	O
19	ml	O
20	)	O
21	and	O
22	the	O
23	second	O
24	littermate	O
25	also	O
26	had	O
27	reduced	O
28	serum	O
29	IgA	O
30	(<	O
31	0	O
32	.	O
33	1	O
34	to	O
35	0	O
36	.	O
37	15	O
38	mg	O
39	/	O
40	ml	O
41	).	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	function	O
7	of	O
8	the	O
9	DS2	O
10	may	O
11	be	O
12	the	O
13	protection	O
14	of	O
15	the	O
16	nuclear	O
17	DNA	O
18	from	O
19	desiccation	O
20	.	O

1	Spliced	O
2	exons	O
3	of	O
4	adenovirus	O
5	late	O
6	RNAs	O
7	colocalize	O
8	with	O
9	snRNP	O
10	in	O
11	a	O
12	specific	O
13	nuclear	O
14	domain	O
15	.	O

1	Effect	O
2	of	B
3	succimer	I
4	on	I
5	the	I
6	intensity	I
7	of	I
8	tricarboxylic	I
9	acid	I
10	dehydrogenase	I
11	reactions	I
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	O
20	chloride	O

1	At	O
2	each	O
3	level	B
4	of	I
5	PaO2	I
6	we	I
7	obtained	I
8	simultaneous	I
9	measures	O
10	of	O
11	arterial	O
12	and	O
13	venous	O
14	blood	O
15	gases	O
16	,	O
17	venous	O
18	lactate	O
19	concentration	O
20	,	O
21	and	O
22	changes	O
23	in	O
24	the	O
25	relative	O
26	concentrations	O
27	of	O
28	inorganic	O
29	phosphate	O
30	,	O
31	phosphocreatine	O
32	,	O
33	and	O
34	ATP	O
35	measured	O
36	with	O
37	31P	O
38	magnetic	O
39	resonance	O
40	spectroscopy	B
41	.	I

1	Gestational	O
2	trophoblastic	B
3	diseases	I
4	:	I
5	recent	I
6	advances	I
7	in	O
8	the	B
9	understanding	I
10	of	O
11	cytogenetics	O
12	,	O
13	histopathology	O
14	,	O
15	and	O
16	natural	B
17	history	I
18	.	I

1	We	O
2	observed	O
3	abundant	O
4	levels	O
5	of	O
6	Rev	O
7	-	O
8	erbA	O
9	alpha	O
10	mRNA	O
11	in	O
12	dividing	O
13	C2C12	O
14	myoblasts	O
15	,	O
16	which	O
17	were	O
18	suppressed	O
19	when	O
20	the	O
21	cells	O
22	differentiated	O
23	into	O
24	postmitotic	O
25	multinucleated	O
26	myotubes	O
27	.	O

1	Surgical	O
2	treatment	O
3	of	O
4	pulmonary	O
5	metastases	O
6	.	O

1	High	O
2	ADR1	O
3	gene	O
4	dosage	O
5	increased	O
6	the	O
7	transcription	O
8	of	O
9	genes	O
10	encoding	O
11	peroxisomal	O
12	proteins	O
13	as	O
14	compared	O
15	to	O
16	one	O
17	copy	O
18	of	O
19	the	O
20	ADR1	O
21	gene	O
22	.	O

1	A	O
2	chaotropic	O
3	detergent	O
4	,	O
5	0	O
6	.	O
7	1	O
8	%	O
9	Nonidet	O
10	P	O
11	-	O
12	40	O
13	,	O
14	also	O
15	abolished	O
16	the	O
17	interaction	O
18	,	B
19	further	B
20	supporting	O
21	the	O
22	hydrophobic	O
23	nature	O
24	of	O
25	the	O
26	interaction	O
27	.	O

1	Prostate	O
2	specific	O
3	antigen	O
4	shows	O
5	the	O
6	metastatic	O
7	cases	O
8	better	O
9	[	O
10	correction	O
11	of	O
12	worse	O
13	]	O
14	than	O
15	prostatic	O
16	acid	O
17	phosphatase	O
18	.	O

1	Two	O
2	basic	O
3	patterns	O
4	of	O
5	locomotor	O
6	behavior	O
7	and	O
8	corresponding	O
9	torso	B
10	morphology	I
11	exist	I
12	among	O
13	extant	O
14	anthropoids	O
15	.	O

1	Gene	O
2	constructs	O
3	consisting	O
4	of	O
5	human	O
6	growth	O
7	hormone	O
8	(	O
9	hGH	O
10	)	O
11	gene	O
12	driven	O
13	by	O
14	promoter	O
15	/	O
16	regulatory	O
17	sequence	O
18	of	O
19	mouse	O
20	metallothionein	O
21	(	O
22	mMT	O
23	),	O
24	viral	O
25	thymidine	O
26	kinase	O
27	(	O
28	vTK	O
29	),	O
30	rat	O
31	cholecystokinin	O
32	(	O
33	rCCK	O
34	),	O
35	or	O
36	chicken	O
37	beta	O
38	-	O
39	actin	O
40	(	O
41	cBA	O
42	)	O
43	gene	O
44	were	O
45	injected	O
46	into	O
47	the	O
48	cytoplasm	O
49	of	O
50	fertilized	O
51	medaka	O
52	eggs	O
53	via	O
54	the	O
55	micropyle	O
56	.	O

1	Patients	O
2	with	O
3	Parkinson	O
4	'	O
5	s	B
6	disease	I
7	showed	I
8	a	O
9	relatively	O
10	high	O
11	incidence	B
12	to	I
13	psychoses	I
14	during	I
15	drug	I
16	treatment	I
17	(	I
18	51	I
19	.	I
20	47	O
21	%).	O

1	We	O
2	also	O
3	report	O
4	that	O
5	AHR	O
6	interacts	O
7	with	O
8	COUP	O
9	-	O
10	TF	B
11	in	I
12	transfected	I
13	CV	I
14	-	I
15	1	O
16	cells	O
17	.	O

1	Spleen	O
2	weight	O
3	in	O
4	rats	O
5	during	O
6	tumour	O
7	growth	O
8	and	O
9	in	O
10	homograft	O
11	rejection	O
12	.	O

1	Control	O
2	experiments	O
3	showed	O
4	that	O
5	each	O
6	fusion	O
7	protein	O
8	had	O
9	a	O
10	high	O
11	affinity	O
12	binding	O
13	site	O
14	for	O
15	estradiol	O
16	-	O
17	17	O
18	beta	O
19	and	O
20	could	O
21	transactivate	O
22	an	O
23	ERE	O
24	-	O
25	LacZ	O
26	reporter	O
27	gene	O
28	in	O
29	yeast	O
30	similar	O
31	to	O
32	the	B
33	wild	I
34	type	O
35	ER	O
36	.	O

1	We	O
2	suppose	O
3	that	O
4	this	O
5	injection	O
6	speed	O
7	(	O
8	0	O
9	.	O
10	1	O
11	-	O
12	0	O
13	.	O
14	2	O
15	ml	O
16	.	O
17	s	O
18	-	O
19	1	O
20	)	O
21	is	O
22	suitable	O
23	for	O
24	spinal	O
25	anesthesia	O
26	.	O

1	The	O
2	possible	O
3	benefits	O
4	of	O
5	LMW	O
6	heparin	O
7	(	O
8	reduced	O
9	frequency	O
10	of	O
11	bleeding	O
12	,	O
13	alleviation	O
14	of	O
15	hypertriglyceridemia	O
16	)	O
17	were	O
18	not	O
19	,	O
20	however	O
21	,	O
22	apparent	O
23	,	O
24	possibly	O
25	because	O
26	of	O
27	the	O
28	short	O
29	observation	O
30	period	O
31	and	O
32	the	O
33	low	O
34	incidence	O
35	of	O
36	hemorrhagic	O
37	complications	O
38	in	O
39	routine	O
40	dialyses	O
41	.	O

1	It	O
2	brings	O
3	about	O
4	fatigue	O
5	,	O
6	negative	O
7	moods	O
8	,	B
9	and	I
10	impaired	I
11	health	I
12	,	I
13	sleep	I
14	,	O
15	safety	O
16	,	O
17	and	O
18	working	O
19	capacity	O
20	.	O

1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	B
18	were	I
19	normal	I
20	.	I

1	Etiopathogenetic	O
2	and	O
3	therapeutic	O
4	problems	O
5	in	O
6	acute	O
7	orbital	O
8	inflammation	O

1	Primer	O
2	extension	O
3	and	O
4	S1	O
5	nuclease	O
6	mapping	O
7	experiments	O
8	were	O
9	used	B
10	to	I
11	locate	I
12	the	I
13	transcription	I
14	initiation	I
15	site	I
16	of	O
17	Nramp1	O
18	and	O
19	revealed	O
20	the	O
21	presence	O
22	of	O
23	one	O
24	major	O
25	and	O
26	several	O
27	minor	O
28	initiation	O
29	sites	O
30	.	O

1	In	O
2	order	O
3	to	O
4	characterize	O
5	the	B
6	functional	B
7	elements	I
8	of	I
9	the	I
10	promoter	O
11	that	O
12	in	O
13	some	O
14	way	O
15	must	O
16	respond	O
17	to	O
18	these	O
19	regulatory	O
20	signals	O
21	,	O
22	a	O
23	number	O
24	of	B
25	promoter	O
26	mutations	I
27	were	O
28	constructed	O
29	,	O
30	including	O
31	a	O
32	set	O
33	of	O
34	linker	O
35	-	O
36	scanning	O
37	mutations	O
38	across	O
39	the	O
40	entire	O
41	promoter	O
42	region	O
43	.	O

1	Isoform	O
2	C	O
3	beta	O
4	2	O
5	,	O
6	an	O
7	unusual	O
8	form	O
9	of	O
10	the	O
11	bovine	O
12	catalytic	I
13	subunit	I
14	of	I
15	cAMP	I
16	-	O
17	dependent	O
18	protein	O
19	kinase	O
20	.	I

1	Familial	O
2	glutathione	O
3	reductase	B
4	deficiency	I
5	and	I
6	disorder	I
7	of	I
8	glutathione	B
9	synthesis	I
10	in	I
11	the	I
12	erythrocyte	I

1	Evidence	O
2	for	O
3	the	O
4	promoting	O
5	role	O
6	of	O
7	the	O
8	intra	O
9	-	O
10	uterine	O
11	kinin	B
12	release	I
13	in	I
14	the	O
15	development	O
16	of	O
17	late	O
18	hypertonic	O
19	saline	O
20	-	O
21	induced	O
22	abortion	O
23	.	O

1	Another	O
2	sequence	O
3	,	O
4	GGGXGGAG	O
5	,	O
6	which	O
7	is	O
8	repeated	O
9	several	O
10	times	O
11	in	O
12	many	O
13	polyomaviruses	O
14	and	O
15	adenoviruses	O
16	,	O
17	and	O
18	which	O
19	is	O
20	thought	O
21	to	O
22	play	O
23	a	O
24	role	O
25	in	O
26	DNA	O
27	replication	O
28	and	O
29	/	O
30	or	O
31	transcription	O
32	,	O
33	is	O
34	not	O
35	found	O
36	in	O
37	the	O
38	JCV	O
39	sequence	O
40	presented	O
41	.	O

1	The	O
2	accuracies	O
3	of	O
4	presence	O
5	or	O
6	absence	O
7	of	O
8	neuroblastoma	O
9	were	O
10	compared	O
11	between	O
12	131I	O
13	-	O
14	MIBG	O
15	imaging	O
16	and	O
17	several	O
18	tumor	O
19	markers	O
20	.	O

1	Fas	O
2	has	O
3	been	O
4	shown	O
5	to	O
6	require	O
7	ICE	O
8	(	O
9	interleukin	O
10	-	O
11	1	O
12	beta	O
13	-	O
14	converting	O
15	enzyme	O
16	)	O
17	family	O
18	proteases	O
19	to	O
20	induce	O
21	apoptosis	O
22	from	O
23	studies	O
24	utilizing	O
25	the	O
26	cowpox	O
27	ICE	O
28	inhibitor	O
29	protein	O
30	CrmA	O
31	,	O
32	the	O
33	synthetic	O
34	tetrapeptide	O
35	ICE	O
36	inhibitor	O
37	YVAD	O
38	-	O
39	CMK	O
40	,	O
41	and	O
42	the	O
43	tripeptide	O
44	pan	O
45	-	O
46	ICE	O
47	inhibitor	O
48	Z	O
49	-	O
50	VAD	O
51	-	O
52	FMK	O
53	.	O

1	The	O
2	Dox	O
3	-	O
4	A2	O
5	ORF	B
6	driven	I
7	by	I
8	the	I
9	TDH3	I
10	promoter	I
11	complemented	I
12	the	I
13	phenotype	I
14	of	I
15	a	O
16	strain	O
17	deleted	O
18	for	O
19	sun2	O
20	.	O

1	The	O
2	effects	O
3	of	O
4	anabolic	O
5	implants	O
6	on	O
7	rate	O
8	,	O
9	composition	O
10	and	O
11	energetic	O
12	efficiency	O
13	of	O
14	growth	O
15	were	O
16	determined	O
17	in	O
18	steers	O
19	fed	O
20	diets	O
21	varying	O
22	in	O
23	forage	O
24	and	O
25	grain	O
26	content	O
27	.	O

1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O

1	The	O
2	combination	O
3	of	O
4	Pitx2	O
5	and	O
6	another	O
7	homeodomain	O
8	protein	O
9	,	O
10	Pit	B
11	-	I
12	1	I
13	,	I
14	yielded	I
15	a	O
16	synergistic	O
17	55	O
18	-	O
19	fold	O
20	activation	O
21	of	O
22	the	O
23	prolactin	O
24	promoter	O
25	in	O
26	transfection	O
27	assays	O
28	.	I

1	RA	O
2	-	O
3	treatment	O
4	of	O
5	these	O
6	transfectants	O
7	induced	O
8	morphologic	O
9	and	O
10	immunophenotypic	O
11	maturation	O
12	,	O
13	changes	O
14	in	O
15	RA	O
16	-	O
17	regulated	O
18	genes	O
19	,	O
20	and	O
21	a	O
22	G1	O
23	cell	O
24	cycle	O
25	arrest	O
26	in	O
27	a	O
28	manner	O
29	similar	O
30	to	O
31	parental	O
32	NT2	O
33	/	O
34	D1	O
35	cells	O
36	.	O

1	Overexpression	O
2	of	O
3	MDR1	O
4	has	O
5	been	O
6	demonstrated	O
7	in	O
8	many	O
9	cancers	O
10	,	O
11	both	O
12	in	O
13	patient	O
14	tumors	O
15	and	O
16	in	O
17	cell	O
18	lines	O
19	selected	O
20	with	O
21	a	O
22	variety	O
23	of	O
24	chemotherapeutic	O
25	agents	O
26	.	O

1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	P2	O
6	-	O
7	proximal	O
8	CTCF	O
9	binding	O
10	site	O
11	and	O
12	transient	O
13	-	O
14	cotransfection	O
15	experiments	O
16	demonstrate	O
17	that	O
18	CTCF	O
19	is	O
20	a	O
21	transcriptional	O
22	repressor	O
23	of	O
24	the	O
25	human	O
26	c	O
27	-	O
28	myc	O
29	gene	O
30	.	O

1	Because	O
2	PET	O
3	is	O
4	also	O
5	useful	O
6	for	O
7	the	O
8	pretreatment	O
9	and	O
10	follow	O
11	-	O
12	up	O
13	evaluation	O
14	,	O
15	the	O
16	use	O
17	of	O
18	stereotactic	O
19	PET	O
20	in	O
21	these	O
22	patients	O
23	can	O
24	enable	O
25	an	O
26	accurate	O
27	comparison	O
28	of	O
29	PET	O
30	-	O
31	based	O
32	metabolic	O
33	data	O
34	with	O
35	MR	O
36	-	O
37	based	O
38	anatomical	O
39	data	O
40	.	O

1	Receptors	O
2	for	O
3	interleukin	O
4	(	O
5	IL	O
6	)-	O
7	10	O
8	and	O
9	IL	O
10	-	O
11	6	O
12	-	O
13	type	O
14	cytokines	O
15	use	O
16	similar	O
17	signaling	O
18	mechanisms	O
19	for	O
20	inducing	O
21	transcription	O
22	through	O
23	IL	O
24	-	O
25	6	O
26	response	O
27	elements	O
28	.	O

1	Neonatal	O
2	lupus	O
3	erythematosus	O
4	is	O
5	most	O
6	often	O
7	associated	O
8	with	O
9	autoantibodies	O
10	against	O
11	Ro	O
12	and	O
13	La	O
14	antigens	O
15	.	O

1	In	O
2	humans	O
3	,	O
4	three	O
5	tissue	O
6	-	O
7	specific	O
8	plastin	B
9	isoforms	I
10	have	I
11	been	O
12	identified	O
13	.	O

1	Fermentation	O
2	process	O
3	after	O
4	supplementation	O
5	of	O
6	nitrate	B
7	,	I
8	nitrite	I
9	,	O
10	lactic	O
11	acid	O
12	bacteria	O
13	and	O
14	formic	O
15	acid	O

1	This	O
2	inhibitory	O
3	domain	O
4	has	O
5	been	B
6	deleted	I
7	in	O
8	all	O
9	naturally	O
10	occurring	O
11	AHC	O
12	deletion	O
13	mutants	O
14	described	O
15	to	O
16	date	O
17	.	O

1	The	O
2	main	B
3	aim	O
4	of	O
5	the	O
6	contribution	O
7	,	O
8	which	O
9	opens	O
10	an	B
11	arena	I
12	for	O
13	discussion	O
14	on	O
15	the	O
16	Rivista	O
17	dell	O
18	'	O
19	Infermiere	O
20	is	O
21	to	O
22	critically	O
23	appraise	O
24	published	O
25	research	O
26	works	O
27	focusing	O
28	both	O
29	on	O
30	strengths	O
31	and	O
32	novelty	O
33	and	O
34	weaknesses	O
35	in	B
36	the	O
37	hypothesis	O
38	formulation	O
39	,	B
40	methods	O
41	and	O
42	instruments	O
43	used	O
44	,	O
45	discussion	O
46	of	B
47	results	I
48	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	sequencing	O
5	of	O
6	a	O
7	cDNA	O
8	encoding	O
9	SR	O
10	beta	O
11	revealed	O
12	that	O
13	SR	O
14	beta	O
15	is	O
16	a	O
17	transmembrane	O
18	protein	O
19	and	B
20	,	I
21	like	O
22	SR	O
23	alpha	O
24	and	O
25	SRP54	O
26	,	O
27	is	O
28	a	O
29	member	O
30	of	O
31	the	O
32	GTPase	O
33	superfamily	O
34	.	O

1	Local	O
2	graft	O
3	irradiation	O
4	as	O
5	an	O
6	adjunct	O
7	to	O
8	pharmacologic	B
9	immunosuppression	I
10	.	I

1	Daily	O
2	and	O
3	seasonal	O
4	rhythmicity	O
5	in	O
6	the	O
7	methylation	O
8	of	O
9	pineal	O
10	indolic	O
11	compounds	O
12	in	O
13	adult	O
14	male	O
15	golden	O
16	hamsters	O
17	,	O
18	kept	O
19	under	O
20	natural	O
21	conditions	O
22	.	O

1	The	O
2	ARF	O
3	promoter	O
4	was	O
5	also	O
6	found	O
7	to	O
8	be	O
9	highly	O
10	responsive	O
11	to	O
12	E2F1	O
13	expression	O
14	,	O
15	in	O
16	keeping	O
17	with	O
18	previous	O
19	results	O
20	at	O
21	the	O
22	RNA	O
23	level	O
24	.	O

1	In	O
2	10	O
3	patients	O
4	with	O
5	subacute	O
6	cardiac	O
7	tamponade	O
8	,	O
9	pulmonary	O
10	wedge	O
11	pressure	O
12	(	O
13	PWP	O
14	),	O
15	RAP	O
16	,	O
17	and	O
18	IPP	O
19	were	O
20	measured	O
21	along	O
22	with	O
23	indexes	O
24	of	O
25	systolic	O
26	function	O
27	.	O

1	Oxfendazole	O
2	,	O
3	which	O
4	was	O
5	active	O
6	for	O
7	the	O
8	shortest	O
9	time	O
10	(	O
11	about	O
12	65	O
13	days	O
14	)	O
15	from	O
16	the	O
17	start	O
18	of	O
19	grazing	O
20	(	O
21	May	O
22	1	O
23	),	O
24	produced	O
25	a	O
26	78	O
27	.	O
28	1	O
29	per	O
30	cent	O
31	reduction	O
32	in	O
33	Ostertagia	O
34	species	O
35	and	O
36	an	O
37	84	O
38	.	O
39	4	O
40	per	O
41	cent	O
42	reduction	O
43	in	O
44	D	O
45	viviparus	O
46	.	O

1	Wave	O
2	cybernetics	O
3	:	O
4	A	O
5	simple	O
6	model	O
7	of	O
8	wave	O
9	-	O
10	controlled	O
11	nonlinear	O
12	and	O
13	nonlocal	O
14	cooperative	O
15	phenomena	O
16	.	O

1	A	O
2	9	O
3	.	O
4	5	O
5	-	O
6	kb	O
7	KpnI	O
8	-	O
9	SalI	O
10	fragment	O
11	,	O
12	where	B
13	all	I
14	the	O
15	DNA	O
16	changes	O
17	associated	O
18	with	O
19	su	O
20	(	O
21	Hw	O
22	)	O
23	mutations	O
24	were	O
25	mapped	O
26	,	O
27	was	O
28	able	O
29	to	O
30	rescue	O
31	the	O
32	su	O
33	(	O
34	Hw	O
35	)	O
36	mutant	O
37	phenotype	O
38	after	O
39	P	O
40	-	O
41	element	O
42	-	O
43	mediated	O
44	germ	O
45	-	O
46	line	O
47	transformation	O
48	.	B

1	Small	O
2	Maf	O
3	proteins	O
4	heterodimerize	O
5	with	O
6	Fos	O
7	and	O
8	may	O
9	act	O
10	as	O
11	competitive	O
12	repressors	O
13	of	O
14	the	O
15	NF	O
16	-	O
17	E2	B
18	transcription	I
19	factor	I
20	.	I

1	ST	O
2	elevation	O
3	occurs	O
4	in	O
5	5	O
6	patients	O
7	(	O
8	55	O
9	.	O
10	5	O
11	%)	O
12	of	O
13	subgroup	O
14	A	O
15	and	O
16	in	O
17	no	O
18	patient	O
19	of	O
20	the	O
21	subgroup	O
22	B	O
23	.	O

1	Vibrio	O
2	fluvialis	O
3	(	O
4	group	O
5	F	O
6	vibrio	O
7	)	O
8	in	O
9	Maharashtra	O
10	.	O

1	Utilization	O
2	of	O
3	alternative	O
4	polyadenylation	O
5	signals	O
6	was	O
7	previously	O
8	shown	O
9	to	O
10	generate	O
11	two	O
12	sialophorin	O
13	mRNAs	O
14	of	O
15	1	O
16	.	O
17	9	O
18	and	O
19	4	O
20	.	O
21	3	O
22	kb	O
23	,	O
24	which	O
25	differ	O
26	in	O
27	the	O
28	length	O
29	of	O
30	their	O
31	3	O
32	'	O
33	untranslated	O
34	regions	O
35	.	O

1	Because	O
2	of	O
3	the	O
4	functional	O
5	conservation	O
6	of	O
7	cell	O
8	cycle	O
9	control	O
10	elements	O
11	,	O
12	the	O
13	expression	O
14	of	O
15	a	O
16	vertebrate	O
17	wee1	O
18	or	O
19	mik1	O
20	homolog	O
21	would	O
22	be	O
23	expected	O
24	to	O
25	rescue	O
26	such	O
27	lethal	O
28	mutations	B
29	in	I
30	yeast	O
31	.	B

1	The	O
2	effects	O
3	of	O
4	coenzyme	O
5	Q10	O
6	(	O
7	CoQ	O
8	)	O
9	and	O
10	captopril	O
11	on	O
12	functional	O
13	capacity	O
14	,	O
15	hemodynamics	O
16	and	O
17	survival	O
18	were	O
19	studied	O
20	in	O
21	154	O
22	rats	O
23	that	O
24	recovered	O
25	after	O
26	experimental	O
27	myocardial	O
28	infarction	O
29	.	O

1	The	O
2	polyubiquitin	O
3	gene	O
4	was	O
5	transcribed	O
6	throughout	O
7	the	O
8	Volvox	O
9	life	O
10	cycle	O
11	with	O
12	peaks	O
13	in	O
14	the	O
15	1	O
16	.	O
17	6	O
18	-	O
19	kb	O
20	mRNA	O
21	levels	O
22	during	O
23	pre	O
24	-	O
25	cleavage	O
26	,	O
27	cleavage	O
28	,	O
29	and	O
30	post	O
31	-	O
32	inversion	O
33	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	EKLF	B
6	provides	I
7	a	I
8	crucial	I
9	transactivation	O
10	function	O
11	for	O
12	globin	O
13	expression	O
14	and	O
15	further	O
16	reinforce	O
17	the	O
18	idea	O
19	that	O
20	EKLF	O
21	is	O
22	an	B
23	important	I
24	regulator	I
25	of	I
26	CACCC	I
27	element	I
28	-	I
29	directed	I
30	transcription	I
31	in	O
32	erythroid	O
33	cells	O
34	.	O

1	The	O
2	responsiveness	O
3	of	O
4	visual	O
5	cortex	O
6	(	O
7	VC	O
8	)	O
9	and	O
10	superior	O
11	colliculus	O
12	(	O
13	SC	O
14	)	O
15	was	O
16	simultaneously	O
17	compared	O
18	following	O
19	conditioning	O
20	"	O
21	ON	O
22	"	O
23	or	B
24	"	I
25	OFF	I
26	"	I
27	stimulation	I
28	,	O
29	in	O
30	the	O
31	rabbit	O
32	.	O

1	The	O
2	Oct	B
3	-	I
4	2	O
5	glutamine	O
6	-	O
7	rich	O
8	and	O
9	proline	B
10	-	I
11	rich	I
12	activation	I
13	domains	I
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	B

1	Cloning	O
2	and	O
3	sequencing	B
4	of	I
5	the	I
6	upstream	I
7	region	I
8	of	O
9	pepX	O
10	revealed	O
11	the	O
12	presence	O
13	of	O
14	two	O
15	ORFs	O
16	of	O
17	360	O
18	and	O
19	1	O
20	,	O
21	338	O
22	bp	O
23	that	B
24	were	I
25	shown	I
26	to	I
27	be	I
28	able	I
29	to	O
30	encode	B
31	proteins	I
32	with	I
33	high	I
34	homology	I
35	to	O
36	GlnR	O
37	and	O
38	GlnA	O
39	proteins	O
40	,	O
41	respectively	O
42	.	O

1	Removal	O
2	of	O
3	beta	O
4	2	O
5	-	O
6	microglobulin	O
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	Among	O
2	the	O
3	remaining	B
4	22	I
5	sites	I
6	,	I
7	six	I
8	are	I
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	O
15	-	O
16	specific	O
17	genes	O
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	O
25	-	O
26	Mcm1	O
27	-	O
28	dependent	O
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	the	O
5	cytoplasmic	O
6	tail	O
7	appears	O
8	to	O
9	generate	O
10	multiple	O
11	PECAM	O
12	-	O
13	1	O
14	isoforms	O
15	that	O
16	may	O
17	regulate	O
18	phosphorylation	O
19	,	O
20	cytoskeletal	O
21	association	O
22	,	O
23	and	O
24	affinity	O
25	modulation	O
26	of	O
27	the	O
28	mature	O
29	protein	O
30	.	O

1	We	O
2	have	O
3	also	B
4	tested	I
5	Src	I
6	SH2	I
7	mutants	I
8	for	O
9	their	B
10	binding	I
11	properties	O
12	and	O
13	have	O
14	interpreted	O
15	our	O
16	results	O
17	in	O
18	light	O
19	of	O
20	the	O
21	recent	B
22	crystal	O
23	structure	O
24	solution	O
25	for	O
26	the	B
27	Src	O
28	SH2	O
29	domain	O
30	.	O

1	These	O
2	data	O
3	provide	O
4	the	O
5	molecular	O
6	tools	O
7	for	O
8	the	O
9	final	O
10	identification	O
11	of	O
12	the	O
13	MKS	O
14	and	O
15	the	O
16	MUL	O
17	genes	O
18	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequences	O
6	of	O
7	each	O
8	of	O
9	the	O
10	W3A1	O
11	ETF	O
12	subunits	O
13	exhibit	O
14	only	O
15	approximately	O
16	30	O
17	%	O
18	identity	O
19	with	O
20	the	O
21	corresponding	O
22	subunits	O
23	of	O
24	the	O
25	ETF	O
26	from	O
27	human	O
28	,	O
29	rat	O
30	,	O
31	and	O
32	Paracoccus	O
33	denitrificans	O
34	,	O
35	which	O
36	as	O
37	a	O
38	group	O
39	are	O
40	greater	O
41	than	O
42	50	O
43	%	O
44	identical	O
45	.	O

1	PM	O
2	12	O
3	or	O
4	18	O
5	mg	O
6	/	O
7	kg	O
8	daily	O
9	plus	O
10	a	O
11	standard	O
12	dose	O
13	of	O
14	SB	O
15	for	O
16	21	O
17	days	O
18	was	O
19	statistically	O
20	more	O
21	effective	O
22	than	O
23	SB	O
24	in	O
25	producing	O
26	a	O
27	final	O
28	cure	O
29	for	O
30	patients	O
31	with	O
32	VL	O
33	in	O
34	Bihar	O
35	,	O
36	India	O
37	.	O

1	An	O
2	experiment	O
3	was	O
4	carried	O
5	on	O
6	133	O
7	grown	O
8	up	O
9	fowls	O
10	and	O
11	broilers	O
12	from	B
13	4	I
14	industrial	I
15	farms	I
16	,	O
17	vaccinated	O
18	with	O
19	spray	O
20	lento	O
21	and	O
22	mesogenic	O
23	vaccines	O
24	for	O
25	straining	O
26	the	O
27	immunity	O
28	against	O
29	pseodopest	O
30	through	O
31	RIHA	O
32	and	O
33	provoking	O
34	pseudoplague	O
35	with	O
36	a	O
37	pathogenic	O
38	virus	O
39	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	meta	O
5	-	O
6	analysis	O
7	of	O
8	67	O
9	controlled	O
10	trials	O
11	was	O
12	performed	O
13	to	O
14	quantify	O
15	the	O
16	cholesterol	O
17	-	O
18	lowering	O
19	effect	O
20	of	O
21	major	B
22	dietary	I
23	fibers	I
24	.	I

1	Ras	O
2	-	B
3	GRF1	I
4	transiently	I
5	expressed	O
6	with	O
7	v	O
8	-	B
9	Src	I
10	was	I
11	tyrosine	O
12	-	O
13	phosphorylated	O
14	and	O
15	showed	O
16	significant	O
17	GEF	O
18	activity	O
19	toward	O
20	Rac	O
21	,	O
22	but	O
23	not	O
24	Rho	O
25	and	O
26	Cdc42	O
27	,	O
28	which	O
29	was	O
30	comparable	O
31	with	O
32	that	O
33	induced	O
34	by	O
35	Gbetagamma	O
36	.	O

1	When	O
2	O2	O
3	therapy	O
4	was	O
5	controlled	O
6	for	O
7	,	O
8	the	O
9	association	O
10	between	O
11	RBT	O
12	and	O
13	RLF	O
14	did	O
15	not	O
16	achieve	O
17	statistical	O
18	significance	O
19	(	O
20	P	O
21	=	O
22	.	O
23	07	O
24	).	O

1	Our	O
2	data	O
3	complement	O
4	other	O
5	studies	O
6	of	O
7	circumpolar	O
8	populations	O
9	and	O
10	reinforce	O
11	the	O
12	reported	O
13	high	O
14	prevalences	O
15	of	O
16	SPA	O
17	and	O
18	HLA	O
19	-	O
20	B27	O
21	among	O
22	those	O
23	populations	O
24	.	O

1	Of	O
2	the	O
3	53	O
4	units	O
5	tested	O
6	during	O
7	sinusoidal	O
8	motion	O
9	at	O
10	0	B
11	.	I
12	05	I
13	Hz	I
14	(	I
15	9	O
16	.	O
17	1	O
18	cm	O
19	/	O
20	s	O
21	),	O
22	1	O
23	(	O
24	1	O
25	.	O
26	9	O
27	%)	O
28	was	O
29	responsive	O
30	to	O
31	the	O
32	otolith	O
33	input	O
34	only	O
35	,	O
36	13	O
37	(	O
38	24	O
39	.	O
40	5	O
41	%)	O
42	were	O
43	influenced	O
44	by	I
45	the	O
46	visual	I
47	input	I
48	only	I
49	and	O
50	23	O
51	(	O
52	43	O
53	.	O
54	4	O
55	%)	O
56	responded	O
57	to	O
58	both	B
59	modalities	B
60	.	O

1	A	O
2	p21	O
3	peptide	O
4	spanning	O
5	amino	O
6	acids	O
7	139	O
8	-	O
9	164	O
10	was	O
11	found	O
12	to	O
13	bind	O
14	PCNA	O
15	in	O
16	a	O
17	filter	O
18	binding	O
19	assay	O
20	and	O
21	this	O
22	peptide	O
23	suppressed	O
24	recombinant	O
25	p21	O
26	-	O
27	PCNA	O
28	interaction	O
29	.	O

1	The	O
2	next	O
3	twenty	O
4	years	O
5	of	B
6	prevention	I
7	in	I
8	Indian	I
9	country	I
10	:	I
11	visionary	O
12	,	O
13	complex	O
14	,	B
15	and	I
16	practical	O
17	.	O

1	Glomerular	O
2	mesangial	O
3	cells	O
4	expressed	O
5	an	O
6	abundant	O
7	1	O
8	.	O
9	1	O
10	kb	O
11	mRNA	O
12	transcript	O
13	for	O
14	Id1	O
15	,	O
16	but	O
17	in	O
18	contrast	O
19	to	O
20	other	O
21	cell	O
22	types	O
23	Id1	O
24	mRNA	O
25	was	O
26	expressed	O
27	in	O
28	both	O
29	randomly	O
30	cycling	O
31	cells	O
32	and	O
33	in	O
34	serum	O
35	-	O
36	deprived	O
37	,	O
38	quiescent	O
39	cultures	O
40	.	O

1	Calcium	O
2	and	O
3	phosphorus	O
4	metabolism	O
5	in	O
6	chronic	O
7	uremia	O
8	.	O

1	Kinetic	O
2	coupling	O
3	and	O
4	requirement	O
5	for	O
6	ATP	O
7	hydrolysis	O
8	.	O

1	The	O
2	molecular	O
3	basis	O
4	for	O
5	commitment	O
6	of	O
7	progenitors	O
8	to	O
9	the	O
10	eosinophil	O
11	lineage	O
12	and	O
13	mechanisms	O
14	by	O
15	which	O
16	eosinophil	O
17	-	O
18	specific	O
19	genes	O
20	are	O
21	expressed	O
22	and	O
23	regulated	O
24	during	O
25	differentiation	O
26	is	O
27	unknown	O
28	.	O

1	Previous	O
2	studies	O
3	characterized	O
4	a	O
5	cytokine	O
6	-	O
7	inducible	O
8	,	O
9	functional	B
10	nuclear	I
11	factor	I
12	(	I
13	NF	O
14	)-	O
15	kappaB	O
16	consensus	O
17	element	O
18	in	O
19	the	O
20	immediate	O
21	5	O
22	'	O
23	regulatory	O
24	region	O
25	of	O
26	the	O
27	MGSA	O
28	/	O
29	GRO	O
30	-	O
31	alpha	O
32	gene	O
33	at	O
34	-	O
35	78	O
36	bp	O
37	.	O

1	Quantitative	O
2	analysis	O
3	of	O
4	plasmid	O
5	loss	O
6	rates	O
7	in	O
8	cdc28	O
9	-	O
10	1N	O
11	strains	O
12	carrying	O
13	plasmids	O
14	with	O
15	multiple	O
16	replication	O
17	origins	O
18	suggests	O
19	that	O
20	a	O
21	defect	O
22	in	O
23	initiating	O
24	DNA	O
25	replication	O
26	probably	O
27	causes	O
28	this	O
29	plasmid	O
30	loss	O
31	phenotype	O
32	.	O

1	Thomas	O
2	'	O
3	Hospital	O
4	solution	O
5	(	O
6	with	O
7	95	O
8	%	O
9	O2	O
10	:	O
11	5	O
12	%	O
13	CO2	O
14	)	O
15	can	O
16	meet	O
17	the	O
18	metabolic	O
19	demand	O
20	of	O
21	the	O
22	ischaemic	O
23	myocardium	O
24	and	O
25	thus	O
26	increase	O
27	the	B
28	safe	I
29	duration	O
30	of	O
31	cardiac	O
32	arrest	O
33	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	HA	O
7	gene	O
8	in	O
9	these	O
10	two	O
11	mutants	O
12	confirmed	O
13	the	O
14	HA	O
15	-	O
16	phenotype	O
17	.	O

1	During	O
2	pentobarbital	O
3	anesthesia	B
4	,	I
5	the	I
6	basal	I
7	VO2	I
8	was	I
9	5	O
10	.	O
11	26	O
12	ml	O
13	/	O
14	kg	O
15	/	O
16	min	O
17	and	O
18	was	O
19	increased	O
20	by	O
21	epinephrine	O
22	in	O
23	a	O
24	dose	O
25	dependent	O
26	manner	O
27	at	O
28	plasma	O
29	concentrations	O
30	between	O
31	3	O
32	.	O
33	9	O
34	ng	O
35	/	O
36	ml	B
37	(	O
38	VO2	O
39	=	B
40	5	I
41	.	I
42	68	I
43	ml	I
44	/	O
45	kg	O
46	/	O
47	min	O
48	)	O
49	and	O
50	36	O
51	.	B
52	5	I
53	ng	I
54	/	I
55	ml	O
56	(	O
57	VO2	O
58	=	O
59	6	O
60	.	O
61	47	O
62	ml	O
63	/	O
64	kg	O
65	/	O
66	min	O
67	).	O

1	The	O
2	domain	O
3	structure	O
4	of	O
5	bovine	O
6	LTBP	O
7	-	O
8	2	O
9	is	O
10	very	O
11	similar	O
12	to	O
13	that	O
14	of	O
15	the	O
16	human	O
17	LTBP	O
18	-	O
19	2	O
20	,	O
21	containing	O
22	20	O
23	examples	O
24	of	O
25	6	O
26	-	O
27	cysteine	O
28	epidermal	O
29	growth	O
30	factor	O
31	-	O
32	like	B
33	repeats	I
34	,	I
35	16	I
36	of	I
37	which	I
38	have	I
39	the	I
40	consensus	O
41	sequence	O
42	for	O
43	calcium	O
44	binding	O
45	,	O
46	together	O
47	with	O
48	4	O
49	examples	O
50	of	O
51	8	I
52	-	O
53	cysteine	I
54	motifs	I
55	characteristic	O
56	of	O
57	fibrillins	O
58	and	O
59	LTBP	O
60	-	O
61	1	O
62	.	O

1	Remarkably	O
2	,	O
3	a	O
4	construct	O
5	corresponding	O
6	to	O
7	residues	O
8	631	O
9	to	B
10	970	I
11	,	I
12	which	I
13	contains	O
14	only	O
15	the	O
16	LXXLL	O
17	motifs	B
18	and	I
19	the	I
20	AD1	I
21	region	I
22	of	O
23	SRC1	B
24	,	I
25	retained	I
26	strong	O
27	coactivator	O
28	activity	B
29	in	I
30	our	I
31	assays	I
32	.	I

1	Similarly	O
2	,	O
3	a	B
4	human	I
5	but	I
6	not	I
7	a	I
8	bovine	I
9	alpha	I
10	transgene	O
11	was	O
12	expressed	O
13	in	O
14	placenta	B
15	in	I
16	transgenic	I
17	mice	I
18	.	I

1	Experiments	O
2	on	O
3	23	O
4	white	O
5	rats	O
6	and	O
7	10	O
8	guinea	O
9	pigs	O
10	have	O
11	shown	O
12	that	O
13	preliminarily	O
14	indomethacin	O
15	-	O
16	induced	O
17	inhibition	O
18	of	O
19	prostaglandins	O
20	synthesis	O
21	prevented	O
22	development	O
23	of	O
24	pulmonary	O
25	oedema	O
26	,	O
27	evoked	O
28	by	O
29	heterologous	O
30	serum	O
31	in	O
32	rats	O
33	and	O
34	by	O
35	vagotomy	O
36	in	O
37	guinea	O
38	pigs	B
39	.	I

1	A	O
2	recent	O
3	index	O
4	(	O
5	Fluorosis	O
6	Risk	O
7	Index	O
8	)	O
9	developed	O
10	by	O
11	Pendrys	B
12	(	I
13	1990	I
14	)	I
15	is	I
16	also	O
17	included	O
18	in	O
19	this	O
20	review	O
21	.	B

1	The	O
2	daily	O
3	administration	O
4	of	O
5	betamethasone	O
6	for	O
7	three	O
8	weeks	O
9	markedly	O
10	reduced	O
11	the	O
12	absorption	O
13	of	O
14	calcium	O
15	and	O
16	phosphate	O
17	as	O
18	well	O
19	as	O
20	the	O
21	growth	O
22	rate	O
23	.	O

1	The	O
2	dominant	O
3	negative	B
4	mutant	I
5	of	I
6	SHP	I
7	-	I
8	2	I
9	was	I
10	found	O
11	to	O
12	inhibit	O
13	the	B
14	induction	I
15	of	I
16	tyrosine	I
17	phosphorylation	O
18	and	O
19	DNA	O
20	-	O
21	binding	O
22	activity	O
23	of	O
24	m	O
25	-	O
26	Stat5a	O
27	,	O
28	m	O
29	-	O
30	Stat5b	O
31	,	O
32	and	O
33	the	O
34	carboxyl	O
35	-	O
36	terminal	B
37	deletion	B
38	variant	I
39	m	O
40	-	O
41	Stat5adelta749	O
42	,	O
43	as	O
44	well	O
45	as	O
46	the	O
47	transactivation	O
48	potential	O
49	of	O
50	m	O
51	-	O
52	Stat5a	O
53	and	O
54	m	O
55	-	O
56	Stat5b	O
57	.	O

1	Using	O
2	an	O
3	audiotape	O
4	cassette	O
5	and	O
6	headphones	O
7	the	O
8	duration	O
9	of	O
10	the	B
11	hallucinations	I
12	decreased	O
13	significantly	O
14	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	patients	O
6	with	O
7	IS	O
8	,	O
9	67	O
10	%	O
11	had	O
12	significantly	O
13	greater	O
14	values	O
15	of	O
16	directional	O
17	preponderance	O
18	on	O
19	the	O
20	OVAR	O
21	test	O
22	(	O
23	a	O
24	measure	O
25	of	O
26	otolith	O
27	system	O
28	imbalance	O
29	)	O
30	compared	O
31	with	O
32	control	O
33	subjects	O
34	.	O

1	No	O
2	somatic	B
3	mutations	I
4	were	I
5	found	I
6	in	I
7	any	I
8	of	O
9	the	B
10	samples	I
11	,	O
12	suggesting	O
13	that	O
14	ING1	O
15	is	O
16	not	O
17	a	O
18	tumor	O
19	suppressor	O
20	gene	O
21	target	O
22	in	O
23	head	O
24	and	O
25	neck	O
26	cancer	O
27	.	O

1	Her	O
2	serum	O
3	FT3	O
4	concentration	O
5	was	O
6	,	O
7	however	O
8	,	O
9	much	O
10	higher	O
11	than	O
12	the	O
13	ranges	O
14	in	O
15	normal	O
16	pregnancy	O
17	or	O
18	in	O
19	GTD	O
20	patients	O
21	without	O
22	clinical	O
23	hyperthyroidism	I
24	.	I

1	Phosphorylation	O
2	of	O
3	myosin	O
4	-	I
5	binding	I
6	subunit	I
7	(	I
8	MBS	I
9	)	O
10	of	O
11	myosin	O
12	phosphatase	O
13	by	O
14	Rho	O
15	-	O
16	kinase	O
17	in	O
18	vivo	O
19	.	O

1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O

1	The	O
2	high	O
3	selectivity	O
4	of	O
5	arrestins	O
6	for	O
7	this	O
8	particular	O
9	functional	O
10	form	O
11	of	O
12	receptor	O
13	ensures	O
14	their	O
15	timely	O
16	binding	O
17	and	O
18	dissociation	O
19	.	O

1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	O
23	-	O
24	3	O
25	beta	O
26	protein	O
27	(	O
28	amino	O
29	acids	O
30	361	O
31	to	O
32	458	O
33	).	O

1	Efferent	O
2	projections	B
3	of	I
4	the	I
5	ventral	I
6	portion	I
7	of	I
8	the	I
9	putamen	I
10	to	I
11	the	O
12	frontal	B
13	,	B
14	parietal	I
15	and	I
16	temporal	O
17	regions	O
18	of	O
19	the	O
20	cat	O
21	cerebral	O
22	cortex	O

1	Environmental	O
2	factors	O
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	cohorts	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	recall	B
17	).	I

1	As	O
2	with	O
3	VP16	O
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	O
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	O
15	.	O

1	Inherent	O
2	hematology	O
3	of	O
4	old	O
5	age	O

1	The	O
2	genomic	O
3	and	O
4	transcriptional	O
5	complexity	O
6	of	O
7	the	O
8	Crry	O
9	and	O
10	Crry	O
11	-	O
12	ps	O
13	genes	O
14	.	O

1	A	O
2	miracle	O
3	cure	O
4	and	O
5	its	O
6	solution	O

1	BACKGROUND	O
2	:	O
3	We	O
4	conducted	O
5	a	O
6	phase	B
7	I	I
8	study	I
9	with	I
10	MDL	O
11	73	O
12	,	B
13	147EF	I
14	,	I
15	a	I
16	new	I
17	5	O
18	hydroxytryptamine	O
19	3	O
20	(	O
21	5	O
22	-	O
23	HT3	O
24	)	O
25	receptor	O
26	antagonist	O
27	,	O
28	in	O
29	25	O
30	patients	O
31	requiring	O
32	emetogenic	O
33	chemotherapy	O
34	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	E	O
6	.	O
7	O	O
8	.	O
9	R	B
10	.	I
11	T	O
12	.	O
13	C	O
14	.	O

1	Thus	O
2	RV	O
3	O2	O
4	demand	B
5	fell	I
6	when	I
7	RC	O
8	O2	O
9	supply	B
10	was	I
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	B
19	.	I

1	Structural	O
2	features	O
3	of	O
4	the	O
5	minimal	O
6	DNA	O
7	binding	O
8	domain	O
9	(	O
10	M98	O
11	-	O
12	F219	O
13	)	O
14	of	O
15	human	O
16	nucleotide	O
17	excision	O
18	repair	O
19	protein	O
20	XPA	B
21	.	B

1	The	O
2	incidence	O
3	of	O
4	HSV	O
5	-	O
6	2	O
7	positive	O
8	subjects	O
9	(	O
10	HSV	O
11	-	O
12	2	O
13	/	O
14	HSV	O
15	-	O
16	1	O
17	antibody	O
18	ratio	O
19	>	O
20	or	O
21	=	O
22	1	O
23	)	O
24	was	O
25	low	O
26	in	O
27	the	O
28	Jewish	O
29	Israeli	O
30	population	O
31	,	O
32	compared	O
33	to	O
34	other	O
35	demographic	O
36	areas	O
37	.	O

1	Clinical	O
2	applications	O
3	of	O
4	inhibition	O
5	of	O
6	beta	O
7	-	O
8	adrenergic	O
9	receptors	O
10	with	O
11	propranolol	O
12	.	O

1	Also	O
2	,	O
3	HR21ap	O
4	as	O
5	well	O
6	as	O
7	HR21Xap	O
8	are	O
9	specific	O
10	in	O
11	their	O
12	inhibition	O
13	of	O
14	Sp1	O
15	binding	O
16	.	O

1	Recombinant	O
2	human	O
3	serum	O
4	albumin	O
5	(	O
6	rHSA	O
7	)	O
8	produced	O
9	by	O
10	cultured	B
11	fermentation	I
12	has	I
13	been	I
14	prepared	I
15	in	I
16	the	I
17	form	I
18	of	O
19	microcapsules	O
20	nominally	O
21	3	O
22	-	O
23	5	O
24	microns	O
25	in	O
26	diameter	O
27	and	O
28	radiolabelled	O
29	with	O
30	technetium	O
31	-	O
32	99m	O
33	following	O
34	reduction	O
35	with	O
36	stannous	O
37	chloride	O
38	.	O

1	A	O
2	catalytic	O
3	domain	O
4	of	O
5	eukaryotic	O
6	DNA	O
7	topoisomerase	O
8	I	O
9	.	O

1	When	O
2	nifA	B
3	mRNA	I
4	5	I
5	'	I
6	start	I
7	points	O
8	were	O
9	mapped	O
10	by	B
11	primer	I
12	extension	I
13	,	I
14	both	O
15	a	O
16	minor	B
17	upstream	I
18	transcript	I
19	(	I
20	s	I
21	)	O
22	starting	O
23	45	O
24	bp	O
25	distal	O
26	to	O
27	the	O
28	anaerobox	O
29	and	O
30	a	O
31	major	O
32	downstream	O
33	transcript	O
34	starting	O
35	10	O
36	bp	O
37	distal	O
38	to	O
39	the	O
40	sigma	O
41	54	O
42	box	O
43	were	O
44	observed	O
45	.	O

1	Thus	O
2	,	O
3	the	O
4	absence	O
5	of	O
6	residual	O
7	infarct	O
8	-	O
9	zone	O
10	viability	O
11	discriminates	O
12	patients	O
13	who	O
14	develop	O
15	progressive	O
16	left	O
17	ventricular	O
18	dilation	O
19	after	O
20	reperfused	O
21	AMI	O
22	from	O
23	those	O
24	who	O
25	maintain	O
26	normal	O
27	left	O
28	ventricular	O
29	geometry	O
30	.	O

1	Slp1	O
2	represses	O
3	transcription	O
4	via	O
5	this	B
6	binding	I
7	site	I
8	in	I
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	B
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	ftz	O
22	stripes	O
23	in	O
24	interstripe	O
25	regions	O
26	during	O
27	late	O
28	stages	O
29	of	O
30	embryogenesis	O
31	.	O

1	Overlapping	O
2	clones	O
3	representing	O
4	full	O
5	-	O
6	length	O
7	cDNAs	O
8	for	O
9	MMI	O
10	alpha	B
11	were	I
12	obtained	I
13	from	I
14	mouse	I
15	brain	I
16	.	I

1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	B
14	a	I
15	potent	I
16	stressor	I
17	for	I
18	Beagle	I
19	dogs	I
20	.	I

1	A	O
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O

1	NF	O
2	-	O
3	kappaB	O
4	is	O
5	a	O
6	redox	O
7	-	O
8	sensitive	O
9	transcription	O
10	factor	O
11	known	O
12	to	O
13	be	B
14	activated	I
15	by	I
16	oxidative	I
17	stress	I
18	as	I
19	well	I
20	as	I
21	chemical	I
22	and	O
23	biological	O
24	reductants	O
25	.	B

1	The	O
2	ipiO	B
3	genes	I
4	code	I
5	for	I
6	two	I
7	almost	I
8	identical	I
9	152	I
10	-	I
11	aa	I
12	proteins	I
13	which	I
14	do	I
15	not	O
16	have	O
17	any	O
18	homology	B
19	with	I
20	sequences	I
21	present	O
22	in	O
23	data	O
24	libraries	O
25	.	O

1	The	O
2	E6	B
3	/	I
4	E7	I
5	promoter	I
6	of	I
7	all	I
8	genital	I
9	human	I
10	papillomaviruses	I
11	is	I
12	responsible	I
13	for	I
14	expression	I
15	of	I
16	the	I
17	viral	I
18	transforming	I
19	genes	I
20	.	O

1	Here	O
2	we	O
3	describe	O
4	a	O
5	mutant	O
6	alpha	O
7	subunit	O
8	designed	O
9	to	O
10	inhibit	O
11	receptor	O
12	-	O
13	mediated	O
14	hormonal	O
15	activation	O
16	of	O
17	Gs	O
18	,	O
19	the	O
20	stimulatory	O
21	regulator	O
22	of	O
23	adenylyl	O
24	cyclase	B
25	.	I

1	All	O
2	subsequent	O
3	patients	O
4	were	O
5	treated	O
6	at	O
7	the	O
8	maximal	O
9	tolerated	O
10	dose	O
11	of	O
12	EDXR	O
13	(	O
14	35	O
15	mg	O
16	/	O
17	m2	O
18	/	O
19	day	O
20	).	O

1	In	O
2	another	O
3	study	O
4	,	O
5	intravenous	O
6	administration	O
7	of	O
8	devazepide	O
9	,	O
10	a	O
11	specific	O
12	cholecystokinin	O
13	-	O
14	A	O
15	receptor	B
16	antagonist	I
17	,	I
18	at	I
19	a	I
20	dose	I
21	of	I
22	0	I
23	.	O
24	1	B
25	mg	I
26	/	I
27	kg	O
28	/	O
29	hr	O
30	was	O
31	begun	O
32	15	O
33	min	O
34	before	O
35	postprandial	O
36	saline	O
37	intake	O
38	and	O
39	continued	O
40	for	O
41	1	O
42	hr	O
43	.	O

1	Clinical	O
2	use	O
3	of	O
4	absorbable	O
5	polyglycolic	O
6	acid	O
7	suture	O
8	in	O
9	Blalock	O
10	-	O
11	Taussig	O
12	'	O
13	s	O
14	operation	O

1	Riboflavin	O
2	did	O
3	not	O
4	affect	O
5	the	O
6	percentage	O
7	of	O
8	aflatoxin	O
9	-	O
10	treated	O
11	animals	O
12	with	O
13	abnormal	O
14	urinary	O
15	excretion	O
16	patterns	O
17	,	O
18	but	O
19	did	O
20	increase	O
21	the	O
22	magnitude	O
23	of	O
24	the	O
25	disturbances	O
26	in	O
27	elimination	O
28	of	O
29	kynurenic	O
30	and	O
31	xanthurenic	O
32	acids	O
33	.	O

1	The	O
2	FAS	O
3	promoter	O
4	was	O
5	up	O
6	-	O
7	regulated	O
8	by	I
9	insulin	I
10	through	O
11	the	O
12	proximal	O
13	insulin	O
14	response	O
15	sequence	O
16	containing	O
17	an	O
18	E	O
19	-	O
20	box	O
21	motif	O
22	at	O
23	the	O
24	-	O
25	65	O
26	-	O
27	base	O
28	pair	B
29	position	I
30	.	I

1	Gene	O
2	and	O
3	pseudogene	O
4	of	O
5	the	O
6	mouse	O
7	cation	O
8	-	O
9	dependent	O
10	mannose	O
11	6	O
12	-	O
13	phosphate	O
14	receptor	O
15	.	O

1	Since	O
2	RCC1p	O
3	acts	O
4	as	O
5	GNRP	O
6	for	O
7	Ran	O
8	,	O
9	a	O
10	small	O
11	nuclear	O
12	GTPase	O
13	of	O
14	the	O
15	ras	O
16	superfamily	O
17	,	O
18	we	O
19	have	O
20	identified	O
21	two	O
22	homologs	O
23	of	O
24	Ran	O
25	in	O
26	S	O
27	.	O
28	cerevisiae	O
29	(	O
30	CNR1	O
31	and	O
32	CNR2	O
33	).	O

1	Retention	O
2	behavior	O
3	of	O
4	steroids	O
5	in	O
6	gas	O
7	chromatography	O
8	with	O
9	a	O
10	series	O
11	of	O
12	combination	O
13	columns	B
14	.	I

1	ECM	O
2	disruption	O
3	in	O
4	Lytechinus	O
5	embryos	O
6	caused	O
7	a	O
8	relative	O
9	drop	O
10	in	O
11	USF	B
12	RNA	I
13	accumulation	O
14	levels	B
15	to	I
16	approximately	I
17	60	O
18	%	O
19	of	O
20	control	O
21	embryos	O
22	,	O
23	while	O
24	LpS1	O
25	RNA	O
26	accumulation	O
27	levels	O
28	dropped	O
29	to	O
30	less	O
31	than	O
32	5	O
33	%.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	affinities	O
6	of	B
7	CBF2	I
8	for	I
9	binding	I
10	to	O
11	the	B
12	LMP	I
13	-	I
14	1	I
15	,	O
16	LMP	O
17	-	O
18	2	O
19	,	O
20	and	O
21	CD23	O
22	promoters	O
23	were	O
24	also	O
25	measured	O
26	.	O

1	Therefore	O
2	,	O
3	in	O
4	conjunction	O
5	with	O
6	a	O
7	positive	B
8	pregnancy	I
9	test	I
10	and	O
11	the	O
12	patient	O
13	'	O
14	s	O
15	clinical	B
16	history	I
17	,	I
18	a	I
19	severely	I
20	depressed	I
21	or	I
22	absent	I
23	serum	I
24	PAPP	I
25	-	I
26	A	I
27	level	I
28	may	I
29	aid	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	extrauterine	O
35	pregnancy	O
36	.	O

1	Since	O
2	1968	O
3	,	O
4	a	O
5	steep	O
6	decrease	O
7	in	O
8	the	O
9	number	O
10	of	B
11	strains	I
12	resistant	I
13	to	I
14	three	I
15	or	O
16	more	O
17	antibiotics	O
18	(	O
19	multiple	O
20	-	B
21	resistant	I
22	)	I
23	and	I
24	in	O
25	strains	O
26	of	O
27	the	O
28	83A	O
29	complex	O
30	was	O
31	noticed	O
32	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	select	O
10	strong	O
11	enhancer	O
12	-	O
13	type	O
14	activation	O
15	domains	O
16	from	O
17	the	O
18	immediate	O
19	early	O
20	regions	O
21	of	O
22	two	O
23	herpesviruses	O
24	,	O
25	namely	O
26	pseudorabies	O
27	virus	O
28	and	O
29	bovine	O
30	herpesvirus	O
31	1	O
32	.	O

1	Kinetics	O
2	of	O
3	calcium	O
4	metabolism	O
5	.	O

1	A	O
2	decrease	O
3	of	O
4	the	O
5	lysozyme	O
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	B
12	of	I
13	the	I
14	bacterial	I
15	meningitis	I
16	.	I

1	The	O
2	products	O
3	of	O
4	genes	O
5	ura10	O
6	and	O
7	ura3	B
8	are	I
9	proposed	I
10	to	I
11	participate	I
12	in	I
13	the	I
14	channeling	I
15	of	O
16	orotidine	O
17	monophosphate	O
18	.	O

1	Genomic	O
2	DNA	O
3	clones	O
4	containing	O
5	the	O
6	T	O
7	-	O
8	cell	O
9	-	O
10	specific	O
11	human	O
12	MAL	O
13	gene	O
14	were	O
15	isolated	O
16	.	O

1	Exposure	O
2	to	O
3	hepatitis	O
4	B	O
5	virus	O
6	in	B
7	the	I
8	general	I
9	population	O
10	of	B
11	Hisayama	B
12	,	O
13	Japan	O
14	:	O
15	significance	O
16	of	O
17	isolated	O
18	antibody	O
19	to	O
20	hepatitis	O
21	B	O
22	surface	O
23	antigen	O
24	in	O
25	general	O
26	population	O
27	.	O

1	The	O
2	Drosophila	O
3	insulin	O
4	receptor	O
5	homolog	O
6	:	O
7	a	O
8	gene	O
9	essential	O
10	for	O
11	embryonic	O
12	development	O
13	encodes	O
14	two	O
15	receptor	O
16	isoforms	O
17	with	O
18	different	O
19	signaling	O
20	potential	O
21	.	O

1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O

1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	O
13	endogenous	O
14	ferrochelatase	O
15	gene	O
16	(	O
17	HEM15	B
18	)	I
19	had	I
20	been	I
21	deleted	I
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	B
28	transformants	I
29	were	I
30	characterized	I
31	.	O

1	Pregnant	O
2	women	O
3	at	O
4	term	O
5	had	O
6	the	O
7	lowest	O
8	levels	O
9	of	O
10	antithrombin	O
11	III	O
12	.	O

1	Perceptual	O
2	learning	O
3	for	O
4	a	O
5	pattern	O
6	discrimination	O
7	task	O
8	.	O

1	Precipitating	O
2	antibodies	O
3	for	O
4	Thermophilic	O
5	actinomycetes	O
6	and	O
7	M	O
8	.	O
9	f	O
10	.	O
11	were	O
12	negative	O
13	.	O

1	An	O
2	automated	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	the	O
10	polyamines	O
11	putrescine	O
12	,	O
13	spermidine	B
14	and	O
15	spermine	I
16	in	I
17	cerebrospinal	I
18	fluid	I
19	(	I
20	CSF	B
21	)	I
22	was	O
23	used	O
24	to	O
25	analyze	O
26	CSF	O
27	samples	O
28	from	B
29	37	I
30	patients	I
31	with	I
32	central	I
33	nervous	I
34	system	I
35	(	I
36	CNS	O
37	)	O
38	tumors	O
39	and	O
40	from	O
41	13	O
42	patients	O
43	without	O
44	tumors	O
45	.	O

1	Alterations	O
2	of	O
3	the	O
4	5q23	O
5	-	O
6	q31	O
7	interval	O
8	are	O
9	frequently	O
10	observed	O
11	in	O
12	myelodysplasia	O
13	and	O
14	myeloid	O
15	leukemia	O
16	.	O

1	Oncogenic	O
2	activation	O
3	of	O
4	the	B
5	tyrosine	I
6	kinase	I
7	domain	I
8	of	I
9	the	I
10	human	I
11	trk	I
12	proto	I
13	-	O
14	oncogene	O
15	by	B
16	fusion	I
17	to	I
18	a	I
19	cell	I
20	adhesion	I
21	molecule	I
22	.	I

1	ECG	O
2	-	O
3	gated	O
4	myocardial	O
5	Technetium	O
6	-	O
7	99m	O
8	sestamibi	O
9	SPECT	O
10	is	O
11	a	O
12	useful	O
13	technique	O
14	to	O
15	measure	O
16	myocardial	O
17	perfusion	O
18	and	O
19	function	O
20	simultaneously	O
21	.	O

1	Intrastriatal	O
2	grafts	O
3	of	O
4	nigral	O
5	and	B
6	adrenal	I
7	tissues	I
8	have	O
9	been	O
10	found	O
11	to	O
12	be	O
13	effective	O
14	in	O
15	alleviating	O
16	many	O
17	of	O
18	the	O
19	simple	O
20	motor	O
21	and	O
22	sensorimotor	O
23	deficits	O
24	associated	O
25	with	O
26	lesions	O
27	of	O
28	the	O
29	nigrostriatal	O
30	dopamine	O
31	system	O
32	.	O

1	The	O
2	partial	O
3	categories	O
4	of	B
5	the	I
6	SIP	I
7	that	I
8	were	I
9	more	O
10	affected	O
11	were	O
12	work	O
13	,	O
14	recreation	O
15	and	O
16	pastimes	O
17	,	O
18	home	O
19	management	O
20	,	O
21	and	O
22	sleep	O
23	and	O
24	rest	O
25	.	O

1	Several	O
2	studies	O
3	have	O
4	characterized	O
5	the	O
6	upstream	O
7	regulatory	O
8	region	O
9	of	O
10	c	O
11	-	O
12	fos	O
13	,	O
14	and	B
15	identified	I
16	cis	I
17	-	I
18	acting	I
19	elements	I
20	termed	O
21	the	O
22	cyclic	O
23	AMP	O
24	(	O
25	cAMP	O
26	)	O
27	response	O
28	elements	O
29	(	O
30	CREs	B
31	)	I
32	that	I
33	are	O
34	critical	B
35	for	I
36	c	I
37	-	I
38	fos	I
39	transcription	O
40	in	O
41	response	B
42	to	I
43	a	I
44	variety	I
45	of	I
46	extracellular	O
47	stimuli	O
48	.	O

1	No	O
2	difference	O
3	in	B
4	telomere	I
5	length	I
6	was	I
7	seen	I
8	in	I
9	mutants	I
10	affected	I
11	in	I
12	the	I
13	regulation	I
14	of	O
15	Cdc2	B
16	,	I
17	whereas	I
18	some	I
19	of	O
20	the	O
21	DNA	O
22	repair	O
23	mutants	O
24	examined	O
25	had	O
26	slightly	O
27	longer	O
28	telomeres	B
29	than	O
30	did	O
31	the	O
32	wild	O
33	type	O
34	.	O

1	Electromobility	O
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	O
9	,	O
10	but	O
11	not	O
12	HNF4	O
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	O
22	gene	O
23	expression	O
24	.	O

1	A	O
2	comparison	O
3	of	O
4	physical	O
5	and	O
6	cytogenetic	O
7	estimates	O
8	of	O
9	radiation	O
10	dose	O
11	in	O
12	patients	O
13	treated	O
14	with	O
15	iodine	O
16	-	O
17	131	O
18	for	O
19	thyroid	O
20	carcinoma	O
21	.	O

1	Mining	O
2	the	O
3	diagnostic	O
4	iron	O
5	ore	O
6	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	K	O
6	-	O
7	glypican	O
8	is	O
9	a	O
10	novel	O
11	GPI	O
12	-	O
13	anchored	O
14	HSPG	O
15	involved	O
16	in	O
17	embryonic	O
18	development	O
19	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	plasminogen	O
6	,	O
7	alpha	O
8	2AP	O
9	,	O
10	and	O
11	C1	O
12	-	O
13	INH	O
14	,	O
15	should	O
16	be	O
17	considered	B
18	equine	I
19	acute	I
20	-	O
21	phase	O
22	proteins	O
23	.	O

1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	B
7	sedation	I
8	with	I
9	midazolam	O
10	.	O

1	Specific	O
2	IgG	O
3	,	O
4	specific	O
5	IgE	O
6	and	O
7	total	O
8	IgE	O
9	immunoglobulins	O
10	against	O
11	Toxocara	O
12	canis	B
13	excretory	I
14	/	I
15	secretory	I
16	antigens	I
17	(	I
18	TES	O
19	)	O
20	were	O
21	detected	O
22	by	O
23	using	O
24	ELISA	O
25	technique	O
26	.	O

1	Consequently	O
2	functional	O
3	mRNAs	O
4	can	O
5	be	O
6	produced	O
7	by	O
8	endogenous	O
9	RNA	O
10	polymerase	O
11	I	O
12	.	O

1	The	O
2	bactericidal	B
3	activity	I
4	of	I
5	six	I
6	new	O
7	rifamycin	O
8	derivatives	O
9	--	O
10	rifabutin	O
11	(	O
12	RBU	O
13	),	O
14	FCE	O
15	22250	O
16	(	O
17	F22	O
18	),	O
19	rifapentine	O
20	(	O
21	RPE	O
22	),	O
23	CGP	O
24	29861	O
25	(	O
26	C29	O
27	),	O
28	CGP	O
29	7040	O
30	(	O
31	C70	B
32	)	I
33	and	I
34	CGP	O
35	27557	B
36	(	I
37	C27	I
38	)	O
39	and	B
40	rifampicin	I
41	(	O
42	RMP	O
43	)--	O
44	have	O
45	been	O
46	measured	O
47	against	O
48	log	O
49	phase	O
50	and	O
51	,	I
52	as	I
53	a	O
54	better	O
55	test	O
56	of	O
57	sterilising	O
58	activity	O
59	,	O
60	against	O
61	stationary	O
62	phase	O
63	cultures	O
64	of	O
65	Mycobacterium	O
66	tuberculosis	O
67	,	O
68	H37Rv	O
69	.	I

1	VirD2	O
2	is	O
3	one	O
4	of	O
5	the	O
6	key	O
7	Agrobacterium	O
8	tumefaciens	O
9	proteins	O
10	involved	O
11	in	B
12	T	I
13	-	O
14	DNA	O
15	processing	O
16	and	O
17	transfer	O
18	.	O

1	The	O
2	findings	O
3	demonstrate	O
4	that	O
5	AMPH	O
6	administration	O
7	induces	O
8	a	O
9	significant	O
10	increase	O
11	in	O
12	the	O
13	height	O
14	of	O
15	a	O
16	major	O
17	electroactive	O
18	peak	O
19	in	B
20	the	I
21	caudate	I
22	nucleus	I
23	of	I
24	pigtail	I
25	monkeys	I
26	,	I
27	and	I
28	further	I
29	that	O
30	such	O
31	amphetamine	O
32	-	O
33	induced	O
34	increases	O
35	can	O
36	be	O
37	manipulated	O
38	by	O
39	altering	O
40	the	O
41	affective	O
42	and	O
43	/	O
44	or	O
45	emotional	O
46	state	O
47	of	O
48	the	O
49	animal	O
50	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	B
10	a	I
11	21	I
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	Analysis	O
2	of	O
3	the	O
4	E2F1	O
5	gene	O
6	promoter	O
7	showed	O
8	that	O
9	the	O
10	-	O
11	146	O
12	to	O
13	-	O
14	54	O
15	region	O
16	was	O
17	required	O
18	for	O
19	E2	O
20	-	O
21	responsiveness	O
22	in	O
23	transient	O
24	transfection	O
25	assays	O
26	,	O
27	and	O
28	subsequent	O
29	deletion	O
30	/	O
31	mutation	O
32	analysis	O
33	showed	O
34	that	O
35	a	O
36	single	O
37	upstream	O
38	GC	O
39	-	O
40	rich	O
41	and	O
42	two	O
43	downstream	O
44	CCAAT	O
45	-	O
46	binding	O
47	sites	O
48	were	O
49	required	O
50	for	O
51	transactivation	O
52	by	O
53	E2	O
54	.	O

1	A	O
2	total	O
3	of	O
4	7	O
5	(	B
6	4	I
7	males	I
8	and	I
9	3	I
10	females	O
11	)	O
12	patients	O
13	were	O
14	included	B
15	in	I
16	this	I
17	retrospective	I
18	study	I
19	to	O
20	determine	O
21	the	O
22	sensitivity	O
23	of	O
24	radioimmunoscintigraphy	O
25	with	O
26	I	O
27	-	O
28	131	O
29	labeled	O
30	anti	O
31	CEA	O
32	/	O
33	CA	O
34	19	O
35	-	O
36	9	O
37	monoclonal	B
38	antibodies	I
39	.	I

1	The	O
2	effects	O
3	of	O
4	c	O
5	-	O
6	myc	O
7	were	O
8	further	O
9	dissected	O
10	by	O
11	showing	O
12	that	O
13	c	O
14	-	O
15	myc	O
16	can	O
17	inhibit	O
18	differentiation	O
19	independently	O
20	of	O
21	Id	O
22	,	O
23	a	O
24	negative	O
25	regulator	O
26	of	O
27	muscle	O
28	differentiation	O
29	.	O

1	Improved	O
2	methods	O
3	have	O
4	been	O
5	developed	O
6	for	O
7	maintaining	O
8	and	O
9	breeding	O
10	the	O
11	neotropical	O
12	short	O
13	-	O
14	tailed	O
15	fruit	O
16	bat	O
17	,	O
18	Carollia	O
19	perspicillata	O
20	,	B
21	in	I
22	an	I
23	easily	I
24	-	I
25	reproduced	I
26	,	I
27	laboratory	I
28	setting	I
29	.	O

1	Dual	O
2	radionuclide	O
3	subtraction	O
4	imaging	O
5	of	O
6	the	O
7	spleen	O
8	using	O
9	67Ga	B
10	citrate	I
11	and	I
12	99mTc	I
13	is	O
14	useful	O
15	in	O
16	further	O
17	delineating	O
18	lesions	O
19	that	O
20	are	O
21	identified	O
22	on	O
23	either	O
24	a	O
25	routine	O
26	radiogallium	O
27	survey	O
28	or	O
29	on	O
30	a	O
31	conventional	O
32	sulfur	O
33	colloid	O
34	liver	O
35	-	O
36	spleen	O
37	image	O
38	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	B
14	in	I
15	their	I
16	ability	I
17	to	I
18	bypass	I
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	O
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	O
31	the	O
32	weakest	O
33	.	O

1	The	O
2	cysteine	O
3	-	O
4	rich	O
5	region	O
6	of	O
7	raf	O
8	-	O
9	1	O
10	kinase	O
11	contains	B
12	zinc	I
13	,	I
14	translocates	I
15	to	O
16	liposomes	B
17	,	I
18	and	I
19	is	I
20	adjacent	O
21	to	O
22	a	O
23	segment	O
24	that	B
25	binds	I
26	GTP	I
27	-	I
28	ras	I
29	.	O

1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	reliability	O
8	of	O
9	the	O
10	student	O
11	Jenkins	O
12	Activity	B
13	Survey	I
14	(	I
15	JAS	I
16	;	I
17	a	I
18	questionnaire	I
19	measure	I
20	of	I
21	Type	O
22	A	O
23	behavior	O
24	).	O

1	Deletion	O
2	of	O
3	both	O
4	prfA	O
5	and	O
6	ponA	O
7	resulted	O
8	in	O
9	extremely	O
10	slow	O
11	growth	O
12	and	O
13	a	O
14	reduction	O
15	in	O
16	sporulation	O
17	efficiency	O
18	.	O

1	In	O
2	the	O
3	context	O
4	of	O
5	liver	O
6	allograft	O
7	shortage	O
8	,	O
9	our	O
10	results	O
11	suggest	O
12	that	B
13	an	I
14	ELT	I
15	should	O
16	not	O
17	be	O
18	performed	O
19	in	O
20	patients	O
21	with	O
22	cardiac	O
23	failure	O
24	,	O
25	more	O
26	than	O
27	two	O
28	OSF	O
29	,	O
30	or	O
31	an	O
32	APACHE	O
33	II	O
34	score	O
35	higher	O
36	than	O
37	30	O
38	.	O

1	Vacuolar	O
2	membrane	O
3	vesicles	O
4	from	O
5	hum1	O
6	mutants	O
7	lack	O
8	all	O
9	Ca2	O
10	+/	O
11	H	O
12	+	O
13	antiport	O
14	activity	O
15	,	O
16	demonstrating	O
17	that	O
18	Hum1p	O
19	catalyzes	O
20	the	O
21	exchange	O
22	of	O
23	Ca2	O
24	+	O
25	for	O
26	H	O
27	+	O
28	across	O
29	the	O
30	yeast	O
31	vacuolar	O
32	membrane	O
33	.	O

1	The	O
2	MMPI	O
3	-	O
4	A	O
5	(	O
6	Butcher	O
7	et	O
8	al	O
9	.,	I
10	1992	I
11	),	I
12	like	I
13	the	I
14	older	I
15	MMPI	I
16	(	O
17	Hathaway	O
18	&	O
19	McKinley	O
20	,	O
21	1983	O
22	),	O
23	distinguishes	O
24	between	O
25	anorexia	O
26	and	O
27	bulimia	O
28	.	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	EF	O
8	between	O
9	the	O
10	two	O
11	studies	O
12	,	O
13	both	O
14	at	O
15	rest	O
16	(	O
17	56	O
18	.	O
19	0	O
20	+/-	O
21	13	O
22	.	O
23	8	O
24	%	O
25	vs	O
26	58	O
27	.	O
28	2	O
29	+/-	O
30	11	O
31	.	O
32	7	O
33	%,	O
34	p	O
35	=	O
36	NS	O
37	)	O
38	and	O
39	with	O
40	exercise	O
41	(	O
42	51	O
43	.	O
44	1	O
45	+/-	O
46	17	O
47	.	O
48	6	O
49	%	O
50	vs	O
51	54	O
52	.	O
53	3	O
54	+/-	O
55	17	O
56	.	O
57	6	O
58	%,	O
59	p	O
60	=	O
61	NS	O
62	)	O
63	and	O
64	a	O
65	highly	O
66	significant	O
67	correlation	O
68	was	O
69	shown	O
70	between	O
71	the	O
72	two	O
73	groups	O
74	of	O
75	values	O
76	(	O
77	rest	O
78	r	O
79	=	O
80	0	O
81	.	O
82	90	O
83	,	O
84	exercise	O
85	r	O
86	=	O
87	0	O
88	.	O
89	93	O
90	,	O
91	p	O
92	less	O
93	than	O
94	0	O
95	.	O
96	001	O
97	).	O

1	The	O
2	effects	O
3	of	O
4	L655	O
5	,	O
6	240	O
7	,	O
8	a	O
9	selective	O
10	thromboxane	O
11	and	O
12	prostaglandin	O
13	endoperoxide	O
14	antagonist	O
15	,	O
16	on	O
17	ischemia	O
18	-	O
19	and	O
20	reperfusion	O
21	-	O
22	induced	O
23	cardiac	O
24	arrhythmias	O
25	.	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	Thus	O
2	,	O
3	hypoxia	O
4	-	O
5	inducible	O
6	nuclear	O
7	import	O
8	and	O
9	transactivation	O
10	by	O
11	recruitment	O
12	of	O
13	CBP	O
14	can	O
15	be	O
16	functionally	O
17	separated	O
18	from	O
19	one	O
20	another	O
21	and	O
22	play	O
23	critical	O
24	roles	O
25	in	O
26	signal	O
27	transduction	O
28	by	O
29	HIF	O
30	-	O
31	1alpha	O
32	.	O

1	The	O
2	previously	O
3	described	O
4	four	O
5	sets	O
6	of	O
7	13	O
8	-	O
9	to	O
10	18	O
11	-	O
12	base	O
13	-	O
14	pair	O
15	interspersed	O
16	repeat	O
17	elements	O
18	between	O
19	-	O
20	55	O
21	and	O
22	-	O
23	580	O
24	provide	O
25	most	O
26	of	O
27	the	B
28	high	I
29	basal	I
30	transcriptional	O
31	strength	O
32	,	O
33	whereas	O
34	the	O
35	arrangement	O
36	of	O
37	further	O
38	upstream	O
39	tandemly	O
40	repeated	O
41	NF1	O
42	-	O
43	binding	O
44	sites	O
45	may	O
46	contribute	O
47	significantly	O
48	to	O
49	the	O
50	expanded	O
51	biological	O
52	host	O
53	range	O
54	for	O
55	expression	O
56	of	O
57	SCMV	O
58	IE94	O
59	compared	O
60	with	O
61	HCMV	O
62	IE68	O
63	.	O

1	Replacement	O
2	variant	O
3	histone	B
4	genes	I
5	contain	I
6	intervening	I
7	sequences	I
8	.	I

1	We	O
2	have	B
3	previously	B
4	identified	I
5	a	I
6	liver	I
7	-	O
8	enriched	O
9	transcription	O
10	factor	O
11	,	O
12	HNF	O
13	-	O
14	6	I
15	,	I
16	which	I
17	is	I
18	required	I
19	for	I
20	HNF	I
21	-	O
22	3	B
23	beta	O
24	promoter	O
25	activity	O
26	and	O
27	also	O
28	recognizes	O
29	the	O
30	regulatory	O
31	region	O
32	of	O
33	numerous	O
34	hepatocyte	O
35	-	B
36	specific	B
37	genes	B
38	.	B

1	This	O
2	finding	O
3	suggested	O
4	that	O
5	the	O
6	PI3K	O
7	-	O
8	Akt	O
9	activation	O
10	pathway	O
11	plays	O
12	some	O
13	role	O
14	in	O
15	the	O
16	antiapoptotic	O
17	effect	O
18	of	O
19	EPO	O
20	.	O

1	Since	O
2	glutathione	O
3	peroxidase	O
4	(	O
5	GPX	O
6	)	O
7	and	O
8	superoxide	O
9	dismutase	O
10	(	O
11	SOD	O
12	)	O
13	play	O
14	a	O
15	significant	O
16	role	O
17	in	O
18	erythrocyte	O
19	antioxidative	O
20	defence	O
21	,	O
22	it	O
23	is	O
24	very	O
25	important	O
26	to	O
27	determine	O
28	their	O
29	activity	O
30	in	O
31	occupationally	O
32	exposed	O
33	workers	O
34	.	O

1	More	O
2	specific	O
3	adverse	B
4	events	I
5	,	I
6	also	I
7	frequently	I
8	considered	I
9	as	I
10	dose	I
11	-	I
12	limiting	O
13	toxicities	O
14	,	O
15	include	O
16	hypotension	O
17	with	O
18	IL	O
19	-	O
20	1	O
21	,	O
22	severe	O
23	headache	O
24	or	O
25	skin	O
26	rash	O
27	with	O
28	IL	O
29	-	O
30	3	O
31	,	O
32	and	O
33	nasal	O
34	congestion	O
35	and	O
36	gastroduodenal	O
37	lesions	O
38	with	O
39	IL	B
40	-	I
41	4	I
42	.	I

1	Genetic	O
2	and	O
3	molecular	O
4	data	O
5	indicate	O
6	that	O
7	wild	O
8	-	O
9	type	O
10	Pan	O
11	and	O
12	CiD	O
13	compete	O
14	for	O
15	binding	O
16	to	O
17	Arm	O
18	,	O
19	leading	O
20	to	O
21	a	O
22	compromised	O
23	transduction	O
24	of	O
25	the	O
26	Wg	O
27	signal	O
28	in	O
29	heterozygous	O
30	ciD	O
31	/+	O
32	animals	O
33	and	O
34	to	O
35	a	O
36	dramatic	O
37	enhancement	O
38	of	O
39	the	O
40	gain	O
41	-	O
42	of	O
43	-	O
44	function	O
45	activity	O
46	of	O
47	CiD	O
48	in	O
49	homozygous	O
50	mutants	O
51	.	O

1	In	O
2	the	B
3	absence	I
4	of	I
5	histological	I
6	criteria	I
7	,	I
8	which	O
9	it	O
10	is	O
11	difficult	O
12	to	O
13	demand	O
14	in	O
15	view	O
16	of	O
17	the	O
18	variability	O
19	of	O
20	results	O
21	and	O
22	potential	O
23	dangers	O
24	of	O
25	endomyocardial	O
26	biopsy	O
27	involving	O
28	such	O
29	thin	O
30	and	O
31	fragile	O
32	ventricular	O
33	walls	O
34	,	O
35	the	O
36	diagnosis	O
37	of	O
38	ACRV	O
39	is	B
40	based	I
41	upon	I
42	the	I
43	concomitant	I
44	existence	I
45	of	O
46	:	O
47	(	O
48	1	O
49	)	O
50	electrophysiological	O
51	criteria	B
52	:	O
53	ventricular	O
54	arrhythmias	B
55	,	B
56	in	B
57	particular	I
58	sustained	I
59	monomorphous	I
60	VT	B
61	,	O
62	with	I
63	the	O
64	particular	O
65	feature	O
66	of	O
67	a	O
68	very	O
69	high	O
70	degree	B
71	of	I
72	sensitivity	I
73	to	I
74	adrenergic	I
75	stimulation	B
76	(	I
77	exercise	O
78	),	I
79	the	I
80	existence	O
81	of	O
82	late	O
83	potentials	O
84	on	O
85	the	O
86	high	O
87	amplification	O
88	ECG	B
89	,	B
90	a	I
91	highly	I
92	specific	B
93	sign	I
94	,	I
95	though	I
96	unfortunately	I
97	of	O
98	poor	O
99	sensitivity	O
100	in	O
101	localized	O
102	froms	O
103	,	O
104	those	O
105	which	O
106	are	O
107	most	O
108	difficult	O
109	to	O
110	identify	O
111	(	O
112	2	O
113	);	O
114	segmentary	O
115	morphological	O
116	and	O
117	kinetic	O
118	RV	O
119	abnormalities	O
120	,	O
121	most	O
122	often	O
123	resulting	O
124	in	O
125	localized	O
126	akinetic	O
127	or	O
128	dyskinetic	O
129	parietal	O
130	vaulting	O
131	,	B
132	with	I
133	stasis	O
134	"	B
135	in	B
136	situ	I
137	".	I

1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O

1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	O
9	FPGS	O
10	-	O
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	O
38	wild	O
39	-	O
40	type	O
41	enzyme	O
42	.	O

1	The	O
2	interpretation	O
3	of	O
4	antibiotic	O
5	disc	O
6	sensitivities	O
7	.	O

1	Epstein	O
2	-	O
3	Barr	O
4	virus	O
5	(	O
6	EBV	O
7	)	O
8	latent	O
9	membrane	O
10	protein	O
11	1	B
12	(	I
13	LMP1	I
14	)	I
15	is	I
16	essential	I
17	for	O
18	EBV	O
19	-	O
20	mediated	O
21	transformation	O
22	of	O
23	primary	O
24	B	O
25	lymphocytes	O
26	.	O

1	SPP41	O
2	was	O
3	cloned	O
4	and	O
5	sequenced	O
6	and	O
7	found	O
8	to	O
9	be	O
10	essential	O
11	.	O
12	spp43	O
13	is	O
14	allelic	O
15	to	O
16	the	O
17	previously	O
18	identified	O
19	suppressor	O
20	srn1	O
21	,	B
22	which	I
23	encodes	O
24	a	O
25	negative	O
26	regulator	O
27	of	O
28	gene	O
29	expression	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	both	O
5	the	O
6	exon	O
7	1	O
8	-	B
9	and	I
10	exon	I
11	2	O
12	-	O
13	initiated	O
14	forms	O
15	of	O
16	the	O
17	c	O
18	-	O
19	Myc	O
20	protein	O
21	stimulated	O
22	transcription	O
23	of	O
24	a	O
25	Myc	O
26	/	O
27	Max	O
28	-	O
29	responsive	O
30	reporter	O
31	construct	O
32	to	O
33	a	O
34	similar	O
35	level	O
36	.	O

1	Transfection	O
2	experiments	O
3	demonstrated	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	(-	O
11	1894	O
12	to	O
13	+	O
14	37	B
15	)	I
16	of	I
17	the	I
18	mStaf	I
19	gene	O
20	drives	O
21	transcription	O
22	in	O
23	mouse	O
24	NMuMG	B
25	cells	I
26	and	I
27	that	I
28	a	I
29	construct	I
30	containing	I
31	a	O
32	fragment	O
33	from	B
34	-	O
35	387	O
36	to	O
37	+	O
38	37	O
39	showed	O
40	the	O
41	highest	O
42	transcriptional	O
43	activity	O
44	.	O

1	Only	O
2	one	O
3	ADR	O
4	was	O
5	related	O
6	definitely	O
7	to	O
8	ciprofloxacin	O
9	therapy	O
10	.	O

1	Administration	O
2	of	O
3	anticoagulants	O
4	,	O
5	i	O
6	.	O
7	e	O
8	.,	O
9	heparin	O
10	,	O
11	prostaglandin	O
12	E1	O
13	and	O
14	ticlopidine	O
15	seems	O
16	to	O
17	be	O
18	effective	O
19	in	O
20	alleviating	O
21	symptoms	O
22	and	O
23	might	O
24	prevent	O
25	further	O
26	deterioration	O
27	.	O

1	"	O
2	Let	O
3	the	O
4	hundred	O
5	flowers	O
6	bloom	O
7	".	O

1	Mutational	O
2	analysis	O
3	of	O
4	yeast	O
5	CEG1	O
6	demonstrated	O
7	that	O
8	four	O
9	of	O
10	the	O
11	five	B
12	conserved	I
13	motifs	I
14	are	I
15	essential	I
16	for	I
17	capping	O
18	enzyme	O
19	function	O
20	in	O
21	vivo	O
22	.	O

1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	B
19	to	I
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	haloperidol	O
6	selectively	O
7	reduced	O
8	the	O
9	animal	O
10	'	O
11	s	O
12	capacity	O
13	to	O
14	'	O
15	programme	O
16	non	O
17	-	O
18	stimulus	O
19	directed	O
20	motor	O
21	behaviour	O
22	'.	O

1	Processing	O
2	,	O
3	secretion	O
4	,	O
5	and	O
6	immunoreactivity	O
7	of	O
8	carboxy	O
9	terminally	O
10	truncated	O
11	dengue	O
12	-	O
13	2	O
14	virus	O
15	envelope	O
16	proteins	O
17	expressed	O
18	in	O
19	insect	O
20	cells	O
21	by	O
22	recombinant	O
23	baculoviruses	O
24	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	elucidate	O
7	signaling	O
8	pathways	O
9	induced	O
10	by	O
11	photodynamic	O
12	therapy	O
13	(	O
14	PDT	O
15	)	O
16	with	O
17	hypericin	O
18	.	O

1	Studies	O
2	on	O
3	alcoholic	O
4	liver	O
5	injury	O
6	.	O

1	Amounts	O
2	of	O
3	glucose	O
4	infused	O
5	during	O
6	the	B
7	last	I
8	20	I
9	min	O
10	of	O
11	each	O
12	2	O
13	hour	O
14	insulin	O
15	infusion	O
16	were	O
17	(	O
18	at	O
19	1	O
20	and	O
21	10	O
22	m	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	respectively	O
28	):	O
29	before	O
30	treatment	O
31	(	O
32	K	O
33	+	O
34	=	O
35	2	O
36	.	O
37	7	O
38	mmol	O
39	/	O
40	l	O
41	):	O
42	2	B
43	.	O
44	4	O
45	and	O
46	8	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	kg	O
52	/	O
53	min	O
54	;	O
55	after	B
56	spironolactone	O
57	(	O
58	K	O
59	+	O
60	=	O
61	3	O
62	.	O
63	9	O
64	mmol	O
65	/	O
66	l	O
67	):	O
68	3	O
69	.	O
70	3	O
71	and	O
72	15	O
73	.	O
74	4	B
75	mg	I
76	/	I
77	kg	O
78	/	O
79	min	O
80	;	O
81	after	I
82	indomethacine	O
83	(	O
84	K	O
85	+	O
86	=	O
87	3	O
88	.	O
89	7	O
90	mmol	O
91	/	O
92	l	B
93	):	I
94	5	O
95	and	B
96	19	I
97	mg	O
98	/	O
99	kg	O
100	/	O
101	min	O
102	after	O
103	stopping	O
104	drugs	O
105	(	O
106	K	O
107	+	O
108	=	O
109	2	O
110	.	O
111	9	O
112	mmol	O
113	/	O
114	l	O
115	):	O
116	2	O
117	.	O
118	5	O
119	and	O
120	5	O
121	.	O
122	3	O
123	mg	O
124	/	O
125	kg	O
126	/	O
127	min	O
128	.	O

1	We	O
2	sought	B
3	to	I
4	determine	I
5	whether	I
6	such	O
7	differences	O
8	in	O
9	polyadenylation	O
10	affect	O
11	the	O
12	steady	B
13	-	I
14	state	I
15	levels	I
16	of	O
17	DHFR	B
18	and	I
19	mRNAs	I
20	expressed	I
21	from	O
22	either	O
23	allele	O
24	and	O
25	,	O
26	in	O
27	a	O
28	more	O
29	general	O
30	sense	O
31	,	B
32	to	I
33	ask	I
34	whether	I
35	differences	O
36	in	B
37	3	I
38	'	I
39	end	I
40	RNA	O
41	processing	O
42	in	O
43	a	O
44	gene	O
45	containing	O
46	multiple	B
47	poly	I
48	(	I
49	A	I
50	)	O
51	sites	B
52	affects	I
53	the	I
54	final	I
55	level	O
56	of	O
57	gene	O
58	expression	O
59	.	O

1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O

1	The	O
2	retention	O
3	index	O
4	of	O
5	201Tl	O
6	SPECT	O
7	is	O
8	a	O
9	useful	O
10	indicator	O
11	of	O
12	metastatic	O
13	potential	O
14	,	O
15	thereby	O
16	facilitating	O
17	the	O
18	prediction	O
19	of	O
20	prognosis	O
21	,	O
22	and	O
23	provides	O
24	insight	O
25	into	O
26	the	O
27	relationship	O
28	between	O
29	201Tl	O
30	uptake	O
31	and	O
32	malignancy	O
33	.	O

1	Cattaneo	O
2	,	O
3	and	O
4	J	O
5	.	O

1	APOE	O
2	-	O
3	epsilon4	O
4	count	O
5	predicts	O
6	age	O
7	when	O
8	prevalence	O
9	of	O
10	AD	O
11	increases	O
12	,	O
13	then	B
14	declines	I
15	:	I
16	the	I
17	Cache	I
18	County	I
19	Study	I
20	.	O

1	The	O
2	DNA	O
3	binding	O
4	and	O
5	multimerization	O
6	activities	O
7	of	O
8	c	O
9	-	O
10	Myb	O
11	appear	O
12	to	O
13	be	O
14	unaffected	O
15	by	O
16	the	O
17	S528A	O
18	substitution	O
19	,	O
20	suggesting	O
21	that	O
22	phosphorylation	O
23	of	O
24	serine	O
25	528	O
26	may	O
27	mediate	O
28	its	O
29	effect	O
30	on	O
31	the	O
32	transcription	O
33	transactivating	O
34	activity	O
35	of	O
36	c	O
37	-	O
38	Myb	O
39	by	O
40	regulating	O
41	interactions	O
42	with	O
43	other	O
44	proteins	O
45	.	O

1	Analysis	O
2	of	O
3	strains	O
4	harboring	O
5	an	B
6	mds1	I
7	null	I
8	mutation	I
9	demonstrates	I
10	that	I
11	MDS1	O
12	is	O
13	not	O
14	essential	O
15	during	O
16	normal	O
17	vegetative	O
18	growth	O
19	but	O
20	appears	O
21	to	O
22	be	O
23	required	O
24	for	O
25	meiosis	O
26	.	O

1	Plots	O
2	of	O
3	RV	O
4	,	O
5	LV	O
6	+	B
7	S	I
8	and	I
9	2A	I
10	weight	I
11	vs	I
12	real	I
13	hematocrit	I
14	showed	I
15	sharp	I
16	upward	O
17	inflections	B
18	at	I
19	real	I
20	hematocrit	O
21	65	O
22	%,	O
23	suggesting	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	increased	O
29	viscosity	O
30	in	O
31	CO	O
32	cardiomegaly	O
33	at	O
34	the	O
35	higher	O
36	hematocrit	O
37	.	O

1	No	O
2	therapy	O
3	exists	O
4	for	O
5	halting	O
6	the	O
7	progression	O
8	of	O
9	the	O
10	disease	O
11	with	O
12	the	O
13	possible	O
14	exception	O
15	of	O
16	laser	O
17	photocoagulation	O
18	treatment	O
19	used	O
20	to	O
21	ablate	O
22	subretinal	O
23	neovascular	O
24	membranes	O
25	in	O
26	an	O
27	attempt	O
28	to	O
29	avoid	O
30	complications	O
31	of	O
32	subretinal	O
33	hemorrhages	O
34	.	O

1	The	O
2	elevated	O
3	Viso	O
4	V	O
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O

1	Compared	O
2	to	O
3	its	O
4	counterpart	O
5	in	O
6	the	O
7	GPB	O
8	gene	O
9	,	O
10	exon	O
11	3	O
12	of	O
13	the	O
14	GPE	O
15	gene	O
16	contains	O
17	several	O
18	point	O
19	mutations	O
20	,	O
21	an	O
22	insertion	O
23	of	O
24	24	O
25	bp	O
26	,	O
27	and	O
28	a	O
29	stop	O
30	codon	O
31	which	O
32	shortens	O
33	the	O
34	reading	O
35	frame	O
36	.	O

1	Post	O
2	-	O
3	translational	O
4	modifications	O
5	such	O
6	as	O
7	glycosylation	O
8	and	O
9	phosphorylation	O
10	could	B
11	be	I
12	excluded	I
13	as	I
14	potential	I
15	explanations	O
16	for	B
17	the	B
18	protein	I
19	heterogeneity	O
20	.	O

1	Lysine	O
2	-	O
3	ketoglutarate	O
4	reductase	O
5	and	O
6	saccharopine	O
7	dehydrogenase	O
8	from	O
9	Arabidopsis	O
10	thaliana	O
11	:	O
12	nucleotide	O
13	sequence	O
14	and	O
15	characterization	O
16	.	O

1	During	O
2	the	O
3	observation	O
4	period	O
5	of	O
6	0	O
7	.	O
8	4	B
9	-	I
10	30	I
11	weeks	I
12	,	I
13	cardiac	I
14	white	O
15	spots	O
16	on	O
17	the	O
18	right	O
19	ventricle	O
20	of	O
21	BALB	O
22	/	O
23	c	O
24	mice	O
25	were	O
26	first	O
27	detected	O
28	at	O
29	three	O
30	weeks	O
31	(	O
32	6	O
33	of	O
34	20	O
35	mice	O
36	;	O
37	30	O
38	%),	O
39	and	O
40	the	O
41	maximal	O
42	incidence	O
43	of	O
44	cardiac	O
45	white	O
46	spots	O
47	was	O
48	obtained	O
49	at	O
50	nine	O
51	weeks	O
52	(	O
53	39	O
54	of	O
55	44	O
56	mice	O
57	;	O
58	88	O
59	%).	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	microprocessor	O
6	controlled	O
7	current	O
8	based	O
9	defibrillator	O
10	.	O

1	Fragments	O
2	and	O
3	analogs	O
4	of	O
5	the	O
6	hormone	O
7	ACTH	O
8	were	O
9	previously	O
10	shown	O
11	to	O
12	have	O
13	beneficial	O
14	effect	O
15	on	O
16	the	O
17	outcome	O
18	of	O
19	head	O
20	injury	O
21	,	O
22	while	O
23	elevated	O
24	levels	O
25	of	O
26	corticosterone	O
27	(	O
28	CS	O
29	)	O
30	exacerbate	O
31	it	O
32	.	O

1	Radiolabeled	O
2	recombinant	O
3	TARC	O
4	specifically	O
5	bound	O
6	to	O
7	T	O
8	cell	O
9	lines	O
10	and	O
11	peripheral	O
12	T	O
13	cells	O
14	but	O
15	not	O
16	to	O
17	monocytes	O
18	or	O
19	granulocytes	O
20	.	O

1	Here	O
2	we	B
3	demonstrate	I
4	that	I
5	the	I
6	mechanism	O
7	of	O
8	activation	O
9	of	O
10	HIF	O
11	-	O
12	1alpha	O
13	is	O
14	a	O
15	multi	O
16	-	O
17	step	O
18	process	O
19	which	O
20	includes	O
21	hypoxia	O
22	-	O
23	dependent	O
24	nuclear	O
25	import	B
26	and	B
27	activation	I
28	(	O
29	derepression	O
30	)	O
31	of	O
32	the	B
33	transactivation	I
34	domain	I
35	,	O
36	resulting	B
37	in	I
38	recruitment	I
39	of	I
40	the	I
41	CREB	I
42	-	I
43	binding	O
44	protein	B
45	(	B
46	CBP	I
47	)/	I
48	p300	I
49	coactivator	I
50	.	I

1	Reporter	O
2	gene	O
3	expression	B
4	analyses	I
5	indicate	I
6	that	I
7	both	I
8	WASP	I
9	promoters	I
10	show	I
11	high	I
12	levels	O
13	of	B
14	expression	B
15	in	O
16	different	O
17	hematopoietic	O
18	cell	O
19	lines	O
20	.	O

1	In	O
2	study	O
3	2	O
4	,	O
5	the	O
6	correlation	O
7	coefficients	O
8	between	O
9	the	O
10	ISO2	O
11	measurements	O
12	obtained	O
13	at	O
14	the	O
15	ulcer	O
16	margin	O
17	and	O
18	at	O
19	the	O
20	adjacent	O
21	normal	O
22	mucosa	O
23	,	O
24	and	O
25	delta	O
26	ISO2	O
27	obtained	O
28	by	O
29	the	O
30	experienced	O
31	observer	O
32	and	O
33	one	O
34	of	O
35	the	O
36	three	O
37	learners	O
38	were	O
39	0	O
40	.	O
41	94	O
42	,	O
43	0	O
44	.	O
45	97	O
46	,	O
47	and	O
48	0	O
49	.	O
50	94	O
51	,	O
52	respectively	O
53	.	O

1	(	O
2	1998	O
3	)	O
4	FASEB	O
5	J	O
6	.	B

1	Of	O
2	the	O
3	cases	O
4	with	O
5	PLD	O
6	,	O
7	50	O
8	%	O
9	had	O
10	associated	O
11	renal	O
12	cysts	O
13	and	O
14	10	O
15	%	O
16	of	O
17	the	O
18	cases	O
19	with	O
20	APCD	O
21	had	O
22	associated	O
23	liver	O
24	cysts	O
25	.	O

1	However	O
2	,	B
3	whether	I
4	or	I
5	not	O
6	nonsense	O
7	codon	O
8	recognition	O
9	within	B
10	TPI	B
11	transcripts	I
12	takes	I
13	place	I
14	prior	I
15	to	I
16	or	I
17	after	I
18	splicing	I
19	remained	I
20	unresolved	I
21	.	I

1	A	O
2	reduction	O
3	in	O
4	blood	O
5	pressure	O
6	was	O
7	only	B
8	observed	I
9	at	I
10	the	I
11	end	I
12	of	I
13	the	O
14	study	B
15	,	I
16	from	I
17	142	I
18	+/-	I
19	17	I
20	/	O
21	86	O
22	.	O
23	6	O
24	+/-	O
25	9	O
26	.	O
27	1	O
28	to	O
29	139	O
30	+/-	O
31	13	O
32	/	O
33	82	O
34	.	O
35	9	O
36	+/-	O
37	8	O
38	.	O
39	9	O
40	mmHg	O
41	(	O
42	P	O
43	less	B
44	than	I
45	0	I
46	.	I
47	05	I
48	for	I
49	DBP	O
50	).	B

1	The	O
2	roxithromycin	O
3	doses	O
4	that	O
5	were	O
6	chosen	O
7	for	O
8	these	O
9	studies	B
10	were	I
11	less	I
12	than	I
13	achievable	I
14	blood	O
15	levels	O
16	.	O

1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	B
8	with	I
9	low	I
10	disease	I
11	activity	O
12	and	O
13	/	B
14	or	I
15	efficacy	I
16	of	I
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O

1	Two	O
2	-	O
3	dimensional	O
4	gel	O
5	electrophoresis	O
6	of	B
7	anti	I
8	-	O
9	p59fyn	O
10	immunoprecipitates	O
11	obtained	O
12	from	B
13	non	B
14	-	I
15	transformed	I
16	resting	I
17	human	I
18	T	I
19	lymphocytes	O
20	resulted	O
21	in	O
22	the	O
23	identification	O
24	of	O
25	an	O
26	oligomeric	O
27	protein	O
28	complex	B
29	which	I
30	is	I
31	constitutively	I
32	formed	I
33	between	I
34	Fyn	I
35	and	O
36	several	O
37	additional	O
38	phosphoproteins	O
39	(	O
40	pp43	O
41	,	O
42	pp72	O
43	,	O
44	pp85	O
45	,	O
46	the	O
47	protein	O
48	tyrosine	B
49	kinase	B
50	Pyk2	B
51	,	B
52	as	B
53	well	I
54	as	O
55	the	B
56	two	O
57	recently	O
58	cloned	O
59	adaptor	O
60	proteins	O
61	,	O
62	SKAP55	O
63	and	O
64	SLAP	B
65	-	B
66	130	I
67	).	I

1	Since	O
2	each	O
3	transcript	O
4	appears	O
5	to	O
6	encode	O
7	the	O
8	same	O
9	protein	O
10	,	O
11	this	O
12	complexity	B
13	may	I
14	reflect	I
15	the	I
16	need	I
17	for	I
18	lineage	O
19	-	B
20	specific	I
21	or	O
22	differentiation	O
23	-	O
24	dependent	O
25	control	O
26	of	O
27	expression	O
28	.	O

1	Factors	O
2	associated	O
3	with	O
4	intrafamilial	O
5	transmission	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	infection	O
11	in	O
12	Korea	O
13	.	B

1	The	O
2	human	O
3	SHBG	O
4	proximal	O
5	promoter	O
6	was	O
7	analyzed	O
8	by	O
9	DNase	O
10	I	O
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	O
23	-	O
24	FP6	O
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	action	O
6	of	O
7	GLP	O
8	-	O
9	1	O
10	at	O
11	the	O
12	CRE	O
13	was	O
14	not	O
15	blocked	O
16	by	O
17	cotransfection	O
18	with	O
19	M1	O
20	-	O
21	CREB	O
22	,	O
23	an	O
24	isoform	O
25	that	O
26	lacks	O
27	a	O
28	consensus	O
29	serine	O
30	residue	O
31	serving	O
32	as	O
33	substrate	O
34	for	O
35	PKA	O
36	-	O
37	mediated	O
38	phosphorylation	O
39	.	O

1	PRDII	O
2	-	B
3	BF1	I
4	-	I
5	derived	I
6	cDNAs	I
7	did	I
8	not	I
9	result	I
10	in	O
11	stimulation	O
12	of	O
13	either	O
14	basal	O
15	or	O
16	tat	O
17	-	O
18	induced	O
19	activated	O
20	gene	O
21	expression	O
22	.	O

1	Oncogenic	O
2	Raf	O
3	-	O
4	1	O
5	activates	O
6	p70	O
7	S6	O
8	kinase	O
9	via	O
10	a	O
11	mitogen	O
12	-	O
13	activated	O
14	protein	O
15	kinase	O
16	-	O
17	independent	O
18	pathway	O
19	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	rapidly	O
5	induces	O
6	a	B
7	reversible	I
8	change	I
9	in	O
10	the	O
11	electrophoretic	O
12	mobility	O
13	of	O
14	the	O
15	ternary	O
16	complex	O
17	,	O
18	accompanied	O
19	by	O
20	increased	O
21	phosphorylation	O
22	of	O
23	the	O
24	Elk	O
25	-	O
26	1	O
27	C	O
28	-	O
29	terminal	O
30	region	O
31	and	O
32	by	O
33	the	O
34	activation	O
35	of	O
36	a	O
37	42	O
38	kd	O
39	cellular	O
40	Elk	O
41	-	O
42	1	B
43	kinase	O
44	.	O

1	(	O
2	1992	O
3	)	O
4	Biochemistry	O
5	31	O
6	,	O
7	3351	O
8	-	O
9	3358	O
10	].	O

1	The	O
2	5	O
3	'	O
4	regions	O
5	of	O
6	these	O
7	two	O
8	soybean	B
9	actin	I
10	genes	I
11	contain	I
12	many	I
13	unusual	I
14	features	I
15	including	I
16	(	I
17	CT	I
18	)	I
19	repeats	O
20	and	O
21	long	O
22	stretches	O
23	of	O
24	pyrimidine	B
25	-	I
26	rich	I
27	DNA	I
28	.	I

1	This	O
2	philosophy	O
3	was	O
4	instituted	O
5	for	O
6	the	O
7	compound	O
8	RP	O
9	73401	O
10	,	O
11	a	O
12	specific	O
13	phosphodiesterase	O
14	IV	O
15	inhibitor	O
16	,	O
17	that	O
18	was	O
19	being	O
20	developed	O
21	simultaneously	O
22	for	O
23	delivery	O
24	by	O
25	both	O
26	oral	O
27	and	O
28	pulmonary	O
29	routes	O
30	of	O
31	administration	O
32	.	O

1	The	O
2	second	O
3	patient	O
4	had	O
5	received	O
6	pituitary	B
7	-	I
8	derived	I
9	growth	O
10	hormone	B
11	for	I
12	treatment	I
13	of	O
14	growth	O
15	hormone	O
16	deficiency	O
17	,	O
18	secondary	O
19	to	O
20	a	O
21	third	O
22	ventricle	O
23	teratoma	O
24	,	O
25	exised	B
26	13	I
27	yr	I
28	earlier	O
29	.	O

1	Crystal	O
2	structure	O
3	of	B
4	an	I
5	oligomer	O
6	of	B
7	proteolytic	I
8	zymogens	I
9	:	O
10	detailed	O
11	conformational	O
12	analysis	O
13	of	O
14	the	O
15	bovine	O
16	ternary	O
17	complex	O
18	and	O
19	implications	O
20	for	O
21	their	O
22	activation	O
23	.	O

1	DNase	O
2	I	O
3	footprinting	B
4	and	I
5	electrophoretic	I
6	mobility	I
7	shift	I
8	assays	O
9	indicate	O
10	that	O
11	PBP	O
12	binds	O
13	to	O
14	the	O
15	half	O
16	-	O
17	site	O
18	of	O
19	each	O
20	palindrome	O
21	with	O
22	the	O
23	core	O
24	recognition	O
25	sequence	O
26	TGGGAG	O
27	.	O

1	Use	O
2	of	O
3	free	O
4	-	O
5	access	O
6	minerals	O
7	.	O

1	When	O
2	voltage	O
3	-	O
4	operated	O
5	Ca2	O
6	+	B
7	channels	I
8	(	I
9	VOC	O
10	)	O
11	were	O
12	blocked	B
13	by	B
14	nifedipine	I
15	,	O
16	midazolam	O
17	,	O
18	in	O
19	concentrations	O
20	more	B
21	than	I
22	1	I
23	microM	O
24	,	O
25	attenuated	O
26	both	O
27	phasic	O
28	and	O
29	tonic	O
30	responses	O
31	.	B

1	The	O
2	cell	O
3	cycle	O
4	-	O
5	regulated	O
6	transcription	B
7	factor	I
8	E2F	I
9	is	I
10	also	O
11	known	B
12	to	I
13	bend	I
14	DNA	I
15	upon	I
16	binding	I
17	.	O

1	The	O
2	resulting	O
3	R	O
4	protein	B
5	terminates	I
6	five	O
7	codons	O
8	downstream	O
9	of	O
10	the	O
11	frameshift	O
12	site	O
13	at	O
14	the	O
15	V	O
16	protein	O
17	stop	O
18	codon	O
19	.	O

1	In	O
2	this	O
3	article	O
4	,	O
5	the	O
6	clinical	O
7	actions	O
8	of	O
9	the	O
10	principal	O
11	dopamine	B
12	receptor	I
13	stimulating	I
14	agents	O
15	(	O
16	apomorphine	O
17	and	B
18	its	I
19	derivatives	I
20	;	I
21	piribedil	O
22	,	O
23	rye	O
24	-	O
25	ergot	O
26	derivatives	O
27	)	O
28	are	O
29	discussed	O
30	on	O
31	the	O
32	basis	O
33	of	O
34	their	O
35	biochemical	O
36	and	B
37	pharmacological	I
38	properties	I
39	.	I

1	Plasma	O
2	vitamin	O
3	E	O
4	,	O
5	total	B
6	lipids	I
7	and	I
8	myeloperoxidase	I
9	levels	I
10	during	I
11	spinal	O
12	surgery	O
13	.	O

1	This	O
2	suggests	O
3	that	O
4	mechanisms	O
5	other	O
6	than	O
7	an	O
8	excessive	O
9	increase	O
10	in	O
11	myocardial	O
12	oxygen	O
13	demand	O
14	may	O
15	be	O
16	responsible	O
17	for	O
18	the	B
19	many	I
20	episodes	I
21	occurring	I
22	outside	I
23	the	I
24	hospital	I
25	.	I

1	We	O
2	have	O
3	determined	O
4	the	O
5	nucleotide	O
6	(	B
7	nt	I
8	)	I
9	sequence	I
10	of	O
11	the	B
12	7	I
13	.	I
14	5	O
15	-	O
16	kb	B
17	COR	I
18	segment	I
19	that	I
20	encompasses	I
21	a	O
22	cluster	O
23	of	O
24	six	O
25	genes	O
26	(	O
27	CYC1	O
28	,	O
29	UTR1	O
30	,	O
31	UTR3	O
32	,	O
33	OSM1	O
34	,	O
35	tRNA	O
36	(	O
37	Gly	O
38	)	O
39	and	O
40	RAD7	O
41	)	O
42	located	B
43	on	I
44	chromosome	I
45	X	I
46	of	I
47	the	B
48	yeast	I
49	Saccharomyces	O
50	cerevisiae	O
51	.	O

1	Second	O
2	,	O
3	the	O
4	membrane	B
5	expression	I
6	of	I
7	alpha	O
8	and	O
9	beta	B
10	subunits	I
11	was	I
12	mimicked	O
13	by	B
14	cholesterol	I
15	and	O
16	17	O
17	-	O
18	ketocholesterol	O
19	,	O
20	both	O
21	of	O
22	which	O
23	inhibit	O
24	HMG	O
25	-	O
26	CoA	O
27	reductase	O
28	.	O

1	Femoral	O
2	strain	O
3	adaptation	O
4	after	O
5	total	O
6	hip	O
7	replacement	O
8	:	O
9	a	O
10	comparison	O
11	of	O
12	cemented	O
13	and	B
14	porous	I
15	ingrowth	O
16	components	O
17	in	O
18	canines	O
19	.	O

1	Although	O
2	the	O
3	binding	O
4	of	O
5	IE2	O
6	86	O
7	to	O
8	nonphosphorylated	O
9	full	O
10	-	O
11	length	O
12	CREB	O
13	or	O
14	deltaCREB	O
15	is	O
16	minimal	O
17	,	O
18	IE2	O
19	86	O
20	does	O
21	form	O
22	complexes	O
23	with	O
24	p300	O
25	and	O
26	the	O
27	CREB	O
28	-	O
29	binding	O
30	protein	O
31	(	O
32	CBP	O
33	),	O
34	which	O
35	in	O
36	turn	O
37	bind	O
38	to	O
39	CREB	O
40	and	O
41	can	O
42	serve	O
43	as	O
44	adaptor	O
45	proteins	O
46	for	O
47	CREB	O
48	function	O
49	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	show	O
6	that	O
7	the	O
8	differential	O
9	utilization	O
10	of	O
11	Staf	B
12	zinc	I
13	finger	I
14	1	I
15	represents	O
16	a	O
17	new	O
18	,	O
19	critical	O
20	determinant	O
21	of	O
22	the	O
23	transcriptional	O
24	activation	O
25	mechanism	O
26	for	O
27	the	O
28	Xenopus	O
29	tRNA	O
30	(	O
31	Sec	O
32	)	O
33	and	O
34	human	O
35	U6	O
36	snRNA	O
37	genes	O
38	.	O

1	Renal	O
2	cell	O
3	carcinoma	O
4	in	O
5	children	O
6	:	O
7	a	O
8	single	O
9	institution	O
10	'	O
11	s	O
12	experience	O
13	.	O

1	Many	O
2	cells	O
3	were	O
4	negative	O
5	for	O
6	endothelial	O
7	-	O
8	cell	O
9	markers	O
10	,	O
11	and	O
12	they	O
13	reacted	O
14	with	O
15	a	O
16	monoclonal	O
17	antibody	O
18	against	O
19	muscle	O
20	actin	O
21	.	O

1	By	O
2	far	O
3	-	O
4	Western	O
5	analysis	O
6	and	O
7	coimmunoprecipitation	O
8	studies	O
9	,	O
10	we	O
11	demonstrate	O
12	that	O
13	ZNF74	O
14	interacts	O
15	,	O
16	via	O
17	its	O
18	zinc	O
19	finger	O
20	domain	O
21	,	O
22	with	O
23	the	O
24	hyperphosphorylated	O
25	largest	O
26	subunit	O
27	of	O
28	RNA	O
29	polymerase	O
30	II	O
31	(	O
32	pol	O
33	IIo	O
34	)	O
35	but	O
36	not	O
37	with	O
38	the	O
39	hypophosphorylated	O
40	form	O
41	.	O

1	A	O
2	stretch	O
3	of	O
4	16	O
5	nucleotides	O
6	just	O
7	upstream	O
8	of	O
9	the	O
10	IL	O
11	-	O
12	4RE	O
13	contributed	O
14	to	O
15	IL	O
16	-	O
17	4	O
18	inducibility	O
19	and	O
20	formed	B
21	nucleoprotein	I
22	complexes	I
23	with	I
24	constitutive	O
25	factors	O
26	.	O

1	This	O
2	action	O
3	is	O
4	dependent	O
5	on	O
6	helix	O
7	-	O
8	loop	O
9	-	O
10	helix	O
11	factors	O
12	bound	O
13	to	O
14	the	O
15	E1	O
16	element	O
17	.	O

1	Flavonoids	O
2	from	O
3	Brosimum	O
4	acutifolium	O
5	.	O

1	In	O
2	the	B
3	second	I
4	experiment	I
5	,	I
6	a	I
7	stable	I
8	nickel	I
9	isotope	O
10	,	O
11	61Ni	O
12	,	O
13	was	O
14	given	O
15	in	O
16	drinking	O
17	water	O
18	to	B
19	20	I
20	nickel	I
21	-	I
22	sensitized	I
23	women	I
24	and	I
25	20	I
26	age	O
27	-	O
28	matched	O
29	controls	B
30	,	I
31	both	I
32	groups	O
33	having	O
34	vesicular	O
35	hand	O
36	eczema	O
37	of	B
38	the	I
39	pompholyx	I
40	type	I
41	.	I

1	Subsequently	O
2	,	O
3	HD	O
4	inhibited	O
5	healing	O
6	because	O
7	it	O
8	significantly	O
9	delayed	O
10	epithelialization	O
11	and	O
12	caused	O
13	protracted	O
14	inflammation	O
15	.	O

1	Sterol	O
2	analysis	O
3	of	O
4	the	O
5	disrupted	O
6	mutant	O
7	demonstrated	O
8	the	O
9	accumulation	O
10	of	O
11	ignosterol	O
12	,	O
13	indicating	O
14	a	O
15	loss	O
16	of	O
17	Erg24p	O
18	activity	O
19	.	O

1	In	O
2	this	O
3	study	O
4	26	O
5	patients	O
6	(	O
7	20	O
8	females	O
9	and	O
10	6	O
11	males	O
12	)	O
13	were	O
14	evaluated	O
15	.	O

1	Comparison	O
2	of	O
3	immunoassay	O
4	kits	O
5	for	O
6	detection	O
7	of	O
8	staphylococcal	O
9	enterotoxins	O
10	produced	O
11	by	O
12	Staphylococcus	O
13	aureus	O

1	Personal	O
2	satisfaction	O
3	in	O
4	nursing	O
5	:	O
6	an	O
7	encounter	O
8	with	O
9	extremely	O
10	hostile	O
11	patients	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	Maf	O
6	-	O
7	related	O
8	protein	B
9	,	I
10	Nrl	I
11	,	I
12	completely	O
13	mimicked	O
14	c	O
15	-	O
16	Maf	O
17	actions	O
18	.	O

1	Am	O
2	.	O

1	Among	O
2	mammalian	O
3	HSFs	B
4	,	I
5	HSF1	I
6	has	I
7	been	I
8	shown	I
9	to	O
10	be	B
11	important	B
12	for	I
13	regulation	O
14	of	O
15	the	O
16	heat	O
17	-	O
18	induced	O
19	stress	O
20	gene	O
21	expression	O
22	,	O
23	whereas	B
24	the	I
25	function	I
26	of	I
27	HSF2	I
28	in	O
29	stress	B
30	response	B
31	is	I
32	unclear	O
33	.	O

1	Yap1p	O
2	is	O
3	constitutively	O
4	nuclear	O
5	in	O
6	a	O
7	crm1	O
8	mutant	O
9	,	O
10	and	O
11	Crm1p	O
12	binds	O
13	to	O
14	a	B
15	nuclear	I
16	export	I
17	sequence	I
18	(	I
19	NES	O
20	)-	O
21	like	O
22	sequence	O
23	in	O
24	Yap1p	O
25	in	O
26	the	O
27	presence	O
28	of	O
29	RanGTP	O
30	.	O

1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	B
15	pro	I
16	alpha	I
17	1	I
18	(	I
19	II	I
20	)	B
21	collagen	I
22	gene	I
23	.	O

1	Patients	O
2	at	O
3	risk	O
4	of	O
5	hypothyroidism	O
6	.	O

1	Of	O
2	419	O
3	persons	O
4	surveyed	O
5	,	O
6	207	B
7	(	I
8	49	I
9	.	I
10	4	I
11	%)	O
12	were	B
13	antigen	I
14	-	I
15	positive	I
16	with	I
17	the	O
18	Og4C3	O
19	assay	O
20	.	O

1	Lymphatics	O
2	in	O
3	the	O
4	aorta	O
5	of	O
6	rats	O
7	treated	O
8	with	O
9	a	O
10	soy	O
11	-	O
12	bean	O
13	oil	O
14	extract	O
15	(	O
16	lipofundin	O
17	).	O

1	The	O
2	mHIF	O
3	-	O
4	1	O
5	alpha	O
6	structural	O
7	gene	O
8	is	O
9	composed	O
10	of	O
11	15	O
12	exons	O
13	.	O

1	Moreover	O
2	,	O
3	the	O
4	ability	O
5	to	O
6	selectivity	B
7	arrest	I
8	elongation	I
9	by	I
10	polIII	I
11	at	I
12	defined	O
13	positions	B
14	within	I
15	the	I
16	tRNA	I
17	gene	I
18	transcription	I
19	unit	O
20	has	O
21	permitted	O
22	the	O
23	identification	O
24	of	O
25	discrete	O
26	functional	O
27	properties	O
28	of	O
29	paused	O
30	mammalian	O
31	polIII	O
32	ternary	O
33	complexes	O
34	.	O

1	Thus	O
2	,	O
3	ZNF74	O
4	sublocalization	O
5	in	O
6	nuclear	O
7	domains	O
8	enriched	O
9	in	O
10	pre	O
11	-	O
12	mRNA	O
13	maturating	O
14	factors	O
15	,	O
16	its	O
17	RNA	O
18	binding	O
19	activity	O
20	,	O
21	and	O
22	its	O
23	direct	O
24	phosphodependent	O
25	interaction	B
26	with	I
27	the	I
28	pol	I
29	IIo	O
30	,	O
31	a	O
32	form	O
33	of	O
34	the	O
35	RNA	O
36	polymerase	O
37	functionally	O
38	associated	O
39	with	O
40	pre	O
41	-	O
42	mRNA	O
43	processing	O
44	,	O
45	suggest	O
46	a	O
47	role	O
48	for	O
49	this	O
50	member	O
51	of	O
52	the	O
53	KRAB	O
54	multifinger	O
55	protein	O
56	family	O
57	in	O
58	RNA	O
59	processing	O
60	.	O

1	The	O
2	Lm	O
3	increased	O
4	and	O
5	the	O
6	alveoli	O
7	/	O
8	mm2	O
9	and	O
10	elastic	O
11	recoil	O
12	pressure	O
13	decreased	O
14	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	mutants	O
6	that	O
7	remove	O
8	the	O
9	membrane	O
10	anchor	O
11	domain	O
12	,	O
13	all	O
14	of	O
15	the	O
16	mutant	O
17	glycoproteins	O
18	retained	O
19	the	O
20	ability	O
21	to	O
22	cause	O
23	fusion	O
24	of	O
25	CD4	O
26	-	O
27	bearing	O
28	cells	O
29	.	O

1	J	O
2	.	O

1	They	O
2	also	B
3	negatively	I
4	modulate	I
5	the	I
6	PI	I
7	3	I
8	-	I
9	kinase	I
10	catalytic	I
11	activity	I
12	but	I
13	to	O
14	different	B
15	extents	I
16	,	I
17	dependent	I
18	on	I
19	the	O
20	unique	O
21	N	O
22	-	O
23	terminal	O
24	structure	O
25	of	O
26	each	O
27	isoform	O
28	.	O

1	Jean	O
2	Klig	O
3	reviews	O
4	recent	O
5	literature	O
6	about	O
7	lower	O
8	respiratory	O
9	tract	O
10	infection	O
11	in	O
12	children	O
13	.	O

1	There	O
2	is	O
3	a	O
4	national	O
5	effort	O
6	to	O
7	begin	O
8	to	O
9	ask	O
10	all	O
11	female	O
12	patients	O
13	about	O
14	family	O
15	violence	O
16	.	O

1	The	O
2	solution	O
3	structure	O
4	of	O
5	the	O
6	adduct	O
7	derived	O
8	from	O
9	the	O
10	covalent	O
11	bonding	O
12	of	O
13	the	O
14	fjord	O
15	region	O
16	(+)-(	O
17	11S	O
18	,	O
19	12R	O
20	,	O
21	13R	B
22	,	B
23	14S	I
24	)	I
25	stereoisomer	O
26	of	O
27	anti	O
28	-	O
29	11	O
30	,	O
31	12	O
32	-	O
33	dihydroxy	O
34	-	O
35	13	O
36	,	O
37	14	O
38	-	O
39	epoxy	O
40	-	O
41	11	O
42	,	O
43	12	O
44	,	O
45	13	O
46	,	O
47	14	O
48	-	O
49	tetrahydrobenzo	O
50	[	O
51	g	O
52	]	O
53	chrysene	O
54	,	O
55	(+)-	O
56	anti	O
57	-	O
58	B	O
59	[	O
60	g	O
61	]	O
62	CDE	O
63	,	O
64	to	O
65	the	O
66	exocyclic	O
67	N	O
68	(	O
69	6	O
70	)	O
71	amino	O
72	group	O
73	of	O
74	the	O
75	adenine	O
76	residue	O
77	dA6	O
78	,	O
79	(	O
80	designated	O
81	(+)-	O
82	trans	O
83	-	O
84	anti	O
85	-(	O
86	B	O
87	[	O
88	g	O
89	]	O
90	C	O
91	)	O
92	dA6	O
93	),	O
94	positioned	O
95	opposite	O
96	a	O
97	thymine	O
98	residue	O
99	dT17	O
100	in	O
101	the	O
102	DNA	O
103	sequence	O
104	context	O
105	d	O
106	(	O
107	C1	O
108	-	O
109	T2	O
110	-	O
111	C3	O
112	-	I
113	T4	I
114	-	O
115	C5	O
116	-(	O
117	B	O
118	[	O
119	g	O
120	]	O
121	C	O
122	)	O
123	A6	O
124	-	O
125	C7	O
126	-	O
127	T8	O
128	-	O
129	T9	O
130	-	O
131	C10	O
132	-	O
133	C11	O
134	).	O
135	d	O
136	(	O
137	G12	O
138	-	O
139	G13	O
140	-	O
141	A14	O
142	-	O
143	A15	O
144	-	O
145	G16	O
146	-	O
147	T17	O
148	-	O
149	G18	O
150	-	O
151	A19	O
152	-	O
153	G20	O
154	++	O
155	+-	O
156	A21	I
157	-	O
158	G22	O
159	)	O
160	(	O
161	designated	O
162	(	O
163	B	O
164	[	O
165	g	O
166	]	O
167	C	O
168	)	O
169	dA	O
170	.	O
171	dT	O
172	11	O
173	-	O
174	mer	O
175	duplex	O
176	),	O
177	has	O
178	been	O
179	studied	O
180	using	O
181	structural	O
182	information	O
183	derived	O
184	from	O
185	NMR	O
186	data	O
187	in	O
188	combination	O
189	with	O
190	molecular	O
191	dynamics	O
192	(	O
193	MD	O
194	)	O
195	calculations	O
196	.	O

1	The	O
2	indications	O
3	for	O
4	its	O
5	use	O
6	include	O
7	every	O
8	primary	O
9	and	O
10	secondary	O
11	rhinoplasty	O
12	candidate	O
13	unless	O
14	tip	O
15	grafts	O
16	are	O
17	going	O
18	to	O
19	be	O
20	under	O
21	tension	O
22	or	O
23	if	O
24	the	O
25	deformity	O
26	is	O
27	minor	O
28	.	O

1	CONCLUSION	O
2	:	B
3	The	I
4	probability	I
5	of	I
6	cardiopulmonary	O
7	complications	B
8	increases	I
9	significantly	I
10	when	I
11	patients	O
12	develop	O
13	class	O
14	1	O
15	HELLP	O
16	syndrome	O
17	.	O

1	Study	O
2	of	O
3	the	O
4	alterations	O
5	of	O
6	intestinal	O
7	absorption	O
8	,	O
9	by	O
10	means	O
11	of	O
12	I	O
13	-	O
14	131	B
15	-	I
16	triolein	I
17	,	I
18	in	I
19	the	I
20	whole	I
21	body	I
22	irradiated	I
23	rat	I

1	Diet	O
2	and	O
3	atopic	O
4	eczema	O
5	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	O
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	There	O
2	was	O
3	either	O
4	no	O
5	change	O
6	or	O
7	an	O
8	improvement	O
9	in	O
10	renographic	O
11	findings	O
12	(	O
13	t1	O
14	/	O
15	2	O
16	time	O
17	and	O
18	/	O
19	or	O
20	split	O
21	function	O
22	)	O
23	in	O
24	40	O
25	patients	O
26	(	O
27	93	O
28	%).	O

1	In	O
2	1990	O
3	,	O
4	an	O
5	International	O
6	Commission	O
7	for	O
8	the	O
9	Certification	O
10	of	O
11	Eradication	O
12	of	O
13	Poliomyelitis	O
14	Eradication	O
15	(	O
16	ICCPE	O
17	)	O
18	was	O
19	established	O
20	by	O
21	the	O
22	Pan	O
23	American	O
24	Health	O
25	Organization	O
26	to	O
27	eventually	O
28	determine	O
29	if	O
30	transmission	O
31	was	O
32	interrupted	O
33	.	O

1	Collectively	O
2	,	O
3	this	O
4	study	O
5	emphasizes	O
6	a	O
7	critical	O
8	role	O
9	of	O
10	Phox2a	O
11	as	O
12	well	O
13	as	O
14	its	O
15	functional	O
16	synergism	O
17	with	O
18	other	O
19	transcription	O
20	factors	O
21	(	O
22	e	O
23	.	O
24	g	O
25	.,	O
26	CREB	B
27	,	I
28	AP2	I
29	,	I
30	and	I
31	Sp1	I
32	)	I
33	in	O
34	transcriptional	O
35	activation	O
36	of	O
37	the	O
38	DBH	B
39	gene	I
40	.	I

1	Takahashi	O
2	,	O
3	H	O
4	.	O

1	Cell	O
2	lines	O
3	derived	O
4	from	B
5	the	I
6	tumors	I
7	were	I
8	examined	O
9	by	O
10	fluorescent	O
11	in	O
12	situ	O
13	hybridization	O
14	for	O
15	the	O
16	status	O
17	of	O
18	the	B
19	transferred	I
20	human	I
21	chromosome	I
22	and	I
23	by	I
24	PCR	O
25	for	O
26	marker	O
27	loss	O
28	.	O

1	Therefore	O
2	,	B
3	we	I
4	have	I
5	developed	O
6	a	O
7	system	O
8	to	O
9	study	O
10	nuclear	O
11	targeting	O
12	in	B
13	plants	I
14	and	I
15	have	I
16	established	I
17	that	O
18	the	B
19	nuclear	I
20	transport	I
21	machinery	I
22	is	O
23	similar	B
24	in	O
25	monocots	O
26	and	O
27	dicots	O
28	.	O

1	No	O
2	differences	O
3	in	O
4	fixation	O
5	quality	O
6	were	O
7	observed	O
8	between	O
9	cochleas	O
10	fixed	O
11	by	O
12	intravascular	O
13	perfusion	O
14	and	O
15	cochleas	O
16	fixed	O
17	by	O
18	intralabyrinthine	B
19	perfusion	I
20	.	I

1	In	O
2	the	O
3	current	O
4	study	O
5	,	O
6	the	O
7	roles	O
8	of	O
9	two	O
10	putative	O
11	cis	O
12	-	O
13	acting	O
14	elements	O
15	within	O
16	the	B
17	-	I
18	73	I
19	to	I
20	+	I
21	44	I
22	region	O
23	in	O
24	basal	O
25	exon	O
26	2	O
27	promoter	O
28	activity	O
29	were	O
30	evaluated	O
31	using	O
32	mutagenesis	B
33	and	O
34	nuclear	O
35	protein	O
36	-	O
37	DNA	O
38	binding	O
39	assays	O
40	.	O

1	Radiotherapy	O
2	and	O
3	early	O
4	orchiectomy	O
5	in	O
6	stage	O
7	D1	O
8	prostatic	O
9	carcinoma	O

1	The	O
2	pWP	O
3	-	O
4	19	O
5	also	O
6	encodes	O
7	the	O
8	AAV	O
9	inverted	O
10	terminal	O
11	repeats	O
12	for	O
13	integration	O
14	and	O
15	replication	O
16	and	O
17	the	O
18	herpes	O
19	virus	O
20	thymidine	O
21	kinase	O
22	promoter	O
23	-	O
24	driven	O
25	gene	B
26	for	I
27	neomycin	I
28	resistance	I
29	(	O
30	neoR	O
31	).	O

1	Thus	O
2	,	O
3	the	O
4	effects	O
5	of	O
6	father	O
7	absence	O
8	under	O
9	routine	O
10	conditions	O
11	in	O
12	relatively	O
13	healthy	O
14	samples	O
15	may	O
16	exert	O
17	no	O
18	significant	O
19	effects	O
20	independent	O
21	of	O
22	intervening	O
23	family	O
24	stressors	O
25	or	O
26	maternal	O
27	psychopathology	O
28	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	B
6	F	I
7	-	I
8	wave	I
9	may	O
10	be	O
11	elicited	O
12	in	O
13	motoneuron	O
14	of	O
15	different	O
16	depolarization	O
17	threshold	O
18	but	O
19	primarily	O
20	in	O
21	larger	O
22	and	O
23	faster	O
24	nerve	O
25	fibers	O
26	,	O
27	with	O
28	a	O
29	lower	O
30	threshold	B
31	of	I
32	depolarization	I
33	.	I

1	The	O
2	humanized	O
3	LL2	O
4	(	O
5	hLL2	O
6	),	O
7	lacking	O
8	light	O
9	chain	O
10	variable	O
11	region	O
12	glycosylation	O
13	,	O
14	exhibited	O
15	immunoreactivities	B
16	that	I
17	were	I
18	comparable	I
19	to	O
20	that	O
21	of	O
22	chimeric	O
23	LL2	O
24	(	O
25	cLL2	O
26	),	O
27	which	O
28	was	O
29	shown	O
30	previously	O
31	to	O
32	have	O
33	antigen	O
34	-	O
35	binding	O
36	properties	O
37	similar	O
38	to	O
39	its	O
40	murine	O
41	counterpart	O
42	,	O
43	suggesting	O
44	that	O
45	the	O
46	VK	O
47	-	O
48	appended	O
49	oligosaccharides	O
50	found	O
51	in	B
52	mLL2	O
53	are	O
54	not	O
55	necessary	O
56	for	O
57	antigen	O
58	binding	O
59	.	O

1	Regulation	O
2	at	O
3	37	O
4	degrees	O
5	C	O
6	,	O
7	therefore	O
8	,	O
9	involves	O
10	the	O
11	action	O
12	of	O
13	three	O
14	protein	O
15	kinase	O
16	cascades	O
17	that	O
18	repress	O
19	HSF1	O
20	through	O
21	phosphorylation	O
22	of	O
23	serine	O
24	residues	O
25	303	O
26	,	O
27	307	O
28	,	O
29	and	O
30	363	O
31	and	O
32	may	O
33	promote	O
34	growth	O
35	by	O
36	suppressing	O
37	the	O
38	heat	O
39	shock	O
40	response	O
41	.	O

1	THE	O
2	SCALING	B
3	OF	I
4	SONG	I
5	FREQUENCY	O
6	IN	O
7	CICADAS	O

1	After	O
2	age	O
3	30	O
4	,	O
5	mean	O
6	hemoglobin	O
7	levels	O
8	for	O
9	men	O
10	gradually	O
11	declined	O
12	,	O
13	while	O
14	those	O
15	in	O
16	women	O
17	rose	O
18	,	O
19	so	O
20	that	O
21	the	O
22	sex	O
23	difference	O
24	diminished	O
25	after	O
26	60	O
27	years	O
28	of	O
29	age	O
30	.	O

1	The	O
2	films	O
3	were	O
4	analyzed	O
5	using	O
6	a	O
7	scanning	O
8	helium	O
9	-	O
10	neon	O
11	laser	O
12	densitometer	O
13	with	O
14	a	O
15	small	O
16	aperture	O
17	of	O
18	5	O
19	-	O
20	10	O
21	microns	O
22	.	O

1	SL1	O
2	trans	O
3	-	O
4	splicing	O
5	specified	O
6	by	O
7	AU	O
8	-	O
9	rich	O
10	synthetic	O
11	RNA	O
12	inserted	O
13	at	O
14	the	O
15	5	O
16	'	O
17	end	O
18	of	O
19	Caenorhabditis	O
20	elegans	O
21	pre	O
22	-	O
23	mRNA	O
24	.	O

1	The	O
2	effect	O
3	of	B
4	the	I
5	fatty	I
6	acid	I
7	cyclo	I
8	-	I
9	oxygenase	O
10	inhibitor	O
11	indomethacin	O
12	on	O
13	cerebral	O
14	blood	O
15	flow	O
16	(	O
17	CBF	O
18	)	O
19	and	O
20	the	O
21	metabolic	O
22	rate	O
23	for	O
24	oxygen	O
25	(	O
26	CMRO2	O
27	)	O
28	was	O
29	studied	B
30	in	I
31	paralyzed	I
32	and	I
33	artificially	I
34	ventilated	O
35	rats	O
36	.	B

1	The	O
2	P131	O
3	ORF	O
4	is	O
5	followed	O
6	in	O
7	-	O
8	frame	O
9	by	O
10	a	O
11	second	O
12	ORF	O
13	which	O
14	is	O
15	probably	O
16	expressed	O
17	by	O
18	partial	O
19	readthrough	O
20	of	O
21	the	O
22	UGA	O
23	termination	O
24	codon	O
25	of	O
26	the	O
27	P131	O
28	ORF	O
29	to	O
30	produce	O
31	a	O
32	polypeptide	O
33	of	O
34	M	O
35	(	O
36	r	O
37	)	O
38	191044	O
39	(	O
40	P191	O
41	).	O

1	Expression	O
2	of	B
3	six	I
4	genes	I
5	,	I
6	ipaB	O
7	,	O
8	ipaC	B
9	,	I
10	invE	O
11	,	O
12	invG	O
13	,	O
14	invJ	O
15	,	B
16	and	I
17	invK	I
18	,	O
19	was	B
20	apparently	I
21	regulated	I
22	by	I
23	the	O
24	positive	O
25	regulator	O
26	virF	O
27	.	O

1	CNS	O
2	effects	O
3	of	O
4	local	O
5	anesthetics	O
6	only	O
7	partially	O
8	dependent	O
9	on	O
10	biogenic	B
11	amine	B
12	mechanisms	O
13	.	B

1	In	O
2	contrast	O
3	,	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	fragment	O
9	containing	O
10	the	O
11	C	O
12	/	O
13	H1	O
14	domain	B
15	was	I
16	sufficient	I
17	for	I
18	coactivation	O
19	of	O
20	Zta	O
21	transcription	O
22	and	O
23	viral	O
24	reactivation	O
25	function	O
26	.	O

1	Studies	O
2	of	O
3	biochemical	B
4	and	I
5	morphological	I
6	changes	O
7	(	O
8	between	O
9	normal	O
10	and	O
11	treated	O
12	animals	O
13	)	O
14	show	O
15	that	O
16	chrysotile	O
17	induces	O
18	an	O
19	increase	O
20	in	O
21	the	O
22	lung	O
23	free	O
24	cell	O
25	population	O
26	and	O
27	pulmonary	O
28	surfactant	O
29	levels	O
30	.	O

1	Testing	O
2	gravity	O
3	to	O
4	second	O
5	post	O
6	-	O
7	Newtonian	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O

1	This	O
2	mode	O
3	of	O
4	ternary	O
5	complex	O
6	formation	O
7	is	O
8	in	O
9	contrast	O
10	to	O
11	the	O
12	one	O
13	seen	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	the	O
19	c	O
20	-	O
21	fos	O
22	protooncogene	O
23	,	O
24	where	O
25	formation	O
26	of	O
27	the	O
28	ternary	O
29	complex	O
30	is	O
31	dependent	O
32	on	O
33	the	O
34	prior	O
35	assembly	O
36	of	O
37	the	O
38	serum	O
39	response	O
40	factor	O
41	-	O
42	DNA	O
43	binary	O
44	complex	O
45	.	O

1	There	O
2	is	O
3	a	O
4	cysteine	O
5	clustering	O
6	region	O
7	in	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	region	O
13	of	O
14	the	O
15	c	O
16	-	O
17	raf	O
18	(-	O
19	1	O
20	)	O
21	product	O
22	deduced	O
23	from	O
24	the	O
25	nucleotide	O
26	sequence	O
27	,	O
28	and	O
29	this	O
30	cysteine	O
31	clustering	O
32	region	O
33	was	O
34	found	O
35	to	O
36	be	O
37	highly	O
38	homologous	O
39	to	O
40	that	O
41	present	O
42	in	O
43	an	O
44	N	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	protein	O
50	kinase	O
51	C	O
52	,	O
53	although	O
54	,	O
55	in	O
56	the	O
57	latter	O
58	cysteine	O
59	clusters	O
60	are	O
61	present	O
62	in	O
63	duplicate	O
64	.	O

1	The	O
2	Mauriceville	O
3	and	O
4	Varkud	O
5	mitochondrial	O
6	plasmids	O
7	are	O
8	closely	O
9	related	O
10	,	O
11	closed	O
12	-	O
13	circular	O
14	DNAs	O
15	(	B
16	3	I
17	.	I
18	6	I
19	and	I
20	3	I
21	.	I
22	7	I
23	kb	I
24	,	I
25	respectively	I
26	)	O
27	that	O
28	have	O
29	characteristics	O
30	of	O
31	mtDNA	B
32	introns	I
33	and	I
34	retroid	O
35	elements	O
36	.	O

1	An	O
2	experiment	O
3	on	O
4	the	O
5	return	O
6	-	O
7	of	O
8	-	B
9	fear	I
10	(	I
11	ROF	I
12	)	I
13	was	I
14	carried	I
15	out	I
16	on	I
17	40	O
18	snake	O
19	-	O
20	or	O
21	spider	O
22	-	O
23	phobic	O
24	subjects	B
25	in	I
26	order	I
27	to	I
28	determine	I
29	whether	I
30	an	I
31	arousing	I
32	event	I
33	that	O
34	occurs	O
35	shortly	B
36	before	I
37	retest	I
38	influences	I
39	the	I
40	magnitude	I
41	of	I
42	the	I
43	ROF	I
44	.	O

1	Story	O
2	of	O
3	a	O
4	hospital	O
5	that	O
6	filmed	O
7	its	O
8	employee	O
9	orientation	O
10	program	O
11	.	O

1	The	O
2	colony	O
3	-	O
4	stimulating	O
5	factors	O
6	(	O
7	CSFs	O
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	O
20	CSF	O
21	,	O
22	granulocyte	O
23	-	O
24	macrophage	O
25	CSF	O
26	,	O
27	macrophage	O
28	CSF	O
29	,	O
30	and	O
31	interleukin	O
32	3	O
33	(	O
34	sometimes	O
35	called	O
36	multi	O
37	-	O
38	CSF	O
39	).	O

1	Molecular	O
2	cloning	O
3	of	O
4	an	O
5	amphibian	O
6	insulin	O
7	receptor	O
8	substrate	O
9	1	O
10	-	O
11	like	O
12	cDNA	O
13	and	O
14	involvement	O
15	of	O
16	phosphatidylinositol	O
17	3	O
18	-	O
19	kinase	B
20	in	I
21	insulin	I
22	-	O
23	induced	O
24	Xenopus	O
25	oocyte	O
26	maturation	O
27	.	O

1	Purification	O
2	of	O
3	MvaT	O
4	enriched	O
5	for	O
6	two	O
7	polypeptides	O
8	of	O
9	approximate	O
10	molecular	O
11	mass	O
12	15	O
13	kDa	O
14	and	O
15	16	O
16	kDa	O
17	,	O
18	designated	O
19	P15	O
20	and	O
21	P16	O
22	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	analyze	O
9	the	O
10	temporal	O
11	characteristics	O
12	and	O
13	the	O
14	spatial	O
15	mapping	O
16	of	O
17	the	B
18	independent	I
19	components	O
20	identified	B
21	by	O
22	ICA	B
23	when	O
24	the	O
25	subject	O
26	performs	O
27	a	O
28	finger	O
29	-	O
30	tapping	O
31	task	O
32	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	attention	O
6	to	O
7	these	O
8	issues	O
9	can	O
10	substantially	O
11	improve	O
12	the	O
13	quality	O
14	of	O
15	research	O
16	on	O
17	AIDS	O
18	related	O
19	behaviors	O
20	on	O
21	Black	O
22	communities	O
23	.	O

1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	B
24	parameters	I
25	:	I
26	proliferation	I
27	rate	I
28	in	I
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O

1	The	O
2	emerging	O
3	complexity	O
4	of	O
5	the	O
6	5	O
7	'	O
8	regulatory	O
9	region	O
10	of	O
11	the	O
12	GH	O
13	receptor	O
14	gene	B
15	was	B
16	emphasised	I
17	by	I
18	the	I
19	observation	O
20	that	O
21	probes	O
22	derived	O
23	from	O
24	exon	O
25	1B	B
26	and	I
27	the	I
28	distal	I
29	3	I
30	'	O
31	intron	O
32	boundary	B
33	do	I
34	not	I
35	hybridise	I
36	with	I
37	previously	I
38	cloned	O
39	genomic	B
40	sequences	I
41	that	I
42	span	I
43	the	O
44	liver	O
45	-	O
46	specific	I
47	P1	O
48	promoter	O
49	and	O
50	exon	B
51	2	O
52	.	O

1	We	O
2	find	O
3	that	O
4	3T1	O
5	-	O
6	3T2	O
7	mixing	O
8	has	O
9	a	O
10	pronounced	O
11	effect	O
12	on	O
13	the	O
14	line	O
15	shape	O
16	and	O
17	radiative	O
18	decay	O
19	rate	O
20	of	O
21	emission	O
22	from	O
23	the	O
24	3T2	O
25	state	O
26	and	O
27	that	O
28	the	O
29	extent	O
30	of	O
31	mixing	O
32	depends	O
33	critically	O
34	on	O
35	the	O
36	magnitude	B
37	of	O
38	nontetrahedral	I
39	distortions	O
40	.	O

1	To	O
2	elucidate	B
3	the	I
4	functional	I
5	significance	I
6	of	O
7	Fyn	O
8	in	O
9	the	O
10	expression	O
11	of	O
12	viral	O
13	promoters	O
14	,	O
15	we	O
16	transfected	O
17	a	O
18	Fyn	O
19	-	O
20	expression	O
21	vector	O
22	together	O
23	with	O
24	a	O
25	reporter	O
26	plasmid	O
27	containing	O
28	the	O
29	chloramphenicol	B
30	acetyltransferase	I
31	gene	I
32	driven	O
33	by	O
34	HIV	O
35	LTR	O
36	into	O
37	a	O
38	human	O
39	T	O
40	cell	O
41	line	O
42	,	O
43	Jurkat	O
44	.	O

1	Stable	O
2	patients	O
3	have	O
4	mucous	O
5	hypersecretion	O
6	and	B
7	little	I
8	evidence	I
9	of	I
10	acute	O
11	inflammation	O
12	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	Significance	O
2	of	B
3	the	B
4	biopsy	I
5	site	I
6	of	I
7	the	O
8	latissimus	O
9	dorsi	O
10	muscle	O
11	for	O
12	fiber	O
13	typing	O
14	.	O

1	This	O
2	indicates	B
3	that	I
4	recruitment	I
5	of	I
6	large	I
7	T	I
8	antigen	I
9	to	I
10	the	O
11	rRNA	O
12	promoter	O
13	by	O
14	SL1	O
15	constitutes	O
16	a	O
17	crucial	O
18	step	B
19	in	I
20	the	I
21	activation	I
22	process	I
23	.	I

1	Analyses	O
2	of	O
3	hGMR	O
4	beta	O
5	subunit	O
6	mutants	O
7	revealed	O
8	two	O
9	cytoplasmic	O
10	regions	O
11	involved	O
12	in	O
13	activation	O
14	of	O
15	the	O
16	c	O
17	-	O
18	myc	O
19	promoter	O
20	,	O
21	one	O
22	is	O
23	essential	O
24	and	O
25	the	O
26	other	O
27	is	O
28	dispensable	O
29	but	O
30	enhances	O
31	the	O
32	activity	O
33	.	O

1	M	O
2	.,	O
3	and	O
4	D	O
5	.	O

1	Patients	O
2	receiving	O
3	VPA	O
4	showed	O
5	differences	O
6	in	O
7	attention	O
8	,	O
9	visuomotor	O
10	performance	O
11	,	O
12	verbal	O
13	span	O
14	and	O
15	sensory	O
16	discrimination	B
17	tasks	I
18	at	I
19	T1	I
20	,	I
21	in	I
22	visuomotor	O
23	performance	O
24	at	O
25	T2	O
26	and	O
27	in	O
28	spatial	O
29	span	O
30	at	O
31	T3	O
32	,	O
33	whereas	O
34	no	B
35	differences	I
36	were	I
37	detected	I
38	at	I
39	T4	I
40	.	I

1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	hydrophilic	O
13	707	O
14	amino	O
15	acid	O
16	residue	B
17	domain	I
18	with	I
19	8	I
20	N	I
21	-	I
22	glycosylation	I
23	sites	I
24	,	I
25	a	I
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O

1	The	O
2	histidine	O
3	-	O
4	tagged	O
5	gene	O
6	,	O
7	rpoCHIS	O
8	,	O
9	was	O
10	used	O
11	to	O
12	replace	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	allele	O
18	in	O
19	the	O
20	chromosome	O
21	of	O
22	S	O
23	.	O
24	coelicolor	O
25	and	O
26	S	O
27	.	O
28	lividans	O
29	.	O

1	In	O
2	contrast	O
3	,	O
4	when	O
5	the	O
6	isoform	O
7	containing	O
8	the	O
9	C	O
10	epsilon4	O
11	domain	O
12	joined	O
13	directly	O
14	to	O
15	the	O
16	M2	O
17	exon	O
18	(	O
19	IgE	O
20	grande	O
21	)	O
22	is	O
23	expressed	O
24	in	O
25	the	O
26	J558L	O
27	cell	O
28	line	O
29	,	O
30	it	O
31	is	O
32	degraded	O
33	intracellularly	O
34	,	O
35	suggesting	O
36	a	O
37	cell	O
38	line	O
39	-	O
40	dependent	O
41	regulation	O
42	of	O
43	secretion	O
44	.	O

1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	O
10	eccrine	O
11	sweat	O
12	duct	O
13	units	O
14	.	B

1	FDA	O
2	regulations	O
3	for	O
4	growth	O
5	factors	O
6	and	O
7	related	O
8	products	O
9	.	O

1	Following	O
2	EPI	O
3	-	O
4	C0401	O
5	,	O
6	but	O
7	not	O
8	saline	O
9	or	O
10	DepoFoam	O
11	vehicle	O
12	,	O
13	there	O
14	were	O
15	transient	O
16	(<	O
17	72	O
18	hr	O
19	)	O
20	decreases	O
21	in	O
22	food	O
23	consumption	O
24	,	O
25	arousal	O
26	,	O
27	hindlimb	O
28	muscle	O
29	tone	O
30	,	O
31	and	O
32	body	O
33	temperature	O
34	.	O

1	Coronary	O
2	vasoconstriction	O
3	caused	O
4	by	O
5	endothelin	O
6	-	O
7	1	O
8	is	O
9	enhanced	O
10	by	O
11	ischemia	O
12	-	O
13	reperfusion	O
14	and	O
15	by	O
16	norepinephrine	O
17	present	O
18	in	O
19	concentrations	O
20	typically	O
21	observed	O
22	after	O
23	neonatal	O
24	cardiopulmonary	O
25	bypass	O
26	.	O

1	The	O
2	Mif1	O
3	5	O
4	'	O
5	flanking	O
6	region	O
7	contains	O
8	a	O
9	functional	O
10	ER	O
11	stress	O
12	-	O
13	responsive	O
14	element	O
15	which	O
16	is	O
17	sufficient	O
18	for	O
19	induction	O
20	by	O
21	tunicamycin	O
22	.	O

1	The	O
2	cytosolic	O
3	glutathione	O
4	S	O
5	-	O
6	transferases	O
7	(	O
8	GSTs	O
9	,	O
10	EC	O
11	2	O
12	.	I
13	5	I
14	.	O
15	1	O
16	.	O
17	18	O
18	)	O
19	are	O
20	a	O
21	superfamily	I
22	of	I
23	dimeric	O
24	isoenzymes	B
25	which	I
26	catalyze	I
27	the	O
28	conjugation	O
29	of	O
30	electrophilic	O
31	substrates	O
32	with	O
33	glutathione	O
34	.	O

1	Analysis	O
2	with	O
3	additional	O
4	anti	O
5	-	O
6	peptide	O
7	antibodies	O
8	specific	O
9	for	O
10	alpha	O
11	,	O
12	beta	B
13	,	I
14	or	I
15	gamma	O
16	PKC	B
17	indicated	I
18	that	I
19	all	I
20	three	I
21	types	I
22	of	O
23	PKC	B
24	are	I
25	expressed	O
26	in	B
27	JK	I
28	cells	I
29	;	O
30	however	O
31	,	O
32	JKPE	O
33	cells	O
34	lost	O
35	a	O
36	major	O
37	approximately	O
38	82	O
39	kDa	O
40	immunoreactive	O
41	cytosolic	O
42	protein	O
43	detectable	O
44	with	O
45	anti	O
46	-	O
47	PKC	O
48	alpha	B
49	antibody	B
50	.	O

1	100	O
2	years	O
3	of	B
4	dentistry	I
5	at	I
6	the	I
7	Friedrich	O
8	Schiller	O
9	University	O
10	in	O
11	Jena	O

1	The	O
2	retention	O
3	of	O
4	75SeHCAT	O
5	was	O
6	low	O
7	.	O

1	Because	O
2	Trp53	O
3	(	O
4	the	O
5	mouse	O
6	homolog	O
7	of	O
8	human	O
9	TP53	O
10	)	O
11	is	O
12	located	O
13	with	O
14	Tk1	O
15	on	O
16	chromosome	O
17	11	O
18	and	O
19	is	O
20	critical	O
21	in	O
22	regulating	O
23	cellular	O
24	responses	O
25	following	O
26	exposure	O
27	to	O
28	DNA	O
29	damaging	O
30	agents	O
31	,	O
32	we	O
33	wanted	O
34	to	O
35	determine	O
36	if	O
37	these	O
38	mouse	O
39	lymphoma	O
40	cells	B
41	harbor	I
42	mutations	I
43	in	I
44	Trp53	I
45	.	I

1	Hoeben	O
2	,	O
3	F	O
4	.	O
5	J	O
6	.	O

1	Benefits	O
2	of	O
3	obtaining	O
4	board	O
5	certification	O
6	in	O
7	pharmacotherapy	O
8	.	O

1	Therefore	O
2	,	O
3	the	O
4	amino	O
5	-	O
6	terminal	O
7	sequence	O
8	of	O
9	the	O
10	purified	O
11	carA	O
12	product	O
13	is	O
14	identical	O
15	to	O
16	that	O
17	derived	O
18	from	O
19	the	B
20	nucleotide	I
21	sequence	I
22	in	I
23	both	I
24	organisms	O
25	,	O
26	P	O
27	.	O
28	stutzeri	O
29	having	O
30	four	O
31	additional	O
32	amino	O
33	acids	O
34	.	O

1	Pathol	O
2	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	S1	O
6	nuclease	O
7	protection	O
8	analysis	O
9	of	O
10	RNA	O
11	preparations	O
12	from	O
13	several	O
14	mouse	O
15	tissues	O
16	,	O
17	both	O
18	dhfr	O
19	and	O
20	divergent	O
21	genes	O
22	showed	O
23	similar	O
24	levels	O
25	of	O
26	expression	O
27	but	O
28	did	O
29	show	O
30	some	O
31	specificity	O
32	in	O
33	start	O
34	site	O
35	utilization	O
36	.	O

1	Here	O
2	,	B
3	we	I
4	present	I
5	genetic	O
6	evidence	O
7	in	O
8	Saccharomyces	B
9	cerevisiae	I
10	for	I
11	a	I
12	functional	I
13	interaction	I
14	between	I
15	the	I
16	DEAH	I
17	protein	I
18	Prp16	I
19	,	I
20	and	I
21	the	O
22	U6	O
23	and	O
24	U2	O
25	spliceosomal	O
26	snRNAs	O
27	.	O

1	A	O
2	total	O
3	of	O
4	112	O
5	patients	O
6	received	O
7	anistreplase	O
8	and	O
9	119	O
10	received	O
11	heparin	O
12	within	O
13	a	O
14	mean	O
15	period	O
16	of	O
17	188	O
18	+/-	O
19	62	O
20	min	O
21	following	O
22	the	O
23	onset	O
24	of	O
25	symptoms	O
26	.	O

1	DMCM	O
2	also	O
3	permits	O
4	extension	O
5	of	O
6	the	O
7	possibilities	O
8	of	O
9	obtaining	O
10	and	O
11	transplanting	O
12	donor	O
13	organs	O
14	.	O

1	Nonsynonymous	O
2	substitution	O
3	in	O
4	abalone	O
5	sperm	O
6	fertilization	O
7	genes	O
8	exceeds	O
9	substitution	O
10	in	O
11	introns	O
12	and	O
13	mitochondrial	O
14	DNA	O
15	.	O

1	Two	O
2	closely	O
3	related	O
4	IgH	O
5	constant	O
6	region	O
7	genes	O
8	,	O
9	CHA	O
10	and	O
11	CHB	O
12	,	O
13	have	O
14	been	O
15	sequenced	O
16	completely	O
17	.	O

1	His	O
2	carnitine	O
3	palmitoyltransferase	O
4	(	O
5	CPT	O
6	)	O
7	I	O
8	and	O
9	II	O
10	activities	O
11	were	O
12	0	O
13	.	O
14	06	O
15	and	O
16	0	O
17	.	O
18	12	O
19	nmol	O
20	/	O
21	min	O
22	/	O
23	mg	O
24	protein	O
25	,	O
26	as	O
27	compared	O
28	with	O
29	a	O
30	mean	O
31	value	O
32	of	O
33	0	O
34	.	O
35	22	O
36	+/-	O
37	0	O
38	.	O
39	14	O
40	and	O
41	0	O
42	.	O
43	27	O
44	+/-	O
45	0	O
46	.	O
47	07	O
48	nmol	O
49	/	O
50	min	O
51	/	O
52	mg	O
53	protein	O
54	,	O
55	respectively	O
56	,	O
57	in	O
58	control	O
59	subjects	O
60	.	O

1	The	O
2	3	O
3	'	O
4	UTR	O
5	has	O
6	several	O
7	stable	O
8	hairpins	O
9	that	O
10	are	B
11	flanked	I
12	by	I
13	single	I
14	-	O
15	stranded	O
16	(	O
17	A	O
18	/	O
19	U	O
20	)	O
21	UGC	O
22	sequences	B
23	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	O
8	'	O
9	s	O
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	I
15	its	O
16	NBF2	O
17	domain	O
18	,	O
19	after	B
20	folding	I
21	separately	I
22	as	I
23	distinct	I
24	units	I
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	B
41	of	B
42	added	I
43	nucleotides	O
44	or	B
45	exogenously	B
46	induced	I
47	phosphorylation	O
48	.	O

1	As	O
2	hypothesized	O
3	,	O
4	believers	O
5	showed	O
6	relatively	O
7	higher	O
8	right	O
9	hemispheric	O
10	activation	O
11	and	O
12	reduced	O
13	hemispheric	O
14	asymmetry	O
15	of	O
16	functional	O
17	complexity	O
18	.	O

1	In	O
2	addition	O
3	,	B
4	we	I
5	observe	I
6	that	I
7	the	I
8	hUBF	I
9	-	I
10	promoter	O
11	interaction	O
12	is	O
13	highly	O
14	sensitive	O
15	to	O
16	the	O
17	antagonistic	O
18	effects	O
19	of	O
20	cisplatin	O
21	-	O
22	DNA	O
23	adducts	O
24	.	O

1	Gab2	O
2	,	O
3	a	O
4	new	O
5	pleckstrin	O
6	homology	O
7	domain	O
8	-	O
9	containing	O
10	adapter	O
11	protein	B
12	,	B
13	acts	I
14	to	I
15	uncouple	O
16	signaling	B
17	from	B
18	ERK	I
19	kinase	O
20	to	O
21	Elk	O
22	-	O
23	1	O
24	.	O

1	Liquid	O
2	chromatographic	O
3	method	O
4	for	O
5	analysis	O
6	of	O
7	all	O
8	-	O
9	rac	O
10	-	O
11	alpha	O
12	-	O
13	tocopheryl	O
14	acetate	O
15	and	O
16	retinyl	O
17	palmitate	O
18	in	O
19	milk	O
20	-	O
21	based	O
22	infant	O
23	formula	O
24	using	O
25	matrix	O
26	solid	O
27	-	O
28	phase	O
29	dispersion	O
30	.	O

1	Identification	O
2	of	B
3	an	I
4	AfsA	I
5	homologue	I
6	(	O
7	BarX	O
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	relative	O
6	strengths	O
7	of	O
8	the	O
9	promoters	O
10	were	O
11	similar	O
12	in	O
13	different	O
14	contexts	O
15	.	O

1	In	O
2	broken	O
3	L	B
4	-	B
5	cell	I
6	membranes	O
7	expressing	B
8	wild	I
9	type	I
10	or	I
11	mutant	I
12	M6P	I
13	/	O
14	IGF	O
15	II	O
16	receptors	O
17	,	O
18	30	O
19	nM	O
20	IGF	O
21	II	O
22	also	O
23	failed	O
24	to	O
25	affect	O
26	the	O
27	pertussis	O
28	toxin	O
29	substrate	O
30	activity	O
31	.	O

1	No	O
2	post	O
3	-	O
4	operative	O
5	haemorrhages	O
6	from	O
7	the	O
8	prostheses	O
9	were	O
10	observed	O
11	.	O

1	The	O
2	qualitative	O
3	concentrations	O
4	of	O
5	HCG	O
6	had	O
7	a	O
8	sensitivity	O
9	of	O
10	37	O
11	.	O
12	5	O
13	%	O
14	and	O
15	a	O
16	specificity	O
17	of	O
18	100	O
19	%.	O

1	Oligonucleotide	O
2	-	O
3	directed	O
4	mutagenesis	O
5	was	O
6	used	O
7	to	O
8	create	O
9	an	O
10	NdeI	O
11	restriction	O
12	site	O
13	at	O
14	the	O
15	natural	B
16	ATG	I
17	of	I
18	the	I
19	yeast	O
20	R	O
21	.	O

1	Foreign	O
2	profiles	O
3	in	O
4	air	O
5	pollution	O
6	control	O
7	activities	O
8	.	O

1	Angiography	O
2	was	O
3	performed	O
4	following	O
5	the	O
6	rCBF	O
7	study	O
8	and	O
9	the	O
10	degree	O
11	of	O
12	vasospasm	O
13	was	O
14	measured	B
15	on	I
16	the	I
17	angiograms	I
18	.	O

1	METHODS	O
2	:	O
3	All	O
4	these	O
5	30	O
6	non	B
7	-	I
8	responders	I
9	received	O
10	an	O
11	extra	O
12	dose	O
13	of	O
14	the	O
15	same	B
16	vaccine	I
17	2	I
18	months	I
19	after	I
20	primary	O
21	immunization	O
22	and	O
23	a	O
24	booster	O
25	dose	O
26	with	O
27	a	O
28	yeast	O
29	-	O
30	derived	O
31	vaccine	O
32	6	O
33	years	O
34	later	O
35	.	O

1	We	O
2	compared	O
3	the	O
4	inhibitory	O
5	effect	B
6	of	I
7	naturally	I
8	occurring	I
9	mutant	I
10	hTR	I
11	beta	I
12	1	O
13	,	O
14	artificially	O
15	created	O
16	hTR	O
17	alpha	B
18	1	I
19	mutants	I
20	,	I
21	c	I
22	-	I
23	erbA	I
24	alpha	I
25	2	I
26	and	O
27	the	B
28	human	O
29	peroxisome	O
30	proliferator	O
31	-	O
32	activated	O
33	receptor	O
34	(	O
35	hPPAR	O
36	)	O
37	on	O
38	three	B
39	prototypic	O
40	T3	O
41	-	B
42	response	I
43	elements	I
44	(	O
45	TREs	I
46	),	O
47	TRE	O
48	-	O
49	PAL	O
50	,	O
51	DR	O
52	+	O
53	4	B
54	and	I
55	TRE	I
56	-	I
57	LAP	I
58	.	I

1	Leukocyte	O
2	enzyme	O
3	activity	O
4	and	O
5	blood	O
6	lymphocyte	O
7	blast	O
8	transformation	O
9	in	O
10	chronic	O
11	bronchitis	O

1	This	O
2	report	O
3	describes	O
4	the	O
5	identification	O
6	of	O
7	a	O
8	gene	B
9	of	I
10	related	I
11	function	I
12	,	I
13	SMD1	I
14	,	I
15	located	I
16	immediately	O
17	3	O
18	'	O
19	to	O
20	PRP38	O
21	.	O

1	Perhaps	O
2	in	O
3	addition	O
4	to	O
5	,	O
6	or	O
7	as	O
8	part	O
9	of	O
10	,	O
11	its	O
12	essential	O
13	function	O
14	in	O
15	late	O
16	mitosis	O
17	,	O
18	MOB1	O
19	is	O
20	required	O
21	for	O
22	a	O
23	cell	O
24	cycle	O
25	reset	O
26	function	O
27	necessary	O
28	for	O
29	the	O
30	initiation	O
31	of	O
32	the	O
33	spindle	O
34	pole	O
35	body	O
36	duplication	O
37	.	O

1	The	O
2	risk	O
3	factors	O
4	for	O
5	hematuria	O
6	in	O
7	patients	O
8	with	O
9	renal	O
10	hypouricemia	O
11	are	O
12	the	O
13	elevation	O
14	of	O
15	urinary	O
16	urate	O
17	concentration	O
18	and	O
19	the	O
20	subtypes	O
21	of	O
22	Post	O
23	and	O
24	Secretion	O
25	.	O

1	This	O
2	resulted	O
3	in	O
4	a	O
5	complete	O
6	inhibition	O
7	of	O
8	Site	O
9	-	O
10	1	O
11	cleavage	O
12	that	O
13	was	O
14	restored	O
15	by	O
16	concomitant	O
17	overexpression	O
18	of	O
19	full	O
20	-	O
21	length	O
22	SCAP	O
23	.	O

1	Characteristics	O
2	of	O
3	anesthesia	O
4	and	O
5	resuscitation	O
6	in	O
7	emergency	O
8	lung	O
9	surgery	O

1	Here	O
2	we	O
3	have	O
4	tested	O
5	the	O
6	hypothesis	O
7	that	O
8	the	O
9	short	O
10	transcripts	O
11	,	O
12	or	O
13	proteins	O
14	translated	O
15	from	O
16	the	O
17	short	O
18	transcripts	O
19	,	O
20	are	O
21	also	O
22	required	O
23	for	O
24	respiration	O
25	.	O

1	Total	O
2	cumulative	O
3	doses	O
4	of	O
5	doxorubicin	O
6	ranged	O
7	from	O
8	145	O
9	to	O
10	625	O
11	mg	O
12	./	O
13	m	O
14	.	O
15	2	O
16	.	O

1	Troubled	O
2	CareNetwork	O
3	gets	O
4	pact	B
5	from	I
6	largest	I
7	teacher	I
8	union	I
9	in	I
10	Wis	I
11	.	O

1	Overexpression	O
2	of	O
3	CARP	O
4	in	O
5	cardiomyocytes	O
6	suppresses	O
7	cardiac	O
8	troponin	O
9	C	O
10	and	O
11	atrial	O
12	natriuretic	O
13	factor	O
14	transcription	O
15	.	O

1	Hypomagnesemia	O
2	was	O
3	due	O
4	to	O
5	magnesium	O
6	wasting	O
7	by	O
8	the	O
9	kidney	O
10	.	B

1	The	O
2	transit	O
3	time	O
4	was	O
5	significantly	O
6	shortened	O
7	.	O

1	Replacing	O
2	residues	O
3	405	O
4	-	O
5	419	O
6	on	O
7	delta419	O
8	with	O
9	the	O
10	conserved	O
11	AF	B
12	-	I
13	2	I
14	domain	I
15	from	I
16	the	O
17	vitamin	O
18	D3	O
19	receptor	O
20	or	O
21	the	O
22	estrogen	O
23	receptor	O
24	results	O
25	in	O
26	a	O
27	receptor	O
28	with	O
29	wild	O
30	-	O
31	type	O
32	or	O
33	low	O
34	transcriptional	O
35	activity	O
36	,	O
37	respectively	O
38	.	B

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	O
32	-	O
33	and	O
34	beta	O
35	-	O
36	adrenoceptors	O
37	.	O

1	A	O
2	cytosolic	O
3	variant	O
4	of	O
5	the	O
6	protein	O
7	underwent	O
8	efficient	O
9	transphosphorylation	O
10	,	O
11	yet	O
12	failed	O
13	to	O
14	activate	O
15	appreciably	O
16	either	O
17	p70	O
18	(	O
19	S6k	O
20	)	O
21	or	O
22	MAP	O
23	kinase	O
24	following	O
25	treatment	O
26	with	O
27	FK1012	O
28	.	O

1	Finally	O
2	,	O
3	three	O
4	new	O
5	missense	O
6	mutations	O
7	,	O
8	E138V	O
9	,	O
10	R254G	O
11	,	O
12	and	O
13	P362R	O
14	,	O
15	were	O
16	identified	B
17	in	I
18	the	I
19	human	I
20	AC	O
21	gene	B
22	from	I
23	FD	I
24	patients	I
25	.	O

1	In	O
2	the	B
3	brain	I
4	,	I
5	muscarinic	I
6	receptors	I
7	mediate	O
8	motor	O
9	and	O
10	memory	O
11	function	B
12	by	I
13	interaction	I
14	with	I
15	their	I
16	ligand	I
17	acetylcholine	O
18	.	O

1	The	O
2	purified	O
3	recombinant	O
4	protein	O
5	was	O
6	assayed	O
7	for	O
8	its	O
9	enzyme	O
10	activity	O
11	by	O
12	monitoring	O
13	transfer	O
14	of	O
15	[	O
16	3H	O
17	]	O
18	methyl	O
19	groups	O
20	from	O
21	the	O
22	substrate	O
23	DNA	O
24	to	O
25	the	O
26	MGMT	O
27	protein	O
28	;	O
29	the	O
30	activity	O
31	was	O
32	found	O
33	to	O
34	be	O
35	stable	O
36	at	O
37	90	O
38	degrees	O
39	C	O
40	for	O
41	at	O
42	least	O
43	30	O
44	min	O
45	.	O

1	The	O
2	dose	O
3	was	O
4	50	O
5	Gy	O
6	/	O
7	20	O
8	fractions	O
9	/	O
10	5	O
11	weeks	O
12	.	O

1	SRE	O
2	activity	O
3	is	O
4	dependent	O
5	upon	O
6	the	O
7	activation	O
8	by	B
9	phosphorylation	I
10	of	I
11	a	I
12	ternary	I
13	complex	I
14	factor	I
15	;	I
16	included	I
17	among	O
18	the	B
19	ternary	I
20	complex	I
21	factors	O
22	is	O
23	Elk	O
24	-	O
25	1	O
26	.	O

1	60th	O
2	birthday	O
3	of	O
4	colonel	O
5	prof	O
6	.	B
7	e	I
8	.	I
9	cerny	I
10	m	I
11	.	I
12	d	I
13	.	I

1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	B
8	at	I
9	Time	I
10	1	I
11	(	O
12	n	O
13	=	B
14	103	I
15	,	I
16	aged	I
17	2	I
18	-	I
19	3	I
20	years	I
21	)	I
22	were	I
23	considered	I
24	predictors	I
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	indicate	O
7	that	O
8	MAP	O
9	kinase	O
10	stimulates	O
11	the	O
12	hPL	O
13	-	O
14	B	O
15	enhancer	O
16	by	O
17	an	O
18	NF	O
19	-	O
20	IL	O
21	-	O
22	6	O
23	-	O
24	dependent	O
25	pathway	O
26	.	O

1	3	O
2	'-	O
3	Methyl	O
4	,	O
5	8	O
6	-	O
7	methyl	O
8	,	O
9	and	O
10	8	B
11	-	I
12	phenyl	I
13	derivatives	I
14	of	I
15	5	I
16	,	O
17	9	O
18	-	O
19	dimethyl	O
20	-	O
21	6	O
22	,	O
23	7	B
24	-	B
25	benzomorphans	I
26	.	I

1	4	O
2	.	O

1	Hprp3p	O
2	is	O
3	a	O
4	77	O
5	kDa	O
6	protein	O
7	,	O
8	which	O
9	is	O
10	homologous	O
11	to	O
12	the	O
13	Saccharomyces	O
14	cerevisiae	O
15	splicing	O
16	factor	O
17	Prp3p	O
18	.	O

1	These	O
2	defects	O
3	no	O
4	doubt	O
5	impair	O
6	the	O
7	folding	O
8	and	O
9	configuration	B
10	necessary	I
11	for	I
12	normal	I
13	processing	O
14	of	O
15	the	O
16	AVP	O
17	gene	O
18	precursor	O
19	.	O

1	Functional	O
2	flow	O
3	was	O
4	evaluated	B
5	using	I
6	laser	I
7	Doppler	O
8	flowmetry	O
9	(	O
10	LDF	O
11	),	O
12	for	O
13	which	O
14	the	O
15	output	O
16	signal	O
17	,	O
18	blood	O
19	cell	O
20	flux	O
21	(	O
22	BCF	O
23	),	O
24	is	O
25	expressed	O
26	in	O
27	terms	O
28	of	O
29	volts	O
30	.	O

1	Atomic	O
2	absorption	O
3	spectrophotometry	O
4	applied	O
5	to	O
6	bacterially	O
7	expressed	O
8	E1A	O
9	proteins	O
10	revealed	O
11	that	O
12	the	O
13	289	O
14	-	O
15	amino	O
16	acid	O
17	protein	O
18	binds	O
19	one	O
20	zinc	O
21	ion	O
22	,	O
23	whereas	O
24	the	O
25	243	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	binds	O
31	no	O
32	zinc	O
33	.	O

1	In	O
2	contrast	O
3	to	O
4	full	O
5	-	O
6	length	O
7	E2F	O
8	-	O
9	3	O
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	O
23	-	O
24	3B	O
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	B
39	associated	I
40	with	I
41	Rb	I
42	.	I

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	This	O
2	prospective	O
3	study	O
4	compared	O
5	the	O
6	measured	O
7	energy	O
8	expenditures	O
9	of	O
10	30	B
11	patients	I
12	using	I
13	indirect	I
14	calorimetry	I
15	with	I
16	their	O
17	predicted	O
18	basal	O
19	energy	O
20	expenditure	O
21	according	O
22	to	O
23	the	O
24	Harris	O
25	-	O
26	Benedict	O
27	equation	O
28	,	O
29	or	O
30	their	O
31	calculated	O
32	energy	O
33	expenditure	O
34	derived	O
35	from	O
36	basal	O
37	energy	O
38	expenditure	O
39	times	O
40	,	O
41	an	O
42	activity	O
43	factor	O
44	,	O
45	and	O
46	a	B
47	stress	I
48	factor	I
49	.	I

1	Both	O
2	verapamil	O
3	and	O
4	propranolol	O
5	can	O
6	exhibit	O
7	additive	O
8	effects	O
9	with	O
10	adenosine	O
11	in	O
12	prolonging	O
13	AV	O
14	nodal	O
15	conduction	O
16	time	O
17	;	O
18	however	O
19	,	O
20	only	O
21	verapamil	O
22	can	O
23	reduce	O
24	the	O
25	dose	O
26	of	O
27	adenosine	O
28	required	O
29	to	O
30	produce	O
31	AV	O
32	nodal	O
33	block	O
34	.	O

1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O

1	MOP5	O
2	contained	O
3	the	O
4	characteristic	O
5	PAS	O
6	domain	O
7	and	O
8	a	O
9	variable	O
10	C	O
11	terminus	O
12	;	O
13	it	O
14	is	O
15	possible	O
16	that	O
17	the	O
18	cDNA	O
19	contains	O
20	a	O
21	bHLH	O
22	domain	O
23	,	O
24	but	O
25	the	O
26	entire	O
27	open	O
28	reading	O
29	frame	O
30	has	O
31	yet	O
32	to	O
33	be	O
34	completed	O
35	.	O

1	Morphofunctional	O
2	status	O
3	of	O
4	the	O
5	formed	O
6	elements	O
7	of	O
8	the	O
9	blood	O
10	in	O
11	rats	O
12	subjected	O
13	to	O
14	different	O
15	variants	O
16	of	O
17	combined	O
18	and	O
19	isolated	O
20	exposure	O
21	to	O
22	BR	O
23	-	O
24	1	O
25	benzene	O

1	Similarly	O
2	,	O
3	supraventricular	O
4	tachycaydia	O
5	following	O
6	resuscitative	O
7	efforts	O
8	appeared	O
9	to	O
10	be	O
11	associated	O
12	with	O
13	a	O
14	negative	O
15	outcome	O
16	.	O

1	Lauciello	O
2	describes	B
3	a	I
4	technique	I
5	for	I
6	the	I
7	placement	O
8	of	O
9	functionally	O
10	generated	O
11	amalgam	O
12	stops	O
13	as	O
14	restorations	O
15	within	O
16	mandibular	O
17	acrylic	O
18	teeth	O
19	.	O

1	E3	O
2	/	B
3	19K	O
4	resides	O
5	in	B
6	the	I
7	endoplasmic	I
8	reticulum	I
9	where	I
10	it	I
11	binds	O
12	to	O
13	MHC	O
14	class	O
15	I	O
16	molecules	O
17	,	O
18	thereby	O
19	preventing	O
20	their	O
21	transport	O
22	to	O
23	the	O
24	cell	O
25	surface	O
26	.	O

1	Furthermore	O
2	,	O
3	p150	O
4	suppresses	O
5	actin	O
6	gelation	O
7	,	O
8	which	O
9	is	O
10	induced	O
11	by	O
12	smooth	O
13	muscle	O
14	alpha	O
15	-	O
16	actinin	O
17	.	O

1	X	O
2	-	O
3	ray	O
4	crystallographic	O
5	data	O
6	show	B
7	that	I
8	the	O
9	PLZF	B
10	BTB	I
11	/	O
12	POZ	O
13	domain	O
14	forms	O
15	an	O
16	obligate	O
17	homodimer	O
18	via	O
19	an	O
20	extensive	O
21	interface	O
22	.	O

1	One	O
2	hundred	O
3	replicate	O
4	data	O
5	sets	O
6	of	O
7	100	O
8	subjects	O
9	each	O
10	were	O
11	simulated	O
12	for	O
13	each	O
14	missing	O
15	data	O
16	scenario	O
17	.	O

1	The	O
2	presence	O
3	of	O
4	visna	O
5	-	O
6	maedi	O
7	in	O
8	Italy	O
9	is	O
10	reported	O
11	for	B
12	the	I
13	first	I
14	time	I
15	.	O

1	We	O
2	introduced	O
3	the	B
4	gel	I
5	technique	O
6	as	B
7	a	I
8	routine	I
9	assay	O
10	for	O
11	antibody	O
12	detection	O
13	and	O
14	identification	O
15	in	O
16	1993	O
17	.	O

1	Interplane	O
2	coupling	O
3	in	O
4	the	O
5	superconductor	O
6	Y2Ba4Cu7O15	O
7	as	O
8	revealed	O
9	by	O
10	NQR	O
11	spin	O
12	-	O
13	echo	O
14	double	O
15	resonance	O
16	.	O

1	Cerebro	O
2	-	O
3	oculo	O
4	-	O
5	facioskeletal	O
6	syndrome	O
7	(	O
8	Pena	O
9	-	O
10	Shokeir	O
11	syndrome	O
12	II	O
13	)	O

1	HupI	O
2	showed	O
3	strong	O
4	identity	O
5	to	O
6	rubredoxin	O
7	and	O
8	rubredoxin	O
9	-	O
10	like	O
11	proteins	O
12	from	O
13	many	O
14	other	O
15	bacteria	B
16	.	I

1	Two	O
2	specific	B
3	DNA	I
4	-	I
5	protein	I
6	complexes	I
7	were	O
8	identified	O
9	in	O
10	gel	O
11	retardation	O
12	assays	O
13	using	O
14	HeLa	O
15	cell	O
16	nuclear	O
17	extracts	O
18	and	O
19	an	O
20	oligonucleotide	O
21	probe	O
22	spanning	B
23	the	I
24	footprinted	I
25	region	I
26	.	I

1	These	O
2	thyroid	O
3	hormone	O
4	changes	O
5	may	O
6	be	O
7	mediated	O
8	in	O
9	part	O
10	by	O
11	cytokines	O
12	or	O
13	other	O
14	inflammatory	O
15	mediators	O
16	,	O
17	acting	O
18	at	O
19	the	O
20	level	O
21	of	O
22	the	O
23	hypothalamus	O
24	and	O
25	pituitary	O
26	gland	O
27	,	O
28	the	O
29	thyroid	O
30	gland	O
31	,	O
32	and	O
33	the	O
34	hepatic	O
35	deiodinase	O
36	system	O
37	.	O

1	Invited	O
2	editorial	O
3	on	O
4	"	O
5	Acute	O
6	and	O
7	chronic	O
8	effects	O
9	of	O
10	exercise	O
11	on	O
12	leptin	O
13	levels	O
14	in	O
15	humans	O
16	".	O

1	Here	O
2	we	O
3	present	O
4	genetic	O
5	evidence	O
6	suggesting	O
7	that	O
8	PP2A	O
9	functions	O
10	downstream	O
11	of	O
12	Ras1	O
13	in	O
14	the	O
15	Sevenless	O
16	receptor	O
17	tyrosine	O
18	kinase	O
19	(	O
20	RTK	O
21	)	O
22	signal	O
23	transduction	O
24	pathway	O
25	that	O
26	specifies	O
27	R7	O
28	photoreceptor	O
29	cell	O
30	fate	O
31	in	O
32	the	O
33	developing	O
34	Drosophila	O
35	eye	O
36	.	O

1	Aggravating	O
2	process	O
3	induced	O
4	by	O
5	indomethacin	O
6	on	O
7	chronic	O
8	gastric	O
9	lesion	O
10	in	O
11	rat	O
12	.	B

1	In	O
2	supine	O
3	position	O
4	,	O
5	plasma	O
6	ANP	O
7	levels	O
8	ranged	O
9	from	O
10	12	O
11	pg	O
12	/	O
13	ml	O
14	to	O
15	51	O
16	.	O
17	5	O
18	pg	O
19	/	O
20	ml	O
21	,	B
22	with	I
23	an	I
24	average	I
25	level	O
26	of	O
27	35	O
28	.	O
29	3	O
30	+/-	O
31	11	O
32	.	O
33	5	O
34	pg	O
35	/	O
36	ml	O
37	.	O

1	Serum	O
2	magnesium	O
3	in	O
4	79	O
5	patients	O
6	of	O
7	gynecologic	O
8	neoplasms	O
9	treated	O
10	with	O
11	cisplatin	O
12	and	O
13	their	O
14	controls	O
15	was	O
16	measured	O
17	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	XLP	O
9	may	O
10	result	O
11	from	B
12	perturbed	I
13	signaling	O
14	not	O
15	only	O
16	through	O
17	SLAM	O
18	,	O
19	but	O
20	also	O
21	other	O
22	cell	O
23	surface	O
24	molecules	O
25	that	O
26	utilize	O
27	SAP	O
28	as	O
29	a	O
30	signaling	O
31	adaptor	O
32	protein	O
33	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	major	O
6	homology	O
7	region	O
8	of	O
9	Mason	O
10	-	O
11	Pfizer	O
12	monkey	O
13	virus	O
14	by	O
15	use	O
16	of	O
17	saturation	O
18	mutagenesis	O
19	.	O

1	Strategic	O
2	change	O
3	in	O
4	the	O
5	NHS	B
6	.	I

1	Merosin	O
2	positive	O
3	congenital	O
4	muscular	O
5	dystrophy	O
6	with	B
7	mental	I
8	deficiency	I
9	,	I
10	epilepsy	I
11	and	O
12	MRI	O
13	changes	B
14	in	I
15	the	I
16	cerebral	I
17	white	I
18	matter	I
19	.	O

1	Senior	O
2	systems	O
3	--	O
4	45	O
5	;	O
6	Mental	O
7	health	O
8	and	O
9	illness	O
10	in	B
11	old	I
12	age	O
13	--	B
14	3	I
15	.	I

1	A	O
2	set	O
3	of	O
4	peptides	O
5	corresponding	O
6	to	O
7	the	B
8	individual	I
9	elements	I
10	of	I
11	secondary	I
12	structure	I
13	derived	I
14	from	I
15	the	O
16	N	O
17	-	O
18	terminal	O
19	domain	O
20	of	O
21	the	O
22	ribosomal	O
23	protein	O
24	L9	O
25	have	O
26	been	O
27	synthesized	O
28	.	O

1	Regulation	O
2	of	O
3	irgA	O
4	by	O
5	iron	O
6	in	O
7	V	O
8	.	O
9	cholerae	O
10	occurs	O
11	at	I
12	the	I
13	transcriptional	O
14	level	O
15	,	B
16	and	I
17	there	I
18	is	I
19	an	I
20	interrupted	I
21	dyad	I
22	symmetric	I
23	sequence	I
24	in	I
25	the	O
26	vicinity	O
27	of	O
28	the	O
29	promoter	O
30	that	O
31	is	O
32	homologous	O
33	to	B
34	Fur	O
35	binding	O
36	sites	O
37	of	O
38	E	O
39	.	O
40	coli	O
41	.	O

1	Its	O
2	C	O
3	-	O
4	terminal	O
5	catalytic	O
6	domain	O
7	was	O
8	found	O
9	to	O
10	be	O
11	highly	O
12	conserved	O
13	in	O
14	the	O
15	homologues	O
16	p140	O
17	(	O
18	ras	O
19	-	O
20	GRF	O
21	)	O
22	and	O
23	Sos	O
24	.	O

1	These	O
2	observations	B
3	establish	I
4	that	I
5	RsmC	O
6	negatively	O
7	regulates	O
8	rsmB	O
9	transcription	O
10	but	O
11	positively	O
12	affects	O
13	RsmA	O
14	production	O
15	.	O

1	A	O
2	cAMP	O
3	response	O
4	element	O
5	(	O
6	CRE	O
7	)	O
8	consensus	O
9	signal	O
10	was	O
11	identified	O
12	in	O
13	the	O
14	5	O
15	'-	O
16	noncoding	O
17	region	O
18	.	O
19	cAMP	O
20	regulates	O
21	the	O
22	expression	O
23	of	O
24	Kv1	O
25	.	O
26	5	O
27	gene	O
28	in	O
29	a	O
30	cell	O
31	-	O
32	specific	O
33	manner	O
34	.	O

1	The	O
2	alpha	O
3	2A	O
4	-	O
5	adrenergic	O
6	receptor	O
7	(	O
8	alpha	O
9	2AAR	O
10	)	O
11	is	O
12	coupled	O
13	to	O
14	a	O
15	variety	O
16	of	O
17	effectors	O
18	via	O
19	pertussis	O
20	toxin	O
21	-	O
22	sensitive	O
23	GTP	O
24	-	O
25	binding	O
26	proteins	O
27	.	O

1	In	O
2	contrast	O
3	with	O
4	previous	O
5	two	O
6	-	O
7	pool	O
8	models	O
9	,	O
10	provisions	O
11	were	O
12	made	O
13	for	O
14	folate	O
15	turnover	O
16	by	O
17	urinary	O
18	folate	O
19	excretion	O
20	(	O
21	as	O
22	measured	O
23	here	O
24	)	O
25	and	O
26	by	O
27	fecal	O
28	excretion	O
29	and	O
30	catabolic	O
31	processes	O
32	.	O

1	Below	O
2	50	O
3	%	O
4	decrease	O
5	of	O
6	PaO2	O
7	,	O
8	NADH	O
9	was	O
10	reduced	O
11	largely	O
12	.	O

1	These	O
2	studies	O
3	show	O
4	that	O
5	UCRBP	O
6	binds	O
7	to	O
8	various	O
9	target	O
10	motifs	O
11	that	O
12	are	O
13	distinct	O
14	from	O
15	the	O
16	UCR	O
17	motif	O
18	:	O
19	the	O
20	adeno	O
21	-	O
22	associated	O
23	virus	O
24	P5	O
25	promoter	O
26	and	O
27	elements	O
28	in	O
29	the	O
30	immunoglobulin	O
31	light	O
32	-	O
33	and	O
34	heavy	O
35	-	O
36	chain	O
37	genes	O
38	,	O
39	as	O
40	well	O
41	as	O
42	elements	O
43	in	O
44	ribosomal	O
45	protein	O
46	genes	O
47	.	O

1	Ten	O
2	patients	O
3	with	O
4	advanced	O
5	,	O
6	diffuse	O
7	Hodgkin	O
8	'	O
9	s	O
10	and	O
11	non	O
12	-	O
13	Hodgkin	O
14	'	O
15	s	O
16	lymphomas	O
17	responding	O
18	poorly	O
19	to	O
20	the	O
21	most	O
22	widely	O
23	employed	O
24	primary	O
25	chemotherapy	B
26	regimens	I
27	were	I
28	treated	I
29	with	I
30	a	I
31	high	I
32	-	O
33	dose	O
34	chemotherapy	B
35	(	I
36	HDC	I
37	)	I
38	followed	I
39	by	O
40	rescue	O
41	with	O
42	non	O
43	-	O
44	frozen	O
45	autologous	O
46	bone	O
47	marrow	O
48	infusion	O
49	(	O
50	ABMT	O
51	).	O

1	Through	O
2	Southern	O
3	blot	O
4	analyses	O
5	of	O
6	DNA	O
7	from	O
8	backcross	O
9	and	O
10	cogenic	O
11	mice	O
12	,	O
13	recombinant	O
14	inbred	O
15	strains	O
16	,	O
17	and	O
18	somatic	O
19	cell	O
20	hybrids	O
21	,	O
22	the	O
23	genetic	O
24	loci	O
25	that	O
26	produce	O
27	the	O
28	cyclin	O
29	B1	O
30	-	O
31	related	O
32	sequences	O
33	(	O
34	designated	O
35	loci	O
36	Cycb1	O
37	-	O
38	rs1	O
39	to	O
40	Cycb1	O
41	-	O
42	rs9	O
43	)	O
44	were	O
45	mapped	O
46	on	O
47	mouse	O
48	chromosomes	O
49	5	O
50	,	O
51	1	O
52	,	O
53	17	O
54	,	O
55	4	O
56	,	O
57	14	O
58	,	O
59	13	O
60	,	O
61	7	O
62	,	O
63	X	O
64	,	O
65	and	O
66	8	O
67	,	O
68	respectively	O
69	.	O

1	Functional	O
2	analysis	O
3	of	O
4	DNase	O
5	-	O
6	I	O
7	hypersensitive	O
8	sites	O
9	at	O
10	the	O
11	mouse	O
12	porphobilinogen	O
13	deaminase	O
14	gene	O
15	locus	O
16	.	O

1	Both	O
2	in	O
3	vitro	O
4	-	O
5	synthesized	O
6	S2	O
7	protein	O
8	and	O
9	synthetic	O
10	peptides	O
11	corresponding	O
12	to	O
13	S2	O
14	are	O
15	shown	O
16	to	B
17	react	I
18	positively	I
19	with	O
20	sera	O
21	obtained	O
22	from	O
23	EIAV	O
24	-	O
25	infected	O
26	horses	O
27	,	O
28	providing	O
29	the	O
30	first	O
31	direct	O
32	evidence	O
33	of	O
34	expression	O
35	of	O
36	this	O
37	protein	O
38	in	O
39	infected	O
40	animals	O
41	.	O

1	A	O
2	single	O
3	NMSC	O
4	was	O
5	present	O
6	in	O
7	69	B
8	.	I
9	4	I
10	%,	I
11	two	I
12	in	O
13	16	O
14	%,	O
15	three	O
16	in	B
17	6	I
18	.	I
19	4	I
20	%,	I
21	four	I
22	in	O
23	3	O
24	.	O
25	5	O
26	%,	O
27	five	O
28	to	O
29	nine	O
30	in	O
31	4	O
32	.	O
33	2	O
34	%,	O
35	and	O
36	0	B
37	.	I
38	5	I
39	%	I
40	had	I
41	ten	O
42	or	O
43	more	O
44	.	B

1	The	O
2	mean	O
3	value	O
4	of	O
5	the	O
6	CD79b	O
7	to	O
8	the	O
9	CD79b	O
10	internally	O
11	deleted	O
12	ratio	O
13	was	O
14	0	O
15	.	O
16	64	O
17	+/-	O
18	0	O
19	.	O
20	20	O
21	SD	O
22	in	O
23	normal	O
24	donors	O
25	and	O
26	0	O
27	.	O
28	44	O
29	+/-	O
30	0	O
31	.	O
32	27	O
33	SD	O
34	in	O
35	B	O
36	-	O
37	CLL	O
38	(	O
39	P	O
40	=.	O
41	01	O
42	).	O

1	Movement	O
2	programming	O
3	depends	O
4	on	O
5	understanding	O
6	of	B
7	behavioral	I
8	requirements	I
9	.	I

1	We	O
2	did	O
3	not	O
4	detect	O
5	p50	O
6	in	O
7	association	O
8	with	O
9	native	O
10	glucocorticoid	O
11	receptor	O
12	in	O
13	L	O
14	cells	O
15	or	O
16	with	O
17	the	O
18	overexpressed	O
19	glucocorticoid	O
20	receptor	O
21	in	O
22	Chinese	O
23	hamster	O
24	ovary	O
25	cells	O
26	.	O

1	Biol	O
2	.	O

1	We	O
2	conclude	O
3	that	O
4	this	O
5	new	O
6	measurement	O
7	technique	B
8	provides	I
9	an	I
10	easy	I
11	and	I
12	accurate	I
13	P0	O
14	.	B
15	1	I
16	measurement	I
17	using	I
18	standard	O
19	respiratory	O
20	equipment	O
21	when	O
22	tested	O
23	in	O
24	a	O
25	lung	O
26	model	O
27	.	O

1	It	O
2	has	O
3	been	O
4	reported	O
5	that	O
6	rat	O
7	blood	O
8	chloroform	O
9	levels	O
10	were	O
11	significantly	O
12	decreased	O
13	after	O
14	treatment	O
15	with	O
16	ClO2	O
17	.	O

1	The	O
2	values	O
3	were	O
4	consistently	O
5	lower	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	01	O
13	)	O
14	during	O
15	summer	O
16	(	O
17	3	O
18	.	O
19	79	O
20	+/-	O
21	0	O
22	.	O
23	13	O
24	micrograms	O
25	/	O
26	100	O
27	ml	O
28	),	O
29	as	O
30	compared	O
31	to	O
32	winter	O
33	(	O
34	5	O
35	.	O
36	06	O
37	+/-	O
38	0	O
39	.	O
40	27	O
41	).	O

1	The	O
2	product	O
3	of	O
4	rat	O
5	gene	O
6	33	O
7	was	O
8	identified	O
9	as	B
10	an	I
11	ErbB	I
12	-	I
13	2	I
14	-	I
15	interacting	I
16	protein	I
17	in	I
18	a	I
19	two	O
20	-	O
21	hybrid	O
22	screen	O
23	employing	O
24	the	B
25	ErbB	I
26	-	I
27	2	I
28	juxtamembrane	I
29	and	I
30	kinase	I
31	domains	I
32	as	I
33	bait	I
34	.	I

1	Second	O
2	,	O
3	the	O
4	wild	O
5	-	O
6	type	B
7	m8	I
8	3	I
9	'	I
10	UTR	I
11	strongly	I
12	reduces	I
13	accumulation	O
14	of	O
15	heterologous	O
16	transcripts	O
17	in	O
18	vivo	O
19	,	O
20	an	O
21	activity	O
22	that	O
23	requires	O
24	its	O
25	K	O
26	box	B
27	sequences	I
28	.	I

1	Maximum	O
2	induction	B
3	of	I
4	AP	O
5	-	O
6	1	O
7	was	I
8	reached	I
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O

1	An	O
2	approximately	O
3	2	O
4	-	O
5	kilobase	O
6	B2	O
7	transcript	O
8	was	O
9	expressed	O
10	in	O
11	all	O
12	alfalfa	O
13	organs	O
14	tested	O
15	.	O

1	Two	O
2	BASIC	O
3	computer	O
4	programs	O
5	using	O
6	logit	O
7	transformation	O
8	for	O
9	the	O
10	analysis	O
11	of	O
12	S	O
13	-	O
14	shaped	O
15	curves	O
16	are	O
17	presented	O
18	.	O

1	That	O
2	sequence	O
3	strongly	O
4	promoted	O
5	the	O
6	transcription	O
7	of	B
8	the	I
9	promotorless	O
10	chloramphenicol	O
11	acetyltranferase	O
12	(	O
13	CAT	O
14	)	O
15	gene	O
16	in	B
17	cells	I
18	of	I
19	pancreatic	I
20	origin	I
21	(	I
22	AR	O
23	-	B
24	42J	I
25	)	I
26	but	I
27	not	I
28	in	I
29	cells	I
30	of	O
31	non	O
32	-	O
33	pancreatic	O
34	origin	O
35	(	O
36	Rat	O
37	2	O
38	and	O
39	IEC	O
40	6	O
41	).	I

1	Significant	O
2	treatment	O
3	-	O
4	related	O
5	problems	O
6	appeared	O
7	during	O
8	the	O
9	second	O
10	decade	O
11	in	O
12	5	O
13	patients	O
14	,	O
15	including	O
16	one	O
17	chest	O
18	wall	O
19	sarcoma	O
20	;	B
21	all	I
22	of	I
23	these	I
24	patients	I
25	had	O
26	received	O
27	at	O
28	least	O
29	60	O
30	Gy	B
31	to	I
32	breast	O
33	and	B
34	regional	O
35	nodal	O
36	areas	O
37	.	O

1	Various	O
2	mutant	O
3	HN	O
4	genes	O
5	were	O
6	constructed	O
7	to	O
8	examine	O
9	the	O
10	role	O
11	of	O
12	residues	O
13	flanking	O
14	the	O
15	signal	B
16	-	I
17	anchor	I
18	domain	I
19	,	O
20	including	O
21	the	O
22	cytoplasmic	O
23	tail	O
24	,	O
25	on	O
26	assembly	O
27	and	O
28	intracellular	O
29	transport	O
30	of	O
31	the	O
32	HN	O
33	glycoprotein	O
34	.	O

1	To	O
2	determine	O
3	which	O
4	region	O
5	of	O
6	SulA	O
7	is	O
8	essential	O
9	for	O
10	the	O
11	inhibition	O
12	of	O
13	cell	O
14	division	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	series	O
20	of	O
21	N	O
22	-	O
23	terminal	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	deletions	O
29	of	O
30	SulA	O
31	and	O
32	a	O
33	series	O
34	of	O
35	alanine	O
36	substitution	O
37	mutants	O
38	.	O

1	Interestingly	O
2	,	O
3	this	O
4	activation	O
5	occurred	O
6	only	O
7	when	O
8	the	O
9	regions	O
10	were	O
11	cloned	O
12	in	O
13	the	O
14	same	O
15	relative	O
16	orientation	O
17	in	O
18	which	O
19	they	O
20	exist	O
21	on	O
22	wild	O
23	-	O
24	type	O
25	pCF10	O
26	.	O

1	The	O
2	relationships	O
3	among	O
4	four	O
5	descriptors	O
6	of	O
7	lactate	O
8	increase	O
9	:	O
10	lactate	O
11	threshold	O
12	(	B
13	LT	I
14	)	I
15	(	O
16	the	O
17	VO2	O
18	at	O
19	which	O
20	blood	O
21	lactate	O
22	concentration	O
23	begins	O
24	to	O
25	increase	O
26	above	O
27	the	O
28	resting	O
29	level	O
30	during	O
31	an	O
32	incremental	O
33	exercise	O
34	test	O
35	),	O
36	LT1	O
37	(	O
38	the	O
39	VO2	O
40	at	O
41	which	O
42	blood	O
43	lactate	O
44	increases	O
45	1	O
46	mM	O
47	above	O
48	the	B
49	resting	O
50	level	O
51	),	O
52	LT2	O
53	(	O
54	the	O
55	VO2	O
56	at	O
57	which	O
58	blood	O
59	lactate	O
60	concentration	O
61	reaches	O
62	a	O
63	fixed	O
64	value	O
65	of	O
66	2	I
67	mM	O
68	),	O
69	onset	O
70	of	O
71	blood	O
72	lactate	O
73	accumulation	O
74	(	O
75	OBLA	O
76	;	O
77	the	O
78	VO2	O
79	at	O
80	which	O
81	blood	O
82	lactate	O
83	reaches	O
84	a	O
85	concentration	O
86	of	O
87	4	O
88	mM	O
89	),	O
90	were	O
91	compared	O
92	with	O
93	aerobic	O
94	capacity	O
95	(	O
96	VO2max	O
97	)	O
98	and	O
99	12	O
100	min	O
101	running	B
102	performance	O
103	in	I
104	19	I
105	untrained	O
106	female	B
107	students	O
108	.	O

1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	"	O
62	patch	O
63	7D	O
64	").	O

1	Further	O
2	studies	O
3	established	O
4	that	O
5	the	O
6	Ep	O
7	-	O
8	induced	O
9	increase	O
10	in	B
11	beta	I
12	-	I
13	globin	I
14	mRNA	I
15	could	I
16	be	O
17	inhibited	O
18	by	O
19	the	O
20	tyrosine	B
21	kinase	I
22	inhibitor	I
23	genistein	I
24	and	I
25	the	I
26	protein	I
27	kinase	I
28	C	O
29	inhibitor	O
30	Compound	O
31	3	O
32	.(	O
33	ABSTRACT	O
34	TRUNCATED	O
35	AT	O
36	250	O
37	WORDS	O
38	)	O

1	However	O
2	,	O
3	one	O
4	CAK	O
5	-	O
6	phosphorylated	O
7	phosphopeptide	B
8	comigrates	I
9	with	I
10	a	O
11	Cdc2	O
12	-	O
13	phosphorylated	O
14	phosphopeptide	B
15	previously	I
16	shown	I
17	to	I
18	be	I
19	mitosis	I
20	-	O
21	specific	O
22	,	O
23	suggesting	O
24	that	O
25	,	O
26	in	O
27	vitro	O
28	,	O
29	CAK	O
30	is	O
31	able	O
32	to	O
33	phosphorylate	B
34	at	O
35	least	O
36	one	O
37	site	O
38	that	O
39	is	O
40	also	O
41	phosphorylated	I
42	in	O
43	vivo	B
44	.	I

1	The	O
2	sequence	O
3	of	O
4	this	O
5	region	B
6	shows	I
7	high	I
8	G	I
9	+	I
10	C	I
11	content	O
12	(	B
13	62	I
14	%),	O
15	which	B
16	is	I
17	particularly	O
18	emphasized	O
19	in	O
20	the	O
21	200	O
22	bp	O
23	upstream	O
24	from	O
25	the	O
26	mRNA	O
27	start	O
28	(	O
29	80	O
30	%	O
31	G	O
32	+	O
33	C	O
34	).	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	catalytic	O
8	domain	O
9	of	O
10	Nmt1p	O
11	is	O
12	located	O
13	between	O
14	Ile59	O
15	-->	O
16	Phe96	O
17	and	O
18	Gly451	O
19	-->	O
20	Leu455	B
21	.	I

1	Mean	O
2	ROI	O
3	-	O
4	A	O
5	/	O
6	B	O
7	ratio	O
8	was	O
9	49	O
10	.	O
11	6	O
12	+/-	O
13	1	O
14	.	O
15	7	O
16	%	O
17	in	O
18	the	O
19	diabetic	O
20	group	O
21	,	O
22	significantly	O
23	lower	O
24	than	O
25	the	O
26	57	O
27	.	O
28	9	O
29	+/-	O
30	1	O
31	.	O
32	6	O
33	%	O
34	at	O
35	the	O
36	nondiabetic	O
37	group	O
38	(	O
39	p	O
40	less	O
41	than	O
42	0	O
43	.	O
44	005	O
45	).	O

1	Involvement	O
2	of	O
3	AP	O
4	-	O
5	2	O
6	in	O
7	regulation	O
8	of	O
9	the	O
10	R	O
11	-	O
12	FABP	O
13	gene	O
14	in	O
15	the	O
16	developing	O
17	chick	O
18	retina	O
19	.	O

1	We	O
2	suggest	O
3	that	O
4	CT	O
5	scan	O
6	be	O
7	preferable	O
8	in	O
9	diagnosis	O
10	of	O
11	tumors	O
12	in	O
13	that	O
14	area	O
15	.	O

1	Functional	O
2	analysis	O
3	of	O
4	promoter	O
5	activity	O
6	of	B
7	the	B
8	5	I
9	'-	O
10	flanking	O
11	region	O
12	of	B
13	cyclin	I
14	D2	I
15	suggested	I
16	that	I
17	the	O
18	region	O
19	-	O
20	1	O
21	,	O
22	100	O
23	to	O
24	-	O
25	805	O
26	including	O
27	C	O
28	/	O
29	EBP	O
30	,	O
31	PEA3	O
32	,	O
33	AP2	O
34	,	O
35	NF	O
36	-	O
37	Y	O
38	,	B
39	c	O
40	-	O
41	Myc	O
42	,	B
43	and	B
44	Sp1	I
45	may	O
46	have	O
47	a	O
48	major	B
49	positive	I
50	regulatory	I
51	activity	O
52	for	O
53	expression	O
54	of	O
55	cyclin	B
56	D2	I
57	.	O

1	MK	O
2	-	O
3	801	O
4	administration	O
5	resulted	O
6	in	O
7	a	O
8	biphasic	O
9	response	O
10	in	O
11	seizure	O
12	latency	O
13	.	O

1	The	O
2	E1	B
3	nuclear	I
4	transport	I
5	motif	I
6	is	I
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	papillomaviruses	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	O
26	genes	O
27	.	O

1	Cooperative	O
2	dimerization	O
3	of	O
4	paired	O
5	class	O
6	homeo	O
7	domains	O
8	on	O
9	DNA	O
10	.	O

1	(	O
2	1995	O
3	)	O
4	J	O
5	.	O

1	We	O
2	then	O
3	studied	O
4	four	O
5	unrelated	O
6	Japanese	O
7	families	O
8	with	O
9	GSD	O
10	-	O
11	Ib	O
12	,	O
13	and	O
14	found	O
15	three	O
16	novel	O
17	mutations	O
18	:	O
19	a	O
20	four	O
21	-	O
22	base	O
23	deletion	O
24	/	O
25	two	O
26	-	O
27	base	O
28	insertion	O
29	,	O
30	a	O
31	point	O
32	mutation	O
33	within	O
34	a	O
35	consensus	O
36	splicing	O
37	donor	O
38	site	O
39	,	O
40	and	O
41	a	O
42	missense	O
43	mutation	O
44	(	O
45	W118R	O
46	).	O

1	An	O
2	explanation	O
3	explored	O
4	for	O
5	this	O
6	lack	O
7	of	O
8	gene	O
9	expression	O
10	was	O
11	that	O
12	increased	O
13	levels	O
14	of	O
15	RAR	O
16	alpha	O
17	or	O
18	PML	O
19	might	O
20	suppress	O
21	APL	O
22	cell	O
23	growth	O
24	.	O

1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	O
16	c	O
17	-	O
18	myb	O
19	intron	O
20	1	O
21	transcription	O
22	pause	O
23	region	O
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	WI	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	123	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	O
62	regulatory	O
63	factors	O
64	(	O
65	IRFs	O
66	)	O
67	nuclear	O
68	proteins	O
69	.	O

1	In	O
2	eukaryotic	O
3	cells	O
4	,	O
5	premature	O
6	termination	O
7	of	O
8	translation	O
9	at	O
10	nonsense	O
11	codons	O
12	has	O
13	been	O
14	implicated	O
15	as	O
16	the	O
17	cause	O
18	of	O
19	a	O
20	variety	O
21	of	O
22	posttranscriptional	O
23	events	O
24	,	O
25	including	O
26	rapid	O
27	mRNA	O
28	decay	O
29	in	O
30	the	O
31	cytoplasm	O
32	or	O
33	the	O
34	nucleus	O
35	,	O
36	altered	O
37	splice	O
38	site	O
39	selection	O
40	,	O
41	and	O
42	exon	O
43	skipping	O
44	.	O

1	Moreover	O
2	,	O
3	the	O
4	same	O
5	mutations	O
6	alter	O
7	the	O
8	structure	O
9	of	O
10	junB	O
11	5	O
12	'	O
13	flanking	O
14	DNA	O
15	within	O
16	chromatin	O
17	.	O

1	Three	O
2	FGF	O
3	-	O
4	AS	O
5	cDNAs	O
6	were	O
7	isolated	O
8	;	O
9	the	O
10	full	O
11	-	O
12	length	O
13	FGF	O
14	-	O
15	AS	O
16	mRNA	O
17	and	O
18	two	O
19	alternative	O
20	splice	O
21	variants	O
22	lacking	O
23	exon	O
24	2	O
25	or	O
26	exons	O
27	2	O
28	and	O
29	3	O
30	of	O
31	the	O
32	FGF	O
33	-	O
34	AS	O
35	sequence	O
36	.	O

1	Of	O
2	the	B
3	compounds	I
4	tested	O
5	,	B
6	alpha	I
7	-(	I
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	O
13	-	O
14	quinoxalinyl	O
15	)-	O
16	N	O
17	-	O
18	methylnitrone	O
19	1	O
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	B
39	and	O
40	the	O
41	gram	O
42	-	I
43	positive	O
44	organisms	O
45	.	O

1	Imposed	O
2	angular	O
3	displacements	O
4	of	O
5	monkey	B
6	'	I
7	s	I
8	wrist	O
9	produce	O
10	three	O
11	major	O
12	peaks	O
13	of	O
14	activity	O
15	(	B
16	terms	I
17	M1	I
18	,	I
19	M2	I
20	,	I
21	and	I
22	M3	O
23	peaks	O
24	)	O
25	in	O
26	the	O
27	averaged	O
28	gross	O
29	EMG	O
30	activity	O
31	ot	O
32	the	O
33	stretched	O
34	muscles	O
35	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	of	O
5	a	O
6	3213	O
7	bp	O
8	BamHI	O
9	-	O
10	ClaI	O
11	fragment	O
12	revealed	O
13	that	O
14	three	O
15	open	O
16	reading	O
17	frames	O
18	(	O
19	ORFs	O
20	)	O
21	were	O
22	encoded	O
23	in	O
24	the	O
25	same	O
26	orientation	O
27	.	O

1	The	O
2	former	O
3	group	O
4	did	O
5	excrete	O
6	less	O
7	dry	O
8	fecal	I
9	material	I
10	compared	I
11	to	O
12	both	O
13	other	B
14	groups	I
15	.	I

1	Despite	O
2	this	O
3	DNA	O
4	binding	B
5	activity	B
6	,	I
7	AP	O
8	-	O
9	1	O
10	reporter	O
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	bZIP	O
6	protein	O
7	Opaque2	O
8	(	O
9	O2	O
10	),	O
11	there	O
12	are	O
13	other	B
14	maize	I
15	endosperm	I
16	nuclear	I
17	proteins	I
18	that	I
19	recognize	O
20	the	O
21	O2	O
22	box	O
23	in	O
24	22	O
25	kDa	O
26	zein	O
27	gene	O
28	promoters	O
29	.	O

1	Interleukin	O
2	-	B
3	1	I
4	levels	O
5	remained	O
6	low	O
7	throughout	O
8	the	O
9	course	O
10	.	O

1	A	O
2	human	O
3	nuclear	O
4	-	O
5	localized	O
6	chaperone	O
7	that	O
8	regulates	O
9	dimerization	O
10	,	O
11	DNA	O
12	binding	O
13	,	O
14	and	O
15	transcriptional	O
16	activity	O
17	of	O
18	bZIP	O
19	proteins	O
20	.	O

1	Up	O
2	to	O
3	95	O
4	%	O
5	of	O
6	the	O
7	total	O
8	UV	O
9	exposure	O
10	received	O
11	is	O
12	in	O
13	the	O
14	UV	O
15	-	O
16	A	O
17	waveband	O
18	(	O
19	320	O
20	-	O
21	400	O
22	nm	O
23	).	O

1	Based	O
2	on	O
3	peptide	O
4	map	O
5	similarities	O
6	,	O
7	partial	O
8	amino	O
9	-	O
10	terminal	O
11	sequence	O
12	data	O
13	,	O
14	and	O
15	common	O
16	genetic	O
17	origin	O
18	,	O
19	it	O
20	is	O
21	suggested	O
22	that	O
23	p60	O
24	and	O
25	p62	O
26	have	O
27	identical	O
28	amino	O
29	acid	O
30	sequences	O
31	carboxy	O
32	-	O
33	terminal	O
34	to	O
35	the	O
36	p60	O
37	initiator	O
38	methionine	O
39	(	O
40	residue	O
41	21	O
42	of	O
43	p62	O
44	).	O

1	A	O
2	novel	O
3	phosphotyrosine	O
4	-	O
5	binding	O
6	domain	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	transforming	O
13	region	O
14	of	O
15	Cbl	O
16	interacts	O
17	directly	O
18	and	O
19	selectively	O
20	with	O
21	ZAP	O
22	-	O
23	70	O
24	in	O
25	T	O
26	cells	O
27	.	O

1	This	O
2	distribution	O
3	implies	O
4	that	O
5	the	O
6	polycistronic	O
7	precursor	O
8	is	O
9	imported	O
10	into	O
11	the	O
12	nucleolus	O
13	for	O
14	processing	O
15	to	O
16	the	O
17	mature	O
18	snoRNAs	O
19	,	O
20	and	O
21	that	O
22	the	O
23	import	O
24	or	O
25	processing	O
26	pathway	O
27	involves	O
28	coiled	O
29	bodies	O
30	.	O

1	Pharmacological	O
2	and	O
3	pharmacokinetic	O
4	characteristics	B
5	of	I
6	the	I
7	non	I
8	-	I
9	ionic	I
10	monomeric	I
11	X	O
12	-	O
13	ray	O
14	contrast	B
15	agent	I
16	iopromide	I
17	(	I
18	Ultravist	I
19	,	I
20	CAS	I
21	73334	O
22	-	O
23	07	O
24	-	O
25	3	O
26	)	B
27	were	B
28	evaluated	I
29	in	O
30	preclinical	B
31	studies	O
32	.	O

1	Uroflowmetry	O
2	can	B
3	detect	B
4	dysuria	I
5	,	O
6	which	O
7	may	O
8	be	O
9	poorly	O
10	perceived	O
11	or	O
12	even	O
13	unknown	O
14	to	O
15	the	O
16	subjects	O
17	themselves	O
18	.	O

1	5	O
2	)	O
3	Before	O
4	and	O
5	ten	O
6	days	O
7	after	O
8	DOTC	O
9	infusion	O
10	,	O
11	laboratory	O
12	tests	O
13	for	O
14	liver	O
15	and	O
16	renal	O
17	functions	O
18	and	O
19	blood	O
20	were	O
21	performed	O
22	.	O

1	RACK1	O
2	,	O
3	a	O
4	receptor	O
5	for	O
6	activated	O
7	C	O
8	kinase	O
9	and	O
10	a	O
11	homolog	O
12	of	O
13	the	O
14	beta	O
15	subunit	O
16	of	O
17	G	O
18	proteins	O
19	,	O
20	inhibits	O
21	activity	O
22	of	B
23	src	I
24	tyrosine	I
25	kinases	I
26	and	I
27	growth	I
28	of	I
29	NIH	I
30	3T3	I
31	cells	I
32	.	I

1	A	O
2	new	O
3	vector	B
4	,	I
5	pHBK280	I
6	,	I
7	was	I
8	designed	I
9	to	I
10	facilitate	I
11	this	I
12	analysis	O
13	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	Cdk2	O
6	truncations	O
7	,	O
8	however	O
9	,	O
10	were	O
11	non	O
12	-	O
13	functional	O
14	in	O
15	these	O
16	strains	O
17	and	O
18	thus	O
19	dependent	O
20	for	O
21	activity	O
22	on	O
23	the	O
24	pho85	O
25	coding	O
26	region	O
27	which	O
28	remained	O
29	in	O
30	the	O
31	mutant	O
32	pho85	O
33	::	O
34	HIS3	O
35	chromosomal	O
36	locus	O
37	.	O

1	Gel	O
2	-	O
3	shift	O
4	assays	O
5	with	O
6	nuclear	O
7	extracts	O
8	and	O
9	oligonucleotide	O
10	sequences	O
11	spanning	O
12	the	I
13	0	O
14	.	O
15	125	O
16	-	O
17	kb	O
18	promoter	O
19	region	O
20	detected	O
21	an	O
22	ETS	O
23	-	O
24	immunoreactive	O
25	complex	I
26	,	O
27	present	I
28	most	I
29	abundantly	I
30	in	I
31	cells	O
32	overexpressing	B
33	HER2	I
34	,	O
35	whose	O
36	high	O
37	-	O
38	affinity	O
39	binding	O
40	depended	O
41	on	O
42	the	O
43	GAGGAA	O
44	response	O
45	element	O
46	.	O

1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	O
10	enhancers	O
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	O
19	left	O
20	E	O
21	-	O
22	box	O
23	site	O
24	or	O
25	from	O
26	the	O
27	Ig	O
28	kappa	O
29	E2	O
30	E	O
31	-	O
32	box	O
33	.	O

1	62	O
2	:	O
3	2491	O
4	-	O
5	2499	O
6	,	O
7	1987	O
8	).	O

1	Selenium	O
2	,	O
3	as	O
4	a	O
5	constituent	O
6	of	O
7	glutathione	O
8	peroxidase	O
9	,	O
10	plays	O
11	a	O
12	role	O
13	in	O
14	the	O
15	antioxidant	O
16	defense	O
17	systems	O
18	of	O
19	the	O
20	body	O
21	,	O
22	but	O
23	other	O
24	metabolic	O
25	roles	O
26	for	O
27	selenium	O
28	may	O
29	yet	O
30	be	O
31	discovered	O
32	.	O

1	No	O
2	direct	O
3	repeats	O
4	flank	O
5	the	O
6	pseudogene	O
7	in	O
8	the	O
9	U2	O
10	/	O
11	4	O
12	locus	O
13	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	O
7	virulence	O
8	genes	O
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	O
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O

1	Resistance	O
2	training	O
3	shifts	O
4	the	O
5	power	O
6	curve	O
7	in	O
8	a	O
9	positive	O
10	direction	O
11	when	O
12	the	O
13	measurements	O
14	are	O
15	determined	O
16	with	O
17	absolute	O
18	loads	O
19	,	O
20	but	O
21	the	O
22	increased	O
23	power	O
24	may	O
25	not	O
26	be	O
27	transferred	O
28	to	O
29	an	O
30	absolute	O
31	performance	O
32	task	O
33	like	O
34	the	O
35	SSP	O
36	.	O

1	After	O
2	nitric	O
3	oxide	B
4	inhalation	I
5	,	I
6	the	I
7	results	I
8	showed	I
9	moderate	I
10	increases	I
11	in	I
12	PaO2	I
13	and	I
14	SaO2	O
15	(	O
16	P	O
17	>	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	Qs	O
28	/	O
29	Q	O
30	tau	O
31	ratio	O
32	(	O
33	P	O
34	<	O
35	0	O
36	.	B
37	01	O
38	).	O

1	This	O
2	is	O
3	the	O
4	first	O
5	description	O
6	,	O
7	to	O
8	our	O
9	knowledge	O
10	,	O
11	of	O
12	regulatory	O
13	elements	O
14	that	O
15	control	O
16	expression	O
17	of	O
18	a	O
19	gene	O
20	encoding	O
21	a	O
22	B7	O
23	costimulatory	O
24	molecule	O
25	.	O

1	The	O
2	muskox	B
3	is	I
4	a	I
5	new	O
6	host	O
7	record	O
8	for	O
9	T	O
10	.	B
11	gondii	I
12	.	I

1	Although	O
2	IL	O
3	-	O
4	2	O
5	and	O
6	IFN	O
7	-	O
8	alpha	O
9	activated	O
10	STAT1	O
11	alpha	O
12	and	O
13	STAT5	O
14	,	O
15	IL	O
16	-	O
17	2	O
18	predominantly	O
19	activated	O
20	STAT5	O
21	,	O
22	while	O
23	IFN	O
24	-	O
25	alpha	O
26	predominantly	O
27	activated	O
28	STAT1	O
29	alpha	O
30	.	O

1	The	O
2	prevalence	O
3	of	O
4	malnutrition	O
5	was	O
6	30	O
7	%	O
8	in	O
9	the	O
10	47	O
11	patients	O
12	without	O
13	CVD	O
14	and	O
15	was	O
16	significantly	O
17	higher	B
18	(	I
19	70	I
20	%,	I
21	P	O
22	<	B
23	0	I
24	.	I
25	001	I
26	)	I
27	in	I
28	the	I
29	70	I
30	patients	I
31	with	I
32	CVD	I
33	,	O
34	who	O
35	also	O
36	had	O
37	lower	O
38	tHcy	O
39	,	O
40	SAlb	O
41	,	B
42	plasma	O
43	IGF	I
44	-	O
45	1	B
46	,	O
47	serum	I
48	creatinine	O
49	(	O
50	SCr	O
51	),	O
52	and	O
53	blood	O
54	hemoglobin	O
55	.	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	cell	O
6	surface	O
7	CD4	O
8	(-)	O
9	CD8	O
10	(-)	O
11	CD3	O
12	(-)	O
13	cells	O
14	with	O
15	rearranged	O
16	TCR	O
17	genes	O
18	developed	O
19	from	O
20	Id3	O
21	-	O
22	transduced	O
23	but	O
24	not	O
25	from	O
26	control	O
27	-	I
28	transduced	I
29	pre	O
30	-	O
31	T	O
32	cells	O
33	in	O
34	an	O
35	FTOC	O
36	.	O

1	An	O
2	implant	O
3	may	O
4	release	O
5	a	O
6	drug	O
7	either	O
8	by	O
9	diffusion	O
10	concurrent	O
11	with	O
12	dissolution	B
13	of	I
14	the	I
15	polymeric	I
16	implant	I
17	material	I
18	without	I
19	depolymerization	O
20	(	O
21	Type	O
22	A	O
23	)	O
24	or	O
25	by	O
26	bioerosion	B
27	involving	I
28	depolymerization	I
29	(	I
30	Type	B
31	B	I
32	).	I

1	Transactivation	O
2	domain	O
3	is	O
4	located	O
5	downstream	O
6	of	B
7	the	I
8	128	I
9	-	I
10	amino	I
11	-	I
12	acid	I
13	runt	I
14	homology	O
15	region	O
16	,	O
17	referred	O
18	to	O
19	as	O
20	the	O
21	Runt	O
22	domain	O
23	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	kinetically	O
6	more	B
7	damaged	I
8	E44D	I
9	mutant	I
10	detected	I
11	in	I
12	(	I
13	1	O
14	)	O
15	H	O
16	-(	O
17	15	O
18	)	O
19	N	O
20	HSQC	O
21	spectra	O
22	were	O
23	largely	O
24	limited	O
25	to	O
26	the	O
27	loop	O
28	I	O
29	-	O
30	helix	O
31	I	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	Glu	O
37	-	O
38	44	O
39	stabilizes	B
40	the	I
41	active	O
42	site	B
43	region	I
44	.	I

1	Recent	O
2	investigations	O
3	have	O
4	detailed	O
5	a	O
6	selective	O
7	dye	O
8	release	O
9	technique	O
10	in	O
11	which	O
12	a	O
13	pulse	O
14	of	O
15	laser	O
16	light	O
17	induces	O
18	the	O
19	release	O
20	of	O
21	a	O
22	fluorescent	O
23	dye	O
24	from	B
25	temperature	I
26	-	I
27	sensitive	I
28	liposomes	O
29	circulating	B
30	in	I
31	the	I
32	retinal	I
33	vasculature	O
34	.	O

1	Three	O
2	mutants	O
3	(	O
4	pms1	O
5	,	O
6	pms2	O
7	and	O
8	pms3	O
9	)	O
10	isolated	O
11	earlier	O
12	from	O
13	MW104	O
14	-	O
15	1B	O
16	were	O
17	shown	O
18	to	O
19	correct	O
20	in	O
21	vitro	O
22	constructed	O
23	plasmids	O
24	with	O
25	defined	O
26	DNA	O
27	mismatches	O
28	(	O
29	G	O
30	/	O
31	T	O
32	,	O
33	A	O
34	/	O
35	C	O
36	,	O
37	G	O
38	/	O
39	G	O
40	,	O
41	etc	O
42	.)	O
43	poorly	O
44	(	O
45	Kramer	O
46	et	O
47	al	O
48	.,	O
49	1989a	O
50	).	O

1	Many	O
2	cytokine	O
3	receptors	O
4	employ	O
5	Janus	O
6	protein	O
7	tyrosine	O
8	kinases	O
9	(	O
10	Jaks	O
11	)	O
12	and	O
13	signal	O
14	transducers	B
15	and	I
16	activators	I
17	of	I
18	transcription	I
19	(	I
20	Stats	I
21	)	I
22	for	O
23	nuclear	O
24	signaling	O
25	.	O

1	Seventy	O
2	-	O
3	one	O
4	supplementary	O
5	doses	O
6	of	O
7	vecuronium	O
8	were	O
9	used	O
10	for	O
11	muscle	O
12	relaxation	O
13	during	O
14	a	O
15	22	O
16	-	O
17	h	O
18	-	O
19	long	O
20	NLA	O
21	II	O
22	anaesthesia	O
23	.	O

1	HNF	O
2	-	O
3	3	O
4	beta	O
5	amino	O
6	-	O
7	terminal	O
8	sequences	O
9	defined	O
10	by	O
11	conserved	O
12	region	O
13	IV	O
14	also	O
15	contributed	O
16	to	O
17	transactivation	O
18	,	O
19	but	O
20	region	O
21	IV	O
22	activity	O
23	required	O
24	the	O
25	participation	O
26	of	O
27	the	O
28	region	O
29	II	O
30	-	O
31	III	O
32	domain	O
33	.	O

1	The	O
2	application	O
3	of	O
4	these	O
5	microelectrodes	O
6	to	O
7	the	O
8	measurement	O
9	of	O
10	rapid	O
11	,	O
12	transient	O
13	changes	O
14	in	O
15	retinal	O
16	[	O
17	K	O
18	+]	O
19	o	O
20	is	O
21	presented	O
22	.	O

1	Water	O
2	content	O
3	and	O
4	equilibrium	O
5	water	O
6	partition	O
7	in	O
8	immature	O
9	cartilage	O
10	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	show	O
7	that	O
8	,	O
9	like	O
10	BAP2	O
11	,	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	BAP3	O
17	gene	O
18	in	O
19	S	O
20	.	O
21	cerevisiae	O
22	is	O
23	induced	O
24	by	O
25	the	O
26	addition	O
27	of	O
28	branched	O
29	-	O
30	chain	O
31	amino	O
32	acids	O
33	to	O
34	the	O
35	medium	O
36	.	O

1	Myocardial	O
2	antioxidant	O
3	enzymes	O
4	,	O
5	catalase	O
6	,	O
7	glutathione	O
8	peroxidase	O
9	and	O
10	superoxide	O
11	dismutase	O
12	,	O
13	in	O
14	the	O
15	MCT	O
16	-	O
17	treated	O
18	rats	O
19	were	O
20	not	O
21	different	O
22	compared	O
23	to	O
24	control	O
25	rats	O
26	.	O

1	By	O
2	deletion	O
3	analysis	O
4	of	O
5	the	O
6	MLS1	O
7	control	O
8	region	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	sites	O
14	,	O
15	UAS1	O
16	and	O
17	UAS2	O
18	,	O
19	as	O
20	important	O
21	for	O
22	efficient	O
23	derepression	O
24	of	O
25	the	O
26	gene	O
27	.	O

1	The	O
2	major	O
3	promoter	O
4	responds	O
5	strongly	O
6	to	O
7	virus	O
8	-	O
9	encoded	O
10	trans	O
11	activators	O
12	EIA	O
13	and	O
14	EIV	O
15	and	O
16	contains	O
17	four	O
18	elements	O
19	:	O
20	a	O
21	TAGA	O
22	motif	O
23	analogous	O
24	to	O
25	the	O
26	TATA	O
27	box	O
28	,	O
29	two	O
30	EIIF	O
31	sites	O
32	present	O
33	in	O
34	an	O
35	inverted	O
36	orientation	O
37	,	O
38	and	O
39	an	O
40	ATF	O
41	/	O
42	CREB	O
43	site	O
44	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	optimization	O
6	and	O
7	characterization	O
8	of	O
9	a	O
10	140	O
11	-	O
12	residue	O
13	fragment	O
14	,	O
15	containing	O
16	the	O
17	Runt	O
18	domain	O
19	of	O
20	AML1	O
21	,	O
22	which	O
23	is	O
24	suitable	O
25	for	O
26	structural	B
27	studies	I
28	.	I

1	Two	O
2	transcripts	O
3	of	O
4	1	O
5	.	O
6	6	O
7	kb	O
8	and	O
9	5	O
10	.	O
11	8	O
12	kb	O
13	are	O
14	5	O
15	'	O
16	coterminal	O
17	and	O
18	may	O
19	both	O
20	encode	O
21	the	O
22	novel	O
23	glycoprotein	O
24	gene	O
25	EUS4	O
26	.	O

1	DNA	O
2	-	O
3	protein	O
4	UV	O
5	cross	O
6	-	O
7	linking	O
8	studies	O
9	indicated	O
10	that	O
11	UHF	O
12	-	O
13	1	O
14	has	O
15	an	O
16	electrophoretic	O
17	mobility	O
18	on	O
19	sodium	O
20	dodecyl	O
21	sulfate	O
22	-	O
23	acrylamide	O
24	gels	O
25	of	O
26	approximately	O
27	85	O
28	kDa	O
29	and	O
30	suggested	O
31	that	O
32	additional	O
33	proteins	O
34	,	O
35	specific	O
36	to	O
37	each	O
38	promoter	O
39	,	O
40	bind	O
41	to	O
42	each	O
43	site	O
44	.	O

1	The	O
2	peroxisome	O
3	proliferator	O
4	-	O
5	activated	O
6	receptors	O
7	(	O
8	PPARs	O
9	)	O
10	are	O
11	members	O
12	of	O
13	the	O
14	nuclear	O
15	hormone	O
16	receptor	O
17	superfamily	O
18	.	O

1	The	O
2	influenza	O
3	virus	O
4	NS1	O
5	protein	O
6	is	O
7	a	O
8	unique	O
9	posttranscriptional	O
10	regulator	O
11	that	O
12	has	O
13	two	O
14	activities	O
15	:	O
16	inhibition	O
17	of	B
18	the	I
19	nuclear	I
20	export	I
21	of	O
22	poly	O
23	A	O
24	-	O
25	containing	O
26	mRNAs	O
27	and	O
28	inhibition	O
29	of	O
30	pre	O
31	-	O
32	mRNA	O
33	splicing	O
34	.	O

1	On	O
2	-	O
3	line	O
4	angioscopic	O
5	images	O
6	of	O
7	tissue	O
8	flaps	O
9	floating	O
10	in	O
11	the	O
12	lumen	O
13	,	O
14	recent	B
15	or	B
16	structured	I
17	thrombi	I
18	,	O
19	artery	O
20	wall	O
21	dissections	O
22	,	O
23	plaque	O
24	ruptures	O
25	,	O
26	deep	O
27	fissurations	O
28	and	O
29	sub	O
30	-	O
31	intimal	O
32	haemorrhages	O
33	demonstrate	B
34	,	O
35	in	O
36	live	O
37	colour	O
38	,	O
39	the	O
40	pathophysiological	O
41	mechanisms	O
42	of	O
43	coronary	O
44	artery	O
45	stenosis	O
46	.	O

1	The	O
2	microcirculatory	B
3	dynamics	I
4	of	I
5	prostaglandin	I
6	E1	I
7	and	I
8	/	O
9	or	O
10	nicardipine	O
11	and	O
12	their	O
13	different	O
14	reactions	O
15	in	O
16	the	O
17	hyper	O
18	-	O
19	and	O
20	hypodynamic	O
21	state	O
22	of	B
23	septic	I
24	shock	O
25	in	O
26	a	O
27	rat	O
28	model	O

1	Stress	O
2	effects	O
3	on	O
4	affiliation	O
5	preferences	O
6	among	O
7	subjects	B
8	possessing	I
9	the	I
10	type	I
11	A	O
12	coronary	O
13	-	O
14	prone	O
15	behavior	O
16	pattern	O
17	.	O

1	cDNA	O
2	encoding	O
3	a	O
4	functional	O
5	feline	O
6	liver	O
7	/	O
8	bone	O
9	/	O
10	kidney	O
11	-	O
12	type	O
13	alkaline	O
14	phosphatase	O
15	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	N	O
7	-	O
8	and	O
9	C	O
10	-	O
11	terminal	O
12	mutations	O
13	are	O
14	required	O
15	to	O
16	inhibit	O
17	transrepression	O
18	by	O
19	FBR	O
20	protein	O
21	and	O
22	that	O
23	multiple	O
24	structural	O
25	mutations	O
26	accompanied	O
27	by	O
28	posttranslational	O
29	protein	O
30	modification	O
31	alter	O
32	gene	O
33	regulation	O
34	by	O
35	FBR	O
36	protein	O
37	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	examined	O
6	hepatic	O
7	stellate	O
8	cell	O
9	regulation	O
10	of	O
11	M6P	O
12	/	O
13	IGFIIR	O
14	expression	O
15	and	O
16	found	O
17	that	O
18	M6P	O
19	/	O
20	IGFIIR	O
21	mRNA	O
22	transcript	O
23	levels	O
24	increased	O
25	in	O
26	stellate	O
27	cells	O
28	from	O
29	rats	O
30	exposed	O
31	to	O
32	carbon	O
33	tetrachloride	O
34	(	O
35	CCl4	O
36	),	O
37	a	O
38	potent	O
39	fibrogenic	O
40	stimulant	O
41	.	O

1	As	O
2	the	O
3	length	O
4	of	O
5	the	O
6	fatty	O
7	acid	O
8	decreased	O
9	,	O
10	the	O
11	binding	O
12	affinity	B
13	was	I
14	reduced	I
15	;	O
16	myristic	O
17	acid	O
18	(	I
19	14	O
20	:	O
21	0	B
22	)	I
23	bound	O
24	with	O
25	a	O
26	K	O
27	(	B
28	d	I
29	)	I
30	of	O
31	1409	O
32	+/-	O
33	423	O
34	nM	O
35	,	O
36	but	O
37	medium	O
38	-	O
39	chain	O
40	(	O
41	decanoic	O
42	acid	O
43	,	O
44	10	O
45	:	O
46	0	O
47	)	O
48	and	O
49	short	O
50	-	O
51	chain	O
52	(	O
53	octanoic	O
54	acid	O
55	,	O
56	8	O
57	:	O
58	0	O
59	)	O
60	lipids	O
61	were	O
62	not	O
63	bound	O
64	at	O
65	all	O
66	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	oasA2	O
9	gene	O
10	represents	O
11	a	O
12	pseudogene	O
13	that	B
14	is	I
15	still	I
16	transcribed	I
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O

1	The	O
2	measurement	B
3	of	I
4	the	I
5	areas	I
6	of	O
7	fibrin	O
8	,	O
9	of	O
10	tissue	O
11	and	O
12	fibrinolysis	O
13	,	O
14	at	O
15	the	O
16	above	O
17	mentioned	O
18	times	O
19	,	O
20	has	O
21	been	O
22	effected	O
23	at	O
24	standard	O
25	magnification	O
26	(	O
27	15	O
28	X	O
29	)	O
30	by	O
31	an	B
32	image	O
33	analyser	B
34	(	B
35	Videoplan	I
36	)	I
37	scale	O
38	1	O
39	:	I
40	8	I
41	.	O

1	A	O
2	critical	O
3	heart	O
4	rate	O
5	and	O
6	/	O
7	or	O
8	appropriate	O
9	sympathetic	O
10	state	O
11	was	O
12	found	O
13	to	O
14	provoke	O
15	all	O
16	instances	O
17	of	B
18	reentrant	B
19	or	I
20	automatic	O
21	atrial	B
22	tachycardia	B
23	and	I
24	atypical	I
25	junctional	O
26	tachycardia	O
27	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	concentrations	O
7	of	O
8	the	O
9	components	O
10	due	O
11	to	O
12	tobacco	O
13	smoke	O
14	are	O
15	:	O
16	CO	O
17	=	O
18	1	O
19	.	O
20	1	O
21	ppm	O
22	,	O
23	NO	O
24	=	O
25	32	O
26	ppb	O
27	,	O
28	NO2	O
29	=	O
30	24	O
31	ppb	B
32	,	I
33	nicotine	I
34	=	I
35	0	O
36	.	I
37	9	O
38	micrograms	O
39	/	O
40	m3	B
41	,	I
42	particulate	I
43	matter	I
44	=	I
45	133	O
46	micrograms	O
47	/	O
48	m3	O
49	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	promoter	O
7	and	O
8	enhancer	O
9	regions	O
10	identified	O
11	here	O
12	are	B
13	essential	I
14	for	I
15	maintaining	I
16	the	O
17	efficient	O
18	promoter	O
19	activity	O
20	of	O
21	the	O
22	human	O
23	activin	O
24	betaA	B
25	subunit	I
26	gene	O
27	.	B

1	Mammalian	O
2	ABPs	O
3	and	O
4	SHBGs	O
5	bind	O
6	sex	O
7	steroids	O
8	with	O
9	high	O
10	affinity	O
11	,	O
12	but	O
13	some	O
14	binding	O
15	properties	O
16	differ	O
17	among	O
18	species	O
19	.	O

1	TG	O
2	-	O
3	day	O
4	and	O
5	TG	O
6	-	O
7	night	O
8	were	B
9	19	I
10	.	I
11	4	I
12	+/-	O
13	6	O
14	.	O
15	1	O
16	%,	O
17	26	O
18	.	O
19	6	O
20	+/-	O
21	5	O
22	.	O
23	3	O
24	%,	B
25	(	B
26	750	I
27	mm3	O
28	<	I
29	T	O
30	.	O

1	All	O
2	mutant	O
3	JCV	O
4	T	O
5	antigens	O
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O

1	The	O
2	psychological	O
3	tests	O
4	consisted	O
5	of	O
6	a	O
7	free	O
8	-	B
9	recall	I
10	task	O
11	,	O
12	a	O
13	test	O
14	for	O
15	visuomotor	O
16	coordination	O
17	and	O
18	a	O
19	recognition	O
20	task	O
21	.	O

1	Primers	O
2	for	O
3	subsequent	O
4	rounds	O
5	of	O
6	RACE	O
7	were	O
8	designed	O
9	from	O
10	the	O
11	5	O
12	'-	O
13	ends	O
14	of	O
15	amplified	O
16	RACE	O
17	products	O
18	.	O

1	Human	O
2	isoforms	O
3	,	B
4	designated	I
5	1	I
6	to	I
7	4	I
8	,	I
9	differ	I
10	from	I
11	each	I
12	other	O
13	by	O
14	the	O
15	start	O
16	codon	B
17	used	I
18	.	I

1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	human	O
9	lactoferrin	O
10	gene	O
11	was	O
12	isolated	O
13	from	O
14	a	O
15	human	O
16	placental	O
17	genomic	O
18	library	O
19	.	O

1	Gene	O
2	constructs	O
3	possessing	O
4	the	O
5	complete	O
6	tat	O
7	,	O
8	rev	O
9	(	O
10	tat	O
11	+	O
12	rev	O
13	+)	O
14	and	O
15	env	O
16	genes	O
17	were	O
18	transiently	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	1	O
24	cells	O
25	as	O
26	precursor	O
27	SU	O
28	-	O
29	TM	O
30	(	O
31	gp160	O
32	),	O
33	SU	O
34	.	O
35	TM	O
36	(	O
37	gp120	O
38	x	O
39	41	O
40	),	O
41	and	O
42	nucleolar	O
43	rev	O
44	protein	O
45	.	O

1	ArgR	O
2	was	O
3	shown	O
4	to	O
5	be	O
6	a	O
7	dimer	O
8	of	O
9	two	O
10	equal	O
11	subunits	O
12	,	O
13	each	O
14	with	O
15	a	O
16	molecular	O
17	mass	O
18	of	O
19	37	O
20	,	O
21	000	O
22	Da	O
23	.	O

1	To	O
2	examine	O
3	whether	O
4	thiamine	O
5	(	O
6	vitamin	O
7	B1	O
8	)	O
9	deficiency	O
10	is	O
11	associated	O
12	with	O
13	recurrent	O
14	aphthous	O
15	stomatitis	O
16	,	O
17	we	O
18	studied	O
19	vitamin	O
20	B1	O
21	levels	O
22	in	O
23	70	O
24	patients	O
25	with	O
26	recurrent	O
27	aphthous	O
28	stomatitis	O
29	and	O
30	in	O
31	50	O
32	members	O
33	of	O
34	a	O
35	control	O
36	group	O
37	.	O

1	RESULTS	O
2	:	B
3	The	I
4	diagnostic	I
5	quality	I
6	of	O
7	FDG	O
8	images	O
9	was	O
10	at	O
11	least	O
12	as	O
13	good	O
14	as	O
15	that	O
16	of	O
17	their	O
18	Tl	O
19	-	O
20	201	O
21	counterparts	O
22	,	B
23	with	I
24	less	I
25	liver	O
26	background	B
27	in	B
28	all	I
29	but	I
30	one	I
31	FDG	O
32	study	B
33	.	B

1	The	O
2	major	O
3	PKC	O
4	beta	O
5	transcription	O
6	initiation	O
7	site	O
8	was	O
9	identified	O
10	by	O
11	primer	O
12	extension	B
13	and	I
14	S1	O
15	nuclease	O
16	protection	O
17	.	O

1	Effects	O
2	of	O
3	intramammary	O
4	endotoxin	O
5	infusion	O
6	on	O
7	milking	O
8	-	O
9	induced	O
10	oxytocin	O
11	release	O
12	.	O

1	On	O
2	the	O
3	third	O
4	occasion	O
5	water	O
6	(	O
7	W	O
8	)	O
9	was	O
10	ingested	B
11	throughout	I
12	the	O
13	run	O
14	.	O

1	Thyroid	O
2	function	O
3	tests	O
4	were	B
5	performed	I
6	on	I
7	300	I
8	admissions	I
9	,	I
10	leaving	I
11	707	I
12	untested	O
13	.	B

1	Accurate	O
2	evaluation	O
3	of	O
4	the	O
5	treatment	O
6	results	O
7	in	O
8	unresectable	O
9	lung	O
10	cancer	O
11	patients	O
12	must	O
13	take	O
14	the	O
15	strong	O
16	prognostic	O
17	factors	O
18	into	O
19	account	O
20	.	O

1	Abnormal	O
2	intrapulmonary	O
3	shunting	B
4	(	I
5	IPS	I
6	),	I
7	which	I
8	was	I
9	proved	O
10	in	I
11	4	I
12	cases	I
13	by	O
14	whole	O
15	-	O
16	body	O
17	radionuclide	O
18	scanning	O
19	with	O
20	99mTc	O
21	-	O
22	MAA	O
23	,	O
24	is	O
25	suggested	O
26	as	O
27	the	O
28	major	O
29	cause	O
30	of	O
31	cyanosis	O
32	in	O
33	liver	O
34	cirrhosis	B
35	.	I

1	Heat	O
2	-	O
3	inducible	O
4	CAT	O
5	activity	O
6	was	O
7	detectable	O
8	when	O
9	additional	O
10	sequences	O
11	from	O
12	the	O
13	native	O
14	promoter	O
15	containing	O
16	three	O
17	CCAAT	O
18	boxes	O
19	and	O
20	a	O
21	single	O
22	HSE	B
23	were	I
24	present	I
25	in	O
26	the	O
27	constructions	O
28	.	O

1	The	O
2	observation	O
3	that	O
4	beta	O
5	2m	O
6	with	O
7	covalently	O
8	attached	O
9	peptide	O
10	can	O
11	effectively	O
12	create	O
13	CTL	O
14	target	O
15	structures	O
16	in	O
17	vitro	O
18	offers	O
19	new	O
20	possibilities	O
21	for	O
22	the	O
23	in	O
24	vivo	O
25	induction	O
26	of	O
27	epitope	O
28	-	O
29	specific	O
30	CTL	O
31	responses	O
32	by	O
33	either	O
34	DNA	O
35	immunization	O
36	or	O
37	injection	O
38	of	O
39	the	O
40	purified	O
41	epitope	O
42	-	O
43	linked	O
44	beta	O
45	2m	O
46	.	O

1	Cyclin	O
2	G2	O
3	is	O
4	highly	O
5	expressed	O
6	in	O
7	the	O
8	immune	O
9	system	O
10	where	O
11	immunologic	O
12	tolerance	O
13	subjects	O
14	self	O
15	-	O
16	reactive	O
17	lymphocytes	O
18	to	O
19	negative	O
20	selection	O
21	and	O
22	clonal	O
23	deletion	O
24	via	O
25	apoptosis	O
26	.	O

1	Transcription	O
2	of	O
3	the	O
4	gene	O
5	for	O
6	ivanolysin	O
7	O	O
8	and	O
9	expression	O
10	of	O
11	other	O
12	genes	O
13	of	O
14	the	O
15	virulence	O
16	gene	O
17	cluster	O
18	in	O
19	L	O
20	.	O
21	ivanovii	O
22	were	O
23	dependent	O
24	on	O
25	PrfA	O
26	.	O

1	The	O
2	Ets	O
3	-	O
4	1	O
5	binding	O
6	site	O
7	was	O
8	localized	O
9	to	O
10	a	O
11	17	B
12	-	I
13	base	I
14	pair	I
15	(	I
16	bp	I
17	)	I
18	region	O
19	from	O
20	the	O
21	3	O
22	'	O
23	end	O
24	of	O
25	T	O
26	alpha	O
27	2	O
28	.	O

1	Ovarian	O
2	tumors	O
3	in	O
4	pregnancy	O
5	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	evaluated	O
5	by	O
6	exercise	O
7	stress	O
8	thallium	O
9	-	O
10	201	O
11	myocardial	O
12	scintigraphy	O
13	:	O
14	a	O
15	comparison	O
16	of	O
17	SPECT	O
18	and	O
19	bull	O
20	'	O
21	s	O
22	eye	O
23	display	O

1	Increased	O
2	dietary	O
3	energy	O
4	decreased	O
5	PAB	O
6	and	O
7	the	O
8	use	O
9	of	O
10	added	O
11	dietary	O
12	CO	O
13	rather	O
14	than	O
15	PF	O
16	decreased	O
17	PSHL	O
18	in	O
19	broiler	O
20	breeders	O
21	between	O
22	26	O
23	and	O
24	47	O
25	wk	O
26	of	O
27	age	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	Rho	O
5	on	O
6	AP	O
7	-	O
8	1	O
9	is	O
10	independent	O
11	of	O
12	the	O
13	mitogen	O
14	-	O
15	activated	O
16	protein	O
17	kinase	O
18	pathway	O
19	,	O
20	as	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	MEK	O
26	and	O
27	a	O
28	MEK	O
29	inhibitor	O
30	(	O
31	PD98059	O
32	)	O
33	did	O
34	not	O
35	affect	O
36	Rho	B
37	-	I
38	induced	I
39	AP	I
40	-	I
41	1	O
42	activity	O
43	.	B

1	In	O
2	addition	O
3	,	O
4	anti	O
5	-	O
6	phosphotyrosine	O
7	antibodies	O
8	immunoprecipitated	O
9	80K	O
10	-	O
11	H	O
12	from	O
13	cell	O
14	lysates	O
15	of	O
16	FGF	O
17	-	O
18	stimulated	O
19	but	O
20	not	O
21	from	O
22	control	O
23	fibroblasts	O
24	.	O

1	RESULTS	O
2	:	O
3	Plasma	O
4	AVP	O
5	responses	O
6	to	O
7	osmotic	O
8	stimulation	O
9	,	O
10	and	O
11	non	O
12	-	O
13	osmotic	O
14	inhibition	O
15	by	O
16	drinking	O
17	,	O
18	were	O
19	normal	O
20	in	O
21	patients	O
22	with	O
23	compulsive	O
24	water	O
25	drinking	O
26	.	O

1	Taste	O
2	reactivity	O
3	tests	O
4	were	O
5	used	O
6	to	O
7	examine	O
8	the	O
9	orofacial	O
10	responses	O
11	of	O
12	alcohol	O
13	preferring	O
14	(	O
15	P	O
16	)	O
17	rats	O
18	and	O
19	alcohol	O
20	nonpreferring	O
21	(	O
22	NP	O
23	)	O
24	rats	O
25	to	O
26	the	O
27	taste	O
28	of	O
29	alcohol	O
30	.	O

1	These	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	majority	O
8	of	O
9	tested	O
10	staphylococci	O
11	were	O
12	resistant	O
13	to	O
14	penicillin	O
15	G	O
16	,	O
17	erythromycin	O
18	,	O
19	and	O
20	produced	O
21	beta	O
22	-	O
23	lactamase	O
24	.	O

1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	B
7	MHC	I
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O

1	According	O
2	to	O
3	Sugiura	O
4	'	O
5	s	O
6	classification	O
7	,	O
8	they	O
9	consisted	O
10	of	O
11	Type	O
12	Ia	O
13	in	B
14	63	B
15	%,	I
16	Type	I
17	Ib	O
18	in	O
19	11	B
20	%,	I
21	Type	I
22	II	O
23	in	O
24	11	O
25	%,	O
26	and	O
27	Type	O
28	III	O
29	in	O
30	16	O
31	%.	O

1	The	O
2	sequencing	B
3	of	I
4	the	O
5	conditional	O
6	lethal	O
7	mutation	O
8	ts	O
9	-	O
10	A13	O
11	,	O
12	localized	O
13	in	O
14	the	O
15	nrdE	O
16	cistron	O
17	,	O
18	and	O
19	the	O
20	lethality	O
21	of	O
22	insertional	O
23	mutations	O
24	targeted	O
25	in	O
26	the	O
27	internal	O
28	region	O
29	of	O
30	nrdE	O
31	and	O
32	nrdF	O
33	,	O
34	demonstrated	B
35	the	O
36	essential	O
37	role	O
38	of	O
39	this	I
40	locus	O
41	.	O

1	Histochemistry	O
2	and	O
3	electron	O
4	microscopy	O
5	of	O
6	acute	O
7	liver	O
8	lesions	O
9	induced	O
10	by	O
11	Aflatoxin	O
12	B1	O
13	in	O
14	ducklings	O
15	.	O

1	In	O
2	earlier	O
3	studies	O
4	we	O
5	identified	O
6	several	O
7	regulatory	O
8	elements	O
9	that	O
10	control	O
11	transcriptional	O
12	activation	O
13	and	O
14	aerobic	O
15	repression	O
16	of	O
17	one	O
18	of	O
19	these	O
20	genes	O
21	,	O
22	COX5b	O
23	.	O

1	Cardiovascular	O
2	and	O
3	adrenal	O
4	medullo	O
5	-	O
6	sympathetic	O
7	reactions	O
8	to	O
9	acute	O
10	tobacco	O
11	poisoning	O

1	Angiographic	O
2	work	O
3	-	O
4	up	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	late	O
10	vaginal	O
11	metastasis	O
12	from	O
13	a	O
14	renal	O
15	carcinoma	O
16	.	O

1	This	O
2	protein	O
3	encoded	O
4	by	O
5	this	O
6	cDNA	O
7	,	O
8	which	O
9	we	O
10	have	O
11	termed	O
12	p150TSP	O
13	(	O
14	for	O
15	TPR	O
16	-	O
17	containing	O
18	,	O
19	SH2	O
20	-	O
21	binding	O
22	phosphoprotein	O
23	),	O
24	is	O
25	located	O
26	predominantly	O
27	in	O
28	the	O
29	nucleus	O
30	and	O
31	is	O
32	highly	O
33	conserved	O
34	in	O
35	evolution	O
36	.	O

1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	O
9	binding	O
10	site	O
11	II	O
12	sequence	I
13	that	I
14	was	O
15	required	I
16	for	B
17	this	I
18	regulation	I
19	.	I

1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	spindle	O
5	pole	O
6	body	O
7	duplication	O
8	gene	O
9	MPS1	O
10	is	O
11	part	O
12	of	O
13	a	O
14	mitotic	O
15	checkpoint	O
16	.	O

1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	Ft	O
9	')	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	Fm	O
16	').	O

1	We	O
2	have	O
3	now	O
4	identified	O
5	,	O
6	after	O
7	21	O
8	serial	O
9	undiluted	O
10	passages	O
11	of	O
12	MHV	O
13	,	O
14	a	O
15	small	O
16	DI	O
17	RNA	O
18	,	O
19	DIssF	O
20	,	O
21	which	O
22	is	O
23	efficiently	O
24	packaged	O
25	into	O
26	virions	O
27	.	O

1	In	O
2	marked	O
3	contrast	O
4	to	O
5	AgfA	O
6	,	O
7	none	B
8	of	I
9	the	I
10	chimeric	O
11	SefA	O
12	proteins	O
13	were	O
14	expressed	O
15	or	O
16	assembled	O
17	into	O
18	fimbriae	O
19	.	O

1	By	O
2	using	O
3	reporter	O
4	gene	O
5	constructs	O
6	,	O
7	it	O
8	is	O
9	shown	O
10	that	O
11	upstream	O
12	sequences	O
13	of	O
14	the	O
15	P1	O
16	promoter	O
17	contain	O
18	several	O
19	regions	O
20	that	O
21	modulate	O
22	the	O
23	expression	O
24	either	O
25	positively	O
26	or	O
27	negatively	O
28	.	O

1	The	O
2	opioid	O
3	antagonist	O
4	naltrexone	O
5	(	O
6	0	O
7	.	O
8	01	O
9	-	O
10	1	O
11	.	O
12	0	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	antagonized	O
18	the	O
19	discriminative	O
20	stimulus	O
21	effects	O
22	of	O
23	heroin	O
24	,	O
25	but	O
26	naltrexone	O
27	at	O
28	doses	O
29	up	O
30	to	O
31	10	O
32	mg	O
33	/	O
34	kg	O
35	had	O
36	no	O
37	effect	O
38	on	O
39	the	O
40	discriminative	O
41	stimulus	O
42	effects	O
43	of	O
44	cocaine	O
45	.	O

1	Alanine	O
2	aminotransferase	O
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	Binding	O
2	to	O
3	sulphatides	O
4	and	O
5	the	O
6	alpha	O
7	-	O
8	dystroglycan	O
9	receptor	O
10	was	O
11	much	O
12	stronger	O
13	and	O
14	required	O
15	at	O
16	least	O
17	two	O
18	LG	O
19	modules	O
20	.	O

1	Our	O
2	laboratory	O
3	has	O
4	recently	O
5	identified	O
6	two	O
7	phosducin	O
8	-	O
9	like	O
10	orphan	O
11	proteins	O
12	(	O
13	PhLOP1	O
14	and	O
15	PhLOP2	O
16	)	O
17	that	O
18	lack	O
19	the	O
20	ability	O
21	to	O
22	interact	O
23	with	O
24	Gbetagamma	O
25	.	O

1	Using	O
2	the	O
3	yeast	O
4	two	O
5	-	O
6	hybrid	O
7	system	O
8	to	O
9	screen	O
10	for	O
11	proteins	O
12	which	O
13	interact	O
14	with	O
15	Tax1	O
16	,	O
17	we	O
18	isolated	O
19	the	O
20	B	O
21	subunit	O
22	of	O
23	the	O
24	CCAAT	O
25	binding	O
26	protein	O
27	NF	O
28	-	O
29	Y	O
30	from	O
31	a	O
32	HeLa	O
33	cDNA	O
34	library	O
35	.	O

1	There	O
2	was	O
3	a	O
4	general	O
5	broadening	B
6	of	I
7	proton	O
8	resonances	B
9	for	I
10	a	O
11	three	O
12	-	O
13	nucleotide	O
14	segment	O
15	centered	O
16	about	O
17	the	O
18	lesion	O
19	site	O
20	which	O
21	resulted	O
22	in	O
23	a	O
24	tentative	O
25	assignment	O
26	for	O
27	the	O
28	sugar	O
29	protons	O
30	of	O
31	the	O
32	C7	O
33	residue	O
34	in	O
35	the	O
36	spectrum	O
37	of	O
38	the	B
39	adduct	O
40	duplex	O
41	.	B

1	The	O
2	magnitude	O
3	of	O
4	the	O
5	early	O
6	response	B
7	was	I
8	241	I
9	+/-	O
10	51	O
11	%	O
12	in	O
13	A	O
14	(%	O
15	baseline	O
16	RL	O
17	;	O
18	mean	O
19	+/-	O
20	SE	O
21	),	O
22	and	O
23	significantly	O
24	less	O
25	in	O
26	B	O
27	(	O
28	119	O
29	+/-	O
30	7	O
31	%)	O
32	and	O
33	C	O
34	(	O
35	131	O
36	+/-	O
37	16	O
38	%)	O
39	(	O
40	p	O
41	<	O
42	0	B
43	.	B
44	01	O
45	).	O

1	Two	O
2	of	B
3	the	I
4	three	I
5	groups	O
6	were	O
7	administered	O
8	dauricine	O
9	,	O
10	as	O
11	a	O
12	new	O
13	calcium	O
14	channel	O
15	blocker	O
16	,	O
17	and	O
18	verapamil	O
19	,	O
20	as	O
21	a	O
22	generally	O
23	recognized	O
24	calcium	O
25	channel	O
26	blocker	O
27	,	O
28	respectively	O
29	,	O
30	from	O
31	15	O
32	minutes	O
33	pre	O
34	-	O
35	bypass	O
36	to	O
37	the	O
38	end	B
39	of	I
40	the	O
41	bypass	O
42	procedure	B
43	(	O
44	a	O
45	period	O
46	of	O
47	95	B
48	minutes	O
49	).	O

1	A	O
2	16	O
3	-	O
4	year	O
5	follow	O
6	-	O
7	up	O
8	study	O
9	of	O
10	69	O
11	paraplegics	O
12	with	O
13	complete	O
14	lesions	O
15	from	O
16	T1	O
17	-	O
18	L3	O
19	is	O
20	presented	O
21	.	O

1	HRES	O
2	has	O
3	been	O
4	found	O
5	to	O
6	be	O
7	clinically	O
8	useful	O
9	in	O
10	assessing	O
11	histologic	B
12	damage	I
13	following	I
14	pneumatic	O
15	dilatation	B
16	and	I
17	in	I
18	localizing	I
19	the	O
20	LES	O
21	during	O
22	the	O
23	administration	O
24	of	O
25	intrasphincter	O
26	botulinum	O
27	toxin	O
28	injection	O
29	in	O
30	the	O
31	treatment	O
32	of	O
33	achalasia	O
34	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	cDNA	O
6	encoding	O
7	rat	O
8	NADH	O
9	-	O
10	cytochrome	O
11	b5	O
12	reductase	O
13	and	O
14	the	O
15	corresponding	O
16	gene	O
17	.	O

1	As	O
2	demonstrated	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	analysis	O
8	and	O
9	supershift	O
10	experiments	O
11	,	O
12	FIRE1	O
13	,	O
14	located	O
15	between	O
16	-	O
17	516	O
18	and	O
19	-	O
20	498	O
21	,	O
22	is	O
23	responsible	O
24	for	O
25	binding	O
26	NF	O
27	-	O
28	Y	O
29	.	O

1	On	O
2	the	O
3	comparison	B
4	of	I
5	correlated	I
6	proportions	I
7	for	O
8	clustered	O
9	data	O
10	.	O

1	To	O
2	test	O
3	whether	O
4	Sp1	O
5	and	O
6	zif268	O
7	/	O
8	egr	O
9	-	B
10	1	I
11	interact	I
12	with	I
13	this	I
14	motif	I
15	,	I
16	gel	I
17	retardation	I
18	assays	I
19	were	O
20	performed	O
21	.	O

1	Nucleotide	O
2	sequences	O
3	between	O
4	the	O
5	env	O
6	gene	O
7	and	O
8	the	O
9	LTR	O
10	of	O
11	SFV	O
12	-	O
13	1	O
14	were	O
15	determined	O
16	.	O

1	A	O
2	.,	O
3	Swift	O
4	,	O
5	A	O
6	.	O

1	In	O
2	cerebrospinal	O
3	fluid	O
4	,	O
5	an	O
6	ADA	O
7	catalytic	O
8	concentration	O
9	above	O
10	0	O
11	.	O
12	15	O
13	mu	O
14	kat	O
15	/	O
16	L	O
17	strongly	O
18	suggests	O
19	tuberculous	O
20	meningitis	O
21	in	O
22	patients	O
23	older	O
24	than	O
25	7	O
26	years	O
27	(	O
28	sensitivity	O
29	1	O
30	.	O
31	00	O
32	,	O
33	specificity	O
34	0	O
35	.	O
36	99	O
37	and	O
38	efficiency	O
39	0	O
40	.	O
41	99	O
42	).	O

1	This	O
2	domain	B
3	,	I
4	although	I
5	adjacent	I
6	to	I
7	the	I
8	5	I
9	'	O
10	edge	O
11	of	O
12	the	O
13	SD	O
14	sequence	O
15	,	O
16	does	O
17	not	B
18	inhibit	I
19	ribosome	I
20	binding	I
21	as	I
22	long	I
23	as	I
24	the	O
25	single	B
26	-	O
27	stranded	O
28	region	O
29	of	O
30	domain	O
31	3	O
32	is	O
33	present	O
34	.	B

1	It	O
2	is	O
3	likely	O
4	that	O
5	other	O
6	pathways	O
7	involve	O
8	alternate	O
9	signal	O
10	transduction	O
11	events	O
12	(	O
13	e	O
14	.	O
15	g	O
16	.,	O
17	calcium	O
18	mobilization	O
19	)	O
20	and	O
21	promoter	O
22	response	O
23	elements	O
24	(	O
25	e	O
26	.	O
27	g	O
28	.,	O
29	SRE	O
30	).	O

1	It	O
2	is	O
3	likely	O
4	that	O
5	the	O
6	sequence	O
7	similarities	O
8	reflect	O
9	a	O
10	common	O
11	molecular	O
12	architecture	O
13	of	O
14	the	O
15	two	O
16	heme	B
17	binding	I
18	sites	I
19	and	I
20	of	I
21	a	I
22	copper	I
23	binding	O
24	site	O
25	in	O
26	these	O
27	enzymes	O
28	.	O

1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	O
11	B	O
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	O
19	immunodeficiency	O
20	virus	O
21	long	O
22	terminal	O
23	repeat	O
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	endometriosis	O
8	increases	O
9	soluble	O
10	CD23	O
11	levels	O
12	,	O
13	which	O
14	can	O
15	be	O
16	suppressed	O
17	with	O
18	either	O
19	danazol	O
20	or	O
21	leuprolide	O
22	acetate	O
23	injection	O
24	.	O

1	Consistent	O
2	with	O
3	the	O
4	in	O
5	vivo	O
6	result	O
7	,	O
8	the	O
9	pseudorevertant	O
10	endonucleases	O
11	in	O
12	the	O
13	crude	O
14	cell	O
15	extract	O
16	display	O
17	site	O
18	-	O
19	specific	O
20	partial	O
21	DNA	O
22	cleavage	O
23	activity	O
24	.	O

1	Natl	O
2	.	O

1	The	O
2	pCMBS	O
3	-	O
4	reactive	O
5	sulfhydryl	O
6	groups	B
7	were	I
8	located	I
9	exclusively	I
10	in	I
11	the	I
12	exofacial	I
13	half	I
14	of	O
15	the	O
16	plasma	B
17	membrane	I
18	and	I
19	,	I
20	when	I
21	presented	I
22	in	I
23	a	I
24	helical	I
25	model	I
26	,	I
27	lie	I
28	along	I
29	one	I
30	side	O
31	of	B
32	the	I
33	helices	O
34	.	O

1	A	O
2	stochastic	O
3	version	O
4	of	O
5	Kernell	O
6	'	B
7	s	I
8	(	I
9	1968	I
10	,	I
11	1972	O
12	)	O
13	model	I
14	with	I
15	cumulative	I
16	afterhyperpolarization	O
17	(	O
18	AHP	O
19	)	I
20	was	O
21	simulated	B
22	.	I

1	The	O
2	PAC	O
3	clone	O
4	with	O
5	an	O
6	insert	O
7	size	O
8	of	O
9	120kb	O
10	was	O
11	isolated	O
12	and	O
13	mapped	O
14	by	O
15	restriction	O
16	analysis	O
17	.	B

1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	O
18	-	O
19	1	O
20	treatment	O
21	.	O

1	Isomers	O
2	were	O
3	differentiated	O
4	based	O
5	on	O
6	the	O
7	MS	O
8	-	O
9	MS	O
10	data	O
11	of	O
12	the	O
13	trofluoroacetyl	O
14	-	O
15	biphenylol	O
16	derivatives	O
17	.	O

1	UAS1	O
2	is	O
3	the	O
4	binding	O
5	site	O
6	for	O
7	the	O
8	transcriptional	O
9	regulator	O
10	Adr1p	O
11	.	O

1	Since	O
2	GAGs	O
3	are	O
4	the	O
5	components	O
6	of	O
7	cartilage	O
8	matrix	O
9	,	O
10	the	O
11	depletion	O
12	of	O
13	which	O
14	is	O
15	associated	O
16	with	O
17	osteoarthrosis	O
18	,	O
19	a	O
20	method	O
21	for	O
22	measuring	O
23	sulphated	O
24	GAG	O
25	synthesis	O
26	in	O
27	culture	O
28	has	O
29	been	O
30	investigated	O
31	.	O

1	Unified	O
2	theory	O
3	of	O
4	segregated	O
5	-	O
6	stack	O
7	organic	O
8	charge	O
9	-	O
10	transfer	B
11	solids	I
12	:	I
13	Magnetic	I
14	properties	I
15	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	these	O
6	results	O
7	may	O
8	raise	O
9	the	O
10	interesting	O
11	possibility	O
12	of	O
13	providing	O
14	a	O
15	means	O
16	of	O
17	identifying	O
18	greater	O
19	or	O
20	lesser	O
21	susceptibility	O
22	to	O
23	the	O
24	coronary	O
25	effects	O
26	of	O
27	Type	O
28	A	O
29	behavior	O
30	.	O

1	However	O
2	,	O
3	at	O
4	18	O
5	months	O
6	of	O
7	age	O
8	,	O
9	significantly	O
10	higher	I
11	levels	I
12	of	I
13	IgG1	I
14	(	I
15	P	I
16	less	I
17	than	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	of	O
24	IgG4	B
25	(	O
26	P	B
27	less	I
28	than	O
29	0	O
30	.	O
31	01	O
32	)	O
33	were	O
34	found	O
35	in	O
36	infants	O
37	with	O
38	an	O
39	elevated	O
40	IgE	O
41	(	O
42	greater	O
43	than	O
44	or	O
45	equal	I
46	to	I
47	8	I
48	.	I
49	0	O
50	kU	I
51	/	I
52	l	O
53	)	O
54	than	O
55	in	O
56	those	O
57	with	O
58	a	O
59	lower	O
60	level	O
61	.	I

1	31	O
2	,	O
3	1997	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	ERA	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	ERA	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O

1	LMP2A	O
2	enhances	O
3	Lyn	O
4	and	O
5	Syk	O
6	ubiquitination	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	Nedd4	O
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	B
24	destabilization	I
25	of	I
26	the	O
27	Lyn	O
28	tyrosine	O
29	kinase	O
30	.	O

1	Liver	O
2	transplantation	O
3	in	O
4	one	O
5	patient	O
6	resolved	O
7	metabolic	O
8	complications	O
9	but	O
10	did	O
11	not	O
12	improve	O
13	PMN	O
14	count	O
15	or	O
16	the	B
17	infectious	O
18	status	O
19	,	O
20	while	O
21	neutropenia	O
22	was	O
23	corrected	O
24	by	O
25	G	O
26	-	O
27	CSF	O
28	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	ATF	O
9	family	O
10	are	B
11	involved	I
12	in	I
13	mediating	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	the	O
19	KGF	B
20	gene	I
21	in	I
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	via	O
27	a	B
28	novel	I
29	CRE	I
30	regulatory	I
31	element	I
32	.	O

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	Many	O
2	children	O
3	with	O
4	BGC	O
5	are	O
6	delayed	O
7	in	O
8	their	O
9	development	O
10	,	O
11	but	O
12	calcifications	O
13	are	O
14	not	O
15	directly	O
16	related	O
17	to	O
18	specific	O
19	forms	O
20	of	O
21	neurologic	O
22	dysfunction	O
23	.	O

1	Exogenous	O
2	LHRH	O
3	is	B
4	also	I
5	known	I
6	to	I
7	facilitate	O
8	mating	O
9	behavior	O
10	in	O
11	several	O
12	species	O
13	.	O

1	The	O
2	rates	O
3	of	O
4	total	O
5	energy	O
6	use	O
7	(	O
8	mean	O
9	+/-	O
10	SD	O
11	=	O
12	39	O
13	.	O
14	3	O
15	+/-	O
16	1	O
17	.	O
18	2	O
19	vs	O
20	35	O
21	.	O
22	7	O
23	+/-	O
24	1	O
25	.	O
26	3	O
27	kJ	O
28	X	O
29	min	O
30	-	O
31	1	O
32	;	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	)	O
40	were	O
41	significantly	O
42	higher	O
43	at	O
44	-	O
45	10	O
46	degrees	O
47	C	O
48	than	O
49	at	O
50	22	O
51	degrees	O
52	C	O
53	.	O

1	Innervation	O
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O

1	In	O
2	on	B
3	-	I
4	going	I
5	screening	I
6	programmes	I
7	,	I
8	the	I
9	Haemoccult	I
10	test	I
11	consists	I
12	of	I
13	six	I
14	slides	I
15	and	O
16	a	O
17	test	O
18	is	O
19	considered	O
20	positive	O
21	if	B
22	at	I
23	least	I
24	one	O
25	slide	O
26	is	O
27	coloured	O
28	.	O

1	Finally	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	C	O
7	/	O
8	EBP	O
9	alpha	O
10	can	O
11	also	O
12	active	O
13	the	O
14	GM	O
15	-	O
16	CSF	O
17	receptor	O
18	alpha	O
19	promoter	O
20	in	O
21	nonmyeloid	O
22	cells	O
23	.	O

1	A	O
2	technique	O
3	for	O
4	thermal	O
5	imaging	O
6	of	O
7	the	O
8	animal	B
9	and	I
10	human	O
11	brain	B
12	cortex	I
13	using	O
14	an	B
15	infrared	I
16	optical	O
17	system	B
18	is	I
19	described	I
20	.	O

1	Men	O
2	were	O
3	more	O
4	positive	O
5	about	O
6	their	O
7	physical	O
8	fitness	O
9	than	O
10	women	O
11	.	O

1	Cotransfection	O
2	of	O
3	the	O
4	coactivator	O
5	CREB	O
6	-	O
7	binding	B
8	protein	I
9	relieved	I
10	the	I
11	transcriptional	I
12	repression	I
13	of	I
14	PPARalphawt	O
15	by	O
16	PPARalphatr	O
17	,	O
18	suggesting	O
19	that	O
20	the	O
21	dominant	O
22	negative	O
23	effect	O
24	of	O
25	PPARalphatr	O
26	might	O
27	occur	O
28	through	O
29	competition	O
30	for	O
31	essential	O
32	coactivators	O
33	.	O

1	Mouse	O
2	growth	O
3	hormone	O
4	transcription	O
5	factor	O
6	Zn	O
7	-	O
8	16	O
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	O
23	Zn	O
24	-	O
25	15	O
26	.	O

1	During	O
2	both	O
3	encephalopathy	O
4	episodes	O
5	,	O
6	CSF	O
7	protein	O
8	and	O
9	immunoglobulin	O
10	G	O
11	(	O
12	IgG	O
13	)	O
14	levels	O
15	were	O
16	elevated	O
17	without	O
18	an	O
19	increased	O
20	IgG	O
21	index	O
22	or	O
23	IgG	O
24	synthesis	O
25	rate	O
26	.	O

1	In	O
2	assays	O
3	with	B
4	purified	I
5	enzymes	I
6	,	I
7	wild	I
8	-	I
9	type	I
10	but	I
11	not	I
12	PTPS	I
13	-	I
14	S19A	I
15	was	O
16	a	O
17	specific	O
18	substrate	O
19	for	O
20	the	O
21	cGMP	O
22	-	O
23	dependent	O
24	protein	B
25	kinase	I
26	(	I
27	cGK	I
28	)	I
29	type	I
30	I	I
31	and	I
32	II	O
33	.	O

1	However	O
2	,	O
3	three	O
4	Hm1	O
5	mutants	O
6	that	O
7	were	O
8	moderately	O
9	deficient	O
10	in	O
11	stimulating	O
12	PI	O
13	turnover	O
14	displayed	O
15	normal	O
16	sequestration	O
17	,	O
18	suggesting	O
19	distinct	O
20	mechanisms	O
21	.	O

1	Five	O
2	additional	O
3	copies	O
4	of	O
5	Lian	O
6	elements	O
7	were	O
8	isolated	O
9	,	O
10	mapped	O
11	by	O
12	restriction	O
13	digestion	O
14	,	O
15	and	O
16	partially	O
17	sequenced	O
18	.	O

1	A	O
2	given	O
3	standard	O
4	input	O
5	function	O
6	and	O
7	a	O
8	given	O
9	value	O
10	of	O
11	distribution	O
12	volume	O
13	(	O
14	Vd	O
15	)	O
16	used	O
17	for	O
18	the	O
19	rCBF	O
20	measurement	O
21	of	O
22	this	B
23	method	I
24	were	I
25	calculated	I
26	from	I
27	the	I
28	dynamic	I
29	study	I
30	by	O
31	six	O
32	normal	O
33	volunteers	O
34	.	O

1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	O
11	guanine	O
12	nucleotide	O
13	exchange	O
14	factors	O
15	or	O
16	GTPase	O
17	-	O
18	activating	B
19	proteins	I
20	in	I
21	the	O
22	c	O
23	-	O
24	cbl	O
25	gene	O
26	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	new	O
6	experiment	O
7	in	O
8	which	O
9	the	O
10	deletion	O
11	task	O
12	was	O
13	presented	O
14	as	O
15	a	O
16	puppet	O
17	game	O
18	,	O
19	and	O
20	with	O
21	pretraining	O
22	and	O
23	selection	O
24	on	O
25	vowel	O
26	deletion	O
27	,	O
28	a	O
29	significantly	O
30	higher	O
31	level	O
32	of	O
33	success	O
34	was	O
35	achieved	O
36	by	O
37	the	O
38	children	O
39	working	O
40	with	O
41	the	O
42	CVCC	O
43	material	O
44	.	O

1	Stress	O
2	-	O
3	activated	O
4	protein	O
5	kinase	O
6	1	O
7	(	O
8	SAPK1	O
9	),	O
10	also	O
11	called	O
12	c	O
13	-	O
14	Jun	O
15	N	O
16	-	O
17	terminal	O
18	kinase	O
19	(	O
20	JNK	O
21	),	O
22	becomes	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	stresses	O
36	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	phosphoinositide	O
6	3	O
7	-	O
8	kinase	O
9	with	O
10	a	O
11	C2	O
12	domain	O
13	that	O
14	displays	O
15	reduced	O
16	sensitivity	O
17	to	O
18	the	O
19	inhibitor	O
20	wortmannin	O
21	.	O

1	Expression	O
2	of	O
3	neuronal	O
4	traits	O
5	in	O
6	pancreatic	O
7	beta	O
8	cells	O
9	.	O

1	Therefore	O
2	,	O
3	it	O
4	was	O
5	concluded	O
6	that	O
7	thrombotic	O
8	tendency	O
9	certainly	O
10	existed	O
11	in	O
12	patients	O
13	with	O
14	MS	O
15	compared	O
16	to	O
17	those	O
18	with	O
19	non	O
20	RHD	O
21	and	O
22	that	O
23	it	O
24	was	O
25	one	O
26	of	O
27	the	O
28	causes	O
29	of	O
30	the	O
31	significantly	O
32	high	O
33	incidence	O
34	of	O
35	thromboembolism	O
36	in	O
37	comparison	O
38	with	O
39	non	O
40	RHD	O
41	.	O

1	BRCA1	O
2	protein	O
3	contains	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	zinc	O
9	finger	O
10	motif	O
11	and	O
12	a	O
13	carboxy	O
14	-	O
15	terminal	O
16	acidic	O
17	region	O
18	.	B

1	CONCLUSIONS	O
2	:	O
3	Valproate	O
4	appears	O
5	to	O
6	inhibit	O
7	the	O
8	glucuronidation	B
9	of	I
10	carbamazepine	I
11	-	I
12	10	O
13	,	O
14	11	O
15	-	O
16	trans	O
17	-	O
18	diol	O
19	,	O
20	and	O
21	probably	O
22	also	O
23	inhibits	O
24	the	O
25	conversion	O
26	of	O
27	carbamazepine	O
28	-	O
29	10	O
30	,	O
31	11	O
32	-	O
33	epoxide	O
34	to	O
35	this	O
36	trans	O
37	-	O
38	diol	O
39	derivative	O
40	,	O
41	rather	O
42	than	O
43	simply	O
44	inhibiting	O
45	the	O
46	latter	O
47	reaction	O
48	only	B
49	.	I

1	The	O
2	p53	O
3	tumor	O
4	suppressor	O
5	gene	O
6	product	O
7	,	O
8	a	O
9	sequence	O
10	-	O
11	specific	O
12	DNA	O
13	-	O
14	binding	O
15	protein	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	act	O
22	as	O
23	a	O
24	transcriptional	O
25	activator	O
26	and	O
27	repressor	O
28	both	O
29	in	O
30	vitro	O
31	and	O
32	in	O
33	vivo	O
34	.	O

1	These	O
2	regions	O
3	contain	O
4	inverted	O
5	E	O
6	-	O
7	box	O
8	palindromic	O
9	or	O
10	direct	O
11	repeat	O
12	motifs	O
13	and	O
14	bind	O
15	SREBP	O
16	-	O
17	1	O
18	with	O
19	different	O
20	affinities	O
21	.	O

1	Volume	O
2	of	O
3	distribution	O
4	of	O
5	total	O
6	DMDZ	O
7	(	O
8	range	O
9	,	O
10	1	O
11	.	O
12	33	O
13	to	O
14	6	O
15	.	O
16	30	O
17	l	O
18	/	O
19	kg	O
20	)	O
21	and	O
22	of	O
23	unbound	O
24	DMDZ	O
25	after	O
26	correction	O
27	for	O
28	protein	O
29	binding	O
30	(	O
31	range	O
32	,	O
33	43	O
34	to	O
35	243	O
36	l	O
37	/	O
38	kg	O
39	)	O
40	was	O
41	larger	O
42	in	O
43	women	O
44	than	O
45	in	O
46	men	O
47	of	O
48	all	O
49	ages	O
50	,	O
51	and	O
52	in	O
53	the	O
54	elderly	O
55	as	O
56	opposed	O
57	to	O
58	the	O
59	young	O
60	.	O

1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	O
12	interaction	B
13	.	I

1	To	O
2	assess	O
3	the	O
4	function	O
5	(	O
6	s	O
7	)	O
8	of	O
9	E74	O
10	during	O
11	metamorphosis	O
12	,	O
13	we	O
14	have	O
15	isolated	O
16	and	O
17	characterized	O
18	recessive	O
19	loss	O
20	-	O
21	of	O
22	-	O
23	function	O
24	mutations	O
25	specific	O
26	to	O
27	each	O
28	transcription	O
29	unit	O
30	.	O

1	The	O
2	'	O
3	Newcastle	B
4	'	I
5	model	I
6	,	I
7	which	I
8	is	I
9	based	I
10	on	O
11	Hotelling	O
12	'	O
13	s	O
14	T2	O
15	statistic	O
16	,	O
17	proved	O
18	to	O
19	be	O
20	more	O
21	sensitive	O
22	and	O
23	diagnosed	O
24	a	O
25	systematic	O
26	displacement	O
27	for	O
28	three	O
29	prostate	O
30	patients	O
31	.	O

1	Mutation	O
2	of	O
3	the	O
4	P450BM	O
5	-	O
6	3	O
7	Barbie	O
8	box	O
9	significantly	O
10	increased	O
11	the	O
12	expression	O
13	of	O
14	both	O
15	P450BM	O
16	-	O
17	3	O
18	and	O
19	Bm3P1	O
20	(	O
21	another	O
22	small	O
23	gene	B
24	located	I
25	upstream	I
26	of	I
27	the	I
28	P450BM	I
29	-	O
30	3	O
31	gene	O
32	that	O
33	encodes	O
34	a	O
35	second	O
36	putative	O
37	regulatory	O
38	protein	O
39	)	O
40	in	O
41	response	O
42	to	O
43	pentobarbital	O
44	induction	O
45	but	O
46	left	O
47	the	O
48	basal	O
49	levels	O
50	unaffected	O
51	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	the	O
5	50	B
6	-	I
7	and	I
8	57	I
9	-	O
10	kDa	O
11	subunits	O
12	of	O
13	the	O
14	bovine	O
15	vacuolar	O
16	proton	O
17	pump	O
18	.	O

1	A	O
2	hospital	O
3	-	O
4	based	O
5	study	O
6	of	O
7	the	O
8	relationship	O
9	between	O
10	retained	O
11	placenta	O
12	and	O
13	mastitis	O
14	in	O
15	dairy	O
16	cows	O
17	.	O

1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	B
33	or	I
34	non	I
35	Q	I
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O

1	The	O
2	gene	O
3	product	O
4	of	O
5	cotS	O
6	was	O
7	confirmed	O
8	to	O
9	be	O
10	identical	O
11	to	O
12	Cot40	O
13	-	O
14	2	O
15	by	O
16	SDS	B
17	-	I
18	PAGE	I
19	and	I
20	immunoblotting	I
21	from	I
22	Escherichia	I
23	coli	I
24	transformed	O
25	with	B
26	a	I
27	plasmid	O
28	containing	O
29	the	O
30	cotS	O
31	region	O
32	.	O

1	Productive	O
2	growth	O
3	of	O
4	phage	O
5	P22	O
6	in	O
7	wild	O
8	-	O
9	type	O
10	Salmonella	O
11	typhimurium	O
12	correlates	O
13	with	O
14	the	O
15	presence	O
16	of	O
17	Abc2	O
18	,	O
19	but	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	absolute	O
25	level	O
26	of	O
27	ATP	O
28	-	O
29	dependent	O
30	nuclease	O
31	activity	O
32	,	O
33	suggesting	O
34	a	O
35	qualitative	O
36	change	O
37	in	O
38	the	O
39	nature	O
40	of	O
41	Abc2	O
42	-	O
43	modified	O
44	RecBCD	O
45	nuclease	O
46	activity	O
47	relative	O
48	to	O
49	the	O
50	native	O
51	enzyme	O
52	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	thromboxane	O
6	A2	O
7	(	O
8	TXA2	O
9	)/	O
10	prostaglandin	O
11	endoperoxide	O
12	receptor	O
13	antagonist	O
14	,	O
15	SQ	O
16	29	O
17	,	O
18	548	O
19	on	O
20	pacing	O
21	-	O
22	induced	O
23	ischemia	O
24	was	O
25	determined	O
26	in	O
27	anesthetized	O
28	open	O
29	-	O
30	chest	O
31	dogs	O
32	.	O

1	The	O
2	sample	O
3	includes	O
4	all	O
5	the	O
6	HIV	O
7	-	O
8	infected	O
9	-	I
10	patients	I
11	continuously	I
12	referred	O
13	to	O
14	the	O
15	Outpatient	O
16	Service	O
17	of	O
18	the	O
19	Infectious	O
20	Diseases	O
21	dept	O
22	.	O
23	of	O
24	Bologna	O
25	'	O
26	s	B
27	"	B
28	Ospedale	O
29	Maggiore	O
30	"	O
31	General	O
32	Hospital	O
33	during	O
34	some	O
35	five	O
36	days	O
37	(	O
38	19	O
39	-	O
40	23rd	O
41	,	O
42	July	O
43	1993	B
44	).	O

1	Twenty	O
2	-	O
3	two	O
4	consecutive	O
5	patients	O
6	with	O
7	ischaemic	O
8	ulcers	O
9	had	O
10	tcPO2	O
11	measured	O
12	and	O
13	the	O
14	ankle	O
15	/	O
16	brachial	O
17	(	O
18	ABI	O
19	)	O
20	and	O
21	toe	O
22	/	O
23	brachial	O
24	(	O
25	TBI	O
26	)	O
27	indices	O
28	calculated	O
29	.	O

1	Our	O
2	study	B
3	also	I
4	demonstrated	I
5	significant	I
6	increases	I
7	in	I
8	the	O
9	number	O
10	of	O
11	larger	O
12	myelinated	O
13	fibers	O
14	crossing	O
15	the	O
16	repair	O
17	site	O
18	in	O
19	comparison	O
20	with	O
21	the	O
22	neonatal	O
23	and	O
24	adult	O
25	groups	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	04	O
32	).	O

1	The	O
2	RI	O
3	alpha	O
4	gene	O
5	is	O
6	composed	O
7	of	O
8	nine	B
9	coding	I
10	exons	I
11	of	I
12	varying	I
13	lengths	O
14	,	O
15	separated	O
16	by	O
17	introns	O
18	,	O
19	giving	O
20	the	O
21	gene	O
22	a	O
23	total	B
24	length	I
25	of	I
26	at	O
27	least	O
28	21	O
29	kb	O
30	.	O
31	our	O
32	recent	O
33	cloning	O
34	of	O
35	a	O
36	processed	O
37	RI	O
38	alpha	O
39	pseudogene	O
40	with	O
41	a	O
42	5	O
43	'-	O
44	noncoding	B
45	region	I
46	different	I
47	from	O
48	the	O
49	previously	O
50	reported	O
51	RI	O
52	alpha	O
53	complementary	O
54	RNA	O
55	indicated	O
56	that	O
57	the	O
58	RI	O
59	alpha	O
60	gene	B
61	may	B
62	have	I
63	multiple	I
64	leader	O
65	exons	O
66	giving	O
67	rise	O
68	to	O
69	alternately	O
70	spliced	O
71	messenger	O
72	RNAs	O
73	(	O
74	mRNAs	O
75	).	O

1	Atopic	O
2	dermatitis	O
3	is	O
4	an	O
5	"	O
6	itch	O
7	which	O
8	rashes	O
9	and	O
10	not	O
11	a	O
12	rash	O
13	which	O
14	itches	O
15	"	O
16	and	O
17	therefore	O
18	,	O
19	any	O
20	patient	O
21	treatment	O
22	program	O
23	should	O
24	address	O
25	the	O
26	multiplicity	O
27	of	O
28	potential	O
29	trigger	O
30	factors	O
31	that	O
32	provoke	O
33	this	O
34	itching	O
35	.	O

1	Thyrotropin	O
2	-	O
3	induced	O
4	expression	O
5	of	O
6	a	O
7	gene	O
8	for	O
9	a	O
10	ribosomal	O
11	protein	O
12	related	O
13	to	O
14	the	O
15	trk	O
16	oncogene	O
17	.	O

1	HFA	O
2	134a	O
3	had	O
4	a	O
5	greater	O
6	tendency	O
7	to	O
8	take	O
9	up	O
10	moisture	O
11	from	O
12	the	O
13	environment	O
14	than	O
15	did	O
16	HFA	O
17	227	O
18	.	O

1	The	O
2	active	B
3	derivatives	B
4	of	I
5	the	I
6	present	I
7	series	O
8	were	I
9	also	I
10	tested	O
11	for	O
12	their	O
13	analgesic	O
14	activity	O
15	against	O
16	aconitine	O
17	-	O
18	induced	O
19	writhing	O
20	in	O
21	albino	O
22	mice	O
23	and	O
24	ulcerogenic	O
25	activity	O
26	in	O
27	albino	O
28	rats	O
29	.	O

1	Testosterone	O
2	,	O
3	free	O
4	testosterone	O
5	,	O
6	non	O
7	-	O
8	sex	O
9	hormone	O
10	-	B
11	binding	B
12	globulin	I
13	-	I
14	bound	I
15	testosterone	O
16	,	O
17	and	O
18	free	O
19	androgen	O
20	index	O
21	:	O
22	which	O
23	testosterone	O
24	measurement	O
25	is	O
26	most	O
27	relevant	O
28	to	O
29	reproductive	O
30	and	O
31	sexual	O
32	function	O
33	in	O
34	men	O
35	with	O
36	epilepsy	O
37	?	O

1	The	O
2	evaluation	O
3	was	O
4	performed	O
5	using	O
6	a	O
7	retrospective	O
8	study	O
9	design	O
10	with	O
11	newborn	O
12	blood	O
13	samples	O
14	from	O
15	three	O
16	screening	O
17	centres	O
18	.	O

1	PKA	O
2	phosphorylated	O
3	WT1	O
4	at	O
5	Ser	O
6	-	O
7	365	O
8	and	O
9	Ser	O
10	-	O
11	393	O
12	in	O
13	vitro	O
14	,	O
15	as	O
16	well	O
17	as	O
18	at	O
19	additional	O
20	sites	O
21	,	O
22	and	O
23	this	O
24	phosphorylation	O
25	abolished	O
26	the	O
27	DNA	O
28	-	O
29	binding	O
30	activity	O
31	of	O
32	WT1	O
33	in	O
34	vitro	O
35	.	O

1	Irmiere	O
2	,	O
3	and	O
4	W	O
5	.	O

1	Most	O
2	strains	O
3	(	O
4	95	O
5	%)	O
6	of	O
7	S	O
8	.	O
9	lugdunensis	O
10	produced	O
11	a	O
12	delta	O
13	hemolysin	O
14	like	O
15	that	O
16	seen	O
17	with	O
18	nine	O
19	other	O
20	species	O
21	of	O
22	CNS	O
23	.	O

1	Advances	O
2	in	B
3	the	I
4	management	I
5	of	I
6	gynecologic	O
7	cancer	O
8	--	O
9	radiation	O
10	therapy	O
11	.	O

1	A	O
2	general	O
3	model	O
4	for	O
5	ARE	O
6	-	O
7	mediated	O
8	mRNA	O
9	degradation	O
10	involving	O
11	a	O
12	potential	O
13	role	O
14	for	O
15	certain	O
16	heterogeneous	O
17	nuclear	O
18	ribonucleoproteins	O
19	and	O
20	ARE	O
21	-	O
22	binding	O
23	proteins	O
24	is	O
25	proposed	O
26	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	O
14	PCI	O
15	gene	O
16	required	B
17	for	I
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	O
34	PCI	O
35	mRNA	O
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	Hence	O
2	,	O
3	the	O
4	uPA	O
5	promoter	O
6	contains	O
7	multiple	O
8	weak	O
9	cis	O
10	-	O
11	acting	O
12	elements	O
13	distributed	O
14	over	O
15	7	O
16	.	O
17	0	O
18	kb	O
19	5	O
20	'	O
21	to	O
22	the	O
23	translation	O
24	start	O
25	site	O
26	.	O

1	The	O
2	modalities	O
3	for	B
4	using	I
5	reference	I
6	values	I
7	for	I
8	individual	I
9	subjects	I
10	as	I
11	well	I
12	as	I
13	for	I
14	groups	O
15	are	O
16	then	O
17	discussed	O
18	and	O
19	the	O
20	main	O
21	points	O
22	of	O
23	research	O
24	which	O
25	must	O
26	be	O
27	faced	O
28	in	O
29	the	O
30	near	O
31	future	O
32	regarding	O
33	reference	O
34	values	O
35	are	O
36	highlighted	B
37	.	B

1	Individuals	O
2	attending	B
3	the	I
4	GUM	I
5	Department	I
6	in	I
7	the	I
8	Royal	I
9	Infirmary	I
10	of	I
11	Edinburgh	I
12	between	I
13	1990	I
14	and	O
15	1994	O
16	with	O
17	the	O
18	diagnosis	O
19	of	O
20	HIV	O
21	infection	O
22	,	O
23	genital	O
24	warts	O
25	,	O
26	genital	O
27	herpes	O
28	,	O
29	non	O
30	-	O
31	specific	O
32	genital	O
33	infection	O
34	(	O
35	NSGI	O
36	),	O
37	gonorrhoea	O
38	and	O
39	syphilis	O
40	were	O
41	included	O
42	in	O
43	the	O
44	study	I
45	.	B

1	CONCLUSION	O
2	:	O
3	Some	O
4	Gulf	O
5	War	O
6	veterans	O
7	may	O
8	have	O
9	delayed	O
10	,	O
11	chronic	O
12	neurotoxic	O
13	syndromes	O
14	from	O
15	wartime	O
16	exposure	O
17	to	O
18	combinations	O
19	of	O
20	chemicals	O
21	that	O
22	inhibit	O
23	butyrylcholinesterase	O
24	and	O
25	neuropathy	O
26	target	O
27	esterase	O
28	.	O

1	The	O
2	ED30	O
3	values	O
4	were	O
5	2	O
6	.	O
7	4	O
8	and	O
9	2	O
10	.	O
11	2	O
12	mg	O
13	/	O
14	kg	O
15	and	O
16	similar	O
17	to	O
18	the	O
19	respective	O
20	values	O
21	of	O
22	nifedipine	O
23	(	O
24	ED	O
25	30	O
26	:	O
27	2	O
28	.	O
29	4	O
30	,	O
31	2	O
32	.	O
33	1	O
34	mg	O
35	/	O
36	kg	O
37	).	O

1	Drug	O
2	and	O
3	personnel	O
4	costs	O
5	were	O
6	reduced	O
7	when	O
8	batch	O
9	manufacturing	O
10	with	O
11	40	O
12	-	O
13	mL	O
14	multidose	O
15	vials	O
16	was	O
17	compared	O
18	with	O
19	extemporaneous	O
20	compounding	O
21	with	O
22	unit	B
23	-	I
24	dose	I
25	vials	I
26	.	O

1	There	O
2	is	O
3	now	O
4	a	O
5	significative	O
6	difference	O
7	between	O
8	age	O
9	group	O
10	1	O
11	-	O
12	5	O
13	and	B
14	the	I
15	others	I
16	(	I
17	p	I
18	Less	I
19	Than	I
20	0	I
21	,	I
22	02	I
23	).	I

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	the	O
8	PERE	O
9	formed	B
10	three	I
11	major	O
12	complexes	O
13	(	B
14	P1	I
15	,	I
16	P2	I
17	and	O
18	P3	O
19	)	O
20	with	O
21	proteins	O
22	in	O
23	nuclear	O
24	extracts	O
25	from	O
26	HeLa	O
27	or	O
28	293	O
29	cells	O
30	.	O

1	Fourteen	O
2	healthy	O
3	male	O
4	volunteers	O
5	completed	O
6	the	O
7	study	O
8	.	O

1	The	O
2	HPLC	O
3	method	O
4	involves	O
5	an	O
6	octadecylsilane	O
7	column	O
8	at	O
9	55	O
10	degrees	O
11	C	O
12	,	O
13	a	O
14	mixture	O
15	of	O
16	water	O
17	-	O
18	acetonitrile	O
19	-	O
20	orthophosphoric	O
21	acid	O
22	(	O
23	779	O
24	:	O
25	220	O
26	:	O
27	1	O
28	,	O
29	v	O
30	/	O
31	v	O
32	)	O
33	as	O
34	mobile	O
35	phase	O
36	and	O
37	detection	O
38	at	O
39	226	O
40	nm	O
41	.	O

1	The	O
2	Cili	O
3	-	O
4	2	O
5	sequences	O
6	possess	O
7	similarity	O
8	to	O
9	the	O
10	RNaseH	O
11	domain	O
12	of	O
13	Lian	O
14	-	B
15	Aa1	I
16	,	O
17	a	O
18	mosquito	O
19	non	O
20	-	O
21	LTR	O
22	retrotransposon	O
23	.	B

1	Chemical	O
2	constituents	O
3	of	O
4	the	O
5	gentianaceae	O
6	V	O
7	:	O
8	tetraoxygenated	O
9	xanthones	O
10	of	O
11	Swertia	O
12	chirata	O
13	Buch	O
14	.-	O
15	Ham	O
16	.	O

1	Because	O
2	the	O
3	human	O
4	Antp	O
5	TATAA	O
6	binding	O
7	protein	O
8	is	O
9	expressed	O
10	in	O
11	both	O
12	lymphoid	O
13	and	O
14	non	O
15	-	O
16	lymphoid	O
17	cells	O
18	,	O
19	we	O
20	suggest	O
21	that	O
22	this	O
23	homeobox	O
24	gene	O
25	has	O
26	evolved	O
27	a	O
28	more	O
29	general	O
30	transcriptional	O
31	regulatory	O
32	function	O
33	in	O
34	higher	O
35	eukaryotic	O
36	cells	O
37	.	O

1	Management	O
2	often	O
3	involves	O
4	beta	O
5	-	O
6	and	O
7	calcium	O
8	channel	O
9	blocking	O
10	drugs	O
11	or	O
12	type	O
13	IC	O
14	antiarrhythmic	O
15	drugs	O
16	.	O

1	This	O
2	repression	O
3	was	O
4	mediated	O
5	through	O
6	binding	B
7	to	I
8	the	I
9	E2	I
10	DNA	O
11	-	O
12	binding	O
13	site	O
14	immediately	O
15	upstream	O
16	of	O
17	the	O
18	P105	O
19	promoter	O
20	TATA	O
21	box	O
22	and	O
23	could	O
24	be	B
25	abrogated	I
26	by	I
27	preincubation	O
28	of	O
29	the	O
30	HPV	O
31	-	O
32	18	O
33	P105	O
34	promoter	B
35	template	I
36	with	I
37	the	I
38	nuclear	I
39	extract	O
40	allowing	O
41	the	O
42	formation	O
43	of	O
44	the	O
45	preinitiation	O
46	complex	O
47	.	O

1	A	O
2	coiled	O
3	-	O
4	coil	O
5	domain	O
6	,	O
7	conserved	O
8	within	O
9	each	O
10	encoded	O
11	protein	O
12	,	O
13	serves	O
14	as	O
15	a	O
16	potential	O
17	interaction	O
18	motif	O
19	for	O
20	FLI	O
21	LRR	O
22	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	residues	O
7	in	O
8	this	O
9	domain	O
10	(	O
11	R82A	O
12	,	O
13	K85A	O
14	,	O
15	K88A	O
16	,	O
17	and	O
18	V89A	O
19	)	O
20	resulted	O
21	in	O
22	proteins	O
23	which	O
24	failed	O
25	to	O
26	transactivate	O
27	from	O
28	the	O
29	HTLV	O
30	-	O
31	1	O
32	LTR	O
33	in	O
34	vivo	O
35	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	O
6	induced	O
7	a	O
8	beta	O
9	-	O
10	endorphin	O
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	O
16	-	O
17	cortisol	O
18	release	O
19	.	O

1	When	O
2	pollen	O
3	allergen	O
4	from	O
5	three	O
6	grass	O
7	species	O
8	were	O
9	used	O
10	,	O
11	The	O
12	RAST	O
13	-	O
14	test	O
15	results	O
16	did	O
17	not	O
18	differ	O
19	from	O
20	duplicate	O
21	values	O
22	either	O
23	.	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	had	O
6	locally	O
7	advanced	O
8	lesions	O
9	(	O
10	63	O
11	T3	O
12	-	O
13	4	O
14	:	O
15	91	O
16	.	O
17	5	O
18	%)	O
19	according	O
20	to	O
21	the	O
22	adopted	O
23	TNM	B
24	system	I
25	(	O
26	Lederman	B
27	-	I
28	Gadeberg	O
29	,	O
30	Sisson	O
31	-	O
32	Jesse	O
33	).	O

1	Inhibition	O
2	of	O
3	the	O
4	Raf	O
5	-	O
6	1	O
7	kinase	O
8	by	O
9	cyclic	O
10	AMP	O
11	agonists	O
12	causes	O
13	apoptosis	O
14	of	O
15	v	O
16	-	O
17	abl	O
18	-	O
19	transformed	O
20	cells	O
21	.	O

1	In	O
2	this	B
3	study	I
4	we	I
5	have	I
6	introduced	I
7	mutations	I
8	into	I
9	the	I
10	corresponding	O
11	elements	B
12	of	I
13	two	I
14	cox3	I
15	promoters	I
16	and	I
17	show	I
18	that	I
19	while	O
20	the	B
21	core	I
22	element	I
23	is	I
24	essential	I
25	for	I
26	cox3	I
27	promoter	O
28	activity	O
29	,	O
30	upstream	O
31	element	O
32	mutations	O
33	have	O
34	little	O
35	or	O
36	no	O
37	effect	O
38	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	putative	O
6	RNA	O
7	and	O
8	/	O
9	or	O
10	DNA	O
11	helicase	O
12	has	O
13	been	O
14	isolated	O
15	from	O
16	Arabidopsis	O
17	thaliana	O
18	cDNA	O
19	libraries	O
20	.	O

1	Previous	O
2	studies	O
3	indicated	O
4	that	O
5	the	O
6	20S	O
7	proteasome	O
8	is	O
9	a	O
10	catalytic	O
11	core	O
12	of	O
13	the	O
14	26S	O
15	proteolytic	O
16	complex	O
17	that	O
18	possesses	O
19	a	O
20	latent	O
21	multicatalytic	O
22	proteinase	O
23	activity	O
24	and	O
25	catalyzes	O
26	an	O
27	ATP	O
28	-	O
29	dependent	O
30	,	O
31	selective	O
32	breakdown	O
33	of	O
34	proteins	O
35	ligated	O
36	to	O
37	ubiquitin	O
38	.	O

1	In	O
2	addition	O
3	,	B
4	we	I
5	demonstrate	I
6	that	O
7	the	O
8	production	B
9	of	I
10	active	I
11	recombinant	I
12	telomerase	I
13	requires	I
14	a	I
15	factor	I
16	in	I
17	rabbit	O
18	reticulocyte	O
19	lysate	O
20	that	O
21	promotes	B
22	ribonucleoprotein	I
23	assembly	I
24	.	O

1	The	O
2	STE20	O
3	gene	O
4	,	O
5	encoding	O
6	a	O
7	protein	O
8	kinase	O
9	required	O
10	for	O
11	pheromone	O
12	signal	O
13	transduction	O
14	,	O
15	has	O
16	recently	O
17	been	O
18	identified	O
19	in	O
20	a	O
21	genetic	O
22	screen	O
23	for	O
24	high	O
25	-	O
26	gene	O
27	-	O
28	dosage	O
29	suppressors	O
30	of	O
31	a	O
32	partly	O
33	defective	O
34	G	O
35	beta	O
36	mutation	O
37	.	O

1	The	O
2	DNA	O
3	sequences	O
4	upstream	O
5	of	O
6	these	O
7	termini	O
8	exhibit	O
9	homology	O
10	to	O
11	plant	B
12	mitochondrial	I
13	-	I
14	processing	I
15	sites	O
16	,	B
17	therefore	I
18	the	I
19	proximal	I
20	5	O
21	'	B
22	ends	I
23	are	I
24	most	I
25	probably	O
26	generated	O
27	by	O
28	RNA	O
29	processing	O
30	.	O

1	Induction	O
2	in	O
3	AP	O
4	-	O
5	1	B
6	DNA	I
7	binding	I
8	correlates	I
9	with	I
10	a	I
11	concomitant	I
12	GH	O
13	trans	B
14	-	I
15	activation	I
16	of	I
17	c	I
18	-	O
19	jun	O
20	and	B
21	c	I
22	-	I
23	fos	I
24	genes	I
25	described	O
26	previously	O
27	.	O

1	Neural	O
2	-	O
3	specific	O
4	expression	O
5	,	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	chromosomal	O
11	localization	O
12	of	O
13	the	O
14	gene	O
15	encoding	O
16	the	O
17	zinc	O
18	-	O
19	finger	O
20	transcription	O
21	factor	O
22	NGFI	O
23	-	O
24	C	O
25	.	O

1	Doctor	O
2	Berglund	O
3	warns	O
4	members	O
5	of	O
6	union	O
7	pitfalls	O
8	.	O

1	Exercise	O
2	training	O
3	has	O
4	become	O
5	increasingly	O
6	important	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	heart	O
12	failure	O
13	patients	O
14	.	O

1	Fast	O
2	continuous	O
3	expansion	O
4	.	O

1	An	O
2	expression	O
3	library	O
4	was	O
5	constructed	O
6	by	O
7	inserting	O
8	5	O
9	'	O
10	portion	B
11	-	I
12	enriched	I
13	cDNAs	O
14	from	B
15	phytohemagglutinin	I
16	-	O
17	stimulated	O
18	peripheral	O
19	blood	O
20	mononuclear	O
21	cells	O
22	into	O
23	upstream	O
24	of	O
25	signal	O
26	sequence	O
27	-	O
28	deleted	O
29	CD4	O
30	cDNA	O
31	in	O
32	an	O
33	Epstein	O
34	-	B
35	Barr	I
36	virus	I
37	shuttle	I
38	vector	I
39	.	O

1	The	O
2	ability	O
3	of	O
4	spt2	O
5	mutations	O
6	to	B
7	suppress	I
8	the	I
9	transcriptional	I
10	interference	I
11	caused	I
12	by	I
13	the	I
14	delta	I
15	promoter	O
16	insertion	O
17	his	O
18	-	O
19	4	O
20	-	O
21	912	O
22	delta	O
23	correlates	O
24	with	O
25	an	O
26	increase	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	HIS4	O
32	mRNA	O
33	levels	O
34	.	O

1	An	O
2	analysis	O
3	of	O
4	synthetic	O
5	peptides	O
6	revealed	O
7	a	O
8	minimal	B
9	CTD	I
10	sequence	I
11	that	I
12	is	I
13	sufficient	I
14	to	I
15	bind	I
16	to	O
17	the	B
18	second	I
19	Rsp5	I
20	WW	O
21	domain	O
22	(	O
23	Rsp5	O
24	WW2	B
25	)	I
26	in	I
27	vitro	O
28	and	O
29	in	O
30	yeast	B
31	two	I
32	-	I
33	hybrid	O
34	assays	O
35	.	O

1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	people	O
9	for	O
10	many	O
11	years	B
12	and	I
13	no	I
14	claim	I
15	is	I
16	being	O
17	made	O
18	for	O
19	any	O
20	innovation	O
21	in	O
22	this	O
23	regard	O
24	.	O

1	The	O
2	gcd2	O
3	-	O
4	503	O
5	mutation	O
6	also	O
7	results	O
8	in	O
9	polysome	B
10	runoff	I
11	,	O
12	accumulation	B
13	of	I
14	inactive	I
15	80S	I
16	ribosomal	O
17	couples	O
18	,	O
19	and	O
20	accumulation	O
21	of	O
22	at	O
23	least	O
24	one	O
25	of	O
26	the	O
27	subunits	O
28	of	O
29	the	O
30	general	O
31	translation	B
32	initiation	I
33	factor	I
34	2	I
35	(	O
36	eIF	O
37	-	B
38	2	O
39	alpha	O
40	)	O
41	in	O
42	43S	O
43	-	O
44	48S	O
45	particles	B
46	following	I
47	a	O
48	shift	B
49	to	I
50	the	I
51	restrictive	O
52	temperature	O
53	.	O

1	Preliminary	O
2	experiments	O
3	demonstrated	O
4	that	O
5	it	O
6	was	O
7	possible	O
8	to	O
9	produce	O
10	fasD	O
11	mutants	O
12	,	O
13	whose	O
14	products	O
15	remain	O
16	functional	O
17	for	O
18	fimbrial	O
19	export	O
20	and	O
21	assembly	O
22	.	O

1	Our	O
2	results	O
3	,	O
4	when	O
5	combined	O
6	with	O
7	previously	O
8	published	O
9	in	O
10	vitro	O
11	results	O
12	,	O
13	support	O
14	a	O
15	direct	O
16	role	O
17	for	O
18	Prp44p	O
19	in	O
20	unwinding	O
21	of	O
22	the	O
23	U4	O
24	/	O
25	U6	O
26	helix	O
27	.	O

1	Association	O
2	of	O
3	human	O
4	Pur	O
5	alpha	O
6	with	O
7	the	O
8	retinoblastoma	O
9	protein	O
10	,	O
11	Rb	O
12	,	O
13	regulates	O
14	binding	O
15	to	O
16	the	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	Pur	O
22	alpha	O
23	recognition	O
24	element	O
25	.	O

1	Members	O
2	of	O
3	the	O
4	Ras	O
5	subfamily	O
6	of	O
7	small	O
8	GTP	O
9	-	O
10	binding	O
11	proteins	O
12	have	O
13	been	O
14	shown	O
15	to	O
16	be	O
17	promiscuous	O
18	towards	O
19	a	O
20	variety	O
21	of	O
22	putative	O
23	effector	O
24	molecules	O
25	such	O
26	as	O
27	the	O
28	protein	O
29	kinase	O
30	c	O
31	-	O
32	Raf	O
33	and	O
34	the	O
35	Ral	O
36	-	O
37	specific	O
38	guanine	O
39	nucleotide	O
40	exchange	O
41	factor	O
42	(	O
43	Ral	O
44	-	O
45	GEF	O
46	).	O

1	Chlamydia	O
2	trachomatis	O
3	and	O
4	Chlamydia	O
5	psittaci	O
6	were	O
7	not	O
8	affected	O
9	by	O
10	methanol	O
11	fixation	O
12	.	O

1	The	O
2	spectrum	O
3	of	O
4	phenotypes	O
5	caused	O
6	by	O
7	these	O
8	mutations	O
9	was	O
10	strikingly	O
11	different	O
12	than	B
13	mutations	I
14	in	I
15	the	O
16	adaptor	O
17	for	O
18	the	O
19	VP16	O
20	activation	O
21	domain	O
22	.	O

1	Ketamine	O
2	in	O
3	the	O
4	treatment	O
5	of	O
6	bronchospasm	O
7	during	O
8	mechanical	O
9	ventilation	O
10	.	O

1	The	O
2	nmr	O
3	gene	O
4	is	O
5	the	O
6	major	B
7	negative	I
8	regulatory	I
9	gene	I
10	in	I
11	the	O
12	nitrogen	O
13	control	O
14	circuit	O
15	of	I
16	Neurospora	O
17	crassa	O
18	,	B
19	which	I
20	,	I
21	together	I
22	with	I
23	positive	I
24	regulatory	I
25	genes	I
26	,	I
27	governs	I
28	the	I
29	expression	I
30	of	I
31	multiple	I
32	unlinked	I
33	structural	O
34	genes	B
35	of	O
36	the	O
37	circuit	O
38	.	O

1	Characterization	O
2	of	O
3	an	O
4	EcR	O
5	/	O
6	USP	O
7	heterodimer	O
8	target	B
9	site	I
10	that	I
11	mediates	I
12	ecdysone	I
13	responsiveness	O
14	of	O
15	the	O
16	Drosophila	O
17	Lsp	O
18	-	O
19	2	O
20	gene	O
21	.	O

1	These	O
2	findings	O
3	and	O
4	the	O
5	differential	O
6	tissue	O
7	distribution	O
8	of	O
9	p54	O
10	suggest	O
11	that	B
12	this	I
13	novel	I
14	SR	I
15	protein	I
16	may	I
17	participate	I
18	in	I
19	regulation	O
20	of	O
21	alternative	O
22	splicing	O
23	in	O
24	a	O
25	tissue	O
26	-	O
27	and	O
28	substrate	O
29	-	O
30	dependent	O
31	manner	O
32	.	B

1	Amino	O
2	acid	O
3	sequence	O
4	of	O
5	one	O
6	human	O
7	liver	O
8	clone	O
9	(	O
10	HL	O
11	-	O
12	14	O
13	)	B
14	was	I
15	identical	I
16	to	I
17	the	I
18	rabbit	I
19	skeletal	I
20	muscle	I
21	phosphatase	O
22	2A	O
23	cDNA	O
24	(	O
25	with	O
26	97	O
27	%	O
28	nucleotide	O
29	identity	O
30	).	O

1	W	O
2	.	O

1	The	O
2	microdensitometric	O
3	scores	O
4	and	O
5	their	O
6	side	O
7	-	O
8	to	O
9	-	O
10	side	O
11	differences	O
12	in	O
13	patients	O
14	correlated	O
15	negatively	O
16	with	O
17	the	O
18	serum	O
19	25	O
20	-	O
21	OHD	O
22	concentration	O
23	and	O
24	positively	O
25	with	O
26	the	O
27	degree	O
28	of	O
29	paralysis	O
30	.	O

1	Additionally	O
2	,	O
3	observations	O
4	that	O
5	patients	O
6	with	O
7	mitral	O
8	versus	O
9	aortic	O
10	regurgitation	O
11	respond	O
12	differently	O
13	to	O
14	valve	O
15	replacement	O
16	suggest	O
17	that	O
18	differences	O
19	exist	O
20	preoperatively	O
21	between	O
22	these	O
23	two	O
24	types	O
25	of	O
26	volume	O
27	overload	O
28	.	O

1	In	O
2	our	O
3	opinion	O
4	,	O
5	the	O
6	SM	B
7	-	I
8	CMA	I
9	system	I
10	is	O
11	,	O
12	despite	O
13	some	O
14	shortcomings	B
15	in	I
16	its	I
17	user	I
18	-	I
19	interface	I
20	,	I
21	a	O
22	useful	O
23	and	O
24	versatile	O
25	instrument	O
26	for	O
27	examination	O
28	of	O
29	human	O
30	semen	O
31	samples	O
32	,	O
33	with	O
34	desirable	O
35	features	O
36	.	O

1	Response	O
2	was	O
3	extremely	O
4	poor	O
5	in	O
6	African	O
7	Americans	O
8	and	O
9	those	O
10	with	O
11	HCV	O
12	genotype	O
13	1	O
14	.	O

1	The	O
2	starting	O
3	point	O
4	is	O
5	the	O
6	consideration	O
7	that	O
8	the	O
9	conceptions	B
10	underlying	I
11	the	O
12	ICIDH	O
13	are	O
14	not	O
15	suitable	O
16	to	O
17	serve	O
18	as	O
19	a	O
20	mainstay	O
21	of	O
22	a	O
23	model	O
24	for	O
25	diagnostics	O
26	in	O
27	rehabilitation	O
28	because	O
29	they	O
30	do	O
31	not	O
32	reflect	O
33	essential	O
34	characteristics	O
35	of	O
36	the	O
37	diagnostic	O
38	process	O
39	which	O
40	is	O
41	the	O
42	basis	O
43	for	O
44	intervention	O
45	.	B

1	They	O
2	were	O
3	then	O
4	subjected	O
5	to	O
6	whole	O
7	-	O
8	body	O
9	heat	O
10	stress	O
11	(	O
12	water	O
13	-	O
14	perfused	O
15	suits	O
16	),	O
17	and	O
18	the	O
19	3	O
20	minutes	O
21	of	O
22	LBNP	O
23	was	O
24	repeated	O
25	.	B

1	These	O
2	fusion	O
3	proteins	O
4	also	O
5	allowed	O
6	the	O
7	localization	O
8	of	O
9	the	O
10	transcriptional	O
11	activation	O
12	and	O
13	DNA	O
14	binding	O
15	domains	O
16	of	O
17	the	O
18	ToxR	O
19	protein	O
20	to	O
21	its	O
22	cytoplasmically	O
23	located	O
24	N	O
25	-	O
26	terminal	O
27	portion	O
28	.	O

1	Using	O
2	gel	O
3	retardation	O
4	assays	O
5	with	O
6	HepG2	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	the	O
13	presence	O
14	of	O
15	a	O
16	specific	O
17	protein	O
18	which	O
19	bound	O
20	to	O
21	the	O
22	NRE	O
23	fragment	O
24	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	sought	O
7	to	B
8	identify	I
9	mechanisms	I
10	that	I
11	could	I
12	account	I
13	for	O
14	the	O
15	antimitogenic	O
16	effects	O
17	of	O
18	IL	O
19	-	O
20	4	O
21	.	O

1	One	O
2	enigmatic	O
3	aspect	O
4	of	O
5	GATA	O
6	factor	O
7	expression	O
8	is	O
9	that	O
10	several	O
11	GATA	O
12	proteins	O
13	,	O
14	which	O
15	ostensibly	O
16	share	O
17	the	O
18	same	O
19	DNA	O
20	-	O
21	binding	O
22	site	O
23	specificity	O
24	,	O
25	are	O
26	coexpressed	O
27	in	O
28	erythroid	O
29	cells	O
30	.	O

1	Mis3	O
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	O
9	ribosome	O
10	RNA	O
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O

1	Monitoring	O
2	changes	O
3	in	O
4	the	B
5	heart	I
6	rate	O
7	of	O
8	the	O
9	premature	O
10	fetus	O
11	during	O
12	tocolysis	O
13	with	O
14	the	O
15	beta	O
16	-	O
17	adrenomimetics	O
18	partusisten	O
19	and	B
20	Pre	I
21	-	O
22	par	O

1	Twelve	O
2	patients	O
3	had	O
4	stage	O
5	IBG3	O
6	,	O
7	14	O
8	had	O
9	ICG1	O
10	,	O
11	9	O
12	had	O
13	ICG2	O
14	,	O
15	and	O
16	3	O
17	had	O
18	ICG3	O
19	disease	O
20	.	O

1	Seventy	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	patients	O
7	treated	O
8	with	O
9	ticarcillin	O
10	alone	O
11	responded	O
12	favorably	O
13	.	B

1	The	O
2	lethal	O
3	toxicity	O
4	of	O
5	inorganic	O
6	(	O
7	HgCl2	O
8	)	O
9	and	B
10	organic	I
11	(	I
12	CH3HgCl	I
13	)	O
14	mercury	O
15	chloride	O
16	was	O
17	compared	O
18	for	O
19	Coturnix	B
20	(	I
21	Japanese	O
22	quail	O
23	,	O
24	Coturnix	O
25	japonica	O
26	)	O
27	of	O
28	different	O
29	ages	O
30	from	O
31	hatch	B
32	through	O
33	adulthood	O
34	by	O
35	single	O
36	-	O
37	dose	O
38	acute	O
39	oral	O
40	and	O
41	intramuscular	O
42	injections	O
43	and	O
44	by	O
45	a	B
46	5	I
47	-	O
48	d	O
49	dietary	O
50	trial	O
51	.	O

1	The	O
2	junctions	O
3	between	O
4	viral	O
5	and	O
6	cellular	O
7	sequences	B
8	were	I
9	determined	I
10	by	I
11	DNA	I
12	sequence	O
13	analysis	O
14	to	O
15	be	O
16	517	O
17	nucleotides	O
18	into	O
19	the	O
20	p30	O
21	sequence	O
22	and	O
23	1	O
24	,	O
25	920	O
26	nucleotides	O
27	into	B
28	the	I
29	polymerase	I
30	sequence	I
31	.	I

1	Cytogenetic	O
2	studies	O
3	were	O
4	performed	O
5	in	O
6	lymphocytes	O
7	from	O
8	hospital	O
9	workers	O
10	exposed	O
11	to	B
12	low	I
13	doses	I
14	of	I
15	radiation	I
16	(	I
17	1	I
18	.	I
19	6	O
20	-	O
21	42	O
22	.	O
23	71	O
24	mSv	O
25	).	O

1	Pokeweed	O
2	antiviral	O
3	protein	O
4	(	O
5	PAP	O
6	)	O
7	from	O
8	Phytolacca	B
9	americana	I
10	is	O
11	a	B
12	highly	B
13	specific	I
14	N	I
15	-	I
16	glycosidase	O
17	removing	O
18	adenine	O
19	residues	O
20	(	O
21	A4324	O
22	in	O
23	28S	O
24	rRNA	O
25	and	O
26	A2660	O
27	in	O
28	23S	O
29	rRNA	O
30	)	O
31	from	B
32	intact	I
33	ribosomes	I
34	of	O
35	both	O
36	eukaryotes	O
37	and	O
38	prokaryotes	O
39	.	O

1	Erythema	O
2	exsudativum	B
3	multiforme	I
4	induced	I
5	by	I
6	granulocyte	I
7	colony	I
8	-	I
9	stimulating	O
10	factor	O
11	in	B
12	an	I
13	allogeneic	I
14	peripheral	I
15	blood	I
16	stem	O
17	cell	O
18	donor	B
19	.	I

1	As	O
2	with	O
3	the	O
4	murine	O
5	and	O
6	human	O
7	mb	O
8	-	O
9	1	O
10	genes	B
11	,	I
12	the	I
13	5	I
14	'	I
15	region	O
16	of	O
17	the	O
18	bovine	O
19	mb	O
20	-	O
21	1	O
22	gene	O
23	lacked	B
24	a	O
25	TATA	B
26	box	I
27	.	I

1	The	O
2	effects	O
3	of	O
4	mean	O
5	luminance	O
6	were	O
7	also	O
8	measured	O
9	and	O
10	a	O
11	general	O
12	expression	O
13	that	O
14	would	O
15	take	B
16	them	I
17	into	O
18	account	O
19	was	O
20	derived	O
21	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	acetyltransferase	O
6	activity	O
7	of	O
8	p300	O
9	was	O
10	observed	O
11	to	O
12	be	O
13	distinct	O
14	from	B
15	the	I
16	broadly	I
17	essential	I
18	activation	O
19	function	O
20	of	O
21	the	B
22	CH3	I
23	domain	I
24	/	I
25	E1A	I
26	-	I
27	binding	I
28	region	I
29	.	I

1	Activation	O
2	of	O
3	T	O
4	cells	O
5	via	O
6	the	O
7	TCR	O
8	and	O
9	other	O
10	costimulatory	O
11	receptors	O
12	triggers	O
13	a	O
14	number	O
15	of	O
16	signaling	O
17	cascades	O
18	.	B

1	In	O
2	contrast	B
3	to	I
4	behavioral	I
5	deviation	O
6	(	B
7	the	I
8	avoidance	O
9	conditioning	O
10	lost	O
11	),	O
12	the	O
13	haloperidol	O
14	intrastriatal	O
15	microinjections	B
16	did	I
17	not	I
18	affect	I
19	the	I
20	DA	O
21	synaptic	O
22	level	O
23	in	O
24	rostral	O
25	neostriatum	O
26	.	O

1	Several	O
2	different	O
3	oncogenes	O
4	and	O
5	growth	O
6	factors	O
7	promote	O
8	G1	O
9	phase	O
10	progression	O
11	.	O

1	Furthermore	O
2	,	O
3	in	O
4	vitro	O
5	decay	O
6	reaction	O
7	mixtures	O
8	supplemented	O
9	with	O
10	the	O
11	20	O
12	-	O
13	nt	O
14	sense	O
15	RNA	O
16	transcript	O
17	resulted	O
18	in	O
19	stabilization	O
20	of	O
21	R2	O
22	message	O
23	.	O

1	This	O
2	would	O
3	have	O
4	had	O
5	the	O
6	effect	O
7	of	O
8	positioning	B
9	the	I
10	genes	I
11	currently	I
12	on	I
13	the	I
14	long	I
15	arm	I
16	adjacent	I
17	to	I
18	the	I
19	centromeric	I
20	heterochromatin	I
21	,	I
22	perhaps	I
23	resulting	O
24	in	O
25	a	B
26	"	I
27	position	I
28	effect	I
29	"	I
30	on	O
31	transcription	O
32	of	B
33	these	I
34	genes	I
35	.	O

1	202	O
2	-	O
3	8	O
4	.	O

1	In	O
2	H4IIE	O
3	rat	O
4	hepatoma	O
5	cells	O
6	,	O
7	glucocorticoids	B
8	,	I
9	retinoic	I
10	acid	O
11	and	O
12	cyclic	B
13	AMP	I
14	(	I
15	cAMP	I
16	)	I
17	increase	I
18	PEPCK	I
19	gene	I
20	transcription	I
21	whereas	I
22	insulin	I
23	and	I
24	phorbol	I
25	esters	I
26	have	I
27	the	O
28	opposite	O
29	effect	O
30	.	O

1	Furthermore	O
2	,	O
3	early	O
4	-	O
5	and	O
6	late	O
7	-	O
8	firing	O
9	origins	O
10	differ	O
11	not	O
12	in	O
13	the	O
14	timing	O
15	of	O
16	their	O
17	recruitment	O
18	of	O
19	an	O
20	Mcm	O
21	protein	O
22	,	O
23	but	O
24	in	O
25	the	O
26	timing	O
27	of	O
28	RPA	O
29	'	O
30	s	O
31	recruitment	O
32	.	O

1	All	O
2	radiologists	O
3	using	O
4	the	O
5	machine	O
6	found	O
7	that	O
8	the	O
9	reporting	O
10	terminal	O
11	was	O
12	simple	O
13	to	O
14	operate	O
15	,	O
16	but	O
17	found	O
18	that	O
19	reporting	O
20	abnormalities	O
21	caused	O
22	an	O
23	increased	O
24	effort	O
25	and	O
26	took	O
27	a	O
28	longer	O
29	time	O
30	.	O

1	RT	O
2	-	O
3	PCR	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	analyses	O
9	of	O
10	a	O
11	time	O
12	course	O
13	of	O
14	juvenile	O
15	testis	O
16	development	O
17	indicate	B
18	that	B
19	Spo11	I
20	expression	I
21	begins	I
22	in	I
23	early	I
24	meiotic	O
25	Prophase	O
26	I	O
27	,	O
28	prior	O
29	to	O
30	the	O
31	pachytene	O
32	stage	O
33	,	O
34	with	O
35	increasing	O
36	accumulation	O
37	of	O
38	mRNA	O
39	through	O
40	the	O
41	pachytene	O
42	stage	O
43	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	B
10	'-	I
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	O
16	nidogen	O
17	gene	O
18	.	O

1	One	O
2	extract	O
3	with	B
4	the	I
5	lowest	I
6	PCA	I
7	content	O
8	was	O
9	non	O
10	-	O
11	carcinogenic	O
12	.	O

1	Both	O
2	antidepressants	O
3	elevated	O
4	the	O
5	pain	O
6	threshold	O
7	acutely	O
8	,	O
9	while	O
10	pretreatment	O
11	with	O
12	pCPA	O
13	largely	O
14	blocked	O
15	the	O
16	analgesia	O
17	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	contribution	O
6	of	O
7	specific	O
8	TATA	O
9	-	O
10	binding	O
11	protein	O
12	(	O
13	TBP	O
14	)-	O
15	TATA	O
16	interactions	O
17	to	O
18	the	O
19	promoter	O
20	activity	O
21	of	O
22	a	O
23	constitutively	O
24	expressed	O
25	silkworm	O
26	tRNA	O
27	(	O
28	C	O
29	)(	O
30	Ala	O
31	)	O
32	gene	O
33	and	O
34	have	O
35	also	O
36	asked	O
37	whether	O
38	the	O
39	lack	O
40	of	O
41	similar	O
42	interactions	O
43	accounts	O
44	for	O
45	the	O
46	low	O
47	promoter	O
48	activity	O
49	of	O
50	a	O
51	silk	O
52	gland	O
53	-	O
54	specific	O
55	tRNA	O
56	(	O
57	SG	O
58	)(	O
59	Ala	O
60	)	O
61	gene	O
62	.	O

1	A	O
2	single	O
3	amino	O
4	acid	O
5	change	O
6	in	B
7	the	I
8	CPY	I
9	vacuolar	I
10	sorting	O
11	signal	O
12	prevents	O
13	this	O
14	interaction	O
15	.	O

1	Liver	O
2	dysfunction	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	different	O
8	adverse	O
9	reactions	O
10	presented	O
11	with	O
12	a	O
13	higher	O
14	activity	O
15	in	O
16	the	O
17	blood	O
18	serum	O
19	of	O
20	indicator	O
21	liver	O
22	enzymes	O
23	and	O
24	its	O
25	impaired	O
26	protein	O
27	-	O
28	forming	O
29	function	O
30	.	O

1	The	O
2	naltrexone	O
3	/	O
4	lofexidine	O
5	combination	O
6	was	O
7	associated	O
8	with	O
9	a	O
10	more	O
11	rapid	O
12	resolution	O
13	of	O
14	the	O
15	opiate	O
16	withdrawal	O
17	syndrome	O
18	than	O
19	a	O
20	7	O
21	-	O
22	day	O
23	lofexidine	O
24	-	O
25	only	O
26	treatment	O
27	schedule	O
28	,	O
29	without	O
30	substantial	O
31	increases	O
32	in	O
33	withdrawal	O
34	symptoms	O
35	or	O
36	hypotensive	O
37	side	O
38	-	O
39	effects	O
40	.	O

1	Bilateral	O
2	basal	O
3	arteries	O
4	were	O
5	measured	O
6	by	O
7	the	O
8	transtemporal	O
9	approach	O
10	with	O
11	a	O
12	2	O
13	MHz	O
14	pulsed	O
15	Doppler	O
16	instrument	O
17	(	O
18	TC	O
19	-	O
20	2	O
21	64B	O
22	EME	O
23	).	O

1	Rather	O
2	,	O
3	usp	O
4	is	O
5	required	O
6	in	O
7	late	O
8	third	O
9	instar	O
10	larvae	O
11	for	O
12	appropriate	O
13	developmental	O
14	and	O
15	transcriptional	O
16	responses	O
17	to	O
18	the	O
19	ecdysone	O
20	pulse	O
21	that	O
22	triggers	O
23	puparium	O
24	formation	O
25	.	O

1	Urease	O
2	activity	B
3	of	I
4	97	O
5	%	O
6	of	O
7	these	O
8	organisms	O
9	became	O
10	evident	O
11	within	O
12	30	O
13	min	O
14	.	O

1	The	O
2	changes	O
3	after	O
4	treatment	O
5	were	O
6	observed	O
7	chiefly	O
8	by	O
9	electromyography	O
10	while	O
11	sensory	O
12	and	O
13	motor	O
14	improvement	O
15	were	O
16	also	O
17	recorded	O
18	as	O
19	auxiliary	O
20	indicators	O
21	.	O

1	No	O
2	UOxase	O
3	mRNA	O
4	was	O
5	detected	O
6	in	O
7	11	O
8	nonhepatic	O
9	tissues	O
10	of	O
11	rat	O
12	,	O
13	suggesting	O
14	tissue	O
15	specificity	O
16	of	B
17	expression	I
18	of	I
19	this	I
20	UOxase	I
21	gene	I
22	.	O

1	Metal	O
2	coordination	O
3	compounds	O
4	of	O
5	thiabendazole	O
6	.	O

1	The	O
2	neuroleptic	O
3	-	O
4	induced	O
5	increase	O
6	in	O
7	central	O
8	DA	O
9	turnover	O
10	(	O
11	an	O
12	indicator	O
13	for	O
14	the	O
15	degree	O
16	of	O
17	DA	O
18	receptor	O
19	blocking	O
20	)	O
21	was	O
22	found	O
23	to	O
24	be	O
25	positively	O
26	correlated	O
27	with	O
28	the	O
29	therapeutic	O
30	effect	O
31	of	O
32	neuroleptics	O
33	and	O
34	the	O
35	development	O
36	of	O
37	hypokinetic	O
38	-	O
39	rigid	O
40	symptoms	O
41	.	O

1	Both	O
2	mutant	O
3	receptors	O
4	were	O
5	expressed	O
6	on	O
7	the	O
8	cell	B
9	surface	I
10	and	I
11	bound	I
12	insulin	O
13	normally	O
14	,	O
15	but	O
16	showed	O
17	markedly	O
18	impaired	O
19	autophosphorylation	O
20	in	O
21	response	O
22	to	O
23	insulin	O
24	.	O

1	The	O
2	cDNA	O
3	encoded	O
4	a	O
5	mature	O
6	protein	O
7	of	O
8	240	O
9	amino	O
10	acids	O
11	,	O
12	including	O
13	a	O
14	29	O
15	-	O
16	amino	O
17	acid	O
18	signal	O
19	sequence	O
20	.	O

1	The	O
2	enzymic	O
3	hydrolysis	O
4	of	O
5	urea	O
6	produces	O
7	ammonia	B
8	which	I
9	causes	I
10	a	I
11	vivid	O
12	yellow	B
13	to	I
14	purple	O
15	colour	O
16	change	O
17	in	O
18	the	O
19	pH	O
20	indicator	O
21	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	short	B
6	synthetic	I
7	peptides	I
8	containing	O
9	the	O
10	pRB	I
11	-	O
12	binding	O
13	sequences	O
14	of	O
15	E1A	O
16	are	O
17	sufficient	O
18	for	O
19	interaction	O
20	with	O
21	p107	O
22	,	O
23	cyclin	O
24	A	O
25	,	O
26	and	O
27	p130	O
28	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	B
6	report	I
7	a	I
8	detailed	I
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	O
20	binding	O
21	sites	O
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	B
27	divergent	I
28	pulAp	I
29	and	I
30	pulCp	O
31	promoters	O
32	.	O

1	The	O
2	distribution	O
3	phase	O
4	is	O
5	followed	O
6	by	O
7	an	O
8	elimination	O
9	phase	O
10	with	O
11	a	B
12	much	I
13	longer	O
14	half	O
15	-	O
16	life	O
17	(	O
18	mean	O
19	value	O
20	375	O
21	min	O
22	)	O
23	and	B
24	a	I
25	volume	O
26	of	O
27	distribution	O
28	of	O
29	approximately	O
30	200	O
31	-	O
32	400	O
33	l	O
34	.	B

1	Sequence	O
2	analysis	O
3	revealed	B
4	that	I
5	in	I
6	addition	I
7	to	I
8	the	I
9	non	I
10	-	I
11	spliced	O
12	variant	O
13	,	O
14	multiple	O
15	mRNA	O
16	species	O
17	were	O
18	generated	O
19	by	O
20	alternative	O
21	splicing	O
22	resulting	O
23	in	O
24	the	O
25	exclusion	O
26	of	O
27	92	O
28	,	B
29	166	I
30	,	I
31	170	I
32	,	I
33	174	I
34	and	I
35	263	O
36	nucleotides	O
37	(	O
38	nt	B
39	),	O
40	respectively	I
41	,	I
42	from	I
43	exon	I
44	1	I
45	.	I

1	The	O
2	reduction	B
3	in	I
4	saturated	I
5	fatty	O
6	acids	O
7	intake	O
8	led	B
9	to	I
10	modest	I
11	(	I
12	but	O
13	in	O
14	group	B
15	1	I
16	significant	I
17	)	I
18	0	I
19	.	I
20	15	I
21	mmol	I
22	/	I
23	l	I
24	(	I
25	2	I
26	.	O
27	5	B
28	%)	O
29	reduction	O
30	in	O
31	total	O
32	serum	O
33	cholesterol	O
34	level	O
35	.	B

1	The	O
2	9	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	characteristic	O
8	of	O
9	CML	O
10	results	O
11	in	O
12	a	O
13	fused	O
14	bcr	O
15	/	O
16	abl	O
17	gene	O
18	and	O
19	an	O
20	abnormal	O
21	fusion	O
22	protein	O
23	,	O
24	p210bcr	O
25	/	O
26	abl	O
27	.	O

1	Partial	O
2	sequencing	O
3	of	O
4	the	O
5	region	O
6	downstream	O
7	of	O
8	ORF	O
9	-	O
10	Pto	O
11	revealed	O
12	homology	O
13	to	O
14	the	O
15	ru	O
16	/	O
17	AB	O
18	genes	O
19	,	O
20	involved	O
21	in	O
22	UV	O
23	resistance	O
24	,	O
25	from	O
26	plasmid	O
27	pPSR1	O
28	.	O

1	The	O
2	recently	O
3	developed	O
4	gamma	O
5	-	O
6	interferon	O
7	(	O
8	IFN	O
9	-	O
10	gamma	O
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	accredited	O
25	by	O
26	the	O
27	Standing	O
28	Committee	O
29	on	O
30	Agriculture	O
31	for	O
32	use	O
33	in	O
34	Australia	O
35	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	putative	O
10	adhesive	O
11	molecule	O
12	from	O
13	P	B
14	.	I
15	falciparum	I
16	that	I
17	shares	O
18	both	O
19	sequence	O
20	and	O
21	structural	O
22	similarities	O
23	with	O
24	a	O
25	sporozoite	O
26	surface	O
27	molecule	O
28	from	O
29	Plasmodium	O
30	termed	O
31	the	O
32	thrombospondin	O
33	-	O
34	related	O
35	anonymous	O
36	protein	O
37	(	O
38	TRAP	O
39	)	O
40	and	O
41	,	O
42	to	O
43	a	O
44	lesser	O
45	extent	O
46	,	O
47	with	O
48	the	O
49	circumsporozoite	B
50	(	I
51	CS	I
52	)	O
53	protein	O
54	.	O

1	Armed	O
2	with	O
3	a	O
4	clear	O
5	understanding	O
6	of	O
7	the	O
8	pathophysiologic	O
9	pathways	O
10	that	O
11	may	O
12	cause	O
13	and	O
14	/	O
15	or	O
16	contribute	O
17	to	O
18	the	O
19	development	O
20	of	O
21	unconjugated	O
22	hyperbilirubinemia	O
23	and	O
24	the	O
25	associated	O
26	jaundice	O
27	,	O
28	the	O
29	practitioner	O
30	will	O
31	be	O
32	successful	O
33	in	O
34	helping	O
35	the	O
36	family	O
37	understand	O
38	their	O
39	child	O
40	'	O
41	s	O
42	illness	O
43	.	O

1	Comparable	O
2	amounts	O
3	of	O
4	alpha	O
5	5	O
6	beta	O
7	1	O
8	integrin	O
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	O
22	cell	O
23	-	O
24	binding	O
25	fragment	O
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O

1	Epstein	O
2	-	O
3	Barr	O
4	virus	O
5	-	O
6	encoded	B
7	latent	I
8	membrane	I
9	protein	I
10	1	I
11	activates	O
12	the	O
13	JNK	O
14	pathway	O
15	through	O
16	its	B
17	extreme	I
18	C	I
19	terminus	I
20	via	I
21	a	I
22	mechanism	I
23	involving	I
24	TRADD	I
25	and	I
26	TRAF2	I
27	.	I

1	In	O
2	rubella	O
3	patients	O
4	with	O
5	serologic	O
6	confirmation	O
7	by	O
8	HI	O
9	,	O
10	the	O
11	IF	O
12	test	O
13	detected	O
14	significant	O
15	rises	O
16	in	O
17	219	O
18	(	O
19	99	O
20	.	O
21	1	O
22	%)	O
23	of	O
24	221	O
25	patients	O
26	and	O
27	the	O
28	PHA	O
29	test	O
30	detected	O
31	antibody	O
32	conversion	O
33	in	O
34	68	O
35	(	O
36	93	O
37	%)	O
38	of	O
39	73	O
40	patients	O
41	.	O

1	This	O
2	mechanism	O
3	is	O
4	not	O
5	due	O
6	to	O
7	the	O
8	observed	O
9	grain	O
10	boundary	O
11	precipitates	O
12	.	O

1	This	O
2	study	O
3	indicates	O
4	that	O
5	this	O
6	dose	O
7	-	O
8	intense	O
9	regimen	O
10	can	O
11	be	O
12	safely	O
13	administered	O
14	,	O
15	even	O
16	with	O
17	the	O
18	use	O
19	of	O
20	purged	O
21	marrow	O
22	,	O
23	with	O
24	an	O
25	acceptable	O
26	toxicity	O
27	profile	O
28	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	B
17	serologic	I
18	groups	I
19	on	I
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	The	O
2	disturbance	O
3	of	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	,	O
8	as	O
9	revealed	O
10	by	O
11	the	O
12	high	O
13	value	O
14	of	O
15	AaDO2	O
16	,	B
17	existed	I
18	without	O
19	left	O
20	ventricular	O
21	dysfunction	O
22	,	O
23	and	O
24	AaDO2	O
25	had	O
26	no	O
27	significant	O
28	relationship	O
29	with	O
30	any	O
31	of	O
32	the	O
33	hemodynamic	O
34	parameters	O
35	including	O
36	the	O
37	difference	O
38	between	O
39	plasma	O
40	colloid	O
41	osmotic	O
42	pressure	O
43	and	O
44	PCW	O
45	.	O

1	The	O
2	rate	O
3	of	O
4	enzymic	O
5	stimulation	O
6	induced	O
7	by	O
8	a	O
9	given	O
10	nitrate	O
11	correlates	O
12	closely	O
13	with	O
14	the	O
15	rate	O
16	of	O
17	measured	O
18	NO	O
19	production	O
20	from	O
21	the	O
22	nitrate	O
23	molecule	O
24	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	upstream	O
7	promoter	O
8	element	O
9	of	O
10	the	O
11	yeast	O
12	RP39A	O
13	gene	O
14	consists	O
15	of	O
16	these	O
17	identical	O
18	sequence	O
19	motifs	O
20	.	O

1	Eukaryotic	O
2	initiation	O
3	factor	O
4	3	O
5	(	O
6	eIF3	O
7	)	O
8	is	O
9	a	O
10	large	O
11	multisubunit	O
12	complex	O
13	that	O
14	stabilizes	O
15	the	O
16	ternary	O
17	complex	O
18	,	O
19	eIF2	O
20	x	O
21	GTP	B
22	x	I
23	tRNA	I
24	(	I
25	Met	O
26	)	O
27	i	O
28	and	O
29	promotes	O
30	mRNA	B
31	binding	I
32	to	I
33	the	O
34	40	O
35	S	O
36	ribosomal	O
37	subunit	O
38	.	O
39	eIF3	O
40	also	O
41	functions	O
42	as	O
43	a	O
44	ribosome	O
45	subunit	O
46	anti	O
47	-	O
48	association	O
49	factor	O
50	.	O

1	Cloning	O
2	and	O
3	sequence	O
4	analyses	O
5	revealed	O
6	a	O
7	second	O
8	cDNA	O
9	with	O
10	a	B
11	95	I
12	-	I
13	nt	I
14	deletion	I
15	in	O
16	the	O
17	region	O
18	coding	O
19	for	O
20	the	O
21	putative	O
22	second	B
23	intracellular	I
24	loop	I
25	and	I
26	the	I
27	fourth	O
28	transmembrane	B
29	domain	I
30	of	O
31	the	O
32	5	O
33	-	B
34	HT2C	I
35	-	O
36	R	B
37	.	I

1	Inefficacy	O
2	of	O
3	phosphine	O
4	fumigation	O
5	against	O
6	ticks	O
7	.	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O

1	Protein	O
2	tyrosine	B
3	phosphatases	I
4	(	I
5	PTPs	I
6	),	O
7	together	O
8	with	O
9	protein	O
10	tyrosine	O
11	kinases	O
12	(	O
13	PTKs	O
14	),	O
15	are	O
16	involved	O
17	in	O
18	the	O
19	regulation	B
20	of	O
21	cell	I
22	activation	O
23	,	O
24	growth	O
25	,	O
26	and	O
27	differentiation	O
28	.	O

1	73	O
2	:	O
3	658	O
4	-	O
5	666	O
6	,	O
7	1999	O
8	).	O

1	Except	O
2	for	B
3	nonperfusion	I
4	of	I
5	neurosensory	I
6	retinal	I
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	B
13	150	B
14	J	I
15	/	I
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	To	O
2	illustrate	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	photoluminescence	O
9	in	O
10	GaAs	B
11	/	I
12	AlGaAs	O
13	heterostructures	O
14	are	O
15	presented	O
16	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	The	O
2	pyramidal	O
3	tract	O
4	and	O
5	Mesencephalic	O
6	Reticular	O
7	Formation	O
8	(	O
9	MRF	O
10	)	O
11	were	O
12	stimulated	O
13	before	O
14	and	O
15	after	O
16	the	O
17	transection	O
18	.	O

1	The	O
2	recommendation	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	sub	O
8	-	O
9	groups	O
10	of	O
11	attempters	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	warrant	O
19	specialized	O
20	intervention	O
21	strategies	O
22	.	O

1	EM	O
2	analysis	O
3	demonstrated	B
4	that	I
5	only	I
6	one	I
7	Rep	O
8	-	B
9	DNA	I
10	complex	I
11	was	O
12	formed	O
13	on	O
14	ch	O
15	-	O
16	19	O
17	target	O
18	DNA	O
19	.	O

1	Improvement	O
2	of	O
3	the	O
4	CRT	O
5	display	O
6	of	O
7	an	O
8	averager	O
9	.	O

1	Tolterodine	O
2	users	O
3	were	O
4	7	O
5	.	O
6	5	O
7	times	O
8	more	O
9	likely	O
10	to	O
11	have	O
12	received	O
13	another	O
14	spasmolytic	O
15	drug	O
16	(	O
17	RR	O
18	7	O
19	.	O
20	5	O
21	,	O
22	95	O
23	%	O
24	CI	O
25	4	O
26	.	O
27	8	O
28	to	O
29	11	O
30	.	O
31	9	O
32	).	O

1	Role	O
2	of	O
3	the	O
4	infectious	O
5	-	O
6	disease	O
7	specialist	O
8	of	O
9	a	O
10	polyclinic	O
11	in	O
12	reducing	O
13	the	O
14	incidence	O
15	of	O
16	communicable	O
17	diseases	O

1	Six	O
2	healthy	O
3	male	O
4	subjects	O
5	received	O
6	single	O
7	oral	O
8	doses	O
9	of	O
10	regular	O
11	release	O
12	(	O
13	RR	O
14	)	O
15	quinidine	O
16	sulfate	O
17	,	O
18	sustained	O
19	release	O
20	(	O
21	SR	O
22	)	O
23	quinidine	O
24	bisulfate	O
25	and	O
26	the	O
27	same	O
28	dose	O
29	of	O
30	the	O
31	SR	O
32	product	O
33	with	O
34	food	O
35	(	O
36	SR	O
37	-	O
38	F	O
39	).	O

1	During	O
2	the	O
3	years	O
4	1980	O
5	-	O
6	87	O
7	a	O
8	total	O
9	of	O
10	287	O
11	persons	O
12	received	O
13	disability	O
14	pensions	O
15	in	O
16	the	O
17	municipality	O
18	of	O
19	Nordreisa	O
20	in	O
21	northern	O
22	Norway	O
23	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	,	O
5	age	O
6	of	O
7	more	O
8	than	O
9	75	O
10	years	O
11	,	O
12	and	O
13	the	O
14	fact	O
15	that	O
16	the	O
17	patient	O
18	was	O
19	a	O
20	woman	O
21	were	O
22	independent	O
23	predictors	O
24	of	O
25	poor	O
26	cardiac	O
27	function	O
28	.	O

1	The	O
2	combination	O
3	PIP	O
4	64	O
5	micrograms	O
6	-	O
7	PEF	O
8	4	O
9	micrograms	B
10	prevents	I
11	the	I
12	frequent	I
13	secondary	I
14	regrowth	I
15	seen	I
16	after	I
17	6	I
18	hours	I
19	with	I
20	the	O
21	antibiotics	B
22	used	I
23	alone	I
24	.	O

1	However	O
2	,	O
3	the	O
4	a1	O
5	isoform	O
6	is	O
7	expressed	O
8	most	O
9	heavily	O
10	in	O
11	brain	O
12	and	O
13	heart	O
14	,	O
15	a2	O
16	in	O
17	liver	O
18	and	O
19	kidney	O
20	,	O
21	and	O
22	a3	O
23	in	O
24	liver	O
25	,	O
26	lung	O
27	,	O
28	heart	O
29	,	O
30	brain	O
31	,	O
32	spleen	O
33	,	O
34	and	O
35	kidney	O
36	.	O

1	The	O
2	distribution	O
3	of	O
4	body	O
5	fluids	O
6	following	O
7	hemorrhage	O
8	and	B
9	resuscitation	B
10	in	I
11	combat	I
12	casualties	I
13	.	O

1	During	O
2	coronary	O
3	stenosis	B
4	,	I
5	on	I
6	the	O
7	contrary	B
8	,	B
9	intracoronary	I
10	procaterol	O
11	at	O
12	the	O
13	same	O
14	dose	O
15	significantly	O
16	deteriorated	O
17	regional	O
18	myocardial	O
19	dysfunction	O
20	without	O
21	changing	O
22	LCX	O
23	flow	O
24	,	O
25	global	O
26	hemodynamics	O
27	and	O
28	cardiac	O
29	lactate	O
30	metabolism	O
31	.	O

1	Similarly	O
2	,	O
3	expression	O
4	of	O
5	a	O
6	transiently	O
7	transfected	O
8	wild	O
9	-	O
10	type	O
11	prothymosin	O
12	alpha	O
13	gene	O
14	as	O
15	the	O
16	reporter	O
17	was	O
18	not	O
19	affected	O
20	by	O
21	a	O
22	repertoire	O
23	of	O
24	myc	O
25	-	O
26	derived	O
27	genes	O
28	,	O
29	including	O
30	myc	O
31	itself	O
32	and	O
33	dominant	O
34	or	O
35	recessive	O
36	negative	O
37	myc	O
38	mutants	O
39	.	O

1	DESIGN	O
2	:	O
3	Serum	O
4	aldosterone	O
5	and	O
6	plasma	O
7	renin	O
8	activity	O
9	were	B
10	measured	I
11	supine	I
12	prior	I
13	to	O
14	and	O
15	60	O
16	,	O
17	90	O
18	,	O
19	120	O
20	minutes	O
21	after	O
22	oral	O
23	captopril	O
24	,	O
25	25	O
26	mg	O
27	.	O

1	CCAAT	O
2	displacement	O
3	protein	O
4	binds	O
5	to	O
6	and	O
7	negatively	O
8	regulates	O
9	human	O
10	papillomavirus	O
11	type	O
12	6	O
13	E6	O
14	,	O
15	E7	O
16	,	O
17	and	O
18	E1	O
19	promoters	O
20	.	O

1	Antivitamin	O
2	K	O
3	agents	O

1	Preheparin	O
2	LPL	O
3	mass	O
4	level	O
5	did	O
6	not	O
7	significantly	O
8	differ	O
9	in	O
10	individuals	O
11	from	O
12	19	O
13	to	O
14	70	O
15	years	O
16	old	O
17	,	O
18	for	O
19	both	O
20	men	O
21	and	O
22	women	O
23	.	O

1	Mutation	O
2	of	O
3	the	O
4	C	O
5	/	O
6	EBP	B
7	binding	I
8	sites	I
9	in	O
10	the	O
11	Rous	O
12	sarcoma	O
13	virus	O
14	long	O
15	terminal	O
16	repeat	O
17	and	O
18	gag	O
19	enhancers	O
20	.	O

1	On	O
2	the	O
3	other	O
4	side	B
5	,	I
6	when	I
7	the	O
8	aortic	O
9	ring	O
10	was	O
11	perfused	O
12	with	O
13	L	O
14	-	O
15	NNA	O
16	(	O
17	NO	O
18	-	O
19	synthesis	O
20	inhibitor	B
21	)	I
22	or	I
23	methylene	I
24	blue	I
25	(	O
26	soluble	B
27	cGMPase	I
28	inhibitor	I
29	),	I
30	the	I
31	changes	I
32	could	I
33	be	O
34	attenuated	O
35	.	O

1	Consanguinity	O
2	and	O
3	migration	B
4	in	I
5	the	I
6	marriages	I
7	of	I
8	the	I
9	region	O
10	of	O
11	Nunoa	O
12	,	B
13	Santiago	I
14	,	I
15	1850	I
16	-	O
17	1960	O

1	Human	O
2	adenovirus	O
3	type	O
4	41	O
5	contains	O
6	two	O
7	fibers	O
8	.	O

1	A	O
2	genetic	O
3	and	O
4	molecular	O
5	analysis	O
6	of	O
7	non	O
8	-	O
9	inducible	O
10	qutA	O
11	mutants	O
12	showed	O
13	that	B
14	all	B
15	23	O
16	mutations	O
17	analysed	O
18	map	O
19	within	O
20	the	O
21	N	O
22	-	B
23	terminal	I
24	half	I
25	of	I
26	the	O
27	encoded	O
28	QUTA	O
29	protein	O
30	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	revealed	O
6	that	O
7	Sp1	O
8	binds	O
9	to	O
10	two	O
11	different	O
12	regions	O
13	in	O
14	the	O
15	proximal	O
16	promoter	O
17	,	O
18	a	O
19	typical	O
20	Sp1	O
21	site	O
22	located	O
23	at	O
24	(-	O
25	38	O
26	;	O
27	-	O
28	33	O
29	)	O
30	and	O
31	a	O
32	G	O
33	/	O
34	C	O
35	-	O
36	rich	O
37	region	O
38	between	O
39	(-	O
40	67	O
41	;	O
42	-	O
43	62	O
44	).	O

1	Following	O
2	the	O
3	observation	O
4	that	O
5	non	O
6	-	O
7	organ	O
8	-	O
9	specific	O
10	antibodies	O
11	are	B
12	related	I
13	with	I
14	pregnancy	O
15	loss	O
16	and	O
17	preeclampsia	O
18	,	O
19	the	O
20	role	O
21	of	O
22	organ	O
23	-	O
24	specific	O
25	antibodies	O
26	is	O
27	currently	O
28	being	O
29	extensively	O
30	investigated	O
31	.	O

1	Mutating	O
2	the	O
3	E	O
4	-	B
5	box	I
6	in	I
7	the	I
8	context	I
9	of	I
10	the	O
11	3	O
12	'-	O
13	flanking	O
14	region	O
15	confirmed	O
16	that	O
17	it	O
18	contributes	O
19	to	O
20	the	O
21	enhancement	O
22	of	O
23	transcriptional	O
24	activity	O
25	of	O
26	the	O
27	alpha1	O
28	(	O
29	I	O
30	)	O
31	collagen	O
32	gene	O
33	promoter	O
34	.	O

1	The	O
2	current	O
3	study	O
4	defines	O
5	the	O
6	vinculin	O
7	-	O
8	and	O
9	FAK	O
10	-	O
11	interaction	O
12	domains	O
13	on	O
14	paxillin	B
15	and	I
16	identifies	I
17	the	I
18	principal	I
19	paxillin	I
20	focal	I
21	adhesion	I
22	targeting	I
23	motif	I
24	.	I

1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mature	O
6	region	O
7	is	O
8	highly	O
9	conserved	O
10	in	O
11	other	O
12	serine	B
13	carboxypeptidases	I
14	.	I

1	VP5	O
2	,	O
3	which	O
4	encodes	O
5	the	O
6	major	O
7	capsid	O
8	protein	O
9	,	B
10	each	B
11	fused	I
12	to	I
13	the	O
14	chloramphenicol	O
15	acetyltransferase	O
16	gene	O
17	.	O

1	UDP	O
2	-	O
3	GlcNAc	O
4	:	O
5	alpha	O
6	-	O
7	6	O
8	-	O
9	D	O
10	-	O
11	mannoside	O
12	beta	O
13	-	O
14	1	O
15	,	O
16	2	O
17	-	O
18	N	O
19	-	O
20	acetylglucosaminyltransferase	O
21	II	O
22	(	O
23	GnT	O
24	II	O
25	;	O
26	EC	O
27	2	O
28	.	O
29	4	O
30	.	O
31	1	O
32	.	O
33	143	O
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	a	O
7	synthetic	O
8	E6	B
9	motif	I
10	detected	I
11	a	I
12	B	I
13	-	I
14	cell	I
15	-	I
16	specific	O
17	complex	B
18	in	I
19	addition	I
20	to	I
21	a	O
22	ubiquitous	B
23	band	I
24	found	I
25	also	I
26	in	O
27	T	O
28	cells	O
29	and	O
30	HeLa	O
31	cells	O
32	.	O

1	The	O
2	deduced	O
3	96	O
4	-	O
5	residue	O
6	amino	O
7	acid	O
8	coding	O
9	sequence	O
10	of	O
11	the	O
12	murine	B
13	HMG	I
14	-	I
15	I	O
16	(	O
17	Y	O
18	)	O
19	cDNA	O
20	is	O
21	very	O
22	similar	O
23	to	O
24	the	O
25	reported	O
26	amino	O
27	acid	O
28	sequence	O
29	of	O
30	human	O
31	HMG	O
32	-	O
33	I	O
34	,	O
35	except	O
36	that	O
37	it	O
38	lacks	O
39	11	O
40	internal	O
41	amino	O
42	acids	O
43	reported	O
44	in	O
45	the	O
46	human	O
47	protein	O
48	.	B

1	We	O
2	discuss	O
3	these	O
4	results	O
5	with	O
6	respect	O
7	to	O
8	the	O
9	transcriptional	O
10	induction	O
11	of	O
12	the	O
13	HNF	O
14	-	O
15	3	O
16	alpha	O
17	gene	O
18	in	O
19	respiratory	O
20	epithelium	O
21	during	O
22	embryogenesis	O
23	.	O

1	Complete	O
2	recovery	O
3	of	O
4	liver	O
5	function	O
6	after	O
7	this	B
8	surgery	I
9	tended	O
10	to	O
11	be	O
12	slow	O
13	.	O

1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O

1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	Although	O
2	linker	O
3	regions	O
4	in	O
5	transcription	O
6	factors	O
7	are	O
8	known	O
9	to	O
10	modulate	O
11	DNA	O
12	binding	O
13	specificity	O
14	,	O
15	our	O
16	studies	O
17	suggest	O
18	that	O
19	the	O
20	human	O
21	HSF1	O
22	linker	O
23	plays	O
24	no	O
25	role	O
26	in	O
27	determining	O
28	HSF1	O
29	binding	O
30	preferences	O
31	in	O
32	vivo	O
33	but	O
34	is	O
35	a	O
36	critical	O
37	determinant	O
38	in	O
39	regulating	O
40	the	O
41	HSF1	O
42	monomer	O
43	-	O
44	trimer	O
45	equilibrium	O
46	.	O

1	Clones	O
2	that	O
3	expressed	O
4	DBD	O
5	exhibited	O
6	a	O
7	dominant	O
8	negative	O
9	phenotype	O
10	and	O
11	did	O
12	not	O
13	elicit	O
14	antiviral	O
15	activity	O
16	against	O
17	vesicular	O
18	stomatitis	O
19	virus	O
20	(	O
21	VSV	O
22	)	O
23	infection	O
24	upon	O
25	IFN	O
26	treatment	O
27	.	O

1	JNK	O
2	is	O
3	additionally	O
4	regulated	O
5	by	O
6	the	O
7	Ras	O
8	-	O
9	related	O
10	G	O
11	proteins	O
12	Rac	O
13	and	O
14	Cdc42	O
15	.	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	multicentre	O
6	trial	O
7	the	O
8	efficacy	O
9	of	O
10	an	O
11	Vitex	O
12	agnus	O
13	castus	O
14	L	O
15	extract	O
16	Ze	O
17	440	O
18	was	O
19	investigated	O
20	in	O
21	50	O
22	patients	O
23	with	O
24	pre	O
25	-	O
26	menstrual	O
27	syndrome	O
28	(	O
29	PMS	O
30	).	O

1	Multi	O
2	drug	O
3	regimens	O
4	like	O
5	C	O
6	-	O
7	MOPP	O
8	,	O
9	CHOP	O
10	and	O
11	BACOP	O
12	led	O
13	to	O
14	high	O
15	remission	O
16	rates	O
17	and	O
18	in	O
19	some	O
20	cases	O
21	probably	O
22	also	O
23	to	O
24	a	O
25	cure	O
26	of	O
27	the	O
28	disease	O
29	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Percentage	O
6	change	O
7	in	O
8	the	O
9	apnea	O
10	-	O
11	hypopnea	O
12	index	O
13	(	O
14	AHI	O
15	;	O
16	apnea	O
17	events	O
18	+	O
19	hypopnea	O
20	events	O
21	per	O
22	hour	O
23	of	B
24	sleep	I
25	)	I
26	and	I
27	odds	O
28	of	O
29	developing	O
30	moderate	O
31	-	O
32	to	O
33	-	O
34	severe	O
35	SDB	O
36	(	O
37	defined	O
38	by	B
39	an	I
40	AHI	I
41	>	I
42	or	O
43	=	O
44	15	O
45	events	O
46	per	O
47	hour	O
48	of	O
49	sleep	O
50	),	O
51	with	O
52	respect	O
53	to	O
54	change	O
55	in	I
56	weight	I
57	.	O

1	Azithromycin	O
2	is	O
3	a	B
4	new	I
5	generation	I
6	macrolide	O
7	antibiotic	O
8	with	O
9	unusual	O
10	and	O
11	favorable	O
12	pharmacokinetics	O
13	,	O
14	and	O
15	seems	O
16	to	O
17	be	O
18	a	O
19	very	O
20	promising	O
21	agent	I
22	for	O
23	innovative	O
24	anti	O
25	-	O
26	H	O
27	.	O
28	pylori	O
29	regimens	O
30	.	O

1	Use	O
2	of	O
3	serum	O
4	thyroglobulin	O
5	determination	O
6	in	O
7	the	O
8	follow	O
9	-	O
10	up	B
11	of	I
12	differentiated	I
13	carcinomas	I
14	of	O
15	the	O
16	thyroid	O

1	During	O
2	the	O
3	dose	O
4	-	O
5	finding	O
6	,	O
7	two	O
8	patients	O
9	were	O
10	temporarily	B
11	withdrawn	I
12	from	I
13	medication	I
14	and	I
15	one	I
16	patient	O
17	was	O
18	excluded	B
19	because	I
20	of	I
21	elevated	I
22	levels	I
23	of	O
24	liver	B
25	enzymes	I
26	.	O

1	In	O
2	addition	O
3	,	O
4	these	O
5	cells	O
6	contained	O
7	one	B
8	,	I
9	two	I
10	,	O
11	or	B
12	multiple	I
13	nuclei	I
14	indicative	O
15	of	O
16	a	O
17	G2	O
18	/	O
19	M	O
20	delay	O
21	in	O
22	nuclear	O
23	division	B
24	and	I
25	also	I
26	a	I
27	defect	I
28	in	I
29	cytokinesis	O
30	and	B
31	/	B
32	or	O
33	cell	O
34	separation	B
35	.	I

1	To	O
2	overcome	O
3	this	O
4	problem	O
5	,	O
6	we	O
7	have	O
8	overexpressed	O
9	Kex2p	O
10	using	O
11	the	O
12	baculovirus	O
13	/	O
14	insect	O
15	cell	O
16	expression	O
17	system	O
18	.	O

1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	R	O
8	.	O
9	N	O
10	.	O

1	Ki	O
2	-	O
3	ras	O
4	and	O
5	p53	O
6	mutations	O
7	in	O
8	pancreatic	O
9	ductal	O
10	adenocarcinoma	O
11	.	O

1	Ras	O
2	p21Val	O
3	inhibits	O
4	myogenesis	O
5	without	O
6	altering	O
7	the	O
8	DNA	O
9	binding	O
10	or	O
11	transcriptional	O
12	activities	O
13	of	B
14	the	I
15	myogenic	I
16	basic	O
17	helix	O
18	-	O
19	loop	O
20	-	O
21	helix	O
22	factors	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	and	O
5	in	O
6	support	O
7	of	O
8	a	O
9	mediating	O
10	role	O
11	of	O
12	STATs	O
13	in	O
14	the	O
15	activation	O
16	of	O
17	the	O
18	p21	O
19	promoter	O
20	,	B
21	overexpression	I
22	of	I
23	Stat3	I
24	potentiated	I
25	the	I
26	cytokine	I
27	effect	I
28	on	I
29	the	O
30	p21	B
31	promoter	I
32	;	O
33	whereas	O
34	a	O
35	dominant	O
36	negative	O
37	Stat3	O
38	,	O
39	or	O
40	a	O
41	mutation	O
42	of	O
43	the	O
44	STAT	O
45	response	O
46	element	O
47	on	O
48	the	O
49	promoter	O
50	,	O
51	significantly	O
52	reduced	O
53	the	O
54	cytokine	O
55	effect	O
56	.	O

1	Isolation	O
2	of	O
3	a	O
4	near	O
5	full	O
6	-	O
7	length	O
8	cDNA	O
9	from	O
10	a	O
11	human	O
12	fetal	O
13	brain	O
14	cDNA	O
15	library	O
16	revealed	O
17	a	O
18	protein	O
19	serine	O
20	-	O
21	threonine	B
22	phosphatase	I
23	with	I
24	a	O
25	tetratricopeptide	B
26	motif	I
27	,	O
28	almost	B
29	identical	B
30	to	I
31	human	O
32	PPP5C	O
33	(	B
34	PP5	B
35	)	O
36	and	O
37	highly	O
38	homologous	O
39	to	O
40	rat	O
41	PPT	O
42	.	O

1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	B
23	putative	I
24	RNA	I
25	template	I
26	-	I
27	binding	I
28	site	O
29	of	O
30	the	O
31	PLRV	O
32	replicase	O
33	in	B
34	the	I
35	ORF2a	O
36	/	B
37	ORF2b	I
38	transframe	I
39	protein	I
40	.	I

1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	O
12	alpha	O
13	s1	O
14	-	O
15	casein	O
16	transcription	O
17	unit	O
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O

1	Analysis	O
2	of	O
3	this	O
4	sequence	O
5	combined	O
6	with	O
7	that	O
8	previously	O
9	reported	O
10	for	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	directly	O
17	proximal	O
18	to	B
19	the	B
20	start	I
21	of	I
22	transcription	I
23	revealed	O
24	several	O
25	putative	O
26	regulatory	B
27	sequences	B
28	.	I

1	In	O
2	our	O
3	studies	O
4	,	O
5	we	O
6	utilized	O
7	HIV	O
8	-	O
9	1	O
10	HXB2	O
11	and	O
12	HIV	O
13	-	O
14	1	O
15	Z2Z6	O
16	core	O
17	enhancers	O
18	because	O
19	the	O
20	Z2Z6	O
21	strain	O
22	has	O
23	a	O
24	single	O
25	point	O
26	mutation	O
27	flanking	O
28	the	O
29	right	O
30	ETS	O
31	-	O
32	binding	O
33	site	O
34	.	O

1	Sodium	O
2	polystyrene	B
3	sulfonate	I
4	treatment	I
5	for	I
6	lithium	I
7	toxicity	O
8	:	O
9	effects	O
10	on	B
11	serum	O
12	potassium	O
13	concentrations	O
14	.	O

1	In	O
2	these	O
3	cases	O
4	,	O
5	greatly	O
6	increased	O
7	human	B
8	chorionic	I
9	gonadotropin	I
10	(	O
11	hCG	O
12	)	O
13	levels	O
14	and	O
15	suppressed	O
16	TSH	O
17	levels	O
18	suggest	O
19	that	O
20	hCG	O
21	has	O
22	thyrotropic	O
23	activity	O
24	.	O

1	The	O
2	results	B
3	indicate	I
4	that	I
5	increased	I
6	pulmonary	I
7	blood	I
8	flow	I
9	and	I
10	decreased	I
11	pulmonary	I
12	vascular	I
13	resistance	I
14	with	O
15	advancing	B
16	gestation	I
17	are	I
18	due	I
19	to	I
20	an	I
21	increase	I
22	in	I
23	the	I
24	total	I
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	I
45	the	I
46	thickness	B
47	of	O
48	muscle	I
49	in	O
50	individual	B
51	vessels	I
52	remains	I
53	constant	I
54	.	I

1	In	O
2	Rat	O
3	1a	O
4	cells	O
5	,	O
6	m1R	O
7	stimulation	O
8	of	O
9	phospholipase	O
10	C	B
11	beta	I
12	and	I
13	the	I
14	marked	O
15	rise	O
16	in	O
17	intracellular	O
18	calcium	O
19	stimulated	O
20	cyclic	O
21	AMP	O
22	(	O
23	cAMP	O
24	)	O
25	synthesis	B
26	,	I
27	resulting	I
28	in	I
29	the	I
30	activation	I
31	of	O
32	protein	O
33	kinase	O
34	A	O
35	.	O

1	The	O
2	region	O
3	that	O
4	imparts	O
5	inducibility	O
6	by	O
7	IL	O
8	-	O
9	1	O
10	or	O
11	TNF	O
12	(	O
13	positions	O
14	-	O
15	165	O
16	to	O
17	-	O
18	58	O
19	)	O
20	contains	O
21	potential	O
22	binding	O
23	sites	O
24	for	O
25	IRF	O
26	-	O
27	1	O
28	and	O
29	-	O
30	2	O
31	,	O
32	AP	O
33	-	O
34	1	O
35	,	O
36	and	O
37	NF	O
38	-	O
39	IL	O
40	-	O
41	6	O
42	.	O

1	The	O
2	homeobox	O
3	gene	O
4	ATK1	O
5	of	O
6	Arabidopsis	O
7	thaliana	O
8	is	O
9	expressed	O
10	in	O
11	the	O
12	shoot	O
13	apex	O
14	of	O
15	the	O
16	seedling	O
17	and	O
18	in	O
19	flowers	O
20	and	O
21	inflorescence	O
22	stems	O
23	of	O
24	mature	O
25	plants	O
26	.	O

1	Promoter	O
2	activity	O
3	was	O
4	high	O
5	in	O
6	cell	O
7	lines	O
8	that	O
9	expressed	O
10	high	O
11	levels	O
12	of	O
13	endogenous	O
14	D3	O
15	mRNA	O
16	,	O
17	as	O
18	indicated	O
19	by	O
20	Northern	O
21	blot	O
22	analyses	O
23	,	O
24	and	O
25	was	O
26	significantly	O
27	reduced	O
28	when	O
29	the	O
30	promoter	O
31	was	O
32	truncated	O
33	to	O
34	-	O
35	122	O
36	bp	O
37	.	O

1	Evaluation	O
2	of	O
3	desmopressin	O
4	for	O
5	dental	O
6	extractions	B
7	in	I
8	patients	I
9	with	O
10	hemostatic	B
11	disorders	I
12	.	I

1	Other	O
2	uncertainties	O
3	in	O
4	the	O
5	dosimetry	O
6	at	O
7	Y	O
8	-	B
9	12	I
10	and	I
11	Vinca	O
12	are	O
13	unaltered	B
14	.	B

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	identify	O
7	and	O
8	characterize	O
9	two	O
10	overlapping	O
11	ELL	O
12	functional	O
13	domains	O
14	that	O
15	govern	O
16	its	O
17	interaction	O
18	with	O
19	RNA	O
20	polymerase	O
21	II	O
22	and	O
23	the	O
24	ternary	O
25	elongation	O
26	complex	O
27	.	O

1	In	O
2	the	O
3	artificial	O
4	lung	O
5	,	O
6	like	O
7	in	O
8	the	O
9	natural	O
10	lung	O
11	and	O
12	peripheral	O
13	tissues	O
14	,	O
15	gas	O
16	exchanges	O
17	depend	O
18	on	O
19	several	O
20	parameters	O
21	:	O
22	blood	O
23	inlet	O
24	conditions	O
25	,	O
26	blood	O
27	flow	O
28	rate	O
29	,	O
30	temperature	O
31	,	O
32	composition	O
33	of	O
34	the	O
35	gas	O
36	mixture	O
37	used	O
38	for	O
39	ventilation	O
40	,	O
41	blood	O
42	tissue	O
43	perfusion	O
44	,	O
45	O2	O
46	consumption	O
47	,	O
48	etc	O
49	.	O

1	The	O
2	smaller	O
3	uptake	O
4	rate	O
5	and	O
6	faster	O
7	clearance	O
8	rate	O
9	resulted	O
10	in	O
11	the	O
12	lower	O
13	BCF	O
14	for	O
15	SWA	O
16	killifish	O
17	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	,	O
7	expression	O
8	,	O
9	and	O
10	biochemical	O
11	characterization	O
12	of	O
13	the	O
14	32	O
15	-	O
16	kDa	O
17	subunit	O
18	of	O
19	human	O
20	(	O
21	h	O
22	)	O
23	TFIID	O
24	,	O
25	termed	O
26	hTAFII32	O
27	.	O

1	Middle	O
2	-	O
3	latency	O
4	auditory	O
5	evoked	O
6	potentials	O
7	(	O
8	MAEPs	O
9	)	O
10	were	O
11	recorded	O
12	in	O
13	controls	O
14	and	O
15	patients	O
16	with	O
17	focal	O
18	lesions	O
19	in	O
20	dorsolateral	O
21	prefrontal	O
22	cortex	O
23	.	O

1	Aneurysmal	O
2	bone	O
3	cyst	O
4	of	O
5	the	O
6	jaws	O
7	:	O
8	analysis	O
9	of	O
10	11	O
11	cases	O
12	.	O

1	In	O
2	conclusion	O
3	,	O
4	these	O
5	observations	O
6	demonstrated	O
7	that	O
8	stratification	O
9	of	O
10	acute	O
11	MI	O
12	patients	O
13	by	O
14	plasma	O
15	ANF	O
16	level	O
17	is	O
18	a	O
19	useful	O
20	non	O
21	-	O
22	invasive	O
23	method	O
24	for	O
25	predicting	O
26	prognosis	O
27	and	O
28	for	O
29	identifying	O
30	individuals	O
31	at	O
32	high	O
33	risk	O
34	of	O
35	cardiac	O
36	death	O
37	.	O

1	1	O
2	-(	O
3	1	O
4	-	O
5	Naphthyl	B
6	)	I
7	piperazine	I
8	(	O
9	1	O
10	-	O
11	NP	O
12	)	O
13	has	O
14	been	O
15	reported	O
16	to	O
17	have	O
18	serotonin	O
19	antagonist	O
20	properties	O
21	at	O
22	the	O
23	5	O
24	-	O
25	HT2	O
26	subtype	O
27	of	O
28	receptor	O
29	,	O
30	and	O
31	it	O
32	has	O
33	been	O
34	suggested	O
35	that	O
36	it	O
37	may	O
38	have	O
39	agonist	O
40	actions	O
41	at	O
42	the	O
43	5	O
44	-	O
45	HT1	O
46	site	O
47	.	O

1	RNase	O
2	protection	O
3	analyses	O
4	indicate	O
5	that	O
6	either	O
7	61	O
8	-	O
9	kDa	O
10	CaM	O
11	PDE	B
12	mRNA	I
13	or	I
14	structurally	I
15	related	I
16	transcripts	O
17	encoding	O
18	different	O
19	CaM	O
20	PDE	O
21	isoforms	O
22	are	O
23	expressed	O
24	in	O
25	a	O
26	tissue	O
27	-	O
28	specific	O
29	manner	O
30	.	O

1	Defects	O
2	of	O
3	fibrillin	O
4	(	O
5	FBN1	O
6	),	B
7	a	I
8	glycoprotein	I
9	component	O
10	of	O
11	the	O
12	extracellular	B
13	microfibril	B
14	,	I
15	cause	O
16	Marfan	O
17	syndrome	O
18	.	O

1	Further	O
2	research	O
3	is	O
4	required	B
5	to	I
6	better	I
7	measure	I
8	treatment	O
9	effects	O
10	,	O
11	modification	O
12	of	O
13	MS	O
14	natural	O
15	history	O
16	,	O
17	and	O
18	net	O
19	societal	O
20	costs	O
21	of	O
22	IFN	O
23	beta	O
24	-	O
25	1b	O
26	in	O
27	RRMS	O
28	.	O

1	Results	O
2	from	O
3	in	O
4	vitro	O
5	transcription	O
6	-	O
7	translation	O
8	analysis	O
9	and	O
10	maxicell	O
11	experiments	O
12	suggested	O
13	that	O
14	the	O
15	447	O
16	-	O
17	bp	O
18	ORF	O
19	was	O
20	the	O
21	one	O
22	being	O
23	actively	O
24	expressed	O
25	.	O

1	The	O
2	galactose	O
3	transporter	O
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	O
15	transporters	O
16	which	O
17	includes	O
18	the	O
19	human	O
20	HepG2	O
21	-	O
22	erythrocyte	O
23	and	O
24	fetal	O
25	muscle	O
26	glucose	O
27	transporters	O
28	,	O
29	the	O
30	rat	O
31	brain	O
32	and	O
33	liver	O
34	glucose	O
35	transporters	O
36	,	O
37	the	O
38	Escherichia	O
39	coli	O
40	xylose	O
41	and	O
42	arabinose	O
43	permeases	O
44	,	O
45	and	O
46	the	O
47	S	O
48	.	O
49	cerevisiae	O
50	glucose	O
51	,	O
52	maltose	O
53	,	O
54	and	O
55	galactose	O
56	transporters	O
57	.	O

1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	B

1	The	O
2	protein	O
3	expressed	O
4	from	O
5	the	O
6	cloned	O
7	cDNA	O
8	is	O
9	secreted	O
10	into	O
11	the	O
12	culture	O
13	medium	O
14	and	O
15	yields	O
16	of	O
17	up	O
18	to	O
19	40	O
20	mg	O
21	per	O
22	litre	O
23	have	O
24	been	O
25	obtained	O
26	.	O

1	For	O
2	example	O
3	,	O
4	introduction	O
5	of	O
6	immunogenic	O
7	and	O
8	purification	O
9	tag	O
10	sequences	O
11	into	O
12	the	O
13	C	O
14	-	O
15	terminal	O
16	coding	B
17	region	I
18	significantly	O
19	decreased	O
20	bop	O
21	gene	O
22	mRNA	O
23	and	O
24	protein	O
25	accumulation	O
26	.	O

1	Enhancers	O
2	containing	O
3	disrupted	O
4	Ets	O
5	-	O
6	1	O
7	binding	O
8	sites	O
9	were	B
10	tested	I
11	in	I
12	transient	I
13	expression	I
14	assays	O
15	in	O
16	the	O
17	murine	O
18	T	O
19	-	O
20	cell	O
21	line	O
22	EL4	O
23	.	O
24	E1	O
25	;	O
26	alterations	O
27	in	O
28	the	O
29	LVb	O
30	element	O
31	affected	O
32	constitutive	O
33	enhancer	O
34	activity	O
35	,	O
36	while	O
37	mutation	O
38	of	O
39	either	O
40	the	O
41	LVb	O
42	or	O
43	LVc	O
44	element	O
45	disrupted	B
46	phorbol	I
47	ester	I
48	-	I
49	induced	I
50	enhancer	O
51	activity	O
52	.	O

1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O

1	The	O
2	Tullio	O
3	phenomenon	O
4	,	B
5	fistula	O
6	test	I
7	,	O
8	and	O
9	Hennebert	O
10	'	O
11	s	O
12	sign	O
13	:	O
14	clinical	O
15	significance	O
16	.	O

1	The	O
2	highly	O
3	restrained	O
4	girls	O
5	had	O
6	a	O
7	significantly	O
8	higher	O
9	EAT	O
10	score	O
11	than	O
12	the	O
13	low	O
14	-	O
15	restrained	O
16	girls	O
17	,	O
18	and	O
19	shared	O
20	with	O
21	their	O
22	mothers	O
23	a	O
24	susceptibility	O
25	to	O
26	the	O
27	disinhibitory	O
28	effects	O
29	of	O
30	negative	O
31	mood	O
32	states	O
33	on	O
34	their	O
35	eating	O
36	behaviour	O
37	.	O

1	Insertional	O
2	inactivation	O
3	of	O
4	sms	O
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	The	O
2	patients	O
3	undergoing	B
4	VTLB	I
5	had	I
6	significantly	I
7	shorter	I
8	operative	O
9	times	O
10	(	O
11	VTLB	O
12	,	O
13	100	O
14	.	O
15	2	O
16	+/-	O
17	27	O
18	.	O
19	2	O
20	min	O
21	.	O
22	vs	O
23	OLB	O
24	,	O
25	119	O
26	.	O
27	8	O
28	+/-	O
29	42	O
30	.	O
31	6	O
32	min	O
33	;	O
34	p	O
35	<	O
36	0	B
37	.	I
38	01	I
39	)	I
40	and	I
41	less	O
42	blood	O
43	loss	O
44	(	O
45	VTLB	O
46	,	O
47	4	O
48	.	O
49	7	O
50	+/-	O
51	14	O
52	.	O
53	6	O
54	ml	O
55	vs	O
56	OLB	O
57	,	B
58	65	I
59	.	I
60	7	O
61	+/-	O
62	77	O
63	.	O
64	0	O
65	ml	O
66	;	O
67	p	O
68	<	O
69	0	O
70	.	O
71	001	I
72	).	B

1	H	O
2	-	O
3	7	O
4	,	O
5	which	O
6	specifically	O
7	,	O
8	although	O
9	weakly	O
10	,	O
11	inhibited	O
12	PKC	O
13	activation	O
14	,	B
15	had	I
16	no	I
17	effect	I
18	on	I
19	tyrosine	O
20	phosphorylation	O
21	and	O
22	PtdIns	O
23	(	O
24	3	O
25	,	O
26	4	O
27	)	O
28	P2	O
29	production	B
30	.	I

1	Treatment	O
2	of	O
3	unstable	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	antithrombotic	O
9	therapy	O
10	.	O

1	The	O
2	Ntl1	O
3	gene	O
4	is	O
5	present	O
6	as	O
7	a	O
8	unique	O
9	copy	O
10	in	O
11	the	O
12	diploid	O
13	N	O
14	.	O
15	plumbaginifolia	O
16	species	O
17	.	O

1	Peter	O
2	Elfer	O
3	explores	O
4	the	O
5	implications	O
6	of	O
7	the	O
8	ruling	O
9	.	O

1	Substantial	O
2	evidence	O
3	supports	O
4	a	O
5	critical	O
6	role	O
7	for	O
8	the	O
9	activation	O
10	of	O
11	the	O
12	Raf	O
13	-	O
14	1	O
15	/	O
16	MEK	O
17	/	O
18	mitogen	O
19	-	B
20	activated	I
21	protein	I
22	kinase	I
23	pathway	I
24	in	I
25	oncogenic	I
26	Ras	I
27	-	O
28	mediated	O
29	transformation	O
30	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	protein	O
7	product	O
8	of	O
9	the	O
10	ref	O
11	-	O
12	1	O
13	gene	O
14	stimulates	O
15	the	O
16	DNA	O
17	binding	O
18	activity	O
19	of	O
20	Fos	O
21	-	O
22	Jun	O
23	heterodimers	O
24	,	O
25	Jun	O
26	-	O
27	Jun	O
28	homodimers	O
29	and	O
30	Hela	O
31	cell	O
32	AP	O
33	-	O
34	1	O
35	proteins	O
36	as	O
37	well	O
38	as	O
39	that	O
40	of	O
41	several	O
42	other	O
43	transcription	O
44	factors	O
45	including	O
46	NF	O
47	-	O
48	kappa	O
49	B	O
50	,	O
51	Myb	O
52	and	O
53	members	O
54	of	O
55	the	O
56	ATF	O
57	/	O
58	CREB	O
59	family	O
60	.	O

1	In	O
2	the	O
3	DNA	O
4	recognition	O
5	helix	O
6	of	O
7	finger	O
8	II	O
9	,	O
10	the	O
11	conserved	O
12	Arg	O
13	at	O
14	position	O
15	62	O
16	(	O
17	N	O
18	-	O
19	terminal	O
20	side	O
21	of	O
22	the	O
23	first	O
24	zinc	O
25	-	O
26	coordinating	O
27	histidine	O
28	)	O
29	was	O
30	changed	O
31	to	O
32	a	O
33	Leu	O
34	or	O
35	Gln	O
36	.	O

1	Spontaneous	O
2	sensitization	O
3	to	O
4	cross	O
5	-	O
6	reacting	O
7	chemicals	O
8	in	O
9	a	O
10	proportion	O
11	of	O
12	control	O
13	animals	O
14	is	O
15	strongly	O
16	suggested	O
17	,	O
18	somewhat	B
19	akin	B
20	to	I
21	spontaneous	O
22	sensitization	O
23	in	O
24	patients	O
25	with	O
26	anaphylactoid	O
27	reactions	O
28	to	O
29	neuromuscular	O
30	blockers	O
31	on	O
32	first	O
33	exposure	O
34	,	O
35	and	O
36	in	O
37	whom	O
38	IgE	O
39	antibodies	O
40	are	O
41	detected	O
42	.	O

1	These	O
2	and	B
3	other	I
4	comparisons	I
5	suggest	I
6	that	I
7	,	I
8	during	I
9	evolution	I
10	,	I
11	both	O
12	the	O
13	RNA	O
14	-	O
15	polymerase	O
16	specificity	O
17	of	O
18	telomerase	O
19	RNA	O
20	-	O
21	gene	O
22	promoters	B
23	and	O
24	,	O
25	more	B
26	recently	O
27	,	O
28	the	O
29	position	O
30	of	O
31	the	B
32	template	I
33	sequence	O
34	in	O
35	the	B
36	telomerase	I
37	RNA	I
38	changed	I
39	.	I

1	The	O
2	zta	O
3	transactivator	O
4	involved	O
5	in	O
6	induction	O
7	of	O
8	lytic	O
9	cycle	O
10	gene	O
11	expression	O
12	in	O
13	Epstein	O
14	-	O
15	Barr	O
16	virus	O
17	-	O
18	infected	O
19	lymphocytes	O
20	binds	O
21	to	O
22	both	O
23	AP	O
24	-	O
25	1	O
26	and	O
27	ZRE	O
28	sites	O
29	in	O
30	target	O
31	promoter	O
32	and	O
33	enhancer	O
34	regions	O
35	.	O

1	Group	O
2	A	O
3	was	O
4	treated	O
5	with	O
6	three	O
7	or	O
8	four	O
9	doses	O
10	of	O
11	hepatitis	O
12	B	O
13	immune	O
14	globulin	O
15	(	O
16	HBIG	O
17	)	O
18	in	O
19	one	O
20	of	O
21	three	O
22	different	O
23	schedules	O
24	.	O

1	After	O
2	determining	O
3	isoflurane	O
4	MAC	O
5	in	O
6	triplicate	B
7	,	I
8	birds	I
9	were	I
10	given	I
11	a	I
12	mu	O
13	-	O
14	opioid	O
15	agonist	O
16	(	O
17	morphine	O
18	,	O
19	n	O
20	=	I
21	9	O
22	)	O
23	or	I
24	a	I
25	kappa	I
26	-	O
27	opioid	O
28	agonist	O
29	(	O
30	U50488H	O
31	,	O
32	n	O
33	=	O
34	9	O
35	).	O

1	Response	O
2	durations	O
3	were	O
4	short	O
5	.	O

1	Here	O
2	we	B
3	show	I
4	that	I
5	epidermal	I
6	growth	I
7	factor	I
8	or	I
9	platelet	I
10	-	I
11	derived	O
12	growth	B
13	factor	B
14	stimulation	I
15	of	O
16	intact	O
17	human	B
18	or	I
19	murine	I
20	cells	I
21	leads	I
22	to	I
23	phosphorylation	I
24	of	O
25	Nck	O
26	protein	O
27	on	O
28	tyrosine	O
29	,	O
30	serine	O
31	,	O
32	and	O
33	threonine	O
34	residues	O
35	.	O

1	The	O
2	greatest	O
3	difference	O
4	between	O
5	the	B
6	Ad7	I
7	and	I
8	Ad5	I
9	DBPs	I
10	is	O
11	the	O
12	absence	O
13	,	O
14	in	O
15	the	O
16	Ad7	B
17	protein	I
18	,	I
19	of	I
20	12	I
21	amino	O
22	acids	O
23	located	O
24	between	O
25	the	I
26	two	O
27	functional	O
28	domains	O
29	in	O
30	the	O
31	Ad5	O
32	protein	O
33	(	O
34	amino	O
35	acids	O
36	151	O
37	-	O
38	162	B
39	).	I

1	The	O
2	latter	O
3	was	O
4	determined	O
5	as	O
6	follows	B
7	:	I
8	Type	I
9	I	O
10	-	B
11	solid	I
12	tumor	I
13	tissue	I
14	without	O
15	significant	O
16	peripheral	O
17	isolated	O
18	tumor	O
19	cells	O
20	;	O
21	Type	O
22	II	O
23	-	O
24	solid	O
25	tumor	O
26	tissue	O
27	associated	O
28	with	O
29	peripheral	O
30	isolated	O
31	tumor	O
32	cells	O
33	;	O
34	Type	O
35	III	O
36	-	O
37	isolated	O
38	tumor	O
39	cells	O
40	only	O
41	.	O

1	The	O
2	Community	O
3	Adjustment	O
4	Scale	O
5	provided	O
6	outcome	O
7	data	O
8	related	O
9	to	O
10	the	O
11	subjects	O
12	'	O
13	degree	O
14	of	O
15	productivity	O
16	,	O
17	ability	O
18	to	O
19	maintain	O
20	close	O
21	relationships	O
22	,	O
23	and	O
24	presence	O
25	/	O
26	absence	O
27	of	O
28	symptomatology	O
29	an	O
30	average	O
31	of	O
32	32	O
33	years	O
34	after	O
35	initial	O
36	admission	O
37	.	O

1	We	O
2	have	O
3	visualized	O
4	DNA	O
5	-	O
6	protein	O
7	complexes	O
8	by	O
9	electron	O
10	microscopy	O
11	and	O
12	a	O
13	high	O
14	-	O
15	affinity	O
16	binding	O
17	site	O
18	of	O
19	WDV	O
20	Rep	O
21	protein	O
22	within	O
23	the	O
24	core	O
25	element	O
26	has	O
27	been	O
28	mapped	O
29	to	O
30	approximately	O
31	144	O
32	+/-	O
33	18	O
34	bp	O
35	upstream	O
36	from	O
37	the	O
38	initiation	O
39	site	O
40	,	O
41	between	O
42	the	O
43	start	O
44	site	O
45	for	O
46	complementary	O
47	-	O
48	sense	O
49	transcription	O
50	and	O
51	the	O
52	TATA	O
53	box	O
54	.	O

1	In	O
2	these	O
3	cases	O
4	,	O
5	asbestos	O
6	or	O
7	erionite	O
8	-	O
9	tissue	O
10	burden	O
11	followed	O
12	by	O
13	fibrosis	O
14	was	O
15	frequently	O
16	observed	O
17	.	O

1	The	O
2	DNA	O
3	sequence	O
4	conferring	O
5	AP	O
6	-	O
7	1	O
8	activity	O
9	was	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	region	O
16	.	O

1	These	O
2	analyses	O
3	demonstrate	O
4	that	O
5	the	O
6	dUTPase	O
7	isoforms	O
8	are	O
9	encoded	O
10	by	O
11	the	O
12	same	O
13	gene	O
14	with	O
15	isoform	O
16	-	O
17	specific	O
18	transcripts	O
19	arising	O
20	through	O
21	the	O
22	use	O
23	of	O
24	alternative	O
25	5	O
26	'	O
27	exons	O
28	.	O

1	Despite	O
2	an	O
3	overall	O
4	survival	O
5	rate	O
6	of	O
7	43	O
8	%,	O
9	survival	O
10	to	O
11	discharge	O
12	varied	O
13	greatly	O
14	(	O
15	0	O
16	to	O
17	100	O
18	%)	O
19	among	O
20	the	O
21	24	O
22	diagnostic	O
23	groups	O
24	:	O
25	tumor	O
26	lysis	O
27	syndrome	O
28	and	O
29	systemic	O
30	lupus	O
31	erythematosus	O
32	(	O
33	3	O
34	/	O
35	3	O
36	patients	O
37	each	O
38	,	O
39	100	O
40	%),	O
41	hemolytic	O
42	uremic	O
43	syndrome	O
44	(	O
45	8	O
46	/	O
47	9	O
48	patients	O
49	,	O
50	89	O
51	%).	O

1	Albumin	O
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	B
19	CAAT	I
20	enhancer	I
21	-	I
22	binding	I
23	protein	I
24	(	I
25	C	I
26	/	O
27	EBP	O
28	)	O
29	alpha	O
30	and	O
31	C	O
32	/	O
33	EBPbeta	O
34	.	O

1	Homozygous	O
2	mutation	O
3	in	O
4	two	O
5	children	O
6	led	O
7	to	O
8	amputation	O
9	of	O
10	legs	O
11	due	O
12	to	O
13	purpura	B
14	fulminans	I
15	.	I

1	If	O
2	no	O
3	alloantibodies	O
4	are	O
5	detected	O
6	,	O
7	further	O
8	analysis	O
9	to	O
10	define	O
11	a	O
12	role	O
13	of	O
14	drug	O
15	-	O
16	related	O
17	or	O
18	autoantibodies	O
19	is	O
20	required	O
21	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	B

1	In	O
2	addition	O
3	,	O
4	on	O
5	the	O
6	Cohler	O
7	'	O
8	s	O
9	maternal	O
10	scale	O
11	,	O
12	Korean	O
13	mothers	O
14	were	O
15	found	O
16	to	O
17	view	O
18	their	O
19	infants	O
20	as	O
21	more	O
22	passive	O
23	and	O
24	dependent	O
25	than	O
26	American	O
27	mothers	O
28	did	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	00	O
36	).	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	ORF113	O
6	contains	O
7	a	O
8	transmembrane	O
9	domain	O
10	.	O

1	No	O
2	correlation	O
3	between	O
4	the	O
5	age	O
6	of	B
7	the	B
8	horses	I
9	and	O
10	the	B
11	antibody	I
12	level	O
13	could	O
14	be	O
15	found	O
16	.	O

1	No	O
2	local	O
3	destruction	O
4	by	O
5	tumor	O
6	or	O
7	infection	O
8	could	O
9	be	O
10	demonstrated	O
11	apart	O
12	from	O
13	HIV	O
14	infection	O
15	.	O

1	Regulation	O
2	of	O
3	avian	O
4	fibroblast	O
5	growth	O
6	factor	O
7	receptor	O
8	1	O
9	(	B
10	FGFR	I
11	-	I
12	1	I
13	)	I
14	gene	O
15	expression	O
16	during	O
17	skeletal	O
18	muscle	O
19	differentiation	O
20	.	O

1	Comparison	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	gamma	O
10	-	O
11	kafirin	O
12	with	O
13	the	O
14	published	O
15	sequences	O
16	of	O
17	gamma	O
18	-	O
19	prolamins	O
20	of	O
21	maize	O
22	,	O
23	and	O
24	Coix	O
25	revealed	O
26	highly	O
27	conserved	O
28	domains	O
29	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	,	O
6	at	O
7	least	O
8	at	O
9	high	O
10	temperature	O
11	,	B
12	a	I
13	critical	I
14	minimal	I
15	level	O
16	of	O
17	Ypt	O
18	protein	O
19	prenylation	O
20	is	O
21	required	O
22	for	O
23	maintaining	O
24	vesicle	O
25	polarization	O
26	.	O

1	Effects	O
2	of	O
3	alterations	O
4	of	O
5	primer	O
6	-	O
7	binding	O
8	site	O
9	sequences	O
10	on	O
11	human	O
12	immunodeficiency	O
13	virus	B
14	type	I
15	1	O
16	replication	O
17	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	Sp1	O
13	sites	O
14	or	O
15	Sp1	O
16	sites	O
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	O
33	RNA	O
34	polymerase	O
35	III	O
36	promoter	O
37	.	O

1	Large	O
2	T	O
3	antigen	O
4	was	O
5	coimmunoprecipitated	O
6	by	O
7	antibodies	O
8	to	O
9	epitope	O
10	-	O
11	tagged	O
12	TBP	O
13	,	O
14	endogenous	O
15	TBP	O
16	,	O
17	hTAF	O
18	(	O
19	II	O
20	)	O
21	100	O
22	,	O
23	hTAF	O
24	(	O
25	II	O
26	)	O
27	130	O
28	,	O
29	and	O
30	hTAF	O
31	(	O
32	II	O
33	)	O
34	250	O
35	,	O
36	under	O
37	conditions	O
38	where	O
39	holo	O
40	-	O
41	TFIID	O
42	would	O
43	be	O
44	precipitated	O
45	.	O

1	Problems	O
2	in	O
3	the	O
4	determination	O
5	of	O
6	the	O
7	antigenic	O
8	content	O
9	of	O
10	influenza	O
11	vaccines	O
12	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	B
6	demonstrate	I
7	that	I
8	the	I
9	rat	I
10	HDL	I
11	receptor	O
12	SR	O
13	-	O
14	BI	O
15	promoter	O
16	contains	O
17	two	O
18	sterol	O
19	response	O
20	elements	O
21	(	O
22	pSRE	O
23	and	B
24	dSRE	I
25	)	O
26	through	O
27	which	O
28	SREBP	O
29	-	O
30	1a	O
31	can	O
32	bind	O
33	and	O
34	activate	O
35	transcription	O
36	of	O
37	this	O
38	gene	O
39	.	O

1	Hepatitis	O
2	B	O
3	vaccine	O
4	:	O
5	still	O
6	has	O
7	its	O
8	problems	O
9	.	B

1	Nernst	O
2	--	O
3	Planck	O
4	analog	O
5	equations	O
6	and	O
7	stationary	O
8	state	O
9	membrane	O
10	electric	O
11	potentials	O
12	.	O

1	Validation	O
2	of	O
3	the	O
4	survey	O
5	of	O
6	work	O
7	styles	O
8	:	O
9	a	O
10	profile	O
11	measure	O
12	of	O
13	the	O
14	type	O
15	A	O
16	behaviour	O
17	pattern	O
18	.	O

1	Identification	O
2	and	B
3	characterization	I
4	of	I
5	IS2404	O
6	and	B
7	IS2606	I
8	:	I
9	two	I
10	distinct	I
11	repeated	O
12	sequences	B
13	for	I
14	detection	I
15	of	I
16	Mycobacterium	O
17	ulcerans	O
18	by	O
19	PCR	O
20	.	O

1	To	O
2	assess	O
3	the	O
4	ability	O
5	of	O
6	the	O
7	atria	O
8	to	O
9	maintain	O
10	elevated	O
11	plasma	O
12	concentrations	O
13	of	B
14	atrial	I
15	natriuretic	I
16	peptide	I
17	(	I
18	ANP	I
19	),	I
20	the	I
21	temporal	I
22	changes	O
23	in	O
24	plasma	O
25	ANP	O
26	concentrations	O
27	were	O
28	studied	O
29	in	O
30	seven	O
31	chloralose	O
32	-	O
33	anaesthetized	O
34	dogs	O
35	during	O
36	4	O
37	h	O
38	of	O
39	sustained	O
40	rapid	O
41	cardiac	O
42	pacing	O
43	.	O

1	Although	O
2	there	O
3	are	O
4	no	B
5	octamer	I
6	elements	I
7	in	I
8	the	O
9	adenovirus	O
10	genome	B
11	that	I
12	are	I
13	known	I
14	to	I
15	be	O
16	important	B
17	for	I
18	transcription	O
19	,	O
20	there	O
21	are	O
22	octamer	O
23	elements	O
24	in	B
25	the	I
26	viral	I
27	terminal	I
28	repeat	I
29	sequences	I
30	.	I

1	The	O
2	results	O
3	of	O
4	a	O
5	quantitative	O
6	study	O
7	of	O
8	vasculosyncytial	O
9	membranes	O
10	in	O
11	123	O
12	placentas	O
13	are	O
14	presented	O
15	.	O

1	In	O
2	mammalian	B
3	cells	I
4	,	I
5	phosphorylation	I
6	of	I
7	eIF	I
8	-	I
9	2	O
10	alpha	O
11	inhibits	O
12	the	O
13	activity	B
14	of	I
15	eIF	I
16	-	I
17	2B	I
18	,	I
19	the	O
20	GDP	O
21	-	O
22	GTP	O
23	exchange	O
24	factor	O
25	for	O
26	eIF	O
27	-	O
28	2	O
29	.	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	B
16	and	I
17	a	I
18	17	I
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	B
25	R7G	I
26	family	I
27	of	I
28	G	I
29	-	I
30	protein	O
31	coupled	O
32	membrane	O
33	-	O
34	bound	O
35	receptors	O
36	.	O

1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	high	O
7	level	O
8	human	O
9	desmin	O
10	expression	O
11	depends	O
12	on	O
13	a	O
14	280	O
15	-	O
16	base	O
17	pair	O
18	muscle	O
19	-	O
20	specific	O
21	enhancer	O
22	which	O
23	can	O
24	function	O
25	not	O
26	only	O
27	in	O
28	myotubes	O
29	,	O
30	but	O
31	can	O
32	also	O
33	activate	O
34	gene	O
35	expression	O
36	in	O
37	myoblasts	O
38	.	O

1	Each	O
2	parent	O
3	interacted	O
4	with	O
5	their	O
6	4	O
7	-	O
8	or	O
9	5	B
10	-	I
11	year	I
12	-	I
13	old	I
14	son	O
15	or	O
16	daughter	O
17	in	O
18	each	O
19	of	O
20	two	O
21	conversations	O
22	--	O
23	unstructured	O
24	(	O
25	social	O
26	conversation	O
27	)	O
28	and	O
29	structured	O
30	(	O
31	task	O
32	activity	O
33	).	O

1	RNA	O
2	of	O
3	GBV	O
4	-	O
5	C	O
6	was	B
7	detected	I
8	in	I
9	14	I
10	(	O
11	18	O
12	%)	O
13	patients	O
14	before	O
15	BMT	O
16	.	O

1	The	O
2	gene	O
3	amplification	O
4	model	O
5	of	O
6	Coquelle	B
7	et	I
8	al	I
9	.	I

1	However	O
2	,	O
3	in	O
4	those	O
5	studies	O
6	due	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	thiol	O
12	agents	O
13	in	O
14	the	O
15	PKC	O
16	preparations	O
17	,	O
18	the	O
19	sensitive	O
20	reaction	O
21	of	O
22	BPO	O
23	with	O
24	redox	O
25	-	O
26	active	O
27	cysteine	O
28	residues	O
29	in	O
30	PKC	O
31	was	O
32	not	O
33	observed	O
34	.	O

1	RESULTS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	(	O
7	26	O
8	%)	O
9	patients	O
10	had	O
11	PHG	O
12	before	O
13	(	O
14	group	O
15	A	B
16	)	I
17	and	I
18	64	I
19	(	I
20	74	O
21	%)	O
22	developed	O
23	PHG	O
24	after	O
25	variceal	O
26	eradication	O
27	(	O
28	group	O
29	B	O
30	).	O

1	TPTA	O
2	produced	O
3	brain	O
4	congestion	O
5	,	O
6	and	O
7	hepatic	B
8	and	I
9	pulmonary	I
10	petechial	I
11	and	O
12	generalized	O
13	hemorrhages	B
14	.	I

1	Abnormal	O
2	urinary	O
3	coproporphyrin	O
4	levels	O
5	in	B
6	patients	I
7	infected	I
8	by	O
9	hepatitis	O
10	C	B
11	virus	I
12	with	I
13	or	I
14	without	I
15	human	O
16	immunodeficiency	B
17	virus	I
18	.	I

1	Comparison	O
2	of	O
3	the	O
4	plant	O
5	nuclear	O
6	tRNA	O
7	3	O
8	'	O
9	processing	O
10	enzyme	O
11	with	O
12	the	O
13	plant	O
14	mitochondrial	O
15	one	O
16	suggests	O
17	that	O
18	both	B
19	activities	I
20	are	I
21	different	I
22	enzymes	O
23	.	O

1	This	O
2	mutant	O
3	was	O
4	identified	O
5	by	O
6	screening	O
7	with	O
8	a	O
9	TGF	O
10	-	O
11	beta	O
12	-	B
13	inducible	I
14	vector	O
15	a	B
16	series	I
17	of	I
18	mink	O
19	lung	O
20	epithelial	O
21	cell	O
22	clones	O
23	that	O
24	have	O
25	normal	O
26	TGF	O
27	-	O
28	beta	O
29	binding	O
30	activity	O
31	but	O
32	have	O
33	lost	O
34	antiproliferative	O
35	and	O
36	transcriptional	O
37	responses	O
38	to	O
39	TGF	O
40	-	O
41	beta	O
42	.	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	gene	O
10	encoding	B
11	human	I
12	K14	O
13	(	B
14	D	B
15	.	I

1	Acupuncture	O
2	effect	O
3	on	O
4	deep	B
5	receptors	B
6	was	I
7	not	I
8	limited	O
9	to	O
10	one	O
11	point	O
12	but	O
13	within	O
14	a	O
15	certain	O
16	area	O
17	,	O
18	namely	O
19	distant	O
20	effect	O
21	existed	O
22	.	O

1	The	O
2	por	O
3	gene	O
4	has	O
5	been	O
6	expressed	O
7	,	O
8	for	O
9	the	O
10	first	O
11	time	O
12	,	O
13	in	O
14	anaerobically	O
15	grown	O
16	Escherichia	O
17	coli	O
18	behind	O
19	the	O
20	isopropyl	O
21	-	O
22	beta	O
23	-	O
24	D	O
25	-	O
26	thiogalactopyranoside	O
27	-	O
28	inducible	O
29	tac	O
30	promoter	O
31	,	O
32	resulting	O
33	in	O
34	the	O
35	production	O
36	of	O
37	POR	O
38	in	O
39	its	O
40	active	O
41	form	O
42	.	O

1	Echocardiography	O
2	revealed	O
3	right	O
4	ventricular	O
5	diastolic	O
6	collapse	O
7	(	O
8	RVDC	O
9	)	O
10	without	B
11	physical	I
12	signs	I
13	of	I
14	cardiac	I
15	tamponade	I
16	.	O

1	Various	O
2	companies	O
3	produce	O
4	this	O
5	type	O
6	of	O
7	lens	O
8	.	O

1	The	O
2	German	O
3	Society	B
4	of	I
5	Pediatric	I
6	Oncology	I
7	in	I
8	1981	I
9	initiated	I
10	the	O
11	Cooperative	O
12	Ewing	O
13	'	O
14	s	O
15	Sarcoma	O
16	Study	O
17	(	O
18	CESS	O
19	81	O
20	)	O
21	using	O
22	a	O
23	four	O
24	-	O
25	drug	O
26	combination	O
27	of	O
28	chemotherapy	O
29	prior	O
30	to	O
31	definitive	O
32	local	O
33	control	O
34	with	O
35	surgery	O
36	and	O
37	/	I
38	or	O
39	radiation	B
40	.	I

1	The	O
2	HOI	O
3	induced	O
4	a	O
5	nearly	O
6	fourfold	O
7	increase	O
8	in	O
9	ANF	O
10	in	O
11	the	O
12	elderly	O
13	,	O
14	whereas	O
15	that	O
16	for	O
17	the	O
18	young	O
19	was	O
20	threefold	O
21	.	O

1	The	O
2	Oct	O
3	-	O
4	3	B
5	/	I
6	4	I
7	gene	I
8	product	I
9	,	I
10	which	I
11	belongs	O
12	to	O
13	the	O
14	POU	O
15	family	O
16	of	O
17	transcription	B
18	factors	I
19	,	I
20	is	I
21	a	I
22	good	O
23	candidate	O
24	for	O
25	regulating	O
26	initial	O
27	differentiation	O
28	decisions	O
29	.	O

1	Four	O
2	forms	O
3	of	O
4	salmonellosis	B
5	were	I
6	recognised	I
7	in	I
8	feedlots	I
9	and	I
10	during	I
11	transport	I
12	by	I
13	sea	I
14	:	I
15	septicaemic	I
16	,	I
17	and	I
18	acute	I
19	,	O
20	subacute	O
21	and	O
22	chronic	B
23	enteric	I
24	.	I

1	Immunelectrophoretic	O
2	pattern	O
3	of	O
4	Wassermann	O
5	reagin	O
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	B
12	between	O
13	RPCF	O
14	and	O
15	FTA	O
16	antibodies	O

1	The	O
2	role	O
3	of	O
4	pharmacological	O
5	profiling	O
6	in	O
7	safety	O
8	assessment	O
9	.	O

1	Tristetraprolin	O
2	(	O
3	TTP	O
4	)	O
5	is	O
6	the	O
7	prototype	O
8	of	O
9	a	O
10	group	O
11	of	O
12	potential	B
13	transcription	I
14	factors	I
15	that	I
16	contain	I
17	two	O
18	or	B
19	more	B
20	unusual	I
21	CCCH	O
22	zinc	O
23	fingers	O
24	.	O

1	These	O
2	repressor	O
3	sites	O
4	are	O
5	pyrimidine	O
6	rich	O
7	and	O
8	bind	O
9	avidly	O
10	to	O
11	the	O
12	polypyrimidine	O
13	tract	O
14	binding	B
15	protein	I
16	(	I
17	PTB	I
18	)	O
19	in	O
20	HeLa	O
21	nuclear	O
22	extracts	O
23	as	O
24	determined	O
25	by	B
26	UV	I
27	crosslinking	I
28	/	I
29	competition	I
30	assays	I
31	.	O

1	A	O
2	reduced	O
3	matrix	O
4	distribution	O
5	and	O
6	enhanced	O
7	cell	O
8	density	B
9	were	I
10	observed	I
11	as	I
12	the	I
13	biofilm	O
14	aged	I
15	.	I

1	At	O
2	this	O
3	stage	O
4	,	O
5	the	O
6	eventual	O
7	high	O
8	mortality	O
9	of	O
10	acute	O
11	ischemia	O
12	is	O
13	established	O
14	whatever	O
15	the	O
16	urgency	O
17	of	O
18	the	O
19	operation	O
20	or	O
21	the	O
22	skill	O
23	with	O
24	which	O
25	it	O
26	is	O
27	performed	O
28	.	O

1	The	O
2	1489	O
3	-	O
4	base	O
5	pair	O
6	EFIA	O
7	cDNA	O
8	encodes	O
9	a	O
10	322	O
11	-	O
12	amino	O
13	acid	O
14	protein	O
15	which	O
16	is	O
17	nearly	O
18	identical	O
19	to	O
20	two	O
21	previously	O
22	described	O
23	human	O
24	DNA	O
25	binding	O
26	proteins	O
27	.	O

1	Greater	O
2	rupture	O
3	force	O
4	was	O
5	required	O
6	in	O
7	the	O
8	adult	O
9	pigs	O
10	than	O
11	in	O
12	the	O
13	young	O
14	pigs	O
15	.	O

1	Blood	O
2	platelets	O
3	,	O
4	coagulation	O
5	factors	O
6	and	O
7	morphologic	O
8	organ	O
9	changes	O
10	following	O
11	scalding	O
12	shock	O
13	in	O
14	rhesus	O
15	monkeys	O

1	Tranilast	O
2	in	O
3	the	O
4	Therapy	O
5	of	O
6	Coronary	O
7	Artery	O
8	Disease	O
9	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	regulatory	O
6	properties	O
7	of	O
8	an	O
9	872	O
10	bp	O
11	promoter	O
12	fragment	O
13	of	O
14	a	O
15	B	O
16	.	O
17	napus	O
18	oleosin	O
19	gene	O
20	were	O
21	examined	O
22	by	O
23	analysis	O
24	of	O
25	beta	O
26	-	O
27	glucuronidase	O
28	(	O
29	GUS	O
30	)	O
31	expression	O
32	in	O
33	transgenic	O
34	tobacco	O
35	plants	O
36	containing	O
37	an	O
38	oleosin	O
39	promoter	O
40	-	O
41	GUS	O
42	transcriptional	O
43	fusion	O
44	.	O

1	Survival	O
2	was	O
3	calculated	O
4	both	O
5	from	O
6	the	B
7	date	B
8	of	I
9	onset	O
10	and	O
11	from	O
12	the	O
13	date	O
14	of	O
15	diagnosis	O
16	.	O

1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	B
12	varied	B
13	from	I
14	17	O
15	.	I
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	B
48	with	I
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	I
65	severe	I
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	B
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O

1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	O
6	Oct	O
7	-	O
8	1	O
9	from	B
10	the	I
11	nuclear	I
12	extract	O
13	by	O
14	using	B
15	Oct	I
16	-	I
17	1	I
18	-	I
19	specific	I
20	antiserum	O
21	or	O
22	a	B
23	sequence	I
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	MMTV	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	B
45	that	I
46	obtained	I
47	from	I
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	B
56	related	I
57	sequences	I
58	were	O
59	mutated	O
60	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	Rb	O
6	protein	O
7	is	O
8	interacting	O
9	with	O
10	some	O
11	component	O
12	(	O
13	s	O
14	)	O
15	of	O
16	the	O
17	cell	O
18	cycle	O
19	-	O
20	regulatory	O
21	machinery	O
22	during	O
23	G2	O
24	phase	O
25	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	a	O
6	study	O
7	of	O
8	low	O
9	dose	O
10	X	O
11	-	O
12	rays	O
13	effects	O
14	,	O
15	we	O
16	found	O
17	that	O
18	male	O
19	ICR	O
20	white	O
21	Swiss	O
22	mice	O
23	showed	O
24	remarkable	O
25	suppression	O
26	of	O
27	mounting	O
28	behavior	O
29	after	O
30	whole	O
31	body	O
32	irradiation	O
33	by	O
34	5	O
35	to	O
36	15	O
37	cGy	O
38	X	O
39	-	O
40	rays	O
41	.	O

1	Cloning	O
2	and	B
3	sequencing	O
4	revealed	O
5	that	O
6	dMax	O
7	contains	O
8	a	O
9	deletion	O
10	spanning	B
11	the	I
12	basic	I
13	region	I
14	and	I
15	helix	O
16	1	O
17	and	O
18	the	O
19	loop	O
20	of	O
21	the	B
22	helix	I
23	-	I
24	loop	I
25	-	I
26	helix	O
27	region	O
28	,	O
29	presumably	O
30	as	O
31	a	O
32	result	O
33	of	O
34	alternative	O
35	splicing	O
36	of	O
37	max	O
38	RNA	O
39	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	these	O
6	sequences	O
7	located	O
8	immediately	O
9	3	O
10	'	O
11	to	O
12	the	O
13	breakpoint	O
14	of	O
15	the	O
16	HPFH	O
17	-	O
18	3	O
19	deletion	O
20	,	O
21	exhibit	O
22	both	O
23	the	O
24	structure	O
25	and	O
26	the	O
27	function	O
28	of	O
29	an	O
30	enhancer	O
31	,	O
32	and	O
33	can	O
34	modify	O
35	the	O
36	developmental	O
37	specificity	O
38	of	O
39	the	O
40	fetal	O
41	gamma	O
42	-	O
43	globin	O
44	genes	O
45	,	O
46	resulting	O
47	in	O
48	their	O
49	continued	O
50	expression	O
51	during	O
52	adult	O
53	life	O
54	.	O

1	A	O
2	phylogenetic	O
3	analysis	O
4	with	O
5	the	O
6	TK	O
7	domains	O
8	from	O
9	these	O
10	sequences	O
11	and	O
12	a	O
13	fourth	O
14	,	O
15	from	O
16	a	O
17	novel	O
18	scavenger	O
19	RTK	O
20	(	O
21	all	O
22	domains	O
23	comprise	O
24	the	O
25	signature	O
26	for	O
27	the	O
28	TK	O
29	class	O
30	II	O
31	receptors	O
32	),	O
33	showed	O
34	that	O
35	they	O
36	are	O
37	distantly	O
38	related	O
39	to	O
40	the	O
41	insulin	O
42	and	O
43	insulin	O
44	-	O
45	like	O
46	receptors	O
47	.	O

1	The	O
2	data	O
3	normally	O
4	available	O
5	are	O
6	insufficient	O
7	and	O
8	take	O
9	no	O
10	account	O
11	of	O
12	the	O
13	direction	O
14	of	O
15	recirculation	O
16	,	O
17	which	O
18	may	O
19	be	O
20	a	O
21	determining	O
22	factor	O
23	.	O

1	Two	O
2	US	O
3	commercial	O
4	cultivars	O
5	(	O
6	Tehama	O
7	and	O
8	Vina	O
9	),	O
10	three	O
11	European	O
12	commercial	O
13	cultivars	O
14	(	O
15	Esterhazy	O
16	,	O
17	139	O
18	,	O
19	G120	O
20	)	O
21	and	O
22	five	O
23	New	O
24	Zealand	O
25	selections	O
26	(	O
27	Rex	O
28	,	O
29	Dublin	O
30	'	O
31	s	O
32	Glory	O
33	,	O
34	Meyric	O
35	,	O
36	McKinster	O
37	,	O
38	Stanley	O
39	)	O
40	were	O
41	evaluated	O
42	.	O

1	GETS	O
2	-	B
3	1	I
4	is	I
5	expressed	I
6	in	I
7	many	I
8	tissues	O
9	,	O
10	but	O
11	is	O
12	enriched	O
13	in	O
14	retina	O
15	and	O
16	brain	O
17	.	O

1	Promoter	O
2	activity	O
3	was	O
4	dose	O
5	-	O
6	dependently	B
7	inhibited	I
8	by	I
9	cotransfection	I
10	with	I
11	either	I
12	ras	I
13	or	I
14	mos	I
15	oncogenes	O
16	,	O
17	but	O
18	oncogene	O
19	inhibition	O
20	was	O
21	reversed	O
22	and	O
23	the	O
24	overall	I
25	activity	I
26	increased	I
27	when	I
28	cells	I
29	were	I
30	treated	O
31	with	O
32	the	O
33	MAP	O
34	kinase	O
35	kinase	O
36	(	O
37	MKK	O
38	)	O
39	inhibitor	O
40	PD98059	I
41	.	I

1	Thus	O
2	,	O
3	chronic	O
4	hematocrit	O
5	decrease	O
6	induced	O
7	by	O
8	H	O
9	or	O
10	P	O
11	resulted	B
12	in	I
13	a	I
14	significant	I
15	fall	I
16	in	I
17	blood	I
18	pressure	O
19	compared	O
20	to	O
21	control	O
22	(	O
23	201	O
24	+/-	O
25	3	O
26	v	O
27	175	O
28	+/-	O
29	4	O
30	,	O
31	167	O
32	+/-	O
33	4	O
34	mm	O
35	Hg	O
36	,	O
37	respectively	O
38	;	O
39	P	O
40	<	O
41	.	O
42	05	O
43	).	O

1	OBJECTIVES	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	the	O
7	study	B
8	was	I
9	to	I
10	analyze	I
11	the	O
12	clinical	O
13	characteristics	O
14	,	O
15	treatment	O
16	and	O
17	outcome	O
18	of	O
19	310	O
20	patients	O
21	with	O
22	hydatidiform	O
23	mole	O
24	.	O

1	Sequence	O
2	determination	O
3	of	O
4	isolated	O
5	peptides	O
6	suggested	O
7	that	O
8	Asn120	O
9	is	O
10	glycosylated	O
11	,	O
12	Asn65	O
13	and	O
14	Asn109	O
15	glycosylated	O
16	in	O
17	some	O
18	molecules	O
19	but	O
20	not	O
21	in	O
22	others	O
23	,	O
24	and	O
25	Asn72	O
26	not	O
27	glycosylated	O
28	.	O

1	The	O
2	relatively	O
3	mild	O
4	defects	O
5	observed	O
6	in	O
7	Rpd3	O
8	mutants	O
9	suggest	O
10	that	O
11	the	O
12	recently	O
13	identified	O
14	Groucho	O
15	and	O
16	dCtBP	O
17	corepressor	O
18	proteins	O
19	do	O
20	not	O
21	function	B
22	solely	I
23	through	I
24	the	I
25	recruitment	O
26	of	O
27	histone	O
28	deacetylases	O
29	.	O

1	In	O
2	addition	O
3	to	O
4	homologues	O
5	of	O
6	the	O
7	human	O
8	genes	O
9	PSMB5	O
10	through	O
11	PSMB9	O
12	,	O
13	two	O
14	new	O
15	genes	O
16	,	O
17	PSMB11	O
18	and	O
19	PSMB12	O
20	,	O
21	have	O
22	been	O
23	found	O
24	for	O
25	which	O
26	there	O
27	are	O
28	no	O
29	known	O
30	corresponding	O
31	genes	O
32	in	O
33	humans	O
34	.	O

1	From	O
2	S3	O
3	(	O
4	CBF	B
5	:	I
6	79	I
7	-	I
8	60	I
9	%)	I
10	to	O
11	S5	O
12	(	O
13	CBF	O
14	:	O
15	39	O
16	-	O
17	0	O
18	%),	O
19	%	O
20	WTh	O
21	,	I
22	1	I
23	/	I
24	TPC	I
25	and	I
26	1	I
27	/	I
28	T	I
29	were	I
30	significantly	I
31	decreased	I
32	from	I
33	those	I
34	of	I
35	the	O
36	control	O
37	levels	O
38	(	O
39	all	O
40	p	B
41	less	O
42	than	I
43	0	I
44	.	I
45	01	O
46	).	O

1	In	O
2	vivo	O
3	,	O
4	selective	O
5	activation	O
6	of	O
7	SAPKs	O
8	stimulates	O
9	formation	O
10	of	O
11	the	O
12	ternary	O
13	complex	O
14	containing	O
15	Elk	O
16	-	O
17	1	O
18	,	O
19	serum	O
20	response	O
21	factor	O
22	and	O
23	the	O
24	serum	O
25	response	O
26	element	O
27	,	O
28	and	O
29	enhances	O
30	Elk	O
31	-	O
32	1	O
33	-	O
34	dependent	O
35	transcription	O
36	.	O

1	The	O
2	data	O
3	imply	O
4	that	O
5	JAK	O
6	/	O
7	STAT	O
8	signaling	O
9	has	O
10	a	O
11	role	O
12	in	O
13	EBV	O
14	-	O
15	associated	O
16	malignancies	O
17	.	O

1	Using	O
2	a	O
3	v	O
4	-	O
5	erbA	O
6	probe	O
7	,	O
8	we	O
9	obtained	O
10	a	O
11	cDNA	O
12	which	O
13	encodes	O
14	a	O
15	novel	I
16	445	I
17	-	I
18	amino	I
19	-	O
20	acid	O
21	protein	O
22	,	O
23	RLD	O
24	-	O
25	1	O
26	,	O
27	that	O
28	contains	O
29	the	O
30	characteristic	O
31	domains	O
32	of	I
33	nuclear	O
34	receptors	O
35	.	O

1	Simultaneously	O
2	a	O
3	greater	O
4	NA	O
5	was	O
6	found	O
7	with	O
8	no	O
9	change	B
10	in	I
11	plasma	I
12	epinephrine	I
13	response	I
14	.	O

1	Taken	O
2	together	O
3	,	O
4	they	O
5	uphold	O
6	the	O
7	emerging	O
8	concern	O
9	that	O
10	women	O
11	with	O
12	ER	O
13	(+)	O
14	cancers	O
15	may	O
16	not	O
17	benefit	O
18	significantly	O
19	from	B
20	endocrine	I
21	treatment	I
22	if	I
23	the	I
24	tumors	I
25	also	I
26	overexpress	O
27	HER	O
28	-	O
29	2	O
30	.	O

1	Computer	O
2	-	O
3	aided	O
4	"	O
5	FRAME	O
6	"	O
7	analysis	O
8	revealed	O
9	four	O
10	possible	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	),	O
17	three	O
18	in	O
19	one	O
20	direction	O
21	and	O
22	one	O
23	in	O
24	the	O
25	opposite	O
26	direction	O
27	.	O

1	In	O
2	vitro	O
3	protein	O
4	retention	O
5	experiments	O
6	in	O
7	which	O
8	Hsp90	O
9	heterocomplexes	O
10	were	O
11	precipitated	O
12	resulted	O
13	in	O
14	coprecipitation	O
15	of	O
16	Cns1	B
17	.	I

1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O

1	Differential	O
2	expression	O
3	of	O
4	the	O
5	"	O
6	B	B
7	"	I
8	subunit	I
9	of	I
10	the	O
11	vacuolar	O
12	H	O
13	(+)-	O
14	ATPase	O
15	in	O
16	bovine	O
17	tissues	O
18	.	O

1	The	O
2	hypertension	B
3	with	I
4	elevated	I
5	PRA	O
6	,	O
7	however	O
8	,	O
9	was	O
10	resistant	O
11	to	O
12	the	B
13	angiotensin	B
14	II	I
15	(	I
16	AII	I
17	)	I
18	analog	I
19	[	I
20	Sar1	I
21	,	I
22	Ile8	I
23	]	I
24	ALL	O
25	.	O

1	Alanine	O
2	aminotransferase	O
3	(	O
4	ALT	O
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O

1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O

1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	O
12	-	O
13	CSF	O
14	to	O
15	GM	O
16	-	O
17	CSF	O
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	O
24	-	O
25	fms	O
26	mRNA	O
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	GluR2	O
6	gene	O
7	:	O
8	neural	O
9	-	O
10	specific	O
11	expression	O
12	,	O
13	multiple	O
14	promoters	O
15	,	O
16	and	O
17	regulatory	O
18	elements	O
19	.	O

1	Unlike	O
2	the	O
3	mammalian	O
4	proteins	O
5	,	O
6	XFGF3	O
7	is	O
8	efficiently	B
9	secreted	B
10	as	I
11	a	I
12	Mr	I
13	31	I
14	,	I
15	000	I
16	glycoprotein	I
17	,	I
18	gp31	I
19	,	I
20	which	I
21	undergoes	I
22	proteolytic	I
23	cleavage	I
24	to	I
25	produce	I
26	an	O
27	NH2	O
28	-	O
29	terminally	O
30	truncated	O
31	product	O
32	,	O
33	gp27	O
34	.	O

1	Evoked	O
2	potential	O
3	and	O
4	single	O
5	unit	O
6	responses	O
7	to	O
8	olfactory	O
9	nerve	O
10	volleys	O
11	in	O
12	the	O
13	isolated	O
14	turtle	O
15	olfactory	O
16	bulb	O
17	.	O

1	Two	O
2	differentially	O
3	expressed	B
4	LNX	I
5	messages	I
6	encode	I
7	overlapping	I
8	proteins	I
9	with	I
10	predicted	O
11	molecular	B
12	masses	I
13	of	I
14	80	I
15	kDa	I
16	(	O
17	LNX	O
18	)	O
19	and	O
20	70	O
21	kDa	O
22	(	O
23	LNX	O
24	-	B
25	b	I
26	).	I

1	A	O
2	cDNA	O
3	library	O
4	of	O
5	tumour	O
6	cells	O
7	was	O
8	screened	O
9	with	B
10	an	I
11	interleukin	I
12	2	I
13	gene	I
14	-	O
15	specific	O
16	probe	O
17	.	O

1	The	O
2	influence	O
3	of	O
4	p53	O
5	on	O
6	cytokine	O
7	-	O
8	triggered	O
9	Janus	O
10	kinase	O
11	-	O
12	STAT	O
13	signaling	O
14	was	O
15	investigated	O
16	in	O
17	human	O
18	hepatoma	O
19	Hep3B	O
20	cell	O
21	lines	O
22	engineered	O
23	to	O
24	constitutively	O
25	express	O
26	the	O
27	temperature	O
28	-	B
29	sensitive	I
30	Val135	I
31	mutant	I
32	of	I
33	p53	I
34	.	O

1	Replacing	O
2	the	O
3	aspartic	O
4	acid	O
5	with	B
6	a	I
7	lysine	I
8	but	O
9	not	O
10	with	O
11	an	O
12	alanine	O
13	or	O
14	valine	O
15	residue	O
16	allowed	O
17	formation	O
18	of	O
19	disulfide	O
20	-	O
21	linked	O
22	dimers	O
23	.	O

1	Distant	O
2	spread	O
3	was	O
4	found	O
5	in	O
6	46	O
7	patients	O
8	(	O
9	34	O
10	%),	O
11	42	O
12	of	O
13	whom	O
14	had	O
15	serum	O
16	Tg	O
17	greater	O
18	than	O
19	10	O
20	micrograms	O
21	/	O
22	l	O
23	.	O

1	Consistent	O
2	with	O
3	a	O
4	possible	O
5	role	O
6	in	O
7	transcription	O
8	,	O
9	Paf1p	O
10	is	O
11	localized	O
12	to	O
13	the	O
14	nucleus	O
15	.	O

1	All	O
2	patients	O
3	were	O
4	evaluable	O
5	for	O
6	toxicity	O
7	and	O
8	9	O
9	for	O
10	response	O
11	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	cis	O
6	elements	O
7	positioned	O
8	between	O
9	the	O
10	alpha	O
11	3	O
12	and	O
13	beta	O
14	4	O
15	coding	O
16	regions	O
17	are	O
18	important	O
19	for	O
20	establishing	O
21	part	O
22	of	O
23	the	O
24	restricted	O
25	CNS	O
26	patterns	O
27	of	O
28	beta	O
29	4	O
30	,	O
31	alpha	O
32	3	O
33	,	O
34	and	O
35	alpha	O
36	5	O
37	gene	O
38	transcription	O
39	.	O

1	The	O
2	results	O
3	obtained	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	The	O
9	mitral	O
10	valve	O
11	orifice	O
12	area	O
13	(	O
14	MVA	O
15	)	O
16	was	O
17	significantly	O
18	smaller	O
19	in	O
20	patients	O
21	with	O
22	type	O
23	III	O
24	of	O
25	the	O
26	LVIT	O
27	flow	O
28	velocity	O
29	pattern	O
30	than	O
31	in	O
32	patients	O
33	with	O
34	type	O
35	I	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	Another	O
2	segment	O
3	of	O
4	CRL3	O
5	(-	O
6	296	O
7	to	O
8	-	O
9	184	O
10	),	O
11	also	O
12	displaying	O
13	enhancer	O
14	function	O
15	,	O
16	contained	O
17	tandem	O
18	repeated	O
19	sequences	O
20	(	B
21	DR	I
22	-	I
23	A1	I
24	and	I
25	DR	O
26	-	O
27	A2	O
28	).	O

1	Despite	O
2	the	O
3	absence	O
4	of	O
5	exercise	O
6	-	O
7	induced	O
8	asthma	B
9	(	I
10	EIA	I
11	)	I
12	while	I
13	breathing	I
14	WH	O
15	air	B
16	,	I
17	asthmatic	I
18	patients	O
19	still	O
20	had	O
21	significantly	O
22	higher	O
23	mean	B
24	GH	I
25	increments	I
26	than	I
27	normal	I
28	subjects	O
29	(	O
30	9	O
31	.	O
32	2	B
33	vs	O
34	2	O
35	.	O
36	3	O
37	ng	O
38	/	O
39	ml	O
40	,	O
41	P	B
42	less	O
43	than	O
44	0	B
45	.	O
46	05	O
47	).	I

1	The	O
2	average	O
3	backscatter	O
4	coefficient	O
5	was	O
6	six	O
7	time	O
8	larger	O
9	in	O
10	regions	O
11	of	O
12	infarct	O
13	studied	O
14	8	O
15	--	O
16	10	O
17	weeks	O
18	after	O
19	occlusion	O
20	than	O
21	that	O
22	in	O
23	regions	O
24	of	O
25	infarct	O
26	studied	O
27	5	O
28	--	O
29	6	O
30	weeks	O
31	after	O
32	occlusion	O
33	.	O

1	Demonstration	O
2	of	O
3	fine	O
4	structure	O
5	of	O
6	the	B
7	guinea	I
8	pig	I
9	organ	I
10	of	I
11	Corti	I
12	after	I
13	electron	I
14	microscopic	I
15	silver	I
16	staining	O

1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	O
14	type	O
15	IV	O
16	than	O
17	similarly	O
18	sized	O
19	vessels	B
20	in	I
21	the	I
22	submucosa	I
23	,	I
24	and	O
25	perforating	B
26	vessels	I
27	appeared	I
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	B
40	mucosae	I
41	.	I

1	The	O
2	nucleosomal	O
3	arrays	B
4	detected	I
5	by	I
6	MPE	I
7	X	O
8	Fe	O
9	(	O
10	II	O
11	)	O
12	were	O
13	characterized	O
14	by	O
15	a	O
16	considerable	O
17	loss	O
18	of	O
19	detail	O
20	and	O
21	significantly	O
22	enhanced	O
23	accessibility	O
24	,	O
25	the	O
26	extent	O
27	of	O
28	which	O
29	probably	O
30	reflected	O
31	the	O
32	relative	O
33	transcription	B
34	rate	O
35	of	O
36	each	B
37	gene	I
38	.	B

1	Alternatively	O
2	,	O
3	loss	O
4	-	O
5	of	O
6	-	O
7	function	O
8	alleles	O
9	of	O
10	genes	O
11	that	O
12	inhibit	O
13	cAPK	B
14	lead	I
15	to	I
16	the	O
17	inability	B
18	to	B
19	undergo	O
20	sexual	O
21	differentiation	O
22	.	O

1	Two	O
2	hundred	O
3	forty	O
4	-	O
5	three	O
6	patients	O
7	have	O
8	received	O
9	WR	O
10	-	O
11	2721	O
12	in	O
13	Phase	O
14	I	O
15	-	O
16	II	O
17	studies	O
18	.	O

1	The	O
2	occurrence	O
3	,	O
4	maintenance	O
5	and	O
6	possible	O
7	involvement	O
8	of	O
9	these	O
10	repeated	O
11	sequences	O
12	,	O
13	capable	O
14	of	O
15	forming	O
16	stable	O
17	secondary	O
18	structures	O
19	,	O
20	are	O
21	discussed	O
22	in	O
23	relation	O
24	to	O
25	their	O
26	location	O
27	in	O
28	the	O
29	region	O
30	of	O
31	control	O
32	signals	O
33	.	O

1	Possible	O
2	relationship	O
3	between	O
4	hyperinsulinemia	O
5	and	O
6	glomerular	O
7	hypertrophy	O
8	in	O
9	nephrosclerosis	O
10	.	O

1	Intracellular	O
2	activity	O
3	studies	B
4	indicated	I
5	that	I
6	,	O
7	at	O
8	ten	O
9	times	O
10	MBC	O
11	,	O
12	only	O
13	penicillin	O
14	had	O
15	any	O
16	significant	O
17	activity	O
18	against	O
19	intracellular	O
20	staphylococci	O
21	,	O
22	reducing	O
23	survival	O
24	by	O
25	28	O
26	%.	O

1	The	O
2	second	O
3	part	O
4	of	O
5	this	O
6	paper	O
7	shows	O
8	some	B
9	medical	I
10	applications	I
11	of	O
12	these	O
13	two	O
14	aspects	O
15	of	B
16	NMR	I
17	,	I
18	with	I
19	help	I
20	of	I
21	some	I
22	examples	I
23	,	O
24	taken	O
25	from	O
26	the	O
27	literature	O
28	,	O
29	according	O
30	to	O
31	what	O
32	is	O
33	concerned	O
34	with	O
35	endocrinology	O
36	.	O

1	Between	O
2	the	O
3	subgroups	O
4	of	O
5	dementia	O
6	disorders	O
7	there	O
8	were	O
9	no	O
10	significant	O
11	differences	O
12	in	O
13	basal	O
14	cortisol	O
15	levels	O
16	.	O

1	Symposium	O
2	on	O
3	presenile	O
4	spongy	O
5	encephalopathies	O
6	.	O

1	Moreover	O
2	,	O
3	xTAK1KN	O
4	could	O
5	block	O
6	the	O
7	expression	O
8	of	O
9	ventral	O
10	mesoderm	O
11	marker	O
12	genes	O
13	induced	O
14	by	O
15	Smad1	O
16	or	O
17	5	O
18	.	O

1	Changes	O
2	in	O
3	dopamine	O
4	receptor	O
5	sensitivity	O
6	in	O
7	humans	O
8	after	O
9	heavy	O
10	alcohol	O
11	intake	O
12	.	O

1	A	O
2	human	O
3	cytoplasmic	O
4	signaling	O
5	protein	O
6	has	O
7	been	B
8	cloned	I
9	that	I
10	possesses	I
11	the	I
12	same	I
13	structural	I
14	arrangement	O
15	of	O
16	SH3	O
17	-	O
18	SH2	O
19	-	O
20	SH3	O
21	domains	O
22	as	O
23	Grb2	O
24	.	O

1	The	O
2	R2	O
3	region	O
4	within	O
5	the	O
6	class	O
7	I	O
8	enhancer	O
9	acts	O
10	as	O
11	a	O
12	negative	O
13	element	O
14	in	O
15	Ad12	O
16	-	O
17	transformed	O
18	cells	O
19	and	O
20	exhibits	O
21	a	O
22	stronger	O
23	binding	O
24	activity	O
25	than	O
26	is	O
27	observed	O
28	in	O
29	nontumorigenic	O
30	Ad5	O
31	-	O
32	transformed	O
33	cells	O
34	,	B
35	which	I
36	are	I
37	not	I
38	reduced	I
39	in	O
40	class	O
41	I	O
42	expression	O
43	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	serum	O
7	LH	O
8	and	O
9	chronological	O
10	or	O
11	bone	O
12	age	O
13	in	O
14	this	O
15	age	O
16	group	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	the	O
22	correlation	O
23	found	O
24	is	O
25	not	O
26	due	O
27	to	O
28	age	O
29	-	O
30	related	O
31	parallel	O
32	phenomena	O
33	.	O

1	Lead	O
2	fixation	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	RF	O
8	energy	O
9	.	O

1	This	O
2	intracellular	O
3	signaling	O
4	,	O
5	known	O
6	as	O
7	the	O
8	unfolded	O
9	protein	O
10	response	O
11	(	O
12	UPR	O
13	),	O
14	is	O
15	mediated	O
16	by	O
17	the	O
18	cis	O
19	-	O
20	acting	O
21	ER	O
22	stress	O
23	response	O
24	element	O
25	(	O
26	ERSE	O
27	)	O
28	in	O
29	mammals	O
30	.	O

1	Two	O
2	patients	O
3	with	O
4	recurrent	O
5	tumors	O
6	had	O
7	high	O
8	S	O
9	-	O
10	phase	O
11	fractions	O
12	both	O
13	on	O
14	the	O
15	first	O
16	resected	O
17	specimens	O
18	and	O
19	at	O
20	the	B
21	time	I
22	of	I
23	the	I
24	second	I
25	operation	I
26	.	O

1	Two	O
2	alternatively	O
3	spliced	O
4	5	O
5	'	O
6	UTRs	O
7	,	O
8	designated	O
9	type	O
10	I	O
11	and	O
12	type	O
13	II	O
14	,	B
15	of	I
16	222	I
17	and	O
18	115	O
19	bp	O
20	,	O
21	respectively	O
22	,	O
23	were	B
24	found	I
25	associated	I
26	with	O
27	PFP	O
28	.	O

1	The	O
2	pia	O
3	mater	O
4	at	O
5	the	O
6	site	O
7	of	O
8	the	O
9	entry	O
10	of	O
11	blood	O
12	vessels	O
13	into	O
14	the	O
15	central	O
16	nervous	O
17	system	O
18	.	O

1	Expression	O
2	of	O
3	the	O
4	dibasic	O
5	proprotein	O
6	processing	O
7	enzyme	O
8	furin	O
9	is	O
10	directed	O
11	by	O
12	multiple	O
13	promoters	O
14	.	O

1	SAM	O
2	-	O
3	TR	O
4	-	O
5	68	O
6	-	O
7	54	O
8	.	O

1	GLUT5	O
2	mRNA	O
3	is	O
4	expressed	O
5	at	O
6	highest	O
7	levels	O
8	in	O
9	small	O
10	intestine	O
11	and	O
12	at	O
13	much	B
14	lower	I
15	levels	I
16	in	I
17	kidney	I
18	,	I
19	skeletal	O
20	muscle	O
21	,	O
22	and	O
23	adipose	B
24	tissue	I
25	.	I

1	Our	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	mtr	O
7	product	O
8	causes	O
9	both	O
10	transcription	O
11	attenuation	O
12	and	O
13	inhibition	O
14	of	O
15	translation	O
16	of	O
17	trpE	O
18	mRNA	O
19	.	O

1	The	O
2	STAT	O
3	-	O
4	1	O
5	signaling	O
6	pathway	O
7	provides	O
8	at	O
9	least	O
10	one	O
11	mechanism	O
12	for	O
13	activation	O
14	of	O
15	the	O
16	CAEV	O
17	LTR	O
18	by	O
19	IFN	O
20	-	O
21	gamma	O
22	in	O
23	monocytes	O
24	.	O

1	DNA	O
2	strand	B
3	exchange	I
4	catalyzed	O
5	by	B
6	Rad51	B
7	protein	I
8	is	I
9	also	O
10	greatly	O
11	stimulated	O
12	by	O
13	RPA	O
14	.	B

1	Cleidocranial	O
2	dysostosis	O

1	Max	O
2	was	O
3	constantly	O
4	transcribed	O
5	at	O
6	a	O
7	relatively	O
8	low	O
9	level	O
10	during	O
11	cell	O
12	cycle	O
13	progression	O
14	.	O

1	Advances	O
2	in	O
3	hemophilia	O
4	treatment	O
5	:	O
6	a	O
7	hepatitis	O
8	-	O
9	safe	O
10	factor	O
11	VIII	O
12	concentrate	O

1	These	O
2	fusions	O
3	are	O
4	contained	O
5	on	O
6	plasmids	O
7	which	O
8	have	O
9	both	O
10	yeast	O
11	and	O
12	E	O
13	.	O
14	coli	O
15	replication	O
16	origins	O
17	and	O
18	selectable	O
19	markers	O
20	and	O
21	,	O
22	therefore	O
23	,	O
24	can	O
25	be	O
26	used	O
27	to	O
28	transform	O
29	either	O
30	yeast	O
31	or	O
32	E	O
33	.	O
34	coli	O
35	cells	O
36	.	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	substituted	O
7	and	O
8	wild	B
9	type	I
10	peptides	I
11	were	I
12	observed	I
13	,	O
14	suggesting	O
15	that	O
16	this	O
17	substitution	O
18	in	O
19	the	O
20	intact	O
21	protein	O
22	may	O
23	cause	O
24	disruption	O
25	of	O
26	global	O
27	rather	O
28	than	O
29	local	O
30	structures	O
31	.	O

1	The	O
2	ORF	O
3	4	O
4	gene	O
5	was	O
6	minimally	O
7	active	O
8	,	O
9	whereas	O
10	the	O
11	ORF	O
12	62	O
13	gene	O
14	gave	O
15	twofold	O
16	induction	O
17	;	O
18	both	O
19	genes	O
20	,	O
21	acting	O
22	together	O
23	,	O
24	gave	O
25	fivefold	O
26	induction	O
27	.	O

1	The	O
2	relation	O
3	between	O
4	myocardial	O
5	beta	O
6	-	O
7	adrenergic	O
8	receptor	O
9	and	O
10	left	O
11	ventricular	O
12	(	O
13	LV	O
14	)	O
15	function	O
16	was	O
17	studied	O
18	in	O
19	10	O
20	patients	O
21	,	O
22	aged	O
23	41	O
24	to	O
25	61	O
26	years	O
27	(	O
28	average	O
29	51	O
30	),	O
31	with	O
32	LV	O
33	volume	O
34	overload	O
35	mainly	O
36	due	O
37	to	O
38	chronic	O
39	mitral	O
40	regurgitation	O
41	.	O

1	Although	O
2	the	O
3	molecular	O
4	mechanisms	O
5	involved	O
6	in	O
7	this	O
8	regulation	O
9	are	O
10	currently	O
11	being	O
12	elucidated	O
13	,	O
14	very	O
15	little	O
16	is	O
17	known	O
18	about	O
19	the	O
20	trans	O
21	-	O
22	acting	O
23	factors	O
24	that	O
25	allow	O
26	expression	O
27	of	O
28	the	O
29	nitrate	O
30	and	O
31	nitrite	O
32	reductase	O
33	genes	O
34	which	O
35	code	O
36	for	O
37	the	O
38	first	O
39	enzymes	O
40	in	O
41	the	O
42	pathway	O
43	.	O

1	Nonvascular	O
2	ophthalmic	O
3	and	O
4	neurologic	O
5	disorders	B
6	that	I
7	can	I
8	be	O
9	confused	O
10	with	O
11	amaurosis	O
12	fugax	O
13	are	O
14	listed	O
15	,	O
16	and	O
17	an	O
18	algorithm	O
19	for	O
20	evaluation	O
21	(	O
22	which	O
23	includes	O
24	ophthalmic	O
25	examination	O
26	,	O
27	laboratory	O
28	studies	O
29	,	O
30	and	O
31	noninvasive	O
32	carotid	O
33	artery	O
34	studies	O
35	)	O
36	is	O
37	given	O
38	.	O

1	In	O
2	contrast	O
3	,	O
4	in	O
5	LL	O
6	patients	O
7	during	O
8	ENL	B
9	the	I
10	ConA	O
11	-	O
12	induced	O
13	suppressor	O
14	response	O
15	was	O
16	markedly	O
17	reduced	O
18	.	O

1	The	O
2	DNA	O
3	binding	O
4	activities	O
5	of	O
6	the	O
7	three	O
8	repressor	O
9	preparations	O
10	were	B
11	studied	I
12	using	I
13	fragments	O
14	containing	O
15	CIRs	O
16	(	O
17	CIR3	O
18	-	O
19	CIR6	O
20	)	O
21	from	O
22	the	O
23	essential	O
24	early	O
25	region	O
26	as	O
27	templates	O
28	for	O
29	DNase	O
30	I	B
31	footprinting	I
32	.	I

1	RESULTS	O
2	:	O
3	CK	O
4	-	O
5	MB	O
6	elevation	O
7	was	B
8	detected	I
9	in	I
10	313	I
11	patients	I
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	I
45	.	O

1	We	O
2	have	O
3	examined	O
4	by	O
5	in	O
6	vitro	O
7	footprinting	O
8	a	O
9	region	O
10	located	O
11	downstream	O
12	of	O
13	the	O
14	human	O
15	immunodeficiency	O
16	virus	O
17	,	O
18	type	O
19	1	O
20	(	O
21	HIV	O
22	-	O
23	1	O
24	)	O
25	promoter	O
26	found	O
27	to	O
28	be	O
29	hypersensitive	O
30	to	O
31	DNase	O
32	I	O
33	digestion	O
34	in	O
35	vivo	O
36	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	a	O
6	tat	O
7	expressing	O
8	plasmid	O
9	with	O
10	these	O
11	viruses	O
12	containing	O
13	the	O
14	tat	O
15	ORF	O
16	mutations	O
17	resulted	O
18	in	O
19	higher	O
20	levels	O
21	of	O
22	virus	O
23	production	O
24	demonstrating	O
25	that	O
26	the	O
27	effects	B
28	of	I
29	both	I
30	mutants	I
31	are	O
32	tat	O
33	specific	O
34	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	both	O
6	in	O
7	atrial	O
8	myocytes	O
9	and	O
10	in	O
11	Xenopus	O
12	oocytes	O
13	,	O
14	beta	O
15	-	O
16	adrenergic	O
17	stimulation	O
18	potentiates	O
19	the	O
20	ACh	O
21	-	B
22	evoked	I
23	GIRK	I
24	channels	O
25	via	O
26	a	O
27	pathway	O
28	that	O
29	involves	O
30	PKA	O
31	-	O
32	catalyzed	O
33	phosphorylation	O
34	downstream	O
35	from	O
36	beta	B
37	(	I
38	2	I
39	)	I
40	AR	I
41	.	O

1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	3	O
7	subgroups	O
8	:	O
9	1	O
10	)	O
11	13	O
12	N	O
13	+	O
14	patients	O
15	with	O
16	multiple	O
17	hot	O
18	spots	O
19	(	O
20	greater	O
21	than	O
22	2	O
23	)	O
24	(	O
25	N	O
26	+	O
27	IM	O
28	);	O
29	2	O
30	)	O
31	24	O
32	N	O
33	+	O
34	patients	O
35	with	O
36	single	O
37	hot	O
38	spots	O
39	(	O
40	less	O
41	than	O
42	or	O
43	equal	O
44	to	O
45	2	O
46	)	B
47	(	I
48	N	I
49	+	I
50	IS	I
51	);	I
52	3	I
53	)	O
54	12	O
55	N	O
56	-	O
57	patients	O
58	with	O
59	single	O
60	hot	O
61	spots	O
62	(	O
63	less	O
64	than	O
65	or	O
66	equal	O
67	to	O
68	2	O
69	)	O
70	(	O
71	N	O
72	-	O
73	IS	O
74	).	O

1	Static	O
2	orthoses	O
3	for	O
4	the	O
5	management	O
6	of	O
7	microstomia	O
8	.	O

1	Moreover	O
2	,	O
3	the	O
4	mass	O
5	estimated	O
6	with	O
7	the	O
8	QCM	O
9	response	O
10	through	O
11	the	O
12	Sauerbrey	O
13	equation	O
14	and	B
15	the	B
16	mass	I
17	which	O
18	can	O
19	be	O
20	measured	O
21	thanks	O
22	to	O
23	other	O
24	analytical	O
25	techniques	O
26	,	O
27	in	O
28	our	O
29	case	O
30	an	O
31	enzymatic	O
32	assay	O
33	,	O
34	are	O
35	different	O
36	:	O
37	the	O
38	deposited	O
39	mass	O
40	is	O
41	generally	O
42	overestimated	O
43	by	O
44	the	O
45	QCM	O
46	.	O

1	Per	O
2	kg	O
3	FFM	O
4	SMR	O
5	was	O
6	almost	O
7	restored	O
8	to	O
9	baseline	O
10	values	O
11	for	O
12	the	O
13	EX	O
14	group	O
15	,	O
16	whereas	O
17	the	O
18	non	O
19	-	O
20	exercising	O
21	subjects	O
22	still	O
23	showed	O
24	depressed	O
25	values	O
26	(	O
27	EX	O
28	3	O
29	.	O
30	7	O
31	per	O
32	cent	O
33	and	O
34	D	O
35	+	O
36	DE	O
37	15	O
38	.	O
39	8	O
40	per	O
41	cent	O
42	lower	O
43	than	O
44	before	O
45	treatment	O
46	;	O
47	P	O
48	less	O
49	than	O
50	0	O
51	.	O
52	05	O
53	).	O

1	We	O
2	conclude	B
3	that	I
4	TA	I
5	caused	O
6	a	O
7	specific	O
8	decrease	O
9	in	O
10	AGD	B
11	on	I
12	GD	O
13	20	O
14	that	I
15	was	O
16	largely	I
17	reversed	I
18	by	O
19	PCD	B
20	23	I
21	.	I

1	The	O
2	DRF	O
3	-	O
4	2	O
5	nuclear	O
6	protein	O
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	O
15	-	O
16	specific	O
17	regulatory	O
18	factor	O
19	,	O
20	MEF	O
21	-	O
22	2	O
23	(	O
24	Buskin	O
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	Subsequent	O
2	to	O
3	their	O
4	secretion	O
5	,	O
6	the	O
7	IGF	O
8	-	O
9	II	O
10	in	O
11	xz97	O
12	and	O
13	G11	O
14	cells	O
15	accumulated	O
16	in	O
17	the	O
18	conditioned	O
19	medium	O
20	mostly	B
21	as	I
22	two	I
23	partially	I
24	processed	I
25	species	I
26	with	I
27	appMr	I
28	,	I
29	of	O
30	17K	O
31	and	O
32	14K	O
33	,	O
34	respectively	O
35	.	O

1	We	O
2	compared	O
3	the	O
4	volume	O
5	of	O
6	the	O
7	pulmonary	O
8	extravascular	O
9	,	O
10	extracellular	O
11	water	O
12	space	O
13	using	O
14	sodium	O
15	and	O
16	sucrose	B
17	indicators	I
18	in	I
19	8	I
20	normal	O
21	and	O
22	11	O
23	edematous	O
24	rabbit	O
25	lungs	O
26	by	O
27	steady	O
28	-	O
29	state	O
30	techniques	O
31	.	O

1	ORF	O
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	O
9	,	B
10	while	I
11	ORF	I
12	M11	I
13	encodes	I
14	a	I
15	potential	I
16	homolog	I
17	of	O
18	Bcl	O
19	-	O
20	2	O
21	-	O
22	like	O
23	molecules	O
24	encoded	O
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	O
30	16	O
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	O
38	gene	O
39	of	O
40	EBV	O
41	).	O

1	Organization	O
2	of	O
3	the	O
4	human	O
5	LU	O
6	gene	O
7	and	O
8	molecular	O
9	basis	O
10	of	O
11	the	O
12	Lu	O
13	(	O
14	a	O
15	)/	O
16	Lu	O
17	(	O
18	b	O
19	)	O
20	blood	O
21	group	O
22	polymorphism	O
23	.	O

1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O

1	These	O
2	lesions	O
3	were	O
4	asymptomatic	O
5	,	O
6	but	O
7	both	O
8	were	O
9	characterized	O
10	clinically	O
11	by	B
12	central	I
13	ulceration	I
14	.	I

1	Our	O
2	findings	O
3	also	O
4	provide	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	development	O
10	of	O
11	assays	O
12	to	O
13	screen	O
14	for	O
15	the	O
16	ligands	O
17	to	O
18	testis	O
19	receptor	O
20	2	O
21	and	O
22	hERR1	O
23	.	O

1	Analysis	O
2	of	O
3	lacZ	O
4	transcriptional	O
5	fusions	O
6	shows	O
7	that	O
8	the	O
9	KdgR	O
10	-	O
11	binding	O
12	sites	O
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	O
19	.	O

1	We	O
2	conclude	O
3	that	O
4	androgenic	O
5	hormones	O
6	reduce	O
7	HDL	O
8	-	O
9	cholesterol	O
10	concentrations	O
11	and	O
12	the	O
13	HDL2	O
14	-	O
15	cholesterol	O
16	subfraction	O
17	,	O
18	possibly	O
19	by	O
20	enhancing	O
21	hepatic	O
22	triglyceride	O
23	lipase	O
24	activity	O
25	.	O

1	Lck	O
2	has	O
3	been	O
4	postulated	O
5	to	O
6	dimerize	O
7	through	O
8	the	O
9	SH2	O
10	and	O
11	SH3	O
12	domains	O
13	.	O

1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O

1	We	O
2	describe	O
3	49	B
4	cases	I
5	with	I
6	papillary	I
7	tumor	I
8	<	I
9	1	I
10	cm	I
11	.	I

1	Renal	O
2	excretion	O
3	of	O
4	sulphadimidine	O
5	in	O
6	normal	O
7	and	O
8	uraemic	B
9	subjects	I
10	.	I

1	Copyright	O
2	2000	O
3	Academic	B
4	Press	I
5	.	I

1	Based	O
2	on	B
3	AUC	I
4	infinity	I
5	analyses	I
6	,	I
7	the	O
8	pharmacokinetics	O
9	of	O
10	buflomedil	O
11	were	O
12	found	O
13	to	O
14	be	O
15	linear	O
16	within	O
17	the	O
18	dose	O
19	ranges	O
20	studied	O
21	(	B
22	50	O
23	to	O
24	200	O
25	mg	O
26	for	O
27	i	O
28	.	O
29	v	O
30	.	O
31	injection	O
32	and	O
33	150	B
34	to	O
35	450	B
36	mg	I
37	for	I
38	oral	I
39	administration	I
40	).	I

1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	B
6	bcp	I
7	from	I
8	the	O
9	chromosome	I
10	had	I
11	no	I
12	effect	I
13	on	I
14	gcv	O
15	-	O
16	lacZ	O
17	expression	B
18	.	I

1	In	O
2	one	O
3	acromegalic	O
4	patient	O
5	visual	O
6	improvement	O
7	was	O
8	obtained	O
9	while	O
10	the	O
11	abnormal	O
12	GH	O
13	secretion	O
14	remained	O
15	unaltered	O
16	.	O

1	18F	O
2	and	O
3	85Sr	O
4	scintimetry	O
5	in	O
6	the	O
7	study	O
8	of	O
9	primary	O
10	arthropathies	O
11	.	O

1	In	O
2	the	O
3	work	O
4	reported	O
5	here	O
6	,	O
7	we	O
8	used	O
9	peptide	O
10	mapping	O
11	,	O
12	mass	O
13	spectrometry	O
14	,	I
15	and	I
16	site	O
17	-	O
18	directed	O
19	mutagenesis	O
20	to	O
21	identify	B
22	two	I
23	sets	I
24	of	I
25	pAP	I
26	phosphorylation	I
27	sites	I
28	.	I

1	Judicious	O
2	use	O
3	of	O
4	laboratory	O
5	testing	O
6	,	O
7	including	O
8	monitoring	O
9	of	O
10	CD4	O
11	cell	O
12	counts	O
13	,	O
14	is	O
15	recommended	O
16	.	O

1	Acad	O
2	.	O

1	Expression	O
2	,	B
3	cellular	I
4	localization	I
5	and	I
6	in	I
7	vitro	I
8	transcription	I
9	studies	O
10	establish	B
11	that	I
12	cloned	O
13	hUBF	O
14	encodes	O
15	a	O
16	nucleolar	O
17	factor	O
18	that	O
19	binds	O
20	specifically	O
21	to	O
22	the	O
23	upstream	O
24	control	O
25	element	O
26	and	O
27	core	O
28	of	O
29	the	O
30	rRNA	O
31	gene	O
32	promoter	B
33	to	B
34	activate	O
35	transcription	B
36	in	I
37	a	I
38	binding	I
39	site	I
40	-	I
41	dependent	I
42	manner	I
43	.	I

1	KEY	O
2	WORDS	O
3	:	O
4	Melaleuca	O
5	;	O
6	Lake	O
7	Okeechobee	O
8	;	O
9	Littoral	O
10	zone	O
11	;	O
12	Water	O
13	level	O
14	;	O
15	Regulation	O
16	schedule	O

1	The	O
2	elements	O
3	responsible	O
4	for	O
5	glucocorticoid	O
6	stimulation	O
7	of	O
8	ADH	O
9	gene	O
10	transcription	O
11	appear	O
12	to	O
13	reside	O
14	outside	O
15	of	O
16	this	O
17	region	O
18	.	O

1	Genomic	O
2	and	O
3	functional	O
4	characterization	O
5	of	O
6	the	O
7	oas	O
8	gene	O
9	family	O
10	encoding	O
11	O	O
12	-	O
13	acetylserine	O
14	(	O
15	thiol	O
16	)	O
17	lyases	O
18	,	O
19	enzymes	O
20	catalyzing	O
21	the	O
22	final	O
23	step	O
24	in	O
25	cysteine	B
26	biosynthesis	I
27	in	I
28	Arabidopsis	I
29	thaliana	I
30	.	O

1	SETTING	O
2	:	O
3	A	O
4	division	O
5	of	O
6	a	O
7	large	O
8	tea	O
9	plantation	O
10	in	O
11	Kandy	O
12	.	O

1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	B
11	65	I
12	%).	I

1	The	O
2	fourth	O
3	dose	O
4	produced	O
5	favorable	O
6	results	O
7	(	O
8	66	O
9	.	O
10	7	O
11	%)	O
12	in	O
13	individuals	O
14	with	O
15	HB	O
16	antibodies	O
17	between	O
18	10	O
19	and	O
20	100	O
21	IU	O
22	/	O
23	ml	O
24	and	O
25	unfavorable	O
26	ones	O
27	(	O
28	3	O
29	.	O
30	8	O
31	%)	O
32	where	O
33	the	O
34	HB	O
35	antibodies	O
36	were	O
37	below	O
38	10	O
39	IU	O
40	/	O
41	ml	O
42	.	O

1	Identification	O
2	of	O
3	a	O
4	novel	O
5	E2F3	O
6	product	O
7	suggests	O
8	a	O
9	mechanism	O
10	for	O
11	determining	O
12	specificity	O
13	of	O
14	repression	O
15	by	O
16	Rb	O
17	proteins	O
18	.	O

1	Using	O
2	one	O
3	of	O
4	the	O
5	six	O
6	fragments	O
7	(	O
8	CPK3	O
9	-	O
10	8	O
11	),	O
12	we	O
13	isolated	O
14	a	O
15	2022	O
16	bp	O
17	cDNA	O
18	(	O
19	VrCDPK	O
20	-	O
21	1	O
22	)	O
23	from	O
24	a	O
25	Vigna	O
26	radiata	O
27	lambda	O
28	gt11	O
29	library	O
30	.	O

1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	O
40	formula	O
41	,	O
42	soy	O
43	/	O
44	pork	O
45	collagen	O
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O

1	Glycogen	O
2	synthesis	O
3	and	O
4	catabolism	O
5	,	O
6	gluconeogenesis	O
7	,	O
8	glycolysis	O
9	,	O
10	motility	O
11	,	O
12	cell	O
13	surface	O
14	properties	O
15	and	O
16	adherence	O
17	are	O
18	modulated	O
19	by	O
20	csrA	O
21	in	O
22	Escherichia	O
23	coli	O
24	,	O
25	while	O
26	the	O
27	production	O
28	of	O
29	several	O
30	secreted	O
31	virulence	O
32	factors	O
33	,	O
34	the	O
35	plant	O
36	hypersensitive	O
37	response	O
38	elicitor	O
39	HrpN	O
40	(	O
41	Ecc	O
42	)	O
43	and	O
44	,	O
45	potentially	O
46	,	O
47	other	O
48	secondary	O
49	metabolites	O
50	are	O
51	regulated	O
52	by	O
53	rsmA	O
54	in	O
55	Erwinia	O
56	carotovora	O
57	.	O

1	This	O
2	DNA	O
3	containing	O
4	promoter	O
5	activity	O
6	has	O
7	been	O
8	sequenced	O
9	in	O
10	its	O
11	entirety	O
12	and	O
13	found	O
14	to	O
15	contain	O
16	multiple	O
17	putative	O
18	regulatory	O
19	sites	O
20	.	O

1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	VP5	O
19	mutant	O
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	VP5	O
26	and	O
27	VP23	O
28	null	O
29	mutants	O
30	.	O

1	One	O
2	phage	O
3	clone	B
4	contains	I
5	a	I
6	junction	I
7	between	I
8	alpha	I
9	satellite	I
10	DNA	I
11	and	O
12	a	I
13	novel	O
14	low	O
15	-	O
16	copy	O
17	repeated	O
18	sequence	O
19	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	effect	O
7	of	O
8	the	O
9	isomers	O
10	of	O
11	pentobarbital	O
12	and	O
13	secobarbital	O
14	on	B
15	mult	I
16	FR30	I
17	FI600	I
18	responding	I
19	and	I
20	on	I
21	suppressed	I
22	responding	I
23	are	I
24	qualitatively	I
25	similar	I
26	.(	I
27	ABSTRACT	I
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	Yeast	O
2	U1	O
3	snRNP	O
4	is	O
5	considerably	O
6	more	O
7	complex	O
8	than	O
9	its	O
10	metazoan	O
11	counterpart	O
12	,	O
13	which	O
14	suggests	O
15	possible	O
16	differences	O
17	between	O
18	yeast	O
19	and	O
20	metazoa	O
21	in	O
22	early	O
23	splicing	O
24	events	O
25	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	O
30	-	O
31	fos	O
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	The	O
2	recovery	O
3	index	O
4	(	O
5	T25	B
6	-	I
7	T75	I
8	)	I
9	after	I
10	the	O
11	infusion	B
12	stopped	I
13	was	I
14	similar	I
15	in	I
16	patients	I
17	who	I
18	received	I
19	mivacurium	O
20	and	O
21	those	O
22	who	O
23	received	O
24	suxamethonium	O
25	.	O

1	No	O
2	difference	O
3	in	O
4	elastin	O
5	peptide	O
6	concentration	O
7	was	O
8	observed	O
9	between	O
10	emphysematous	O
11	patients	O
12	and	B
13	control	I
14	subjects	I
15	(	I
16	mean	O
17	+/-	O
18	SD	O
19	=	O
20	2	O
21	.	O
22	39	O
23	+/-	O
24	1	O
25	.	O
26	18	O
27	micrograms	O
28	/	O
29	ml	O
30	in	O
31	patients	O
32	versus	O
33	2	O
34	.	O
35	55	O
36	+/-	O
37	1	O
38	.	O
39	34	O
40	micrograms	O
41	/	O
42	ml	O
43	in	O
44	policemen	O
45	and	O
46	2	O
47	.	O
48	59	B
49	+/-	I
50	1	I
51	.	O
52	20	O
53	micrograms	O
54	/	O
55	ml	O
56	in	O
57	coal	O
58	miners	O
59	).	O

1	For	O
2	oral	O
3	administration	O
4	,	O
5	AUC0	O
6	-	O
7	infinity	O
8	was	O
9	58	O
10	.	O
11	47	O
12	+/-	O
13	16	O
14	.	O
15	37	O
16	microg	O
17	x	O
18	h	O
19	/	O
20	ml	O
21	,	O
22	t1	O
23	/	O
24	2beta	O
25	was	O
26	18	O
27	.	O
28	39	O
29	+/-	O
30	0	O
31	.	O
32	06	O
33	hours	O
34	,	O
35	maximum	O
36	concentration	O
37	(	O
38	Cmax	O
39	)	O
40	was	O
41	2	O
42	.	O
43	12	O
44	+/-	O
45	00	O
46	.	O
47	51	O
48	microg	O
49	/	O
50	ml	O
51	,	O
52	time	O
53	to	O
54	Cmax	O
55	was	O
56	2	O
57	.	O
58	20	O
59	+/-	O
60	2	O
61	.	O
62	17	O
63	hours	O
64	,	O
65	mean	O
66	absorption	O
67	time	O
68	was	O
69	2	O
70	.	O
71	09	O
72	+/-	O
73	0	O
74	.	O
75	51	O
76	hours	O
77	,	O
78	and	O
79	bioavailability	O
80	was	O
81	42	O
82	+/-	O
83	0	O
84	.	O
85	42	O
86	%.	O

1	Identification	O
2	of	O
3	dynein	O
4	heavy	O
5	chain	O
6	genes	O
7	expressed	O
8	in	O
9	human	O
10	and	O
11	mouse	O
12	testis	O
13	:	O
14	chromosomal	O
15	localization	O
16	of	O
17	an	O
18	axonemal	O
19	dynein	O
20	gene	O
21	.	O

1	CD7	O
2	+/	O
3	CD3	O
4	-	O
5	T	O
6	-	B
7	cell	O
8	precursors	O
9	exhibit	O
10	V	O
11	delta	O
12	2D	O
13	delta	O
14	3	O
15	rearrangements	O
16	.	O

1	The	O
2	pulpal	O
3	tissues	O
4	of	O
5	the	O
6	permanent	O
7	mandibular	O
8	molars	O
9	were	O
10	amputated	O
11	and	O
12	then	O
13	dressed	O
14	with	O
15	calcium	O
16	hydrate	O
17	.	O

1	RNase	O
2	protection	O
3	and	O
4	primer	O
5	extension	O
6	assays	O
7	confirmed	B
8	that	I
9	the	I
10	5	I
11	'	I
12	non	I
13	-	I
14	coding	O
15	exon	O
16	is	O
17	included	O
18	in	O
19	the	O
20	DDT1	O
21	aFGF	B
22	mRNA	I
23	and	I
24	that	O
25	a	O
26	major	O
27	transcription	O
28	start	O
29	site	O
30	is	O
31	approximately	O
32	136	O
33	bp	O
34	upstream	O
35	of	O
36	the	O
37	5	O
38	'	O
39	non	O
40	-	O
41	coding	O
42	splice	O
43	junction	O
44	of	O
45	this	O
46	exon	O
47	.	O

1	Two	O
2	separate	O
3	NF1	O
4	-	O
5	binding	O
6	loci	O
7	were	O
8	also	O
9	found	O
10	in	O
11	the	O
12	equivalent	O
13	IE68	O
14	gene	O
15	of	O
16	HCMV	O
17	(	O
18	Towne	O
19	)	O
20	DNA	O
21	,	O
22	but	O
23	in	O
24	this	O
25	case	O
26	the	O
27	DNA	O
28	sequence	O
29	and	O
30	competition	O
31	filter	O
32	binding	O
33	experiments	O
34	indicated	O
35	a	O
36	maximum	O
37	of	O
38	only	O
39	four	O
40	to	O
41	five	O
42	consensus	O
43	binding	O
44	sites	O
45	encompassing	O
46	the	O
47	promoter	O
48	-	O
49	enhancer	O
50	region	O
51	.	O

1	Basing	O
2	on	O
3	experimental	O
4	toxicity	O
5	research	O
6	it	O
7	was	O
8	established	O
9	that	O
10	,	O
11	out	O
12	of	O
13	50	O
14	atmosphere	O
15	metal	O
16	corrosion	O
17	inhibitors	O
18	,	B
19	some	I
20	14	I
21	per	O
22	cent	B
23	were	I
24	found	I
25	extremely	O
26	hazardous	O
27	,	O
28	42	O
29	per	O
30	cent	O
31	--	O
32	of	O
33	high	O
34	level	O
35	hazardous	O
36	,	O
37	33	O
38	percent	O
39	--	O
40	of	O
41	moderate	O
42	and	O
43	11	O
44	per	O
45	cent	O
46	--	O
47	of	O
48	low	O
49	hazardous	O
50	.	O

1	Sp1	O
2	can	O
3	activate	O
4	transcription	O
5	through	O
6	immunoglobulin	O
7	kappa	O
8	-	O
9	chain	O
10	enhancer	O
11	or	O
12	P	O
13	-	O
14	selectin	O
15	promoter	O
16	NF	O
17	-	O
18	kappaB	O
19	sites	O
20	.	O
21	p50	O
22	homodimers	O
23	replace	O
24	Sp1	O
25	from	O
26	the	O
27	P	O
28	-	O
29	selectin	O
30	promoter	O
31	by	O
32	binding	O
33	site	O
34	competition	O
35	and	O
36	thereby	O
37	either	O
38	inhibit	O
39	basal	O
40	Sp1	O
41	-	O
42	driven	O
43	expression	O
44	or	O
45	,	O
46	in	O
47	concert	O
48	with	O
49	Bcl	O
50	-	O
51	3	O
52	,	O
53	stimulate	O
54	expression	O
55	.	O

1	In	O
2	vivo	O
3	epiluminescence	O
4	microscopy	O
5	of	O
6	pigmented	O
7	skin	O
8	lesions	O
9	.	O

1	McCann	O
2	III	O
3	,	O
4	F	O
5	.	O

1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	4	O
7	groups	O
8	receiving	O
9	NLA	O
10	II	O
11	with	O
12	or	O
13	without	O
14	nalorphine	O
15	,	O
16	morphine	O
17	or	O
18	Micoren	O
19	.	O

1	Several	O
2	highly	O
3	conserved	O
4	regions	O
5	were	O
6	identified	O
7	at	O
8	the	O
9	near	O
10	N	O
11	terminus	O
12	,	O
13	middle	B
14	and	I
15	C	I
16	terminus	I
17	.	I

1	Some	O
2	studies	O
3	of	O
4	exercise	O
5	have	O
6	associated	O
7	beta	O
8	-	O
9	endorphin	O
10	release	O
11	with	O
12	increased	O
13	exertion	O
14	levels	O
15	,	O
16	but	O
17	other	O
18	evidence	O
19	suggests	O
20	that	O
21	acidosis	O
22	may	O
23	stimulate	O
24	the	O
25	release	O
26	of	O
27	beta	O
28	-	O
29	endorphin	O
30	.	O

1	Isolation	O
2	by	O
3	PCR	O
4	of	O
5	a	O
6	cDNA	O
7	clone	O
8	from	O
9	pea	O
10	petals	O
11	with	O
12	similarity	O
13	to	O
14	petunia	O
15	and	O
16	wheat	O
17	zinc	O
18	finger	O
19	proteins	O
20	.	O

1	Dystonic	O
2	movement	O
3	of	O
4	the	O
5	left	O
6	upper	O
7	limb	O
8	in	O
9	a	O
10	case	O
11	of	O
12	the	O
13	right	O
14	pontine	O
15	hemorrhage	O

1	Three	O
2	cysteine	O
3	and	O
4	four	O
5	tryptophan	O
6	residues	O
7	,	O
8	previously	O
9	identified	O
10	as	O
11	conserved	O
12	amongst	O
13	nitrous	O
14	-	O
15	oxide	O
16	reductases	O
17	,	O
18	are	O
19	found	O
20	in	O
21	the	O
22	Paracoccus	O
23	enzyme	O
24	.	O

1	We	O
2	have	B
3	isolated	I
4	a	I
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	O
10	anemia	O
11	group	O
12	C	O
13	protein	O
14	(	O
15	FANCC	O
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O

1	Hydrocortisone	O
2	seems	O
3	to	O
4	be	O
5	unable	O
6	to	O
7	hinder	O
8	the	O
9	postdenervation	O
10	changes	O
11	in	O
12	the	O
13	muscle	O
14	membrane	O
15	whereas	O
16	high	O
17	doses	O
18	of	O
19	the	O
20	hormone	O
21	are	O
22	able	O
23	to	O
24	induce	O
25	changes	O
26	in	B
27	the	I
28	muscle	I
29	membrane	I
30	.	I

1	The	O
2	distal	O
3	portion	O
4	of	O
5	the	O
6	rat	O
7	insulin	O
8	I	O
9	gene	O
10	5	O
11	'-	B
12	flanking	I
13	DNA	I
14	contains	I
15	two	O
16	sequence	B
17	elements	I
18	,	I
19	the	O
20	Far	O
21	and	O
22	FLAT	O
23	elements	O
24	,	O
25	that	O
26	can	O
27	function	O
28	in	O
29	combination	O
30	,	O
31	but	O
32	not	O
33	separately	O
34	,	O
35	as	O
36	a	O
37	beta	O
38	-	O
39	cell	O
40	-	O
41	specific	O
42	transcriptional	O
43	enhancer	O
44	.	O

1	However	O
2	,	O
3	by	O
4	an	O
5	NS35	O
6	-	O
7	specific	O
8	RNA	O
9	capture	O
10	assay	O
11	,	O
12	the	O
13	multimers	O
14	were	O
15	shown	O
16	to	O
17	possess	O
18	the	O
19	RNA	O
20	-	O
21	binding	O
22	activity	O
23	previously	O
24	demonstrated	O
25	for	O
26	NS35	O
27	.	O

1	As	O
2	expected	O
3	,	O
4	glycosylation	O
5	of	O
6	Env	O
7	produced	O
8	from	O
9	mutants	O
10	was	O
11	affected	O
12	but	O
13	,	O
14	irrespective	O
15	of	O
16	the	O
17	glycosylation	O
18	phenotype	O
19	,	O
20	(	O
21	i	O
22	)	O
23	similar	O
24	quantities	O
25	of	O
26	Env	O
27	were	O
28	synthesized	O
29	,	O
30	(	O
31	ii	O
32	)	O
33	the	O
34	immunoreactivity	O
35	of	O
36	V3	O
37	was	O
38	similar	O
39	,	O
40	(	O
41	iii	O
42	)	O
43	gp160	O
44	was	O
45	efficiently	O
46	cleaved	O
47	into	O
48	gp120	O
49	and	O
50	gp41	O
51	,	O
52	(	O
53	vi	O
54	)	O
55	Env	O
56	was	O
57	exposed	O
58	at	O
59	the	O
60	cell	O
61	membrane	O
62	,	O
63	(	O
64	v	O
65	)	O
66	secreted	O
67	gp120	O
68	bound	O
69	CD4	O
70	,	O
71	and	O
72	(	O
73	vi	O
74	)	O
75	membrane	O
76	gp41	O
77	was	O
78	able	O
79	to	O
80	induce	O
81	membrane	O
82	fusion	O
83	with	O
84	CD4	O
85	+	O
86	cells	O
87	.	O

1	A	O
2	third	O
3	ORF	O
4	,	O
5	ORF5	O
6	,	O
7	shows	O
8	homology	O
9	with	O
10	gene	O
11	agrB	O
12	from	O
13	Staphylococcus	O
14	aureus	O
15	,	O
16	which	O
17	is	O
18	involved	O
19	in	O
20	the	O
21	mechanism	O
22	of	O
23	regulation	O
24	of	B
25	the	I
26	virulence	I
27	phenotype	I
28	in	I
29	this	I
30	species	I
31	.	I

1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	B
13	not	I
14	directly	I
15	involved	I
16	in	O
17	transrepression	O
18	of	O
19	AP	O
20	-	O
21	1	O
22	activity	O
23	.	O

1	Dimerization	O
2	of	O
3	Myf	O
4	-	O
5	5	O
6	with	O
7	the	B
8	ubiquitously	I
9	expressed	I
10	bHLH	I
11	protein	O
12	E12	B
13	not	I
14	only	I
15	increases	I
16	the	I
17	affinity	O
18	for	O
19	DNA	B
20	but	I
21	also	I
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	Despite	O
2	the	O
3	favourable	O
4	natural	O
5	history	O
6	of	O
7	acute	O
8	BI	B
9	,	I
10	mild	O
11	,	O
12	moderate	O
13	,	O
14	and	O
15	severe	O
16	posttraumatic	O
17	changes	O
18	were	O
19	shown	O
20	to	O
21	appear	O
22	as	O
23	cicatricial	O
24	-	O
25	adhesive	O
26	and	O
27	atrophic	O
28	processes	O
29	,	O
30	intracerebral	O
31	cysts	O
32	,	O
33	porencephaly	O
34	,	O
35	which	O
36	result	O
37	in	O
38	posttraumatic	O
39	epilepsy	O
40	,	O
41	hydrocephalus	O
42	,	O
43	etc	O
44	.	O

1	Tl	O
2	-	O
3	201	O
4	uptake	O
5	ratio	O
6	of	O
7	the	O
8	right	O
9	ventricle	O
10	,	O
11	which	O
12	represents	O
13	the	O
14	ratio	O
15	of	O
16	total	O
17	counts	O
18	of	O
19	the	O
20	right	O
21	ventricle	O
22	to	O
23	counts	I
24	of	O
25	the	O
26	administered	O
27	dose	O
28	of	O
29	Tl	O
30	-	O
31	201	O
32	,	O
33	was	O
34	higher	O
35	in	O
36	COPD	O
37	,	B
38	especially	I
39	in	I
40	pulmonary	I
41	emphysema	O
42	and	O
43	B	O
44	type	O
45	COPD	O
46	by	B
47	Burrows	I
48	classification	I
49	than	I
50	in	I
51	controls	I
52	.	O

1	In	O
2	general	O
3	lookback	O
4	,	O
5	all	O
6	patients	O
7	who	O
8	received	O
9	blood	O
10	before	O
11	being	O
12	tested	O
13	for	O
14	hepatitis	O
15	C	O
16	are	O
17	advised	O
18	to	O
19	undergo	O
20	testing	O
21	.	O

1	The	O
2	general	O
3	transcription	O
4	factor	O
5	IIA	O
6	(	O
7	TFIIA	O
8	)	O
9	interacts	O
10	with	O
11	the	O
12	TATA	O
13	binding	O
14	protein	O
15	(	O
16	TBP	O
17	)	B
18	and	B
19	promoter	I
20	DNA	I
21	to	I
22	mediate	I
23	transcription	I
24	activation	I
25	in	I
26	vitro	I
27	.	I

1	The	O
2	stoichiometry	O
3	of	O
4	the	O
5	complexes	O
6	formed	O
7	with	O
8	the	O
9	dodeca	I
10	-	I
11	satellite	I
12	C	I
13	strand	I
14	suggests	I
15	that	O
16	,	O
17	in	O
18	DDP1	O
19	,	O
20	the	O
21	15	O
22	consecutive	O
23	KH	O
24	domains	O
25	are	O
26	organized	O
27	such	O
28	that	O
29	they	O
30	define	O
31	two	O
32	nucleic	O
33	acid	O
34	binding	O
35	surfaces	O
36	.	O

1	Effects	O
2	of	O
3	estrogen	O
4	and	O
5	glucocorticoids	O
6	on	O
7	the	O
8	adrenal	O
9	development	O
10	of	O
11	the	B
12	fetus	I
13	.	O

1	Interestingly	O
2	,	O
3	although	O
4	E	O
5	domains	O
6	of	O
7	these	O
8	two	B
9	receptors	I
10	are	I
11	much	I
12	less	O
13	conserved	O
14	,	O
15	replacement	O
16	of	O
17	this	O
18	domain	O
19	in	O
20	rtER	O
21	by	O
22	its	O
23	human	O
24	counterpart	O
25	resulted	I
26	in	O
27	higher	O
28	estradiol	O
29	sensitivity	O
30	but	O
31	no	O
32	increase	O
33	in	O
34	the	O
35	magnitude	O
36	of	O
37	transactivation	O
38	.	O

1	Ang	O
2	II	O
3	-	O
4	induced	O
5	fibronectin	O
6	mRNA	O
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	O
12	inhibitors	O
13	or	O
14	PKC	O
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	O
22	-	O
23	R	O
24	function	O
25	by	O
26	a	O
27	dominant	O
28	negative	O
29	EGF	O
30	-	O
31	R	O
32	mutant	O
33	and	O
34	tyrphostin	O
35	AG1478	O
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	O
40	mRNA	O
41	.	O

1	From	O
2	February	O
3	1991	O
4	to	O
5	August	O
6	1997	O
7	,	O
8	124	O
9	patients	O
10	with	O
11	endometrial	O
12	carcinoma	O
13	were	O
14	treated	O
15	postoperatively	O
16	with	O
17	high	O
18	-	O
19	dose	O
20	-	O
21	rate	O
22	vaginal	O
23	vault	O
24	brachytherapy	O
25	as	O
26	the	O
27	only	O
28	adjuvant	O
29	treatment	O
30	.	O

1	Low	O
2	-	O
3	dose	O
4	D	O
5	(	O
6	0	O
7	.	O
8	4	O
9	-	O
10	0	O
11	.	O
12	8	O
13	mg	O
14	)	O
15	and	O
16	DB	O
17	(	O
18	1	O
19	.	O
20	0	O
21	-	O
22	5	O
23	.	O
24	0	O
25	mg	O
26	)	O
27	did	O
28	not	O
29	significantly	O
30	alter	O
31	any	O
32	parameter	O
33	from	O
34	control	O
35	.	O

1	Concomitant	O
2	chronic	O
3	lymphocytic	O
4	leukemia	O
5	,	O
6	acute	O
7	myeloid	O
8	leukemia	O
9	,	O
10	and	O
11	thrombosis	O
12	with	O
13	protein	O
14	C	O
15	deficiency	O
16	.	O

1	The	O
2	results	O
3	indicated	O
4	that	O
5	two	O
6	genes	O
7	(	O
8	citA	O
9	and	O
10	citB	O
11	)	O
12	have	O
13	separate	O
14	promoters	O
15	,	O
16	and	O
17	the	O
18	location	O
19	of	O
20	the	O
21	promoter	O
22	for	O
23	the	O
24	citB	O
25	gene	O
26	in	O
27	the	O
28	Tn3411	O
29	nucleotide	O
30	sequence	O
31	was	B
32	different	I
33	from	O
34	that	O
35	in	O
36	pMS185	O
37	.	O

1	This	O
2	study	O
3	indicated	O
4	that	O
5	the	O
6	Japanese	O
7	quail	O
8	was	O
9	less	O
10	sensitive	O
11	to	O
12	particulate	O
13	Mn3O4	O
14	exposure	O
15	than	O
16	rodents	O
17	treated	O
18	comparably	O
19	.	O

1	Eight	O
2	hours	O
3	after	O
4	the	O
5	administration	O
6	of	O
7	colchicine	O
8	,	O
9	the	O
10	serum	O
11	ceruloplasmin	O
12	level	O
13	began	O
14	to	O
15	rise	O
16	again	O
17	in	O
18	female	O
19	rats	O
20	,	O
21	but	O
22	not	O
23	in	O
24	male	O
25	rats	O
26	.	O

1	The	O
2	program	O
3	has	O
4	been	O
5	written	O
6	in	O
7	a	O
8	generic	O
9	BASIC	O
10	in	O
11	order	O
12	to	O
13	make	O
14	the	O
15	procedure	O
16	user	O
17	-	O
18	friendly	O
19	.	O

1	Again	O
2	residue	O
3	Glu	O
4	-	O
5	381	O
6	of	O
7	beta	O
8	was	O
9	notably	O
10	reduced	O
11	and	O
12	no	O
13	missing	O
14	residue	O
15	from	O
16	the	O
17	epsilon	O
18	peptide	O
19	could	B
20	be	I
21	identified	I
22	,	I
23	but	I
24	the	O
25	peptide	O
26	sequence	O
27	limited	O
28	the	O
29	possible	O
30	choices	O
31	to	O
32	Ser	O
33	-	O
34	106	O
35	,	O
36	Ser	O
37	-	O
38	107	B
39	,	I
40	or	I
41	Ser	I
42	-	I
43	108	O
44	.	O

1	METHODS	O
2	:	O
3	109	B
4	suspected	I
5	cases	I
6	with	O
7	SS	O
8	underwent	O
9	the	O
10	biopsies	O
11	.	O

1	Trial	O
2	3	O
3	broiler	O
4	chickens	O
5	were	O
6	maintained	O
7	on	O
8	control	O
9	feed	O
10	until	O
11	they	O
12	reached	O
13	3	O
14	weeks	O
15	of	O
16	age	O
17	at	O
18	which	O
19	time	O
20	they	O
21	were	O
22	taken	O
23	off	B
24	of	B
25	feed	I
26	for	I
27	2	I
28	.	I
29	5	I
30	hr	I
31	and	I
32	then	I
33	placed	O
34	on	O
35	either	O
36	control	O
37	feed	O
38	or	O
39	feed	O
40	containing	O
41	4	O
42	.	O
43	0	O
44	ppm	O
45	ochratoxin	O
46	A	O
47	,	O
48	and	O
49	heart	O
50	rate	O
51	and	O
52	blood	O
53	pressure	O
54	were	O
55	measured	O
56	every	O
57	half	O
58	hour	O
59	through	O
60	7	O
61	hr	O
62	.	O

1	Unlike	O
2	p59v	B
3	-	I
4	rel	I
5	,	I
6	which	I
7	is	O
8	a	O
9	nuclear	O
10	protein	O
11	in	O
12	CEF	O
13	,	O
14	indirect	O
15	immunofluorescence	O
16	showed	O
17	that	O
18	p68c	O
19	-	O
20	rel	O
21	in	I
22	JD214c	I
23	-	O
24	rel	B
25	infected	I
26	CEF	O
27	is	O
28	located	B
29	exclusively	I
30	in	I
31	the	O
32	cytoplasm	O
33	of	O
34	these	B
35	cells	B
36	,	B
37	even	I
38	though	B
39	the	B
40	sequence	B
41	of	I
42	p68c	I
43	-	O
44	rel	O
45	showed	O
46	that	O
47	it	O
48	contains	O
49	a	O
50	nuclear	B
51	localizing	I
52	sequence	I
53	identical	I
54	to	I
55	the	I
56	one	O
57	previously	B
58	identified	I
59	in	I
60	p59v	B
61	-	O
62	rel	O
63	.	O

1	The	O
2	effect	O
3	of	O
4	antilymphocyte	O
5	sera	O
6	on	O
7	formation	O
8	of	O
9	transplantation	O
10	and	O
11	anti	O
12	-	O
13	infection	O
14	immunity	O
15	in	O
16	mice	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	O
7	cyclin	O
8	,	O
9	cyclin	O
10	E2	O
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	O
18	E	O
19	.	O

1	Epigenetic	O
2	switching	O
3	of	O
4	transcriptional	O
5	states	O
6	:	B
7	cis	I
8	-	I
9	and	I
10	trans	O
11	-	O
12	acting	O
13	factors	O
14	affecting	O
15	establishment	O
16	of	O
17	silencing	O
18	at	O
19	the	O
20	HMR	O
21	locus	O
22	in	O
23	Saccharomyces	O
24	cerevisiae	O
25	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	O
9	-	O
10	related	O
11	kinase	O
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	O
17	yeast	O
18	cdc28	O
19	mutation	O
20	.	O

1	For	O
2	higher	O
3	expression	O
4	of	O
5	lipA	O
6	in	O
7	S	O
8	.	O
9	lividans	O
10	,	O
11	the	O
12	gene	O
13	was	O
14	cloned	O
15	next	O
16	to	O
17	the	O
18	strong	O
19	aphII	O
20	promoter	O
21	.	O

1	Although	O
2	popular	O
3	this	O
4	hypothesis	O
5	is	O
6	far	O
7	from	O
8	explaining	O
9	all	O
10	the	O
11	clinical	O
12	facts	O
13	,	O
14	namely	O
15	that	O
16	rigidity	O
17	is	O
18	equal	O
19	in	O
20	extensor	O
21	and	O
22	flexor	O
23	,	O
24	proximal	O
25	and	O
26	distal	O
27	muscles	O
28	.	O

1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	O
15	c	O
16	-	O
17	myc	O
18	deregulation	O
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	O
38	c	O
39	-	O
40	myc	O
41	alleles	O
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	germinal	O
49	vesicles	O
50	.	O

1	Value	O
2	of	O
3	Normotest	O
4	and	O
5	antithrombin	O
6	3	O
7	in	O
8	the	O
9	assessment	O
10	of	O
11	liver	O
12	function	O
13	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	temporally	O
10	and	O
11	spatially	O
12	specific	O
13	mef2	O
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	array	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	modules	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O

1	Forty	O
2	-	O
3	one	O
4	ASA	O
5	physical	O
6	status	O
7	I	O
8	or	O
9	II	O
10	adult	O
11	patients	O
12	undergoing	O
13	a	O
14	variety	B
15	of	B
16	1	I
17	-	O
18	1	O
19	.	O
20	5	O
21	h	O
22	surgical	O
23	procedures	O
24	were	O
25	randomly	O
26	allocated	O
27	to	O
28	receive	O
29	CCA	O
30	with	O
31	desflurane	O
32	or	O
33	isoflurane	O
34	with	O
35	ventilation	O
36	being	O
37	either	O
38	spontaneous	O
39	or	O
40	controlled	O
41	.	O

1	Soluble	O
2	FasR	O
3	ligand	B
4	-	I
5	binding	I
6	domain	I
7	:	O
8	high	O
9	-	O
10	yield	O
11	production	O
12	of	O
13	active	O
14	fusion	O
15	and	O
16	non	O
17	-	O
18	fusion	O
19	recombinant	O
20	proteins	O
21	using	O
22	the	O
23	baculovirus	O
24	/	O
25	insect	O
26	cell	O
27	system	O
28	.	O

1	SPECT	O
2	examination	O
3	of	O
4	the	O
5	TMJ	O
6	using	O
7	99m	O
8	Tc	O
9	-	O
10	MDP	O
11	was	O
12	performed	O
13	in	O
14	43	O
15	patients	O
16	with	O
17	arthrographically	O
18	proven	O
19	anterior	O
20	dislocation	O
21	of	O
22	the	O
23	disc	O
24	and	O
25	in	O
26	30	O
27	normals	O
28	.	O

1	There	O
2	were	O
3	significant	B
4	differences	I
5	(	I
6	p	I
7	<	I
8	0	O
9	.	O
10	05	O
11	)	O
12	between	O
13	the	O
14	fracture	O
15	and	O
16	nonfracture	O
17	groups	O
18	in	O
19	the	O
20	total	O
21	femur	O
22	BMD	O
23	(	O
24	13	O
25	%),	O
26	trabecular	O
27	BMD	O
28	in	O
29	the	O
30	distal	O
31	radius	O
32	(	O
33	4	O
34	%),	O
35	and	O
36	the	O
37	fractal	O
38	dimension	O
39	in	B
40	the	O
41	radiographs	O
42	(	O
43	FD2	O
44	)	O
45	(	O
46	3	O
47	%).	O

1	V	O
2	.	O

1	The	O
2	positive	O
3	-	O
4	acting	O
5	global	O
6	sulfur	O
7	regulatory	O
8	protein	O
9	,	O
10	CYS3	O
11	,	O
12	of	O
13	Neurospora	O
14	crassa	O
15	turns	O
16	on	O
17	the	B
18	expression	I
19	of	I
20	a	I
21	family	I
22	of	O
23	unlinked	O
24	structural	O
25	genes	O
26	that	O
27	encode	O
28	enzymes	O
29	of	O
30	sulfur	O
31	catabolism	O
32	.	O

1	A	O
2	case	O
3	of	O
4	a	O
5	dense	O
6	epidermoid	O
7	cyst	O
8	of	O
9	the	O
10	suprasellar	O
11	cistern	O
12	is	O
13	presented	O
14	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	peptide	O
6	sequences	O
7	of	O
8	the	O
9	human	O
10	lymphocyte	O
11	-	O
12	specific	O
13	high	O
14	mobility	O
15	group	O
16	(	O
17	HMG	O
18	)-	O
19	box	O
20	transcription	O
21	factor	O
22	TCF	O
23	-	O
24	1	O
25	are	O
26	determined	O
27	by	O
28	alternative	O
29	splice	O
30	mechanisms	O
31	affecting	O
32	the	O
33	exons	O
34	VIII	O
35	to	O
36	X	O
37	.	O

1	Lymphoproliferative	O
2	disorders	O
3	arising	O
4	under	O
5	immunosuppression	O
6	with	O
7	FK	O
8	506	O
9	:	O
10	initial	O
11	observations	O
12	in	O
13	a	O
14	large	O
15	transplant	B
16	population	I
17	.	I

1	Lung	O
2	mesenchyme	O
3	serves	O
4	as	O
5	a	O
6	'	O
7	compleat	O
8	'	O
9	inducer	O
10	of	O
11	lung	O
12	morphogenesis	O
13	by	O
14	secreting	O
15	soluble	O
16	peptide	O
17	growth	O
18	factors	O
19	.	O

1	The	O
2	orbitofrontal	O
3	,	O
4	cingulate	O
5	,	O
6	and	O
7	anteromedial	O
8	part	O
9	of	O
10	the	O
11	dorsal	O
12	premotor	O
13	areas	O
14	were	O
15	preferentially	O
16	activated	O
17	by	O
18	the	O
19	self	O
20	-	O
21	initiated	O
22	hand	O
23	movement	O
24	task	O
25	(	O
26	SELF	O
27	).	O

1	C	O
2	-	O
3	SP	O
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O

1	Cut	O
2	-	O
3	off	O
4	levels	O
5	that	O
6	define	O
7	abnormality	O
8	are	O
9	rather	O
10	arbitrary	O
11	and	O
12	this	O
13	decreases	O
14	the	O
15	specificity	O
16	of	O
17	the	O
18	test	O
19	in	O
20	apparently	O
21	healthy	O
22	patients	O
23	.	B

1	An	O
2	immunologic	O
3	test	O
4	using	O
5	stomach	O
6	and	O
7	tumor	O
8	antigens	O
9	for	O
10	screening	O
11	of	O
12	those	O
13	at	O
14	high	O
15	risk	O
16	for	O
17	stomach	O
18	cancer	O
19	is	O
20	suggested	O
21	.	O

1	These	O
2	findings	O
3	suggest	O
4	a	O
5	functional	O
6	cross	O
7	-	O
8	talk	O
9	between	O
10	RB	O
11	protein	O
12	and	O
13	p21ras	O
14	,	O
15	which	O
16	balances	O
17	the	B
18	cell	I
19	phenotype	I
20	between	I
21	normal	O
22	and	O
23	transformed	O
24	states	O
25	.	O

1	Methods	O
2	used	O
3	include	B
4	Cobb	I
5	angle	I
6	and	I
7	a	I
8	segmental	I
9	evaluation	I
10	(	I
11	T7	O
12	-	B
13	T12	I
14	)	O
15	of	O
16	each	B
17	of	I
18	convex	I
19	and	I
20	concave	I
21	rib	I
22	-	O
23	vertebra	B
24	angles	I
25	(	O
26	RVAs	O
27	),	O
28	rib	O
29	-	O
30	vertebra	O
31	angle	O
32	differences	O
33	(	O
34	RVADs	O
35	),	O
36	vertebral	O
37	rotation	O
38	,	O
39	tilt	O
40	and	O
41	displacement	O
42	.	O

1	Is	O
2	more	O
3	better	O
4	?	O
5	About	O
6	dose	O
7	levels	O
8	of	O
9	ACE	O
10	inhibitors	O
11	in	O
12	chronic	O
13	heart	O
14	failure	O
15	.	O

1	A	O
2	family	O
3	of	O
4	RNA	O
5	molecules	O
6	in	O
7	the	O
8	2	O
9	.	O
10	0	O
11	-	O
12	2	O
13	.	O
14	2	O
15	-	O
16	kilobase	O
17	range	O
18	identified	O
19	with	O
20	a	O
21	probe	O
22	from	O
23	this	O
24	gene	O
25	was	O
26	overexpressed	O
27	in	O
28	the	O
29	resistant	O
30	cells	O
31	.	O

1	Serum	O
2	creatine	O
3	kinase	O
4	(	O
5	SCK	O
6	)	O
7	was	O
8	measured	O
9	in	B
10	ten	I
11	subjects	O
12	in	O
13	the	O
14	laboratory	O
15	before	O
16	and	O
17	after	O
18	the	O
19	performance	O
20	of	O
21	bicycle	O
22	ergometry	O
23	and	O
24	a	O
25	lifting	O
26	task	O
27	.	O

1	Catheter	O
2	transit	O
3	slows	B
4	the	I
5	response	O
6	to	B
7	a	I
8	step	I
9	increase	O
10	in	O
11	concentration	O
12	by	O
13	about	O
14	0	O
15	.	O
16	13	O
17	s	O
18	(	O
19	from	B
20	10	I
21	per	I
22	cent	I
23	-	I
24	90	I
25	per	I
26	cent	I
27	)	I
28	and	I
29	prolongs	O
30	the	O
31	transit	O
32	time	O
33	through	O
34	the	O
35	catheter	O
36	for	B
37	a	O
38	volatile	B
39	anesthetic	B
40	by	B
41	about	O
42	0	B
43	.	O
44	04	O
45	s	O
46	more	O
47	than	O
48	N2	O
49	.	O

1	The	O
2	1	O
3	.	O
4	7	O
5	kb	O
6	cloned	O
7	fragment	O
8	was	O
9	sequenced	O
10	and	O
11	shown	O
12	to	O
13	contain	O
14	the	O
15	entire	O
16	fliA	O
17	gene	O
18	.	O

1	Its	O
2	hydropathy	O
3	profile	O
4	predicts	O
5	seven	O
6	transmembrane	O
7	spans	O
8	and	O
9	a	O
10	hydrophilic	O
11	amino	O
12	terminus	O
13	of	O
14	approximately	O
15	100	O
16	residues	O
17	,	O
18	and	O
19	it	O
20	suggests	O
21	the	O
22	presence	O
23	of	O
24	an	O
25	amphiphilic	O
26	alpha	O
27	-	O
28	helix	O
29	(	O
30	L	O
31	-	O
32	61	O
33	to	O
34	F	O
35	-	O
36	97	O
37	)	O
38	in	O
39	close	O
40	proximity	O
41	to	O
42	the	O
43	first	O
44	strongly	O
45	hydrophobic	O
46	segment	O
47	of	O
48	ProW	O
49	.	O

1	Tec	O
2	kinase	O
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	O
11	3	O
12	-	O
13	kinase	O
14	and	O
15	the	O
16	Tec	O
17	pleckstrin	O
18	homology	O
19	domain	O
20	.	O

1	CRS	O
2	function	O
3	in	O
4	a	O
5	5	O
6	'	O
7	LTR	O
8	-	O
9	linked	O
10	gene	O
11	expression	O
12	assay	O
13	correlates	O
14	with	O
15	the	O
16	ability	O
17	of	O
18	both	O
19	p60CRS	O
20	and	O
21	p40CRS	O
22	to	O
23	interact	O
24	with	O
25	5	O
26	'	O
27	LTR	O
28	RNA	O
29	in	O
30	vitro	O
31	.	O

1	i	O
2	.	O

1	Like	O
2	Epo	O
3	,	O
4	HNF	O
5	-	O
6	4	O
7	is	O
8	expressed	O
9	in	O
10	kidney	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	Hep3B	O
16	cells	O
17	but	O
18	not	O
19	in	O
20	HeLa	O
21	cells	O
22	.	O

1	G	O
2	-	O
3	DNA	O
4	is	O
5	a	O
6	four	O
7	-	O
8	stranded	O
9	DNA	O
10	structure	O
11	with	O
12	diverse	O
13	putative	O
14	biological	O
15	roles	O
16	.	O

1	Although	O
2	neither	B
3	constitutively	I
4	activated	I
5	MEK	I
6	(	I
7	MEK	I
8	-	O
9	2E	O
10	)	O
11	nor	O
12	v	O
13	-	O
14	Src	O
15	was	O
16	sufficient	O
17	individually	O
18	to	O
19	differentiate	O
20	the	I
21	H19	I
22	-	I
23	7	B
24	cells	O
25	,	O
26	coexpression	O
27	of	O
28	constitutively	O
29	activated	O
30	MEK	O
31	and	O
32	v	O
33	-	O
34	Src	O
35	induced	B
36	neurite	I
37	outgrowth	I
38	.	I

1	These	O
2	cells	O
3	produced	O
4	P2Y	O
5	(	O
6	11	O
7	)	O
8	mRNA	O
9	during	O
10	culture	O
11	.	O

1	Acute	O
2	inhalation	O
3	toxicity	O
4	of	O
5	T	O
6	-	O
7	2	O
8	mycotoxin	O
9	in	O
10	mice	O
11	.	O

1	Addition	O
2	of	O
3	soluble	O
4	recombinant	O
5	human	O
6	SLF	O
7	to	O
8	SI4	O
9	-	O
10	h220	O
11	cultures	O
12	enhanced	O
13	reduction	O
14	of	O
15	cell	O
16	-	O
17	surface	O
18	c	O
19	-	O
20	kit	O
21	expression	O
22	and	O
23	its	O
24	protein	O
25	degradation	O
26	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	constitutively	O
6	active	O
7	Mek1	O
8	could	O
9	activate	O
10	p96h2bk	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	oncogenic	O
16	Ras	O
17	.	O

1	Scanning	O
2	electron	O
3	microscopic	O
4	investigations	O
5	on	O
6	the	B
7	formation	I
8	of	I
9	Reissner	I
10	'	I
11	s	I
12	fiber	I
13	in	I
14	Rattus	I
15	rattus	I

1	Since	O
2	very	O
3	recent	O
4	scanning	O
5	-	O
6	deletion	O
7	analysis	O
8	indicates	O
9	that	O
10	there	O
11	is	O
12	a	O
13	critical	O
14	region	O
15	for	O
16	activity	O
17	near	O
18	Cys	O
19	-	B
20	118	I
21	and	I
22	that	I
23	Cys	I
24	-	I
25	118	I
26	is	I
27	necessary	O
28	for	O
29	maximal	O
30	activity	O
31	,	O
32	we	O
33	conclude	O
34	that	O
35	the	O
36	Cys	O
37	-	O
38	118	O
39	residue	O
40	is	O
41	necessary	O
42	for	B
43	proper	I
44	glycosylation	I
45	and	I
46	maximal	I
47	biologic	I
48	activity	I
49	of	I
50	GM	I
51	-	I
52	CSF	I
53	.	I

1	Optima	O
2	)	O
3	genomic	O
4	library	O
5	by	O
6	hybridizing	O
7	with	O
8	elicitor	O
9	-	O
10	induced	O
11	stilbene	O
12	synthase	O
13	cDNA	O
14	as	O
15	a	O
16	probe	O
17	.	O

1	Psychiatric	O
2	disorders	O
3	in	O
4	children	O
5	and	O
6	adolescents	O
7	carry	O
8	considerable	O
9	morbidity	O
10	,	O
11	impede	O
12	development	O
13	,	O
14	and	O
15	carry	O
16	a	O
17	significant	O
18	mortality	O
19	by	B
20	suicide	I
21	.	I

1	Bone	O
2	and	O
3	bones	O
4	.	O

1	Assuming	O
2	O2	O
3	consumption	O
4	of	O
5	the	O
6	isolated	O
7	skin	O
8	to	O
9	be	O
10	same	O
11	as	O
12	in	O
13	situ	O
14	,	O
15	calculations	O
16	showed	O
17	that	O
18	when	O
19	water	O
20	PO2	O
21	was	O
22	high	O
23	(	O
24	150	O
25	mm	O
26	Hg	O
27	),	O
28	about	O
29	40	O
30	%	O
31	of	O
32	total	O
33	cutaneous	O
34	O2	O
35	uptake	O
36	was	O
37	consumed	O
38	by	O
39	the	O
40	skin	O
41	.	O

1	TNF	O
2	-	O
3	alpha	O
4	induced	O
5	a	O
6	dose	O
7	-	O
8	and	O
9	time	O
10	-	O
11	dependent	O
12	increase	O
13	in	O
14	cyclooxygenase	O
15	-	O
16	2	O
17	(	O
18	COX	O
19	-	O
20	2	O
21	)	O
22	expression	O
23	and	O
24	PGE2	O
25	formation	O
26	in	O
27	human	O
28	NCI	O
29	-	B
30	H292	I
31	epithelial	I
32	cells	I
33	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	competition	O
7	experiments	O
8	showed	O
9	that	O
10	site	O
11	A	O
12	is	O
13	recognized	O
14	by	O
15	an	O
16	NF1	O
17	protein	O
18	.	O

1	Using	O
2	GST	O
3	-	O
4	PKR	O
5	fusion	O
6	chromatography	O
7	,	O
8	direct	O
9	physical	O
10	interaction	O
11	between	O
12	the	O
13	mouse	O
14	and	O
15	human	O
16	PKR	O
17	homologs	O
18	was	O
19	established	O
20	.	O

1	SCA	O
2	was	O
3	resistant	O
4	to	O
5	inhibitors	O
6	of	O
7	serine	O
8	,	B
9	aspartyl	I
10	,	I
11	and	I
12	metalloproteases	I
13	,	I
14	but	O
15	it	O
16	was	O
17	sensitive	O
18	to	O
19	N	O
20	-	O
21	ethylmaleimide	O
22	.	O

1	Infectious	O
2	mutant	O
3	virus	O
4	progeny	O
5	was	O
6	obtained	O
7	only	O
8	on	O
9	complementing	O
10	gK	O
11	-	O
12	expressing	O
13	cells	O
14	,	O
15	suggesting	O
16	that	O
17	gK	O
18	has	O
19	an	O
20	important	O
21	function	O
22	in	O
23	the	O
24	replication	O
25	cycle	O
26	.	O

1	The	O
2	clinical	O
3	picture	O
4	and	O
5	laboratory	O
6	parameters	O
7	were	O
8	consistent	O
9	with	O
10	a	O
11	serum	O
12	sickness	O
13	reaction	O
14	.	O

1	However	O
2	,	O
3	a	O
4	clear	O
5	difference	O
6	exists	O
7	between	O
8	myoblasts	O
9	and	O
10	10T1	O
11	/	O
12	2	O
13	cells	O
14	(	O
15	and	O
16	other	O
17	non	O
18	-	O
19	muscle	O
20	cell	O
21	types	O
22	)	O
23	in	O
24	the	O
25	chromatin	O
26	structure	O
27	of	O
28	the	O
29	chromosomal	O
30	myoD	O
31	core	O
32	enhancer	O
33	,	O
34	suggesting	O
35	that	O
36	the	O
37	myoD	O
38	enhancer	O
39	is	O
40	repressed	O
41	by	O
42	epigenetic	O
43	mechanisms	O
44	in	O
45	10T1	O
46	/	O
47	2	O
48	cells	O
49	.	O

1	A	O
2	further	O
3	study	O
4	on	O
5	plasminogen	O
6	activator	O
7	release	O
8	by	O
9	vasoactive	O
10	agents	O
11	in	O
12	the	O
13	isolated	O
14	perfused	O
15	dog	O
16	leg	O
17	.	O

1	Videonystagmoscopy	O
2	has	O
3	been	O
4	used	O
5	to	O
6	subjectively	O
7	observe	O
8	the	O
9	responses	O
10	of	O
11	the	O
12	vestibular	O
13	system	O
14	in	O
15	a	O
16	population	B
17	of	I
18	patients	I
19	with	O
20	vestibular	B
21	deficits	I
22	.	I

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	with	O
6	both	O
7	regimens	O
8	.	O

1	Effect	O
2	of	O
3	immune	O
4	lymphocytes	O
5	and	O
6	of	O
7	rabbit	O
8	-	O
9	anti	O
10	-	O
11	lymphocyte	O
12	globulin	O
13	(	O
14	RAMLG	O
15	)	O
16	on	O
17	infected	O
18	macrophages	O
19	exposed	O
20	to	O
21	increased	O
22	incubation	O
23	temperature	O
24	in	O
25	vitro	O
26	.	O

1	Cestode	O
2	invasion	O
3	in	O
4	irradiated	O
5	host	O
6	organism	O
7	increases	O
8	the	O
9	negative	O
10	effect	O
11	of	O
12	ionizing	O
13	radiation	O
14	on	O
15	the	O
16	hamster	O
17	immune	O
18	system	O
19	.	O

1	The	O
2	main	O
3	issues	O
4	are	O
5	the	O
6	need	O
7	to	O
8	explain	O
9	a	O
10	number	O
11	of	O
12	still	O
13	unknown	O
14	mechanisms	O
15	,	O
16	to	O
17	determine	O
18	which	O
19	"	O
20	natural	O
21	diet	O
22	"	O
23	carries	O
24	the	O
25	minimum	O
26	coronary	O
27	risk	O
28	and	O
29	whether	O
30	"	O
31	new	O
32	"	O
33	foods	O
34	produced	O
35	by	O
36	modern	O
37	technology	O
38	are	O
39	really	O
40	needed	O
41	to	O
42	contrast	O
43	this	O
44	epidemic	O
45	.	O

1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	B
8	32	I
9	.	I
10	6	I
11	nm	I
12	in	O
13	Ne	O
14	-	O
15	like	I
16	Ti	I
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	B
27	-	I
28	ps	I
29	laser	I
30	pulses	I
31	.	I

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	O
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	O
13	to	O
14	the	O
15	estrogen	O
16	receptor	O
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	O
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	B
28	to	I
29	recruit	I
30	CBP	O
31	and	B
32	p300	B
33	.	O

1	We	O
2	established	O
3	the	O
4	radiosensitive	O
5	cell	O
6	line	O
7	SX9	O
8	from	O
9	mammary	O
10	carcinoma	O
11	cell	O
12	line	O
13	FM3A	O
14	.	O

1	Weight	O
2	and	O
3	height	O
4	z	O
5	-	O
6	scores	O
7	were	O
8	significantly	B
9	associated	I
10	with	I
11	BMD	I
12	z	I
13	-	I
14	scores	O
15	.	O

1	CONCLUSION	O
2	:	O
3	Although	O
4	quantitative	O
5	and	B
6	qualitative	O
7	criteria	B
8	for	I
9	diagnosing	I
10	fatty	O
11	liver	O
12	on	O
13	helical	O
14	CT	O
15	can	O
16	be	O
17	determined	O
18	,	O
19	they	O
20	are	O
21	protocol	O
22	-	O
23	specific	O
24	.	O

1	The	O
2	uncomplicated	O
3	cases	O
4	of	O
5	typhoid	O
6	fever	O
7	were	O
8	found	O
9	to	O
10	have	O
11	an	O
12	intact	O
13	CMIR	O
14	as	O
15	compared	O
16	to	O
17	the	O
18	complicated	O
19	cases	O
20	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	on	O
5	coronary	O
6	circulation	O
7	:	O
8	effect	O
9	on	O
10	ECG	B
11	tracing	I

1	Hydroxypropyl	O
2	methacrylate	O
3	,	O
4	a	O
5	new	O
6	water	O
7	-	O
8	miscible	O
9	embedding	O
10	medium	B
11	for	I
12	electron	I
13	microscopy	I
14	.	O

1	Effect	O
2	of	O
3	time	O
4	and	O
5	dose	O
6	on	O
7	alterations	O
8	following	O
9	inhalation	O
10	of	O
11	plutonium	O
12	-	O
13	239	O
14	dioxide	O
15	aerosol	O
16	in	O
17	rat	O
18	.	O

1	Immunohistochemical	O
2	staining	O
3	with	O
4	MIB	O
5	-	B
6	1	I
7	and	O
8	p53	O
9	antibodies	B
10	showed	I
11	low	I
12	(<	I
13	1	I
14	%)	I
15	and	I
16	negative	I
17	reaction	O
18	.	O

1	To	O
2	assess	O
3	the	O
4	relationship	O
5	between	O
6	G	O
7	(	O
8	q	O
9	)/	O
10	G	O
11	(	O
12	11	O
13	)	O
14	function	O
15	with	O
16	the	O
17	phosphatidylinositol	O
18	3	O
19	-	O
20	kinase	O
21	dependent	O
22	pathway	O
23	,	O
24	expression	O
25	of	O
26	a	O
27	dominant	O
28	-	O
29	interfering	O
30	p85	O
31	regulatory	O
32	subunit	O
33	,	O
34	as	O
35	well	O
36	as	O
37	wortmannin	B
38	treatment	I
39	inhibited	I
40	insulin	I
41	-	O
42	stimulated	O
43	but	O
44	not	O
45	G	O
46	(	O
47	q	O
48	)/	O
49	Q209L	O
50	-	O
51	stimulated	O
52	GLUT4	O
53	-	O
54	EGFP	O
55	translocation	O
56	.	O

1	Using	O
2	PRL	O
3	-	O
4	R	O
5	tagged	O
6	both	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	B
12	or	I
13	C	I
14	-	I
15	terminal	I
16	regions	I
17	of	I
18	the	I
19	mature	O
20	receptor	B
21	excludes	I
22	the	I
23	possibility	I
24	of	I
25	a	O
26	cleaved	O
27	fragment	B
28	which	B
29	could	I
30	have	I
31	been	I
32	subsequently	I
33	imported	I
34	into	O
35	the	B
36	nucleus	I
37	.	O

1	The	O
2	pexB	O
3	upstream	O
4	region	O
5	contained	O
6	245	O
7	nucleotides	O
8	within	O
9	which	O
10	sequences	O
11	approximating	O
12	the	O
13	consensus	O
14	for	O
15	cyclic	O
16	AMP	O
17	receptor	O
18	protein	O
19	and	O
20	integration	O
21	host	B
22	factor	I
23	binding	I
24	sites	I
25	were	I
26	discernible	I
27	.	I

1	Doxorubicin	O
2	,	O
3	dacarbazine	B
4	,	I
5	vincristine	I
6	,	I
7	and	I
8	cyclophosphamide	I
9	in	I
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	B
15	leiomyosarcoma	I
16	.	I

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	O
19	-	O
20	kappaB	O
21	/	O
22	Rel	O
23	and	O
24	PI	O
25	-	O
26	3K	O
27	are	O
28	crucial	O
29	for	O
30	CD40	O
31	-	O
32	induced	O
33	proliferation	O
34	.	O

1	OBJECTIVE	O
2	:	O
3	Although	O
4	the	O
5	preponderance	O
6	of	O
7	findings	O
8	offer	O
9	support	O
10	for	O
11	transient	O
12	(	O
13	where	O
14	is	O
15	it	O
16	?)	O
17	as	O
18	opposed	O
19	to	O
20	sustained	O
21	(	O
22	what	O
23	is	O
24	it	O
25	?)	O
26	deficit	O
27	,	O
28	a	O
29	need	O
30	remains	O
31	for	O
32	specific	O
33	depiction	O
34	of	O
35	the	O
36	deficit	O
37	.	O

1	Neither	O
2	ethanol	O
3	regimen	O
4	impaired	O
5	spontaneous	O
6	alternation	O
7	,	O
8	but	O
9	the	O
10	4	O
11	g	O
12	ethanol	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	x	O
18	day	O
19	-	O
20	1	O
21	regimen	O
22	increased	O
23	the	O
24	percent	O
25	completed	O
26	trials	O
27	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	B
25	the	I
26	higher	I
27	levels	I
28	of	I
29	an	I
30	enhancer	I
31	-	I
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O

1	In	O
2	addition	O
3	,	O
4	this	O
5	kinase	O
6	is	O
7	well	O
8	conserved	O
9	evolutionarily	O
10	,	O
11	ubiquitously	O
12	expressed	O
13	,	B
14	and	I
15	its	I
16	genes	I
17	map	I
18	to	O
19	a	O
20	position	O
21	on	O
22	human	O
23	chromosome	O
24	1	O
25	frequently	O
26	deleted	O
27	in	O
28	the	O
29	late	B
30	stages	O
31	of	O
32	tumorigenesis	O
33	.	O

1	These	O
2	mutations	O
3	are	O
4	localized	O
5	in	O
6	the	O
7	same	O
8	region	O
9	where	O
10	the	O
11	HSV	O
12	transactivator	O
13	VP16	O
14	binds	O
15	,	O
16	but	O
17	did	O
18	not	O
19	coincide	O
20	with	O
21	the	O
22	VP16	O
23	contacts	O
24	.	O

1	In	O
2	order	O
3	to	O
4	decipher	O
5	the	O
6	pathway	O
7	that	O
8	leads	O
9	to	O
10	Hox	O
11	gene	O
12	induction	O
13	,	O
14	we	O
15	have	O
16	investigated	O
17	whether	O
18	a	O
19	Hox	O
20	gene	O
21	regulator	O
22	,	O
23	the	O
24	leucine	O
25	zipper	O
26	transcription	O
27	factor	O
28	MafB	O
29	/	O
30	Kr	O
31	,	O
32	is	O
33	itself	O
34	transcriptionally	O
35	regulated	O
36	by	O
37	the	O
38	environmental	O
39	signals	O
40	.	O

1	Patients	O
2	were	O
3	randomly	O
4	assigned	O
5	to	O
6	treatment	O
7	with	O
8	the	O
9	ACE	O
10	inhibitor	O
11	perindopril	O
12	(	O
13	and	O
14	the	O
15	diuretic	O
16	indapamide	O
17	for	O
18	those	O
19	with	O
20	no	O
21	definite	O
22	indication	O
23	for	O
24	or	O
25	contraindication	O
26	to	O
27	treatment	O
28	with	O
29	a	O
30	diuretic	O
31	)	O
32	or	O
33	matching	O
34	placebo	O
35	(	O
36	s	O
37	).	O

1	Bulbar	O
2	pouches	O
3	were	O
4	perfused	O
5	with	O
6	solutions	O
7	of	O
8	0	O
9	.	O
10	9	O
11	%	O
12	Na	O
13	C1	B
14	,	I
15	0	I
16	.	I
17	1	I
18	N	O
19	HC1	O
20	,	O
21	40	O
22	%	O
23	glucose	O
24	,	O
25	40	O
26	%	O
27	NaC1	O
28	,	O
29	and	O
30	40	O
31	%	O
32	peptone	O
33	or	O
34	with	O
35	0	O
36	.	O
37	1	O
38	%	O
39	solutions	O
40	of	O
41	acetylcholine	O
42	chloride	O
43	.	O

1	Human	O
2	immunodeficiency	O
3	virus	O
4	type	B
5	1	I
6	Vpr	I
7	is	I
8	a	I
9	virion	I
10	-	I
11	associated	O
12	,	O
13	regulatory	O
14	protein	O
15	that	O
16	is	O
17	required	O
18	for	O
19	efficient	O
20	viral	O
21	replication	O
22	in	O
23	monocytes	O
24	/	O
25	macrophages	I
26	.	I

1	The	O
2	effect	O
3	of	O
4	pure	O
5	natural	O
6	porcine	O
7	secretin	O
8	on	O
9	endocrine	O
10	and	O
11	exocrine	O
12	pancreatic	O
13	secretion	O
14	was	O
15	studied	O
16	in	O
17	the	O
18	totally	O
19	isolated	O
20	perfused	O
21	porcine	O
22	pancreas	O
23	.	O

1	The	O
2	debate	O
3	over	O
4	electives	O
5	--	O
6	1899	O
7	.	B

1	These	O
2	temperature	O
3	-	O
4	and	O
5	cold	O
6	-	O
7	sensitive	O
8	strains	O
9	were	O
10	used	O
11	to	O
12	prepare	O
13	extracts	O
14	deficient	O
15	in	O
16	BRF1	O
17	activity	O
18	and	O
19	were	O
20	tested	O
21	for	O
22	transcriptional	O
23	activity	O
24	by	O
25	RNA	O
26	polymerases	O
27	I	O
28	,	O
29	II	O
30	,	O
31	and	O
32	III	O
33	in	O
34	vitro	O
35	.	O

1	Immediately	O
2	before	O
3	surgery	O
4	patients	O
5	received	O
6	either	O
7	intravenous	O
8	hydrocortisone	O
9	100	O
10	mg	O
11	or	O
12	placebo	O
13	in	O
14	random	O
15	,	O
16	double	O
17	-	O
18	blind	B
19	order	I
20	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	domains	O
6	(	B
7	CTDs	I
8	)	O
9	of	O
10	the	O
11	RPase	O
12	beta	O
13	subunit	O
14	and	O
15	DNA	O
16	primase	O
17	(	O
18	dnaG	O
19	protein	O
20	)	O
21	were	O
22	not	O
23	only	O
24	strongly	O
25	homologous	O
26	to	O
27	each	O
28	other	O
29	but	O
30	also	O
31	considerably	O
32	homologous	O
33	to	O
34	the	O
35	RPase	O
36	alpha	O
37	,	O
38	suggesting	B
39	that	O
40	an	O
41	alpha	O
42	subunit	B
43	-	O
44	like	O
45	enzyme	O
46	must	O
47	have	O
48	been	O
49	commonly	O
50	ancestral	O
51	to	O
52	core	O
53	enzyme	O
54	subunits	O
55	and	O
56	primase	O
57	.	O

1	Mutation	O
2	of	O
3	Enh4	O
4	,	B
5	an	I
6	essential	I
7	GT	I
8	-	I
9	IIC	O
10	-	O
11	like	O
12	enhanson	O
13	in	O
14	the	O
15	context	O
16	of	O
17	the	O
18	intact	O
19	enhancer	O
20	,	O
21	abolishes	O
22	silencer	O
23	activity	O
24	,	O
25	and	O
26	multimerized	O
27	GT	O
28	-	O
29	IIC	O
30	enhansons	B
31	mimic	I
32	the	I
33	intact	I
34	CSEn	O
35	enhancer	O
36	/	O
37	silencer	O
38	activities	O
39	in	O
40	BeWo	O
41	and	O
42	GC	O
43	cells	O
44	,	O
45	respectively	O
46	.	O

1	The	O
2	SH2	O
3	-	B
4	containing	I
5	adapter	I
6	protein	O
7	GRB10	O
8	interacts	I
9	with	O
10	BCR	O
11	-	O
12	ABL	O
13	.	B

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Depending	O
2	on	O
3	treatment	O
4	exposures	O
5	,	O
6	this	O
7	at	B
8	-	I
9	risk	I
10	population	I
11	may	I
12	experience	I
13	life	I
14	-	I
15	threatening	B
16	late	I
17	effects	I
18	,	O
19	such	O
20	as	O
21	cirrhosis	O
22	secondary	O
23	to	O
24	hepatitis	O
25	C	O
26	or	O
27	late	O
28	-	O
29	onset	O
30	anthracycline	O
31	-	O
32	induced	O
33	cardiomyopathy	O
34	,	O
35	or	O
36	life	O
37	-	O
38	changing	O
39	late	O
40	effects	O
41	,	O
42	such	O
43	as	O
44	cognitive	I
45	dysfunction	I
46	.	I

1	We	O
2	now	O
3	show	O
4	that	O
5	the	O
6	BAT1	O
7	translation	O
8	product	O
9	is	B
10	the	I
11	homolog	I
12	of	I
13	the	I
14	rat	O
15	p47	B
16	nuclear	B
17	protein	I
18	,	I
19	the	O
20	WM6	O
21	Drosophila	O
22	gene	O
23	product	O
24	,	O
25	and	O
26	probably	O
27	also	O
28	Ce08102	O
29	of	O
30	Caenorhabditis	O
31	elegans	O
32	,	O
33	all	O
34	members	O
35	of	O
36	the	O
37	DEAD	O
38	protein	O
39	family	O
40	of	O
41	ATP	O
42	-	O
43	dependent	O
44	RNA	O
45	helicases	B
46	.	I

1	Sp1	O
2	and	O
3	two	O
4	Sp3	O
5	isoforms	O
6	were	O
7	detected	O
8	as	B
9	the	I
10	primary	I
11	cellular	I
12	constituents	I
13	of	O
14	DNA	O
15	-	O
16	protein	B
17	complexes	I
18	formed	I
19	with	O
20	the	O
21	NF	O
22	-	O
23	kappaB	O
24	-	O
25	proximal	O
26	site	O
27	.	O

1	Surprisingly	O
2	,	O
3	calf	O
4	thymus	O
5	CstF	O
6	contained	O
7	an	O
8	additional	O
9	,	O
10	novel	O
11	form	O
12	of	O
13	the	B
14	64	I
15	-	I
16	kDa	O
17	subunit	O
18	with	O
19	a	O
20	molecular	O
21	mass	O
22	of	O
23	70	O
24	kDa	O
25	.	O

1	Potential	O
2	consensus	O
3	sequences	B
4	for	I
5	early	I
6	and	I
7	late	O
8	regulatory	O
9	elements	O
10	were	O
11	identified	O
12	.	O

1	Sequencing	O
2	of	O
3	the	O
4	TP53	O
5	transcripts	O
6	from	O
7	exons	O
8	2	O
9	to	O
10	10	O
11	,	O
12	however	O
13	,	O
14	did	O
15	not	O
16	reveal	O
17	mutations	O
18	of	O
19	the	O
20	remaining	O
21	allele	O
22	in	O
23	any	O
24	of	O
25	these	O
26	tumors	O
27	.	O

1	This	O
2	enabled	O
3	the	O
4	formation	O
5	of	O
6	stem	O
7	-	O
8	loop	O
9	templates	O
10	with	O
11	the	O
12	fusion	O
13	point	O
14	of	O
15	the	O
16	chimeric	B
17	transcript	I
18	in	I
19	the	O
20	loop	O
21	and	O
22	the	O
23	use	O
24	of	O
25	MLL	O
26	primers	O
27	in	O
28	two	O
29	-	O
30	sided	O
31	PCR	O
32	.	O

1	Thus	O
2	,	O
3	VF	O
4	resistant	O
5	to	O
6	defibrillation	O
7	is	O
8	not	O
9	necessarily	O
10	associated	O
11	with	O
12	both	O
13	toxic	O
14	plasma	O
15	drug	O
16	level	O
17	and	O
18	remarkably	O
19	decreased	O
20	conduction	O
21	.	O

1	The	O
2	PEBP2	O
3	alpha	O
4	proteins	O
5	contain	O
6	a	O
7	128	O
8	-	O
9	amino	O
10	-	O
11	acid	O
12	(	O
13	aa	O
14	)	O
15	region	O
16	highly	O
17	homologous	O
18	to	O
19	the	O
20	Drosophila	O
21	melanogaster	O
22	segmentation	O
23	gene	O
24	runt	O
25	.	O

1	Malignant	O
2	lymphoma	O
3	is	O
4	very	O
5	heterogeneous	O
6	in	O
7	terms	O
8	of	O
9	its	O
10	biological	O
11	behavior	O
12	.	O

1	Maternal	O
2	seizures	O
3	had	O
4	occurred	O
5	during	O
6	pregnancy	O
7	in	O
8	52	O
9	per	O
10	cent	O
11	.	O

1	Also	O
2	,	O
3	the	O
4	deduced	O
5	amino	O
6	acids	O
7	of	O
8	the	O
9	antigenic	O
10	regions	O
11	A	O
12	,	O
13	B	O
14	and	O
15	C	O
16	of	O
17	VP7	O
18	were	O
19	nearly	B
20	conserved	I
21	within	I
22	the	O
23	phylogenetic	O
24	lineages	O
25	.	O

1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O

1	Estrus	O
2	and	O
3	copulative	O
4	abilities	O
5	of	O
6	androgen	O
7	-	O
8	sterilized	O
9	rats	O

1	Transformed	O
2	cell	O
3	lines	O
4	expressing	O
5	solely	O
6	E1a	O
7	or	O
8	E1a	O
9	and	O
10	E1b	O
11	gene	O
12	products	O
13	derived	O
14	from	O
15	these	O
16	viruses	O
17	display	O
18	enhanced	O
19	anchorage	O
20	-	O
21	independent	O
22	growth	O
23	at	O
24	37	O
25	degrees	O
26	C	O
27	versus	O
28	32	O
29	degrees	O
30	C	O
31	and	O
32	display	O
33	a	O
34	cytoskeletal	O
35	architecture	O
36	resembling	O
37	untransformed	O
38	fibroblastic	O
39	CREF	O
40	cells	O
41	.	O

1	Inhibition	O
2	of	O
3	Fusarium	O
4	moniliforme	O
5	var	O
6	.	O
7	subglutinans	O
8	,	O
9	the	O
10	causal	O
11	agent	O
12	of	O
13	pine	O
14	pitch	O
15	canker	O
16	,	O
17	by	O
18	the	O
19	soil	O
20	bacterium	O
21	Arthrobacter	O
22	sp	O
23	.	O

1	To	O
2	identify	O
3	the	O
4	precise	O
5	location	O
6	of	O
7	the	O
8	phosphorylation	O
9	site	O
10	on	O
11	the	O
12	64	O
13	-	O
14	kDa	O
15	protein	O
16	,	O
17	a	O
18	step	O
19	-	O
20	by	O
21	-	O
22	step	O
23	mutagenesis	O
24	procedures	O
25	was	O
26	followed	O
27	.	O

1	Proceedings	O
2	:	O
3	Reversible	O
4	complete	O
5	heart	O
6	block	O
7	following	O
8	surgery	O
9	of	O
10	congenital	O
11	heart	O
12	defects	O

1	These	O
2	results	O
3	strongly	O
4	suggested	O
5	that	O
6	similar	O
7	,	O
8	if	O
9	not	B
10	identical	I
11	,	I
12	the	I
13	CArG	I
14	box	I
15	binding	I
16	proteins	O
17	interact	O
18	with	O
19	the	O
20	functionally	O
21	different	O
22	promoter	O
23	element	O
24	in	O
25	the	O
26	VLC1	O
27	,	O
28	cardiac	O
29	alpha	O
30	-	O
31	actin	O
32	,	O
33	and	O
34	c	O
35	-	O
36	fos	O
37	genes	O
38	.	O

1	These	O
2	results	O
3	are	B
4	the	I
5	first	I
6	to	I
7	demonstrate	I
8	the	O
9	structural	O
10	organization	O
11	of	O
12	a	B
13	vertebrate	I
14	gene	I
15	encoding	I
16	an	I
17	integral	O
18	membrane	B
19	protein	I
20	of	I
21	the	I
22	nuclear	I
23	envelope	I
24	that	O
25	may	O
26	be	O
27	a	O
28	member	O
29	of	O
30	a	O
31	family	B
32	of	I
33	polypeptides	I
34	conserved	I
35	in	I
36	evolution	I
37	.	I

1	These	O
2	cells	B
3	averaged	I
4	17	I
5	microns	I
6	in	I
7	diameter	I
8	and	I
9	reproduced	I
10	by	O
11	fission	B
12	,	I
13	forming	O
14	clusters	B
15	of	I
16	two	O
17	or	O
18	four	O
19	daughter	O
20	cells	O
21	.	O

1	The	O
2	diagnostic	O
3	significance	O
4	of	O
5	creatine	O
6	phosphokinase	O
7	antibodies	O
8	in	O
9	the	O
10	cardiac	O
11	muscle	O
12	in	O
13	non	O
14	-	O
15	coronarogenic	O
16	myocardial	O
17	diseases	O

1	A	O
2	736	O
3	-	O
4	bp	O
5	sequence	O
6	of	B
7	the	I
8	5	I
9	'	I
10	flanking	O
11	region	O
12	adjacent	O
13	to	O
14	the	O
15	cap	O
16	site	O
17	of	O
18	the	O
19	human	O
20	AFP	O
21	gene	B
22	shows	I
23	a	I
24	61	I
25	%	O
26	similarity	B
27	with	I
28	the	I
29	corresponding	I
30	region	I
31	of	O
32	the	O
33	mouse	O
34	AFP	O
35	gene	O
36	.	O

1	We	O
2	report	O
3	a	O
4	patient	O
5	developing	O
6	factor	O
7	VII	O
8	inhibitor	O
9	possibly	O
10	as	O
11	a	O
12	reaction	O
13	to	O
14	penicillin	O
15	administration	O
16	;	O
17	it	O
18	gave	O
19	rise	O
20	to	O
21	fatal	O
22	haemorrhage	O
23	.	O

1	It	O
2	may	O
3	also	O
4	be	O
5	suggested	O
6	that	O
7	particular	O
8	care	O
9	should	O
10	be	O
11	taken	O
12	when	O
13	such	O
14	a	O
15	trans	O
16	-	O
17	dominant	O
18	Rev	O
19	mutant	O
20	is	O
21	considered	O
22	to	O
23	be	O
24	used	O
25	as	O
26	a	O
27	genetic	O
28	therapy	O
29	against	O
30	HIV	O
31	-	O
32	I	O
33	infection	O
34	,	O
35	in	O
36	individuals	O
37	infected	O
38	with	O
39	both	O
40	HIV	O
41	-	O
42	I	O
43	and	O
44	HTLV	O
45	-	O
46	1	O
47	.	O

1	Regional	O
2	CBF	O
3	was	O
4	determined	O
5	by	O
6	clearance	O
7	of	O
8	xenon	B
9	133	I
10	in	I
11	67	I
12	patients	I
13	undergoing	I
14	coronary	O
15	bypass	O
16	grafting	O
17	procedures	O
18	.	O

1	Observations	O
2	on	O
3	the	O
4	flight	O
5	activities	O
6	of	O
7	Chrysops	O
8	caecutiens	O
9	L	O
10	.	I

1	Disruption	O
2	of	O
3	microtubules	O
4	did	O
5	not	O
6	affect	O
7	the	O
8	fidelity	O
9	or	O
10	kinetics	O
11	of	O
12	vacuolar	O
13	protein	O
14	sorting	O
15	,	O
16	indicating	O
17	that	O
18	Vps1p	O
19	function	O
20	is	O
21	not	O
22	dependent	O
23	on	O
24	microtubules	O
25	.	O

1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	hematological	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	gases	O
18	.	O

1	To	O
2	further	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	cis	O
8	-	O
9	acting	B
10	elements	I
11	in	I
12	these	I
13	regulatory	I
14	mechanisms	I
15	,	I
16	we	I
17	have	I
18	characterized	I
19	a	O
20	transcriptional	O
21	promoter	O
22	that	O
23	drives	O
24	germline	O
25	expression	B
26	of	I
27	TCR	I
28	beta	I
29	gene	I
30	segments	I
31	in	O
32	vivo	B
33	.	I

1	Substitution	O
2	of	O
3	a	O
4	threonine	O
5	residue	O
6	by	O
7	an	O
8	alanine	O
9	residue	O
10	at	B
11	position	I
12	-	I
13	2	I
14	(	I
15	P2	I
16	)	I
17	of	I
18	this	O
19	cleavage	B
20	site	I
21	abolished	I
22	cleavage	O
23	,	O
24	whereas	O
25	substitution	O
26	of	O
27	a	O
28	tyrosine	O
29	residue	O
30	by	O
31	a	O
32	phenylalanine	O
33	residue	O
34	at	O
35	amino	O
36	acid	O
37	position	O
38	-	O
39	1	O
40	(	O
41	P1	O
42	)	O
43	of	O
44	the	O
45	cleavage	O
46	site	I
47	did	I
48	not	I
49	influence	I
50	processing	I
51	.	O

1	Thrombosis	O
2	of	O
3	the	O
4	renal	O
5	vein	O
6	may	O
7	be	O
8	dramatic	O
9	and	O
10	include	O
11	renal	O
12	failure	O
13	.	B

1	Studies	O
2	on	O
3	powdered	O
4	preparations	O
5	.	O

1	We	O
2	have	O
3	now	O
4	located	O
5	the	O
6	5	O
7	'	O
8	ends	O
9	of	O
10	the	O
11	two	O
12	remaining	O
13	late	O
14	mRNAs	O
15	.	O

1	Differential	O
2	expression	O
3	of	O
4	AP	O
5	-	O
6	2alpha	O
7	and	O
8	AP	O
9	-	O
10	2beta	O
11	in	O
12	the	O
13	developing	O
14	chick	O
15	retina	O
16	:	O
17	repression	O
18	of	O
19	R	O
20	-	O
21	FABP	O
22	promoter	O
23	activity	O
24	by	O
25	AP	O
26	-	O
27	2	O
28	.	O

1	Here	O
2	we	O
3	focused	O
4	on	O
5	the	O
6	role	O
7	of	O
8	the	O
9	5	I
10	'	I
11	proximal	I
12	regulatory	I
13	cassette	I
14	(-	I
15	190	O
16	;	B
17	+	I
18	53	I
19	bp	I
20	)	I
21	of	I
22	the	I
23	rat	I
24	enkephalin	I
25	(	I
26	rENK	O
27	)	O
28	gene	O
29	in	O
30	the	O
31	developmental	O
32	regulation	O
33	of	O
34	the	O
35	enkephalin	O
36	phenotype	O
37	.	O

1	Although	O
2	the	O
3	RAD23	O
4	equivalents	O
5	are	O
6	well	O
7	conserved	O
8	during	O
9	evolution	O
10	,	O
11	the	O
12	mammalian	O
13	genes	O
14	did	O
15	not	O
16	express	O
17	the	O
18	UV	O
19	-	O
20	inducible	O
21	phenotype	O
22	of	O
23	their	B
24	yeast	I
25	counterpart	I
26	.	I

1	2	O
2	Silastic	B
3	capsules	I
4	,	I
5	each	I
6	containing	I
7	22	I
8	-	I
9	23	I
10	mg	I
11	of	I
12	ethinyl	I
13	estradiol	I
14	,	I
15	were	I
16	inserted	I
17	subcutaneously	I
18	in	O
19	5	B
20	men	I
21	with	I
22	benign	O
23	prostatic	O
24	hypertrophy	O
25	.	O

1	Monkeys	O
2	were	O
3	evaluated	O
4	before	O
5	and	O
6	after	O
7	unilateral	O
8	and	O
9	serial	O
10	bilateral	B
11	removal	I
12	of	I
13	superior	I
14	temporal	I
15	cortex	O
16	.	O

1	Consciousness	O
2	is	O
3	connected	O
4	with	O
5	attention	O
6	,	O
7	working	O
8	memory	O
9	and	O
10	perception	O
11	.	O

1	Medicare	O
2	SNF	O
3	benefits	O
4	revised	O
5	--	O
6	again	O
7	.	O

1	From	O
2	day	O
3	30	O
4	after	O
5	turnout	O
6	,	O
7	the	O
8	PFB	O
9	-	O
10	group	O
11	had	O
12	significantly	O
13	lower	O
14	serum	O
15	pepsinogen	O
16	levels	O
17	,	O
18	which	O
19	reflects	O
20	the	B
21	low	I
22	degree	I
23	of	O
24	abomasal	O
25	damage	O
26	in	B
27	these	I
28	animals	I
29	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	O
8	-	O
9	type	O
10	Fus3	O
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	O
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	Piperacillin	O
2	-	O
3	tazobactam	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	B
17	,	I
18	gram	I
19	-	I
20	positive	I
21	,	I
22	aerobic	I
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O

1	Blood	O
2	levels	B
3	of	B
4	melatonin	I
5	,	O
6	serotonin	B
7	,	B
8	cortisol	I
9	,	O
10	and	O
11	prolactin	O
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	O
21	uptake	O
22	.	O

1	The	O
2	human	O
3	RAD30B	O
4	and	O
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	O
9	,	B
10	like	I
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O

1	Glomerular	O
2	hemodynamics	O
3	during	O
4	abortion	O
5	induced	O
6	by	O
7	RU	O
8	486	O
9	and	O
10	sepsis	O
11	in	O
12	rats	O
13	.	O

1	2	O
2	.	O
3	numerous	O
4	narrow	O
5	shunt	O
6	vessels	B
7	departing	I
8	continuously	I
9	from	I
10	the	O
11	primary	O
12	arteries	O
13	to	O
14	feed	O
15	a	O
16	secondary	O
17	arterial	O
18	system	O
19	which	B
20	parallels	I
21	the	I
22	primary	I
23	one	I
24	.	I

1	The	O
2	QT	B
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	O
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	O
19	sensitivity	O
20	.	O

1	In	O
2	vitro	O
3	interaction	O
4	studies	O
5	,	O
6	using	O
7	proteins	O
8	fused	O
9	to	B
10	glutathione	I
11	-	I
12	S	I
13	-	I
14	transferase	I
15	,	O
16	showed	O
17	that	O
18	RBP	O
19	-	O
20	J	O
21	kappa	O
22	and	O
23	Su	B
24	(	I
25	H	O
26	)	O
27	bind	O
28	directly	O
29	to	O
30	the	O
31	RAM23	O
32	regions	O
33	of	O
34	mouse	O
35	Notch1	O
36	and	O
37	Drosophila	O
38	Notch	O
39	,	O
40	respectively	O
41	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	purified	O
7	and	O
8	characterized	O
9	the	O
10	recombinant	O
11	furin	O
12	from	O
13	the	O
14	conditioned	O
15	medium	O
16	of	O
17	these	O
18	cells	O
19	.	O

1	Six	O
2	patients	O
3	with	B
4	glomerulonephritis	I
5	in	I
6	association	I
7	with	I
8	a	I
9	ventriculovascular	I
10	shunt	I
11	were	O
12	treated	O
13	with	O
14	three	O
15	basic	O
16	modes	O
17	of	O
18	therapy	O
19	.	O

1	Autotransfusion	O
2	was	O
3	performed	O
4	as	O
5	follows	O
6	:	O
7	Heparin	O
8	-	O
9	ACD	O
10	-	O
11	B	O
12	-	O
13	Heparin	O
14	-	O
15	DPD	O
16	-	O
17	Heparin	O
18	-	O
19	ACD	O
20	-	O
21	B	O
22	etc	B
23	.	B

1	This	O
2	suggested	O
3	that	O
4	delta	O
5	6	O
6	and	O
7	delta	O
8	5	O
9	desaturation	O
10	activities	O
11	are	O
12	normal	O
13	in	O
14	these	O
15	conditions	O
16	with	O
17	this	O
18	C18	O
19	:	O
20	2w6	O
21	supply	O
22	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	PCNA	O
7	gene	O
8	is	O
9	a	O
10	likely	O
11	target	O
12	gene	O
13	of	O
14	E2F	O
15	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	investigate	O
7	the	O
8	mechanism	O
9	underlying	O
10	Ras	O
11	activation	B
12	upon	I
13	stimulation	I
14	of	I
15	these	I
16	two	O
17	types	O
18	of	O
19	receptors	O
20	in	O
21	hematopoietic	O
22	cells	O
23	.	O

1	Activated	O
2	PKR	O
3	may	O
4	exist	O
5	as	O
6	a	O
7	dimer	O
8	and	O
9	phosphorylates	O
10	the	O
11	eukaryotic	O
12	translation	O
13	initiation	O
14	factor	O
15	2	O
16	alpha	O
17	subunit	O
18	(	O
19	cIF	O
20	-	O
21	2	O
22	alpha	O
23	)	O
24	to	O
25	inhibit	O
26	polypeptide	O
27	chain	O
28	initiation	O
29	.	O

1	Idiopathic	O
2	bilateral	O
3	recurrent	O
4	branch	O
5	retinal	O
6	arterial	O
7	occlusion	O
8	(	O
9	IBRBRAO	B
10	)	I
11	is	I
12	a	I
13	rare	O
14	syndrome	O
15	characterized	O
16	by	O
17	migraine	B
18	headaches	I
19	,	I
20	tinnitus	I
21	,	I
22	vertigo	I
23	,	O
24	hearing	O
25	loss	O
26	,	O
27	and	O
28	recurrent	O
29	branch	O
30	retinal	O
31	artery	O
32	occlusion	O
33	of	B
34	unknown	I
35	etiology	I
36	.	I

1	A	O
2	hydrodynamic	O
3	description	O
4	of	O
5	the	O
6	osmotic	O
7	reflection	O
8	coefficient	O
9	with	B
10	application	I
11	to	I
12	the	O
13	pore	O
14	theory	O
15	of	O
16	transcapillary	O
17	exchange	O
18	.	O

1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	B
8	the	I
9	ITI	I
10	(	I
11	International	I
12	Team	I
13	fur	I
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O

1	A	O
2	double	O
3	-	O
4	blind	O
5	trial	O
6	of	O
7	half	O
8	-	O
9	strength	O
10	Polybactrin	O
11	Soluble	O
12	GU	O
13	bladder	O
14	irrigation	O
15	in	O
16	cystoscopy	O
17	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	Hepatitis	O
6	A	O
7	HBs	O
8	-	O
9	and	O
10	HBe	O
11	-	O
12	antigen	O
13	as	O
14	well	O
15	as	O
16	HBc	O
17	(	O
18	IgM	O
19	and	O
20	IgG	O
21	)-,	O
22	HBs	O
23	-	O
24	and	O
25	HBe	O
26	-	O
27	antibodies	O
28	can	O
29	be	O
30	detected	O
31	.	O

1	BACKGROUND	O
2	AND	O
3	DESIGN	O
4	:	O
5	Fifty	O
6	-	B
7	nine	I
8	melanocytic	I
9	nevi	I
10	with	I
11	eccentric	I
12	foci	I
13	of	I
14	hyperpigmentation	I
15	("	I
16	small	I
17	dark	I
18	dots	O
19	")	O
20	that	O
21	measured	O
22	primarily	O
23	1	O
24	to	O
25	2	O
26	mm	O
27	in	O
28	diameter	O
29	were	O
30	prospectively	O
31	examined	O
32	to	O
33	determine	O
34	the	O
35	histologic	O
36	correlates	O
37	of	O
38	the	O
39	dark	O
40	dots	B
41	.	I

1	In	O
2	the	O
3	budding	O
4	yeast	O
5	,	B
6	Saccharomyces	I
7	cerevisiae	I
8	,	I
9	replicators	O
10	can	B
11	function	I
12	outside	I
13	the	O
14	chromosome	O
15	as	O
16	autonomously	O
17	replicating	O
18	sequence	O
19	(	O
20	ARS	O
21	)	O
22	elements	O
23	;	O
24	however	O
25	,	O
26	within	O
27	chromosome	O
28	III	O
29	,	O
30	certain	O
31	ARSs	O
32	near	O
33	the	O
34	transcriptionally	O
35	silent	O
36	HML	B
37	locus	O
38	show	I
39	no	I
40	replication	O
41	origin	O
42	activity	I
43	.	B

1	These	O
2	results	O
3	illuminate	O
4	a	O
5	hitherto	O
6	unanticipated	O
7	function	O
8	of	O
9	U6	O
10	RNA	O
11	:	O
12	the	O
13	modulation	O
14	of	O
15	a	O
16	phosphorylation	O
17	-	O
18	dephosphorylation	O
19	cycle	O
20	of	O
21	C1	O
22	hnRNP	O
23	protein	O
24	that	O
25	influences	O
26	the	O
27	binding	O
28	affinity	O
29	of	O
30	this	O
31	protein	O
32	for	O
33	pre	O
34	-	O
35	mRNA	O
36	.	O

1	H19	O
2	and	O
3	Igf2	O
4	monoallelic	O
5	expression	O
6	is	O
7	regulated	O
8	in	O
9	two	O
10	distinct	O
11	ways	I
12	by	I
13	a	I
14	shared	I
15	cis	I
16	acting	I
17	regulatory	I
18	region	I
19	upstream	I
20	of	I
21	H19	O
22	.	O

1	To	O
2	characterize	O
3	the	O
4	gene	O
5	products	O
6	,	O
7	the	O
8	cvaA	O
9	gene	O
10	was	O
11	subcloned	O
12	and	O
13	expressed	O
14	under	O
15	the	O
16	control	O
17	of	O
18	T7	O
19	RNA	O
20	polymerase	O
21	promoter	O
22	.	O

1	The	O
2	derivatives	B
3	of	O
4	the	I
5	latter	I
6	two	I
7	cell	I
8	lines	I
9	showed	I
10	increased	I
11	expression	I
12	of	O
13	the	O
14	p27Kip1	B
15	protein	I
16	and	I
17	inhibition	I
18	of	I
19	cell	O
20	growth	O
21	.	O

1	The	O
2	downstream	O
3	,	O
4	TATA	O
5	-	O
6	less	O
7	promoter	O
8	has	O
9	high	O
10	G	O
11	+	O
12	C	O
13	content	O
14	,	O
15	and	O
16	exon	O
17	1b	O
18	predominates	O
19	among	O
20	abundantly	O
21	expressed	O
22	mRNA	O
23	species	O
24	.	O

1	RVR	O
2	'	O
3	loss	O
4	of	O
5	function	O
6	'	O
7	studies	O
8	by	O
9	constitutive	O
10	over	O
11	-	O
12	expression	O
13	of	O
14	a	O
15	dominant	O
16	negative	O
17	RVR	O
18	delta	O
19	E	O
20	resulted	O
21	in	O
22	increased	O
23	levels	O
24	of	O
25	p21Cip1	O
26	/	O
27	Waf1	O
28	and	O
29	myogenin	O
30	mRNAs	O
31	after	O
32	serum	O
33	withdrawal	O
34	.	O

1	The	O
2	pJR	O
3	vectors	O
4	differ	O
5	among	O
6	them	O
7	in	O
8	:	B
9	(	I
10	a	I
11	)	I
12	the	O
13	selectable	O
14	marker	O
15	(	O
16	Saccharomyces	O
17	cerevisiae	O
18	LEU	O
19	2	O
20	gene	O
21	,	O
22	which	O
23	complements	O
24	S	O
25	.	O
26	pombe	O
27	leu1	O
28	-	O
29	gene	O
30	and	O
31	S	O
32	.	O
33	pombe	O
34	ura4	O
35	+	O
36	and	O
37	his3	O
38	+	O
39	genes	O
40	);	O
41	(	O
42	b	O
43	)	O
44	the	O
45	thiamine	O
46	-	O
47	repressible	O
48	nmt1	O
49	promoter	B
50	(	I
51	3X	I
52	,	I
53	41X	I
54	and	O
55	81X	O
56	with	O
57	extremely	O
58	high	O
59	,	O
60	moderate	O
61	or	O
62	low	O
63	transcription	O
64	efficiency	O
65	,	O
66	respectively	O
67	);	O
68	and	O
69	(	O
70	c	O
71	)	O
72	the	O
73	multiple	O
74	cloning	O
75	site	O
76	(	O
77	two	O
78	multiple	O
79	cloning	O
80	sites	O
81	,	O
82	with	O
83	12	O
84	restriction	O
85	sites	O
86	each	B
87	).	O

1	The	O
2	5	O
3	'	O
4	and	O
5	3	B
6	'	I
7	untranslated	I
8	sequences	O
9	contain	O
10	characteristic	O
11	sequences	O
12	that	O
13	are	O
14	involved	O
15	in	O
16	the	O
17	initiation	O
18	and	O
19	termination	O
20	of	O
21	transcription	O
22	,	O
23	including	O
24	two	O
25	possible	O
26	promoters	O
27	,	O
28	one	O
29	of	O
30	which	O
31	may	O
32	contain	O
33	two	O
34	overlapping	O
35	-	O
36	10	O
37	sequences	O
38	.	O

1	Resting	O
2	VE	O
3	in	O
4	the	O
5	luteal	O
6	phase	O
7	was	O
8	7	O
9	.	O
10	8	O
11	%	O
12	greater	O
13	than	O
14	that	O
15	in	O
16	the	O
17	follicular	O
18	phase	O
19	.	O

1	The	O
2	bearing	O
3	of	O
4	season	O
5	and	O
6	sequence	O
7	of	O
8	calving	O
9	on	O
10	frequency	O
11	of	O
12	male	O
13	,	O
14	female	O
15	and	O
16	total	O
17	calvings	O
18	in	O
19	Hariana	O
20	cows	O
21	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	for	O
6	expression	O
7	of	O
8	snRNA	O
9	genes	O
10	in	O
11	maize	O
12	,	O
13	a	O
14	monocotyledonous	O
15	plant	O
16	,	O
17	the	O
18	USE	O
19	and	O
20	TATA	O
21	elements	O
22	are	O
23	essential	O
24	,	O
25	but	O
26	not	O
27	sufficient	O
28	,	O
29	for	O
30	transcription	O
31	.	O

1	Echinostomiasis	O
2	is	O
3	aggravated	O
4	by	O
5	socioeconomic	O
6	factors	O
7	such	O
8	as	O
9	poverty	O
10	,	O
11	malnutrition	O
12	,	O
13	an	O
14	explosively	O
15	growing	O
16	free	O
17	-	O
18	food	O
19	market	O
20	,	O
21	a	B
22	lack	I
23	of	I
24	supervised	O
25	food	O
26	inspection	O
27	,	O
28	poor	O
29	or	O
30	insufficient	O
31	sanitation	O
32	,	O
33	other	O
34	helminthiases	O
35	,	O
36	and	O
37	declining	O
38	economic	O
39	conditions	O
40	.	O

1	A	O
2	genomic	O
3	clone	B
4	,	I
5	pTt21	I
6	,	I
7	containing	I
8	DNA	O
9	apparently	O
10	transcribed	O
11	specifically	O
12	in	O
13	Trypanosoma	O
14	cruzi	O
15	trypomastigotes	O
16	,	O
17	was	O
18	obtained	O
19	by	O
20	differentially	O
21	screening	O
22	a	O
23	genomic	B
24	library	I
25	with	I
26	trypomastigote	I
27	and	I
28	epimastigote	I
29	cDNA	I
30	.	I

1	Double	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	CD68	O
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	XIIIa	O
17	-	O
18	positive	O
19	dendrocytes	O
20	.	O

1	All	O
2	patients	O
3	diagnosed	O
4	of	O
5	H	O
6	.	O
7	influenza	O
8	type	O
9	b	O
10	meningitis	O
11	were	O
12	less	O
13	than	O
14	3	O
15	years	O
16	old	O
17	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	Overexpression	O
2	of	O
3	H411	O
4	cDNA	O
5	in	O
6	the	O
7	RAW	O
8	264	O
9	.	O
10	7	O
11	macrophage	O
12	cell	O
13	line	O
14	promoted	O
15	an	O
16	increased	O
17	growth	O
18	rate	O
19	,	O
20	suggesting	O
21	that	O
22	expression	O
23	of	O
24	H411	O
25	is	O
26	part	O
27	of	O
28	the	O
29	proliferative	O
30	cell	O
31	response	O
32	to	O
33	LPS	O
34	.	O

1	When	O
2	expressed	O
3	alone	O
4	in	O
5	test	O
6	cells	O
7	,	O
8	Atr	O
9	-	O
10	I	O
11	is	O
12	unable	O
13	to	O
14	bind	O
15	TGF	O
16	-	O
17	beta	O
18	,	O
19	activin	O
20	,	O
21	or	O
22	bone	O
23	morphogenetic	O
24	protein	O
25	2	O
26	.	O

1	A	O
2	3	O
3	-	O
4	yr	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	detects	O
11	94	O
12	%	O
13	of	O
14	the	O
15	undercalls	O
16	.	O

1	Activation	O
2	of	B
3	c	I
4	-	I
5	fos	I
6	gene	I
7	expression	I
8	by	I
9	a	O
10	kinase	B
11	-	I
12	deficient	O
13	epidermal	O
14	growth	O
15	factor	O
16	receptor	O
17	.	O

1	The	O
2	mature	O
3	AP	O
4	-	O
5	2	O
6	mRNA	O
7	is	O
8	spliced	O
9	from	O
10	7	O
11	exons	O
12	distributed	O
13	over	O
14	a	O
15	region	O
16	of	O
17	18	O
18	kb	O
19	genomic	O
20	DNA	O
21	.	O

1	Introductory	O
2	remarks	O
3	.	O

1	Rinit	O
2	reflects	O
3	the	O
4	Newtonian	O
5	resistances	O
6	and	O
7	Rdiff	O
8	represents	O
9	the	O
10	viscoelastic	O
11	/	O
12	inhomogeneous	O
13	pressure	O
14	dissipations	O
15	in	O
16	the	O
17	system	B
18	.	I

1	The	O
2	ORF1	O
3	product	O
4	was	O
5	required	O
6	for	O
7	competence	O
8	,	O
9	while	O
10	ORF2	O
11	,	O
12	which	O
13	was	O
14	cotranscribed	O
15	with	O
16	ORF1	O
17	and	O
18	encoded	O
19	a	O
20	predicted	O
21	protein	O
22	of	O
23	126	O
24	amino	O
25	acids	O
26	,	O
27	was	O
28	not	O
29	.	O

1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O

1	By	O
2	stepwise	O
3	linear	O
4	multiple	O
5	regression	O
6	analysis	O
7	,	O
8	ionized	O
9	magnesium	O
10	was	O
11	significantly	O
12	related	O
13	to	O
14	cyclosporin	O
15	trough	O
16	level	O
17	and	O
18	total	O
19	cholesterol	O
20	but	O
21	not	O
22	to	O
23	serum	O
24	creatinine	O
25	,	O
26	time	O
27	after	O
28	transplant	O
29	or	O
30	the	O
31	dose	O
32	of	O
33	cyclosporin	O
34	.	O

1	Furthermore	O
2	,	O
3	plasma	O
4	fibrinogen	O
5	levels	O
6	increased	O
7	by	O
8	a	O
9	mean	O
10	of	O
11	17	O
12	.	O
13	6	O
14	%,	O
15	a	O
16	potentially	O
17	adverse	O
18	effect	O
19	of	O
20	gemfibrozil	O
21	that	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	.	B

1	The	O
2	pentafluorobenzyl	O
3	derivative	O
4	of	O
5	clonidine	O
6	yields	O
7	an	O
8	intense	O
9	ion	O
10	fragment	O
11	at	O
12	m	O
13	/	O
14	z	O
15	354	O
16	,	O
17	and	O
18	the	O
19	lower	O
20	limit	O
21	of	O
22	detection	O
23	is	O
24	0	O
25	.	O
26	025	O
27	ng	O
28	/	O
29	ml	O
30	for	O
31	a	O
32	1	O
33	-	O
34	ml	O
35	plasma	O
36	sample	O
37	.	O

1	We	O
2	also	O
3	present	O
4	evidence	O
5	for	O
6	a	B
7	negative	I
8	regulatory	I
9	element	I
10	in	I
11	the	O
12	5	B
13	'	I
14	flanking	O
15	region	O
16	of	O
17	the	O
18	Mlu	O
19	I	O
20	upstream	O
21	activation	O
22	sequence	O
23	.	O

1	Vacuum	O
2	Rabi	O
3	splitting	O
4	as	O
5	a	O
6	feature	O
7	of	O
8	linear	O
9	-	O
10	dispersion	O
11	theory	O
12	:	O
13	Analysis	O
14	and	O
15	experimental	O
16	observations	O
17	.	O

1	Estimated	O
2	nucleic	O
3	acid	O
4	N	O
5	absorption	O
6	is	O
7	7	O
8	-	O
9	8	O
10	%	O
11	of	O
12	N	B
13	intake	I
14	.	I

1	PAO	O
2	blocks	O
3	turnover	O
4	of	O
5	the	O
6	phosphoryl	O
7	group	O
8	of	O
9	pp15	O
10	,	O
11	causing	O
12	its	O
13	accumulation	O
14	,	O
15	and	O
16	thereby	O
17	appears	O
18	to	O
19	interrupt	O
20	signal	O
21	transmission	O
22	from	O
23	the	O
24	receptor	O
25	to	O
26	the	O
27	glucose	B
28	-	I
29	transport	I
30	system	O
31	.	O

1	Hyperthyroidism	O

1	In	O
2	conclusion	O
3	,	O
4	marmoset	O
5	monkey	B
6	LHR	I
7	seems	I
8	to	O
9	lack	O
10	the	O
11	sequence	O
12	corresponding	O
13	to	O
14	exon	O
15	10	O
16	of	O
17	the	O
18	LHR	O
19	gene	B
20	in	I
21	other	O
22	mammalian	O
23	species	O
24	.	O

1	These	O
2	different	O
3	observations	O
4	exclude	O
5	a	O
6	heterozygosity	O
7	of	O
8	the	O
9	A	O
10	-->	O
11	G	O
12	mutation	O
13	at	O
14	codon	O
15	beta	O
16	77	O
17	,	O
18	as	O
19	well	O
20	as	O
21	a	O
22	deletion	O
23	comparable	O
24	to	O
25	that	O
26	of	O
27	Hbs	O
28	Lepore	O
29	or	O
30	Kenya	O
31	,	O
32	or	O
33	a	O
34	beta	O
35	-	O
36	globin	O
37	gene	O
38	duplication	O
39	,	O
40	and	O
41	point	O
42	to	O
43	a	O
44	nontraditional	O
45	inheritance	O
46	of	O
47	Hb	O
48	Costa	O
49	Rica	O
50	.	O

1	In	O
2	a	O
3	maxicell	O
4	system	O
5	a	O
6	protein	O
7	with	O
8	an	O
9	approximate	O
10	molecular	O
11	weight	O
12	of	O
13	36	O
14	,	O
15	000	O
16	was	O
17	synthesized	O
18	.	O

1	Therefore	O
2	,	O
3	it	O
4	is	O
5	important	O
6	to	O
7	control	O
8	hypertension	O
9	and	O
10	keep	O
11	appropriate	O
12	renal	O
13	blood	O
14	flow	O
15	during	O
16	living	O
17	renal	B
18	transplantation	I
19	surgery	I
20	.	I

1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	B
7	Whipple	I
8	-	I
9	specific	I
10	DNA	I
11	fragments	O
12	of	B
13	284	I
14	base	I
15	pairs	O
16	from	B
17	the	I
18	genome	I
19	of	I
20	the	O
21	Whipple	O
22	bacterium	O
23	(	O
24	Tropheryma	O
25	whippelii	O
26	)	O
27	were	B
28	demonstrated	I
29	.	I

1	NF	O
2	-	O
3	kappa	O
4	B	O
5	/	O
6	Rel	O
7	transcription	O
8	factors	O
9	participate	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	numerous	O
15	genes	O
16	involved	O
17	in	O
18	immune	O
19	regulation	B
20	/	I
21	inflammation	I
22	including	I
23	cytokines	I
24	,	I
25	cell	I
26	surface	I
27	receptors	O
28	,	B
29	adhesion	I
30	molecules	I
31	,	I
32	and	O
33	acute	O
34	phase	B
35	proteins	I
36	.	I

1	The	O
2	mutants	O
3	were	O
4	obtained	O
5	by	O
6	substitution	O
7	into	O
8	a	O
9	molecular	O
10	clone	O
11	of	O
12	M	O
13	-	O
14	MuLV	O
15	DNA	O
16	by	O
17	DNA	O
18	from	O
19	two	O
20	acutely	O
21	transforming	O
22	viruses	O
23	,	O
24	Ableson	O
25	MuLV	O
26	(	O
27	Ab	O
28	-	O
29	MuLV	O
30	)	O
31	and	O
32	Moloney	O
33	murine	O
34	sarcoma	O
35	virus	O
36	(	O
37	M	O
38	-	O
39	MSV	O
40	).	O

1	Studies	O
2	using	O
3	the	O
4	yeast	O
5	two	O
6	-	O
7	hybrid	O
8	system	O
9	also	O
10	did	O
11	not	O
12	provide	O
13	evidence	O
14	for	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	VDR	O
20	-	B
21	TR	O
22	protein	I
23	-	I
24	protein	I
25	interaction	O
26	.	O

1	Current	O
2	world	O
3	literature	B
4	.	I

1	Structure	O
2	,	O
3	promoter	O
4	analysis	O
5	and	O
6	chromosomal	O
7	assignment	O
8	of	O
9	the	O
10	human	O
11	APEX	O
12	gene	O
13	.	O

1	A	O
2	.	O

1	The	O
2	tyrosine	O
3	hydroxylase	O
4	gene	O
5	(	O
6	TH	O
7	)	O
8	contains	O
9	a	O
10	single	O
11	copy	O
12	of	O
13	a	O
14	consensus	O
15	CRE	O
16	at	O
17	-	O
18	45	O
19	to	O
20	-	O
21	38	O
22	base	O
23	pair	O
24	(	O
25	bp	O
26	)	O
27	upstream	O
28	of	O
29	the	O
30	transcription	O
31	initiation	O
32	site	O
33	.	O

1	The	O
2	kinase	O
3	is	O
4	essential	O
5	in	O
6	vivo	O
7	for	O
8	normal	O
9	phosphorylation	O
10	of	O
11	the	O
12	CTD	O
13	and	O
14	for	O
15	normal	O
16	growth	O
17	and	O
18	differentiation	O
19	.	O

1	Thiopentone	O
2	sodium	O
3	administered	O
4	at	O
5	30	O
6	and	O
7	10	O
8	min	O
9	before	O
10	or	O
11	5	O
12	,	O
13	10	B
14	and	I
15	15	O
16	min	O
17	after	B
18	exposure	I
19	to	I
20	NOC	I
21	-	I
22	5	I
23	,	I
24	but	I
25	not	O
26	thereafter	O
27	,	O
28	significantly	O
29	attenuated	O
30	NO	O
31	-	O
32	induced	O
33	neurotoxicity	O
34	compared	O
35	with	B
36	controls	I
37	.	I

1	RESULTS	O
2	:	O
3	Cholinergic	O
4	nerves	O
5	are	O
6	mainly	O
7	involved	O
8	in	O
9	the	B
10	regulation	I
11	of	I
12	enteric	O
13	nerve	O
14	responses	O
15	to	O
16	EFS	O
17	in	O
18	the	O
19	normal	B
20	IAS	I
21	.	I

1	The	O
2	virus	O
3	encodes	O
4	a	O
5	40	O
6	-	O
7	kDa	O
8	protein	O
9	,	O
10	tax	O
11	,	O
12	that	O
13	is	O
14	important	O
15	for	O
16	the	O
17	immortalization	O
18	of	O
19	T	O
20	cells	O
21	.	O

1	Protein	O
2	S	O
3	levels	O
4	were	O
5	virtually	O
6	undetectable	O
7	at	O
8	the	O
9	time	O
10	of	O
11	admission	O
12	and	O
13	failed	O
14	to	O
15	respond	O
16	to	O
17	infusions	O
18	of	O
19	fresh	O
20	frozen	O
21	plasma	O
22	,	O
23	despite	O
24	correction	O
25	of	O
26	other	O
27	procoagulant	O
28	and	O
29	anticoagulant	O
30	factors	O
31	.	O

1	We	O
2	show	B
3	that	I
4	the	I
5	5	I
6	'	O
7	UTR	B
8	characteristic	I
9	of	O
10	testis	O
11	-	O
12	specific	O
13	c	O
14	-	O
15	mos	O
16	mRNA	O
17	strongly	O
18	represses	O
19	translation	O
20	relative	O
21	to	O
22	the	O
23	translation	O
24	of	O
25	transcripts	O
26	that	O
27	contain	O
28	a	O
29	5	O
30	'	O
31	UTR	O
32	derived	O
33	from	O
34	beta	O
35	-	B
36	globin	I
37	mRNA	I
38	,	O
39	and	I
40	this	I
41	is	O
42	mainly	O
43	due	O
44	to	O
45	the	O
46	four	O
47	uORFs	O
48	.	O

1	Acute	O
2	appearance	O
3	of	O
4	hemiparesis	O
5	or	O
6	hemiplegia	O
7	with	O
8	initial	O
9	marked	O
10	spasticity	O
11	was	O
12	observed	O
13	in	O
14	8	O
15	stroke	O
16	patients	O
17	.	O

1	The	O
2	maximal	O
3	effect	O
4	was	O
5	seen	O
6	at	O
7	100	O
8	ng	O
9	/	O
10	ml	O
11	EGF	O
12	,	O
13	with	O
14	a	O
15	time	O
16	lag	O
17	of	O
18	about	O
19	5	O
20	h	O
21	.	O

1	Constrictive	O
2	pericarditis	O
3	and	O
4	pleuropulmonary	O
5	disease	O
6	linked	O
7	to	O
8	ergot	O
9	dopamine	O
10	agonist	O
11	therapy	O
12	(	O
13	cabergoline	O
14	)	O
15	for	O
16	Parkinson	O
17	'	O
18	s	O
19	disease	O
20	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	hGCSFR	O
6	gene	O
7	was	B
8	chromosomally	I
9	localized	I
10	by	I
11	Southern	O
12	blot	O
13	analysis	O
14	of	O
15	its	O
16	segregation	B
17	pattern	I
18	in	I
19	a	I
20	panel	I
21	of	O
22	rodent	O
23	-	O
24	human	O
25	hybrid	O
26	DNAs	O
27	using	O
28	the	O
29	radiolabeled	O
30	cDNA	O
31	probe	O
32	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	support	O
7	a	O
8	model	O
9	in	O
10	which	O
11	VirB4	O
12	dimers	O
13	or	O
14	homomultimers	O
15	contribute	O
16	structural	O
17	information	O
18	for	O
19	the	O
20	assembly	O
21	of	O
22	a	O
23	transenvelope	O
24	channel	O
25	competent	O
26	for	O
27	bidirectional	O
28	DNA	O
29	transfer	O
30	,	O
31	whereas	O
32	an	O
33	ATP	O
34	-	O
35	dependent	O
36	activity	O
37	is	O
38	required	O
39	for	O
40	configuring	O
41	this	O
42	channel	O
43	as	O
44	a	O
45	dedicated	O
46	export	O
47	machine	O
48	.	O

1	The	O
2	site	O
3	of	O
4	autophosphorylation	O
5	is	O
6	Tyr397	O
7	which	O
8	corresponds	O
9	to	O
10	the	O
11	consensus	O
12	autophosphorylation	B
13	site	I
14	of	I
15	other	O
16	Src	B
17	family	I
18	tyrosine	I
19	kinases	I
20	.	I

1	The	O
2	present	O
3	study	O
4	describes	O
5	the	O
6	cell	O
7	volume	O
8	dynamics	O
9	in	O
10	intact	O
11	rat	O
12	hearts	O
13	,	O
14	during	O
15	ischemia	B
16	and	I
17	after	I
18	reperfusion	I
19	.	I

1	In	O
2	a	O
3	series	O
4	of	O
5	patients	O
6	with	O
7	neuroinfection	O
8	,	O
9	Lyme	O
10	disease	O
11	,	O
12	Guillain	O
13	Barre	O
14	syndrome	O
15	,	O
16	demyelinization	O
17	,	O
18	partial	O
19	or	O
20	generalized	O
21	,	O
22	epilepsy	O
23	,	O
24	we	O
25	have	O
26	investigated	O
27	antiphospholipid	O
28	antibodies	O
29	of	O
30	IgG	O
31	and	O
32	IgM	O
33	subtypes	O
34	,	O
35	together	O
36	with	O
37	anticoagulant	O
38	factors	O
39	,	O
40	member	O
41	of	O
42	thrombocytes	O
43	,	O
44	sedimentation	O
45	rate	O
46	of	O
47	erythrocytes	O
48	.	O

1	Simian	O
2	immunodeficiency	O
3	virus	O
4	(	O
5	SIV	O
6	)	O
7	is	O
8	a	O
9	lentivirus	O
10	with	I
11	morphological	O
12	and	O
13	antigenic	O
14	similarities	O
15	to	O
16	human	I
17	immunodeficiency	I
18	virus	I
19	,	I
20	the	I
21	causative	I
22	agent	O
23	of	O
24	acquired	O
25	immunodeficiency	O
26	syndrome	O
27	(	O
28	AIDS	O
29	)	O
30	of	I
31	humans	O
32	.	O

1	We	O
2	conclude	O
3	that	O
4	DNA	O
5	ploidy	O
6	is	O
7	a	O
8	major	O
9	objective	O
10	prognostic	O
11	factor	O
12	and	O
13	therapeutic	O
14	determinant	O
15	for	O
16	endometrial	O
17	carcinoma	O
18	.	O

1	The	O
2	imino	O
3	proton	O
4	of	O
5	T3	O
6	in	O
7	the	O
8	O6meG	O
9	.	O
10	T	O
11	12	O
12	-	O
13	mer	O
14	and	O
15	G3	B
16	in	I
17	the	I
18	O6meG	I
19	.	O
20	N	O
21	12	O
22	-	O
23	mer	O
24	helix	O
25	,	O
26	which	O
27	are	O
28	associated	O
29	with	O
30	the	O
31	modification	O
32	site	O
33	,	O
34	resonate	O
35	at	O
36	unusually	O
37	high	O
38	field	O
39	(	O
40	8	O
41	.	O
42	5	O
43	to	O
44	9	O
45	.	O
46	0	O
47	ppm	O
48	)	O
49	compared	O
50	to	O
51	imino	O
52	protons	O
53	in	O
54	Watson	O
55	-	O
56	Crick	O
57	base	O
58	pairs	O
59	(	O
60	12	O
61	.	O
62	5	O
63	to	O
64	14	O
65	.	O
66	5	O
67	ppm	O
68	).	O

1	FZD4	O
2	is	O
3	homologous	O
4	to	O
5	FZD9	O
6	and	O
7	FZD10	O
8	,	B
9	and	I
10	overall	I
11	amino	I
12	acid	I
13	identity	I
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	O
19	vs	O
20	FZD9	O
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	O
27	vs	O
28	FZD10	O
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	O
35	vs	O
36	FZD10	O
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	established	O
6	that	O
7	progression	O
8	through	O
9	the	O
10	eukaryotic	O
11	cell	O
12	cycle	O
13	is	O
14	controlled	O
15	by	O
16	oscillations	O
17	in	O
18	the	O
19	activity	O
20	of	O
21	cyclin	O
22	-	O
23	dependent	O
24	kinases	O
25	(	O
26	CDKs	O
27	).	O

1	This	O
2	paper	O
3	reviews	O
4	the	O
5	middleware	O
6	-	O
7	based	O
8	approach	O
9	adopted	O
10	by	O
11	CEN	O
12	ENV	O
13	12967	O
14	-	O
15	1	O
16	and	O
17	the	O
18	specialisation	O
19	necessary	O
20	for	O
21	the	O
22	healthcare	O
23	record	O
24	based	O
25	on	O
26	CEN	O
27	ENV	O
28	12265	O
29	'	O
30	Electronic	O
31	Healthcare	O
32	Record	O
33	Architecture	O
34	'.	O

1	Morphology	O
2	of	O
3	bacteriophages	O
4	of	O
5	Klebsiella	O
6	bacilli	O
7	.	O

1	Following	O
2	the	O
3	satisfactory	O
4	results	O
5	and	O
6	taking	O
7	into	O
8	account	O
9	that	O
10	the	O
11	complications	O
12	had	O
13	reduced	O
14	to	O
15	a	O
16	very	O
17	low	O
18	rate	O
19	(	O
20	in	O
21	2	O
22	cases	O
23	lead	O
24	tip	O
25	displacement	O
26	and	O
27	pouch	O
28	haematoma	O
29	occurred	O
30	respectively	O
31	),	O
32	the	O
33	Authors	O
34	consider	O
35	the	O
36	adopted	O
37	method	O
38	an	O
39	useful	O
40	approach	O
41	for	O
42	PMK	O
43	implantation	O
44	particularly	O
45	when	O
46	the	O
47	use	O
48	of	O
49	the	O
50	vena	O
51	cephalica	O
52	is	O
53	deemed	O
54	impossible	O
55	.	O

1	The	O
2	pathophysiology	O
3	and	O
4	clinical	B
5	management	I
6	of	I
7	acute	I
8	brain	I
9	injury	I
10	in	I
11	infancy	I
12	and	O
13	childhood	O
14	are	O
15	presented	O
16	using	O
17	acute	O
18	traumatic	O
19	brain	O
20	injury	O
21	as	O
22	a	O
23	model	O
24	.	O

1	Re	O
2	-	O
3	evaluation	O
4	of	O
5	the	O
6	biopsy	O
7	specimen	O
8	from	O
9	the	O
10	right	B
11	hip	I
12	taken	O
13	at	O
14	the	O
15	time	O
16	of	O
17	the	B
18	initial	I
19	operation	O
20	showed	B
21	areas	B
22	of	O
23	chondrosarcoma	O
24	arising	O
25	in	O
26	the	O
27	background	O
28	of	O
29	synovial	O
30	chondromatosis	O
31	.	O

1	Focused	O
2	beams	O
3	of	O
4	classical	O
5	light	O
6	ablate	O
7	elements	O
8	of	O
9	the	O
10	cell	O
11	division	O
12	machinery	O
13	and	O
14	switch	O
15	the	O
16	beating	O
17	of	O
18	hearts	O
19	on	O
20	a	O
21	cellular	O
22	basis	O
23	.	O

1	Reperfusion	O
2	caused	O
3	a	O
4	transient	O
5	reduction	O
6	in	O
7	lactate	O
8	production	O
9	and	B
10	a	I
11	significant	I
12	increase	I
13	in	I
14	LDH	O
15	release	O
16	.	O

1	Expression	O
2	of	O
3	a	B
4	dominant	I
5	-	I
6	negative	I
7	ras	O
8	gene	O
9	also	O
10	blocks	O
11	TIS10	O
12	/	O
13	PGS2	O
14	induction	B
15	by	I
16	v	I
17	-	I
18	src	O
19	.	O

1	Regulatory	O
2	motifs	B
3	for	I
4	gene	I
5	expression	I
6	such	I
7	as	O
8	nuclear	O
9	-	O
10	factor	O
11	-	O
12	kappaB	O
13	-	O
14	binding	O
15	-	O
16	site	O
17	-	O
18	like	O
19	sequence	O
20	(	O
21	kappaB	O
22	site	O
23	)	O
24	and	O
25	nuclear	O
26	-	O
27	factor	O
28	-	O
29	interleukin	O
30	-	O
31	6	O
32	-	O
33	binding	O
34	-	O
35	site	O
36	-	O
37	like	O
38	sequence	O
39	(	O
40	NF	O
41	-	O
42	IL	O
43	-	O
44	6	O
45	site	O
46	)	O
47	were	O
48	found	O
49	in	O
50	the	B
51	5	I
52	'-	I
53	upstream	I
54	regulatory	O
55	region	O
56	.	O

1	IFN	O
2	-	O
3	gamma	O
4	was	O
5	elevated	O
6	during	O
7	active	O
8	TB	O
9	when	O
10	compared	O
11	with	O
12	healthy	O
13	controls	O
14	,	O
15	declining	O
16	during	O
17	and	O
18	after	O
19	treatment	O
20	.	O

1	The	O
2	results	O
3	support	B
4	earlier	I
5	reports	I
6	that	I
7	collagenase	I
8	inhibitors	I
9	are	I
10	useful	O
11	in	O
12	controlling	O
13	blister	O
14	formation	O
15	in	O
16	recessive	B
17	dystrophic	I
18	epidermolysis	I
19	bullosa	I
20	.	I

1	We	O
2	show	O
3	that	O
4	c	O
5	-	O
6	Fos	O
7	(	B
8	the	I
9	c	O
10	-	O
11	fos	O
12	protooncogene	O
13	product	O
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	O
20	nuclear	O
21	protein	O
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	O
41	.	O

1	Three	O
2	separate	O
3	activation	O
4	subdomains	O
5	,	O
6	and	O
7	one	O
8	negative	O
9	-	O
10	acting	O
11	region	O
12	,	O
13	which	O
14	function	O
15	in	O
16	yeast	O
17	were	O
18	located	O
19	in	O
20	the	O
21	carboxyl	O
22	-	O
23	terminal	O
24	region	O
25	of	O
26	NIT4	O
27	.	O

1	This	O
2	region	O
3	is	O
4	required	O
5	for	O
6	activation	O
7	of	O
8	DNA	O
9	binding	O
10	of	O
11	MyoD	O
12	and	O
13	E12	O
14	homodimers	O
15	and	O
16	E12	O
17	/	O
18	MyoD	O
19	heterodimers	O
20	.	O

1	In	O
2	patients	O
3	resistant	O
4	to	O
5	VAD	O
6	,	O
7	high	O
8	-	O
9	dose	O
10	therapies	O
11	with	O
12	intravenous	O
13	melphalan	O
14	,	O
15	a	O
16	CBV	O
17	combination	O
18	(	O
19	cyclophosphamide	O
20	-	O
21	BCNU	O
22	-	O
23	VP	O
24	-	O
25	16	O
26	)	O
27	or	O
28	an	O
29	EDAP	O
30	regimen	O
31	(	O
32	VP	O
33	-	O
34	16	O
35	-	O
36	platinum	O
37	)	O
38	produced	O
39	responses	O
40	in	O
41	about	O
42	40	O
43	%	O
44	of	O
45	patients	O
46	.	O

1	Comparison	O
2	of	O
3	three	O
4	different	O
5	preparations	O
6	of	O
7	disodium	O
8	cromoglycate	O
9	in	O
10	the	O
11	prevention	O
12	of	O
13	exercise	O
14	-	O
15	induced	O
16	bronchospasm	O
17	:	O
18	a	I
19	double	I
20	-	I
21	blind	O
22	study	O
23	.	O

1	At	O
2	different	O
3	times	B
4	of	I
5	the	I
6	surgical	I
7	procedures	I
8	(	I
9	thorax	O
10	opening	O
11	and	O
12	closure	O
13	,	O
14	period	O
15	of	O
16	cardiopulmonary	O
17	bypass	O
18	)	O
19	67	O
20	to	O
21	100	B
22	%	I
23	of	I
24	the	I
25	patients	I
26	in	O
27	group	O
28	1	O
29	had	O
30	vancomycin	O
31	concentrations	O
32	in	O
33	the	O
34	studied	O
35	tissues	O
36	above	O
37	the	O
38	MIC	O
39	90	B
40	for	O
41	Staphylococcus	I
42	aureus	I
43	(	O
44	1	I
45	microgram	O
46	/	O
47	g	O
48	)	O
49	and	O
50	Staphylococcus	O
51	epidermidis	B
52	(	B
53	2	I
54	micrograms	I
55	/	I
56	g	I
57	).	O

1	The	O
2	T	O
3	-	B
4	cyt	I
5	promoter	I
6	,	I
7	although	I
8	of	I
9	bacterial	O
10	origin	O
11	is	O
12	active	O
13	in	O
14	planta	O
15	and	O
16	the	O
17	30	O
18	bp	O
19	cyt	O
20	-	O
21	1	O
22	element	O
23	is	O
24	located	O
25	within	O
26	a	O
27	region	O
28	that	O
29	is	O
30	essential	O
31	for	O
32	T	O
33	-	B
34	cyt	I
35	promotor	I
36	activity	O
37	in	B
38	leaf	I
39	,	I
40	stem	O
41	and	O
42	root	O
43	cells	O
44	of	O
45	tobacco	O
46	plants	O
47	.	O

1	Regulators	O
2	of	O
3	G	O
4	protein	O
5	signaling	O
6	(	O
7	RGS	O
8	)	O
9	proteins	O
10	that	O
11	contain	O
12	DEP	O
13	(	O
14	disheveled	O
15	,	O
16	EGL	O
17	-	O
18	10	O
19	,	O
20	pleckstrin	O
21	)	O
22	and	O
23	GGL	O
24	(	O
25	G	O
26	protein	O
27	gamma	O
28	subunit	O
29	-	O
30	like	O
31	)	O
32	domains	O
33	form	O
34	a	O
35	subfamily	O
36	that	O
37	includes	O
38	the	O
39	mammalian	O
40	RGS	O
41	proteins	O
42	RGS6	O
43	,	O
44	RGS7	O
45	,	O
46	RGS9	O
47	,	O
48	and	O
49	RGS11	O
50	.	O

1	To	O
2	determine	O
3	whether	O
4	P35	O
5	could	O
6	activate	O
7	the	O
8	39k	O
9	promoter	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	IE1	O
15	,	O
16	the	O
17	p35	O
18	open	O
19	reading	O
20	frame	O
21	was	O
22	cloned	O
23	under	O
24	the	O
25	control	O
26	of	O
27	the	O
28	ie1	O
29	promoter	O
30	.	O

1	Responses	O
2	to	O
3	the	O
4	Plowright	O
5	Rinderpest	O
6	vaccine	O
7	by	O
8	43	O
9	calves	O
10	and	O
11	70	O
12	adult	O
13	cattle	O
14	in	O
15	Uganda	O
16	in	O
17	1990	O
18	,	O
19	through	O
20	the	O
21	production	O
22	of	O
23	IgG	O
24	antibodies	O
25	,	O
26	were	O
27	monitored	O
28	for	O
29	4	O
30	weeks	O
31	using	O
32	the	O
33	ELISA	O
34	assay	O
35	.	O

1	Age	O
2	and	O
3	sex	O
4	structure	O
5	of	O
6	the	O
7	natural	O
8	population	O
9	of	O
10	Ornithodoros	O
11	tatarovski	O
12	Ol	O
13	.	O

1	Most	O
2	smokers	O
3	would	O
4	prefer	O
5	to	O
6	quit	O
7	smoking	O
8	on	O
9	their	O
10	own	O
11	.	O

1	Supplementing	O
2	a	B
3	soybean	I
4	protein	I
5	and	O
6	sucrose	O
7	-	B
8	based	I
9	diet	I
10	with	I
11	levels	I
12	of	I
13	2	I
14	.	O
15	2	O
16	,	O
17	11	O
18	,	O
19	and	O
20	55	O
21	ppm	O
22	of	O
23	the	O
24	antibiotic	O
25	,	O
26	from	O
27	the	O
28	two	O
29	sources	O
30	each	O
31	with	O
32	two	O
33	different	O
34	purities	O
35	,	O
36	improved	O
37	weight	O
38	gain	O
39	of	O
40	chicks	O
41	an	O
42	average	O
43	of	O
44	23	O
45	%	O
46	and	O
47	improved	B
48	feed	O
49	efficiency	O
50	an	O
51	average	O
52	of	O
53	13	O
54	%	O
55	at	O
56	the	I
57	higher	O
58	levels	O
59	(	O
60	all	O
61	P	I
62	less	I
63	than	I
64	.	I
65	01	I
66	).	O

1	The	O
2	enhancer	O
3	region	O
4	of	O
5	Akv	O
6	murine	O
7	leukemia	O
8	virus	O
9	contains	O
10	the	O
11	sequence	O
12	motif	O
13	ACAGATGG	O
14	.	O

1	Ligand	O
2	-	O
3	independent	O
4	activation	O
5	of	O
6	platelet	O
7	-	O
8	derived	O
9	growth	O
10	factor	O
11	receptor	O
12	is	O
13	a	O
14	necessary	O
15	intermediate	O
16	in	O
17	lysophosphatidic	O
18	,	O
19	acid	O
20	-	O
21	stimulated	O
22	mitogenic	O
23	activity	O
24	in	O
25	L	O
26	cells	O
27	.	O

1	Four	O
2	full	O
3	-	O
4	thickness	O
5	skin	O
6	incisions	O
7	were	O
8	made	O
9	in	O
10	the	O
11	back	O
12	of	O
13	10	O
14	female	O
15	pigs	O
16	that	O
17	treated	O
18	twice	O
19	a	O
20	day	O
21	for	O
22	14	O
23	days	O
24	with	O
25	2	O
26	ml	O
27	of	O
28	epidermal	O
29	growth	O
30	factor	O
31	(	O
32	300	O
33	ng	O
34	/	O
35	ml	O
36	)	O
37	or	O
38	2	O
39	ml	O
40	of	O
41	Ringer	O
42	'	O
43	s	O
44	lactate	O
45	solution	O
46	in	O
47	a	O
48	single	O
49	-	O
50	blind	O
51	,	O
52	randomized	O
53	fashion	O
54	.	O

1	We	O
2	have	O
3	mutated	B
4	to	I
5	cysteine	I
6	,	I
7	one	I
8	at	I
9	a	O
10	time	O
11	,	O
12	21	O
13	consecutive	O
14	residues	B
15	in	I
16	the	I
17	fourth	I
18	TMS	I
19	(	I
20	TM4	I
21	).	O

1	Comparison	O
2	of	O
3	elastase	O
4	-	O
5	1	O
6	with	O
7	amylase	O
8	,	O
9	lipase	O
10	,	O
11	and	O
12	trypsin	O
13	-	O
14	like	O
15	immunoreactivity	O
16	in	O
17	the	O
18	diagnosis	O
19	of	O
20	acute	O
21	pancreatitis	O
22	.	O

1	Thus	O
2	adaptation	O
3	to	O
4	continuous	O
5	mild	O
6	stress	O
7	has	O
8	a	O
9	potent	O
10	antiarrhythmic	O
11	effect	O
12	which	O
13	occurs	O
14	due	O
15	to	O
16	the	O
17	increased	O
18	vagal	O
19	tone	O
20	.	O

1	Finally	O
2	,	O
3	the	O
4	recovery	O
5	indexes	O
6	represented	O
7	by	O
8	the	O
9	times	O
10	required	O
11	for	O
12	T1	O
13	/	O
14	T0	O
15	and	B
16	T4	I
17	/	I
18	T1	O
19	to	O
20	rise	O
21	from	O
22	25	O
23	%	O
24	to	O
25	75	B
26	%	B
27	respectively	I
28	were	I
29	studied	O
30	.	O

1	Potential	O
2	indicators	O
3	were	O
4	assessed	O
5	for	O
6	the	O
7	two	O
8	classifications	O
9	of	O
10	protein	O
11	-	O
12	energy	O
13	malnutrition	O
14	in	O
15	the	O
16	guidelines	O
17	for	O
18	integrated	O
19	management	O
20	of	O
21	childhood	O
22	illness	O
23	:	O
24	severe	O
25	malnutrition	O
26	,	O
27	which	O
28	requires	O
29	immediate	O
30	referral	O
31	to	O
32	hospital	O
33	,	O
34	and	O
35	very	O
36	low	O
37	weight	O
38	,	O
39	which	O
40	calls	O
41	for	O
42	feeding	O
43	assessment	O
44	,	O
45	nutritional	O
46	counselling	O
47	and	O
48	follow	O
49	-	O
50	up	O
51	.	O

1	Therefore	O
2	,	O
3	we	O
4	studied	O
5	ninety	O
6	coagulopathic	B
7	patients	I
8	with	I
9	the	I
10	aim	I
11	of	I
12	determining	I
13	the	I
14	prevalence	I
15	of	O
16	hepatitis	O
17	C	O
18	virus	O
19	(	O
20	HCV	O
21	)	O
22	antibodies	O
23	using	O
24	the	O
25	ELISA	O
26	and	O
27	RIBA	O
28	methods	O
29	.	O

1	Further	O
2	investigation	O
3	on	O
4	the	O
5	chemotactic	O
6	influence	O
7	of	O
8	thymic	O
9	hormone	O
10	on	O
11	lymphocytes	O

1	Increasing	O
2	the	O
3	cut	O
4	-	O
5	off	O
6	point	O
7	to	O
8	3	O
9	positive	O
10	responses	O
11	decreased	O
12	the	O
13	sensitivity	O
14	to	O
15	81	O
16	%	O
17	and	O
18	increased	O
19	the	O
20	specificity	O
21	to	O
22	94	O
23	%.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	Serotonin	O
2	receptors	O
3	in	B
4	suicide	I
5	victims	I
6	with	O
7	major	O
8	depression	O
9	.	O

1	In	O
2	wild	O
3	-	O
4	type	O
5	cells	O
6	,	O
7	SSM1b	O
8	transcripts	O
9	accumulate	O
10	to	O
11	twice	O
12	the	O
13	level	O
14	of	O
15	SSM1a	O
16	transcripts	O
17	,	O
18	suggesting	O
19	that	O
20	SSM1b	O
21	is	O
22	responsible	O
23	for	O
24	the	O
25	majority	O
26	of	O
27	the	O
28	Ssm1p	O
29	pool	O
30	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	B
23	plasmid	I
24	pGKL2	I
25	,	I
26	using	I
27	terminal	I
28	protein	O
29	(	O
30	TP	O
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O

1	Nevertheless	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	entire	O
8	three	O
9	-	O
10	component	O
11	yeast	O
12	capping	O
13	apparatus	O
14	,	O
15	consisting	O
16	of	O
17	RNA	O
18	5	O
19	'-	O
20	triphosphatase	O
21	(	O
22	Cet1p	O
23	),	O
24	RNA	O
25	guanylyltransferase	O
26	(	O
27	Ceg1p	O
28	),	O
29	and	O
30	Abd1p	O
31	could	O
32	be	O
33	replaced	O
34	in	O
35	vivo	O
36	by	O
37	the	O
38	two	O
39	-	O
40	component	O
41	mammalian	O
42	apparatus	O
43	consisting	O
44	of	O
45	a	O
46	bifunctional	O
47	triphosphatase	O
48	-	O
49	guanylyltransferase	O
50	Mce1p	O
51	and	O
52	the	O
53	methyltransferase	O
54	Hcm1	O
55	(	O
56	121	O
57	-	O
58	476	O
59	)	O
60	p	O
61	.	O

1	Dissipation	O
2	of	O
3	claudication	O
4	pain	O
5	after	O
6	walking	O
7	:	O
8	implications	O
9	for	O
10	endurance	O
11	training	O
12	.	O

1	Vitrectomy	O
2	in	O
3	ocular	O
4	traumatology	O

1	ATP	O
2	gamma	O
3	S	O
4	inhibition	O
5	can	O
6	be	O
7	overcome	O
8	by	O
9	high	O
10	concentrations	O
11	of	O
12	ATP	O
13	,	O
14	dATP	O
15	,	O
16	araATP	O
17	,	O
18	or	O
19	ddATP	O
20	.	O

1	Thus	O
2	,	B
3	the	I
4	positive	O
5	effect	O
6	of	O
7	NS1	O
8	on	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	levels	O
14	of	O
15	P4	O
16	transcripts	O
17	depends	O
18	on	O
19	the	O
20	amplification	O
21	of	O
22	gene	O
23	copy	B
24	number	I
25	and	I
26	the	O
27	integrity	O
28	of	O
29	the	O
30	terminal	O
31	repeats	O
32	.	O

1	Demographic	O
2	and	O
3	clinical	O
4	data	O
5	were	O
6	compared	O
7	with	O
8	a	O
9	control	O
10	group	O
11	of	O
12	339	O
13	healthy	O
14	age	O
15	-	O
16	matched	O
17	women	O
18	and	B
19	with	B
20	a	I
21	sample	O
22	of	O
23	224	O
24	women	O
25	with	O
26	wrist	O
27	fracture	O
28	.	O

1	Furthermore	O
2	,	O
3	expression	O
4	of	O
5	the	O
6	promoter	O
7	in	B
8	embryonic	I
9	Drosophila	I
10	melanogaster	I
11	cells	I
12	that	O
13	lack	O
14	MyoD1	O
15	and	O
16	Sp1	O
17	is	O
18	strictly	O
19	dependent	O
20	on	O
21	all	O
22	three	O
23	sites	O
24	remaining	O
25	intact	O
26	and	O
27	on	O
28	the	O
29	presence	O
30	of	O
31	exogenously	O
32	supplied	O
33	Sp1	O
34	and	O
35	MyoD1	O
36	.	O

1	The	O
2	hybridizing	O
3	clone	O
4	of	O
5	V	B
6	.	I
7	vulnificus	I
8	chromosomal	O
9	DNA	O
10	complemented	O
11	a	O
12	V	B
13	.	B
14	cholerae	I
15	fur	I
16	mutant	O
17	.	B

1	The	O
2	upstream	O
3	promoter	O
4	is	O
5	located	O
6	within	O
7	the	O
8	coding	O
9	sequence	O
10	of	O
11	a	O
12	divergent	O
13	gene	O
14	expressing	O
15	a	O
16	protein	O
17	of	O
18	Mr	O
19	39	O
20	kDa	O
21	of	O
22	unknown	O
23	function	O
24	.	O

1	Comparison	O
2	of	O
3	the	O
4	cDNA	O
5	-	O
6	predicted	O
7	avian	O
8	TnIcardiac	O
9	amino	O
10	acid	O
11	sequences	O
12	with	O
13	known	O
14	TnI	O
15	sequences	O
16	indicated	O
17	1	O
18	)	O
19	that	O
20	the	O
21	presence	O
22	of	O
23	an	O
24	N	O
25	-	O
26	terminal	O
27	extension	O
28	sequence	O
29	carrying	O
30	a	O
31	dual	O
32	protein	O
33	kinase	O
34	A	O
35	phosphorylation	O
36	target	O
37	site	O
38	and	O
39	an	O
40	adjacent	O
41	proline	O
42	-	O
43	rich	O
44	segment	O
45	is	O
46	an	O
47	ancient	O
48	cardiac	O
49	-	O
50	specific	O
51	feature	O
52	of	O
53	TnI	O
54	which	O
55	has	O
56	been	O
57	conserved	O
58	since	O
59	the	O
60	bird	O
61	/	O
62	mammal	O
63	divergence	O
64	,	O
65	2	O
66	)	O
67	that	O
68	features	O
69	of	O
70	the	O
71	near	O
72	-	O
73	N	O
74	-	O
75	terminal	O
76	troponin	O
77	C	O
78	(	O
79	TnC	O
80	)-	O
81	binding	O
82	site	O
83	sequence	O
84	suggest	O
85	isoform	O
86	-	O
87	specific	O
88	adaptation	O
89	of	O
90	TnI	O
91	and	O
92	TnC	O
93	,	O
94	and	O
95	3	O
96	)	O
97	that	O
98	the	O
99	avian	O
100	TnIcardiac	O
101	internal	O
102	actin	O
103	/	O
104	TnC	O
105	-	O
106	binding	O
107	,	O
108	actomyosin	O
109	-	O
110	inhibitory	O
111	,	O
112	domain	O
113	shows	O
114	significant	O
115	sequence	O
116	divergence	O
117	from	O
118	mammalian	O
119	TnIcardiac	O
120	sequences	O
121	,	O
122	including	O
123	the	O
124	absence	O
125	of	O
126	a	O
127	protein	O
128	kinase	O
129	C	O
130	target	O
131	site	O
132	which	O
133	is	O
134	a	O
135	cardiac	O
136	-	O
137	specific	O
138	feature	O
139	of	O
140	TnI	O
141	in	O
142	mammals	O
143	.	O

1	In	O
2	contrast	O
3	,	O
4	capsid	O
5	proteins	O
6	derived	O
7	from	O
8	the	B
9	P1	I
10	precursor	I
11	with	I
12	a	I
13	valine	I
14	substitution	O
15	at	O
16	the	B
17	amino	I
18	terminus	I
19	of	I
20	VP1	I
21	(	I
22	VP1	I
23	-	I
24	G001V	I
25	)	O
26	assembled	O
27	empty	O
28	capsid	O
29	particles	O
30	but	O
31	were	O
32	deficient	O
33	in	O
34	assembling	O
35	RNA	O
36	-	O
37	containing	O
38	virions	O
39	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	ORF	O
7	of	O
8	hAMPK	O
9	encodes	O
10	552	O
11	amino	O
12	acids	O
13	(	O
14	aa	O
15	)	O
16	(	O
17	62	O
18	.	O
19	250	O
20	kDa	O
21	)	O
22	and	O
23	is	O
24	highly	O
25	conserved	O
26	with	O
27	rAMPK	O
28	with	O
29	identities	O
30	of	O
31	97	O
32	.	O
33	3	O
34	and	O
35	90	O
36	%	O
37	at	O
38	the	O
39	aa	O
40	and	O
41	nt	O
42	levels	O
43	,	O
44	respectively	O
45	.	O

1	An	O
2	inactive	O
3	analog	O
4	of	O
5	wortmannin	O
6	,	O
7	WM12	O
8	,	O
9	did	O
10	not	O
11	affect	O
12	TCR	O
13	/	O
14	CD3	O
15	-	O
16	induced	O
17	Erk2	O
18	activation	O
19	,	O
20	and	O
21	wortmannin	O
22	had	O
23	no	O
24	effect	O
25	on	O
26	the	O
27	activity	O
28	of	O
29	Erk2	O
30	when	O
31	added	O
32	directly	O
33	to	O
34	the	O
35	in	O
36	vitro	O
37	assays	O
38	.	O

1	During	O
2	the	O
3	first	O
4	3	O
5	min	O
6	of	O
7	recovery	O
8	,	O
9	plasma	O
10	potassium	O
11	fell	O
12	rapidly	O
13	in	O
14	spite	O
15	of	O
16	nearly	O
17	unchanged	O
18	blood	O
19	acidosis	O
20	and	O
21	significantly	O
22	decreasing	O
23	bicarbonate	O
24	concentration	O
25	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	it	O
6	is	O
7	concluded	O
8	that	O
9	EDLF	O
10	has	O
11	clear	O
12	vasoconstrictor	O
13	properties	O
14	which	O
15	are	O
16	not	O
17	due	O
18	to	O
19	adrenergic	O
20	or	O
21	calcium	O
22	entry	O
23	mechanisms	O
24	and	O
25	that	O
26	there	O
27	are	O
28	differences	B
29	in	I
30	the	I
31	vasoconstrictor	I
32	effects	I
33	of	I
34	EDLFs	I
35	with	O
36	respect	B
37	to	I
38	different	I
39	vascular	O
40	beds	O
41	.	O

1	Current	O
2	status	O
3	of	O
4	telepathology	O
5	.	O

1	Mouse	O
2	Impact	O
3	is	O
4	a	O
5	paternally	O
6	expressed	O
7	gene	O
8	encoding	O
9	an	O
10	evolutionarily	O
11	conserved	O
12	protein	O
13	of	O
14	unknown	O
15	function	O
16	.	O

1	Treatment	O
2	of	O
3	Paget	O
4	'	O
5	s	O
6	disease	O
7	.	O

1	Insulin	O
2	-	O
3	stimulated	O
4	glucose	O
5	transport	O
6	in	O
7	adipocytes	O
8	is	O
9	mediated	O
10	by	O
11	the	O
12	insulin	O
13	receptor	O
14	.	O

1	Approximately	O
2	50	O
3	%	O
4	of	O
5	the	O
6	residues	O
7	are	O
8	conserved	O
9	among	O
10	all	O
11	three	O
12	sequences	O
13	,	O
14	yet	O
15	all	O
16	three	O
17	viruses	O
18	have	O
19	retained	O
20	response	O
21	elements	O
22	for	O
23	glucocorticoids	O
24	,	O
25	two	O
26	positionally	O
27	conserved	O
28	CCAAT	O
29	boxes	O
30	,	B
31	and	I
32	positionally	I
33	conserved	I
34	TATA	I
35	boxes	I
36	.	I

1	However	O
2	,	O
3	only	O
4	complete	O
5	DnaJ	O
6	can	O
7	cooperate	O
8	with	O
9	DnaK	O
10	and	O
11	a	O
12	third	O
13	protein	O
14	,	O
15	GrpE	O
16	,	O
17	in	O
18	refolding	O
19	denatured	O
20	firefly	O
21	luciferase	O
22	.	O

1	Organization	O
2	of	O
3	the	O
4	bovine	O
5	gene	O
6	encoding	O
7	the	O
8	endothelial	O
9	nitric	O
10	oxide	O
11	synthase	O
12	.	O

1	How	O
2	does	O
3	a	O
4	nurse	O
5	go	O
6	about	O
7	maintaining	O
8	her	O
9	level	O
10	of	O
11	competence	O
12	when	O
13	she	O
14	is	O
15	one	O
16	of	O
17	the	O
18	few	O
19	local	O
20	practitioners	O
21	in	O
22	her	O
23	field	O
24	?	O
25	Vancouver	O
26	sex	O
27	therapist	O
28	Bianca	O
29	Rucker	O
30	is	O
31	doing	O
32	it	O
33	by	O
34	cultivating	O
35	a	O
36	network	O
37	of	O
38	colleagues	O
39	and	O
40	mentors	O
41	in	O
42	related	O
43	fields	O
44	both	O
45	at	O
46	home	O
47	and	O
48	across	O
49	the	O
50	continent	O
51	.	O

1	We	O
2	have	B
3	cloned	I
4	and	I
5	sequenced	I
6	COX12	I
7	,	I
8	the	I
9	nuclear	I
10	gene	I
11	for	I
12	subunit	I
13	VIb	I
14	of	O
15	Saccharomyces	O
16	cerevisiae	O
17	cytochrome	O
18	c	O
19	oxidase	O
20	.	O

1	The	O
2	therapeutic	O
3	use	O
4	of	O
5	botulinum	O
6	toxin	O
7	(	O
8	Botox	O
9	)	O
10	is	O
11	increasing	O
12	in	O
13	popularity	O
14	.	O

1	Persistent	O
2	acantholytic	O
3	dermatosis	O
4	with	O
5	increased	O
6	light	O
7	sensitivity	O

1	L	O
2	.,	B
3	Greer	I
4	,	I
5	J	O
6	.	O
7	&	O
8	Carter	O
9	,	O
10	G	O
11	.	O

1	Sequence	O
2	comparisons	O
3	of	O
4	prokaryotic	O
5	RCR	O
6	initiators	B
7	has	I
8	revealed	I
9	a	I
10	set	I
11	of	I
12	three	I
13	common	I
14	motifs	I
15	,	I
16	two	I
17	of	I
18	which	I
19	,	I
20	a	I
21	putative	O
22	metal	O
23	coordination	O
24	site	B
25	and	I
26	a	I
27	downstream	I
28	active	B
29	-	I
30	site	I
31	tyrosine	I
32	motif	I
33	,	I
34	could	I
35	be	O
36	tentatively	O
37	identified	O
38	in	B
39	parvoviral	I
40	replicator	I
41	proteins	I
42	.	O

1	Four	O
2	short	O
3	nucleotide	B
4	sequences	I
5	(	I
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	B
13	the	B
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	O
19	chalcone	O
20	synthase	O
21	promoter	O
22	.	O

1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	attP	O
7	,	O
8	attB	O
9	and	O
10	bacteria	O
11	-	O
12	prophage	O
13	junctions	O
14	attL	O
15	and	O
16	attR	O
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	takes	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	integrase	O
38	gene	O
39	.	O

1	Clinical	O
2	value	B
3	of	I
4	the	I
5	estimation	I
6	of	I
7	growth	O
8	kinetics	O
9	of	O
10	primary	O
11	ovarian	O
12	cancer	O
13	recurrences	O
14	by	O
15	CA125	O
16	doubling	O
17	time	O

1	Alignment	O
2	of	O
3	the	O
4	selected	O
5	sequences	O
6	allowed	O
7	us	O
8	to	O
9	predict	O
10	a	O
11	consensus	O
12	sequence	O
13	for	O
14	binding	O
15	of	O
16	the	O
17	individual	O
18	homodimeric	O
19	Rel	O
20	-	O
21	related	O
22	proteins	O
23	,	O
24	and	O
25	DNA	O
26	-	O
27	protein	O
28	binding	O
29	analysis	O
30	of	O
31	the	O
32	selected	O
33	DNA	O
34	sequences	O
35	revealed	O
36	sequence	O
37	specificity	O
38	of	O
39	the	O
40	proteins	O
41	.	O

1	Restarting	O
2	time	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	magnesium	O
8	cardioplegia	O
9	.	O

1	(	O
2	1992	O
3	)	O
4	Genomics	O
5	12	O
6	,	O
7	58	O
8	-	O
9	62	O
10	).	O

1	There	O
2	was	O
3	a	O
4	significant	O
5	but	O
6	similar	B
7	elevation	O
8	of	I
9	mean	O
10	O2	O
11	uptake	O
12	during	O
13	40	O
14	min	O
15	postexercise	O
16	by	O
17	13	O
18	.	O
19	6	O
20	%	O
21	in	O
22	both	O
23	the	O
24	fasted	O
25	(	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	)	O
33	and	O
34	fed	O
35	state	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	Presentation	O
2	of	O
3	a	O
4	horse	O
5	cytochrome	O
6	c	O
7	peptide	O
8	by	O
9	multiple	O
10	H	O
11	-	O
12	2b	O
13	class	O
14	I	O
15	major	O
16	histocompatibility	O
17	complex	O
18	(	O
19	MHC	O
20	)	O
21	molecules	O
22	to	O
23	C57BL	O
24	/	O
25	6	O
26	-	O
27	and	O
28	bm1	O
29	-	O
30	derived	O
31	cytotoxic	O
32	T	O
33	lymphocytes	O
34	:	O
35	presence	O
36	of	O
37	a	O
38	single	O
39	MHC	O
40	anchor	O
41	residue	O
42	may	O
43	confer	O
44	efficient	O
45	peptide	O
46	-	O
47	specific	O
48	CTL	O
49	recognition	O
50	.	O

1	Furthermore	O
2	,	B
3	the	I
4	negative	O
5	transcriptional	B
6	effect	I
7	of	I
8	COUP	I
9	-	O
10	TFs	O
11	is	O
12	dominant	O
13	over	O
14	the	O
15	activating	O
16	effect	O
17	of	O
18	the	O
19	Oct4	O
20	embryonic	O
21	stem	O
22	cell	O
23	-	O
24	specific	O
25	enhancer	O
26	.	O

1	Snail	O
2	family	B
3	proteins	I
4	are	I
5	zinc	I
6	finger	I
7	transcriptional	I
8	regulators	I
9	first	I
10	identified	I
11	in	O
12	Drosophila	O
13	which	O
14	play	O
15	critical	O
16	roles	O
17	in	O
18	cell	O
19	fate	O
20	determination	O
21	.	O

1	Within	O
2	the	O
3	human	O
4	enhancer	O
5	,	O
6	these	O
7	two	O
8	sites	O
9	are	O
10	located	B
11	within	I
12	the	I
13	previously	I
14	defined	I
15	DNase	I
16	I	I
17	footprints	I
18	,	I
19	NFAT	I
20	-	I
21	1	I
22	and	O
23	NFIL	B
24	-	I
25	2B	I
26	,	I
27	respectively	I
28	.	I

1	High	O
2	levels	B
3	of	I
4	IC	I
5	coincided	O
6	with	O
7	relative	O
8	hypocomplementemia	O
9	.	O

1	A	O
2	Dictyostelium	O
3	transformant	O
4	overexpressing	O
5	DdPTPa	O
6	does	O
7	not	O
8	develop	O
9	normally	O
10	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	relationship	O
7	between	O
8	blood	B
9	flow	I
10	in	I
11	the	O
12	tumor	O
13	assessed	O
14	by	O
15	color	O
16	Doppler	O
17	ultrasound	O
18	,	O
19	microvessel	O
20	density	O
21	,	O
22	and	O
23	vascular	O
24	endothelial	O
25	growth	O
26	factor	O
27	levels	O
28	in	O
29	endometrial	O
30	carcinoma	O
31	.	O

1	Four	O
2	putative	O
3	positive	O
4	cDNA	O
5	clones	B
6	were	I
7	isolated	O
8	,	O
9	and	O
10	the	O
11	largest	O
12	insert	O
13	(	O
14	pASB	O
15	-	O
16	1	O
17	)	B
18	was	I
19	sequenced	I
20	in	O
21	both	O
22	orientations	B
23	.	I

1	The	O
2	prevalence	B
3	of	I
4	opportunistic	I
5	infection	I
6	among	I
7	surviving	I
8	AIDS	O
9	patients	O
10	and	O
11	the	O
12	probability	O
13	of	O
14	being	O
15	in	O
16	tumour	O
17	response	O
18	following	O
19	cancer	O
20	therapy	O
21	conditional	O
22	on	O
23	being	O
24	alive	O
25	are	O
26	two	O
27	examples	O
28	of	O
29	such	O
30	functions	O
31	.	B

1	Our	O
2	studies	O
3	extend	O
4	these	O
5	findings	O
6	and	O
7	show	O
8	that	B
9	the	O
10	E2	O
11	transactivation	B
12	gene	I
13	is	I
14	expressed	O
15	from	O
16	multiple	O
17	promoters	O
18	.	O

1	Truncated	O
2	ICSBP	B
3	lacking	B
4	the	I
5	first	I
6	33	I
7	amino	I
8	-	O
9	terminal	B
10	amino	I
11	acids	O
12	fails	O
13	to	O
14	bind	O
15	to	O
16	the	O
17	ICS	O
18	,	O
19	indicating	O
20	that	O
21	at	O
22	least	O
23	part	O
24	of	O
25	the	O
26	DNA	O
27	binding	O
28	domain	O
29	is	O
30	located	O
31	within	O
32	the	O
33	well	O
34	conserved	O
35	amino	O
36	terminus	O
37	.	O

1	These	O
2	regions	O
3	overlap	O
4	with	O
5	the	O
6	HIT	O
7	protein	O
8	similarity	O
9	regions	O
10	.	O

1	Eighty	O
2	patients	O
3	presenting	B
4	to	I
5	HGGM	I
6	with	I
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	lymphomas	O
13	between	O
14	1962	O
15	and	O
16	1986	O
17	,	O
18	were	O
19	reviewed	O
20	.	O

1	A	O
2	xylE	B
3	transcriptional	I
4	fusion	O
5	to	O
6	the	O
7	putative	I
8	mxbD	I
9	promoter	I
10	showed	I
11	low	O
12	-	B
13	level	I
14	expression	I
15	in	I
16	wild	I
17	-	I
18	type	I
19	cells	O
20	grown	O
21	on	O
22	one	O
23	-	B
24	carbon	I
25	(	I
26	C1	I
27	)	I
28	compounds	I
29	and	I
30	no	O
31	detectable	B
32	expression	I
33	in	O
34	cells	O
35	grown	B
36	on	I
37	succinate	I
38	.	I

1	We	O
2	have	O
3	determined	O
4	that	O
5	several	O
6	E1	O
7	mutants	O
8	mapping	O
9	in	O
10	both	I
11	the	I
12	M	I
13	and	I
14	R	I
15	regions	I
16	and	I
17	a	I
18	single	I
19	mutant	I
20	of	O
21	the	O
22	upstream	O
23	regulatory	O
24	region	O
25	have	O
26	a	O
27	higher	O
28	transforming	O
29	activity	O
30	on	O
31	mouse	O
32	C127	O
33	cells	O
34	than	O
35	the	O
36	wild	O
37	-	O
38	type	O
39	genome	O
40	does	O
41	.	O

1	Three	O
2	sequence	O
3	elements	O
4	are	B
5	shown	I
6	to	I
7	be	I
8	required	I
9	for	I
10	accurate	I
11	and	I
12	efficient	O
13	transcription	O
14	termination	O
15	by	O
16	RNA	O
17	polymerase	O
18	I	O
19	(	O
20	pol	O
21	I	O
22	)	O
23	assayed	B
24	both	O
25	in	I
26	a	O
27	cell	O
28	-	I
29	free	O
30	transcription	O
31	system	O
32	and	O
33	in	O
34	vivo	O
35	after	O
36	transfection	O
37	of	O
38	rDNA	B
39	minigene	I
40	constructs	B
41	into	I
42	3T6	I
43	cells	I
44	.	I

1	NH2	O
2	-	O
3	and	B
4	COOH	I
5	-	I
6	terminal	I
7	deletion	I
8	analysis	O
9	revealed	O
10	that	O
11	both	O
12	the	O
13	PH	O
14	and	O
15	putative	O
16	guanine	O
17	nucleotide	O
18	exchange	O
19	factor	O
20	domains	O
21	are	O
22	required	O
23	,	O
24	but	O
25	the	O
26	zinc	O
27	butterfly	O
28	is	B
29	dispensable	I
30	,	I
31	for	I
32	transformation	I
33	.	I

1	Results	O
2	for	O
3	men	O
4	who	O
5	drank	O
6	up	O
7	to	O
8	two	O
9	drinks	O
10	per	O
11	day	O
12	suggest	O
13	that	O
14	if	O
15	the	O
16	dependence	O
17	criteria	O
18	were	O
19	invalid	O
20	,	O
21	reductions	O
22	in	O
23	the	O
24	prevalence	O
25	of	O
26	specific	O
27	indicators	O
28	of	O
29	alcohol	O
30	dependence	O
31	would	O
32	range	O
33	from	O
34	0	O
35	.	O
36	3	O
37	%	O
38	to	O
39	5	O
40	.	O
41	2	O
42	%.	O

1	The	O
2	bcl	O
3	-	O
4	2	O
5	gene	O
6	can	O
7	potentially	O
8	encode	O
9	26	B
10	-	I
11	and	I
12	22	O
13	-	O
14	kDa	O
15	proteins	O
16	that	O
17	differ	O
18	only	O
19	in	O
20	their	O
21	carboxyl	O
22	tails	O
23	because	O
24	of	O
25	an	O
26	alternative	O
27	splicing	O
28	mechanism	O
29	.	O

1	Furthermore	O
2	,	O
3	the	O
4	insertion	O
5	of	O
6	the	O
7	ColE1	O
8	cer	O
9	site	O
10	into	O
11	the	O
12	RK2	O
13	plasmid	O
14	deleted	O
15	for	O
16	the	O
17	par	O
18	region	O
19	failed	O
20	to	O
21	stabilize	O
22	the	O
23	plasmid	O
24	in	O
25	the	O
26	MC1061K	O
27	strain	O
28	,	O
29	indicating	O
30	that	O
31	the	O
32	multimer	O
33	resolution	O
34	activity	O
35	encoded	O
36	by	O
37	parCBA	O
38	is	O
39	not	O
40	by	O
41	itself	O
42	responsible	O
43	for	O
44	the	O
45	stabilization	O
46	activity	O
47	observed	O
48	for	O
49	this	O
50	operon	O
51	.	O

1	Further	O
2	,	O
3	they	O
4	are	O
5	consistent	O
6	with	B
7	the	I
8	suggestion	I
9	that	I
10	sites	I
11	homologous	I
12	to	I
13	the	I
14	CAR1	I
15	URS	I
16	may	I
17	be	I
18	situated	I
19	in	I
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	regions	O
25	of	O
26	multiple	O
27	unrelated	O
28	yeast	O
29	genes	B
30	.	I

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	and	O
6	DNase	O
7	I	O
8	footprinting	O
9	experiments	O
10	using	O
11	purified	O
12	42	O
13	kDa	O
14	repressor	O
15	isoform	O
16	confirmed	O
17	that	O
18	CIRs	O
19	5	O
20	and	O
21	6	O
22	were	O
23	indeed	O
24	the	O
25	targets	O
26	for	O
27	binding	O
28	of	O
29	this	O
30	protein	O
31	.	O

1	Two	O
2	overlapping	B
3	clones	I
4	contained	O
5	the	O
6	complete	O
7	Adh	O
8	-	O
9	2	O
10	gene	O
11	composed	B
12	of	I
13	nine	I
14	exons	O
15	in	B
16	a	O
17	12	O
18	-	O
19	kb	O
20	region	O
21	,	O
22	with	O
23	the	O
24	placement	O
25	of	O
26	introns	O
27	matching	O
28	that	O
29	observed	O
30	in	O
31	other	O
32	mammalian	I
33	ADH	O
34	genes	O
35	.	O

1	The	O
2	Y	O
3	-	O
4	type	O
5	structural	B
6	motif	I
7	is	I
8	also	I
9	conserved	I
10	among	O
11	a	O
12	number	O
13	of	O
14	divergent	O
15	BiP	O
16	mRNAs	O
17	.	O

1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	GAG	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	hyperheparinuria	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	O
6	inhibits	O
7	tyrosine	O
8	phosphatases	O
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	O
16	.	O

1	The	O
2	case	O
3	described	O
4	is	O
5	that	O
6	of	O
7	a	O
8	72	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	with	O
15	ochronosis	O
16	who	O
17	suffered	O
18	a	O
19	hyperextension	O
20	injury	O
21	to	O
22	his	O
23	spine	O
24	in	O
25	a	O
26	fall	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	fracture	O
32	through	O
33	an	O
34	ankylosed	O
35	L2	O
36	-	O
37	L3	O
38	disk	O
39	space	O
40	.	O

1	Extramedullary	O
2	relapse	O
3	in	O
4	childhood	O
5	leukemia	O
6	.	O

1	The	O
2	model	O
3	captures	O
4	the	O
5	essence	O
6	of	O
7	predator	O
8	-	O
9	prey	O
10	dynamics	O
11	to	O
12	provide	O
13	reasonable	B
14	predictions	I
15	of	I
16	population	I
17	patterns	O
18	.	O

1	To	O
2	establish	O
3	a	B
4	possible	I
5	association	I
6	between	I
7	familial	O
8	dysfibrinogenemia	O
9	and	O
10	thrombophilia	O
11	,	O
12	data	O
13	on	O
14	cases	O
15	with	O
16	both	O
17	affections	O
18	were	O
19	collected	O
20	in	O
21	a	O
22	study	O
23	within	B
24	the	B
25	framework	I
26	of	I
27	the	I
28	SSC	I
29	Subcommittee	I
30	on	I
31	Fibrinogen	O
32	of	B
33	the	I
34	International	I
35	Society	I
36	on	I
37	Thrombosis	O
38	and	O
39	Haemostasis	O
40	.	O

1	Marked	O
2	sedative	O
3	activity	O
4	was	O
5	observed	O
6	with	O
7	9	O
8	-	O
9	methoxy	O
10	-	O
11	5	O
12	-	O
13	phenylpyrrolo	O
14	[	O
15	2	O
16	,	O
17	1	O
18	-	O
19	d	O
20	][	O
21	1	O
22	,	O
23	5	O
24	]	O
25	benzothiazepin	O
26	-	O
27	6	O
28	,	O
29	6	O
30	-	O
31	dioxide	O
32	(	O
33	NF19	O
34	)	O
35	and	O
36	9	O
37	-	O
38	chloro	O
39	-	O
40	5	O
41	-	O
42	p	O
43	-	O
44	nitrophenylpyrrolo	O
45	[	O
46	2	O
47	,	O
48	1	O
49	-	O
50	d	O
51	][	O
52	1	O
53	,	O
54	5	O
55	]	O
56	benzothiazepin	O
57	-	O
58	6	O
59	,	O
60	6	O
61	-	O
62	dioxide	O
63	(	O
64	NF20	O
65	).	O

1	Binding	O
2	affinities	O
3	of	O
4	different	O
5	nucleotide	O
6	mono	O
7	-,	O
8	di	O
9	-	O
10	and	O
11	triphosphates	O
12	and	O
13	non	O
14	-	O
15	hydrolyzable	O
16	analogs	O
17	indicate	O
18	that	O
19	the	O
20	beta	O
21	-	O
22	phosphate	O
23	moiety	O
24	is	O
25	required	O
26	for	O
27	substrate	O
28	binding	O
29	.	O

1	A	O
2	contiguous	O
3	and	O
4	sequentially	O
5	occupied	O
6	secondary	O
7	Fur	O
8	-	B
9	binding	I
10	site	I
11	in	I
12	entC	I
13	was	I
14	protected	I
15	at	I
16	higher	I
17	Fur	I
18	concentrations	I
19	,	I
20	extending	I
21	the	I
22	protected	I
23	region	I
24	to	O
25	+	O
26	49	O
27	,	O
28	and	O
29	sequestering	O
30	the	O
31	putative	O
32	Shine	O
33	-	O
34	Dalgarno	O
35	sequence	O
36	.	O

1	Initiation	O
2	of	B
3	translation	I
4	of	I
5	the	I
6	human	I
7	hepatitis	I
8	C	O
9	virus	O
10	(	B
11	HCV	I
12	)	I
13	RNA	O
14	genome	O
15	occurs	O
16	by	O
17	internal	O
18	ribosome	O
19	entry	B
20	into	I
21	the	I
22	5	I
23	'	I
24	noncoding	I
25	region	I
26	(	I
27	5	I
28	'	I
29	NCR	I
30	)	I
31	in	O
32	a	B
33	cap	I
34	-	I
35	independent	I
36	manner	I
37	.	O

1	This	O
2	technique	B
3	was	I
4	employed	I
5	in	I
6	12	I
7	patients	I
8	with	I
9	a	I
10	unicameral	I
11	bone	O
12	cyst	O
13	.	B

1	ORFA	O
2	and	O
3	ccdA	O
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	To	O
2	lower	O
3	the	O
4	current	O
5	high	O
6	incidence	O
7	of	O
8	NANB	O
9	-	O
10	induced	O
11	PTH	O
12	,	O
13	in	O
14	1986	O
15	,	O
16	the	O
17	American	O
18	Association	O
19	of	O
20	Blood	O
21	Banks	O
22	(	O
23	AABB	O
24	)	O
25	recommended	O
26	testing	O
27	for	O
28	these	O
29	PTH	O
30	-	O
31	associated	O
32	"	O
33	surrogate	O
34	"	O
35	markers	O
36	on	O
37	all	O
38	donated	O
39	units	O
40	of	O
41	blood	O
42	.	O

1	Pregnant	O
2	rats	O
3	were	O
4	exposed	O
5	to	O
6	one	O
7	of	O
8	the	O
9	following	O
10	:	O
11	(	O
12	1	O
13	)	O
14	10	O
15	%	O
16	O2	O
17	in	O
18	N2	O
19	or	O
20	100	O
21	%	O
22	O2	O
23	for	O
24	2	O
25	days	O
26	beginning	O
27	at	O
28	day	O
29	7	O
30	,	O
31	11	O
32	,	O
33	14	O
34	,	O
35	or	O
36	18	O
37	of	O
38	pregnancy	O
39	;	O
40	(	O
41	2	O
42	)	O
43	10	O
44	%	O
45	O2	O
46	in	O
47	N2	O
48	or	O
49	100	O
50	%	O
51	O2	O
52	for	O
53	10	O
54	h	O
55	/	O
56	day	O
57	beginning	O
58	at	O
59	day	O
60	7	O
61	;	O
62	or	O
63	(	O
64	3	O
65	)	O
66	14	O
67	-	O
68	11	O
69	%	O
70	O2	O
71	in	O
72	N2	O
73	continuously	O
74	beginning	O
75	at	O
76	day	O
77	14	O
78	till	O
79	day	O
80	21	O
81	when	O
82	they	O
83	were	O
84	sacrificed	O
85	.	O

1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	bacterially	O
6	produced	O
7	beta	O
8	gal	O
9	-	O
10	trk	O
11	receptor	O
12	kinase	O
13	fusion	O
14	protein	O
15	recognized	O
16	a	O
17	44	O
18	kd	O
19	phosphoprotein	O
20	phosphorylated	O
21	on	O
22	serine	O
23	,	O
24	threonine	O
25	and	O
26	tyrosine	O
27	in	O
28	extracts	O
29	of	O
30	trk	O
31	-	O
32	2h	O
33	transformed	O
34	NIH3T3	O
35	cells	O
36	.	O

1	There	O
2	was	O
3	however	O
4	,	O
5	no	O
6	significant	O
7	difference	O
8	in	O
9	the	O
10	prevalence	O
11	of	O
12	chronic	O
13	respiratory	O
14	symptoms	O
15	between	O
16	animal	O
17	food	O
18	workers	O
19	with	O
20	positive	O
21	and	O
22	negative	O
23	skin	O
24	tests	O
25	to	O
26	house	O
27	dust	O
28	or	O
29	to	O
30	fish	O
31	flour	O
32	or	O
33	among	O
34	those	O
35	with	O
36	increased	O
37	or	O
38	normal	O
39	IgE	O
40	(	O
41	except	O
42	for	O
43	dyspnea	O
44	).	O

1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	B
8	solution	I
9	excluded	I
10	trypan	I
11	blue	I
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	B
27	less	I
28	than	I
29	0	O
30	.	O
31	001	O
32	.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	pecT	O
5	regulatory	O
6	region	O
7	revealed	O
8	the	O
9	presence	O
10	of	O
11	two	O
12	sites	O
13	in	O
14	which	O
15	insertions	O
16	reproduced	B
17	the	I
18	pec	I
19	-	O
20	1	O
21	phenotype	O
22	.	O

1	Isopenicillin	O
2	N	O
3	isomerase	O
4	(	O
5	epimerase	O
6	)	O
7	has	O
8	been	B
9	purified	I
10	from	I
11	Streptomyces	I
12	clavuligerus	I
13	,	I
14	and	I
15	the	I
16	amino	O
17	acid	O
18	sequence	O
19	of	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	has	O
25	been	B
26	determined	B
27	.	B

1	Inclusion	O
2	in	O
3	this	O
4	family	O
5	of	O
6	proteins	O
7	suggests	O
8	that	O
9	FliQ	B
10	and	I
11	FliR	I
12	may	I
13	participate	O
14	in	O
15	an	O
16	export	O
17	pathway	O
18	required	O
19	for	O
20	flagellum	O
21	assembly	O
22	.	O

1	Proposals	O
2	on	O
3	authorization	O
4	;	O
5	by	B
6	a	I
7	group	I
8	of	I
9	nurses	O
10	from	O
11	psychiatric	O
12	hospitals	O

1	According	O
2	to	O
3	the	I
4	results	I
5	of	I
6	assays	I
7	obtained	I
8	with	I
9	the	I
10	use	I
11	of	I
12	assay	I
13	systems	I
14	ORTHO	O
15	ELISA	O
16	and	O
17	ABBOTT	O
18	HCV	O
19	EIA	O
20	(	O
21	USA	O
22	),	O
23	the	O
24	detection	O
25	rate	O
26	of	O
27	anti	O
28	-	O
29	HCV	O
30	-	O
31	C100	O
32	-	O
33	3	O
34	among	O
35	primary	O
36	blood	O
37	donors	O
38	in	O
39	Moscow	O
40	was	O
41	1	O
42	.	O
43	37	O
44	%	O
45	and	O
46	was	O
47	not	O
48	different	O
49	from	O
50	that	O
51	among	O
52	HBsAg	O
53	carriers	B
54	(	O
55	1	O
56	.	O
57	8	I
58	%)	I
59	and	I
60	among	O
61	donors	I
62	with	I
63	anti	I
64	-	I
65	HCV	I
66	-	I
67	C100	O
68	-	O
69	3	O
70	in	O
71	the	O
72	blood	O
73	(	I
74	1	I
75	.	O
76	6	I
77	%)	O
78	(	I
79	p	I
80	<	I
81	0	I
82	.	I
83	01	O
84	).	O

1	Studies	O
2	on	O
3	the	B
4	organic	I
5	matrix	I
6	of	I
7	human	I
8	ear	O
9	ossicles	B

1	Because	O
2	of	O
3	the	O
4	potential	O
5	implications	O
6	of	O
7	these	O
8	findings	O
9	in	O
10	human	O
11	physiology	O
12	,	O
13	we	O
14	cloned	O
15	the	O
16	hPACAP	O
17	-	O
18	R	O
19	gene	O
20	.	O

1	These	O
2	observed	O
3	drug	O
4	interactions	O
5	,	O
6	plus	O
7	the	O
8	known	O
9	effect	O
10	of	O
11	probenecid	O
12	to	O
13	block	O
14	secretion	O
15	of	O
16	PZA	O
17	,	O
18	have	O
19	to	O
20	be	O
21	considered	O
22	in	O
23	evaluating	O
24	the	O
25	effect	O
26	of	O
27	the	O
28	two	O
29	drugs	O
30	given	O
31	together	O
32	,	O
33	compared	O
34	to	O
35	the	O
36	effect	O
37	of	O
38	each	O
39	drug	O
40	given	O
41	separately	O
42	.	O

1	E2F	O
2	is	O
3	a	O
4	heterodimeric	O
5	complex	O
6	consisting	O
7	of	O
8	E2F	O
9	family	O
10	members	O
11	(	O
12	1	B
13	-	I
14	5	I
15	)	I
16	and	I
17	DP	I
18	proteins	I
19	(	I
20	1	O
21	-	O
22	3	O
23	).	O

1	The	O
2	monkey	O
3	LHR	O
4	cDNA	O
5	displayed	O
6	83	O
7	-	O
8	94	O
9	%	O
10	overall	O
11	sequence	O
12	homology	O
13	with	O
14	the	O
15	other	O
16	mammalian	O
17	LHR	O
18	cDNAs	O
19	.	O

1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	PILOT	O
10	gene	O
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	B
18	)	I
19	and	I
20	is	O
21	not	O
22	affected	O
23	by	O
24	CyA	O
25	.	O

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	tmy	O
8	-	O
9	1	O
10	gene	B
11	was	I
12	determined	I
13	by	I
14	microinjection	I
15	of	I
16	a	I
17	promoter	O
18	/	O
19	lacZ	O
20	fusion	O
21	gene	O
22	and	B
23	with	I
24	immunohistochemistry	I
25	by	I
26	using	I
27	affinity	I
28	-	I
29	purified	I
30	tissue	I
31	-	I
32	specific	I
33	anti	I
34	-	I
35	tropomyosins	I
36	.	I

1	In	O
2	serum	O
3	-	O
4	stimulated	O
5	cells	O
6	,	O
7	the	O
8	binding	O
9	of	O
10	NF	O
11	-	O
12	Y	O
13	/	O
14	CBF	O
15	to	O
16	TKC1	O
17	increased	O
18	gradually	O
19	,	O
20	reaching	O
21	a	O
22	plateau	O
23	at	O
24	the	O
25	S	O
26	phase	O
27	.	O

1	Transcripts	O
2	for	O
3	both	O
4	ODV	O
5	-	O
6	E18	O
7	and	O
8	ODV	O
9	-	O
10	EC27	O
11	initiate	O
12	from	O
13	conserved	O
14	TAAG	O
15	motifs	O
16	,	O
17	and	O
18	transcripts	O
19	are	O
20	detected	O
21	from	O
22	16	O
23	through	O
24	72	O
25	hr	O
26	p	O
27	.	O
28	i	O
29	.	O

1	The	O
2	associations	O
3	between	B
4	sex	I
5	-	O
6	hormone	O
7	-	B
8	binding	I
9	globulin	O
10	capacity	O
11	(	O
12	SHBG	O
13	),	O
14	age	O
15	,	O
16	body	O
17	mass	O
18	index	O
19	(	O
20	BMI	O
21	),	O
22	and	O
23	physical	O
24	fitness	O
25	have	O
26	been	O
27	studied	O
28	in	O
29	34	O
30	men	O
31	and	O
32	36	O
33	women	O
34	.	O

1	Gastrointestinal	O
2	manifestations	O
3	of	O
4	systemic	O
5	sclerosis	O

1	It	O
2	is	O
3	the	O
4	oxidation	O
5	peak	O
6	of	O
7	this	B
8	product	I
9	,	I
10	arising	I
11	in	I
12	acidic	I
13	media	I
14	at	I
15	0	O
16	.	O
17	42	O
18	V	O
19	,	O
20	which	O
21	was	O
22	analysed	O
23	using	O
24	DPV	O
25	,	O
26	again	O
27	following	O
28	the	O
29	accumulation	O
30	of	O
31	clenbuterol	O
32	at	O
33	the	O
34	Nafion	O
35	-	O
36	modified	O
37	CPE	O
38	.	O

1	The	O
2	promoter	O
3	region	O
4	showed	O
5	no	O
6	consensus	O
7	TATA	O
8	box	O
9	but	O
10	it	O
11	contains	O
12	CCAAT	O
13	and	O
14	CreA	O
15	boxes	O
16	known	O
17	to	O
18	be	O
19	involved	O
20	in	O
21	both	O
22	stress	O
23	and	O
24	carbon	O
25	-	O
26	catabolite	O
27	regulation	O
28	of	O
29	fungal	O
30	promoters	O
31	.	O

1	The	O
2	financial	O
3	impact	O
4	of	O
5	childhood	O
6	asthma	O
7	has	O
8	not	B
9	been	I
10	assessed	I
11	since	I
12	Vance	O
13	and	B
14	Taylor	I
15	reported	O
16	their	B
17	data	I
18	in	I
19	Annals	O
20	of	O
21	Allergy	O
22	13	O
23	years	O
24	ago	O
25	.	O

1	In	O
2	DNase	O
3	I	O
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	O
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	O
17	S	O
18	-	O
19	transferase	O
20	-	O
21	ERRalpha1	O
22	fusion	O
23	protein	O
24	.	O

1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O

1	We	O
2	have	O
3	tested	O
4	the	O
5	function	B
6	of	I
7	two	I
8	potential	I
9	NF	I
10	-	I
11	kappaB	I
12	-	O
13	like	O
14	sites	O
15	present	B
16	in	I
17	the	O
18	PAI	O
19	-	O
20	2	O
21	proximal	O
22	promoter	O
23	for	B
24	responsiveness	I
25	to	I
26	TNFalpha	I
27	using	I
28	chloramphenicol	I
29	acetyl	I
30	transferase	O
31	reporter	O
32	gene	O
33	deletion	O
34	and	O
35	mutation	O
36	analyses	O
37	.	O

1	Early	O
2	cirrhosis	O
3	,	O
4	an	O
5	early	O
6	modality	B
7	of	I
8	the	I
9	evolution	I
10	of	O
11	acute	O
12	hepatitis	O
13	.	O

1	Helicobacter	O
2	pylori	O
3	and	O
4	stomach	O
5	diseases	O
6	:	O
7	from	O
8	clinical	O
9	point	O
10	of	O
11	view	O

1	The	O
2	active	B
3	open	I
4	reading	O
5	frame	O
6	in	O
7	the	O
8	clone	O
9	maps	O
10	at	O
11	27	O
12	min	O
13	on	O
14	the	O
15	E	O
16	.	O
17	coli	O
18	chromosome	O
19	and	B
20	is	I
21	identical	I
22	in	O
23	sequence	O
24	to	O
25	a	O
26	wild	O
27	type	B
28	counterpart	I
29	.	O

1	Evolutionary	O
2	conservation	O
3	of	O
4	homeodomain	O
5	-	O
6	binding	O
7	sites	O
8	and	O
9	other	O
10	sequences	O
11	upstream	O
12	and	O
13	within	O
14	the	O
15	major	O
16	transcription	O
17	unit	O
18	of	O
19	the	O
20	Drosophila	O
21	segmentation	O
22	gene	O
23	engrailed	O
24	.	O

1	Furthermore	O
2	,	O
3	rhoA	B
4	-	I
5	mediated	I
6	SRE	I
7	activation	O
8	was	B
9	blocked	I
10	by	O
11	dominant	O
12	negative	O
13	mutants	O
14	of	O
15	PKC	O
16	-	O
17	alpha	O
18	or	O
19	PKC	O
20	-	O
21	epsilon	O
22	.	O

1	Tonsillectomy	O
2	is	O
3	an	O
4	effective	O
5	means	B
6	of	I
7	prophylaxis	I
8	for	O
9	upper	B
10	respiratory	I
11	infection	O
12	in	O
13	habitual	B
14	angina	I
15	patients	I
16	.	O

1	LH	O
2	/	O
3	CG	O
4	receptor	O
5	activation	O
6	of	O
7	ARNO	O
8	is	O
9	not	O
10	mediated	O
11	by	O
12	activation	O
13	of	O
14	phosphatidylinositol	O
15	3	O
16	-	O
17	kinase	O
18	(	O
19	PI	O
20	3	O
21	-	O
22	kinase	O
23	)	O
24	or	O
25	by	O
26	G	O
27	protein	O
28	beta	O
29	gamma	O
30	subunits	O
31	.	O

1	The	O
2	nucleosomal	O
3	response	O
4	associated	O
5	with	O
6	immediate	B
7	-	I
8	early	O
9	gene	O
10	induction	O
11	is	B
12	mediated	B
13	via	I
14	alternative	O
15	MAP	O
16	kinase	O
17	cascades	O
18	:	O
19	MSK1	O
20	as	O
21	a	O
22	potential	O
23	histone	O
24	H3	O
25	/	O
26	HMG	O
27	-	O
28	14	O
29	kinase	O
30	.	O

1	The	O
2	PDE4A	O
3	-	O
4	subfamily	O
5	-	O
6	specific	O
7	linker	O
8	region	O
9	LR1	O
10	,	O
11	which	O
12	joins	O
13	UCR1	O
14	and	O
15	UCR2	O
16	,	O
17	is	O
18	encoded	O
19	by	O
20	two	O
21	exons	O
22	,	O
23	whereas	O
24	LR2	O
25	,	O
26	which	O
27	joins	O
28	UCR2	O
29	to	O
30	the	O
31	catalytic	O
32	unit	O
33	,	O
34	is	O
35	encoded	O
36	by	O
37	a	O
38	single	O
39	exon	O
40	.	O

1	L	O
2	-	O
3	735	O
4	,	O
5	524	B
6	free	I
7	base	I
8	or	O
9	sulfate	B
10	salt	I
11	was	I
12	administered	O
13	orally	O
14	as	O
15	suspension	O
16	,	O
17	solution	O
18	or	B
19	in	I
20	solid	I
21	dosage	O
22	forms	B
23	to	I
24	fasted	I
25	or	I
26	fed	I
27	Beagle	I
28	dogs	O
29	.	B

1	Functional	O
2	characterization	O
3	of	O
4	a	O
5	fraction	O
6	identified	O
7	by	O
8	its	O
9	activity	O
10	in	O
11	a	O
12	second	O
13	template	O
14	rescue	O
15	assay	B
16	.	I

1	Combination	O
2	of	O
3	a	O
4	Shwachman	O
5	syndrome	O
6	and	O
7	a	O
8	complex	O
9	granulocyte	O
10	function	O
11	disorder	O
12	in	O
13	a	O
14	girl	O

1	During	O
2	skeletal	O
3	muscle	O
4	development	O
5	,	O
6	different	O
7	types	O
8	of	O
9	muscle	O
10	fibers	B
11	are	I
12	generated	O
13	,	B
14	which	O
15	express	O
16	different	O
17	combinations	O
18	of	O
19	muscle	O
20	-	O
21	specific	O
22	gene	O
23	products	O
24	.	O

1	Chemical	O
2	histologic	O
3	and	O
4	immunologic	O
5	responses	O
6	in	O
7	rats	O
8	to	O
9	CC1	O
10	-	O
11	4	O
12	by	O
13	different	O
14	routes	O
15	of	O
16	administration	O
17	.	O

1	The	O
2	gene	O
3	contains	O
4	six	O
5	exons	O
6	separated	O
7	by	O
8	1	O
9	.	O
10	1	O
11	-	O
12	5	O
13	.	O
14	8	O
15	kb	O
16	introns	O
17	and	O
18	has	O
19	been	O
20	localized	O
21	to	O
22	the	O
23	murine	O
24	chromosome	O
25	2	O
26	by	O
27	linkage	O
28	analysis	O
29	.	O

1	Unlike	O
2	ARF	O
3	,	O
4	the	O
5	ARP	O
6	immunoreactivity	O
7	was	O
8	detected	O
9	in	O
10	plasma	O
11	membranes	O
12	but	O
13	not	O
14	in	O
15	cytosol	O
16	of	O
17	fractionated	O
18	3T3	O
19	-	O
20	L1	O
21	cells	O
22	.	O

1	Such	O
2	an	O
3	interaction	O
4	could	O
5	be	O
6	detected	O
7	using	O
8	a	O
9	GST	O
10	-	O
11	POU	O
12	fusion	O
13	protein	O
14	bound	O
15	to	O
16	glutathione	O
17	-	O
18	agarose	O
19	beads	O
20	.	O

1	Malonate	O
2	decarboxylation	O
3	in	O
4	Malonomonas	O
5	rubra	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	malonyl	O
11	-	O
12	S	O
13	-[	O
14	acyl	O
15	-	O
16	carrier	O
17	protein	O
18	]	O
19	from	O
20	acetyl	O
21	-	O
22	S	O
23	-[	O
24	acyl	O
25	-	O
26	carrier	O
27	protein	O
28	]	O
29	and	O
30	malonate	O
31	,	O
32	carboxyltransfer	O
33	to	O
34	a	O
35	biotin	O
36	protein	O
37	and	O
38	its	O
39	decarboxylation	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	O
45	mu	O
46	Na	O
47	+	O
48	generation	O
49	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	opiate	O
6	receptors	B
7	bordering	I
8	the	I
9	fourth	O
10	cerebral	O
11	ventricle	O
12	mediate	O
13	the	O
14	cardiovascular	O
15	and	O
16	hypnotic	O
17	action	B
18	of	I
19	fentanyl	I
20	.	O

1	These	O
2	results	O
3	are	O
4	very	O
5	useful	O
6	for	O
7	deciding	O
8	on	O
9	the	O
10	doses	O
11	of	O
12	hormones	O
13	and	O
14	the	O
15	expected	O
16	serum	O
17	estradiol	O
18	level	O
19	in	O
20	HRT	O
21	for	O
22	Japanese	O
23	women	B
24	.	I

1	Is	O
2	radical	O
3	trachelectomy	O
4	a	O
5	safe	O
6	alternative	O
7	to	O
8	radical	O
9	hysterectomy	O
10	for	O
11	patients	O
12	with	O
13	stage	O
14	IA	O
15	-	O
16	B	O
17	carcinoma	B
18	of	I
19	the	I
20	cervix	I
21	?	I
22	BACKGROUND	I
23	:	I
24	The	I
25	prognosis	I
26	associated	O
27	with	O
28	lymph	O
29	node	O
30	negative	O
31	,	O
32	early	B
33	stage	I
34	carcinoma	I
35	of	I
36	the	I
37	cervix	I
38	is	O
39	excellent	O
40	,	O
41	with	O
42	5	O
43	-	O
44	year	O
45	survival	O
46	rates	O
47	greater	O
48	than	O
49	90	O
50	%.	O

1	We	O
2	have	O
3	therefore	O
4	studied	O
5	the	O
6	molecular	O
7	mechanisms	O
8	of	O
9	TGF	O
10	-	O
11	beta1	O
12	action	O
13	on	O
14	thyroglobulin	O
15	(	O
16	TG	O
17	)	O
18	gene	O
19	expression	O
20	by	O
21	focusing	O
22	our	O
23	attention	O
24	on	O
25	TGF	O
26	-	O
27	beta1	O
28	regulation	O
29	of	O
30	thyroid	O
31	-	O
32	specific	O
33	transcription	O
34	factors	O
35	.	O

1	GRP78	O
2	,	O
3	a	O
4	molecular	O
5	chaperone	O
6	expressed	O
7	in	O
8	the	O
9	endoplasmic	O
10	reticulum	B
11	,	I
12	is	I
13	a	O
14	"	O
15	glucose	O
16	-	O
17	regulated	O
18	protein	O
19	"	O
20	induced	O
21	by	O
22	stress	O
23	responses	O
24	that	O
25	deplete	O
26	glucose	O
27	or	O
28	intracisternal	O
29	calcium	O
30	or	O
31	otherwise	O
32	disrupt	O
33	glycoprotein	O
34	trafficking	O
35	.	O

1	However	O
2	,	O
3	study	O
4	of	O
5	the	O
6	productive	O
7	gamma	O
8	gene	O
9	showed	O
10	that	O
11	the	O
12	skipped	O
13	variable	O
14	exon	O
15	was	O
16	bounded	O
17	by	O
18	normal	O
19	splicing	O
20	signals	O
21	and	O
22	that	O
23	the	O
24	adjacent	O
25	intron	O
26	organization	O
27	was	O
28	not	O
29	altered	O
30	.	O

1	We	O
2	exploit	O
3	the	O
4	properties	O
5	of	O
6	LexA	O
7	fusion	O
8	proteins	O
9	to	O
10	study	O
11	the	O
12	dimerization	O
13	and	O
14	DNA	O
15	-	O
16	contacting	O
17	domains	O
18	of	O
19	cRel	O
20	.	O

1	SUP46	O
2	is	O
3	implicated	O
4	in	O
5	translation	O
6	fidelity	O
7	and	O
8	encodes	O
9	the	O
10	ribosomal	O
11	protein	O
12	S13	O
13	.	O

1	The	O
2	manifestations	O
3	often	O
4	include	O
5	a	O
6	moderate	O
7	thrombocytopenia	O
8	and	O
9	,	O
10	less	O
11	commonly	O
12	,	O
13	hemolysis	O
14	.	O

1	Morphine	O
2	-	O
3	dependent	O
4	and	O
5	control	O
6	rats	O
7	in	O
8	an	O
9	oral	O
10	free	O
11	-	O
12	choice	O
13	protocol	O
14	were	O
15	treated	O
16	with	O
17	gamma	O
18	-	O
19	vinyl	O
20	GABA	O
21	(	O
22	GVG	O
23	),	O
24	60	O
25	,	O
26	120	O
27	and	O
28	240	O
29	mg	O
30	/	O
31	kg	O
32	IP	O
33	,	O
34	for	O
35	3	O
36	days	O
37	over	O
38	three	O
39	successive	O
40	periods	O
41	.	O

1	Multistep	O
2	transformation	O
3	by	O
4	defined	O
5	fragments	O
6	of	O
7	herpes	O
8	simplex	O
9	virus	O
10	type	O
11	2	O
12	DNA	O
13	:	O
14	oncogenic	O
15	region	O
16	and	O
17	its	O
18	gene	O
19	product	O
20	.	O

1	Derivatives	O
2	of	O
3	fluorene	O
4	.	O

1	Screening	O
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	O
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	O
16	IgE	O
17	antibodies	O

1	Ent	O
2	-	O
3	kaurene	O
4	synthase	O
5	from	O
6	the	O
7	fungus	O
8	Phaeosphaeria	O
9	sp	O
10	.	B

1	Precision	O
2	measurement	O
3	of	O
4	the	O
5	pion	O
6	mass	O
7	difference	O
8	m	O
9	pi	O
10	--	O
11	m	O
12	pi	O
13	0	O
14	.	O

1	When	O
2	differentiated	O
3	G0	O
4	-	O
5	arrested	O
6	leaf	B
7	cells	I
8	were	I
9	induced	O
10	to	O
11	resume	O
12	cell	O
13	division	O
14	by	O
15	treatment	O
16	with	O
17	plant	O
18	hormones	O
19	,	O
20	cycMs4	O
21	transcription	O
22	was	O
23	induced	O
24	before	O
25	the	O
26	onset	O
27	of	O
28	DNA	O
29	synthesis	O
30	.	O

1	These	O
2	incisors	O
3	were	O
4	studied	O
5	by	O
6	scanning	O
7	electron	O
8	microscopy	O
9	-	O
10	energy	B
11	dispersive	I
12	spectroscopy	I
13	analysis	O
14	(	O
15	SEM	O
16	-	O
17	EDS	O
18	)	O
19	and	O
20	light	O
21	microscopy	O
22	to	O
23	examine	O
24	the	O
25	calciotraumatic	O
26	lines	O
27	of	O
28	strontium	O
29	in	O
30	the	O
31	rat	O
32	incisor	O
33	labial	O
34	dentin	O
35	.	O

1	Km	O
2	and	O
3	Vmax	O
4	for	O
5	two	O
6	substrates	O
7	,	O
8	src	O
9	-	O
10	related	O
11	peptide	O
12	and	O
13	poly	O
14	(	O
15	Glu	O
16	,	O
17	Tyr	O
18	)	O
19	(	B
20	4	I
21	:	I
22	1	I
23	),	O
24	were	O
25	2	O
26	.	O
27	4	O
28	mM	O
29	and	O
30	2	O
31	.	O
32	5	O
33	mumol	O
34	min	O
35	-	O
36	1	O
37	mg	O
38	-	O
39	1	O
40	and	O
41	0	O
42	.	O
43	26	O
44	mM	O
45	and	O
46	1	O
47	.	O
48	2	O
49	mumol	O
50	min	O
51	-	O
52	1	O
53	mg	O
54	-	O
55	1	O
56	,	O
57	respectively	O
58	.	O

1	Strikingly	O
2	,	O
3	this	O
4	subdomain	O
5	is	O
6	also	O
7	present	O
8	in	O
9	the	O
10	otherwise	O
11	unrelated	O
12	N	O
13	-	O
14	terminal	O
15	activating	O
16	region	O
17	of	O
18	p58c	O
19	-	O
20	ets	O
21	-	O
22	2	O
23	and	O
24	was	O
25	thus	O
26	named	O
27	BEC	O
28	for	O
29	Ets	O
30	-	O
31	1	O
32	-	O
33	beta	O
34	/	O
35	Ets	O
36	-	O
37	2	O
38	-	O
39	Conserved	O
40	sequence	O
41	.	O

1	Contributions	O
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	A	O
2	group	O
3	of	O
4	66	O
5	DSM	O
6	-	O
7	IV	O
8	paranoid	O
9	schizophrenic	O
10	in	O
11	-	O
12	patients	O
13	were	O
14	assessed	O
15	three	O
16	times	O
17	using	O
18	the	O
19	SAPS	O
20	,	O
21	SANS	O
22	,	O
23	BPRS	O
24	and	O
25	PAS	O
26	.	O

1	Ly	O
2	-	B
3	49	I
4	is	I
5	a	I
6	family	I
7	type	I
8	II	I
9	transmembrane	I
10	proteins	I
11	encoded	O
12	by	O
13	a	O
14	gene	O
15	cluster	O
16	on	O
17	murine	O
18	chromosome	O
19	6	O
20	.	O

1	CONCLUSION	O
2	:	O
3	In	O
4	women	O
5	who	O
6	want	O
7	or	O
8	require	O
9	conservative	O
10	management	O
11	of	O
12	grade	O
13	4	O
14	prolapse	B
15	and	I
16	are	I
17	unable	I
18	to	I
19	retain	O
20	a	O
21	single	O
22	pessary	O
23	,	O
24	the	O
25	placement	O
26	of	O
27	two	O
28	pessaries	O
29	often	O
30	will	O
31	be	O
32	successful	O
33	.	O

1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	O
8	-	O
9	binding	O
10	domain	O
11	suggests	B
12	a	I
13	mechanism	I
14	for	I
15	the	I
16	observed	I
17	autoregulation	I
18	of	I
19	bacteriophage	O
20	T4	O
21	DNA	O
22	polymerase	O
23	synthesis	B
24	by	I
25	binding	I
26	to	I
27	its	I
28	own	I
29	mRNA	O
30	.	I

1	Optimal	O
2	activation	O
3	of	O
4	T	O
5	cells	O
6	requires	B
7	at	I
8	least	I
9	two	I
10	signals	I
11	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	contribute	O
6	to	O
7	the	O
8	transcript	O
9	map	O
10	of	O
11	human	O
12	chromosome	O
13	21	O
14	and	O
15	the	O
16	understanding	O
17	of	O
18	the	O
19	pathophysiology	O
20	of	O
21	trisomy	O
22	21	O
23	,	O
24	we	O
25	have	O
26	used	O
27	exon	O
28	trapping	O
29	to	O
30	identify	O
31	fragments	O
32	of	O
33	chromosome	O
34	21	O
35	genes	O
36	.	O

1	However	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	SF	O
9	levels	O
10	of	O
11	IL	O
12	-	O
13	8	O
14	with	O
15	those	O
16	of	O
17	lactate	O
18	,	O
19	LDH	O
20	,	O
21	beta	O
22	2	O
23	-	O
24	microglobulin	O
25	and	O
26	glucose	O
27	.	O

1	All	O
2	ribosomal	O
3	protein	O
4	(	O
5	rp	O
6	)	O
7	gene	O
8	promoters	O
9	from	O
10	Saccharomyces	O
11	cerevisiae	O
12	studied	O
13	so	O
14	far	O
15	contain	O
16	either	O
17	(	O
18	usually	O
19	two	O
20	)	O
21	binding	O
22	sites	O
23	for	O
24	the	O
25	global	O
26	gene	O
27	regulator	O
28	Rap1p	O
29	or	O
30	one	O
31	binding	O
32	site	O
33	for	O
34	another	O
35	global	O
36	factor	O
37	,	O
38	Abf1p	O
39	.	O

1	Labial	O
2	bar	B
3	.	I

1	Facioscapulohumeral	O
2	muscular	O
3	dystrophy	B
4	(	I
5	FSHD	I
6	)	I
7	is	I
8	an	O
9	autosomal	O
10	dominant	O
11	,	O
12	neuromuscular	O
13	disorder	O
14	characterized	O
15	by	O
16	progressive	O
17	weakness	O
18	of	O
19	muscles	O
20	in	B
21	the	I
22	face	I
23	,	I
24	shoulder	I
25	and	I
26	upper	I
27	arm	I
28	.	O

1	In	O
2	6	O
3	of	O
4	24	O
5	infants	O
6	studied	O
7	(	O
8	27th	O
9	-	O
10	40th	O
11	weeks	O
12	of	O
13	gestation	O
14	),	O
15	acquired	O
16	and	O
17	congenital	O
18	structural	O
19	anomalies	O
20	of	O
21	the	O
22	airways	O
23	were	O
24	detected	O
25	with	O
26	an	O
27	ultrathin	O
28	flexible	O
29	fiberscope	O
30	(	O
31	Olympus	O
32	PF18	O
33	S	O
34	,	O
35	1	O
36	.	O
37	8	O
38	mm	O
39	).	O

1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O

1	The	O
2	implications	O
3	for	O
4	estimates	O
5	of	O
6	cortical	O
7	magnification	O
8	and	O
9	possible	O
10	differences	O
11	in	O
12	the	O
13	specializations	O
14	of	O
15	foveal	O
16	and	O
17	peripheral	O
18	vision	O
19	are	O
20	discussed	O
21	.	O

1	Routine	O
2	clinical	O
3	analysis	O
4	revealed	O
5	lower	O
6	hematocrit	O
7	and	O
8	hemoglobin	O
9	,	O
10	and	O
11	elevated	O
12	BUN	O
13	and	O
14	alkaline	O
15	phosphatase	O
16	in	O
17	the	O
18	treated	O
19	group	O
20	.	O

1	The	O
2	Ras	O
3	-	O
4	related	B
5	GTPases	I
6	are	I
7	small	O
8	,	O
9	20	O
10	-	O
11	to	O
12	25	O
13	-	O
14	kDa	O
15	proteins	O
16	which	O
17	cycle	O
18	between	O
19	an	O
20	inactive	B
21	GDP	I
22	-	I
23	bound	I
24	form	I
25	and	I
26	an	I
27	active	I
28	GTP	I
29	-	I
30	bound	O
31	state	B
32	.	I

1	The	O
2	average	B
3	annual	I
4	cost	I
5	per	I
6	head	O
7	of	O
8	population	O
9	was	O
10	US	O
11	+	O
12	0	O
13	X	O
14	46	O
15	.	O

1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	O
18	minimal	O
19	promoter	O
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	O
25	gene	O
26	expression	O
27	.	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	O
16	-	O
17	1	O
18	(	O
19	C	O
20	-	O
21	terminal	O
22	399	O
23	amino	O
24	acids	O
25	)	O
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	O
38	-	O
39	S	O
40	-	O
41	transferase	O
42	(	O
43	GST	O
44	).	O

1	A	O
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	B
6	method	I
7	for	I
8	the	O
9	determination	B
10	of	I
11	p	I
12	-	I
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O

1	To	O
2	determine	O
3	the	O
4	relationship	O
5	of	O
6	these	O
7	viruses	O
8	,	O
9	the	O
10	complete	O
11	DNA	O
12	sequence	O
13	of	O
14	KV	O
15	consisting	O
16	of	O
17	4754	O
18	bp	O
19	was	O
20	determined	O
21	.	O

1	Dopamine	O
2	neurons	O
3	in	O
4	subjects	O
5	that	O
6	received	O
7	6	O
8	-	O
9	OHDA	O
10	were	O
11	protected	O
12	by	O
13	pre	O
14	-	O
15	treatment	O
16	with	O
17	GBR	O
18	-	O
19	12909	O
20	.	O

1	To	O
2	determine	O
3	whether	B
4	the	I
5	NTP	O
6	-	O
7	binding	O
8	motif	O
9	is	O
10	important	O
11	for	O
12	Rad24	O
13	function	O
14	,	O
15	we	O
16	mutated	O
17	the	O
18	conserved	O
19	lysine	O
20	(	O
21	115	O
22	)	O
23	residue	O
24	in	O
25	this	O
26	motif	O
27	.	O

1	Exons	O
2	III	O
3	to	O
4	VIII	O
5	,	O
6	which	O
7	cover	O
8	the	O
9	coding	O
10	region	O
11	and	O
12	the	O
13	3	O
14	'	O
15	untranslated	O
16	region	O
17	,	O
18	are	O
19	almost	O
20	identical	O
21	in	O
22	all	O
23	types	O
24	of	O
25	PST	O
26	or	O
27	AST	O
28	cDNAs	O
29	.	O

1	Mutant	O
2	enzyme	O
3	forms	O
4	were	O
5	prepared	O
6	to	O
7	eliminate	O
8	the	O
9	initial	O
10	autoprocessing	B
11	site	I
12	and	I
13	thus	O
14	form	O
15	an	O
16	active	B
17	single	I
18	-	I
19	chain	I
20	protein	I
21	for	I
22	structure	O
23	-	O
24	function	B
25	studies	I
26	.	I

1	Full	O
2	thyroid	O
3	function	O
4	testing	O
5	was	O
6	performed	O
7	on	O
8	600	O
9	randomly	O
10	selected	O
11	samples	O
12	with	O
13	normal	O
14	TSH	O
15	values	O
16	and	O
17	also	O
18	on	O
19	subjects	O
20	with	O
21	abnormal	O
22	TSH	O
23	levels	O
24	.	O

1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	deterioration	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	injured	O
13	patient	O
14	is	O
15	irreversible	O
16	vesicoureteral	O
17	reflux	O
18	.	O

1	The	O
2	population	O
3	of	O
4	between	O
5	75	O
6	,	O
7	000	O
8	and	O
9	100	O
10	,	O
11	000	O
12	was	O
13	largely	O
14	unstable	O
15	,	O
16	and	O
17	cost	O
18	per	O
19	capita	O
20	was	O
21	$	O
22	0	O
23	.	O
24	95	O
25	to	O
26	$	O
27	1	O
28	.	O
29	21	O
30	.	O

1	Ethylene	O
2	glycol	O
3	and	O
4	diethylene	O
5	glycol	O
6	were	O
7	each	O
8	administered	O
9	once	O
10	weekly	O
11	subcutaneously	O
12	to	O
13	groups	O
14	of	O
15	100	O
16	female	O
17	NMRI	O
18	mice	O
19	at	O
20	3	O
21	dosages	O
22	(	O
23	30	O
24	;	O
25	10	O
26	und	O
27	3	O
28	mg	O
29	single	O
30	dose	O
31	per	O
32	mouse	O
33	).	O

1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	insight	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	UCP2	O
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	anyone	O
32	of	O
33	the	O
34	above	O
35	mentioned	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O

1	A	O
2	direct	O
3	role	O
4	for	O
5	sterol	O
6	regulatory	O
7	element	O
8	binding	O
9	protein	O
10	in	O
11	activation	O
12	of	O
13	3	O
14	-	O
15	hydroxy	O
16	-	O
17	3	O
18	-	O
19	methylglutaryl	O
20	coenzyme	O
21	A	O
22	reductase	O
23	gene	O
24	.	O

1	Overexpressing	O
2	the	O
3	coactivator	B
4	,	I
5	SRC1a	I
6	or	O
7	GRIP1	O
8	,	B
9	further	I
10	enhances	O
11	ERRalpha1	B
12	-	I
13	induced	I
14	transcriptional	I
15	activity	I
16	.	I

1	CONCLUSION	O
2	:	O
3	These	O
4	results	O
5	suggest	B
6	that	I
7	vibration	I
8	-	I
9	induced	I
10	neural	O
11	involvement	O
12	can	O
13	be	O
14	considered	O
15	neither	O
16	pure	O
17	digital	O
18	neuropathy	O
19	,	B
20	nor	I
21	definite	O
22	CTS	O
23	,	O
24	as	O
25	previously	O
26	described	O
27	.	B

1	During	O
2	presentation	O
3	of	O
4	happy	O
5	facial	O
6	expressions	O
7	,	O
8	we	O
9	detected	O
10	a	O
11	signal	O
12	increase	O
13	predominantly	O
14	in	O
15	the	O
16	left	O
17	anterior	O
18	cingulate	O
19	gyrus	O
20	,	O
21	bilateral	O
22	posterior	O
23	cingulate	O
24	gyri	O
25	,	O
26	medial	O
27	frontal	O
28	cortex	O
29	and	O
30	right	O
31	supramarginal	O
32	gyrus	O
33	,	O
34	brain	O
35	regions	O
36	previously	O
37	implicated	O
38	in	O
39	visuospatial	O
40	and	O
41	emotion	O
42	processing	O
43	tasks	O
44	.	O

1	When	O
2	desipramine	O
3	was	O
4	injected	O
5	16	O
6	hrs	O
7	after	O
8	fluoxetine	O
9	injection	O
10	,	O
11	brain	O
12	levels	O
13	of	O
14	desipramine	O
15	were	O
16	no	O
17	longer	O
18	elevated	O
19	.	O

1	Pyk2	O
2	phosphorylation	O
3	increased	O
4	upon	O
5	adherence	O
6	of	O
7	FLG	O
8	29	O
9	.	O
10	1	O
11	cells	O
12	to	O
13	fibronectin	O
14	and	B
15	to	I
16	ST2	I
17	stromal	I
18	cells	I
19	.	I

1	USF	O
2	synthesized	O
3	in	O
4	an	O
5	in	O
6	vitro	O
7	transcription	O
8	and	O
9	translation	O
10	system	O
11	also	O
12	binds	O
13	to	O
14	the	O
15	ADH	O
16	promoter	O
17	as	O
18	well	O
19	as	O
20	to	O
21	the	O
22	MLP	O
23	.	O

1	RESULTS	O
2	:	O
3	Total	O
4	IgE	O
5	levels	O
6	showed	O
7	a	O
8	tendency	O
9	to	O
10	diminish	O
11	.	O

1	Glutathione	O
2	S	O
3	-	O
4	transferase	O
5	(	O
6	GST	O
7	)-	O
8	E2F	O
9	and	O
10	GST	O
11	-	O
12	DP	O
13	fusion	O
14	proteins	O
15	were	O
16	found	O
17	to	O
18	cooperate	O
19	in	O
20	binding	O
21	to	O
22	the	O
23	three	O
24	E2F	O
25	sites	O
26	in	O
27	the	O
28	DNA	O
29	polymerase	O
30	alpha	O
31	gene	O
32	promoter	O
33	in	O
34	vitro	O
35	.	O

1	Transcription	O
2	initiation	O
3	sites	O
4	of	O
5	the	O
6	rat	O
7	II	O
8	beta	O
9	-,	O
10	III	O
11	beta	O
12	,	O
13	and	O
14	O	O
15	beta	O
16	-	O
17	globin	O
18	genes	O
19	were	O
20	determined	O
21	to	O
22	be	O
23	52	O
24	base	O
25	pairs	O
26	(	O
27	bp	O
28	)	O
29	5	O
30	'-	O
31	upstream	O
32	of	O
33	the	O
34	translation	O
35	initiation	O
36	codon	O
37	(	O
38	ATG	O
39	),	O
40	in	O
41	each	O
42	gene	O
43	by	O
44	primer	O
45	extension	O
46	analysis	O
47	.	O

1	The	O
2	elevation	O
3	of	I
4	cyclic	I
5	AMP	I
6	(	I
7	cAMP	I
8	)	I
9	levels	I
10	in	I
11	the	I
12	cell	O
13	downregulates	O
14	the	O
15	activity	O
16	of	O
17	the	O
18	Raf	O
19	-	O
20	1	O
21	kinase	O
22	.	O

1	Neither	O
2	is	O
3	it	O
4	a	O
5	major	O
6	cause	O
7	of	O
8	rehydration	O
9	-	O
10	induced	O
11	renal	O
12	Na	O
13	retention	O
14	.	O

1	In	O
2	synchronized	O
3	HeLa	O
4	cells	O
5	,	O
6	expression	O
7	of	O
8	luciferase	B
9	activity	I
10	was	I
11	induced	I
12	at	I
13	the	I
14	beginning	I
15	of	I
16	DNA	I
17	synthesis	I
18	and	O
19	was	O
20	dependent	O
21	on	O
22	the	O
23	presence	O
24	of	O
25	an	O
26	E2F	O
27	-	O
28	binding	O
29	site	O
30	in	O
31	the	O
32	H2A	O
33	.	O
34	1	O
35	promoter	O
36	.	O

1	Sera	O
2	from	O
3	euthyroid	O
4	post	O
5	-	B
6	menopausal	I
7	or	I
8	pregnant	I
9	women	I
10	yielded	I
11	TSH	I
12	levels	I
13	within	I
14	the	O
15	normal	O
16	range	O
17	.	O

1	In	O
2	electromobility	O
3	shift	O
4	assays	O
5	,	O
6	EWS	O
7	-	O
8	FLI	O
9	-	O
10	1	O
11	binding	O
12	to	O
13	the	O
14	SRE	O
15	is	O
16	detectable	O
17	in	O
18	the	O
19	absence	O
20	of	O
21	SRF	O
22	whereas	O
23	the	O
24	binding	O
25	of	O
26	FLI	O
27	-	O
28	1	O
29	is	O
30	not	O
31	,	O
32	suggesting	O
33	that	O
34	the	O
35	interaction	O
36	with	O
37	DNA	O
38	is	O
39	the	O
40	step	O
41	which	O
42	limits	O
43	ternary	O
44	complex	O
45	formation	O
46	by	O
47	FLI	O
48	-	O
49	1	O
50	.	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	B
9	or	I
10	phosphorylation	I
11	of	I
12	Ag35	I
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	B
20	rich	B
21	sequence	I
22	which	O
23	occurs	B
24	in	I
25	this	I
26	polypeptide	I
27	.	I

1	In	O
2	contrast	O
3	,	O
4	AP	O
5	-	O
6	2	O
7	binding	O
8	activity	O
9	was	O
10	significantly	O
11	greater	O
12	in	O
13	T47D	O
14	cells	O
15	,	O
16	and	O
17	Western	O
18	blots	O
19	confirmed	O
20	increased	O
21	AP	O
22	-	O
23	2	O
24	protein	O
25	levels	O
26	in	O
27	these	O
28	cells	O
29	.	O

1	Three	O
2	patients	O
3	had	O
4	well	O
5	-,	O
6	6	O
7	patients	O
8	had	O
9	moderately	O
10	-,	O
11	and	O
12	5	O
13	patients	O
14	had	O
15	poorly	O
16	-	O
17	differentiated	O
18	adenocarcinoma	O
19	of	O
20	the	O
21	prostate	O
22	.	O

1	Results	O
2	of	O
3	two	O
4	-	O
5	hybrid	O
6	assays	O
7	and	O
8	electrophoretic	O
9	mobility	O
10	shift	O
11	assays	O
12	strongly	O
13	suggest	O
14	that	O
15	all	O
16	HD	O
17	-	O
18	Zip	O
19	proteins	O
20	of	O
21	families	O
22	I	O
23	and	O
24	II	O
25	can	O
26	form	O
27	homodimers	O
28	and	O
29	also	O
30	heterodimers	O
31	with	O
32	all	O
33	HD	O
34	-	O
35	Zip	O
36	proteins	O
37	of	O
38	the	O
39	same	O
40	family	O
41	.	O

1	Accordingly	O
2	,	O
3	no	O
4	Ha	O
5	-	O
6	ras	O
7	codon	O
8	12	O
9	mutations	O
10	are	O
11	found	O
12	in	O
13	the	O
14	EtNU	O
15	-	O
16	induced	O
17	mammary	O
18	tumors	O
19	.	O

1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	O
6	polymerase	O
7	II	O
8	is	O
9	designated	O
10	IIA	O
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	O
19	.	O

1	The	O
2	induction	O
3	of	O
4	RNKP	O
5	-	O
6	1	O
7	expression	O
8	in	O
9	the	O
10	Con	O
11	A	O
12	-	B
13	cultured	I
14	spleen	I
15	cells	O
16	is	O
17	accompanied	O
18	by	O
19	increases	O
20	in	O
21	both	O
22	NK	O
23	and	B
24	lymphokine	I
25	-	I
26	activated	I
27	killer	I
28	lymphocyte	I
29	activities	I
30	.	I

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	B
7	1a	I
8	is	I
9	a	I
10	distant	I
11	homolog	I
12	of	I
13	alphavirus	O
14	nonstructural	B
15	protein	I
16	nsP1	O
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	I
23	capping	I
24	viral	I
25	RNAs	I
26	.	I

1	Although	O
2	a	O
3	great	O
4	deal	O
5	is	O
6	understood	O
7	about	O
8	how	O
9	bHLH	O
10	factors	O
11	activate	O
12	gene	O
13	transcription	O
14	via	O
15	E	O
16	-	O
17	box	O
18	DNA	O
19	consensus	O
20	sequences	O
21	,	O
22	studies	O
23	of	O
24	bHLH	O
25	factor	O
26	function	O
27	in	O
28	higher	O
29	eukaryotes	O
30	often	O
31	have	O
32	been	O
33	hindered	O
34	by	O
35	the	O
36	presence	O
37	of	O
38	multiple	O
39	family	O
40	members	O
41	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	the	O
6	t	O
7	(	O
8	4	O
9	;	O
10	14	O
11	)(	O
12	p16	O
13	.	O
14	3	O
15	;	O
16	q32	O
17	)	O
18	represents	O
19	a	O
20	novel	O
21	,	O
22	recurrent	O
23	chromosomal	O
24	translocation	O
25	in	O
26	MM	O
27	,	O
28	and	O
29	suggest	O
30	that	O
31	the	O
32	FGFR3	O
33	gene	O
34	may	O
35	be	O
36	the	O
37	target	O
38	of	O
39	this	O
40	abnormality	O
41	and	O
42	thus	O
43	contribute	O
44	to	O
45	tumorigenesis	O
46	in	O
47	MM	O
48	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	Genetic	O
2	abnormalities	B
3	that	B
4	could	I
5	lead	I
6	to	I
7	mutagenesis	I
8	include	I
9	chromosomal	I
10	abnormalities	O
11	and	I
12	single	I
13	-	O
14	gene	O
15	mutations	B
16	.	B

1	We	O
2	also	O
3	recovered	O
4	mutations	O
5	in	O
6	the	O
7	60A	O
8	gene	O
9	which	O
10	encodes	O
11	another	O
12	TGF	O
13	-	O
14	beta	O
15	-	O
16	related	O
17	factor	O
18	in	O
19	Drosophila	O
20	.	O

1	These	O
2	results	O
3	also	O
4	suggest	B
5	the	B
6	involvement	I
7	of	I
8	additional	O
9	elements	O
10	in	O
11	the	B
12	UPR	B
13	.	I

1	In	O
2	this	O
3	animal	O
4	,	O
5	infected	O
6	with	O
7	what	O
8	was	O
9	judged	O
10	previously	O
11	to	O
12	be	O
13	the	O
14	less	O
15	virulent	O
16	of	O
17	the	O
18	two	O
19	T	O
20	.	O
21	cruzi	O
22	stocks	O
23	used	I
24	('	I
25	strain	O
26	7	O
27	'),	O
28	there	O
29	was	O
30	severe	O
31	myocarditis	O
32	,	O
33	with	O
34	myofibre	O
35	degeneration	O
36	,	O
37	and	O
38	lesions	O
39	of	O
40	the	O
41	oesophagus	O
42	.	O

1	Considering	O
2	these	O
3	sources	O
4	of	O
5	error	O
6	some	O
7	of	O
8	the	O
9	variability	O
10	in	O
11	the	O
12	present	O
13	investigation	O
14	might	O
15	be	O
16	avoided	O
17	by	O
18	systematic	O
19	instructions	O
20	.	O

1	One	O
2	defective	B
3	RNA	I
4	with	I
5	a	I
6	large	I
7	deletion	I
8	in	I
9	the	O
10	p70	O
11	coding	O
12	region	O
13	was	O
14	able	O
15	to	O
16	replicate	O
17	efficiently	O
18	,	O
19	both	O
20	when	I
21	inoculated	O
22	with	I
23	the	B
24	helper	I
25	genome	O
26	and	O
27	when	O
28	inoculated	O
29	with	O
30	a	O
31	second	O
32	complementing	O
33	defective	O
34	RNA	O
35	that	I
36	supplied	I
37	a	I
38	wild	I
39	-	I
40	type	I
41	p70	I
42	.	I

1	We	O
2	studied	O
3	the	O
4	effect	O
5	of	O
6	skinfold	O
7	thickness	B
8	on	I
9	the	I
10	correlation	O
11	between	O
12	serum	O
13	total	O
14	bilirubin	O
15	level	O
16	and	O
17	transcutaneous	O
18	bilirubin	O
19	(	O
20	TcB	O
21	)	O
22	readings	O
23	.	O

1	The	O
2	effect	O
3	of	O
4	ICRF	O
5	-	O
6	187	O
7	on	O
8	the	O
9	antitumor	O
10	response	O
11	induced	O
12	by	O
13	the	O
14	combination	O
15	of	B
16	ADR	I
17	and	I
18	WBH	O
19	was	O
20	also	O
21	investigated	O
22	in	O
23	order	O
24	to	O
25	assess	O
26	alterations	O
27	in	O
28	the	I
29	therapeutic	I
30	index	I
31	of	I
32	this	I
33	combined	I
34	therapeutic	O
35	modality	B
36	treatment	I
37	.	I

1	The	O
2	lengths	O
3	of	O
4	the	O
5	complete	O
6	polypeptide	O
7	chain	B
8	of	I
9	the	I
10	recombinant	I
11	enzyme	I
12	and	O
13	its	O
14	transit	O
15	peptide	O
16	are	O
17	388	O
18	and	O
19	53	B
20	residues	I
21	,	I
22	respectively	I
23	.	I

1	The	O
2	expression	O
3	of	O
4	ERV3	O
5	env	O
6	mRNA	B
7	was	I
8	found	I
9	to	O
10	be	O
11	differentiation	O
12	-	O
13	associated	O
14	,	O
15	with	O
16	high	O
17	expression	B
18	detected	I
19	in	I
20	the	I
21	late	O
22	stages	O
23	of	O
24	monocytic	O
25	development	O
26	.	O

1	To	O
2	evaluate	O
3	the	O
4	hepatic	O
5	regenerative	O
6	response	O
7	in	O
8	patients	O
9	with	O
10	alcoholic	O
11	liver	O
12	disease	O
13	,	O
14	sera	O
15	from	O
16	263	O
17	patients	O
18	with	O
19	severe	O
20	alcoholic	O
21	hepatitis	O
22	and	O
23	/	O
24	or	O
25	cirrhosis	O
26	were	O
27	analyzed	O
28	for	O
29	hepatocyte	O
30	growth	O
31	factor	O
32	(	O
33	HGF	O
34	)	O
35	and	O
36	alpha	O
37	-	O
38	fetoprotein	O
39	(	O
40	AFP	O
41	).	O

1	Nonetheless	O
2	,	O
3	that	O
4	ventricular	O
5	afferents	O
6	,	O
7	in	O
8	certain	O
9	special	O
10	settings	O
11	,	O
12	are	O
13	able	O
14	to	O
15	induce	O
16	e	O
17	.	O
18	g	O
19	.	O
20	generalised	O
21	vasodilation	O
22	and	O
23	hypotension	O
24	cannot	O
25	be	O
26	excluded	O
27	.	O

1	Histamine	O
2	metabolism	O
3	in	B
4	hemorrhagic	I
5	-	I
6	hypotensive	I
7	shock	I

1	Restriction	O
2	analysis	B
3	and	I
4	Southern	I
5	hybridization	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	Tn5422	O
11	in	O
12	all	O
13	the	O
14	plasmid	O
15	-	B
16	mediated	I
17	cadmium	I
18	-	I
19	resistant	I
20	L	I
21	.	I
22	monocytogenes	I
23	strains	O
24	tested	B
25	but	I
26	not	I
27	in	O
28	strains	B
29	encoding	B
30	cadmium	I
31	resistance	I
32	on	I
33	the	O
34	chromosome	O
35	.	O

1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O

1	Muscle	O
2	GSH	O
3	-	O
4	Px	O
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	Analysis	O
2	of	O
3	nucleotide	O
4	sequence	O
5	of	O
6	the	O
7	rightmost	O
8	43	O
9	kbp	O
10	of	O
11	herpesvirus	O
12	saimiri	O
13	(	O
14	HVS	O
15	)	O
16	L	O
17	-	O
18	DNA	O
19	:	O
20	general	O
21	conservation	O
22	of	O
23	genetic	O
24	organization	O
25	between	O
26	HVS	O
27	and	O
28	Epstein	O
29	-	O
30	Barr	O
31	virus	O
32	.	O

1	RAS2val19	O
2	,	O
3	a	O
4	dominant	O
5	activated	O
6	form	O
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	Ras2	O
11	,	O
12	stimulates	O
13	both	O
14	filamentous	O
15	growth	O
16	and	O
17	expression	O
18	of	O
19	a	O
20	transcriptional	O
21	reporter	O
22	FG	O
23	(	O
24	TyA	O
25	)::	O
26	lacZ	O
27	but	O
28	does	O
29	not	O
30	induce	O
31	the	O
32	mating	O
33	pathway	O
34	reporter	O
35	FUS1	O
36	::	O
37	lacZ	O
38	.	O

1	The	O
2	Ras	B
3	guanine	I
4	nucleotide	I
5	-	I
6	binding	O
7	protein	O
8	functions	O
9	as	O
10	a	O
11	molecular	O
12	switch	O
13	in	O
14	signalling	O
15	downstream	O
16	of	O
17	protein	O
18	-	O
19	tyrosine	O
20	kinases	B
21	.	B

1	To	O
2	characterize	O
3	this	O
4	effect	O
5	,	O
6	we	O
7	looked	O
8	for	O
9	targets	O
10	of	O
11	NS1	O
12	influenza	O
13	virus	O
14	protein	O
15	among	B
16	cellular	I
17	translation	I
18	factors	I
19	.	I

1	Patch	O
2	test	O
3	results	O
4	obtained	O
5	with	O
6	corticosteroid	O
7	allergic	O
8	patients	O
9	tested	O
10	with	O
11	a	O
12	large	O
13	corticosteroid	O
14	series	O
15	validated	O
16	the	O
17	earlier	O
18	classification	O
19	of	B
20	corticosteroid	I
21	molecules	O
22	in	O
23	four	O
24	groups	O
25	of	O
26	cross	O
27	-	O
28	reacting	O
29	molecules	O
30	:	O
31	i	B
32	.	I
33	e	O
34	.,	O
35	group	O
36	A	O
37	(	O
38	hydrocortisone	O
39	type	O
40	),	O
41	group	O
42	B	O
43	(	O
44	acetonides	O
45	),	O
46	group	O
47	C	O
48	(	O
49	betamethasone	O
50	type	O
51	-	O
52	non	O
53	esterified	O
54	)	O
55	and	O
56	group	O
57	D	O
58	(	O
59	esters	O
60	).	O

1	Relationship	O
2	of	O
3	mast	O
4	cells	O
5	to	O
6	sarcoidosis	O
7	granuloma	O
8	of	O
9	the	O
10	skin	O

1	This	O
2	study	O
3	allows	O
4	us	O
5	to	O
6	draw	O
7	conclusions	O
8	about	O
9	the	O
10	identity	O
11	of	O
12	proteins	O
13	required	O
14	for	O
15	the	O
16	development	O
17	of	O
18	the	O
19	nervous	O
20	system	O
21	in	O
22	Drosophila	O
23	and	O
24	provides	O
25	an	O
26	example	O
27	of	O
28	a	O
29	molecular	O
30	approach	O
31	to	O
32	characterize	O
33	en	O
34	masse	O
35	transposon	O
36	-	O
37	tagged	O
38	mutations	O
39	identified	O
40	in	O
41	genetic	O
42	screens	O
43	.	O

1	Pharmacokinetics	O
2	of	O
3	FK	O
4	506	O
5	in	O
6	transplant	O
7	patients	O
8	.	O

1	The	O
2	overexpressed	O
3	His6	O
4	-	O
5	tagged	O
6	GrsA	O
7	derivatives	O
8	were	O
9	affinity	O
10	-	O
11	purified	O
12	,	O
13	and	O
14	the	O
15	catalytic	O
16	properties	O
17	of	O
18	the	O
19	deletion	O
20	mutants	O
21	were	O
22	examined	O
23	by	O
24	biochemical	O
25	studies	O
26	including	O
27	ATP	O
28	-	B
29	dependent	I
30	amino	I
31	acid	O
32	activation	O
33	,	O
34	carboxyl	O
35	thioester	O
36	formation	O
37	,	O
38	and	O
39	the	O
40	ability	O
41	to	O
42	racemize	O
43	the	O
44	covalently	O
45	bound	O
46	phenylalanine	O
47	from	O
48	L	O
49	-	O
50	to	O
51	the	O
52	D	O
53	-	O
54	isomer	O
55	.	O

1	We	O
2	found	O
3	that	O
4	virulent	O
5	Ngo	O
6	strains	O
7	induce	O
8	phosphorylation	O
9	and	O
10	activation	O
11	of	O
12	JNK	O
13	but	O
14	not	O
15	of	O
16	p38	O
17	kinase	O
18	.	O

1	The	O
2	mei4	O
3	+	O
4	gene	O
5	of	O
6	the	O
7	fission	O
8	yeast	O
9	Schizosaccharomyces	O
10	pombe	O
11	was	O
12	cloned	O
13	by	O
14	functional	O
15	complementation	O
16	.	O

1	Amino	O
2	acid	O
3	residues	O
4	of	O
5	beta	O
6	1	O
7	',	O
8	alpha	O
9	A	O
10	',	O
11	alpha	O
12	B	O
13	',	O
14	and	O
15	the	O
16	loop	O
17	containing	O
18	His539	O
19	of	O
20	the	B
21	RNase	I
22	H	I
23	domain	I
24	interact	I
25	with	O
26	the	O
27	primer	O
28	strand	O
29	of	O
30	the	O
31	dsDNA	O
32	.	O

1	Follow	O
2	-	O
3	up	O
4	study	O
5	showed	O
6	85	O
7	%	O
8	of	O
9	these	O
10	patients	O
11	with	O
12	effectiveness	O
13	.	O

1	CONCLUSION	O
2	:	O
3	Chronic	O
4	administration	O
5	of	O
6	misoprostol	O
7	may	B
8	have	I
9	caused	I
10	a	I
11	negative	I
12	natriuretic	I
13	effect	O
14	in	O
15	cirrhotic	O
16	patients	O
17	with	O
18	ascites	O
19	.	O

1	Technetium	O
2	-	O
3	99m	O
4	methylene	O
5	diphosphonate	O
6	scintimammography	O
7	for	O
8	evaluation	O
9	of	O
10	palpable	O
11	breast	O
12	masses	O
13	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	nine	O
6	and	O
7	51	O
8	terminal	O
9	amino	O
10	acid	O
11	forms	O
12	already	O
13	known	O
14	,	O
15	we	O
16	identified	O
17	a	O
18	third	O
19	with	O
20	43	O
21	terminal	O
22	amino	B
23	acids	B
24	predicted	I
25	to	I
26	encode	O
27	a	O
28	novel	O
29	RET	O
30	protein	O
31	isoform	O
32	.	O

1	Catha	O
2	edulis	O
3	,	O
4	a	O
5	plant	O
6	that	O
7	has	O
8	amphetamine	O
9	effects	O
10	.	O

1	Penicillin	O
2	acylase	O
3	(	O
4	PA	O
5	)	O
6	from	O
7	Escherichia	O
8	coli	O
9	ATCC11105	O
10	is	O
11	a	O
12	periplasmic	O
13	heterodimer	O
14	consisting	O
15	of	O
16	a	O
17	24	O
18	kDa	O
19	small	O
20	subunit	O
21	and	O
22	a	O
23	65	O
24	kDa	O
25	large	O
26	subunit	O
27	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	both	O
6	the	O
7	amino	O
8	and	O
9	carboxy	O
10	termini	O
11	of	O
12	the	O
13	NS1	O
14	protein	O
15	molecule	O
16	and	O
17	the	O
18	cysteines	O
19	at	O
20	residues	O
21	337	O
22	and	O
23	340	O
24	are	O
25	essential	O
26	for	O
27	tubule	O
28	formation	O
29	.	O

1	In	O
2	transient	O
3	cotransfections	O
4	E1A	O
5	could	O
6	induce	O
7	the	O
8	activity	O
9	of	O
10	the	O
11	p53	O
12	promoter	O
13	to	O
14	a	O
15	high	O
16	level	O
17	;	O
18	12S	O
19	E1A	O
20	was	O
21	threefold	O
22	as	O
23	efficient	O
24	as	O
25	13S	O
26	E1A	O
27	in	O
28	this	O
29	activity	O
30	,	O
31	and	O
32	YY1	O
33	bound	O
34	to	O
35	the	O
36	composite	O
37	element	O
38	was	O
39	shown	O
40	to	O
41	mediate	O
42	55	O
43	%	O
44	of	O
45	this	O
46	induction	O
47	.	O

1	He	O
2	visited	O
3	our	O
4	hospital	O
5	and	O
6	left	O
7	solitary	O
8	renal	O
9	cyst	O
10	was	O
11	suspected	O
12	.	O

1	Metabolic	O
2	labeling	O
3	studies	O
4	in	O
5	S	O
6	.	O
7	cerevisiae	O
8	and	O
9	co	O
10	-	O
11	expression	O
12	of	O
13	nmt72p	O
14	with	O
15	several	O
16	protein	O
17	substrates	O
18	of	O
19	Nmt1p	O
20	in	O
21	Escherichia	O
22	coli	O
23	indicate	O
24	that	O
25	the	O
26	Leu99	O
27	-->	O
28	Pro	O
29	substitution	O
30	causes	O
31	a	O
32	reduction	O
33	in	O
34	the	O
35	acylation	O
36	of	O
37	some	O
38	but	O
39	not	O
40	all	O
41	protein	O
42	substrates	O
43	.	O

1	Comparison	O
2	with	O
3	the	O
4	bovine	O
5	gene	O
6	showed	O
7	that	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	hATP1	O
16	gene	O
17	has	O
18	an	B
19	unconserved	I
20	guanine	I
21	-	I
22	cytosine	I
23	(	I
24	GC	I
25	)	I
26	rich	I
27	region	I
28	,	O
29	including	O
30	several	O
31	binding	O
32	motifs	O
33	of	O
34	transcriptional	O
35	factors	O
36	,	O
37	such	O
38	as	O
39	Sp1	O
40	,	O
41	AP	O
42	-	O
43	2	O
44	,	O
45	and	O
46	GCF	O
47	.	O

1	Most	O
2	apneic	B
3	events	I
4	occurred	I
5	during	I
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	B
23	study	I
24	(	I
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	B
51	2	I
52	.	B
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	B
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	Thus	O
2	,	O
3	transcriptional	O
4	regulation	O
5	,	O
6	splicing	B
7	,	I
8	kinase	I
9	interaction	I
10	sites	I
11	,	I
12	and	I
13	tyrosine	I
14	phosphorylation	I
15	of	I
16	the	I
17	LMP2A	I
18	homologs	I
19	have	I
20	been	O
21	conserved	O
22	despite	O
23	significant	O
24	sequences	I
25	heterogeneity	I
26	in	O
27	the	I
28	preterminal	I
29	repeat	I
30	regions	I
31	of	O
32	these	O
33	human	O
34	and	O
35	nonhuman	O
36	primate	O
37	EBVs	O
38	.	O

1	Sodium	O
2	dodecyl	O
3	sulphate	O
4	-	O
5	induced	O
6	cleavage	O
7	by	O
8	eukaryotic	B
9	topoisomerase	I
10	I	I
11	is	O
12	known	O
13	to	B
14	yield	I
15	enzyme	O
16	covalently	O
17	attached	O
18	to	O
19	the	O
20	3	O
21	'	O
22	cut	O
23	end	O
24	of	B
25	the	I
26	DNA	I
27	.	I

1	The	B
2	specific	B
3	interaction	I
4	between	I
5	a	I
6	defined	I
7	structural	I
8	element	I
9	of	O
10	the	O
11	human	O
12	immunodeficiency	O
13	virus	B
14	mRNA	O
15	(	B
16	RRE	B
17	,	I
18	the	I
19	Rev	I
20	response	I
21	element	I
22	)	I
23	and	I
24	the	O
25	virus	O
26	-	O
27	encoded	O
28	protein	O
29	Rev	O
30	has	O
31	been	B
32	implicated	I
33	in	I
34	the	B
35	regulation	I
36	of	I
37	the	I
38	export	I
39	of	I
40	unspliced	I
41	or	I
42	singly	I
43	spliced	I
44	mRNA	O
45	from	O
46	the	O
47	nucleus	O
48	to	O
49	the	B
50	cytoplasm	B
51	.	I

1	Linear	O
2	regression	O
3	analysis	O
4	was	O
5	performed	O
6	and	O
7	the	O
8	following	O
9	result	O
10	was	O
11	obtained	O
12	:	O
13	clearance	O
14	(	B
15	HMPAO	I
16	)	I
17	=	I
18	0	O
19	.	O
20	07	O
21	+	O
22	0	O
23	.	O
24	43	B
25	.	I
26	rCBF	I
27	with	I
28	a	I
29	high	I
30	significance	I
31	(	O
32	p	O
33	less	O
34	than	O
35	0	O
36	.	O
37	001	O
38	).	O

1	Analysis	O
2	of	O
3	clearance	O
4	curve	O
5	of	O
6	rose	O
7	bengal	O
8	-	O
9	I	O
10	-	O
11	131	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	like	O
6	in	O
7	yeast	O
8	,	O
9	in	B
10	plants	B
11	a	I
12	certain	O
13	subfamily	O
14	of	O
15	UBC	O
16	is	O
17	specifically	O
18	involved	O
19	in	O
20	the	O
21	proteolytic	O
22	degradation	O
23	of	O
24	abnormal	O
25	proteins	O
26	as	O
27	result	O
28	of	O
29	stress	O
30	.	O

1	We	O
2	studied	O
3	the	O
4	human	O
5	vestibulo	O
6	-	B
7	ocular	I
8	reflex	I
9	(	I
10	VOR	I
11	)	O
12	in	O
13	response	O
14	to	O
15	head	O
16	'	O
17	impulses	O
18	':	O
19	brief	O
20	,	O
21	unpredictable	O
22	,	O
23	passive	O
24	,	O
25	high	O
26	-	O
27	acceleration	O
28	(	O
29	up	O
30	to	O
31	4000	O
32	degrees	O
33	/	O
34	s2	O
35	),	O
36	low	O
37	-	O
38	amplitude	O
39	(	B
40	20	O
41	-	I
42	30	I
43	degrees	I
44	)	I
45	head	I
46	rotations	O
47	.	O

1	MZF	O
2	-	O
3	1	O
4	represses	O
5	CAT	O
6	reporter	O
7	gene	O
8	expression	O
9	via	O
10	GAL4	O
11	binding	O
12	sites	O
13	in	O
14	the	O
15	nonhematopoietic	O
16	cell	O
17	lines	O
18	NIH	O
19	3T3	O
20	and	O
21	293	O
22	.	O

1	The	O
2	short	O
3	-	O
4	term	O
5	synthesis	O
6	and	O
7	infant	O
8	-	O
9	regulated	O
10	removal	O
11	of	B
12	milk	I
13	in	I
14	lactating	I
15	women	I
16	.	I

1	Immediate	O
2	-	O
3	early	O
4	transcription	O
5	from	O
6	the	O
7	channel	O
8	catfish	O
9	virus	O
10	genome	O
11	:	O
12	characterization	O
13	of	O
14	two	O
15	immediate	O
16	-	O
17	early	O
18	transcripts	O
19	.	O

1	The	O
2	alcoholic	O
3	patient	O
4	,	O
5	his	O
6	work	O
7	and	O
8	the	O
9	subjectivity	O
10	of	O
11	the	O
12	period	O

1	Genetic	O
2	alterations	O
3	in	O
4	elements	O
5	of	O
6	normal	O
7	signal	O
8	transduction	O
9	mechanisms	O
10	are	B
11	known	I
12	to	I
13	be	I
14	oncogenic	I
15	events	I
16	often	I
17	resulting	I
18	in	I
19	aberrant	O
20	activation	O
21	of	O
22	programs	O
23	of	O
24	gene	O
25	transcription	O
26	.	O

1	Four	O
2	transcription	O
3	initiation	O
4	sites	O
5	have	O
6	been	B
7	identified	I
8	by	I
9	full	I
10	-	I
11	length	O
12	RNA	B
13	ligase	B
14	-	I
15	mediated	I
16	rapid	O
17	amplification	O
18	of	O
19	cDNA	O
20	ends	O
21	(	O
22	RLM	O
23	-	O
24	RACE	O
25	)	O
26	between	O
27	-	O
28	61	O
29	and	O
30	-	O
31	32	O
32	bp	O
33	from	O
34	the	O
35	translation	O
36	initiation	O
37	codon	O
38	.	B
39	Reverse	O
40	transcription	O
41	-	I
42	PCR	B
43	analysis	B
44	revealed	I
45	that	I
46	PFK	O
47	-	O
48	A	B
49	,	B
50	PFK	I
51	-	O
52	B	O
53	and	O
54	PFK	O
55	-	B
56	C	I
57	genes	B
58	were	B
59	expressed	I
60	,	I
61	in	O
62	all	O
63	mouse	O
64	tissues	B
65	tested	B
66	,	O
67	at	O
68	varying	B
69	levels	O
70	.	O

1	Mutational	O
2	analysis	O
3	of	B
4	the	I
5	L1	I
6	binding	I
7	site	O
8	of	O
9	23S	O
10	rRNA	O
11	in	O
12	Escherichia	O
13	coli	O
14	.	O

1	Diltiazem	O
2	decreased	O
3	the	O
4	total	O
5	body	O
6	clearance	O
7	from	O
8	34	O
9	.	O
10	0	O
11	+/-	O
12	8	O
13	.	O
14	0	O
15	to	O
16	28	O
17	.	O
18	6	O
19	+/-	O
20	6	O
21	.	O
22	1	O
23	mL	O
24	/	O
25	min	O
26	(	O
27	P	O
28	less	O
29	than	O
30	.	O
31	01	O
32	),	O
33	and	O
34	prolonged	O
35	the	O
36	elimination	O
37	half	O
38	-	O
39	life	O
40	from	O
41	12	O
42	.	O
43	6	O
44	+/-	O
45	3	O
46	.	O
47	0	O
48	to	O
49	14	O
50	.	O
51	3	O
52	+/-	O
53	2	O
54	.	O
55	5	O
56	hours	O
57	(	O
58	P	O
59	less	O
60	than	O
61	.	O
62	01	O
63	)	O
64	of	O
65	antipyrine	O
66	without	O
67	any	O
68	changes	O
69	in	O
70	volume	O
71	of	O
72	distribution	O
73	.	O

1	During	O
2	treatment	O
3	,	O
4	the	O
5	phosphorylation	O
6	state	O
7	of	O
8	Rb	O
9	shifted	O
10	to	O
11	a	O
12	hypophosphorylated	O
13	form	O
14	.	O
15	mRNA	O
16	for	O
17	the	O
18	HPV	O
19	E6	O
20	/	O
21	E7	O
22	genes	O
23	decreased	O
24	;	O
25	however	O
26	,	O
27	significant	O
28	changes	O
29	in	O
30	the	O
31	E7	O
32	protein	O
33	were	O
34	not	O
35	observed	O
36	,	O
37	while	O
38	increased	O
39	levels	O
40	of	O
41	Rb	O
42	immunoprecipitated	O
43	with	O
44	anti	O
45	-	O
46	E7	O
47	antibodies	O
48	were	O
49	observed	O
50	.	O

1	In	O
2	the	O
3	evening	O
4	,	O
5	the	O
6	amplitude	O
7	of	O
8	the	O
9	responses	O
10	to	O
11	both	O
12	O2	O
13	and	O
14	CO2	O
15	increased	O
16	but	O
17	the	O
18	increase	O
19	in	O
20	CO2	O
21	sensitivity	O
22	was	O
23	proportionally	O
24	more	O
25	important	O
26	.	O

1	Agonist	O
2	-	O
3	induced	O
4	receptor	O
5	internalization	O
6	,	O
7	determined	O
8	as	O
9	the	O
10	percent	O
11	of	O
12	total	O
13	[	O
14	125I	O
15	]	O
16	Tyr0	O
17	-	O
18	oCRF	O
19	bound	O
20	located	O
21	in	O
22	the	O
23	acid	O
24	-	O
25	resistant	O
26	fraction	O
27	of	O
28	transfected	O
29	Cos	O
30	7	O
31	cells	O
32	,	O
33	increased	O
34	with	O
35	time	O
36	(	O
37	0	O
38	-	O
39	60	O
40	min	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	)	O
46	for	O
47	both	O
48	wild	O
49	-	O
50	type	O
51	and	O
52	variant	O
53	oCRF1	O
54	.	O

1	An	O
2	exon	O
3	that	O
4	prevents	O
5	transport	O
6	of	O
7	a	O
8	mature	O
9	mRNA	O
10	.	O

1	A	O
2	secondary	O
3	spread	O
4	of	O
5	an	O
6	imported	O
7	methicillin	O
8	-	O
9	resistant	O
10	Staphylococcus	O
11	aureus	O
12	strain	O
13	(	O
14	MRSA	O
15	)	O
16	to	O
17	two	O
18	other	O
19	patients	O
20	occurred	O
21	within	O
22	a	O
23	Danish	O
24	surgical	O
25	ward	O
26	in	O
27	spite	O
28	of	O
29	isolation	O
30	of	O
31	a	O
32	multitraumatized	O
33	index	O
34	-	O
35	patient	O
36	immediately	O
37	after	O
38	arrival	O
39	from	O
40	a	O
41	hospital	O
42	in	O
43	the	O
44	Mediterranean	O
45	area	O
46	.	O

1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	penile	O
8	foreskin	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	B
23	to	I
24	150	I
25	-	O
26	200	B
27	%	I
28	after	I
29	the	O
30	induction	B
31	of	I
32	anesthesia	I
33	,	I
34	and	I
35	then	I
36	decreased	I
37	to	I
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	created	O
46	parameatal	O
47	foreskin	O
48	flap	O
49	.	O

1	Conditions	O
2	influencing	O
3	inhibitors	O
4	of	O
5	the	O
6	colony	O
7	-	O
8	stimulating	O
9	factor	O
10	(	O
11	CSF	O
12	).	O

1	Five	O
2	-	O
3	year	O
4	prospective	O
5	study	O
6	of	O
7	peripheral	O
8	white	O
9	blood	O
10	cells	O
11	in	O
12	infectious	O
13	mononucleosis	O
14	.	O

1	Induction	O
2	requires	O
3	the	O
4	ACE1	O
5	gene	O
6	product	O
7	,	O
8	which	O
9	binds	B
10	to	I
11	specific	I
12	sites	I
13	in	I
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	CUP1	O
20	gene	O
21	.	O

1	Phenobarbital	O
2	-	O
3	induced	O
4	alterations	O
5	in	O
6	the	O
7	metabolism	O
8	of	O
9	[	O
10	3H	O
11	]	O
12	vitamin	O
13	D3	O
14	by	O
15	the	O
16	perfused	O
17	rachitic	O
18	rat	O
19	liver	O
20	in	B
21	vitro	I
22	.	I

1	Pulmonary	O
2	vascular	O
3	resistance	O
4	was	O
5	not	O
6	altered	O
7	,	O
8	ejection	O
9	fraction	O
10	remained	O
11	unchanged	O
12	and	O
13	isovolumic	O
14	relaxation	O
15	period	O
16	was	O
17	lengthened	O
18	(	O
19	119	O
20	+/-	O
21	20	O
22	.	O
23	1	O
24	to	O
25	147	O
26	.	O
27	39	O
28	+/-	O
29	21	O
30	.	O
31	15	O
32	,	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	Nip7p	O
2	-	O
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	O
11	-	O
12	depleted	O
13	cells	O
14	,	B
15	except	I
16	that	I
17	they	I
18	accumulated	I
19	27S	I
20	precursors	I
21	.	I

1	MEF	O
2	and	O
3	AML1B	O
4	synergistically	O
5	transactivated	O
6	an	O
7	interleukin	O
8	3	O
9	promoter	O
10	reporter	O
11	gene	O
12	construct	O
13	,	O
14	yet	O
15	the	O
16	activating	O
17	activity	O
18	of	O
19	MEF	O
20	was	O
21	abolished	O
22	when	O
23	MEF	O
24	was	O
25	coexpressed	O
26	with	O
27	AML1	O
28	/	O
29	ETO	O
30	.	O

1	It	O
2	has	B
3	come	B
4	out	I
5	that	I
6	CAEC	I
7	is	I
8	between	I
9	CC	I
10	and	I
11	CIEC	O
12	and	B
13	that	I
14	attacks	I
15	of	I
16	biliary	I
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	B
22	alkaline	I
23	phosphatase	I
24	and	O
25	transaminases	B
26	in	I
27	the	I
28	serum	I
29	are	I
30	the	I
31	helpful	I
32	findings	I
33	for	I
34	preoperative	O
35	diagnosis	B
36	.	O

1	Interferon	O
2	beta	O
3	therapy	O
4	was	B
5	discontinued	I
6	for	O
7	4	O
8	weeks	O
9	.	O

1	The	O
2	frequency	O
3	of	O
4	previous	O
5	transfusion	O
6	in	O
7	chronic	O
8	hepatitis	O
9	,	O
10	cirrhosis	O
11	and	O
12	hepatocellular	O
13	carcinoma	O
14	of	O
15	type	O
16	NANB	O
17	was	O
18	42	O
19	.	O
20	8	O
21	,	O
22	37	O
23	.	O
24	1	O
25	and	O
26	15	O
27	.	O
28	1	O
29	%,	O
30	respectively	O
31	,	O
32	whereas	O
33	the	O
34	incidence	O
35	of	O
36	early	O
37	posttransfusion	O
38	hepatitis	O
39	was	O
40	8	O
41	.	O
42	5	O
43	,	O
44	8	O
45	.	O
46	6	O
47	and	O
48	7	O
49	.	O
50	5	O
51	%,	O
52	respectively	O
53	.	O
54	in	O
55	chronic	O
56	liver	O
57	diseases	O
58	with	O
59	a	O
60	history	O
61	of	O
62	jaundice	O
63	and	O
64	/	O
65	or	O
66	hepatitis	O
67	,	O
68	previous	O
69	transfusions	O
70	are	O
71	more	O
72	frequently	O
73	associated	O
74	with	O
75	type	O
76	NANB	O
77	than	O
78	with	O
79	type	O
80	B	O
81	disease	O
82	.	O

1	After	O
2	14	O
3	d	O
4	of	O
5	overfeeding	O
6	,	O
7	hepatic	O
8	PL	O
9	profiles	O
10	were	O
11	identical	O
12	in	O
13	the	O
14	two	O
15	breeds	O
16	and	O
17	similar	O
18	to	O
19	that	O
20	in	O
21	control	O
22	livers	O
23	;	O
24	choline	O
25	-	O
26	containing	O
27	PL	O
28	accounted	O
29	for	O
30	95	O
31	%	O
32	of	O
33	total	O
34	PL	O
35	.	O

1	Using	O
2	mouse	O
3	-	O
4	human	O
5	somatic	O
6	hybrids	O
7	and	O
8	FISH	O
9	analysis	O
10	,	B
11	the	I
12	PE	I
13	-	I
14	2	I
15	gene	I
16	is	O
17	localized	O
18	to	B
19	human	I
20	chromosome	I
21	19q13	I
22	.	O
23	2	O
24	,	O
25	a	O
26	region	O
27	involved	O
28	in	O
29	translocations	O
30	and	O
31	deletions	O
32	in	O
33	leukemias	O
34	and	O
35	several	O
36	solid	O
37	tumors	O
38	,	O
39	suggesting	O
40	that	O
41	this	O
42	novel	O
43	ETS	O
44	factor	O
45	may	O
46	play	I
47	a	B
48	role	I
49	in	I
50	carcinogenesis	I
51	.	O

1	The	O
2	salient	O
3	clinical	O
4	features	O
5	,	O
6	the	O
7	problems	O
8	of	O
9	management	O
10	and	O
11	the	O
12	modern	O
13	approaches	O
14	to	O
15	the	O
16	reconstruction	O
17	of	O
18	facial	O
19	deformities	O
20	seen	O
21	in	O
22	this	O
23	disease	O
24	are	O
25	described	O
26	.	O

1	The	O
2	gene	O
3	for	O
4	the	O
5	RNA	O
6	-	O
7	dependent	O
8	eIF	O
9	-	O
10	2	O
11	alpha	O
12	protein	O
13	kinase	O
14	(	O
15	PKR	O
16	)	O
17	was	O
18	isolated	O
19	from	O
20	mouse	O
21	genomic	O
22	DNA	O
23	and	O
24	characterized	O
25	.	O

1	The	O
2	new	O
3	FIGO	O
4	definition	O
5	of	O
6	cervical	O
7	cancer	O
8	stage	B
9	IA	I
10	:	I
11	a	I
12	critique	I
13	.	O

1	Amyloid	O
2	beta	O
3	-	O
4	protein	O
5	(	O
6	Abeta	O
7	)	O
8	is	O
9	the	O
10	main	O
11	constituent	O
12	of	O
13	amyloid	O
14	fibrils	O
15	found	O
16	in	O
17	senile	O
18	plaques	O
19	and	O
20	cerebral	O
21	vessels	O
22	in	O
23	Alzheimer	O
24	'	O
25	s	B
26	disease	I
27	(	I
28	AD	I
29	)	I
30	and	I
31	is	O
32	derived	O
33	by	O
34	proteolysis	O
35	from	O
36	the	O
37	beta	O
38	-	O
39	amyloid	O
40	precursor	O
41	protein	O
42	(	O
43	APP	O
44	).	O

1	These	O
2	results	O
3	provide	O
4	the	O
5	first	B
6	demonstration	I
7	that	I
8	an	O
9	SR	O
10	protein	O
11	can	O
12	influence	O
13	splicing	O
14	of	O
15	specific	O
16	pre	O
17	-	O
18	mRNAs	O
19	in	O
20	vivo	O
21	.	O

1	Gal4	O
2	-	O
3	Eed	O
4	fusion	O
5	protein	O
6	represses	O
7	transcription	O
8	of	O
9	a	O
10	reporter	O
11	gene	O
12	driven	O
13	by	O
14	a	O
15	promoter	O
16	that	O
17	contains	O
18	Gal4	O
19	-	O
20	binding	O
21	DNA	O
22	elements	O
23	.	O

1	The	O
2	number	B
3	of	I
4	fecal	I
5	pellets	O
6	ingested	O
7	peaked	O
8	at	O
9	5	O
10	to	O
11	6	O
12	weeks	O
13	old	O
14	(	O
15	13	O
16	pellets	O
17	/	B
18	day	I
19	)	I
20	and	I
21	gradually	O
22	decreased	O
23	,	O
24	thereafter	O
25	(	O
26	2	O
27	.	O
28	1	O
29	pellets	O
30	at	O
31	78	B
32	weeks	O
33	old	O
34	,	O
35	1	B
36	.	B
37	5	O
38	pellets	O
39	at	I
40	104	O
41	weeks	O
42	old	O
43	).	O

1	The	O
2	outcome	O
3	of	O
4	the	O
5	optimization	O
6	of	O
7	the	O
8	seven	O
9	-	O
10	field	O
11	plan	O
12	prompted	O
13	an	O
14	investigation	O
15	into	O
16	the	O
17	best	O
18	results	O
19	that	O
20	could	O
21	be	O
22	achieved	O
23	by	O
24	an	O
25	"	O
26	ideal	O
27	"	O
28	conformal	O
29	radiotherapy	O
30	technique	O
31	.	O

1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	B
7	randomized	I
8	into	I
9	two	I
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	O
21	IFN	O
22	-	O
23	beta	O
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	O
35	therapy	O
36	.	O

1	The	O
2	neural	O
3	mechanism	O
4	of	O
5	parkinsonian	O
6	motor	O
7	symptoms	B
8	,	I
9	i	I
10	.	I
11	e	I
12	.,	I
13	rigidity	I
14	,	I
15	tremor	I
16	and	I
17	akinesia	I
18	,	O
19	which	O
20	are	O
21	the	O
22	result	O
23	of	O
24	nigrostriatal	O
25	dopamine	O
26	deficiency	O
27	,	O
28	is	O
29	interpreted	O
30	from	O
31	long	O
32	-	O
33	term	O
34	observations	O
35	on	O
36	the	O
37	effect	O
38	of	O
39	surgical	O
40	and	O
41	pharmacological	O
42	treatment	O
43	of	B
44	the	I
45	disease	I
46	in	I
47	relation	I
48	to	I
49	the	I
50	neuropathological	I
51	findings	B
52	within	I
53	the	O
54	substantia	O
55	nigra	O
56	zona	I
57	compacta	I
58	(	O
59	SNc	O
60	).	O

1	The	O
2	COOH	O
3	-	O
4	terminal	O
5	region	O
6	of	O
7	the	O
8	transcripts	O
9	contained	O
10	fifteen	O
11	triplet	O
12	repeats	O
13	(	O
14	GCT	O
15	;	O
16	alanine	O
17	)	O
18	at	O
19	nucleotide	O
20	465	O
21	to	O
22	509	O
23	,	O
24	which	O
25	is	O
26	significantly	O
27	expanded	O
28	compared	O
29	to	O
30	the	O
31	rat	O
32	RL14	O
33	.	O

1	Determination	O
2	of	O
3	diquat	O
4	in	O
5	biological	O
6	materials	O
7	by	O
8	electron	O
9	spin	O
10	resonance	O
11	spectroscopy	O
12	.	O

1	The	O
2	96	O
3	-	O
4	bp	O
5	insert	O
6	contained	O
7	a	O
8	termination	O
9	signal	O
10	which	O
11	caused	O
12	the	O
13	premature	O
14	termination	O
15	of	O
16	the	O
17	protein	O
18	,	O
19	leading	O
20	to	O
21	the	O
22	generation	O
23	of	O
24	a	O
25	p53	O
26	product	O
27	9	O
28	amino	O
29	acids	O
30	shorter	O
31	than	O
32	usual	O
33	.	O

1	Cp	O
2	is	O
3	normally	O
4	the	O
5	main	O
6	promoter	O
7	for	O
8	EBNA	O
9	mRNA	O
10	initiation	O
11	,	O
12	so	O
13	it	O
14	appears	O
15	that	O
16	EBNA3C	O
17	contributes	O
18	to	O
19	a	O
20	negative	O
21	autoregulatory	O
22	control	O
23	loop	O
24	.	O

1	A	O
2	transparent	O
3	overlay	O
4	for	O
5	assessing	O
6	amplitude	O
7	of	O
8	ECG	B
9	wave	I
10	forms	I
11	.	I

1	Yeast	O
2	U1	O
3	snRNP	O
4	therefore	B
5	contains	I
6	16	I
7	different	O
8	proteins	O
9	,	B
10	including	I
11	seven	I
12	snRNP	O
13	core	O
14	proteins	B
15	,	I
16	three	I
17	homologues	I
18	of	I
19	the	I
20	metazoan	I
21	U1	I
22	snRNP	I
23	-	I
24	specific	O
25	proteins	O
26	,	O
27	and	O
28	six	O
29	yeast	O
30	-	O
31	specific	O
32	U1	O
33	snRNP	O
34	proteins	O
35	.	O

1	Ribonuclease	O
2	protection	O
3	assays	O
4	revealed	O
5	that	O
6	hmg1	O
7	and	O
8	hmg2	O
9	are	O
10	differentially	O
11	expressed	O
12	in	O
13	a	O
14	developmentally	B
15	-	I
16	and	O
17	spatially	O
18	-	B
19	modulated	I
20	manner	I
21	during	I
22	morphogenesis	O
23	of	O
24	specialized	O
25	terpenoid	O
26	-	O
27	containing	O
28	pigment	O
29	glands	O
30	in	O
31	embryos	O
32	.	O

1	The	O
2	coding	O
3	sequences	O
4	of	O
5	the	O
6	Crry	O
7	gene	O
8	encompass	O
9	over	O
10	25	B
11	kb	I
12	of	I
13	DNA	I
14	,	I
15	whereas	O
16	the	O
17	Crry	O
18	-	O
19	ps	O
20	sequences	O
21	are	O
22	included	O
23	within	O
24	a	O
25	single	O
26	5	O
27	.	O
28	6	O
29	-	O
30	kb	O
31	Eco	O
32	-	O
33	R1	O
34	fragment	O
35	.	O

1	The	O
2	GPI	B
3	anchor	B
4	moiety	I
5	is	I
6	either	I
7	absent	I
8	or	I
9	present	O
10	at	B
11	a	I
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	I
27	peptide	I
28	and	I
29	GPI	I
30	signal	I
31	sequences	I
32	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	O
7	-	O
8	catenin	O
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	O
14	receptor	O
15	(	O
16	RAR	O
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	O
30	X	O
31	receptor	O
32	(	O
33	RXR	O
34	),	O
35	and	O
36	RAR	O
37	competed	O
38	with	O
39	TCF	O
40	for	O
41	beta	O
42	-	O
43	catenin	O
44	binding	O
45	.	O

1	Within	O
2	their	O
3	polypeptide	O
4	chain	O
5	,	O
6	they	O
7	all	O
8	contain	O
9	those	O
10	conserved	O
11	features	O
12	that	O
13	define	O
14	a	O
15	plant	O
16	CDPK	O
17	;	O
18	kinase	O
19	catalytic	O
20	sequences	O
21	are	O
22	linked	O
23	to	O
24	a	O
25	calmodulin	O
26	-	O
27	like	O
28	regulatory	O
29	domain	O
30	through	O
31	a	O
32	junction	O
33	region	O
34	.	O

1	All	O
2	patients	O
3	in	O
4	the	O
5	control	O
6	group	O
7	showed	O
8	a	O
9	significant	O
10	improvement	O
11	in	O
12	their	O
13	PEFR	O
14	while	O
15	only	O
16	3	O
17	patients	O
18	in	O
19	the	O
20	treated	O
21	group	O
22	showed	O
23	an	O
24	improvement	O
25	.	O

1	Overexpression	O
2	of	O
3	either	O
4	DAP	O
5	-	O
6	1	O
7	or	O
8	sentrin	O
9	causes	O
10	apoptosis	O
11	of	O
12	TNF	O
13	-	O
14	sensitive	O
15	L929	O
16	fibroblast	O
17	cell	O
18	line	O
19	,	O
20	as	O
21	well	O
22	as	O
23	TNF	O
24	-	O
25	resistant	O
26	osteosarcoma	O
27	cell	O
28	line	O
29	,	O
30	U2OS	O
31	.	O

1	Similarly	O
2	,	O
3	in	B
4	mammalian	I
5	cells	I
6	PBP74	I
7	is	I
8	synthesized	I
9	as	I
10	a	I
11	pre	I
12	-	I
13	protein	O
14	that	O
15	requires	O
16	membrane	B
17	potential	I
18	-	O
19	dependent	B
20	import	I
21	into	O
22	mitochondria	B
23	for	O
24	its	O
25	maturation	O
26	.	B

1	Serum	O
2	beta	O
3	2	O
4	-	O
5	microglobulin	O
6	levels	O
7	(	O
8	beta	O
9	-	O
10	2	O
11	-	O
12	M	O
13	)	O
14	were	O
15	studied	O
16	in	O
17	150	O
18	drug	O
19	addicts	O
20	,	O
21	50	O
22	of	O
23	them	O
24	asymptomatic	O
25	carriers	O
26	of	O
27	anti	O
28	HIV	O
29	-	O
30	1	O
31	antibodies	O
32	,	O
33	50	O
34	symptomatic	O
35	carriers	O
36	with	O
37	persistent	O
38	generalized	O
39	lymphadenopathy	O
40	(	O
41	P	O
42	.	O
43	G	O
44	.	O
45	L	O
46	.)	O
47	and	O
48	50	O
49	serum	O
50	negative	O
51	patients	O
52	who	O
53	had	O
54	been	O
55	living	O
56	in	O
57	a	O
58	closed	O
59	community	O
60	for	O
61	at	O
62	least	O
63	2	O
64	years	O
65	.	O

1	These	O
2	overall	O
3	results	O
4	indicate	O
5	that	O
6	there	O
7	is	O
8	generally	O
9	one	O
10	PERV	O
11	copy	O
12	per	O
13	integration	O
14	site	O
15	.	O

1	Action	O
2	of	O
3	strontium	O
4	-	O
5	90	O
6	and	O
7	metaphos	O
8	on	O
9	Cyprinus	O
10	carpio	O

1	Electrocardiographic	O
2	QRS	O
3	complexes	O
4	and	O
5	vectorcardiographic	O
6	QRS	O
7	loop	O

1	The	O
2	detection	O
3	ratio	O
4	peaked	B
5	at	I
6	ages	I
7	30	O
8	to	O
9	34	O
10	and	O
11	decreased	O
12	heavily	O
13	during	O
14	the	O
15	next	O
16	15	O
17	years	O
18	of	O
19	age	O
20	.	O

1	Consistent	O
2	with	O
3	the	O
4	hypothesis	O
5	that	O
6	it	O
7	acts	O
8	as	O
9	transcriptional	O
10	regulator	O
11	,	O
12	wild	O
13	-	O
14	type	O
15	p53	O
16	protein	O
17	binds	O
18	DNA	O
19	and	O
20	activates	O
21	transcription	O
22	of	O
23	several	O
24	promoters	O
25	.	O

1	CONCLUSION	O
2	:	O
3	Presence	O
4	of	O
5	APOE	O
6	epsilon4	O
7	/*	O
8	seems	O
9	to	O
10	increase	O
11	the	O
12	risk	O
13	for	O
14	dementia	B
15	and	I
16	AD	I
17	independently	O
18	of	O
19	its	O
20	effect	O
21	on	O
22	dyslipidemia	O
23	and	O
24	atherogenesis	O
25	.	O

1	A	O
2	mutant	O
3	(	O
4	residues	O
5	1	O
6	-	O
7	332	O
8	)	O
9	showed	O
10	complete	O
11	Ca2	O
12	+/	O
13	CaM	O
14	-	O
15	dependent	O
16	activity	O
17	.	O

1	A	O
2	-	O
3	tracts	O
4	functioned	O
5	best	O
6	when	O
7	positioned	O
8	close	O
9	to	O
10	the	O
11	-	O
12	35	O
13	hexamer	O
14	rather	O
15	than	O
16	one	O
17	helical	O
18	turn	B
19	farther	I
20	upstream	I
21	,	I
22	similar	I
23	to	O
24	the	O
25	positioning	O
26	optimal	O
27	for	O
28	UP	O
29	element	O
30	function	O
31	.	O

1	A	O
2	secondary	O
3	phosphorylation	O
4	of	O
5	CREB341	O
6	at	O
7	Ser129	O
8	is	O
9	required	O
10	for	O
11	the	O
12	cAMP	O
13	-	O
14	mediated	O
15	control	O
16	of	B
17	gene	I
18	expression	I
19	.	I

1	Preferential	O
2	heterodimeric	O
3	parallel	O
4	coiled	O
5	-	O
6	coil	O
7	formation	O
8	by	O
9	synthetic	O
10	Max	O
11	and	O
12	c	O
13	-	O
14	Myc	O
15	leucine	O
16	zippers	B
17	:	I
18	a	I
19	description	I
20	of	I
21	putative	I
22	electrostatic	I
23	interactions	I
24	responsible	I
25	for	I
26	the	I
27	specificity	I
28	of	I
29	heterodimerization	I
30	.	O

1	S	O
2	.,	O
3	K	O
4	.	O

1	Currents	O
2	aspects	O
3	of	O
4	H2	O
5	receptor	O
6	antagonists	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	ulcers	O

1	The	O
2	locus	O
3	encoding	O
4	the	O
5	XD	O
6	gene	O
7	(	O
8	designated	O
9	Xd	O
10	)	O
11	was	O
12	mapped	O
13	to	O
14	the	O
15	distal	O
16	part	O
17	of	O
18	mouse	O
19	chromosome	O
20	17	O
21	by	O
22	haplotype	O
23	analysis	O
24	of	O
25	114	O
26	interspecific	O
27	backcross	O
28	mice	O
29	.	O

1	In	O
2	this	O
3	method	O
4	,	O
5	PLP	O
6	in	O
7	plasma	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	high	O
13	sensitivity	O
14	using	O
15	derivatization	O
16	with	O
17	sodium	O
18	bisulfite	O
19	in	O
20	the	O
21	mobile	O
22	phase	O
23	.	O

1	Constitutive	O
2	activation	O
3	of	O
4	Rac1	O
5	and	O
6	RhoA	O
7	causes	O
8	tumorigenic	O
9	transformation	O
10	of	O
11	NIH	O
12	3T3	O
13	cells	O
14	,	O
15	and	B
16	their	I
17	functions	I
18	may	O
19	be	O
20	required	O
21	for	O
22	full	O
23	Ras	O
24	transformation	O
25	.	O

1	Elledge	O
2	,	O
3	P	O
4	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O

1	Of	O
2	115	O
3	hepatitis	O
4	B	O
5	patients	O
6	seen	O
7	at	O
8	12	O
9	months	O
10	,	O
11	6	B
12	%	I
13	had	I
14	chronic	I
15	hepatitis	I
16	Bs	I
17	antigenaemia	I
18	,	I
19	60	I
20	%	I
21	had	I
22	developed	I
23	anti	I
24	-	I
25	HBs	I
26	antibodies	I
27	,	I
28	and	I
29	7	I
30	.	I
31	3	I
32	%	I
33	still	O
34	had	O
35	abnormal	O
36	liver	O
37	function	O
38	.	O

1	A	O
2	0	O
3	.	O
4	5	O
5	rating	O
6	was	B
7	intended	I
8	to	I
9	characterize	I
10	subjects	I
11	in	I
12	whom	I
13	mild	I
14	cognitive	I
15	impairment	I
16	due	I
17	to	I
18	senile	O
19	dementia	O
20	of	O
21	the	O
22	Alzheimer	O
23	type	O
24	was	O
25	suspected	O
26	but	O
27	was	O
28	insufficient	B
29	in	B
30	degree	I
31	to	I
32	warrant	O
33	a	O
34	diagnosis	O
35	of	O
36	definite	O
37	dementia	B
38	.	I

1	Aspirin	O
2	causes	O
3	peptic	O
4	ulcers	O
5	predominately	O
6	by	O
7	reducing	O
8	gastric	O
9	mucosal	O
10	cyclooxygenase	O
11	(	O
12	COX	B
13	)	I
14	activity	I
15	and	I
16	prostaglandin	I
17	synthesis	I
18	.	I

1	5	O
2	.	O

1	Thus	O
2	,	O
3	although	O
4	p28	O
5	may	O
6	play	O
7	only	O
8	a	O
9	limited	B
10	role	I
11	during	I
12	the	I
13	early	I
14	embryonic	I
15	cleavages	I
16	,	I
17	it	O
18	may	O
19	function	O
20	later	O
21	in	O
22	development	O
23	to	O
24	establish	O
25	a	O
26	somatic	O
27	type	O
28	of	O
29	cell	O
30	cycle	O
31	.	O

1	Sterols	O
2	in	O
3	pollen	O
4	.	O

1	The	O
2	IPL1	O
3	gene	O
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	fidelity	O
10	chromosome	O
11	segregation	O
12	in	O
13	the	O
14	budding	O
15	yeast	O
16	Saccharomyces	O
17	cerevisiae	O
18	.	O

1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O

1	Activation	O
2	of	B
3	ERK1	I
4	/	O
5	2	O
6	is	O
7	correlated	O
8	with	O
9	induction	B
10	of	I
11	the	I
12	immediate	O
13	-	O
14	early	O
15	response	O
16	genes	O
17	.	O

1	The	O
2	murine	O
3	Mov	O
4	-	O
5	34	O
6	gene	O
7	:	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	and	O
13	genomic	O
14	organization	O
15	.	O

1	Open	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	4556	O
7	nucleotide	O
8	sequence	O
9	within	O
10	MDV	O
11	-	O
12	1	O
13	BamHI	O
14	-	O
15	D	O
16	DNA	O
17	fragment	O
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O

1	Prevention	O
2	of	O
3	maternal	O
4	Rh	O
5	sensitization	O
6	:	O
7	anti	O
8	-	O
9	Rh	O
10	immune	O
11	globulin	O
12	.	O

1	The	O
2	tramtrack	O
3	(	O
4	ttk	O
5	)	O
6	gene	O
7	of	O
8	Drosophila	O
9	encodes	O
10	69	O
11	-	O
12	kDa	O
13	and	O
14	88	O
15	-	O
16	kDa	O
17	proteins	O
18	through	O
19	alternative	O
20	splicing	O
21	of	O
22	the	O
23	primary	O
24	ttk	O
25	transcript	O
26	.	O

1	Enterococcus	O
2	faecium	O
3	strains	O
4	with	O
5	vanA	O
6	-	O
7	mediated	O
8	glycopeptide	O
9	resistance	O
10	were	O
11	isolated	O
12	by	O
13	enrichment	O
14	culture	O
15	from	O
16	the	O
17	intestines	O
18	and	O
19	feces	O
20	of	O
21	several	O
22	animal	O
23	species	O
24	,	O
25	mainly	O
26	horses	O
27	and	O
28	dogs	O
29	(	O
30	8	O
31	%	O
32	positive	O
33	),	O
34	chickens	O
35	(	O
36	7	O
37	%	O
38	positive	O
39	),	O
40	and	O
41	pigs	O
42	(	O
43	6	O
44	%	O
45	positive	O
46	).	O

1	A	O
2	17	O
3	-	B
4	mer	I
5	oligodeoxynucleotide	I
6	,	I
7	corresponding	I
8	to	I
9	a	I
10	region	I
11	of	O
12	the	O
13	VtHb	O
14	amino	O
15	acid	O
16	sequence	O
17	was	O
18	used	O
19	as	O
20	a	O
21	hybridization	O
22	probe	O
23	to	O
24	screen	O
25	a	O
26	Vitreoscilla	O
27	genomic	O
28	library	O
29	constructed	O
30	in	O
31	broad	O
32	-	O
33	host	O
34	-	O
35	range	O
36	cosmid	B
37	vector	O
38	pVK102	I
39	.	I

1	Twenty	O
2	patients	O
3	aged	O
4	45	O
5	or	O
6	older	O
7	with	O
8	the	O
9	diagnosis	B
10	of	I
11	endogenous	I
12	depression	I
13	were	I
14	evaluated	I
15	in	I
16	terms	I
17	of	I
18	safety	I
19	and	I
20	efficacy	I
21	in	O
22	their	O
23	response	O
24	to	O
25	multiple	O
26	monitored	O
27	electroconvulsive	O
28	therapy	O
29	(	O
30	MMECT	B
31	)	I
32	versus	I
33	single	I
34	electroconvulsive	I
35	therapy	I
36	(	I
37	SECT	I
38	).	I

1	Only	O
2	one	O
3	of	O
4	these	O
5	bands	O
6	was	O
7	supershifted	O
8	by	B
9	antibody	I
10	to	I
11	p50	I
12	,	I
13	whereas	I
14	antibodies	I
15	to	O
16	p65	O
17	or	O
18	other	O
19	NF	O
20	-	O
21	kappaB	O
22	proteins	O
23	had	O
24	no	O
25	effect	O
26	.	O

1	Eighteen	O
2	patients	O
3	were	O
4	untreated	O
5	,	O
6	and	O
7	8	O
8	had	O
9	been	O
10	given	O
11	previous	O
12	treatment	O
13	with	O
14	depot	O
15	testosterone	O
16	100	O
17	mg	O
18	intramuscularly	O
19	every	O
20	2	O
21	-	O
22	3	O
23	weeks	O
24	for	O
25	an	O
26	average	O
27	duration	O
28	of	O
29	4	O
30	.	O
31	7	O
32	years	O
33	.	O

1	NH2	O
2	-	O
3	terminal	O
4	trimming	O
5	of	O
6	Xenopus	O
7	and	O
8	mammalian	O
9	FGF3s	O
10	may	O
11	therefore	B
12	be	I
13	a	I
14	prerequisite	I
15	of	I
16	optimal	I
17	biological	O
18	activity	O
19	.	O

1	Circularized	O
2	Ac	O
3	/	O
4	Ds	O
5	transposons	O
6	:	O
7	formation	O
8	,	O
9	structure	O
10	and	O
11	fate	O
12	.	O

1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	deformation	O
6	in	O
7	vertebral	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	flexion	O
15	-	O
16	distraction	O
17	Stage	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	physiologic	O
23	range	O
24	of	O
25	cervical	O
26	flexion	O
27	.	O

1	3	O
2	activities	O
3	of	O
4	the	O
5	factor	O
6	II	O
7	molecule	O
8	in	O
9	the	O
10	newborn	O
11	infant	O
12	at	O
13	term	O

1	We	O
2	show	B
3	also	I
4	that	O
5	RA	O
6	represses	O
7	the	O
8	transcriptional	O
9	activity	B
10	of	I
11	a	I
12	reporter	I
13	gene	I
14	containing	O
15	a	B
16	TPA	I
17	responding	I
18	AP1	I
19	binding	O
20	site	O
21	driving	O
22	the	O
23	HSV	O
24	tk	O
25	promoter	O
26	.	O

1	This	O
2	model	O
3	is	O
4	supported	O
5	by	O
6	experiments	O
7	showing	B
8	that	I
9	Cdr2	I
10	associates	I
11	with	I
12	the	I
13	N	O
14	-	O
15	terminal	O
16	regulatory	O
17	domain	O
18	of	O
19	Wee1	O
20	in	B
21	cell	I
22	lysates	I
23	and	I
24	phosphorylates	I
25	Wee1	I
26	in	I
27	vitro	O
28	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Rho1p	O
6	regulates	O
7	cytoskeletal	O
8	reorganization	O
9	at	O
10	least	O
11	through	O
12	Bni1p	O
13	and	O
14	Pkc1p	O
15	.	O

1	In	O
2	B	O
3	cells	O
4	,	O
5	HEF1	O
6	is	O
7	phosphorylated	O
8	by	O
9	a	O
10	cytoskeleton	B
11	-	I
12	dependent	I
13	mechanism	I
14	that	O
15	is	O
16	triggered	O
17	by	O
18	integrin	O
19	ligation	O
20	.	O

1	The	O
2	temporal	O
3	component	O
4	lacked	O
5	a	O
6	mandibular	O
7	fossa	O
8	as	O
9	well	O
10	as	O
11	articular	O
12	eminence	B
13	.	I

1	The	O
2	retrovesical	O
3	hydatid	O
4	cyst	O
5	is	O
6	a	O
7	very	O
8	rare	O
9	site	O
10	.	O

1	Only	O
2	the	O
3	3	O
4	.	O
5	0	O
6	-	O
7	kb	O
8	transcript	O
9	was	O
10	detected	O
11	in	O
12	adult	O
13	tissues	O
14	,	O
15	where	O
16	its	O
17	expression	O
18	was	O
19	restricted	O
20	almost	O
21	exclusively	O
22	to	O
23	the	O
24	central	O
25	nervous	O
26	system	O
27	.	O

1	Potscoital	O
2	test	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	appropriately	O
7	spaced	O
8	upstream	O
9	from	O
10	the	O
11	transcription	O
12	initiation	O
13	site	O
14	.	O

1	None	O
2	of	O
3	these	O
4	organic	O
5	manifestations	O
6	was	O
7	discovered	O
8	by	O
9	scintigraphic	O
10	means	O
11	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	myoD	O
6	promoter	O
7	,	O
8	the	O
9	myoD	O
10	enhancer	O
11	shows	O
12	striking	O
13	conservation	O
14	between	O
15	humans	O
16	and	O
17	mice	O
18	both	O
19	in	O
20	its	O
21	sequence	O
22	and	O
23	its	O
24	distal	O
25	position	O
26	.	O

1	Increasing	O
2	the	O
3	RH	O
4	beyond	O
5	32	O
6	%	O
7	resulted	O
8	in	O
9	solvation	O
10	of	O
11	the	O
12	peroxy	O
13	radical	O
14	,	O
15	sterically	O
16	hindering	O
17	the	O
18	radical	O
19	from	O
20	entering	O
21	the	O
22	propagation	O
23	transition	O
24	state	O
25	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	report	O
7	the	O
8	isolation	O
9	and	O
10	characterization	O
11	of	O
12	the	O
13	entire	O
14	rat	O
15	GSTA3	O
16	(	O
17	rGST	O
18	Yc1	O
19	)	O
20	subunit	O
21	gene	O
22	.	O

1	Amongst	O
2	other	O
3	qualities	O
4	,	O
5	the	O
6	book	O
7	'	O
8	s	O
9	importance	B
10	lies	I
11	in	I
12	the	I
13	fact	I
14	that	I
15	it	I
16	associates	I
17	an	I
18	elaborate	O
19	theoretical	B
20	construction	I
21	with	O
22	the	O
23	empirical	B
24	data	I
25	,	I
26	working	I
27	within	I
28	the	I
29	possibilities	I
30	provided	I
31	by	I
32	late	I
33	19th	I
34	-	O
35	century	B
36	moral	I
37	statistics	O
38	.	O

1	Upon	O
2	analysis	O
3	of	O
4	various	O
5	deletion	O
6	and	O
7	point	O
8	-	O
9	mutated	O
10	variants	O
11	of	O
12	the	O
13	human	O
14	IL	O
15	-	O
16	6	O
17	gene	O
18	promoter	O
19	coupled	O
20	to	O
21	a	O
22	reporter	O
23	gene	O
24	,	O
25	we	O
26	screened	O
27	for	O
28	possible	O
29	cooperating	O
30	transcription	O
31	factors	O
32	.	O

1	As	O
2	opposed	O
3	to	O
4	in	O
5	vitro	O
6	co	O
7	-	O
8	precipitation	O
9	studies	O
10	,	O
11	the	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screen	O
17	reveals	O
18	in	O
19	vivo	O
20	protein	O
21	-	O
22	protein	O
23	interactions	O
24	.	O

1	A	O
2	motif	O
3	(	O
4	TGATGTCA	O
5	)	O
6	which	O
7	matches	O
8	a	O
9	CREB	O
10	site	O
11	and	O
12	is	O
13	similar	O
14	to	O
15	an	O
16	AP	O
17	-	O
18	1	O
19	site	O
20	is	O
21	embedded	O
22	within	O
23	ER2	O
24	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	the	O
6	CAAT	O
7	-	O
8	region	O
9	is	O
10	involved	O
11	in	O
12	upregulating	O
13	the	O
14	MDR1	B
15	promoter	I
16	in	I
17	HL60	I
18	/	O
19	VCR	O
20	cells	O
21	.	O

1	A	O
2	statistically	O
3	significant	O
4	improvement	O
5	due	O
6	to	O
7	the	O
8	administration	O
9	of	O
10	Bromergon	O
11	was	O
12	observed	O
13	in	O
14	symptoms	O
15	associated	O
16	with	O
17	overreactiveness	O
18	to	O
19	normal	O
20	prolactin	O
21	levels	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	abdominal	O
28	tension	O
29	,	O
30	edema	O
31	,	O
32	weight	O
33	gain	O
34	and	O
35	breast	O
36	tenderness	O
37	.	O

1	Higher	O
2	fasting	O
3	serum	O
4	gastrin	O
5	concentration	O
6	(	O
7	102	O
8	.	O
9	0	O
10	+/-	O
11	21	O
12	.	O
13	1	O
14	vs	O
15	63	B
16	.	I
17	3	I
18	+/-	I
19	8	I
20	.	O
21	3	O
22	ng	B
23	.	I
24	l	I
25	-	I
26	1	O
27	),	B
28	and	I
29	greater	I
30	postprandial	I
31	gastrin	I
32	release	I
33	(	I
34	AUC0	I
35	-	I
36	120	I
37	:	O
38	16690	O
39	+/-	O
40	2648	O
41	vs	O
42	10654	O
43	+/-	O
44	1283	O
45	ng	O
46	.	O
47	l	O
48	-	O
49	1	O
50	min	O
51	)	O
52	were	O
53	observed	O
54	after	O
55	VTP	O
56	-	O
57	HM	O
58	than	O
59	after	O
60	VTP	O
61	-	O
62	Cas	O
63	.	O

1	Since	O
2	considerable	O
3	variations	O
4	in	O
5	length	O
6	and	O
7	primary	O
8	sequence	O
9	in	O
10	the	O
11	CDR3	O
12	(	O
13	complementarity	O
14	determining	O
15	region	O
16	)	O
17	peptides	O
18	of	O
19	all	O
20	the	O
21	H	O
22	-	O
23	chains	O
24	are	O
25	evident	O
26	,	O
27	conservation	O
28	of	O
29	the	O
30	D	O
31	-	O
32	region	O
33	structure	O
34	does	O
35	not	O
36	appear	O
37	to	O
38	be	O
39	necessary	O
40	for	O
41	effective	O
42	hapten	O
43	binding	O
44	.	O

1	Immunocytochemical	O
2	analysis	O
3	demonstrated	O
4	the	O
5	presence	O
6	of	O
7	DREF	O
8	polypeptide	O
9	in	O
10	nuclei	O
11	after	O
12	the	O
13	eighth	O
14	nuclear	O
15	division	O
16	cycle	O
17	,	O
18	suggesting	O
19	that	O
20	nuclear	O
21	accumulation	O
22	of	O
23	DREF	O
24	is	O
25	important	O
26	for	O
27	the	O
28	coordinate	O
29	zygotic	O
30	expression	O
31	of	O
32	DNA	O
33	replication	O
34	-	O
35	related	O
36	genes	O
37	carrying	O
38	DRE	O
39	sequences	O
40	.	O

1	Unaided	O
2	attempts	O
3	to	O
4	quit	O
5	smoking	O
6	are	O
7	generally	O
8	unsuccessful	O
9	.	O

1	To	O
2	further	O
3	our	O
4	knowledge	O
5	about	O
6	the	O
7	systemic	O
8	humoral	O
9	immune	O
10	system	O
11	response	I
12	to	I
13	weak	I
14	hapten	I
15	-	I
16	syngeneic	I
17	or	I
18	allogeneic	I
19	protein	I
20	conjugates	I
21	(	O
22	corrosion	I
23	and	O
24	wear	O
25	products	O
26	of	O
27	metallic	O
28	orthopedic	O
29	devices	O
30	),	O
31	a	O
32	sensitive	O
33	enzyme	O
34	-	O
35	linked	O
36	immunosorbent	O
37	assay	O
38	(	O
39	ELISA	O
40	)	O
41	method	O
42	for	O
43	testing	O
44	for	O
45	antibody	O
46	(	I
47	humoral	I
48	immunity	I
49	)	I
50	to	I
51	metals	O
52	was	I
53	developed	O
54	.	O

1	Rats	O
2	with	O
3	one	O
4	olfactory	O
5	bulb	O
6	removed	O
7	and	O
8	the	O
9	contralateral	O
10	naris	O
11	closed	O
12	can	O
13	detect	O
14	odors	O
15	.	O

